Genotype-Phenotype ID	Genotype	Clinical Phenotype
1447963976	CC	Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1447963993	AA	Male patients with the AA genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.
1448106268	AA	Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1449170173	AA	Patients with the AA genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.
1450372108	AA	Patients with the AA genotype may have a decreased risk of developing alcoholism when exposed to ethanol as compared to patients with the AG or GG genotypes. However, multiple studies have found no significant association between this genotype and risk of alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450372109	AG	Patients with the AG genotype may have an increased risk of developing alcoholism when exposed to ethanol as compared to patients with the AA genotype. However, multiple studies have found no significant association between this genotype and risk of alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1183684976	*1/*1	Patients with the *1/*1 genotype who are treated with oxycodone may have 1) increased metabolism of oxycodone, 2) increased likelihood of response to oxycodone and 3) decreased, but not absent risk for side effects as compared to patients with non-functional alleles or reduced function alleles. Other genetic and clinical factors may also influence a patient's response to oxycodone.
1449170174	AG	Patients with the AG genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.
982030960	CC	Patients with the CC genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030961	CT	Patients with the CT genotype and depression may have increased likelihood  of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030962	TT	Patients with the TT genotype and depression may have decreased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1450373104	TT	Patients with the TT genotype may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.
1450372110	GG	Patients with the GG genotype may have an increased risk of developing alcoholism when exposed to ethanol as compared to patients with the AA genotype. However, multiple studies have found no significant association between this genotype and risk of alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450373102	GG	Patients with the GG genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.
1450373103	GT	Patients with the GT genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.
1447963975	AC	Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1448106246	TTAAAG/TTAAAG	Patients with the TTAAAG/TTAAAG genotype and mesothelioma may have shorter progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAG/del or del/del genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1448106247	TTAAAG/del	Patients with the TTAAAG/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1448106248	del/del	Patients with the del/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence response to pemetrexed.
637880259	GG	Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
637880260	GT	Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
637880261	TT	Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
1448255943	AA	Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1448255942	AG	Patients with genotype AG may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1448255941	GG	Patients with genotype GG may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype AG or AA. Other genetic and clinical factors may also influence the response to sorafenib.
637880447	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
637880448	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
637880449	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
637880452	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
637880453	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
637880454	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
637880456	CC	Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
637880457	CT	Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes (inferred).
637880458	TT	Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
637880460	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  prazosin compared to cells with other genotypes.
637880461	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  prazosin compared to cells with other genotypes.
637880462	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  prazosin compared to cells with other genotypes.
637880464	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  verapamil compared to cells with other genotypes.
637880465	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  verapamil compared to cells with other genotypes.
637880466	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  verapamil compared to cells with other genotypes.
637880468	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  vinblastine compared to cells with other genotypes.
637880469	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  vinblastine compared to cells with other genotypes.
637880470	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  vinblastine compared to cells with other genotypes.
637880472	CC	Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.
637880473	CT	Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
637880474	TT	Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
1183960821	A	Male patients with the A genotype (hemizygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183960822	AA	Female patients with the AA genotype (homozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183960823	AG	Female patients with the AG genotype (heterozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the GG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183960824	G	Male patients with the G genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the A genotype (hemizygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
637879865	AA	Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
637879866	AG	Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
637879867	GG	Patients with the GG genotype  who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
637879870	AA	Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
637879871	AG	Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
637879872	GG	Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
637879933	CC	Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
637879934	CT	Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879935	TT	Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879938	CC	Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
637879939	CT	Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
637879940	TT	Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
637879943	CC	Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.
637879944	CT	Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.
637879945	TT	Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to a patient with genotype CC or CT .
637879948	CC	Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT .  Other genetic and clinical factors may also influence a patient's response.
637879949	CT	Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC .  Other genetic and clinical factors may also influence a patient's response.
637879950	TT	Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.
1448109586	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.
1448109587	AG	Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.
1448108727	AA	Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
1448108728	AG	Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
1448108729	GG	Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
1448109588	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.
637879973	GG	Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT.  Other genetic and clinical factors may also influence a patient's response.
637879974	GT	Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patient's response.
637879975	TT	Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patient's response.
637879978	CC	Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.
637879979	CT	Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.
637879980	TT	Rheumatoid Arthritis patients with the genotype TT may be more likely to respond to TNF inhibitors compared with patients with genotypes CC or CT . Other genetic and clinical factors may also influence a patient's response.
637879983	GG	Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes .  Other genetic and clinical factors may also influence a patient's response.
637879984	GT	Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
637879985	TT	Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
637879988	CC	Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.
637879989	CT	Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.
637879990	TT	Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.
637879993	AA	Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879994	AG	Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879995	GG	Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.
637879998	AA	Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
637879999	AG	Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
637880000	GG	Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotype AA or AG.  Other genetic and clinical factors may also influence a patient's response.
637880015	CC	Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
637880016	AC	Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
637880017	CT	Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
1448098977	AA	Pediatric cancer patients with the AA genotype may have a decreased risk for ototoxicity when treated with cisplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
1448098978	AG	Pediatric cancer patients with the AG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
637880088	AA	Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
637880089	AC	Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
637880090	CC	Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448532192	AA	People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.
1448532193	AG	People with the AG genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.
637880244	GG	Patients with the GG genotype may be less sensitive to treatment with erlotinib  compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.
637880245	GT	Patients with the GT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.
637880246	TT	Patients with the TT genotype may be more sensitive to treatment with erlotinib  compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.
637880251	GG	Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
637880252	GT	Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
637880253	TT	Cancer patients with genotype TT may be less likely  to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work).  Other genetic and clinical factors may also influence a patient's response.
1448098979	GG	Pediatric cancer patients with the GG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
1448099024	AA	Pediatric patients with the AA genotype who are undergoing hematopoietic stem cell transplantation may have increased clearance of busulfan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence busulfan clearance.
613976849	CC	Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
613976850	CT	Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
613976851	TT	Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
1448532194	GG	People with the GG genotype may have decreased exposure to dabigatran compared to patients with the AA and AG genotypes, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.
982033837	CG	Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
982033838	GG	Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
982033845	CC	Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
982031158	AA	Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
982031159	AG	Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
982031160	GG	Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
1447963994	AG	Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.
1447963995	GG	Male patients with the GG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.
982033836	CC	Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
982033846	CT	Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
619523390	AA	Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
619523391	AG	Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
619523392	GG	Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1447964004	CC	Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain.
655384596	GG	Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.
655384601	CC	Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
655384600	CT	Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
655384599	TT	Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
655384604	CC	Patients with the CC genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
655384605	CT	Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
655384606	TT	Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
1447964005	CG	Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.
655384608	CC	Patients with the CC genotype and schizophrenia: 1) may have increased treatment response with perphanzine and olanzapine treatment 2) may have decreased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.
655384609	CT	Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.
655384610	TT	Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.
982031352	AA	Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031353	AG	Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031354	GG	Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1447963823	CC	Patients with the CC genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963824	CG	Patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963825	GG	No patients with the GG genotype were available for analysis, but patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
655384628	AA	Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patient's response.
655384629	AG	Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384630	GG	Patients carrying the GG genotype may have increased chance of response to pravastatin compared to patients carrying the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.
655384637	AA	Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.
655384638	AG	Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.
655384639	GG	Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.
1449311673	AG	Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.
1449311674	GG	Patients with the GG genotype who are undergoing surgery may have an increased response to propofol and remifentanil administered as anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.
1449557756	*7	Patients with the *7 allele and Tuberculosis who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have an increased risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1447963831	GG	Patients with the GG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963832	GT	Patients with the GT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963833	TT	Patients with the TT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
982031343	GG	Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1447964006	GG	No patients with the GG genotype were available for analysis, but patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.
1449311672	AA	Patients with the AA genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.
655384667	CC	Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.
655384668	CT	Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.
655384669	TT	Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.
655384673	CC	Patients with the CC genotype may have decreased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the TT or CT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183689598	TT	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1183693355	AA	Patients with the AA (CYP2C9 *1/*1) genotype may have increased metabolism of celecoxib as compared to patients with the AC or CC (*1/*3 or *3/*3) genotype. Other genetic and clinical factors may also influence a metabolism of celecoxib.
1183693356	AC	Patients with the AC (CYP2C9 *1/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA (*1/*1) genotype, and increased metabolism as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib.
1448125546	TT	Patients with TT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.
1448125548	CC	Patients with CC genotype may have increased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.
1448125547	CT	Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.
1448099543	*1/*1	Patients with SLC22A1 *1/*1 genotype may have decreased exposure and increased clearance of sumatriptan as compared to patients who have two decreased functional SLC22A1 alleles. Other genetic and clinical factors may also influence the pharmacokinetic of sumatriptan.
1448099544	*2/*2	Patients with SLC22A1 *2/*2 genotype may have decreased exposure and increased clearance of sumatriptan as compared to patients who have two decreased functional SLC22A1 alleles. Other genetic and clinical factors may also influence the pharmacokinetic of sumatriptan.
1448099545	*3/*3	Patients with decreased function SLC22A1 *3/*3 genotype may have increased exposure and decreased clearance of sumatriptan as compared to patients who have only one or no decreased functional allele. Other genetic and clinical factors may also influence the pharmacokinetic of sumatriptan.
982033847	TT	Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
1448099546	*4/*4	Patients with decreased function SLC22A1 *4/*4 genotype may have increased exposure and decreased clearance of sumatriptan as compared to patients who have only one or no decreased functional allele. Other genetic and clinical factors may also influence the pharmacokinetic of sumatriptan.
1183689596	CC	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1043818288	CT	Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.
1183689597	CT	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
655384824	AA	Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384823	AG	While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.
1448099547	*5/*5	Patients with decreased function SLC22A1 *5/*5 genotype may have increased exposure and decreased clearance of sumatriptan as compared to patients who have only one or no decreased functional allele. Other genetic and clinical factors may also influence the pharmacokinetic of sumatriptan.
655384822	GG	Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.
1043818287	CC	Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.
655384837	CC	Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384836	CT	Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384835	TT	Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384839	CC	Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384840	CT	Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384841	TT	Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
1448099858	CC	Patients with the CC genotype and Depressive Disorder or Depression may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants.
1448099859	CT	Patients with the CT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants.
1448099860	TT	Patients with the TT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants.
1448100189	AA	Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AG and GG genotypes. Other factors may affect response to antidepressants.
1448100190	AG	Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100191	GG	Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448101215	AA	No patients with the AA genotype were available for analysis, but patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
1448101216	AG	Patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
1448101217	GG	Patients with the GG genotype who are smokers may have decreased physical responses to smoking as compared to patients with the AG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
655384863	CC	Patients with the CC genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655384864	CT	Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384865	TT	Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment  as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384869	CC	Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.
655384868	CT	Patients with the CT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the  the CC genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1448099548	*6/*6	Patients with decreased function SLC22A1 *6/*6 genotype may have increased exposure and decreased clearance of sumatriptan as compared to patients who have only one or no decreased functional allele. Other genetic and clinical factors may also influence the pharmacokinetic of sumatriptan.
655384867	TT	Patients with the TT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the  the CC genotype. Please note, while the CT genotype was associated with suggestively better response to haloperidol in unrelated schizophrenic inpatients, no results were shown for the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
655384879	GG	Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype.  Other genetic and clinical factors may also influence a patient's response.
655384880	GT	Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response.
655384881	TT	Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response.
655384885	AA	Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384884	AG	Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384883	GG	Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384889	CC	Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
655384888	CT	Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384887	TT	Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384893	CC	Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
655384892	CT	Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype.   It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype.
655384891	TT	Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
655384897	CC	Patients with the CC genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384896	CG	While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384895	GG	Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384899	GG	Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384900	GT	While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384901	TT	Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384905	AA	Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.
655384904	AC	Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.
655384903	CC	Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.
655384672	CT	Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655384671	TT	Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655384678	AA	Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
655384677	AC	Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
655384676	CC	Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
655384681	CC	Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
655384682	CG	Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
655384683	GG	Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
1448105544	AA	Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1448105545	AG	Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1448105546	GG	Patients with the GG genotype may have increased likelihood of remission on anti-depressants as compared to patients with the AA or AG genotype. Male patients with the GG genotype and depression who are treated with citalopram may have an increased risk of suicidal ideation as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
655384697	AA	Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655384696	AG	Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655384695	GG	Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655384702	CC	Patients with the CC genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.
655384701	CT	Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.
655384700	TT	Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype.
655384705	CC	Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
655384706	CT	Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.
655384707	TT	Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.
655384728	CC	Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
655384727	CT	Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
655384726	TT	Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
1183702972	GG	Patients with the GG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
982032722	CC	Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium or valproic acid as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032723	CT	Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1449752557	AA	Patients with the AA genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.
1449752558	AG	Patients with the AG genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.
1449752563	CC	Patients with cancer and the CC genotype may have a decreased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
982032724	TT	Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1449752559	GG	Patients with the GG genotype and cancer may have an increased risk for drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.
1449752564	CT	Patients with cancer and the CT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183702971	AG	Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1447963848	CC	Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
1447963849	CG	Patients with the CG genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
1447963850	GG	Patients with the GG genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
655384769	AA	Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
655384770	AG	Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
655384771	GG	Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
655384785	CC	Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
655384784	CG	Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
655384783	GG	Patients with the GG genotype and acute coronary artery syndrome who are treated with beta blockers may have a decreased, but not absent, chance of rehospitalization as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
1447963974	AA	Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1448102601	CT	Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.
1000539641	CC	Patients with the CC genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1000539642	CT	Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
637880519	CC	Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
637880520	CT	Cells with the CT genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes(inferred).
637880521	TT	Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
637880523	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
637880524	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
637880525	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
637880527	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
637880528	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
637880529	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
637880531	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
637880532	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
637880533	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastinel compared to cells with other genotypes.
1000539643	TT	Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
637880548	CC	Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.
637880549	CT	Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport  forskolin compared to cells with other genotypes.
637880550	TT	Cells with the T allele show no difference in P-glycoprotein expression or ability to transport  forskolin compared to cells with other alleles.
637880552	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
637880553	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
637880554	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.
637880556	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
637880557	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
637880558	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.
637880560	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
637880561	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
1448102602	TT	Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.
1448102600	CC	Patients with the CC genotype and colon cancer may have an increased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.
1448102606	CC	Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.
637880562	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.
1448100719	AA	Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.
1448100720	AG	Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.
1448100721	GG	Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.
1448101240	CC	Patients with the CC genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence neuropathy risk.
1447980693	CC	Patients with the CC genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
652595206	CC	Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652595207	CT	Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652595209	TT	Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652779373	AA	Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652779374	AG	Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652779375	GG	Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652882847	AA	Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
652882848	AG	Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
652882849	GG	Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
1447980694	CT	Patients with the CT genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype, or less severe effects and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980695	TT	Patients with the TT genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
982031341	CC	Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031342	GC	Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
655384478	AA	Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
655384476	TT	Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
655384480	AT	Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.
655384489	AA	Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.
655384488	AG	Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.
655384487	GG	Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.
1447963986	AA	Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.
1447963987	AG	Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.
982030512	A/del	Patients with the A/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
655384533	CC	Patients with the CC genotype and Schizophrenia may have a decreased response to clozapine compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
655384532	CT	Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
655384531	TT	Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
655384538	AA	Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
655384537	AG	Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
655384536	GG	Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
655384544	AA	Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
655384543	AC	Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
655384545	CC	Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
1447963855	AA	Patients with the AA genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963856	AC	Patients with the AC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963857	CC	Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of diabetes.
982030635	CC	Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles  *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
982030636	CT	Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
982030637	TT	Patients with the TT genotype who are treated with escitalopram may require an increased dose as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
655384560	CC	Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.
655384561	CG	Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.
655384562	GG	Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.
1449565276	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) and cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia and diarrhea at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, overall gastrointestinal toxicities (diarrhea, nausea, vomiting, and mucositis combined) or tumor response. One study found a decreased risk of vomiting for this genotype, and another found a decreased risk of treatment-related death, both compared to the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death.
982030513	AA	Patients with the A/A genotype who are treated with venlafaxine may have average risk of adverse effects (check other variants for PM phenotype) as compared to patients with the del/del or A/del genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982030514	del/del	Patients with the del/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
655384586	AA	Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.
655384585	AC	Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.
655384584	CC	Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.
655384589	AA	Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384590	AT	Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384591	TT	Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.
655384594	CC	Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.
655384595	CG	Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.
1183693450	CT	Patients with the CT genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
982035354	CC	This genotype has no significant effect on the PK or PD of nateglinide.
982035355	CT	This genotype has no significant effect on the PK or PD of nateglinide.
982035356	TT	This genotype has no significant effect on the PK or PD of nateglinide.
982035379	AC	Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
982035380	CC	Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
982035385	AA	Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.
1183693449	TT	Patients with the TT genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693451	CC	Patients with the CC genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
982035386	AG	Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.
982035387	GG	Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.
1449565131	CC	Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565132	CT	Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565133	TT	Patients with the TT genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT or CC genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385261	AA	Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385260	AG	Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385259	GG	Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385266	AA	Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.
655385265	AG	Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.
655385264	GG	Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.
655385276	AA	Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385275	AG	Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385274	GG	Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385279	AA	Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.
655385280	AG	Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.
655385281	GG	Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.
655385288	CC	Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385289	CT	Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385290	TT	Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385296	CC	Patients with the  CC (Arg389) genotype may have a stronger DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele. Other genetic and clinical factors may also influence the patient's response to metoprolol.
655385297	CG	Patients with the CG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.
655385298	GG	Patients with the GG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.
1448531860	TT	Patients with the TT genotype may have lower maximal platelet aggregation than patients with the GT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.
1448531864	AA	People with the AA genotype may have increased inhibition of platelet aggregation in response to ticagrelor compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect response to ticagrelor.
1448531865	AG	People with the AG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.
1448531859	GT	Patients with the GT genotype may have higher maximal platelet aggregation than patients with the TT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.
1448531866	GG	People with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.
655384915	CC	Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
655384916	CT	Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
655384917	TT	Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
1448531870	GG	People with the GG genotype may have increased inhibition of platelet aggregation when taking ticagrelor compared to people with the GT and TT genotypes. Other clinical and genetic factors may affect response to ticagrelor.
1449165700	CC	Patients with the CC genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.
1449165701	CT	Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.
1449165702	TT	Patients with the TT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have decreased trough concentrations of cyclosporine as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.
655384921	GG	Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.
655384920	GT	Patients with this genotype were not studied.
655384919	TT	Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.
655384923	CC	Patients with this genotype were not studied.
655384924	CT	Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype.  Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.
655384925	TT	Patients with the TT genotype who are exposed to methamphetamine may have a decreased, but not absent, risk for psychosis as compared to patients with the TC genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.
655384927	AA	Patients with the AA genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note that in the study reporting this association there were no subjects with the AA genotype, but the A allele was found to be associated with increased risk. Please note the associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.
655384928	AT	Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.
655384929	TT	Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.
655384931	AA	Patients with the AA genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655384932	AG	Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655384933	GG	Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment,  compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655384937	AA	Patients with the AA genotype and asthma who are treated with montelukast  may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
655384936	AG	Patients with the AG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
655384935	GG	Patients with the GG genotype and asthma who are treated with montelukast  may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
655384951	AA	Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
655384952	AG	Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
655384953	GG	Patients with the GG genotype and Alzheimer disease may have decreased but not non-existent risk for treatment-resistance to olanzapine or risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
1449003801	CC	Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003802	CT	Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk of venous thrombosis compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
655384961	AA	Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
655384960	AG	Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
655384959	GG	Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
1449003803	TT	Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
982035276	AA	Patients with the AA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
982035277	AG	Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
982035278	GG	Patients with the GG genotype who are treated with nifedipine may have larger mean changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
1447960635	AA	Patients with the AA genotype may have a greater decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence GFR.
1447960636	AC	Patients with the AC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.
1447960637	CC	Patients with the CC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.
1447960876	AA	Patients with the AA genotype and cancer may have increased exposure to tipifarnib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
1447960877	AG	Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
655384978	GG	Patients with the GG genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.
655384977	GT	Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.
655384976	TT	Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.
655384982	GG	Patients with the GG genotype is associated with better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655384981	GT	Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
1447960878	GG	Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
1447960950	AA	Patients with the AA genotype and epilepsy may require an increased dose of valproic acid as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
1449003719	CC	There is currently no available evidence regarding the effect of the CC genotype on oseltamivir concentrations in patients.
655384980	TT	Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384984	CC	Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.
655384985	CG	Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.
655384986	GG	Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of extreme weight gain as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.
1444705463	AA	Patients with the AA genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1444705464	AG	Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1444705465	GG	Patients with the GG genotype and coronary heart disease may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1444705470	AA	Patients with the AA genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1444705471	AG	Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
655385019	CC	Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.
655385018	CT	Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.
655385017	TT	Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.
1043880586	AA	Patients with the AA genotype may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.
655385036	AA	Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385035	AG	Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385034	GG	Cardiotox was not not found in GG group in this small study. The GG genotype  (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.
655385040	CC	Patients with the CC genotype may have decreased response to pramipexole in Chinese patients with Parkinson's disease compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655385039	CT	Patients with the CT genotype may have lower  response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.
655385038	TT	Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinson's disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patient's response.
655385049	CC	Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.
655385048	CT	Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.
655385047	TT	Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.
1448427974	GG	Patients with the GG genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
1448427975	GT	Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
1448427976	TT	Patients with the TT genotype and depression may have decreased risk of suicidal thoughts when taking antidepressants compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
655385066	CC	Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385065	CT	Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385064	TT	Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have an improvement in symptoms as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448107935	CC	Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.
1448428110	CC	No patients with the CC genotype were available for analysis, but patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428111	CT	Patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
655385074	AA	Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385075	AG	Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385076	GG	Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385079	AA	Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385080	AG	Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385081	GG	Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448104355	CC	Patients with the CC genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
1448104356	CG	Patients with the CG genotype and colorectal cancer may have a poorer response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
1448104357	GG	Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
1448104374	CC	Patients with the CC genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.
1448104375	CT	Patients with the CT genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.
1448104376	TT	Patients with the TT genotype may have decreased risk of drug-induced liver injury compared to patients with the CC genotype. Other factors may affect liver toxicity when treated with atorvastatin.
655385096	CC	Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.
655385095	CG	Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.
1448107933	AA	Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response.
1448107934	AC	It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.
655385094	GG	Patients with the GG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.
655385101	CC	Patients with the CC genotype and type 2 diabetes who are treated with rosiglitazone may have the smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.
655385100	CG	Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.
655385099	GG	Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.
1448634934	AA	Patients with the AA genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.
1448634935	AT	Patients with the AT genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.
1448634936	TT	Patients with the TT genotype may have increased response to salbutamol in people with Asthma as compared to patients with the AA or AT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.
1448634977	TT	Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
655385131	AA	This intronic variant is associated with differential induction, upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively spliced transcript lacking exon 13 (HMGCRv_1). In immortalized lymphocytes, A/A homozygotes exhibit 40% greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 transcript relative to A/G or G/G subjects. These differences may have implications for simvastatin efficacy, since increased induction of the alternatively spliced transcript is correlated with reduced percent response to simvastatin.
655385132	AG	The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript  as compared to AA genotype.
655385133	GG	The GG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript  as compared to AA genotype.
655385138	GG	Patients with the GG genotype and type II diabetes who are treated with sulfonylureas may be more likely to achieve a HbA1c level of <7% as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655385137	GT	Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655385136	TT	Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
1448634975	AA	Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
1448634976	AT	Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
655385146	AA	People with the AA genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.
655385147	AG	People with the AG genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with the GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.
655385148	GG	People with the GG genotype may have higher bioavailablilty of orally administered talinolol as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.
655385151	CC	Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.
655385152	CT	Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.
655385153	TT	Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the  CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.
655385158	AA	The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers
655385157	AG	The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.
655385156	GG	The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.
1449156284	*05:09:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*05:09:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156288	*18:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*18:01 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156053	*67:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*67:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
655385167	CC	Patients with the CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.
655385166	CT	Patients with the CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.
655385165	TT	Patients with the TT genotype may have increased clearance of thiotepa as compared to patients with the CT or TT genotype.
655385181	CC	Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655385180	CT	Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655385182	TT	Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655385580	CC	Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.
655385581	CT	Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.
655385582	TT	Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.
1449156172	*35:10	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*35:10  allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
982009416	AA	Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.
982035403	AA	Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
982035404	AG	Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
982035405	GG	Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
982035485	GG	Patients with the GG genotype may require lower dose of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
982035484	GT	Patients with the GT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
982035483	TT	Patients with the TT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
1444608065	AA	Patients with the AA genotype and soft tissue sarcoma may have a longer progression-free survival time when treated with doxorubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444608066	AG	Patients with the AG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444608067	GG	Patients with the GG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
655385706	GG	Patients with the GG genotype with major depressive disorder may experience a greater response when treated with desipramine or fluoxetine compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to antidepressants.
655385707	GT	Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.
655385708	TT	Patients with the TT genotype with major depressive disorder may experience a  lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.
1444667271	AA	Patients with the AA genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1444667272	AG	Patients with the AG genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1444667273	GG	Patients with the GG genotype 1) may have increased metabolism of clopidogrel and formation of active drug metabolite, resulting in increased response 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1450368645	ATGA/del	Patients with the ATGA/del genotype (DPYD *1/*7) may have decreased DPYD activity as compared to those with the ATGA/ATGA genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
1450368644	ATGA/ATGA	Patients with the ATGA/ATGA genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the ATGA/del or del/del genotypes (DPYD *1/*7 or *7/*7). Other genetic and clinical factors may also affect DPYD activity.
1450368646	del/del	Patients with the del/del genotype (DPYD *7/*7) may have decreased DPYD activity as compared to those with the ATGA/ATGA genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
655386107	GG	Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386110	CC	Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386111	CT	Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386112	TT	Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386115	AA	Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386116	AG	Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386117	GG	Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386121	CC	Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386122	CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386123	TT	Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386127	CC	Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386128	CT	Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386129	TT	Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386132	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386133	CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386134	TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
655386137	CC	Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386138	CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386139	TT	Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386142	AA	Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386143	AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386144	GG	Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386147	AA	Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386148	AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386149	GG	Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386152	CC	Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386153	CT	Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386154	TT	Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
655386157	CC	Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386158	CG	Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386159	GG	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386162	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386163	CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386164	TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
655386167	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386168	CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386169	TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386177	AA	Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386178	AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386179	GG	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386182	CC	Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386183	CG	Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386184	GG	Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386187	AA	Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386188	AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386189	GG	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386192	AA	Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386193	AG	Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386194	GG	Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
1448103922	CC	Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CC genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.
1448103923	CT	Patients with the CT genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CT genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.
655386245	AA	Patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.
655386246	AG	While patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the influence of one A allele with the G allele is. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.
655386247	GG	Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.
1448099769	CC	Patients with the CC genotype and inflammatory diseases may be more likely to respond to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.
655386311	AA	Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386312	AC	Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386313	CC	Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386316	CC	Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386317	CT	Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386318	TT	Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386321	AA	Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386322	AG	Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386323	GG	Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386325	CC	Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386326	CT	Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386327	TT	Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
1448099770	CT	Patients with the CT genotype and inflammatory diseases may be less likely to respond to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.
1448099771	TT	Patients with the TT genotype and inflammatory diseases may be less likely to respond to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.
1448602691	AA	Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
1448602692	AG	Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
1448602693	GG	Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
1448602862	G/del	Patients with the G/del genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
655386448	AA	Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
655386449	AC	Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
655386450	CC	Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a decreased response as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
655386551	AA	Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1448602861	GG	Patients with the GG genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602863	del/del	Patients with the del/del genotype may have decreased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the G/G genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
655386552	AG	Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
655386553	GG	Has average risk for metabolic syndrome when treated with antipsychotics.; Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
655385764	CC	Patients with the CC genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.
655385765	CT	Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.
655385766	TT	Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's repsonse.
1448428112	TT	Patients with the TT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1444705472	GG	Patients with the GG genotype and hypercholesterolemia may have a reduced response to treatment with less reduction in total cholesterol when treated with simvastatin compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1444706128	AA	Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype.  Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706127	AG	Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
655385861	AA	Patients with the AA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.
655385862	AC	Patients with the CA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.
655385863	CC	Patients with the CC, CT or TT genotype and cancer who are treated with anthracyclines 1) may have an increased risk of resistance as compared to patients with the AC and AA genotype 2) may have decreased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.
1444706126	GG	Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706156	AA	Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706157	AG	Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
655385974	AA	Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1444706158	GG	Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1448427407	CC	Patients with the CC genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427408	CT	Patients with the CT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427409	TT	Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
655385975	AT	Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
655385976	TT	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1448634061	CC	Children with the CC genotype and cancer who are treated with cisplatin may have an lower, but not absent, risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448634062	CT	Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448634063	TT	Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
655385982	GG	Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
655385983	GT	Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
655385984	TT	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1448634068	CT	The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634067	CC	The CC genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
655385990	CC	Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.
655385991	CT	Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385992	TT	Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385994	AA	Patients with the AA genotype who are exposed to phenytoin during the first trimester of pregnancy may have a decreased, but not absent, risk for having a child with a craniofacial abnormality as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a person's risk for having a child with a craniofacial abnormality after phenytoin exposure.
655385995	AG	Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385996	GG	Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385998	AA	Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385999	AG	Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386000	GG	Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386003	AA	Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386004	AG	Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386005	GG	Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386029	AA	Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
655386030	AG	Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype.  Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
655386031	GG	Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
1448616680	GG	Patients with the GG genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.
1448616681	GT	Patients with the GT genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the TT genotypes and and an increased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.
1448616682	TT	Patients with the TT genotype and psoriasis may experience an increased response to methotrexate as compared to patients with the GT GG genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.
655386080	AA	Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.
655386081	AG	Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.
655386082	GG	Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.
1448105912	CC	Patients with genotype CC may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.
1448105913	CT	Patients with genotype CT may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.
1448105914	TT	Patients with genotype TT may have increased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to gemcitabine.
1448616695	*06:02:01:01	Patients with one or two copies of the HLA-C*06:02:01 allele and psoriasis may have a better response to treatment with methotrexate as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02. Other genetic and clinical factors may also influence a patient's response to treatment with ustekinumab. *Please note: the study tested for presence/absence of HLA-Cw6 serotype, not the HLA-C*06 alleles.
1448616884	CC	Patients with cancer and the CC genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.
655386094	AA	Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386095	AG	Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386096	GG	Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
1445402087	CC	Patients with the CC genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
655386100	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386101	CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386102	TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386105	AA	Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386106	AG	Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.
1446907928	AA	Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.
1446907929	AG	Patients with the AG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite, and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.
1447946946	CC	Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence risk for renal dysfunction.
1447946947	CT	Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.
1447946948	TT	Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.
1447946952	CC	Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.
1447946953	CT	Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.
1447946954	TT	No individuals with the TT genotype (CYP3A5 *1/*1) were available for analysis. However, patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.
655385325	(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2	Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients who were carriers of the a third 28-bp repeat (for TSER*3/*3,TSER*2/*3). Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385326	(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3	Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385327	(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3	Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385332	AA	Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD).
655385331	AG	Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385330	GG	Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385337	AA	Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD.
655385336	AG	Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385335	GG	Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
1000539574	GT	Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
1000539575	TT	Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
1000539585	AA	In vitro, the construct expressing the wild type allelic protein has average nifedipine metabolism.
1000539586	AG	Expression study did not included heterozygous genotype.
655385371	AA	Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype.  Other genetic and clinical factors may also influence a patient's response.
655385372	AG	Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.
655385373	GG	Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.
655385381	AA	Patients with the AA genotype and Hypercholesterolemia may have a decreased, but not absent, risk of statin-related myalgia as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.
655385382	AG	Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.
655385383	GG	Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.
1183703297	*1/*1	Patients with the CYP2C9 *1/*1 genotype and may have increased metabolism of lornoxicam as compared to patients with the *1/*3 or *1/*13 genotype. Other genetic and clinical factors may also influence metabolism of lornoxicam.
1183703299	*1/*13	Patients with the CYP2C9 *1/*13 genotype and may have decreased metabolism of lornoxicam as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of lornoxicam.
1183703298	*1/*3	Patients with the CYP2C9 *1/*3 genotype and may have decreased metabolism of lornoxicam as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of lornoxicam.
655385389	AA	Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
655385390	AC	Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
655385391	CC	Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
982031519	AG	Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
982031520	GG	Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1000539573	GG	Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
1450342360	CC	Patients with the CC genotype may have decreased metabolism of ondansetron as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
982031518	AA	Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1000539587	GG	In vitro, the recombinant CYP3A4*17 allelic protein exhibits significantly decreased catalytic activity for nifedipine oxidation by 98 to 99% compared to wild-type construct at high concentration of nifedipine.
1000539595	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
1000539657	AA	Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
1000539666	CC	Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.
1000539667	CT	Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.
1000539668	TT	Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.
1043818289	TT	Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.
655385428	CC	Patients with the CC genotype may have decreased but not non-existent, risk for statin-related myalgia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.
655385429	CT	Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.
655385430	TT	Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.
1444666758	AA	Patients with the AA genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone.
1444666759	AG	Patients with the AG genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone
1444666760	GG	Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone
655385467	AA	Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
655385468	AG	Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
655385469	GG	Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
655385472	CC	Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
655385473	CT	Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
655385474	TT	Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
1450342361	CT	Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
1450342362	TT	Patients with the TT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
1450371709	AA	Patients with the AA genotype and rheumatoid arthritis or neuromyelitis optica may have a decreased response to rituximab, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to rituximab.
655385476	AA	Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
655385477	AG	Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
655385478	GG	Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
655385480	AA	Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have less improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
655385481	AG	Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
655385482	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
655385484	AA	Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
655385485	AG	Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
655385486	GG	Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
1444706885	AA	Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706886	AG	Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706887	GG	Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655387939	AA	Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
655387940	AG	Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
655387941	GG	Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
1448100944	CC	Patients with genotype CC and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the CT and TT genotypes. Other factors may affect dabigatran plasma concentrations.
1448100945	CT	Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.
1448100946	TT	Patients with genotype TT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.
1444706892	CC	Patients with the CC genotype and Schizophrenia may have increased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.
1444706893	CT	Patients with the CT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.
1448100950	GG	Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1444706894	TT	Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.
655388023	AA	Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
655388024	AG	Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
655388025	GG	Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
1448266666	CT	Patients with the CT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.
1448266665	TT	Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.
1448266823	CC	Patients with the CC genotype (CYP3A4 *1/*1) and epilepsy may have increased concentrations of carbamazepine as compared to patients with the CT (*1/*1G) or TT (*1G/*1G) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.
1448109628	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
1448109629	AG	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
1448266824	CT	Patients with the CT (CYP3A4 *1/*1G) genotype and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.
699639329	CC	Patients with the CC genotype may have  increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
699639330	CG	Patients with the CG genotype may have  decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
699639331	GG	Patients with the GG genotype may have  decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448109622	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1448109623	AG	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1448109624	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1183944124	A-202A_376G	Male patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with mefloquine 1) may have an increased risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.
1448266667	CC	Patients with the CC genotype may have a worse response to statin therapy compared to patients with the TT genotype. Other clinical and genetic factors may affect response to statins.
1448266825	TT	Patients with the TT genotype (CYP3A4 *1G/*1G) and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.
699639344	AA	Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.
699639345	AG	Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.
699639346	GG	Patients with the GG genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.
699639348	CC	Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.
699639349	CT	Patients with the genotype have not been studied.
699639350	TT	Patients with the TT genotype and hypertension who are treated with ACE inhibitors may have an increased risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.
699639352	CC	Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
699639353	CT	Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
699639354	TT	Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
699642191	CC	Patients with the CC genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
699642192	CT	Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
699642193	TT	Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.
1183944125	B (wildtype)	Male patients with the B haplotype (wildtype, associated with normal G6PD activity) who are treated with mefloquine 1) may have a reduced risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.
1448612789	CC	Patients with the CC genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.
1448612790	CG	Patients with the CG genotype and major depressive disorder may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the CC and GG genotypes. Other genetic and clinical factors may also influence a patient's response to SSRIs.
1448612791	GG	Patients with the GG genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.
981201798	AA	Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201799	AC	Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201800	CC	Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1448573639	AA	Patients with the AA genotype and ulcerative colitis may have a better chance at achieving remission when treated with tacrolimus as compared to patients with the AG or GG genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.
1448615169	AA	Postmenopausal women with HR+breast cancer and the GG genotype may have a decreased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
981203555	AA	Patients with the AA genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the GG genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.
981203556	AG	Patients with the AG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the GG genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.
981203557	GG	Patients with the GG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the AA genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.
1448519698	*22/*22	No patients with the *22/*22 genotype were available for analysis, but patients with the CYP3A4*1/*22 genotype and breast cancer may have increased concentrations of exemestane as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence exemestane concentrations.
1449752595	CC	Patients with the CC genotype may have worse overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma or esophageal cancer or Ovarian Neoplasms as compared to patients with AA and AC genotypes. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.
1448519696	*1/*1	Patients with the CYP3A4*1/*1 genotype and breast cancer may have decreased concentrations of exemestane as compared to patients with the *1/*22 genotype. Other genetic and clinical factors may also influence exemestane concentrations.
1449752604	CC	Patients with lung cancer and the CC genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752605	CT	Patients with lung cancer and the CT genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752606	TT	Patients with lung cancer and the TT genotype may have a decreased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1446898842	CC	Patients with the CC genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have an increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CT and CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain.
1444666940	*02:01:01:01	Patients with one or two copies of the HLA-A*02:01:01:01 allele may have an increased risk for maculopapular eruption when receiving carbamazepine as compared to patients with no HLA-A*02:01:01:01 alleles or negative for the HLA-A*02:01:01:01 test. However, one study found a decreased risk for drug hypersensitivity reactions for carriers of the HLA-A*02 allele. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1444666956	*51:01:01	Patients with one or two copies of the HLA-B*51:01:01 allele may have an increased risk of carbamazepine-induced adverse reactions as compared to patients with no HLA-B*51:01:01 alleles or negative for the HLA-B*51:01:01 test. However, some studies find no association between this allele and adverse reactions. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1446898843	CT	Patients with the CT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain.
1446898844	TT	Patients with the TT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have a decreased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain.
1448519697	*1/*22	Patients with the CYP3A4*1/*22 genotype and breast cancer may have increased concentrations of exemestane as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence exemestane concentrations.
1449752767	CC	Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased response when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
655386662	AA	Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
655386663	AC	Patients with the AC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
655386664	CC	Patients with the CC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
655386666	AA	Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
655386667	AC	Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
655386668	CC	Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
655386853	AA	Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs2227631. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386854	AG	Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386855	GG	Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386857	AA	Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386858	AG	Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386859	GG	Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386870	CC	Patients with the CC genotype who are treated with bisphosphonates may have greater improvement in bone mineral density as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bisphosphonates.
655386871	CT	The response of patients with the CT genotype who are treated with bisphosphonates is not clear compared to that of patients with the CC or the TT genotype.
655386872	TT	Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bisphosphonates.
655386874	AA	Patients with the AA genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clodronate.
655386875	AG	Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.
655386876	GG	Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.
655386889	AA	Patients with the AA genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.
655386890	AG	Patients with the AG genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.
655386891	GG	Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.
1448106364	CC	Patients with ovarian cancer and the CC genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. In a single study, the authors compared outcomes between genotypes between treatments. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.
1448106365	CG	Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.
1448106508	CG	Patients with the CG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
655386962	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386963	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386964	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386970	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386971	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386972	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386982	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386983	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386984	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386986	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for an adverse event.
655386987	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for an adverse event.
655386988	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype.
655386991	AA	Patients with the AA genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
655386992	AG	Patients with the AG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
655386993	GG	Patients with the GG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
655386996	CC	Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
655386997	CT	Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
655386998	TT	Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
655387000	CC	Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
655387001	CT	Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
655387002	TT	Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
655387005	GG	Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.
655387006	GT	Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.
655387007	TT	Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.
1449577056	CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC	Patients with breast cancer and the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.
1449577057	del/CTGGTGAGGAGAGAACC	Patients with breast cancer and the del/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.
1449577058	del/del	Patients with breast cancer and the del/del genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del/CTGGTGAGGAGAGAACC or CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotypes (please note: the del/del genotype was not observed in this cohort). Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.
655387015	CC	Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.
655387016	CT	Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.
655387017	TT	Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence disease-free survival.
1184990020	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with olanzapine, quetiapine or risperidone may have an increased risk of side effects as compared to patients with the HTTLPR short form (S allele)/HTTLPR short form (S allele)(Short/Short) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.
1184990021	HTTLPR short form (S allele)/HTTLPR long form (L allele)	Patients with the HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with olanzapine, quetiapine or risperidone may have an increased risk of side effects as compared to patients with the HTTLPR short form (S allele)/HTTLPR short form (S allele) (Short/Short) genotype and increased response to olanzapine or risperidone as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.
982033853	AG	Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
982033854	GG	Patients with the GG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
982034443	CC	Patients with the CC genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.
1184990022	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype who are treated with olanzapine, quetiapine or risperidone may have a reduced, but not absent, risk of side effects as compared to patients with the  HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.
1446899061	CC	Patients with the CC genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain.
1446899062	CT	Patients with the CT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain.
655387222	CC	Patients with the CC genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.
655387223	CT	Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.
655387224	TT	Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.
655387230	AA	Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.
655387231	AG	Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.
655387232	GG	Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.
655387238	CC	Patients with the CC genotype may have poorer response to risperidone in children with autism as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655387239	CT	Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655387240	TT	Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
1446899063	TT	Patients with the TT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have a decreased risk of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of weight gain.
655387653	CC	Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.
655387654	CT	Patients with the TC genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655387655	TT	Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655387673	CC	Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387674	CT	Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387675	TT	Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype.  Other genetic and clinical factors may also influence a patient's risk for toxicity.
982033852	AA	Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
1444667229	AA	Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
1444667230	AG	Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
655387768	CC	Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
655387769	CT	Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
655387770	TT	Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
1447963600	*05:02:01	Patients with one or two copies of the HLA-DRB1*16:01-HLA-DQB1-*05:02 haplotype who are treated with flupirtine may have an increased risk of drug-induced liver injury (DILI) as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of flupirtine-induced adverse reactions.
655387822	AA	Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have improvement in disease activity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387823	AG	Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387824	GG	Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387826	CC	Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387827	CT	Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387828	TT	Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387836	AA	Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
655387837	AG	Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
655387838	GG	Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
655387877	AA	Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387878	AG	Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444667231	GG	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
655387879	GG	Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
982030494	CT	Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
981201828	AA	Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.
981201829	AC	Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.
981201830	CC	Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.
1444607701	CC	Patients with the CC genotype who are treated with docetaxel may have an increased clearance and decreased risk of leukopenia as compared to patients with the GG genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1444607700	CG	Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1444607699	GG	Patients with the GG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1448100882	AA	Patients with the AA genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
1448100883	AT	Patients with the AT genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
1448100884	TT	Patients with the TT genotype may have an increased risk of becoming addicted to nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
1448100889	AA	Patients with the AA genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1448617759	CC	Patients with the CC genotype may have decreased clearance of atazanavir as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence clearance of atazanavir.
1448617760	CT	Patients with the CT genotype may have decreased clearance of atazanavir as compared to patients with the TT genotype and increased clearance as compared to patients with the CC genotype. Other clinical and genetic factors may also influence clearance of atazanavir.
981201444	CC	Patients with the CC genotype may have increased risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
981201445	CT	Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
1444607706	GG	Patients with the GG genotype and beta-thalassemia may have a better response, but also an increased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.
1444608398	CC	Patients with the CC genotype and gastric cancer may have a poorer response when treated with fluorouracil, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1444608399	CT	Patients with the CT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1448617761	TT	Patients with the TT genotype may have increased clearance of atazanavir as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence clearance of atazanavir.
981201446	TT	Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
981202610	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981202611	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype or may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981202612	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1183700240	CG	Patients with the CG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700241	GG	Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700244	AA	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to first remission induction therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
982032398	CT	Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032399	TT	Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032479	AG	Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032478	GG	Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032498	CC	Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1183700239	CC	Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better overall survival as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1448100890	AG	Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1448100891	GG	Patients with the GG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1448100951	GT	Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1448100952	TT	Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1448100957	AA	Patients with the AA genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.
1448100958	AG	Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.
1183700245	AG	Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1448100959	GG	Patients with the GG genotype and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the AA and AG genotypes. Other clinical factors may affect plasma concentrations of dabigatran.
1183700246	GG	Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700260	AA	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better event-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
982032397	CC	Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1183700259	AT	Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1448109548	AG	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448109549	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448109580	GG	Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448568528	AA	Patients with the AA genotype and cancer who are treated with fluorouracil and oxaliplatin may have poorer treatment outcome (reduced responsiveness, lower overall survival time, increased risk of death) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.
1448568529	AG	Patients with the AG genotype and cancer who are treated with fluorouracil and oxaliplatin may have better treatment outcome as compared to patients with the AA genotype, or may have poorer treatment outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.
1448109547	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183700401	AA	Children with the AA genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183700402	AG	Children with the AG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype or may have a reduced risk of exacerbations as compared to children with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183700403	GG	Children with the GG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have a reduced risk of exacerbations as compared to children with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448519738	AA	Patients with the AA genotype and cancer who are treated with platinum-based drugs may have the highest risk of toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for  toxicity.
1448519739	AG	Patients with the AG genotype and cancer who are treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1447989780	CT	Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.
1447989781	TT	No patients with the TT genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.
1448519740	GG	Patients with the GG genotype and cancer who are treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448568530	GG	Patients with the GG genotype and cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.
981202047	AA	Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the GG or AG genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.
981202048	AG	Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.
981202049	GG	Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.
1183700261	TT	Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700494	CC	Patients with the CC genotype may have decreased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
1450371843	*1A/*7	Patients with HIV and the CYP3A5 *1/*7 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1447952940	GG	Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
1450371844	*3A/*3A	Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1449165796	AA	Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AA genotype may have decreased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.
981202335	GG	Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
981202336	GT	Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
981202337	TT	Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
981202367	AA	Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
981202368	AG	Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates as compared to the AA genotype 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
981202369	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates 2) may have increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
1447952990	CC	Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1447952991	CT	Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1447952992	TT	Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1183700814	CG	Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.
1183700815	GG	Patients with the GG genotype may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.
1183700858	CC	Patients with the CC genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183700813	CC	Patients with the CC genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.
1183700859	CT	Patients with the CT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447949641	CC	Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949642	CT	Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1183697672	*1/*2	Patients with the *1/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.
1183697673	*2/*2	Patients with the *2/*2 genotype who are treated with sipoglitazar may have 1) a better response (as measured by decreased HbgA1c) and 2) decreased clearance as compared to patients with the *2/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.
981188354	AA	Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.
981188355	AG	Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.
981188356	GG	Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.
981202647	AA	Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
981202648	AG	Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
981202649	GG	Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
1447949643	TT	Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1183697671	*1/*1	Patients with the *1/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.
981201806	AA	Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201807	AC	Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201808	CC	Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981202104	CC	Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981202105	CT	Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981202106	TT	Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1448106082	CC	Patients with the CC genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype. Other genetic and clinical factors may also influence response to loop diuretics.
1448106083	CG	Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.
982033815	AA	Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
982033816	AG	Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
982033817	GG	Patients with the GG genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
1447943617	C/del	Patients with the C/del genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.
1447943616	CC	Patients with the CC genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.
1183679127	CC	Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1447989798	CC	No patients with the CC genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
1447989799	CT	Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
1447989800	TT	Patients with the TT genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
1447989805	AA	Patients with the AA genotype and pancreatic cancer may have an increased chance of survival when treated with fluorouracil as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
1447989806	AG	Patients with the AG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
1447989807	GG	Patients with the GG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
1448106084	GG	Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.
1448106092	CC	Patients with the CC genotype who undergo kidney transplant may have a decreased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for PTDM.
1448106093	CT	Patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.
981202357	GG	Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
981202358	GT	Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
981202359	TT	Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
1447943618	del/del	Patients with the del/del genotype and hypertension may have increased response to atenolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to atenolol.
1447943629	C/del	Patients with the C/del genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to metoprolol
1448106094	TT	No patients with the TT genotype were present in the population. However, patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.
1448106101	AA	Patients with the AA genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1449309889	GT	Patients with the GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1449309890	TT	Patients with the TT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1449309888	GG	Patients with the GG genotype and HIV infection may have decreased plasma concentrations and increased clearance of efavirenz as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1444667501	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667502	CG	Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667503	GG	Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
981201550	CC	Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.
981201551	CT	Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.
981201552	TT	Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.
982030493	CC	Patients with the CC genotype who are treated with venlafaxine may have 1) average venlafaxine plasma concentration 2) an average risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CT or TT genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
769171388	AA	Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.
769171389	AG	Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.
769171390	GG	Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil.
1444667514	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667515	AC	Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667516	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1448109728	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1448109729	AG	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1448109730	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1449565045	CT	Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.
1449565046	TT	Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CC or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.
1183679129	TT	Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1448106437	GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1449565074	CC	Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.
1448106435	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1183679778	AA	Patients with the AA genotype may have decreased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype CC or AC. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1446908014	CC	Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.
1446908015	CT	Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.
1448106436	AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1183634103	AA	Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634104	AG	Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the GG genotype and decreased reduction of diastolic blood pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981201889	AA	Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
981201890	AG	Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
981201891	GG	Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
1183679128	CT	Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
982031000	AC	Patients with the AC genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or AA. Other genetic and clinical factors may also influence a patient's response to treatment.
982030999	CC	Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.
982031022	GG	Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1043858973	CC	Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444701092	*10	Patients with the CYP2D6*10 allele in combination with a non-functional allele (*3, *4, *5, *6) who are treated with citalopram or escitalopram may have an increased frequency of remission and a decreased dose as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444701093	*2/*2	Patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with citalopram or escitalopram may have a decreased frequency of remission and an increased dose as compared to patients with two non-functional alleles (*3, *4, *5, *6) or a reduced function allele (*10, *17, *41) and a non-functional allele. However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
982031001	AA	Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment.
1043858971	AA	Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858972	AC	Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1447521686	E2/E2	Patients with APOE E2/E2 genotype may require shorter duration of time to reach a stable warfarin dose as compared to patients with genotype E3/E3 in African-American patients. Other genetic and clinical factors may also influence the response to warfarin.
982035373	GG	The GG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.28). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
982035378	AA	Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
982035371	AA	The AA genotype was found less often in smokers as compared to the GG genotype. In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
982035372	AG	The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
1000539653	AG	Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
1000539654	GG	Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
1447521688	E2/E4	Patients with APOE E2/E4 genotype may require shorter duration of time to reach a stable warfarin dose as compared to patients with genotype E3/E3 in African-American patients. Other genetic and clinical factors may also influence the response to warfarin.
1447521685	E3/E3	Patients with APOE E3/E3 genotype may require longer duration of time to reach a stable warfarin dose as compared to patients with genotype E2/E2, E4/E4 or E2/E4 in African-American patients. Other genetic and clinical factors may also influence the response to warfarin.
1447521687	E4/E4	Patients with APOE E4/E4 genotype may require shorter duration of time to reach a stable warfarin dose as compared to patients with genotype E3/E3 in African-American patients. Other genetic and clinical factors may also influence the response to warfarin.
1000539658	AG	Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
1000539659	GG	Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
1043737552	AA	Patients with the AA genotype may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the AG or GG genotype. Patients with the AA genotype may have a poorer response to statin treatment than patients with the GG or AG genotype. However, contradictory results have also been reported. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
981239557	CC	Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.
981202675	AA	Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
981202676	AG	Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
981202677	GG	Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
1448423468	*1A/*3A	Patients with the CYP3A5*1/*3 genotype and epithelial ovarian cancer may have an increased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with the CYP3A4*3/*3 genotype. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia in patients taking carboplatin and paclitaxel.
1448423469	*3A/*3A	Patients with the CYP3A5*3/*3 genotype and epithelial ovarian cancer may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with the CYP3A4*1/*3 genotype. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia in patients taking carboplatin and paclitaxel.
981201789	CC	Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201790	CT	Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201791	TT	Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
981239558	CT	Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.
981239559	TT	Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.
981239569	AA	Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.
981239570	AC	Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.
1448108737	AA	Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
1448108738	AG	Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
1448108739	GG	Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
1447989779	CC	Patients with the CC genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity.
1448108850	AA	Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
1448108851	AG	Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
978608465	AA	Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.
978608466	AG	Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.
978608467	GG	Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.
1184514205	AA	Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514204	AC	Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514203	CC	Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
981202715	GG	Patients with the GG genotype may have a poorer response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981202716	GT	Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981202717	TT	Patients with the TT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981188337	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2	Patients with the 2R/2R genotype may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.
981188338	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Patients with the 2R/3R genotype may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.
981188339	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Patients with the 3R/3R genotype may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.
1450371840	*1A/*1A	Patients with HIV and the CYP3A5 *1/*1 genotype (designated as normal metabolizers) may have decreased plasma concentrations of maraviroc as compared to patients with intermediate metabolizer or poor metabolizer genotypes. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found either a lack of association or contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1450371841	*1A/*3A	Patients with HIV and the CYP3A5 *1/*3 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1448100328	CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
978639597	CC	Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels.
978639598	CT	Individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.
978639599	TT	Individuals with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.
1447983221	CC	Patients with the CC genotype may have decreased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
1447983220	CT	Patients with the CT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
1183619650	*1/*1	Patients with the CYP2C19 *1/*1 genotype who underwent kidney transplantation and are treated with tacrolimus may have lower tacrolimus dose-normalized trough blood concentrations (C0/D) as compared to patients with the *2/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.
1447983219	TT	Patients with the TT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
1183619651	*1/*2	Patients with the CYP2C19 *1/*2 genotype who underwent kidney transplantation and are treated with tacrolimus may have lower tacrolimus dose-normalized trough blood concentrations (C0/D) as compared to patients with the *2/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.
1449156281	*05:01:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*05:01:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1448100329	TT	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.
1449750381	AA	Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
1449004897	CC	Cancer patients with the CC genotype who are treated with methotrexate may have 1) a decreased likelihood of drug toxicity as compared to those with the CT or TT genotype, 2) a better response as compared to those with the CT or TT genotype and 3) decreased concentrations of methotrexate as compared to those with the TT genotype. However, multiple incidences of negative or contradictory evidence exists for all three of these associations. Other genetic or clinical factors may influence a patient's response to methotrexate.
1449004878	AA	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a worse response to methotrexate as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
982034444	CG	Patients with the CG genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.
982034445	GG	Patients with the GG genotype and hypertensive coronary artery disease may have an increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.
1447952938	AA	Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
1447952939	AG	Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
1449004879	AG	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449004880	GG	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the GG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
982031007	CT	Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment.
982031008	TT	Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.
982031020	AA	Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031006	CC	Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.
982031021	GA	Patients with the GA genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
827864304	TT	Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.
827864180	AA	Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
827864181	AT	Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
827864182	TT	Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
827864160	CC	In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.
827864161	CT	In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.
827864162	TT	In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.
827863844	AA	Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to glucocorticoids.
827863845	AG	Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.
827863846	GG	Patients with the GG genotype may have increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with homozygous GG genotype has the lowest GLCC1 expression value compared to AA or AG.
982032260	GG	Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032354	AG	Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1445402463	*58:01	Patients with one or two copies of the HLA-B*58:01 allele have an increased risk of hypersensitivity reactions, such as Stevens-Johnson Syndrome, toxic epidermal necrolysis or maculopapular eruption, when treated with lamotrigine as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.
827848786	CC	Patients with the CC genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.
827848787	CG	Patients with the CG genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.
827848788	GG	Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.
1445402468	*35:01:01:01	Patients with one or two copies of the HLA-B*35:01 allele have an increased risk of experiencing nevirapine-related adverse events when treated with the drug as compared to patients with no HLA-B*35:01 alleles or negative for the HLA-B*35:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.
1446905333	CC	Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) a decreased, but not absent, risk of hemolysis and severe/ unsafe hemoglobin decreases 2) decreased, but not absent, risk of requiring a blood transfusion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.
1183630579	AA	Patients with the AA genotype and schizophrenia may have a poorer response when treated with antipsychotics as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antipsychotics.
982032259	AG	Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1183630580	AC	Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1446905334	CT	Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. This association was contradicted in another study showing no association of the CT genotype with increased risk of unsafe hemoglobin decreases or requirement for a blood transfusion when treated with artesunate, chlorproguanil and dapsone compared to to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.
1446905335	TT	Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) an increased risk of hemolysis and severe/ unsafe hemoglobin decreases 2) an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.
827847753	CT	Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.
827847754	TT	Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.
827849110	AA	Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.
827849111	AG	Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.
827849112	GG	Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.
1450112803	GG	Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112804	GT	Patients with osteosarcoma and the GT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112805	TT	Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1448106626	AA	Patients with the AA genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1448106627	AG	Patients with the AG genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1449565044	CC	Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.
1446897517	GG	Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
1446897522	AA	Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1448106546	AG	Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106547	GG	Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
827848564	AA	Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
827848565	AG	Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
827848566	GG	Patients with the GG genotype may have decreased but not non-existent risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
827849080	CC	Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
1450371842	*1A/*6	Patients with HIV and the CYP3A5 *1/*6 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1184987050	AA	Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1448106628	GG	Patients with the GG genotype and schizophrenia may have a poorer response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
827849081	CT	Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
827849082	TT	Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
1184748870	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748871	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748872	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748875	AA	Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748876	AG	Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748877	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
827849096	AA	Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.
827849097	AT	Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.
827849098	TT	Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.
1184748880	AA	Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748881	AG	Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
827847760	AA	Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
827847761	AG	Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
827847762	GG	Patients with the GG genotype may have decreased response to duloxetine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
1447946673	AA	Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG genotype (*1/*18B). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus.
1447946674	AG	Patients with the AG genotype (CYP3A4 *1/*18B) who underwent kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype (*1/*1). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus.
1447946675	GG	No patients with this genotype were included in the analysis. However, patients with the AG genotype (CYP3A4 *1/*18B) who underwent kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype (*1/*1). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus.
1043737361	AC	Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
1043737362	CC	Patients with the CC genotype may have decreased metabolism of verapamil as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
827848741	AA	Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.
827848742	AG	Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.
827848743	GG	Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.
827848752	AA	Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.
827848753	AG	Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.
827848754	GG	Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.
1449565103	AA	Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565104	AG	Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565105	GG	Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1043737360	AA	Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
827863929	AA	Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment.
827863930	AG	Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.
827863931	GG	Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.
827864514	AA	Patients with the AA genotype and heart failure may have an elevated risk for death as compared to patients with the TT genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
827864515	AT	Patients with the AT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
827864516	TT	Patients with the TT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype regardless of beta blocker.; treatment. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
1449565108	AA	Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449565109	AC	Patients with the AC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype or may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449565110	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1448099386	TATTT/TATTT	Patients with nasopharyngeal cancer and the TATTT/TATTT diplotype may have increased concentrations of docetaxel as compared to patients with the TGCGC/TGCGC diplotypes. Other clinical and genetic factors may also influence concentrations of docetaxel.
1448099387	TGCGC/TATTT	Patients with nasopharyngeal cancer and the TGCGC/TATTT diplotype may have decreased concentrations of docetaxel as compared to patients with the TATTT/TATTT diplotypes. Other clinical and genetic factors may also influence concentrations of docetaxel.
827847739	AA	Patients with the AA genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
827847740	AT	Patients with the AT genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
827847741	TT	Patients with the TT genotype may have 1) increased event free survival 2) decreased, but not non-existent, risk of central nervous system relapse 3) increased risk of thrombocytopenia when treated with methotrexate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate.
827847745	GG	Patients with the GG genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
827847746	GT	Patients with the GT genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
827847747	TT	Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.
827848549	GG	Patients with the GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.
827848550	GT	Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.
827848551	TT	Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.
827848726	AA	Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.
827848727	AG	Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
827848728	GG	Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
827847752	CC	Patients with the CC genotype may have increased risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.
1447949173	*15:13:01	Patients with one or two copies of the HLA-B*15:13 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS), when treated with phenytoin as compared to patients with no HLA-B*15:13 alleles or negative for the HLA-B*15:13 test. Other genetic and clinical factors, such as HLA-B*15:02, may also influence a patient's risk of phenytoin-induced adverse reactions.
1449270975	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270976	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
827847726	CC	Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.
827847727	CT	Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.
827847728	TT	Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.
1449270977	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
827830328	AA	Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
827830329	AC	Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
827830330	CC	Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
1447963805	CC	Women with the CC genotype and hypertensive nephrosclerosis may have a better response to treatment with metoprolol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to metoprolol.
1448612499	GT	Individuals with the GT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1448612500	TT	Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the GT or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
827836552	CC	Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
827836553	CG	Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
827836554	GG	Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
1448612488	CC	Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1448612489	CT	Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1000539593	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
1000539594	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
827831125	GT	Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
827831126	TT	Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
1449266575	*1/*1	Patients without the *6 allele and with opioid dependence who are taking methadone may have 1) increased pain tolerance and threshold, 2) increased methadone clearance, and 3) decreased risk of prolonged QTc compared to patients with the *6 allele. Other factors may affect pain tolerance and threshold.
1449266576	*1/*6	Patients with the *6 allele and opioid dependence who are taking methadone may have 1) decreased pain tolerance and threshold and 2) decreased methadone clearance compared to patients without the *6 allele. Other factors may affect pain tolerance and threshold.
1448612490	TT	Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
827848733	AA	Patients with the AA genotype may have 1) decreased but not absent risk for drug toxicity 2) decreased event free survival when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.
827848734	AG	Patients with the AG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.
827848735	GG	Patients with the GG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.
827848777	A/del	Patients with the A/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.
1184997027	*27:09	Patients with one or two copies of the HLA-B*27:09 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*27:09 alleles or negative for the HLA-B*27:09 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1449266577	*6/*6	Patients with the *6/*6 genotype and opioid dependence who are taking methadone may have 1) decreased pain tolerance and threshold, 2) decreased methadone clearance, and 3) increased risk of prolonged QTc compared to patients without the *6 allele. Other factors may affect pain tolerance and threshold.
827848778	AA	Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the A/del or del/del genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.
827848779	del/del	Patients with the del/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.
982033498	C/del	Patients with the C/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1447961373	CC	Cells with the CC genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype. Other factors may also influence uptake of these drugs.
1447961374	CT	Cells with the CT genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype, or decreased uptake as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.
1447961375	TT	Cells with the TT genotype may have decreased uptake of catecholamines or metformin as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.
827864302	CC	Patients with the CC genotype: 1) may have increased blood pressure, 2) increased risk for hypertension and 3) slower control of blood pressure when treated with verapamil as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.
827864303	CT	Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.
827831124	GG	Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
1183633755	AG	Asian patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1444705450	CA	Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
1183633756	GG	Asian patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype.  The opposite has been found in White patients.  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1444705451	CC	Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
1444705449	CT	Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
981237923	AA	Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981237924	AG	Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981237925	GG	Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
1444705448	TT	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
1447961396	CC	Smokers with the CC genotype who are treated with nicotine gum or nicotine patches may have a greater likelihood of abstinence as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
1447961397	CT	Smokers with the CT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
1447961398	TT	Smokers with the TT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
1449191742	CC	Patients with the CC genotype (do not have a copy of the CFTR R1070W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
981237698	TT	Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
981237951	AA	Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.
981237952	AG	Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.
981237953	GG	Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.
1449191743	CT	Patients with the CT genotype (one copy of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449564706	AA	Patients with chronic hepatitis C and the AA genotype may have a decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the CC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
1183633754	AA	Asian patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients.  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1449564707	AC	Patients with chronic hepatitis C and the AC genotype may have a decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the CC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
981238398	AA	Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
981238399	AG	Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
981238400	GG	Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
1449564708	CC	Patients with chronic hepatitis C and the CC genotype, may have an increased risk of anemia but a decreased risk of thrombocytopenia as compared to patients with the AA or AC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
1444706833	CG	Patients with the CG genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706834	GG	Patients with the GG genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1450368654	AA	Patients with the AA genotype (DPYD *10/*10) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
981237874	GG	Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1450368655	AC	Patients with the AC genotype (DPYD *1/*10) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
1450368656	CC	Patients with the CC genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AC or AA genotype (DPYD *1/*10 or *10/*10). Other genetic and clinical factors may also affect DPYD activity.
1449164579	AA	Cancer patients with the AA genotype may have a shorter overall and event-free survival time as compared to patients with the AG or GG genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.
982032353	AA	Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
981239571	CC	Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.
1184987051	AG	Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987052	GG	Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1444608380	CT	Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.
1449164580	AG	Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.
1449164581	GG	Cancer patients with the GG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.
1444608379	CC	Patients with the CC genotype and depression may not respond as well to treatment with escitalopram, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to escitalopram.
1449165005	AA	Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
1450368649	AA	Patients with the AA genotype (DPYD *8/*8) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
1184986322	CC	Patients with the CC genotype and cancer may have an improved response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.
1444608381	TT	Patients with the TT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.
1444608400	TT	Patients with the TT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1450368650	AG	Patients with the AG genotype (DPYD *1/*8) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
1444667177	CC	Patients with the CC genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CT and TT genotypes.  Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
1444667178	CT	Patients with the CT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
1444667179	TT	Patients with the TT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
1450368651	GG	Patients with the GG genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AA or AG genotype (DPYD *8/*8 or *1/*8). Other genetic and clinical factors may also affect DPYD activity.
1446900336	CC	Patients with the CC genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the TT genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.
1446900337	CT	Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.
1446900338	TT	Patients with the TT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.
981239545	AA	Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.
981239546	AG	Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.
981239547	GG	Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.
1449155806	CC	Patients with the CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype, but may not be associated with hepatotoxicity. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
1449155807	CT	Patients with the CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype, but may not be associated with hepatotoxicity. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
1184986591	AA	Patients with the AA genotype and lung cancer may have an improved response to platinum compounds as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.
1449155808	TT	Patients with the TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype, but may not be associated with hepatotoxicity. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
1184986592	AG	Patients with the AG genotype and lung cancer may have a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.
981238438	AA	Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
1184986593	GG	Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.
1184986596	GG	Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.
1448634748	CC	Patients with the CC genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the CT and TT genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.
1448634749	CT	Patients with the CT genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the CC genotype, and decreased exposure compared to patients with the TT genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.
981238439	AC	Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
981238440	CC	Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
1448634069	TT	The TT genotype may be associated with increased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634073	CC	The CC genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
981237872	AA	Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.
981237873	AG	Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1449564668	AA	The AA genotype in women with breast cancer who are treated with tamoxifen (with or without anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy) may have INCREASED treatment EFFICACY in PRE-MENOPAUSAL women AND DECREASED treatment EFFICACY in POST-MENOPAUSAL women as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen and other treatment regimens in pre- and post-menopausal women with breast cancer.
1449564669	AC	The AC genotype in women with breast cancer who are treated with tamoxifen (with or without anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy) may have DECREASED treatment EFFICACY in PRE-MENOPAUSAL women and INCREASED treatment EFFICACY in POST-MENOPAUSAL women as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen and other treatment regimens in pre- and post-menopausal women with breast cancer.
982032258	AA	Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1448634074	CT	The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634075	TT	The TT genotype may be associated with increased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1183848121	CT	Patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
1183848123	TT	Patients with the TT genotype were not part of the study. But patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
1183848122	CC	Patients with the CC genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have an increased response to eculizumab as compared with patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
1184233164	CC	Patients with the CC genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1184233163	CT	Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1444700119	*22	Patients with the CYP2C19*22 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*22 allele was catalytic inactive toward clopidogrel during in-vitro characterization. 8% of *1 activity for the substrate clopidogrel were reported.Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1184233162	TT	Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1444700120	*23	Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*23 allele was found to have a decreased clearance of clopidogrel as compared to *1 during in-vitro characterization. 66% of the clearance ratio of *1 for clopidogrel were reported.Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1184989932	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with escitalopram may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and escitalopram response. Other genetic and clinical factors may also influence a patient's response to escitalopram. Please note, study population is Asian.
1448640329	*1/*1	Patients with the *1/*1 genotype and cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to those with the *1/*3B or *1/*3C genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.
1448640330	*1/*3B	Patients with the *1/*3B genotype and cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to those with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.
1448640331	*1/*3C	Patients with the *1/*3C genotype and cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to those with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.
1449565098	AA	Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased response and a decreased risk of adverse drug events as compared to patients with the AG or GG genotype. However, contradictory evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence a patient's response and risk of adverse drug events when treated with methotrexate.
1448820586	CC	Patients undergoing liver transplantation with the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.
981239533	AA	Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.
981239534	AC	Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.
981239535	CC	Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.
1449565099	AG	Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, and an increased response as compared to patients with the AA genotype. However, contradictory evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence a patient's response and risk of adverse drug events when treated with methotrexate.
1449577065	AA	Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448820587	CT	Patients undergoing liver transplantation with the CT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.
1448820588	TT	Patients undergoing liver transplantation with the TT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.
1449565093	AA	Pediatric ALL patients with AA genotypes may have  decreased likelihood of methotrexate induced toxicity (oral mucositis), decreased response and decreased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the GG and AG genotype. Other genetic and clinical factors may also influence response to methotrexate.
1449565094	AG	Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery, increased response and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.
1449565095	GG	Pediatric ALL patients with GG genotypes may have  increased likelihood of methotrexate induced toxicity (oral mucositis), increased response, and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.
981238502	AA	Patients with the AA genotype and with Epilepsy who are treated with phenytoin may have an increased metabolism, decreased plasma free phenytoin concentration, and decreased, but not absent, risk of Drug Toxicity as compared to patients with the AC and CC genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981238503	AC	Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981238504	CC	Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981237696	AA	Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
981237697	AT	Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
981204550	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. The opposite association is found for females in some studies where female patients carrying the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased reduction in blood pressure as compared to female patients with the del/del   genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981204551	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981204552	del/del	Patients with the del/del genotype and essential hypertension who are treated with hydrochlorothiazide may have an increased reduction in blood pressure as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. The opposite association is found for females in some studies where female patients carrying the del/del genotype may have a decreased reduction in blood pressure as compared to female patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC  genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981237931	AA	Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result
981237932	AG	Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.
981237933	GG	Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.
1184747082	*2/*10	Patients with the CYP2D6*2/*10 genotype may have an increased risk for agitation and insomnia when treated with methylphenidate. However, no differences in the pharmacokinetics of methylphenidate with and without quinidine administration are reported in patients with two functional vs one or two non-functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
655387746	CC	Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
1448099388	TGCGC/TGCGC	Patients with nasopharyngeal cancer and the TGCGC/TGCGC diplotype may have decreased concentrations of docetaxel as compared to patients with the TATTT/TATTT or TGCGC/TATTT diplotypes. Other clinical and genetic factors may also influence concentrations of docetaxel.
655387747	CT	Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
655387748	TT	Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
981204028	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981204029	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1448100106	CT	Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1449165006	AG	Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
1445402473	AA	Patients with the AA genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the GG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone.
1448100107	TT	Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1449165007	GG	Patients with the GG genotype and Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events and toxicity as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
981419551	AA	Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981419552	AG	Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981419553	GG	Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1448100119	CC	Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100098	AA	Patients with the AA genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
982032673	AA	Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1448100099	AT	Patients with the AT genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1448100100	TT	Patients with the TT genotype may have an increased likelihood of developing an addiction to methamphetamines as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1448100105	CC	Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448427007	AA	Patients with the AA genotype and non-small cell lung cancer may have an increased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
1448427008	AG	Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
1448427009	GG	Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
1449191692	CC	Patients with the CC genotype (do not have a copy of the CFTR S977F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1447945889	AA	Patients with the AA genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.
1447945890	AC	Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.
1449191693	CT	Patients with the CT genotype (one copy of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1447945891	CC	Patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with infliximab as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.
1449191694	TT	Patients with the TT genotype (two copies of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449270885	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270886	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1448100120	CT	Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
982030522	CC	Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)
982030523	CT	Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.
1447945950	AA	Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.
1447945951	AG	Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.
1447945952	GG	Patients with the GG genotype and renal cell carcinoma may have an increased risk for adverse effects when treated with sunitinib as compared to patients with the AA or AG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.
1448100121	TT	Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1449270887	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1444667463	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1183556310	AA	Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
982030524	TT	Patients with the TT genotype may be less likely to respond to antidepressant treatments as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.
1450044639	CC	Patients with the CC genotype  may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype.  Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1444667464	AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
981478134	CC	Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981478133	CT	Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981478132	TT	Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981501184	TT	Patients with the TT genotype and erectile dysfunction who are treated with sildenafil may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
982045148	AG	Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045149	GG	Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
981501183	CT	Patients with the CT genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
1450044640	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype.  Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1444667465	GG	Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
982045147	AA	Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1444667580	AA	Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667581	AC	Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1183693529	GT	Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183693528	TT	Female patients with the TT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444667582	CC	Patients with asthma and the CC genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1445401441	AA	Patients with the AA genotype and epilepsy may have decreased dose-adjusted trough concentrations of phenytoin as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
1445401442	AT	Patients with the AT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
1445401443	TT	Patients with the TT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
1183693530	GG	Female patients with the GG genotype may have decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1448103820	GG	Patients with the GG genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
1448103821	GT	Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
1448103822	TT	Patients with the TT genotype and hypertension may have a decreased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
1183700539	GG	Patients with the GG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.
1448103862	CC	Patients with the CC genotype who are stopping methadone treatment may have less of an increase in pulse rate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
1448103863	CT	Patients with the CT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
1445402088	CG	Patients with the CG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402089	GG	Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to clozapine.
981204436	AA	Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.
1183700537	AA	Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.
1183700538	AG	Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.
1445402203	CC	Patients with the CC genotype and psychotic illnesses may be at a lower risk for haloperidol-induced toxicities as compared to patients with the CT genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
981204435	AG	Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.
981204434	GG	Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.
1445402204	CT	Patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
1445402205	TT	No patients with the TT genotype were present, but patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
1447953258	AA	Patients with the AA genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the AG or GG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.
1447953259	AG	Patients with the AG genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the GG genotype and may have reduced clearance of efavirenz as compared to patients with the AA genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.
982032452	GT	Patients with the GT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032453	TT	Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032480	AA	Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1447953260	GG	Patients with the GG genotype and HIV infection who are treated with efavirenz may have reduced clearance of efavirenz as compared to patients with the AG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.
1447953265	CC	Patients with the CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's severity of sleep disorders when treated with methadone.
1447953266	CG	Patients with the CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's severity of sleep disorders when treated with methadone.
981419541	AA	Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.
981419542	AG	Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.
981419543	GG	Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.
1183556312	GG	Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
982047854	AA	Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.
981204027	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
982032451	GG	Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1183556311	AG	Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
982047855	AC	Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.
982047856	CC	Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.
1445594345	CC	Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594346	CT	Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
981237960	GG	Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.
981237961	GT	Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.
981237962	TT	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or  fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.
1183614548	AA	Patients with the AA genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.
1183614549	AG	Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.
1445594347	TT	Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594354	AA	Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594355	AG	Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1183614550	GG	Patients with the GG genotype may have better pain relief to opioids in cancer patients as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to opioids.
1445594356	GG	Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594361	AA	Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594362	AG	Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594363	GG	Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445624607	CC	Patients with the CC genotype may have a decreased response to metformin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to metformin.
1449155623	CC	Patients with the CC genotype and inflammatory bowel disease or psoriasis, may have a better response to anti-TNF therapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1449155627	AA	Patients with the AA genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ustekinumab response.
1448100203	CC	Patients with the CC genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100204	CT	Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100205	TT	Patients with the TT genotype may be at increased risk for nicotine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1449155639	CC	Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
981204091	AA	Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.
981204092	AG	Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.
981204093	GG	Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.
1448100210	AA	Patients with the AA genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100112	AA	Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.
981204373	AA	Patients with AA  genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG  genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.
981204374	AG	Patients with AG  genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG  genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.
981204375	GG	Patients with GG  genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.
1448100196	GG	Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GT and TT genotypes. Other factors may affect response to antidepressants.
1183697571	AA	Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1448100197	GT	Patients with the GT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100198	TT	Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG and GT genotypes. Other factors may affect response to antidepressants.
1449155628	AG	Patients with the AG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155629	GG	Patients with the GG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155633	AA	Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155634	AG	Patients with the AG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155635	GG	Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
981204458	AA	Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.
981204457	AG	Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.
981204456	GG	Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.
1444672834	AA	Patients with the AA genotype and acid-related disorders with Helicobacter pylori (H. pylori) infections may have a higher chance of eradication when treated with omeprazole or pantoprazole as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence H. pylori infection eradication.
1444672835	AG	Patients with the AG genotype and acid-related disorders with Helicobacter pylori (H. pylori) infections may have a lower chance of eradication when treated with omeprazole or pantoprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence H. pylori infection eradication.
1183697624	CC	Patients with the CC genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.
1183697572	AG	Women with the AG genotype and breast cancer may have an increased chance of disease recurrence when treated with tamoxifen as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1183697573	GG	Women with the GG genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1444672836	GG	Patients with the GG genotype and acid-related disorders with Helicobacter pylori (H. pylori) infections may have a lower chance of eradication when treated with omeprazole or pantoprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence H. pylori infection eradication.
981203579	CC	Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
981203580	CT	Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
981203581	TT	Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
981204081	CC	Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
981204082	CT	Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
981204083	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
981204309	AA	Patients with genotype AA may have decreased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype GG. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin.
1183697625	CT	Patients with the CT genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.
981204308	AG	Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin.
981204307	GG	Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patient's response to phenytoin.
982009417	AG	Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.
982009418	GG	Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.
1183703653	AG	Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
982032660	GG	Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032674	AG	Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1183697626	TT	Patients with the TT genotype and macular degeneration may have greater increases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the CC or CT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.
1183697630	CT	Pregnant women with the CT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
1183697631	TT	Pregnant women with the TT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
1183697634	AA	Patients with the AA genotype and asthma may have a poorer response when treated with methacholine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methacholine.
1449752580	TT	Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.
1449752588	CC	Patients with the CC genotype and cancer who are treated with platinum-based chemotherapy may have shorter survival times as compared to patients with the CT or TT genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1449752589	CT	Patients with the CT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1449752590	TT	Patients with the TT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1183703654	GG	Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.
981501182	CC	Patients with the CC genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
1183697629	CC	Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
982032659	AG	Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1183703652	AA	Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
981203887	CC	Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.
981203888	CT	Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.
981203889	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.
1184468881	TT	Patients with the T/T genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.
1184468882	del/del	Patients with the del/del genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the T/del or TT genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.
1445624608	CG	Patients with the CG genotype may have a decreased response to metformin as compared to patients with the GG genotype and an increased response to metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to metformin.
1445624609	GG	Patients with the GG genotype may have a decreased response to metformin as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to metformin.
1445722594	CC	Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.
1445722595	CT	Patients with the CT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.
981203603	ATTTGTTCATGCCT/ATTTGTTCATGCCT	Patients with the ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981203604	ATTTGTTCATGCCT/del	Patients with the ATTTGTTCATGCCT/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981203605	del/del	Patients with the del/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a better response as compared to patients with the ATTTGTTCATGCCT/del and ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1445722596	TT	Patients with the TT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.
1184468880	T/del	Patients with the T/del genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.
981238058	AA	Patients with the  AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
981238059	AC	Patients with the  AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
981238060	CC	Patients with the  CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
981204469	AA	Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.
981204468	AG	Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.
981204467	GG	Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.
981238042	AA	Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.
981238043	AC	Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.
981238044	CC	Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.
1447963988	GG	Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.
1448100211	AG	Patients with the AG genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype, or decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100212	GG	Patients with the GG genotype may be at decreased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1449155609	CC	Patients with the CC genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155610	CT	Patients with the CT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155611	TT	Patients with the TT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.
981202791	GG	Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.
981202792	GT	Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.
981202793	TT	Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.
1449155621	AA	Patients with the AA genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1449155622	AC	Patients with the AC genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448428032	AA	Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.
1448100224	CC	Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1444706014	AA	Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.
1444706015	AG	Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.
1444706016	GG	Patients with genotype GG may have decreased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.
1448263849	CC	Patients with the CC genotype may have increased clearance of docetaxel and an increased risk of infusion-related reaction as compared to patients with the TT genotype. These patients may experience an increased risk of neurotoxicity with docetaxel treatment, though reports conflict.  Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.
1448263850	CT	Patients with the CT genotype may have increased clearance of docetaxel as compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Patients with the CT genotype may have an increased risk of an infusion-related reaction as compared to patients with the TT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.
1448263851	TT	Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.
1447959512	GG	Patients with the GG genotype and acute lymphoblastic leukemia (ALL) may have an increased risk for hepatotoxicity when treated with asparaginase as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1448100225	CT	Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1447959510	AA	Patients with the AA genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1448428033	AG	Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.
1448428034	GG	Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.
1447959511	AG	Patients with the AG genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1447959735	CC	Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448428928	CC	Patients with the CC genotype and gout may be more likely to require 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428929	CT	Patients with the CT genotype and gout may be more likely to require 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448100226	TT	Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448100244	AA	Patients with the AA genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence pravastatin response.
1448100245	AG	Patients with the AG genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.
1448428930	TT	Patients with the TT genotype and gout may be more likely to require a dose other than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
981204318	AA	Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.
981204319	AG	Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.
981204320	GG	Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.
1183680573	CC	Patients with the CC genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
1183680572	CT	Patients with the CT genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
1183680571	TT	Patients with the TT genotype may have increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
981203710	CC	Patients with the CC genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
981203711	CT	Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
981203712	TT	Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
981204108	CC	Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.
981204109	CG	Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.
981204110	GG	Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.
981204138	AA	Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981204139	AC	Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981204140	CC	Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1183616416	*1/*2	Children with the *1/*2 genotype scheduled to undergo adenotonsillectomy may have increased clearance of morphine as compared to children with the *2/*2, *2/*3, *2/*4, *2/*5 or *4/*4 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1183616417	*1/*3	Children with the *1/*3 genotype scheduled to undergo adenotonsillectomy may have increased clearance of morphine as compared to children with the *2/*2, *2/*3, *2/*4, *2/*5 or *4/*4 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1444700406	AA	Patients with the AA genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
981203519	CC	Individuals with the CC genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.
981203520	CT	Individuals with the CT genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.
981203521	TT	Individuals with the TT genotype 1) may be more sensitive to caffeine and more likely to experience anxiety 2) may consume less caffeine as compared to individuals with the CC genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.
1444700407	AG	Patients with the AG genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype or a decreased risk for nicotine dependency and decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1183616415	*1/*1	Children with the *1/*1 genotype scheduled to undergo adenotonsillectomy may have increased clearance of morphine as compared to children with the *2/*2, *2/*3, *2/*4, *2/*5 or *4/*4 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
981203546	AA	Patients with the AA genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.
981203547	AG	Patients with the AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.
981203548	GG	Patients with the GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.
981203642	GG	Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
981203643	GT	Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
981203644	TT	Patients with the TT genotype and Epilepsy who are treated with valproic acid may require a lower dose as compared to patients with the GG and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
1447521370	*38:02:01	Patients with Graves disease who carry one or two copies of the HLA-B*38:02:01 allele have an increased risk of agranulocytosis when receiving a thioamide (carbimazole, methimazole or propylthiouracil) as compared to patients with no HLA-B*38:02:01 alleles or negative for the HLA-B*38:02:01 test. There is some limited evidence suggesting that this association may not be significant in patients taking propylthiouracil. Other genetic and clinical factors may also influence a patient's risk of thioamide-induced agranulocytosis.
1444700408	GG	Patients with the GG genotype may have an decreased risk for nicotine dependency, increased lung function when exposed to nicotine, but may experience decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1447990875	AA	Women with the AA genotype and breast cancer who are treated with antineoplastic agents may be associated with improved survival as compared to women with the AG and GG genotypes. Other clinical and genetic factors may also influence survival rates in women with breast cancer.
1447990876	AG	Women with the AG genotype and breast cancer who are treated with antineoplastic agents may be associated improved survival as compared to women with the GG genotypes and worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.
1447990877	GG	Women with the GG genotype and breast cancer who are treated with antineoplastic agents may be associated with worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.
1447990904	AA	Patients with hypertension and the AA genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.
1444700490	CC	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700483	CC	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1447961414	CT	Patients with the CT genotype and epilepsy may be less likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs.
1184986987	AA	Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986988	AG	Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986989	GG	Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1444700484	CT	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1183616533	GG	Patients with the GG genotype may have an increased metabolism of clomipramine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1447961415	TT	Patients with the TT genotype and epilepsy may be more likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs.
1447962622	CC	Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence changes in bone mineral density.
1183960811	A-202A_376G/A-202A_376G	Female patients with the A-202A_376G/ A-202A_376G diplotype (homozygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.
1444700485	TT	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700492	AA	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700491	AC	Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1447961309	AA	White patients with the AA genotype and hypertension who are treated with hydrochlorothiazide  may have poorer response as compared with patients with genotype GG.  The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.
1447961310	AG	White patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have better response  as compared with patients with genotype AA.  The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.
1447961311	GG	White patients with the GG genotype and hypertension who are treated with hydrochlorothiazide  may have better response as compared with patients with genotype AA.    The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.
1447961413	CC	Patients with the CC genotype and epilepsy may be less likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs.
1448602869	AA	Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602868	AG	Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1183960812	A-202A_376G/B (wildtype)	Female patients with the A-202A_376G/ B diplotype (heterozygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.
1183960810	A-202A_376G	Male patients with the A-202A_376G haplotype (hemizygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.
1043737605	CT	No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.
1043737606	TT	Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.
1043737608	GG	Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
982030740	CC	Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.
982030741	CT	Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.
982030742	TT	Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.
1043737609	GT	No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
1043737610	TT	Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
1449165240	CC	Patients with the CC genotype who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotypes, however the opposite is reported in one study, and no association was reported in two studies.  Other clinical and genetic factors may also influence bioavailability of metformin.
1449165241	CT	Patients with the CT genotype and  who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotype, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.
1448602867	GG	Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1449165242	TT	Patients with the TT genotype who are treated with metformin may have decreased bioavailability of metformin as compared to patients with the CC or CT genotypes, however the opposite is reported in one study, and no association was reported in two studies . Other clinical and genetic factors may also influence bioavailability of metformin.
1446908994	CC	Patients with the CC genotype who are treated with clopidogrel may have higher on-treatment ADP-induced platelet aggregation and lower levels of clopidogrel active metabolite as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1450377222	AA	Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377223	AG	Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377224	GG	Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1449750382	AG	Patients with the AG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1449750383	GG	Patients with the GG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447947103	CC	Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447947104	CT	Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447947105	TT	Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447673034	AA	Patients with the AA genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.
1449750540	CC	Patients with the CC (POR *1/*1) genotype and Kidney Transplantation who are treated with tacrolimus 1) may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation, 2) in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3  (rs776746) may require a decreased dose of tacrolimus as compared to patients with the CT and TT (*1/*28 and *28/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1449750541	CT	Patients with the CT (POR *1/*28) genotype and Kidney Transplantation who are treated with tacrolimus 1) may have an increased risk for developing new-onset diabetes after transplantation, 2) in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3  (rs776746) may require an increased dose of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
981345286	CC	Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.
1447673035	AG	Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.
981345287	CT	Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.
981345288	TT	Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.
981238111	AA	Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.
981238110	AC	Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.
981238109	CC	Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.
981204976	AA	Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.
981204977	AG	Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.
1447673036	GG	Patients with the GG genotype may have increased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype AG or AA. Other genetic and clinical factors may also influence the response to warfarin.
1447947085	AA	Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
981204978	GG	Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.
1183630623	GG	Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.
1183630624	GT	Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.
1183630625	TT	Patients with the TT genotype and hypertension may have greater decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence change in systolic and diastolic blood pressure.
1449752573	AA	Patients with the AA genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.
1449752574	AG	Patients with the AG genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.
1449752575	GG	Patients with the GG genotype and non-small-cell lung cancer may be less likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the AA or AG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.
1444608135	CG	Patients with the CG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.
1444608136	GG	Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.
1444608141	*06:02:01:01	Patients with one or two copies of the HLA-C*06:02 allele and psoriasis may have a better response to treatment with ustekinumab as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02 test. Other genetic and clinical factors may also influence a patient's response to treatment with ustekinumab.
1183630627	CC	Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
1183630628	CT	Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
1183630629	TT	Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
1449752578	GG	Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.
1449752579	GT	Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.
1448107918	AA	Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
982045115	GG	Patients with an activating somatic EGFR mutation are presented in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time and increased response rate (RR) when treated with gefitinib vs paclitaxel plus carboplatin. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1444608134	CC	Patients with the CC genotype and choroidal neovascularization may have a poorer response to anti-VEGF treatment, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.
1449752565	TT	Patients with cancer and the TT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1450044472	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1184472678	*15	Patients with the CYP2A6 *15 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with CYP2A6*1A allele. Other genetic and clinical factors may affect enzyme activity of CYP2A6.
1450371711	CC	Patients with the CC genotype and rheumatoid arthritis or neuromyelitis optica may have a better response to rituximab, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence response to rituximab.
1450371845	*3A/*6	Patients with HIV and the CYP3A5 *3/*6 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1183700256	AA	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700255	AG	Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1184472677	*1A	Patients with the CYP2A6 *1A genotype may have increased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with the CYP2A6*15, *21, *22 alleles. Other genetic and clinical factors may affect enzyme activity of CYP2A6.
1184472679	*21	Patients with the CYP2A6 *21 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with CYP2A6*1A allele. Other genetic and clinical factors may affect enzyme activity of CYP2A6.
1450044473	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044474	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
981481601	AA	Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
981481602	AG	Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
981481603	GG	Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1450044575	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the  TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450371710	AC	Patients with the AC genotype and rheumatoid arthritis or neuromyelitis optica may have a decreased response to rituximab, as compared to patients with the CC genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.
1446908546	AG	Patients with the AG genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
1446908545	GG	Patients with the GG genotype and Tobacco Use Disorder who are treated with varenicline may have a decreased response to varenicline as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
1000539615	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  calcein compared to cells with other genotypes.
1000539616	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  calcein compared to cells with other genotypes.
1000539622	CC	Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.
1000539623	CT	Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
1000539624	TT	Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
1000539614	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport  calcein compared to cells with other genotypes.
1000539646	CC	Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.
1000539647	CT	Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.
1000539648	TT	Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.
1000539652	AA	Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
1446908547	AA	Patients with the AA genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
1446908570	AA	Patients with the AA genotype and pain who are receiving Opium alkaloids and derivatives may have an increased severity of Substance-Related Disorders as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
982030766	GG	Patients with genotype GG may have decreased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patient's chance of response.
1183630092	non-null/ non-null	Patients with the non-null/ non-null genotype (has two copies of the GSTM1 gene) and AIDs who are treated with sulfamethoxazole and trimethoprim may have a reduced, but not absent risk, of cutaneous reactions as compared to patients with the null/null genotype combined with a NAT2 slow acetylator genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.
1446908571	AG	Patients with the AG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
982030767	TG	Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's chance of response.
982030768	TT	Patients with genotype TT may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG.  Other genetic and clinical factors may also influence a patient's chance of response.
1449190341	CC	Patients with the CC genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.
1449190342	CT	Patients with the CT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.
1449190343	TT	Patients with the TT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.
1446908572	GG	Patients with the GG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
1449190332	CC	Patients with the CC genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.
1449190333	CT	Patients with the CT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.
1449190334	TT	Patients with the TT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.
1446909049	AA	Patients with the AA genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909050	AG	Patients with the AG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909051	GG	Patients with the GG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909055	AA	Patients with the AA genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
1183630093	non-null/null	Patients with the non-null/ null genotype (has one copy of the GSTM1 gene) and AIDs who are treated with sulfamethoxazole and trimethoprim may have a reduced, but not absent risk, of cutaneous reactions as compared to patients with the null/null genotype combined with a NAT2 slow acetylator genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.
1183630094	null/null	Patients with the null/null genotype (has no copies of the GSTM1 gene) combined with a NAT2 slow acetylator genotype and AIDs who are treated with sulfamethoxazole and trimethoprim may have an increased risk of cutaneous reactions as compared to patients with the non-null/null or non-null/non-null genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.
982030420	AA	Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
982030421	AT	Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
982030422	TT	Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT  genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
982030982	GT	No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
982030983	TT	Patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
982031027	AA	Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.
982031028	AG	Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.
982031029	GG	Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.
982033861	AA	Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.
982033862	AG	Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.
982033863	GG	Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.
1446909056	AG	Patients with the AG genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
1446909045	TT	Patients with the TT genotype may have 1) decreased exposure to clopidogrel active metabolite and 2) an increased risk of poor responder status as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
982031316	CC	Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982031317	CT	Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982031318	TT	Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1184996983	*13:02:01	Patients with one or two copies of the HLA-B*13:02:01 allele may have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*13:02:01 alleles or negative for the HLA-B*13:02:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1446909057	GG	Patients with the GG genotype may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
1446909061	AA	Patients with the AA genotype may have a decreased, but not absent, risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1446909062	AG	Patients with the AG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1184996978	*13:01:01	Patients with one or two copies of the HLA-B*13:01:01 allele may have an increased risk of hypersensitivity dermatitis when exposed to trichloroethylene as compared to patients with no HLA-B*13:01:01 alleles or negative for the HLA-B*13:01:01 test. Other genetic and clinical factors may also influence a patient's risk of trichloroethylene-induced adverse reactions.
1446909063	GG	Patients with the GG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
982029688	AA	Men with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.
982029689	AC	Men with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.
982029690	CC	Men with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.
982030643	CC	Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.
982030644	CT	Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.
982030645	TT	Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype.  Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.
1183703116	AA	Patients with the AA genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the del/A or del/del genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1183703117	del/del	Patients with del/del genotype may require significantly lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1183703153	CC	Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1183703154	CT	Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1183703155	TT	Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
982031796	AA	Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
982031797	AG	Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
982031798	GG	Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
982032340	CC	Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.
982032341	CT	Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.
982032342	TT	Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1183703115	A/del	Patients with A/del genotype may require a lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444608493	AA	Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
982031410	CC	Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031409	CT	Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031408	TT	Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1043858889	CT	Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1043858888	TT	Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1043858897	AA	Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
982032355	GG	Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032373	CT	Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.
982032374	TT	Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.
1444608494	AG	Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1446905263	AA	Patients with the AA genotype who are treated with statins may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
1446905264	AT	Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
1446905265	TT	Patients with the TT genotype are too infrequent to have been assessed for this response.
982032405	CC	Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
982032406	CT	Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
982032407	TT	Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
982032496	AA	Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032497	AC	Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1043858890	CC	Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1448102904	CC	Patients with the CC genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
1448102905	CG	Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
1448102906	GG	Patients with the GG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
982030894	CC	Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030895	CT	Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030896	TT	Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030908	CC	Patients with the CC genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030909	CT	Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030910	TT	Patients with the TT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1448102910	GG	Patients with the GG genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.
1449564398	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have increased metabolism of, and decreased response to, lansoprazole as compared to patients with the *1/*2, *1/*3, *2/*2 or *2/*3 or *3/*3 genotype, and decreased metabolism compared to those with the *17/*17 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: ultrarapid metabolizers = *17/*17, homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2 + *2/*3 + *3/*3. One study was conducted in children. One study found no significant association between CYP2C19 genotypes and metabolism. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1449564399	*1/*2	Patients with the CYP2C19 *1/*2 genotype may have increased metabolism of, and decreased response to, lansoprazole as compared to patients with the *2/*2 or *2/*3 or *3/*3 genotype and decreased metabolism/increased response as compared to patients with the *1/*1 genotype or who are carriers of the *17 allele. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: ultrarapid metabolizers = *17/*17, homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2 + *2/*3 or *3/*3. One study was conducted in children. One study found no significant association between CYP2C19 genotypes and metabolism. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1449155821	*35:05:01	Patients with one or two copies of the HLA-B*35:05:01 allele have an increased risk of skin rash when treated with nevirapine as compared to patients with no HLA-B*35:05:01 alleles or negative for the HLA-B*35:05:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.
1449156915	GG	Individuals with HIV and the GG genotype may have a decreased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome) when treated with nevirapine as compared to patients with the GT or TT genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274  that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.
982030868	AA	Patients with the AA genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030869	AG	Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030870	GG	Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1449156916	GT	Individuals with HIV and the GT genotype may have a decreased risk of SJS/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the TT genotype and an increased risk as compared to patients with the GG genotype, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274  that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.
1449156917	TT	Individuals with HIV and the TT genotype may have an increased risk of SJS/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the GT or GG genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274  that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.
1444842157	*1/*1	Healthy individuals with the *1/*1 genotype may not have decreased concentrations of carisoprodol as compared to those with the *1/*2 genotype. Other genetic and clinical factors may also influence pharmacokinetics of carisoprodol in an individual.
1444842156	*1/*2	Healthy individuals with the *1/*2 genotype may have increased concentrations of carisoprodol as compared to those with the *1/*1 genotype. Other genetic and clinical factors may also influence pharmacokinetics of carisoprodol in an individual.
1449155640	CG	Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
982031643	CCT/CCT	Patients with the CCT/CCT genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the del/del or del/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.
982031644	CCT/del	Patients with the CCT/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.
982031645	del/del	Patients with the del/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.
982031884	AA	Patients with the AA genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.
982031885	AG	Patients with the AG genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.
982031886	GG	Patients with the GG genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.
982032307	CC	Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032308	CT	Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032309	TT	Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032323	CC	Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982030874	CC	Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030875	CT	Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030876	TT	Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1043737392	AC	Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1043737393	CC	Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
982030495	TT	Patients with the TT genotype who are treated with venlafaxine may have 1)  increased venlafaxine plasma concentration 2) an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982031324	AA	Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031325	AG	Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031326	GG	Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032372	CC	Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.
1043737391	AA	Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.
982031455	CC	Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
982031456	CT	Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
982031457	TT	Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
982031724	CC	Patients with the CC genotype may have an increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
982031725	CT	Patients with the CT genotype may have an increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
982031726	TT	Patients with the TT genotype may have a decreased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
982032324	TC	Patients with the TC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032325	TT	Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1043737604	CC	Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.
1446909067	AA	Patients with the AA genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.
1446909068	AG	Patients with the AG genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.
1446909069	GG	Patients with the GG genotype may have 1) decreased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) increased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.
982030922	CC	Female patients with the CC genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030923	CT	Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030924	TT	Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030672	AA	Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030673	AC	Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030674	CC	Patients with the CC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1183630267	AA	Patients with the AA genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.
1183630268	AG	Patients with the AG genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.
1183630269	GG	Patients with the GG genotype and breast cancer who are treated with gemcitabine may have an increased risk of side effects including neutropenia as compared to patients with the AA or AG genotype combined with the G allele at rs9937. This association was not seen in a seperate study in patients with pancreatic cancer.Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.
982030502	A/del	Patients with the A/del genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.
982030503	AA	Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.
982030504	del/del	Patients with the del/del genotype who are treated with metoprolol may have an greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure as compared to patients with the A/del or A/A genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.
982033475	AA	Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
982033476	AG	Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
982030901	CC	Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030902	CT	Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030903	TT	Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1444700159	*9	Patients with the CYP2C19*9 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*9 allele was found to have a decreased clearance of mephenytoin and decreased activity of CYP2C19 as compared to *1 during several in-vitro characterizations. The CYP2C19*9 allele was catalytic inactive toward mephenytoin during one in-vitro characterization. 6% of *1 activity for the substrate mephenytoin were reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700181	*1	Patients with two functional CYP2C19 (*1/*1) alleles may have increased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*9, *10, *16, or *29 allele when assayed with omeprazole. Other genetic and clinical factors may also influence the metabolism of omeprazole.
982030629	CC	Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
982030581	AA	Patients with the AA genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
982030582	AG	Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
982030583	GG	Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
1444700182	*10	Patients with the CYP2C19*10 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. The CYP2C19*10 allele was found to have a decreased clearance of omeprazole and decreased catalytic activity of CYP2C19 as compared to *1 during in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of omeprazole.
982030630	CT	Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
982030631	TT	Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
982032640	AC	Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032641	CC	Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032658	AA	Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982030587	CC	Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982030588	CT	Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982030589	TT	Patients with the TT genotype may have decreased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982030981	GG	Patients with the GG genotype may have more inhibition of platelet aggregation with crangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
982032639	AA	Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1444700183	*11 + *13 +*14 +*15 +*18	Patients with the CYP2C19*11, *13, *14, *15, or *18 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. No significant differences in activity towards omeprazole or clearance of omeprazole were found during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of omeprazole.
982032568	AA	Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032569	AG	Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032570	GG	Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982037066	TGGCGCGTCCCGCCCAGGT/del	Adult patients with the TGGCGCGTCCCGCCCAGGT/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for hepatic toxicity as compared to patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or del/del genotype. Pediatric patients with the TGGCGCGTCCCGCCCAGGT/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or del/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
982037067	del/del	Adult patients with the del/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for hepatic toxicity as compared to patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or TGGCGCGTCCCGCCCAGGT/del genotype. Pediatric patients with the del/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or TGGCGCGTCCCGCCCAGGT/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
982032759	AA	Patients with the AA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.
982032758	GA	Patients with the GA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.
982032757	GG	Patients with the GG genotype and Bipolar Disorder may have an increased risk for sleep disturbances when treated with lithium as compared to patients with the AA genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.
1449577066	AG	Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1449577067	GG	Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1449577070	AA	Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors may also influence a patient's response.
1449577071	AG	Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors may also influence a patient's response.
1449577072	GG	Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors may also influence a patient's response.
982037065	TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT	Pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/del or del/del genotype. Adult patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for hepatic toxicity as compared to adult patients with the TGGCGCGTCCCGCCCAGGT/del or del/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
1449576985	AA	Patients with the AA genotype may have worse response and shorter progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with GG or AG genotype.
1449576986	AG	Patients with the AG genotype may have better response and longer progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype.
1449576987	GG	Patients with the AA genotype may have better response and longer progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype.
982032695	AA	Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032696	AC	Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032697	CC	Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982035725	GT	Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
982035726	TT	Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
982029203	CC	Patients with the CC genotype may have increased plasma concentrations; of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.
982029202	CT	Patients with the CT genotype may have reduced plasma concentrations; of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.
1447679978	CC	Patients with the CC genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.
982035724	GG	Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
1043818283	AA	Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.
1043818284	AC	Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.
982036647	CC	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
982036648	CT	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
982036649	TT	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.
982037131	GG	Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.
982037129	AA	Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to AG and GG genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.
982037130	AG	Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.
982033499	CC	Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
982033500	del/del	Patients with the del/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
982034930	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with acetylcholine as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.
982034931	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may experience greater vasodilation as compared to patients with the del/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with acetylcholine. Other genetic and clinical factors may also influence a patient's response to acetylcholine.
982034932	del/del	Patients with the del/del genotype may experience less vasodilation when treated with acetylcholine as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.
1449161333	A- 202A_376G	Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with rasburicase may have an increased risk of methemoglobinemia and/or hemolysis as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449161334	A- 202A_376G/A- 202A_376G	Female patients with the A- 202A_376G/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with rasburicase may have an increased risk of methemoglobinemia and/or hemolysis as compared to patients with the wildtype B/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449161335	A- 202A_376G/B (wildtype)	Female patients with the A- 202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with rasburicase may have a varying degree of G6PD deficient red blood cells and an unknown risk of methemoglobinemia and hemolysis as compared to patients with the A- 202A_376G/A- 202A_376G or B/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
982036382	AA	Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
982036383	AG	Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
982036384	GG	Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.
982036426	CC	Patients with the CC genotype and cluster headache who are treated with triptans may be less likely to have reduced pain or attack frequency as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
982036427	CT	Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
982036428	TT	Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
1449161336	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency)  who are treated with rasburicase may have a reduced risk of methemoglobinemia and/or hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- or Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
982032513	CC	Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032514	CT	Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032515	TT	Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032737	AA	Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032736	GA	Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032735	GG	Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982033477	GG	Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
1449752768	CG	Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased response when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1449752769	GG	Patients with the GG genotype may have 1) increased risk for toxicity 2) decreased response when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1449752820	AA	Patients with the AA genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
982034817	CT	Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
982034818	TT	Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
982036349	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response.
982036350	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response.
982036351	del/del	Patients with the del/del genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. Other genetic and clinical factors may also influence a patient's response.
982034816	CC	Patients with the CC genotype and schizophrenia who are treated with olanzapine may have greater positive symptom improvement and positive symptom remission as compared to patients with the TT and CT genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
982034947	*2 (PMID: 11503014)/ *2 (PMID: 11503014)	Patients with the ABCB1 *2/*2 diplotype and colorectal cancer may have worse prognosis when treated with oxaliplatin-based chemotherapy as compared to patients with other diplotypes. Other genetic and clinical factors may also influence a patient's response to treatment.
1449752821	AG	Patients with the AG genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
982040487	AA	Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
982040488	AC	Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
1449752822	GG	Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752827	AA	Patients with the AA genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
982040489	CC	Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
982032766	GG	Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032765	GT	Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032764	TT	Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982033426	CC	Patients with the genotype CC who are treated with cytarabine may have reduced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
982033427	CT	Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
982033428	TT	Patients with the genotype TT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
1445616167	CC	Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445616168	CT	Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotypes and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445616169	TT	Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619123	GG	Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1446909037	AA	Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
982034832	AA	Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034833	AG	Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034834	GG	Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034870	AA	Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034871	AG	Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034872	GG	Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1446909043	CC	Patients with the CC genotype may have 1) increased exposure to clopidogrel active metabolite and 2) decreased, but not absent, risk of poor responder status as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909044	CT	Patients with the CT genotype may have 1) decreased exposure to clopidogrel active metabolite and 2) an increased risk of poor responder status as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909038	AG	Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909039	GG	Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448100231	CC	Patients with the CC genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pravastatin response.
982032675	GG	Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
1448100232	CT	Patients with the CT genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.
1448100233	TT	Patients with the TT genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.
1448100246	GG	Patients with the GG genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.
1449000123	CC	Patients with the CC genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased risk for drug toxicities as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity in patients receiving fluoropyrimidines.
1449000124	CT	Patients with the CT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk for drug toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity in patients receiving fluoropyrimidines.
1449000125	TT	Patients with the TT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk for drug toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity in patients receiving fluoropyrimidines.
982034920	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with nitroprusside as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.
982034921	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may experience greater vasodilation as compared to patients with the del/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with nitroprusside. Other genetic and clinical factors may also influence a patient's response to nitroprusside.
982034922	del/del	Patients with the del/del genotype may experience less vasodilation when treated with nitroprusside as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.
982033452	CC	Patients with the CC genotype and Myeloid Leukemia who are treated with cytarabine may have an increased survival time and a decreased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
982033453	CT	Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
982033454	TT	Patients with the TT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
982035269	AA	Patients with the AA genotype who are treated with nifedipine may have larger changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
1448100069	CC	Patients with the CC genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.
1448100070	CG	Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.
1448100071	GG	Patients with the GG genotype and renal cell carcinoma may have an increased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.
982035270	AG	Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
982035271	GG	Patients with the GG genotype who are treated with nifediping may have smaller changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
1449167310	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
982035393	CC	The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.
982035394	CG	While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is.
982035395	GG	The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.
1000539583	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
1446907930	GG	Patients with the GG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have increased metabolism of cyclophosphamide, leading to higher concentrations of the active metabolite and an increased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.
1446908016	TT	Patients with the TT genotype may have increased metabolism of cyclophosphamide, resulting in increased concentrations of active cyclophosphamide metabolites, and increased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.
1449167296	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1184996838	AA	Patients with the AA genotype (homozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1184996839	AG	Patients with the AG genotype (heterozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
982036239	AA	Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982036240	AG	Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982036241	GG	Patients with the GG genotype may have decreased metabolism of verapamil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
1449167311	CG	Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167312	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167313	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1184996840	GG	Patients with the GG genotype may require a lower dose of warfarin as compared to patients with the AG and AA genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449167297	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167298	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
982044831	(CA)16/(CA)16	Advanced non-small-cell lung cancer patients patients with (CA)16/(CA)16 + (CA)16/(CA)17 genotype are more likely to have better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib as compared to patients with (CA)17/(CA)17 genotype.; NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.
982044832	(CA)16/(CA)17	Advanced non-small-cell lung cancer patients patients with (CA)16/(CA)16 + (CA)16/(CA)17 genotype are more likely to have better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib as compared to patients with (CA)17/(CA)17 genotype.; NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.
982044833	(CA)17/(CA)17	Advanced non-small-cell lung cancer patients patients with (CA)17/(CA)17 genotype are more likely to have worse clinical response (decreased response rate (RR), decreased progression-free survival (PFS) and decreased survival time) when treated with gefitinib as compared to (CA)16/(CA)16 + (CA)16/(CA)17 genotype.; NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.
982044868	AA	Patients with the AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.
982044869	AG	Patients with the AG or GG genotypes may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.
982044870	GG	Patients with the AG or GG genotypes may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.
982045116	GT	Patients with an activating somatic EGFR mutation are presented in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time and increased response rate (RR) when treated with gefitinib vs paclitaxel plus carboplatin. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
982045117	TT	Patients who have no activating somatic EGFR mutation were NOT included in these studies where this annotation is derived from. In this annotation and effects of gefitinib vs vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. Genotypes are not compared in this annotation.
1444700591	AA	Patients with the AA genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
1444700592	AG	Patients with the AG genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype or may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
1000539589	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
1444700593	GG	Patients with the GG genotype and breast neoplasms may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
1444700783	AA	Patients with the AA genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.
1000539590	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
1184989933	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with escitalopram may have an increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and escitalopram response. Other genetic and clinical factors may also influence a patient's response to escitalopram. Please note, study population is Asian.
1184989934	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with escitalopram may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and escitalopram response. Other genetic and clinical factors may also influence a patient's response to escitalopram. Please note, study population is Asian.
1043858635	GG	Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1043858634	GT	Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1448107919	AG	There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.
1448107920	GG	Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
1448107979	AA	Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.
1000539591	TT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.
1000539618	CC	Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.
1000539619	CT	Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.
1000539620	TT	Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.
1043737553	AG	Patients with the AG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Statin treatments (Pravastatin or atorvastatin) substantially reduced that risk. Patients with the AG genotype may have a better statin response than patients with the AA genotype.  However, contradictory results have also been reported. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
1043737554	GG	Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Statin treatment (Pravastatin or atorvastatin)  substantially reduced that risk. Patients with the GG genotype may have a better statin response than patients with the AA genotype.  However, contradictory results have also been reported. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.
1043858633	TT	Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
982040610	AG	Patients with the AG genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.
982040611	GG	Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.
1448107980	AC	Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.
982040609	AA	Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.
1448107981	CC	Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC.  Other genetic and clinical factors may also influence a patient's response.
1043818279	CC	Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043818280	CT	Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043818281	TT	Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858653	CT	Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.
1043858652	TT	Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.
1043858659	CC	Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858645	AA	Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858644	AG	Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858643	GG	Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858647	AA	Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858648	AG	Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858649	GG	Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858654	CC	Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.
1043858658	CT	Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858657	TT	Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
982040542	CT	Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.
982040543	TT	Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.
982045140	CC	Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045139	CT	Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045138	TT	Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982040541	CC	Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449164123	GG	Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164611	AA	Patients with the AA genotype were not analyzed in this study, but patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1043858671	GG	Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858677	AG	Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858678	GG	Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858681	AA	Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1449164612	AT	Patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1043858672	GT	Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858673	TT	Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858676	AA	Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858682	AG	Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
982037560	AA	Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982037559	GA	Patients with the GA genotype may have 1) an increased risk for acute rejection after kidney transplantation and 2)  decreased incidence of lymphopenia as compared to patients with the AA genotype but the GA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982037558	GG	Patients with the GG genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the AA genotype but the GG genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
1449164124	GT	Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164613	TT	Patients with the TT genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1043880261	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the insert/del genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880262	del/del	Patients with the del/del genotype may be more likely to benefit from pravastatin treatment as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880289	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the insert/insert genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due to an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1043880210	AA	Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.
1043880211	AG	Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.
982040588	AA	Patients with AA genotype may have a decreased metabolism of citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's citalopram metabolism.
982040589	AG	Patients with AG genotype may have a decreased metabolism of citalopram as compared to patients with the GG genotype or an increased metabolism of citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's citalopram metabolism.
982040590	GG	Patients with GG genotype may have an increased metabolism of citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's citalopram metabolism.
1446909073	AA	Patients with the AA genotype and Coronary Disease who are treated with clopidogrel may have a decreased on-treatment platelet activity as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
1043880212	GG	Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.
1043880260	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the insert/insert genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880290	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the insert/del genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1043873006	CC	Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043873005	CT	Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043873004	TT	Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043873011	GG	Patients with the GG genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.
1446909074	CA	Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
1446909075	CC	Patients with the CC genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
982029201	TT	Patients with the TT genotype may have reduced plasma concentrations; of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.
1043818285	CC	Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.
1447947290	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have increased metabolism of rabeprazole as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of rabeprazole.
1043858616	CC	Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1447947291	*1/*2	Patients with the CYP2C19 *1/*2 genotype may have increased metabolism of rabeprazole as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype, and decreased metabolism as compared to patients with the *1/*1 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of rabeprazole.
1043858617	CT	Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1043858618	TT	Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
1043873010	GT	Patients with the GT genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.
1446908926	AA	Patients with the AA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) a decreased, but not absent, risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) increased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.
1450044559	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to cause MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449167100	AA	Patients with cancer and the AA genotype who are treated with capecitabine may have an increased incidence of adverse events, including hand-foot syndrome, as compared to patients with the AC or CC genotypes, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.
1449167101	AC	Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.
1450044560	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449167102	CC	Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.
1446908909	CC	Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased, but not absent, risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1446908910	CT	Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1446908911	TT	Patients with the TT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982040645	AC	Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982040646	CC	Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1449167314	GT	Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
982040644	AA	Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982040686	CC	Patients with the CC genotype who are treated with mycophenolate mofetil may have 1) no changes in mycophenolic acid exposure-related parameters and 2) a decreased, but not absent, risk of acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982040687	TC	Patients with the TC genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982040688	TT	Patients with the TT genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1183702420	CC	Patients with the CC genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.
1183702419	CT	Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.
1183702418	TT	Patients with the TT genotype may have increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.
1183702970	AA	Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
982038276	AA	Patients with the AA genotype may be less likely to respond to venlafaxine as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982038275	GA	Patients with the GA genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982038274	GG	Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982045085	CC	Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045084	TC	Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045083	TT	Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1448105740	CC	Patients with the CC genotype may have better response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
1448105741	CT	Patients with the CT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
1448105742	TT	Patients with the TT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
1448105918	CC	Patients with the CC genotype may have decreased response (decreased LDL-C reduction) to rosuvastatin as compared to patients who have genotype TT or CT. Other Genetic and clinical factors may also influence the response to rosuvastatin.
1448105919	CT	Patients with the CT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.
1448105920	TT	Patients with the TT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.
1183616500	AA	Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616501	AG	Patients with the AG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616502	GG	Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
982046387	GGGGCGGGGCCG/GGGGCGGGGCCG	Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have increased response to bucindolol as compared to patients with the GGGGCGGGGCCG/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.
982046388	GGGGCGGGGCCG/del	Patients with the GGGGCGGGGCCG/del genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.
982046389	del/del	Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.
1000539581	CC	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
1000539582	CT	Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.
1183616531	AA	Patients with the AA genotype may have a decreased metabolism of clomipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1183616532	AG	Patients with the AG genotype may have a decreased metabolism of clomipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1043858683	GG	Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858725	AA	Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858724	AC	No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858723	CC	Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1449164865	AA	Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically mean arterial pressure, as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449164866	AG	Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.
1043880786	AA	Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
1043880785	GA	Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
1043880784	GG	Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
1449165165	AA	Patients with the AA genotype may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence exists for these associations. Other genetic and clinical factors may also influence methotrexate toxicity.
1045153884	AA	Patients with the AA (CYP2C9*1/*1) genotype may have lower plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or CC (CYP2C9*3/*3) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.
1045153883	AC	Patients with the AC (CYP2C9*1/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.
1449165166	AG	Patients with the AG genotype may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence exists for these associations. Other genetic and clinical factors may also influence methotrexate toxicity.
1045153882	CC	Patients with the CC (CYP2C9*3/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.
1183619613	AA	Patients with the AA genotype who have hypertension and left ventricular hypertrophy may have a smaller decrease in left ventricular mass when treated with irbesartan as compared to patients with the GG genotype. However, no significant association has been seen between this genotype and change in diastolic or systolic pressure for patients on irbesartan. Other genetic and clinical factors may also influence a patient's response to irbesartan treatment.
1183619614	AG	Patients with the AG genotype who have hypertension and left ventricular hypertrophy may have a smaller decrease in left ventricular mass when treated with irbesartan as compared to patients with the GG genotype. However, no significant association has been seen between this genotype and change in diastolic or systolic pressure for patients on irbesartan. Other genetic and clinical factors may also influence a patient's response to irbesartan treatment.
1183619615	GG	Patients with the GG genotype who have hypertension and left ventricular hypertrophy may have a greater decrease in left ventricular mass when treated with irbesartan as compared to patients with the AA or AG genotype. However, no significant association has been seen between this genotype and change in diastolic or systolic pressure for patients on irbesartan. Other genetic and clinical factors may also influence a patient's response to irbesartan treatment.
1447964166	AA	Patients with the AA genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
1447964167	AG	Patients with the AG genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype, or decreased oxidative stress as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
1447964168	GG	Patients with the GG genotype and hypercholesterolemia may have decreased oxidative stress in response to treatment with atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
1447964252	CC	Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964253	CT	Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964254	TT	Patients with the TT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964338	GG	Patients with the GG genotype and stomach cancer may have a poorer survival outcomes when treated with fluorouracil as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival outcome.
1183619568	CC	Patients with the CC genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183619569	CT	Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183619570	TT	Patients with the TT genotype and major depressive disorder may have a reduced response when treated with paroxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1447964339	GT	Patients with the GT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1447964340	TT	Patients with the TT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1448997580	*57:01:01	Patients with one or two copies of the HLA-B*57:01:01 allele have an increased risk of hypersensitivity to abacavir as compared to patients with no HLA-B*57:01:01 alleles or negative for the HLA-B*57:01:01 test. Other genetic and clinical factors may also influence a patient's risk of abacavir-induced adverse reactions.
1449733097	*44:03:01	Patients with one or two copies of the HLA-A*44:03:01 allele who are treated with lamotrigine may have an increased risk of maculopapular exanthema as compared to patients with no HLA-A*44:03:01 alleles or negative for the HLA-A*44:03:01 test, however this is contradicted in two studies. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.
1183624423	AT	Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1183624424	TT	Patients with the TT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1449752544	GG	Genotype GG may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.
1449164759	AA	Patients with the AA genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449752545	GT	Genotype GT may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.
1447945962	TT	Patients with the TT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.
1449164760	AG	Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164754	CC	Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1184349187	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients (Asian population) with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with paroxetine may have an increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, a number of contradictory findings exist showing an increased response for the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1447945960	CC	Patients with the CC genotype who are treated with antihypertensives may have a lower risk for resistant hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.
1447945961	CT	Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.
1449164755	CG	Patients with the CG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1183684980	*5	Patients with the *5 non-functional allele in combination with another non-functional or reduced function allele who are treated with oxycodone may have 1) decreased metabolism of oxycodone, 2) decreased likelihood of response to oxycodone as compared to patients with *1/*1 genotype, who carry two functional alleles. However, conflicting data on oxycodone efficacy have been reported. Patients who are CYP2D6 poor metabolizers may need to avoid oxycodone use due to lack of efficacy and  should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to oxycodone.
1183684981	*6	Patients with the *6 non-functional allele in combination with another non-functional or reduced function allele who are treated with oxycodone may have 1) decreased metabolism of oxycodone, 2) decreased likelihood of response to oxycodone as compared to patients with *1/*1 genotype, who carry two functional alleles. However, conflicting data on oxycodone efficacy have been reported. Patients who are CYP2D6 poor metabolizers may need to avoid oxycodone use due to lack of efficacy and  should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to oxycodone.
1449164756	GG	Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164761	GG	Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449752546	TT	Genotype TT may be associated with overall survival and progression free survival  in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.
1183621980	*1/*1	Patients with the CYP2C9*1/*1, CYP2D6*1/*1 and CYP2C19*1/*1 combined diplotype may have increased metabolism of trimipramine as compared to patients with the CYP2C9*3/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1183621981	*1/*3	Patients with the CYP2C9*1/*3 diplotype may have reduced metabolism of trimipramine as compared to patients with the CYP2C9*1/*1, CYP2D6*1/*1 and CYP2C19*1/*1 combined diplotype or may have increased metabolism of trimipramine as compared to patients with the *3/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1183621982	*3/*3	Patients with the CYP2C9*3/*3 diplotype may have reduced metabolism of trimipramine as compared to patients with the CYP2C9*1/*1, CYP2D6*1/*1 and CYP2C19*1/*1 combined diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1444700554	CC	Patients with the CC genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.
1444700553	CT	Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.
1448106377	AG	Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1448106378	GG	Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1444700499	CC	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1183629477	AG	Patients with the AG genotype who are treated with quetiapine may have a decreased  likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
1183629478	GG	Patients with the GG genotype who are treated with quetiapine may have a decreased  likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
1183629485	AA	Patients with the AA genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG  genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.
1183629486	AG	Patients with the AG genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG  genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.
1183629487	GG	Patients with the GG genotype who are treated with risperidone may have an increased likelihood of adverse reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.
1448262918	CT	Patients with the CT genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262919	TT	Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC or CT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1183629476	AA	Patients with the AA genotype who are treated with quetiapine may have an increased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
1448263278	AA	Women with the AA genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine.
1448106376	AA	Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1444700552	TT	Patients with the TT genotype who are treated with phenprocoumon may require a decreased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.
1444700560	CC	Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1448262917	CC	Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1444700568	CC	Patients with the CC genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1448263279	AG	Women with the AG genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype, or a lower dose as compared to women with the AA genotype. Other genetic and clinical factors may also influence dose of phenylephrine.
1448263280	GG	Women with the GG genotype who are undergoing cesarean delivery may require a lower dose of phenylephrine as compared to women with the AA genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine.
1184749179	GG	Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749180	GT	Patients with the GT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184516189	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfadoxine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1184516190	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients heterozygous for the G6PD Mediterranean variant who are treated with sulfadoxine may have a varying degree of G6PD deficient red blood cells and an unknown rate of red blood cell survival as compared to patients with the Mediterranean/Mediterranean or B/B genotype. Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1448263287	AA	Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.
1184348724	CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1444700184	*16	Patients with the CYP2C19*16 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. The CYP2C19*16 allele was found to have a decreased activity towards omeprazole and decreased clearance of omeprazole as compared to *1 during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of omeprazole.
1444700185	*19	Patients with the CYP2C19*19 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole but the results are inclusive. The CYP2C19*19 allele was found to have an increased activity towards omeprazole and no differences in clearance of omeprazole as compared to *1 during one in-vitro characterization but no differences in activity and a decreased clearance are found in another report . Other genetic and clinical factors may also influence the metabolism of omeprazole.
1444700186	*26	Patients with the CYP2C19*26 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. The CYP2C19*26 allele was found to have a decreased activity towards omeprazole and decreased clearance of omeprazole as compared to *1 during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of omeprazole.
1444700561	CT	Patients with the CT genotype may require a lower dose of phenprocoumon as compared to patients with the CC genotype and may require an increased dose of phenprocoumon as compared to patients with the TT. Other genetic and clinical factors may also influence phenprocoumon dose.
1444700562	TT	Patients with the TT genotype may require the lowest dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1184348725	TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348727	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184749181	TT	Patients with the TT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749404	*14/*14	Patients with the *14/*14 may have enhanced lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *1A/*14 or *1A/*1A genotype. Other genetic and clinical factors may also influence response to fluvastatin.
1444667594	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444700578	CC	Patients with the CC genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700577	CT	Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1448258744	CT	Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1448258743	TT	Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1448258927	CC	Patients with the CC genotype may have increased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1043880069	GG	Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880068	GT	Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880067	TT	Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1444700576	TT	Patients with the TT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700585	AA	Patients with the AA genotype and solid tumors may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
1448258745	CC	Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.
1444700569	CT	Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700570	TT	Patients with the TT genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444667587	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667588	CT	Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667589	TT	Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444700584	GA	Patients with the AG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype or may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
1444700583	GG	Patients with the GG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
1448423684	AA	No patients with the AA genotype were available for analysis, but patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1444667287	CC	No patients with this genotype were present in the population. However, patients with the CT genotype and myotonia permanens may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
1448423685	AG	Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423686	GG	Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423691	AA	Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1183632148	CC	Patients with the CC genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1183632147	CT	Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1183618202	CC	Patients with the CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the TT genotype. Other genetic or clinical factors may influence the response to tramadol.
1183618201	CT	Patients with the CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the CC genotype. Other genetic or clinical factors may influence the response to tramadol.
1183618200	TT	Patients with the TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the CC genotype. Other genetic or clinical factors may influence the response to tramadol.
1448423692	AG	Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1183632146	TT	Patients with the TT genotype may have decreased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1183622369	AA	Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622370	AC	Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622371	CC	Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183632152	CT	Patients with the CT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632151	TT	Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
1448423693	GG	Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1444667288	CT	Patients with the CT genotype and myotonia permanens may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
1183632153	CC	Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the TT genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
1447947160	*3/*3	Patients with the CYP2C19 *3/*3 genotype may have decreased metabolism of esomeprazole (longer time taken for the blood concentration to drop to 50% of the peak plasma drug concentration and a longer mean residence time) as compared to patients with the *1/*1 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2 + *2/*3 (*2 = rs4244285; *3 = rs4986893). No significant associations have been seen for area under the concentration-time curve (AUC), apparent oral clearance (Cl/F) or peak plasma drug concentration (Cmax). Other genetic and clinical factors may also influence metabolism of esomeprazole.
1183631795	CC	Patients with the CC genotype may have increased response to citalopram or escitalopram in people with depression as compared to patients with the TT or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.
1448424088	AA	Female patients with the AA genotype and epilepsy may have a poorer response when treated with antiepileptic drugs as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antiepileptics.
1448424089	AC	Female patients with the AC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.
1448424090	CC	Female patients with the CC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.
1043859464	*1/*1	Patients with the CYP2C9*1/*1 genotype may have an increased clearance of doxepin as compared to patients with the CYP2C9*3/*3 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.
1043859463	*3/*3	Patients with the CYP2C9*3/*3 genotype may have a decreased clearance of doxepin as compared to patients with the CYP2C9*1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.
1447947146	CT	Patients with the CT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447947147	TT	Patients with the TT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447947151	CC	Patients with the CC genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1447947152	CG	Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1447947153	GG	Patients with the GG genotype may benefit more from pravastatin treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1447947167	*1/*1	Patients with two functional CYP2C19 alleles (*1/*1) may have increased metabolism of lansoprazole as compared to patients with one or two CYP2C19 loss-of-function alleles (*8,*9). Other clinical and genetic factors may also affect metabolism of lansoprazole.
1447947145	CC	Patients with the CC genotype who are treated with atorvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447947168	*8	Patients with the CYP2C19*8 allele in combination with another loss-of-function allele (*8,*9) or one functional allele (*1) may have decreased metabolism of lansoprazole as compared to patients with two functional alleles (*1/*1). Other clinical and genetic factors may also affect metabolism of lansoprazole.
1183629912	CC	Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.
1183629913	CT	Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.
1183629914	TT	Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.
1183630406	AA	Patients with the AA genotype (CYP2C19*2/*2) may have a decreased clearance of doxepin as compared to patients with the GG genotype (CYP2C19*1/*1). The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's doxepin metabolism.
1183630407	AG	Patients with the AG genotype (CYP2C19*1/*2) may have a decreased clearance of doxepin as compared to patients with the GG genotype (CYP2C19*1/*1). The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's doxepin metabolism.
1043880655	CC	Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1043880656	CT	Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1043880657	TT	Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1183491301	CC	Patients with the CC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have  higher biochemical response, optimal cytoreduction, and sensitivity to the treatment as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.
1183491300	TC	Patients with the TC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.
1183491299	TT	Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.
1184348729	TT	Patients with the TT genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1449713651	AA	Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713652	AC	Patients with the AC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713653	CC	Patients with the CC genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1183629494	AA	Patients with the AA genotype who are treated with risperidone may have an increased likelihood of cardiovascular adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.
1183629495	AG	Patients with the AG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.
1183629496	GG	Patients with the GG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.
1444668484	CC	Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.
1183622324	CC	Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622323	CT	Patients with the CT genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1184348728	CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1043873000	CC	Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043873001	CT	Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043872999	TT	Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043880670	CC	Patients with the CC genotype may have increased Euphoric and Energetic after amphetamine exposure as compared to patients with the CT or TT genotype.
1043880671	CT	Patients with the CT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.
1043880672	TT	Patients with the TT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.
1449564355	*1/*1	Individuals with the CYP2B6 *1/*1 genotype may have increased metabolism or clearance and decreased concentrations of efavirenz as compared to the *1/*6 and *6/*6 genotypes, although there is some evidence to the contrary. Other genetic and clinical factors may also influence metabolism and clearance of efavirenz.
1447947205	*1/*1	Patients with the CYP2C19 *1/*1 genotype who are infected with Helicobacter pylori (H. pylori) may have a decreased likelihood of eradication when treated with lansoprazole as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. Patients also received amoxicillin and clarithromycin. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no association between CYP2C19 genotypes and H. pylori eradication rate. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1447947206	*1/*2	Patients with the CYP2C19 *1/*2 genotype who are infected with Helicobacter pylori (H. pylori) may have an increased likelihood of eradication when treated with lansoprazole as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and heterozygous extensive metabolizers = *1/*2 + *1/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no association between CYP2C19 genotypes and H. pylori eradication rate. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1449564356	*1/*6	Individuals with the CYP2B6 *1/*6 genotype may have decreased metabolism or clearance and increased concentrations of efavirenz as compared to CYP2B6 *1/*1 genotypes, and possibly increased metabolism as compared to the CYP2B6 *6/*6 genotypes, although there is evidence to the contrary. Other genetic and clinical factors may also influence metabolism and clearance of efavirenz.
1449564357	*6/*6	Individuals with the CYP2B6 *6/*6 genotype may have decreased metabolism of efavirenz as compared to CYP2B6 *1/*6 and *1/*1 genotypes, although there is evidence to the contrary. Other genetic and clinical factors may also influence metabolism and clearance of efavirenz.
1449564370	*1/*1	Patients with the CYP2C19 *1/*1 genotype who are infected with Helicobacter pylori (H. pylori) may have a lower eradication rate when treated with omeprazole as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. Patients also received amoxicillin and clarithromycin. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3  (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183684145	AA	Patients with the AA genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684146	AT	Patients with the AT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype and an increased likelihood of toxic liver disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684147	TT	Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684168	CC	Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.
1043880814	*1/*1	Patients with the UGT1A3*1/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.
1043880813	*2/*2	Patients with the UGT1A3*2/*2 genotype may have an increased atorvastatin lactonization as compared to patients with the UGT1A3*1/*1 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.
1448099748	G/del	Patients with the G/del genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del/del genotype, or a decreased risk as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.
1448099747	GG	Patients with the GG genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.
1448099749	del/del	Patients with the del/del genotype and psychotic disorders may have a decreased risk for side effects when treated with antipsychotics as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.
1183632157	CG	Patients with the CG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics..
1183632158	GG	Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632178	AA	Patients with the AA genotype may have decreased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1183622653	CT	Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622654	TT	Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1448102916	AA	Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
1448102917	AG	Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
1448102918	GG	Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
1448099819	AA	Patients with the AA genotype and major depressive disorder who are treated with antidepressants and other treatments may have a reduced response and reduced likelihood of remission as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.
1448099820	AG	Patients with the AG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.
1448099821	GG	Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.
1183632156	CC	Patients with the CC genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632177	AG	Patients with the AG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1183632176	GG	Patients with the GG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1444694507	AC	Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
1444694506	CC	Patients with the CC genotype who are undergoing kidney transplantation may have an increased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
1444694508	AA	Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
1447946053	non-null/ non-null	Patients with the non-null/ non-null genotype (has two copies of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449002783	AA	Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.
1449002784	AG	Patients with the AG genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.
1183491399	AA	Patients with the AA genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491400	AG	Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491401	GG	Patients with the GG genotype who have Hypercholesterolemia may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1447946054	non-null/ null	Patients with the non-null/ null genotype (has one copy of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449002785	GG	Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.
1447946055	null/null	Patients with the null/null (has no copies of the GSTT1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null/ null or the non-null/ non-null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449002788	CC	Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1449002789	CT	Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1449002790	TT	Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1449002793	CC	Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.
1444666901	CC	Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1446896646	CC	Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1446896647	CT	Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.
1446896648	TT	Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.
1444666902	CT	Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1444666903	TT	Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1446897173	AA	Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1183492245	CC	Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492246	CT	Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492247	TT	Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533593	AA	Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.
1183533594	AT	Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.
1183533595	TT	Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.
1183619323	CC	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619324	CT	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619325	TT	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183622322	TT	Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1446897174	AG	Patients with the AG genotype and schizophrenia may have higher weight gain when treated with antipsychotics as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1444700812	CC	Patients with the CC genotype who are treated gemcitabine and platinum compounds may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
1444608449	AA	Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444608450	AG	Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes.  No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444608451	GG	Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes.  No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444705364	CC	Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.
1444705365	CT	Patients with the CT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.
1444713931	B (wildtype)/ B (wildtype)	Female patients with the B (wildtype)/ B (wildtype) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.
1183491040	AA	Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183491041	AG	Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183491042	GG	Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have increased severity of pain as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1444700826	AA	Patients with the AA genotype may have increased response to hmg coa reductase inhibitors as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444700825	AG	Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444700824	GG	Patients with the GG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444700834	AA	Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1447947207	*1/*3	Patients with the CYP2C19 *1/*3 genotype who are infected with Helicobacter pylori (H. pylori) may have an increased likelihood of eradication when treated with lansoprazole as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and heterozygous extensive metabolizers = *1/*2 + *1/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no association between CYP2C19 genotypes and H. pylori eradication rate. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1447947208	*2/*2	Patients with the CYP2C19 *2/*2 genotype who are infected with Helicobacter pylori (H. pylori) may have an increased likelihood of eradication when treated with lansoprazole as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no association between CYP2C19 genotypes and H. pylori eradication rate. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448107354	AA	Patients with the AA genotype and Bipolar disorder may have increased response to lithium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1444667663	AA	Patients with the AA genotype and diabetes mellitus may have an increased response  when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to metformin.
1444667664	AG	Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin.
1444667665	GG	Patients with the GG genotype and diabetes mellitus may have a decreased response  when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to metformin.
1448107355	AG	Patients with the AG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1448107356	GG	Patients with the GG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1183491828	CT	Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491829	TT	Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183629313	AA	Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183629312	AG	Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183491626	GG	Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
1183491627	GT	Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
1183491628	TT	Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
1183491827	CC	Patients with the CC genotype were not studied. Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183629311	GG	Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183629318	CC	Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1043858694	AA	Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
1444667919	AA	Patients with genotype AA and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.
1444667920	AG	Patients with genotype AG and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.
1448107215	CC	Patients with the CC genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1448107216	TC	Patients with the TC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1448107217	TT	Patients with the TT genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1043858695	AG	Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
1043858696	GG	Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
1043859319	A	Patients with the P2RY12 A genotype may have an increased residual on-clopidogrel platelet reactivity when treated with clopidogrel as compared to patients with the P2RY12 F genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1043859318	F	Patients with the P2RY12 F genotype may have a decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel as compared to patients with the P2RY12 A genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1043880135	AA	Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1043880136	AG	Patients with the AG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1043880137	GG	Patients with the GG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of death or cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1155598164	GT	Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.
1155598167	TT	Patients with the TT genotype may have higher plasma concentrations of atorvastatin as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.
1158843286	AA	Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1158843292	AG	Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1158843298	GG	Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1183491190	CC	Patients with the CC genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1155598161	GG	Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.
1183491191	CT	Patients with the CT genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491192	TT	Patients with the TT genotype and Hypercholesterolemia may have a reduced response to atorvastatin treatment as compared to patients with the CT or CC  genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043880099	AA	Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1043880100	AG	Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1043880101	GG	Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1043880296	CC	Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
1043880295	TC	Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
1043880294	TT	Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
1043880460	AA	Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880461	AG	Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880462	GG	Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1448102871	CC	Patients with the CC genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102872	CG	Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102873	GG	Patients with the GG genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1447682302	CC	Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CG or GG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.
1447682303	CG	Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.
1447678616	GG	Patients with the GG genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1043880385	AG	Patients with the AG genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880386	GG	Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose.
1183491818	AA	Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183684170	TT	Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1448102865	GG	Patients with the GG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1447678617	GT	Patients with the GT genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1448102866	GT	Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102867	TT	Patients with the TT genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448124429	AG	Children with the AG genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
1183630392	non-null/non-null	Men with the non-null/ non-null genotype (has two copies of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1183630289	GG	Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.
1448124430	GG	Children with the GG genotype and acute lymphoblastic leukemia may have increased risk of neurotoxicity when taking methotrexate compared to children with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
1183630393	non-null/null	Men with the non-null/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1183630394	null/null	Men with the null/null genotype (has no copies of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have a reduced, but not absent, risk of hearing impairment as compared to patients with the non-null/null or non-null/non-null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1043880384	AA	Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1183491819	AG	Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491820	GG	Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183684169	CT	Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1448124428	AA	Children with the AA genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
1043858704	AA	Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858705	AG	Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858706	GG	Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
1043880450	AA	Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1043880449	AG	Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1043880448	GG	Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1050579068	GG	Patients with the GG genotype who are treated with pravastatin may be less likely to benefit from treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1050579071	GT	Patients with the GT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1050579074	TT	Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1145963222	CC	Patients with the CC genotype and asthma who are treated with corticosteroids may have increased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1145963223	CG	Patients with the CG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1145963225	GG	Patients with the GG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1183490979	AA	Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490980	AG	Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490981	GG	Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183491622	GG	Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491623	GT	Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491624	TT	Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183492208	E2/E2	Patients with the E2/E2 genotype who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E2/E4, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492209	E2/E3	Patients with the E2/E3 genotype who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E2/E4, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492210	E2/E4	Patients with the E2/E4 genotype who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492211	E3/E3	Patients with the E3/E3 genotype who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043859383	AA	Patients with the AA genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859382	AG	Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859381	GG	Patients with the GG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043880436	CC	Patients with the CC genotype who are treated with atorvastatin may have higher  expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043880435	CT	Patients with the CT genotype who are treated with atorvastatin may have higher  expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043880434	TT	Patients with the TT genotype who are treated with atorvastatin may have reduced expression of SCAP as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491320	*1/*1G	Patients with the *1/*1G diplotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the *1/*1 diplotype or may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the *1G/*1G diplotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491321	*1G/*1G	Patients with the *1G/*1G diplotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the *1/*1G or *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1449311192	CC	Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1449311193	CT	Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1449311194	TT	Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need an increased dose of mercaptopurine, or methotrexate, as compared to children with the CC or CT genotypes. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1444700600	CT	Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
1444700601	TT	Patients with the TT genotype who are treated with gemcitabine and platinum compounds may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
1184514151	AA	Patients with the AA genotype may have decreased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.
1184514150	AT	Patients with the AT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.
1184514149	TT	Patients with the TT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.
1183491319	*1/*1	Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183631923	CC	Patients with the CC genotype (CYP2C19*1/*1) and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the CT or TT genotype (CYP2C19*1/*17 or *17/*17). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1043880377	TG	Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
1043880378	TT	Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
1043880468	AA	Patients with the AA genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.
1043880469	AG	Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.
1043880470	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.
1444700599	CC	Patients with the CC genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
1444700607	AA	Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
1183631794	CT	Patients with the CT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.
1183631793	TT	Patients with the TT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.
1448264445	G/TT	Patients with genotype G/TT may have decreased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
1043880376	GG	Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
1448264446	GG	Patients with genotype GG may have decreased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
1448264444	TT/TT	Patients with genotype TT/TT may have increased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype G/TT or  GG. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
1449192311	del/del	Patients with the del/del genotype (two copies of the CFTR F508del variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence a patient's response to lumacaftor.
1449192415	AG	Patients with the AG genotype (one copy of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H.  Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1043880873	AA	Patients with the AA genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1043880874	AG	Patients with the AG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1043880875	GG	Patients with the GG genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1449192309	CTT/CTT	Patients with the CTT/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to lumacaftor.
1449192310	CTT/del	Patients with the CTT/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence a patient's response to lumacaftor.
1183491362	AA	Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183490973	AC	Patients with the AC genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490974	CC	Patients with the CC genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AC or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183492240	CC	Patients with the CC genotype and Coronary Disease who are treated with pravastatin may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1147261609	AA	The AA genotype was not studied but female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of  progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of  progression-free survival.
1147261606	AT	Female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of  progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of  progression-free survival.
1147261604	TT	Female patients with the TT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of  progression-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's likelihood of  progression-free survival.
1183490972	AA	Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183492241	CT	Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492242	TT	Patients with the TT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1444666894	GG	Patients with the GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.
1444666895	GT	Patients with the GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.
1444666896	TT	Patients with the TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.
1444930910	CC	Patients with genotype CC may have increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all IL28B genotypes (CC, CT, or TT) regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.
1448099836	AA	Patients with the AA genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1444930911	CT	Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all IL28B genotypes (CC, CT, or TT) regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.
1146391452	AG	Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1146391453	GG	Patients with the GG genotype and Crohn Disease who are treated with corticosteroids may have a decreased likelihood of responsiveness as compared to patients with AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1148508970	CC	Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.
1043880596	AA	Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
1043880597	AG	Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
1043880598	GG	Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
1146391451	AA	Patients with the AA genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1148508971	CG	Female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.
1148508972	GG	Patients with the GG genotype were not studied but female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.
1448099837	AG	Patients with the AG genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1445585159	AG	Patients with the AG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.
1445585160	GG	Patients with the GG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.
1448099838	GG	Patients with the GG genotype and depression who are treated with paroxetine may have an increased risk of adverse drug reactions as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1447959176	GG	Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GT or TT genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1447959177	GT	Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1447959178	TT	Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1449717937	AA	Patients with the AA genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1156738777	GG	Patients with the GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin.
1156738780	GT	Patients with the GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin.
1156738792	TT	Patients with the TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin.
1183492088	E2/E2	Patients with the E2/E2 genotype who are treated with atorvastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E2/E4, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183492089	E2/E3	Patients with the E2/E3 genotype who are treated with atorvastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E2/E4, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183492090	E2/E4	Patients with the E2/E4 genotype who are treated with atorvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183492091	E3/E3	Patients with the E3/E3 genotype who are treated with atorvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183492092	E3/E4	Patients with the E3/E4 genotype who are treated with atorvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1449717938	AG	Patients with the AG genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717939	GG	Patients with the GG genotype may have a shorter recovery time from general anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449718313	AA	Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.
1184989944	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with citalopram may have decreased response and increased risk for side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.
1183491022	AA	Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.
1184990011	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype may have an increased risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR short form (S allele)/HTTLPR short form (S allele)  or HTTLPR long form (L allele)/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1449718314	AC	Patients with AC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.
1183491023	AG	The AG genotype was not studied.
1183491024	GG	Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.
1449718319	AA	Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.
1183614748	GG	Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614749	GT	Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614750	TT	Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183679142	TT	Patients with the TT genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183679777	AC	Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1449718320	AG	Patients with AG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.
1183679141	CT	Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183679776	CC	Patients with the CC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1043880726	CC	Patients with the CC genotype and Schizophrenia who are treated antipsychotics with may have an increased risk for antipsychotic-induced parkinsonism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.
1043880725	GC	Patients with the GC genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.
1043880724	GG	Patients with the GG genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.
1143918645	AA	Patients with the AA genotype may have a decreased affinity to losartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to losartan.
1143918648	AG	The AG genotype was not studied in association with affinity to losartan.
1143918651	GG	Patients with the GG genotype may have an increased affinity to losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to losartan.
1183491361	AG	Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491360	GG	Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491657	H2/H2	Patients with the H2/H2 diplotype may have a reduced response to simvastatin (lower changes in LDL-cholesterol and ApoB levels)  as compared to patients with diplotypes that do not include the H7 or H2 haplotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1449718315	CC	Patients with CC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.
1183491658	H2/H7	Patients with the H2/H7 diplotype may have a reduced response to simvastatin (lower changes in LDL-cholesterol and ApoB levels) as compared to patients with diplotypes that do not include the H7 or H2 haplotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491659	H7/H7	Patients with the H7/H7 diplotype may have a reduced response to simvastatin (lower changes in LDL-cholesterol and ApoB levels) as compared to patients with diplotypes that do not include the H7 or H2 haplotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183704244	AA	Patients with the AA genotype may have increased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AG or GG. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
1183704245	AG	Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
1183621040	CC	Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.
1183621041	CT	Children with the CT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.
1183621042	TT	Children with the TT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.
1183704246	GG	Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
1183704253	CC	Patients with the CC genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.
1043858843	CC	Patients with the CC genotype may require increased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
1043858842	CT	Patients with the CT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
1043858841	TT	Patients with the TT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
1043858880	GG	Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
1043858879	GT	Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
1043858878	TT	Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
1127557410	AA	Patients with the AA genotype may have a dereased metabolism of zidovudine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
1127557436	GA	Patients with the GA genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
1127557441	GG	Patients with the GG genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
1131245987	CC	Patients with the CC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have a decreased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1131245983	TC	Patients with the TC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1131245981	TT	Patients with the TT genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1183631407	CC	Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1183631406	CT	Patients with the CT genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1183631405	TT	Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1183491091	H12/H12	Patients with the H12/H12 diplotype who are treated with simvastatin or atorvastatin may be more likely to switch to a different drug or require a lower dose as compared to patients with the H2/H2 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment and risk of adverse drug events.
1183491092	H2/H12	Patients with the H2/H12 diplotype who are treated with simvastatin or atorvastatin may be more likely to switch to a different drug or require a lower dose as compared to patients with the H2/H2 genotype, or may be less likely to switch to a different drug or require a lower dose as compared to patients with the H12/H12 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment and risk of adverse drug events.
1183491093	H2/H2	Patients with the H2/H2 diplotype who are treated with simvastatin or atorvastatin may be less likely to switch to a different drug or require a lower dose as compared to patients with the H12/H12 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment and risk of adverse drug events.
1183491388	AA	Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1043873024	CC	Patients with the CC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
1043873025	CG	Patients with the CG genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
1043873026	GG	Patients with the GG genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CC genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
1043873033	AA	Patients with the AA genotype may require decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.
1043873034	AG	Patients with the AG genotype may 1) require decreased dose of phenytoin, 2) have increase metabolism of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.
1043873035	GG	Patients with the GG genotype may 1) require increased dose of phenytoin, 2) have decrease metabolism of phenytoin in people with Epilepsy as compared to patients with genotype AA or AG. Other clinical or genetic factors may also influence a patient's dose of phenytoin.
1183490960	GG	Patients with the GG genotype may have decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490959	TG	Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490958	TT	Patients with the TT genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183491805	CC	Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491806	CG	Patients with the CG genotype and Acute coronary syndrome who are treated with statins may have a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491807	GG	Patients with the GG genotype and Acute coronary syndrome who are treated with statins may have a deceased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183492093	E4/E4	Patients with the E4/E4 genotype who are treated with atorvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183492212	E3/E4	Patients with the E3/E4 genotype who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492213	E4/E4	Patients with the E4/E4 genotype who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1450044806	CT	Patients with central nervous system infections and the CT genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.
1450044807	TT	Patients with central nervous system infections and the TT genotype may have an increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.
1450044576	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044805	CC	Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.
1450044577	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1183491047	GG	Patients with the GG genotype and Adrenocortical Carcinoma who are treated with mitotane may have lower mitotane plasma concentrations as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
1183491355	AA	Patients with the AA genotype and Schizophrenia who are treated with haloperidol may have an increased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1183491046	TG	Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
1183491045	TT	Patients with the TT genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
1183491356	AG	Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1183491357	GG	Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1447947209	*2/*3	Patients with the CYP2C19 *2/*3 genotype who are infected with Helicobacter pylori (H. pylori) may have an increased likelihood of eradication when treated with lansoprazole as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no association between CYP2C19 genotypes and H. pylori eradication rate. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1447947210	*3/*3	Patients with the CYP2C19 *3/*3 genotype who are infected with Helicobacter pylori (H. pylori) may have an increased likelihood of eradication when treated with lansoprazole as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no association between CYP2C19 genotypes and H. pylori eradication rate. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448995645	AC	Patients with the AC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
1448995646	CC	Patients with the CC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
1448995649	AA	Patients with the AA genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. Evidence is conflicting as to this association.
1183617568	TT	Patients with the TT genotype and depression who are treated with paroxetine may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.
1183617566	AA	Patients with the AA genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.
1183617567	AT	Patients with the AT genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype or may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.
1043880479	AA	Patients with the AA genotype and Coronary Artery Disease may have a decreased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
1043880478	CA	Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
1043880477	CC	Patients with the CC genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
1043880683	AA	Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL/A or DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.
1043880682	DEL/A	Patients with the DEL/A genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.
1043880681	DEL/DEL	Patients with the DEL/DEL genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.
1155650527	AA	Patients with the AA genotype may have a decreased metabolism of clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1155650530	AG	The AG genotype was not studied.
1155650533	GG	Patients with the GG genotype may have an increased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1183491381	AA	Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491382	AT	Patients with the AT genotype and Hypercholesterolemia may have a reduced  response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491383	TT	Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1448995650	AG	Patients with the AG genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype or may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1448995651	GG	Patients with the GG genotype and HIV who are treated with efavirenz may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1448999388	*24	Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or  dextromethorphan or n-desmethyltamoxifen.
1448999393	C	Male patients with neuropathic pain and the C genotype (this is an X chromosome gene so males have only one copy) may have increased pain relief when treated with escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1448999387	*1	Patients with the CYP2D6*1 allele may have increased clearance of codeine or decreased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*24 allele. Other genetic and clinical factors may also influence the metabolism of codeine or  dextromethorphan or n-desmethyltamoxifen.
1183863776	AA	Patients with the AA genotype may have a significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863777	AG	Patients with the AG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863778	GG	Patients with the GG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1051394397	GG	Men with the GG genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1051394401	GT	Men with the GT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1051394404	TT	Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491351	AG	Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491352	GG	Patients with the GG genotype and Hypercholesterolemia may benefit less from simvastatin treatment due to a lower reduction in DNA damage as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491387	AG	Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491217	CC	Patients with the CC genotype may have an decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with an increased metabolic ratio of midazolam as compared to patients with the CT genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.
1183491216	CT	Patients with the TC genotype may have a decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with a decreased metabolic ratio of midazolam as compared to patients with the CC genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.
1183491215	TT	Patients with the TT genotype may have an increased metabolic ratio of midazolam as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.
1183491350	AA	Patients with the AA genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491386	GG	Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1448999394	G	Male patients with neuropathic pain and the G genotype (this is an X chromosome gene so males have only one copy) may have decreased pain relief when treated with escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1183532530	CC	Patients with the CC genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183532529	CG	Patients with the CG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype or may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183532528	GG	Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183533885	CC	Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533884	CG	Patients with the CG genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533883	GG	Patients with the GG genotype who are treated with pravastatin may have a better response (higher decreases in total cholesterol) as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880316	CC	Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880315	CT	Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880314	TT	Patients with TT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1450044482	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044478	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine)  as compared to patients with AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1043880831	AA	Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
1043880830	GA	Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
1043880829	GG	Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
1124035502	GG	Patients with the GG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1124035503	GT	Patients with the GT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1124035504	TT	Patients with the TT genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1183532608	AA	Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183532609	AG	Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183532610	GG	Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043858906	CC	Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.
1043858907	CT	Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.
1043858908	TT	Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.
1043880272	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the insert/insert genotype and Coronary Artery Disease may be less  responsive to fluvastatin treatment as compared to patients with the del/del or del/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1043880273	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the del/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del/del genotype, or may have a better response to fluvastatin treatment as compared to patients with the insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1043880274	del/del	Patients with the del/del genotype and Coronary Artery Disease may have a better response to fluvastatin treatment as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1043880326	AA	Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880325	AG	Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880324	GG	Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1123915620	CC	Patients with the CC genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1123915619	CT	Patients with the CT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1123915618	TT	Patients with the TT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1152935194	AA	Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152935195	AC	Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152935196	AT	Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152935201	CC	Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152935207	TT	Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1043880843	AG	Patients with the AG genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.
1043880844	GG	Patients with the GG genotype and Colorectal Neoplasms may have 1) decreased response, 2) decreased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.
1156228668	GG	Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin.
1183689057	*2/*3	Patients with the CYP2C19 *2/*2 or *2/*3 genotype (poor metabolizers) receiving diazepam for preoperative anxiety may have decreased metabolism of diazepam (higher AUC and lower clearance) as compared to patients with the extensive (*1/*1) or intermediate (*1/*2 or *1/*3) metabolizer phenotypes. Patients with the poor metabolizer phenotype may emerge from anesthesia less rapidly than patients with the extensive metabolizer phenotype (*1/*1). Other genetic and clinical factors may also influence metabolism of diazepam.
1043880842	AA	Patients with the AA genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.
1156228673	GT	Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin.
1156228679	TT	Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin.
1450373527	AA	Postoperative patients with the AA genotype may have lower morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.
1450373528	AG	Postoperative patients with the AG genotype may have lower morphine requirements as compared to patients with the GG genotype, but higher morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.
1183630408	GG	Patients with the GG genotype (CYP2C19*1/*1) may have an increased clearance of doxepin as compared to patients with the AA genotype (CYP2C19*2/*2). The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's doxepin metabolism.
1183491763	AA	Patients with the AA genotype may have a better response (a higher reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491764	AT	Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491765	TT	Patients with the TT genotype were not studied. Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183689056	*2/*2	Patients with the CYP2C19 *2/*2 or *2/*3 genotype (poor metabolizers) receiving diazepam for preoperative anxiety may have decreased metabolism of diazepam (higher AUC and lower clearance) as compared to patients with the extensive (*1/*1) or intermediate (*1/*2 or *1/*3) metabolizer phenotypes. Patients with the poor metabolizer phenotype may emerge from anesthesia less rapidly than patients with the extensive metabolizer phenotype (*1/*1). Other genetic and clinical factors may also influence metabolism of diazepam.
1183545770	CC	Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1450373529	GG	Postoperative patients with the GG genotype may have higher morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.
1447943628	CC	Patients with the CC genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to metoprolol.
1043858736	AA	Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858735	AG	Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858734	GG	Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1183491032	AG	Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1183491033	GG	Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1183574218	AA	Patients with the AA genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.
1183574219	AC	Patients with the AC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype.  An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.
1183574220	CC	Patients with the CC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype.  An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.
1183693440	AC	Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693441	CC	Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693444	CC	Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1043872991	AA	Patients with the AG genotype may have increased progression free survival  in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.
1043872990	AG	Patients with the AG genotype may have increased progression free survival  in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.
1183491031	AA	Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1183693445	CG	Patients with the CG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693439	AA	Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693446	GG	Patients with the GG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1043880321	AA	Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880320	AC	Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880319	CC	Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1448099852	AA	Patients with the AA genotype and rheumatoid arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG or AG genotype. However, those with the AA genotype and psoriatic arthritis may be less likely to respond to anti-TNF treatment as compared to those with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448099853	AG	Patients with the AG genotype and Rheumatoid Arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG genotype but may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the AG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447947294	*2/*3	Patients with the CYP2C19 *2/*3 genotype may have decreased metabolism of rabeprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of rabeprazole.
1447947295	*3/*3	Patients with the CYP2C19 *3/*3 genotype may have decreased metabolism of rabeprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of rabeprazole.
1447947157	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have increased metabolism of esomeprazole (shorter time taken for the blood concentration to drop to 50% of the peak plasma drug concentration and a shorter mean residence time) as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). No significant associations have been seen for area under the concentration-time curve (AUC), apparent oral clearance (Cl/F) or peak plasma drug concentration (Cmax). Other genetic and clinical factors may also influence metabolism of esomeprazole.
1447947158	*2/*2	Patients with the CYP2C19 *2/*2 genotype may have decreased metabolism of esomeprazole (longer time taken for the blood concentration to drop to 50% of the peak plasma drug concentration and a longer mean residence time) as compared to patients with the *1/*1 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2 + *2/*3 (*2 = rs4244285; *3 = rs4986893). No significant associations have been seen for area under the concentration-time curve (AUC), apparent oral clearance (Cl/F) or peak plasma drug concentration (Cmax). Other genetic and clinical factors may also influence metabolism of esomeprazole.
1447947159	*2/*3	Patients with the CYP2C19 *2/*3 genotype may have decreased metabolism of esomeprazole (longer time taken for the blood concentration to drop to 50% of the peak plasma drug concentration and a longer mean residence time) as compared to patients with the *1/*1 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2 + *2/*3 (*2 = rs4244285; *3 = rs4986893). No significant associations have been seen for area under the concentration-time curve (AUC), apparent oral clearance (Cl/F) or peak plasma drug concentration (Cmax). Other genetic and clinical factors may also influence metabolism of esomeprazole.
1448099854	GG	Patients with the GG genotype and Rheumatoid Arthritis may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the GG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183619590	AA	Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1183619591	AG	Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1448100298	CC	Patients with the CC genotype may require an increased dose of warfarin, and may be at decreased risk of over-anticoagulation, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of warfarin and risk of over-anticoagulation.
1448100299	CT	Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Patients with the CT genotype may also be at increased risk of over-anticoagulation as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dosage of warfarin and risk of over-anticoagulation.
1043880429	CC	Patients with the CC genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1450368660	*12	Patients who carry the *12 allele may have decreased DPYD activity and be at increased risk for drug toxicity when receiving fluorouracil. However, evidence is limited for this allele. Other genetic and clinical factors may also affect DPYD activity and risk for fluorouracil-induced drug toxicity.
1449156357	AA	Patients with tuberculosis and the AA genotype who are treated with isoniazid and rifampin may have an increased likelihood of drug-induced liver injury as compared to patients with the AG or GG genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.
1449156358	AG	Patients with tuberculosis and the AG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.
1043880428	CT	Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1043880427	TT	Patients with the TT genotype and Hypercholesterolemia may have a reduced response to simvastatin treatment as compared to patients with the the CT or CC  genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1449167189	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167190	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167191	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449156359	GG	Patients with tuberculosis and the GG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.
1444700113	*1	Patients with the CYP2C19*1 allele may have an increased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*9, *10, *14, *16, *19, *22, *23, *24, *25, *26 alleles. The CYP2C19*1 allele was found to have an increased clearance of clopidogrel as compared to CYP2C19*9, *10, *14, *16, *19, *22, *23, *24, *25, *26 during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1184349185	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients (Asian population) with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with paroxetine may have decreased response or decreased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, a number of contradictory findings exist showing an increased response for the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449167192	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1183490965	CC	Patients with the CC genotype may have an increased sedative response to dexmedetomidine as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490964	GC	Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490963	GG	Patients with the GG genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183491771	CC	Patients with the CC genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a smaller reduction in risk of myocardial infarction compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
1450044641	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner. This clinical annotation is based on two case studies and there were no individuals with the TT genotype.  Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1183491772	CT	Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
1183491773	TT	Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
1183491789	L5	Patients with the L5 allele may have a decreased response to simvastatin as compared to patients without the L5 allele. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183689587	CT	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.
1449577700	*1/*1	Patients with the CYP2D6*1/*1 genotype who are treated with fluvoxamine may have 1) decreased steady-state plasma concentration-to-dose (C/D) ratio as compared to patients with the *1/*5, *1/*10, *5/*10, *10/*10 genotype, 2) decreased plasma concentrations, 3) decreased risk of developing gastrointestinal side effects as compared to patients with the *5/*10, *10/*10 genotype, and 4) decreased AUC, Cmax and half-life time of fluvoxamine as compared to patients with two non-functional CYP2D6 alleles (poor metabolizer phenotypes). However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of fluvoxamine.
1447964130	AA	Patients with the AA genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype. Cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.
1183689588	TT	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.
1447964131	AT	Patients with the AT genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype, or decreased risk as compared to patients with the AA genotype. Patients with the AT genotype may also have decreased clearance of isoniazid as compared to patients with the TT genotype. Additionally, cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.
1447964132	TT	Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for anti-TB drug-induced hepatitis as compared to patients with the AA genotype. Patients with the TT genotype may also have increased clearance of isoniazid as compared to patients with the AT genotype. Additionally, cells with the T allele have been shown to result in increased transcription of the NAT2 gene as compared to those with the A allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.
1447964266	CC	Patients with the CC genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1449577701	*1/*10	Patients with the CYP2D6*1/*10 genotype who are treated with fluvoxamine may have increased steady-state plasma concentration-to-dose (C/D) ratio as compared to patients with the *1/*1 genotype. However, contradictory findings reporting no association with fluvoxamine plasma concentrations are published. Studies investigating multiple antidepressants including fluvoxamine found no association with side effects or response. Other genetic and clinical factors may also influence a patient's metabolism of fluvoxamine.
1043858901	AA	Patients with the AA genotype may have decreased risk of bone fractures when treated with Calcium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
1043858902	AG	Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
1043858903	GG	Patients with the GG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
1043872989	GG	Patients with the GG genotype may have decreased progression free survival  in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's response.
1447964267	CG	Patients with the CG genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964268	GG	Patients with the GG genotype and ADHD may show slower improvement of symptoms when treated with methylphenidate as compared to patients with the CC and CG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1448995644	AA	Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
1450044468	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044469	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1043880422	C/del	Patients with the CC/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein  A1 and C3 levels as compared to patients with the C/C genotype, or may have a larger  change in apolipoprotein  A1 and C3 levels as compared to patients with the del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1043880423	CC	Patients with the CC genotype who are treated with fluvastatin may have a larger  change in apolipoprotein  A1 and C3 levels, as compared to patients with the C/del or del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1043880424	del/del	Patients with the del/del genotype who are treated with fluvastatin may have a smaller  change in apolipoprotein  A1 and C3 levels, as compared to patients with the CC or C/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183699231	AA	Patients with the AA genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
1183699232	AG	Patients with the AG genotype who are treated with carboplatin or cisplatin may have increased risk of progression of disease as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
1183619305	AC	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619306	CC	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183699233	GG	Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
1183617619	CC	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.
1183617620	CT	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased  risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.
1183617621	TT	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.
1183617645	AA	Patients with the AA genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1450044470	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1183619304	AA	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1184233171	*12	Patients with the *12 allele and resistant hypertension who have a rapid or intermediate acetylator phenotype may be less likely to respond to hydralazine treatment as compared to those with two alleles conferring a slow acetylator phenotype (NAT2*5, *6, *7, *14). Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.
1184233172	*13	Patients with the *13 allele and resistant hypertension who have a rapid or intermediate acetylator phenotype may be less likely to respond to hydralazine treatment as compared to those with two alleles conferring a slow acetylator phenotype (NAT2*5, *6, *7, *14). Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.
1043858846	CC	Patients with the CC genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
1043858847	CT	Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
1043858848	TT	Patients with the TT genotype may be associated with a decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
1184233170	*4	Patients with the *4 allele and resistant hypertension who have a rapid or intermediate acetylator phenotype may be less likely to respond to hydralazine treatment as compared to those with two alleles conferring a slow acetylator phenotype (NAT2*5, *6, *7, *14). Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.
1184233167	*5	Patients with the *5 allele and resistant hypertension who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may be more likely to respond to hydralazine treatment as compared to those with one or two NAT2 alleles conferring an intermediate or rapid acetylator phenotype (e.g. *4, *12, *13). Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.
1184233168	*6	Patients with the *6 allele and resistant hypertension who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may be more likely to respond to hydralazine treatment as compared to those with one or two NAT2 alleles conferring an intermediate or rapid acetylator phenotype (e.g. *4, *12, *13). Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.
1183619592	GG	Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1183619594	AA	Patients with the AA genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1043873009	TT	Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.
1184233169	*7	Patients with the *7 allele and resistant hypertension who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may be more likely to respond to hydralazine treatment as compared to those with one or two NAT2 alleles conferring an intermediate or rapid acetylator phenotype (e.g. *4, *12, *13). Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.
1183619595	AG	Patients with the AG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1183619596	GG	Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1183619652	*2/*2	Patients with the CYP2C19 *2/*2 genotype who underwent kidney transplantation and are treated with tacrolimus may have higher tacrolimus dose-normalized trough blood concentrations (C0/D) as compared to patients with the *1/*1 or *1/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.
1184168741	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the HTTLPR long form (L allele)/HTTLPR short form (S allele) genotype may have a decreased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1184168742	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype may have a decreased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the  HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1184516193	B (wildtype)/B (wildtype)	Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1183491742	AA	Patients with the AA genotype may have a better response to simvastatin treatment (a higher reduction in LDL-cholesterol) as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491743	AT	Patients with the AT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491744	TT	Patients with the TT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183614744	AA	Patients with the AA genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614745	AG	Patients with the AG genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614746	GG	Patients with the GG genotype and HIV infection who are treated with efavirenz may have an increased risk of sadness as a side effect as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183702960	CC	Patients with the CC genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1184516192	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1449575747	AA	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.
1449575748	AG	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose as compared to the AA genotype, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.
1184168740	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the  HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype may have an increased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)/HTTLPR short form (S allele) or HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1449575749	GG	Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.
1043880650	AA	Patients with the AA genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1043880651	AT	Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1043880652	TT	Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1047434905	AA	Patients with the AA genotype who are treated with simvastatin and warfarin may require an increased dose of warfarin as compared to patients with the CC or AC genotype (patients with the CYP2C9*3 allele). Simvastatin did not seem to affect warfarin dose in patients who did not have the C allele (CYP2C9*3). This variant does not seem to be associated with response to simvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's required warfarin dosage and response to simvastatin.
1047434912	AC	Patients with the AC genotype (carriers of CYP2C9*3) who are treated with simvastatin and warfarin may require a decreased dose of warfarin  as compared to patients with the AA genotype (patients who do not have the CYP2C9*3 allele). This variant does not seem to be associated with response to simvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's required warfarin dosage and response to simvastatin.
1047434918	CC	Patients with the CC genotype (CYP2C9*3/*3) who are treated with simvastatin and warfarin may require a decreased dose of warfarin as compared to patients with the AA  genotype (patients who do not have the CYP2C9*3 allele). This variant does not seem to be associated with response to simvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's required warfarin dosage and response to simvastatin.
1444713927	A- 202A_376G	Male patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with methylene blue 1) may not respond to treatment for methemoglobinemia 2) may have an increased risk of drug-induced hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.
1444713928	A- 202A_376G/ A- 202A_376G	Female patients with the A- 202A_376G/A- 202A_376G haplotype (homozygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with methylene blue 1) may not respond to treatment for methemoglobinemia 2) may have an increased risk of drug-induced hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.
1183624307	CC	Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624308	CT	Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183622349	CC	Patients with the CC genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622350	CG	Patients with the CG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622351	GG	Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1444713929	A- 202A_376G/B (wildtype)	Female patients with the A- 202A_376G/B (wildtype) haplotype (heterozygous for the G6PD A- variant) who are treated with methylene blue may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G/A- 202A_376G or B/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183624309	TT	Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624422	AA	Patients with the AA genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1043858981	CC	Patients with the CC genotype may have an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858982	CT	Patients with the CT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444713930	B (wildtype)	Male patients with the B (wildtype) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.
1043858983	TT	Patients with the TT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043880388	AA	Patients with the AA genotype may have increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880389	AG	Patients with the AG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880390	GG	Patients with the GG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1183617625	CT	Patients with the CT genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype or may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617626	TT	Patients with the TT genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617646	AG	Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1145764730	AA	Patients with the AA genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1145764731	AC	Patients with the AC genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients who do not have the C allele. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1145764733	AT	Patients with the AT genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients who do not have the C allele. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1145764732	CC	Patients with the CC genotype and Acute Coronary Syndrome who are treated with pravastatin may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or TT genotype. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1145764734	TT	Patients with the TT genotype and Acute Coronary Syndrome who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype. This association was not seen in children with familial hypercholesterolemia. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183617624	CC	Patients with the CC genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617647	GG	Patients with the GG genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617686	CC	Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a slower response time but an increased likelihood of experiencing remission as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183491784	AA	Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491785	AG	Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease  as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491786	GG	Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease  as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1184989111	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*5/*13 or *4/*31 or *4/*69 or *5/*100 or *2/*101 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184989116	*2/*101	Patients with the CYP2D6*2/*101 genotype may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184989112	*4/*31	Patients with the CYP2D6*4/*31 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184233185	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the insert/insert genotype and Migraine with Aura or Chronic Migraine may be less likely to use pharmacological prophylaxis as compared to patients with the ins/del or del/del genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.
1184233186	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the insert/del genotype and Migraine with Aura or Chronic Migraine  may be more likely to use pharmacological prophylaxis as compared to patients with the ins/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.
1184233187	del/del	Patients with the del/del genotype and Migraine with Aura or Chronic Migraine may be more likely to use pharmacological prophylaxis as compared to patients with the ins/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.
1183689918	*1/*1	Patients with two functional CYP2D6 alleles may have an increased metabolism of tolterodine as compared to patients with two non-functional (*3, *4) or two reduced functional (*10/*10) CYP2D6 alleles. However, no association with response is reported. Other genetic and clinical factors may also influence a patient's metabolism of and response to tolterodine.
1183689917	*10/*10	Patients with the CYP2D6*10/*10 genotype may have an increased tolterodine and its active metabolite (5-HM) exposure as compared to patients with the *1/*1 or *1/*10 genotype. Other genetic and clinical factors may also influence a patient's metabolism of tolterodine.
1183622528	AA	Patients with the AA genotype and major depressive disorder who are treated with escitalopram may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183689915	*3	Patients with two non-functional CYP2D6 alleles may have decreased metabolism of tolterodine as compared to patients with two functional CYP2D6 alleles. However, no association with response is reported. Other genetic and clinical factors may also influence a patient's metabolism of and response to tolterodine.
1183689916	*4	Patients with two non-functional CYP2D6 alleles may have decreased metabolism of tolterodine as compared to patients with two functional CYP2D6 alleles. However, no association with response is reported. Other genetic and clinical factors may also influence a patient's metabolism of and response to tolterodine.
1127092673	AA	Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1127092677	AG	Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1127092680	GG	Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1184989113	*4/*69	Patients with the CYP2D6*4/*69 genotype may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184989115	*5/*100	Patients with the CYP2D6*5/*100 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184989114	*5/*13	Patients with the CYP2D6*5/*13 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1449564414	*1/*1	Patients with the *1/*1 genotype may require a higher dose of acenocoumarol as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3, or *3/*3 genotypes, although this is contradicted by some studies. In addition, the *1/*1 genotype may be associated with shorter time to achieve stable dose as compared to the *1/*3 and *3/*3 genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's required acenocoumarol dosage.
1449564415	*1/*2	Patients with the *1/*2 genotype may require a higher dose of acenocoumarol as compared to patients with the *2/*2, *2/*3, or *3/*3 genotypes and a decreased dose of acenocoumarol as compared to patients with the *1/*1 genotype, although this is contradicted by some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dosage.
1449564416	*1/*3	Patients with the *1/*3 genotype may require a higher dose of acenocoumarol as compared to patients with the *2/*2, *2/*3, or *3/*3 genotypes and a decreased dose of acenocoumarol as compared to patients with the *1/*1 genotype, although this is contradicted by some studies. In addition, the *1/*3 genotype may be associated with longer time to achieve stable dose as compared to the *1/*1 genotype and shorter time as compared to the *3/*3 genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's required acenocoumarol dosage.
1183619084	CC	Patients with the CC genotype (CYP2D6*1/*1) and depression may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's dose requirement.
1183619085	CT	Patients with the CT genotype (CYP2D6*1/*4) and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the CC genotype (CYP2D6*1/*1) or may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's dose requirement.
1183619086	TT	Patients with the TT genotype (CYP2D6*4/*4) and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's dose requirement.
1183619232	CC	Patients with the CC genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
1183619233	CT	Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
1183619234	TT	Patients with the TT genotype and major depressive disorder who are treated with fluoxetine may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
1183619609	GG	Patients with the GG genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.
1183619610	GT	Patients with the GT genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype, or a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.
1183619611	TT	Patients with the TT genotype and major depressive disorder may experience a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.
1043858898	AG	Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
1043858899	GG	Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
1156497694	AA	Patients with the AA genotype may have an increased metabolism of clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1156497691	AT	The AT genotype was not studied.
1156497687	TT	Patients with the TT genotype may have a decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1183490997	AA	Patients with the AA genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1183490996	AT	Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1183490995	TT	Patients with the TT genotype and Nephrosclerosis may have a lower baseline mean arterial blood pressure when treated with diuretics as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1447946080	*1A/*1A	Patients with the *1A/*1A genotype and tuberculosis may have a decreased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A/*5B genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.
1447946081	*1A/*5B	Patients with the *1A/*5B genotype and tuberculosis may have an increased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A/*1A genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.
1447946082	*5B/*5B	No patients with this genotype were available for analysis, but patients with the *1A/*5B genotype and tuberculosis may have an increased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A/*1A genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.
1183630277	AA	Patients with the AA genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1183618211	A/del	Patients with the A/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183618212	AA	Patients with the AA genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the del/del genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183618210	del/del	Patients with the del/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1043876906	AC	Patients with the AC genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1043876905	CC	Patients with the CC genotype and major depression and high anxiety may have an increased response to fluoxetine treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1183491002	GG	Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
1447946092	CC	Patients with the CC genotype may be at decreased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.
1447946091	CT	Patients with the CT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.
1447946090	TT	Patients with the TT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for alcoholism.
1043876907	AA	Patients with the AA genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1183491001	TG	Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
1183491000	TT	Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
1447946100	CC	Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.
1184348709	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar  risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1183616512	AA	Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616513	AC	Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616514	CC	Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1184348710	CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348711	TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 1-4 nephrotoxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348733	CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348734	TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 2-4 anemia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184349186	HTTLPR short form (S allele)/HTTLPR long form (L allele)	Patients (Asian population) with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with paroxetine may have a decreased response or decreased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, a number of contradictory findings exist showing an increased response for the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1043880291	del/del	Patients with the del/del genotype and Coronary Artery Disease may benefit less from atorvastatin and quinapril treatment (due to less of a reduction in the fibrinolytic marker D-dimer) as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1043880405	AA	Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880404	AG	Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880403	GG	Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880587	AG	Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.
1043880588	GG	Patients with the GG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.
1043880647	GG	Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1043880646	TG	Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1043880645	TT	Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1043880854	AA	Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.
1043880853	AG	Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.
1043880852	GG	Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.
1183617710	CC	Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617711	CT	Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617712	TT	Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a slower response time as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449749692	CC	Patients with the CC (*3/*3) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1449749693	CT	Patients with the CT genotype (*1/*3) and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3) or a decreased risk of transplant rejection as compared to patients with the TT genotype (*1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1449749694	TT	Patients with the TT (*1/*1) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1043880041	AG	Patients with the AG genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1043880040	GG	Patients with the GG genotype and major Depressive Disorder may have a decreased response to fluvoxamine treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1449187687	AA	Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.
1449748304	CC	Patients with the CC genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.
1043880042	AA	Patients with the AA genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1043880548	*15/*15	Patients with the *15/*15 genotype may have increased bioavailability of pravastatin as compared to individuals with the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin.
1043880549	*1A/*15	Patients with the *1A/*15 genotype may have increased bioavailability of pravastatin as compared to individuals with the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin.
1043880550	*1A/*1A	Patients with the *1A/*1A genotype may have decreased bioavailability of pravastatin as compared to individuals with the *15/*15 or *1A/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin.
1043880551	*1B/*1B	Patients with the *1B/*1B genotype may have decreased bioavailability of pravastatin as compared to individuals with the *15/*15 or *1A/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin.
1157230441	AA	Patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have a decreased response as compared to patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.
1157230442	GA	Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.
1157230443	GG	Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.
1183491136	CC	Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. This may be influenced by rs3808607 genotype, with an increased response in patients with the rs3808607 TT genotype.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491137	CG	Patients with the CG genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. However, this association was not observed in the majority of studies. This may be influenced by rs3808607 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491138	GG	Patients with the GG genotype who are treated with atorvastatin may have a decreased response to treatment (measured by lower decreases in LDL-cholesterol) as compared to patients with the CC genotype. This association may be influenced by rs3808607 genotype. Several studies show no association as compared to the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491311	*1/*1	Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to simvastatin treatment as compared to patients with the *1/*4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491312	*1/*4	Patients with the *1/*4 diplotype and Hyperlipidemia may have a better response to simvastatin treatment as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491367	AA	Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1043859124	AA	Patients with the AA genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1043859125	AC	Patients with the AC genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1043859126	CC	Patients with the CC genotype may have an increased chance of response to citalopram or ecitalopram treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1043880443	AA	Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased  plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
1043880444	AC	Patients with the AC genotype and neoplasms may have a decreased  plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
1043880445	CC	Patients with the CC genotype and neoplasms may have an increased  plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
1043880667	CC	Patients with the CC genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.
1043880666	CT	Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.
1043880665	TT	Patients with the TT genotype may have decreased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the CC or CT genotype.
1444667341	CC	Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667342	CT	Patients with metastasized cancer and the CT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CC genotype and improved response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1183615553	CC	Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.
1183615554	CT	Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.
1183615555	TT	Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.
1183698801	AG	Patients with the AG genotype (CYP3A4 *1/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
1183698800	AA	Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
1183698802	GG	Patients with the GG genotype (CYP3A4 *18B/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1/*1 or *1/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
1043859348	*1	Patients with the CYP2B6 *1 genotype who are CYP2C19*1/*1 carriers and undergoing percutaneous coronary intervention may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *5 genotype who are CYP2C19*1/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1043859347	*5	Patients with the CYP2B6 *5 genotype who are CYP2C19*1/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1043880311	AA	Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880310	AG	Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880309	GG	Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1444704798	CT	Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype or may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444704799	TT	Patients with the TT genotype may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444704814	CC	Patients with the CC genotype may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
1183622624	TC	Patients with the TC genotype and major depressive disorder who are treated with escitalopram  1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects
1183622623	TT	Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183617687	CT	Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617688	TT	Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444704813	CT	Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
1444704812	TT	Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
1183622652	CC	Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622625	CC	Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1449157307	CT	Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.
1449157602	AA	Patients with the AA genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1449157603	AG	Patients with the AG genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1043880631	*15/*15	Patients with the *15/*15 genotype may have increased atorvastatin concentrations  as compared to patients with the *1A/*15, *1B/*15, *1A/*1A, *1A/*1B or *1B/*1B genotype. Other genetic and clinical factors may also influence a patient's atorvastatin pharmacokinetics.
1043880632	*1A/*15	Patients with the *1A/*15 genotype may have decreased atorvastatin concentrations  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin pharmacokinetics.
1043880633	*1A/*1A	Patients with the *1A/*1A genotype may have decreased atorvastatin concentrations  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin pharmacokinetics.
1043880636	*1A/*1B	Patients with the *1A/*1B genotype may have decreased atorvastatin concentrations  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin pharmacokinetics.
1043880635	*1B/*15	Patients with the *1B/*15 genotype may have decreased atorvastatin concentrations  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin pharmacokinetics.
1043880634	*1B/*1B	Patients with the *1B/*1B genotype may have decreased atorvastatin concentrations  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin pharmacokinetics.
1449157308	CC	Patients with the CC genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.
1183619308	AA	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619309	AG	Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619310	GG	Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183685551	CT	Patients with the CT genotype who are treated with pravastatin may have a smaller reduction in total cholesterol as compared to patients with the TT genotype.  This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1449157604	GG	Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1449158198	AA	Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.
1449158199	AG	Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.
1444706211	AA	Patients with the AA genotype may have decreased response to atorvastatin as compared to patients with the CC or AC genotypes.  Other genetic and clinical factors may influence also a patient's atorvastatin response.
1449158200	GG	Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.
1450044476	AA	Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1183685550	CC	Patients with the CC genotype who are treated with pravastatin may have a smaller reduction in total cholesterol as compared to patients with the TT genotype. This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1450044477	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1183685552	TT	Patients with the TT genotype who are treated with pravastatin may have a larger reduction in total cholesterol as compared to patients with the CC or CT genotype.  This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183689586	CC	Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.
1183689054	*1/*2	Patients with the CYP2C19 *1/*2 or *1/*3 genotype (intermediate metabolizers) receiving diazepam for preoperative anxiety may have increased metabolism of diazepam (lower AUC and higher clearance) as compared to patients with the poor metabolizer phenotype (*2/*2 or *2/*3). Patients with the intermediate metabolizer phenotype may emerge from anesthesia less rapidly than patients with the extensive metabolizer phenotype (*1/*1). Other genetic and clinical factors may also influence metabolism of diazepam.
1183702961	CT	Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702962	TT	Patients with the TT genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183491366	AG	Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183491365	GG	Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183574181	CC	Patients with the CC genotype may have less vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to opioids.
1183574182	CT	Patients with the CT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids.
1183574183	TT	Patients with the TT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids.
1449161337	B (wildtype)/B (wildtype)	Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with rasburicase may have a reduced risk of methemoglobinemia and/or hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A- or Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449161338	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male patients who are hemizygous for the Mediterranean variant (rs5030868 allele A, associated with G6PD deficiency) who are treated with rasburicase may have an increased risk of methemoglobinemia and/or hemolysis as compared to patients with the wildtype B haplotype (rs5030868 allele G). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183703015	AA	No AA genotype carrier was found in the study. But patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
1449309966	GG	Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1183703016	AG	Patients with the AG genotype and asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
1183689053	*1/*1	Patients with the CYP2C19 *1/*1 genotype (extensive metabolizers) receiving diazepam for preoperative anxiety may have increased metabolism of diazepam (lower AUC and higher clearance) as compared to patients with the poor metabolizer phenotype (*2/*2 or *2/*3). Patients with the *1/*1 genotype may also emerge from anesthesia more rapidly than patients carrying the *2 or *3 alleles (intermediate and poor metabolizers). Other genetic and clinical factors may also influence metabolism of diazepam.
1183703017	GG	Patients with the GG genotype and Asthma treated with montelukast may have   higher plasma concentration of montelukast and better response to montelukast compared to patients with the GA genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
1449309964	AA	Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1449309965	AG	Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1043859387	CC	Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
1043859388	CT	Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
1043859389	TT	Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
1043880304	AA	Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880305	AC	Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880306	CC	Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1143176300	AA	Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
1143176306	AG	Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
1143176309	GG	Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
1446846516	AG	Patients with the AG genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1446846517	GG	Patients with the GG genotype may have decreased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with genotype AG or AA. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1447947109	CC	Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin  may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183622266	CC	Patients with the CC genotype who are treated with prasugrel may have higher  levels of platelet aggregation inhibition as compared to patients with the TT  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622265	CT	Patients with the CT genotype who are treated with prasugrel may have higher  levels of platelet aggregation inhibition as compared to patients with the TT  genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622264	TT	Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1043858701	AA	Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858700	AG	Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858699	GG	Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1447947110	CT	Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947111	TT	Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947169	*9	Patients with the CYP2C19*9 allele in combination with another loss-of-function allele (*8,*9) or one functional allele (*1) may have decreased metabolism of lansoprazole as compared to patients with two functional alleles (*1/*1). Other clinical and genetic factors may also affect metabolism of lansoprazole.
1183619583	AG	Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1183619584	GG	Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1183619318	CC	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619319	CT	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183617838	CC	Patients with the CC genotype with panic disorder who are treated with paroxetine may have an reduced response at 4 weeks of treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617839	CG	Patients with the CG genotype with panic disorder who are treated with paroxetine may have an reduced response at 4 weeks of treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617840	GG	Patients with the GG genotype with panic disorder who are treated with paroxetine may have a better response at 4 weeks of treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1446846515	AA	Patients with the AA genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1444703117	AA	Patients with the AA genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1444703118	AG	Patients with the AG genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1183619320	TT	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619582	AA	Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.
1447947292	*1/*3	Patients with the CYP2C19 *1/*3 genotype may have increased metabolism of rabeprazole as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype, and decreased metabolism as compared to patients with the *1/*1 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of rabeprazole.
1444703119	GG	Patients with the GG genotype who are treated with rosuvastatin may have increased LDL-C reduction as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1184348715	CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1143306660	AA	Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
1143306672	AG	Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
1143306677	GG	Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
1444703126	del/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the del/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype or may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.
1184348716	TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1447947293	*2/*2	Patients with the CYP2C19 *2/*2 genotype may have decreased metabolism of rabeprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of rabeprazole.
1183689512	*1/*3	Patients with the CYP2D6*1/*3 genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the CYP2D6*1/*1 genotype. However, no associations with differences in olanzapine pharmacokinetic parameters or response are reported in patients with two non-functional or CYP2D6*10 compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183689513	*1/*4	Patients with the CYP2D6*1/*4 genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the CYP2D6*1/*1 genotype. However, no associations with differences in olanzapine pharmacokinetic parameters or response are reported in patients with two non-functional or CYP2D6*10 compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183685523	AA	Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1183685524	AG	Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1183685525	GG	Patients with the GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1183689511	*1/*1	Patients with the CYP2D6*1/*1 genotype may have a decreased, but not absent, risk for weight gain when treated with olanzapine as compared to patients with the CYP2D6*1/*3 or *1/*4 genotype. However, no associations with differences in olanzapine pharmacokinetic parameters or response are reported in patients with two non-functional or with CYP2D6*10 alleles compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1184348714	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1448098378	CC	Patients with the CC genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.
1448098379	CT	Patients with the CT genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.
1183679140	CC	Patients with the CC genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1184348723	CC	Patients with the CC genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1448098380	TT	Patients with the TT genotype and schizophrenia or psychotic disorder may have increased metabolism of antiepileptics compared to patients with the CC or CT genotype. Other factor may affect metabolism of antiepileptics.
1448099073	AA	Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099074	AG	Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1449752828	AG	Patients with the AG genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752829	GG	Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1183616419	*1/*5	Children with the *1/*5 genotype scheduled to undergo adenotonsillectomy may have increased clearance of morphine as compared to children with the *2/*2, *2/*3, *2/*4, *2/*5 or *4/*4 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1183616420	*2/*2	Children with the *2/*2 genotype scheduled to undergo adenotonsillectomy may have reduced clearance of morphine as compared to children with the *1/*2, *1/*3, *1/*4, *1/*5 or *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1183616421	*2/*3	Children with the *2/*3 genotype scheduled to undergo adenotonsillectomy may have reduced clearance of morphine as compared to children with the *1/*2, *1/*3, *1/*4, *1/*5 or *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1183616422	*2/*4	Children with the *2/*4 genotype scheduled to undergo adenotonsillectomy may have reduced clearance of morphine as compared to children with the *1/*2, *1/*3, *1/*4, *1/*5 or *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1183616418	*1/*4	Children with the *1/*4 genotype scheduled to undergo adenotonsillectomy may have increased clearance of morphine as compared to children with the *2/*2, *2/*3, *2/*4, *2/*5 or *4/*4 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1183616423	*2/*5	Children with the *2/*5 genotype scheduled to undergo adenotonsillectomy may have reduced clearance of morphine as compared to children with the *1/*2, *1/*3, *1/*4, *1/*5 or *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1449752778	CC	Patients with the CC genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.
1449752779	CG	Patients with the CG genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.
1449752780	GG	Patients with the GG genotype and colorectal cancer may have increased survival times when treated with oxaliplatin-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.
1183616424	*4/*4	Children with the *4/*4 genotype scheduled to undergo adenotonsillectomy may have reduced clearance of morphine as compared to children with the *1/*2, *1/*3, *1/*4, *1/*5 or *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism and clearance of morphine.
1184168711	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Female patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype may have increased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1184168712	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Female patients with the HTTLPR long form (L allele)/HTTLPR short form (S allele) genotype were not studied. But female patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype may have increased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1184168713	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Female patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype may have a decreased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1043859375	AA	Patients with the AA genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859376	AG	Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859377	GG	Patients with the GG genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1142401281	AA	Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1142401284	AG	Patients with the AG genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype or may have a reduced response (measured by a lower reduction in total cholesterol) as compared to patients with the AA genotype.  In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1142401290	GG	Patients with the GG genotype who are treated with simvastatin may have a reduced response to treatment (measured by a lower reduction in total cholesterol) compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1151460691	AA	Patients with the AA genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1151460697	AC	Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1151460701	AT	Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1151460707	CC	Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1151460708	TT	Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1447520771	*1/*1	Patients with the CYP3A4 *1/*1 diplotype who underwent organ transplantation may have decreased metabolism of tacrolimus, as compared to patients with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors, such as CYP3A5*3 (rs776746), may also influence metabolism of tacrolimus.
1447520772	*1/*1G	Patients with the CYP3A4 *1/*1G diplotype who underwent organ transplantation may have increased metabolism of tacrolimus, as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors, such as CYP3A5*3 (rs776746), may also influence metabolism of tacrolimus.
1447520773	*1G/*1G	Patients with the CYP3A4 *1G/*1G diplotype who underwent organ transplantation may have increased metabolism of tacrolimus, as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors, such as CYP3A5*3 (rs776746), may also influence metabolism of tacrolimus.
1444704766	AG	Patients with the AG genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype or may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.
1444704767	GG	Patients with the GG genotype and major depression may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.
1183619218	CC	Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444704765	AA	Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram.
1183619219	CG	Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183619220	GG	Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
1448106102	AG	Patients with the AG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1448106103	GG	Patients with the GG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to risperidone.
1448106107	GG	Patients with genotype GG may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
1444704777	CC	Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1184169494	*1/*1	Patients with the CYP2C19*1/*1 genotype who are treated with venlafaxine may have increased metabolism of venlafaxine as compared to patients with the CYP2C19*2/*2 genotype. However no associations are found with response or risk for side effects. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
1184169495	*2/*2	Patients with the CYP2C19*2/*2 genotype who are treated with venlafaxine may have decreased metabolism of venlafaxine as compared to patients with the CYP2C19*1/*1 genotype. However no associations are found with response or risk for side effects. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
1448102587	CC	Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
1448102588	CT	Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
1448102589	TT	Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
1448102594	GG	Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
1448106108	GT	Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
1449004790	AA	Patients with the AA genotype and lymphoma or leukemia who are treated with methotrexate may have increased concentrations of the drug and may have an increased risk of toxicity as compared to patients with the GG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicities.
1444704778	CT	Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype or may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1449004791	AG	Patients with the AG genotype and lymphoma or leukemia who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicities.
1449004792	GG	Patients with the GG genotype and lymphoma or leukemia who are treated with methotrexate may have lower concentrations of the drug and may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicities.
1448999131	*3/*3	Patients with the *3/*3, *3/*4, *3/*5 or *3/*6 genotype (two non-functional alleles) and major depressive disorder 1) may have a decreased metabolism of imipramine and 2) may require a lower dose of imipramine as compared to patients with the *1/*1, *1/*2, *2/*2, *1xN/*1, *1xN/*2, *2xN/*1 or *2xN/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1448999130	*2xN/*2	Patients with the *2XN/*2 genotype and major depressive disorder 1) may have a decreased response, 2) may require a higher dose of imipramine as compared to patients with the *1/*1 or *2/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1183629316	TT	Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183622529	AG	Patients with the AG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype or may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183491291	*1A/*1A	Patients with the *1A/*1A genotype who are treated with atorvastatin may have an increased response to treatment as compared to patients with the *3A/*3A genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491292	*1A/*3A	Patients with the *1A/*3A genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3A/*3A genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491293	*3A/*3A	Patients with the *3A/*3A genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1A/*3A and *1A/*1A  genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1A/*3A genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183622530	GG	Patients with the GG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622562	GG	Patients with the GG genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.
1183619313	CC	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619314	CT	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183619315	TT	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1183622563	GT	Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced  metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.
1183622564	TT	Patients with the TT genotype and major depressive disorder may have reduced  metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.
1183624334	AA	Patients with the AA genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624335	AG	Patients with the AG genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624336	GG	Patients with the GG genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183629317	CT	Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.
1184989942	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with citalopram may have increased response and decreased, but not absent, risk for side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705366	TT	Patients with the TT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.
1444705394	CC	Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.
1444705395	CT	Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.
1448100446	AA	Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100447	AC	Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100448	CC	Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.
1184472680	*22	Patients with the CYP2A6 *22 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with CYP2A6*1A allele. Other genetic and clinical factors may affect enzyme activity of CYP2A6.
1449190613	CC	Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448099731	CC	Patients with the CC genotype may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.
1448099732	CT	Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.
1444705396	TT	Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.
1449190614	CT	Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype, but a lower risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448099733	TT	Patients with the TT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.
1184989943	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with citalopram may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.
1448100453	AA	Rheumatoid Arthritis patients with the genotype AA may be more likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
1448100454	AG	Rheumatoid Arthritis patients with the genotype AG may be more likely to respond to TNF inhibitors compared with patients with genotype GG, or less likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
1448099676	AC	Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1043880660	AA	Patients with the AA genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
1043880661	AG	Patients with the AG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
1043880662	GG	Patients with the GG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have a decreased, but not absent, risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
1448099677	CC	Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1184516224	B (wildtype)/B (wildtype)	Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfametopyrazine may have increased survival of red blood cells as compared to patients homozygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1184516225	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfametopyrazine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1184516226	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients heterozygous for the G6PD Mediterranean variant who are treated with sulfametopyrazine may have a varying degree of G6PD deficient red blood cells and an unknown rate of red blood cell survival as compared to patients with the Mediterranean/Mediterranean or B/B genotype. Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1183624314	CC	Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183630279	CC	Patients with the CC genotype and lung cancer who are treated with carboplatin or cisplatin may have a higher risk of distant disease progression as compared to patients with the AC or AA  genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1183630287	AA	Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.
1183630288	AG	Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.
1183624315	CT	Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624316	TT	Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1184516191	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfadoxine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1448099675	AA	Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1183630278	AC	Patients with the AC genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1184516223	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfametopyrazine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1447953286	AA	Patients with the AA genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953287	AG	Patients with the AG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953288	GG	Patients with the GG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1183491552	GG	Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491553	GT	Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491554	TT	Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183684977	*1/*2xN	Patients with more than two copies of CYP2D6 functional alleles (CYP2D6 ultrarapid metabolizers (i.e., a CYP2D6 activity score of >2.0) ) who are treated with oxycodone may have 1) increased metabolism and response to oxycodone and 2) higher risk of toxicity/side effects as compared to patients with *1/*1 genotype who are CYP2D6 normal/extensive metabolizers. Patients who are CYP2D6 ultrarapid metabolizer should avoid oxycodone use (as well as codeine or tramadol) due to potential for toxicity and should be alert to adverse drug events. Other genetic and clinical factors may also influence a patient's response to oxycodone.
1183684978	*3	Patients with the *3 non-functional allele in combination with another non-functional or reduced function allele who are treated with oxycodone may have 1) decreased metabolism of oxycodone, 2) decreased likelihood of response to oxycodone as compared to patients with *1/*1 genotype who carry two functional alleles. However, conflicting data on oxycodone efficacy have been reported. Patients who are CYP2D6 poor metabolizers may need to avoid oxycodone use due to lack of efficacy and  should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to oxycodone.
1183684979	*4	Patients with the *4 non-functional allele in combination with another non-functional or reduced function allele who are treated with oxycodone may have 1) decreased metabolism of oxycodone, 2) decreased likelihood of response to oxycodone as compared to patients with *1/*1 genotype, who carry two functional alleles. However, conflicting data on oxycodone efficacy have been reported. Patients who are CYP2D6 poor metabolizers may need to avoid oxycodone use due to lack of efficacy and  should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to oxycodone.
1444695581	AG	Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1444695582	GG	Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1444695580	AA	Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG, or GG genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1183631463	CC	Patients with the CC genotype and dementia may have increased clearance of memantine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of memantine.
1183631461	CT	Patients with the CT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.
1444695586	AA	Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels.
1447953267	GG	No data is available for patients with GG genotype, but one might expect patients with the GG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's severity of sleep disorders when treated with methadone.
1183689055	*1/*3	Patients with the CYP2C19 *1/*2 or *1/*3 genotype (intermediate metabolizers) receiving diazepam for preoperative anxiety may have increased metabolism of diazepam (lower AUC and higher clearance) as compared to patients with the poor metabolizer phenotype (*2/*2 or *2/*3). Patients with the intermediate metabolizer phenotype may emerge from anesthesia less rapidly than patients with the extensive metabolizer phenotype (*1/*1). Other genetic and clinical factors may also influence metabolism of diazepam.
1183631462	TT	Patients with the TT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.
1183631924	CT	Patients with the CT genotype (CYP2C19*1/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype  (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1183631925	TT	Patients with the TT genotype (CYP2C19*17/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype  (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1183680308	*2/*3	Patients with the CYP2C19 *2/*3 genotype (*2 = rs4244285;  *3 = rs4986893) who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with rabeprazole as compared to patients with the *1/*1 genotype. Patients also received various antibiotics. However, the majority of studies have found no association between CYP2C19 genotypes and H. pylori eradication rate in patients taking rabeprazole. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680309	*3/*3	Patients with the CYP2C19 *3/*3 genotype (*3 = rs4986893) who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with rabeprazole as compared to patients with the *1/*1 genotype. Patients also received various antibiotics. However, the majority of studies have found no association between CYP2C19 genotypes and H. pylori eradication rate in patients taking rabeprazole. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680507	AA	Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680508	AG	Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680509	GG	Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1448099830	CC	Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.
1448099831	CT	Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.
1448099832	TT	Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.
1183697566	AA	Cancer patients with the AA genotype may have a decreased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
1183697567	AG	Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
1183697568	GG	Cancer patients with the GG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
1448820593	CC	Patients undergoing liver transplantation whose donor livers have the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.
1448820592	CT	Patients undergoing liver transplantation whose donor livers have the CT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.
1448820594	TT	Patients undergoing liver transplantation whose donor livers have the TT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.
1448100455	GG	Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
1448100459	AA	Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
1448820850	AA	Patients with the AA genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.
1444704797	CC	Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703078	AA	Patients with the AA genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
1444703079	AG	Patients with the AG genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
1444667289	TT	Patients with the TT genotype and myotonia permanens may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
1444667355	GG	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1183680534	CC	Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.
1183680533	CT	Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.
1183680532	TT	Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.
1183697536	CC	Patients with the CC genotype and metastatic colorectal cancer may have increased rapid response to treatment containing irinotecan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697537	CT	Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697538	TT	Patients with the TT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1444703080	GG	Patients with the GG genotype who are treated with etravirine may have an increased etravirine clearance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
1444667359	CC	Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.
1444703127	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.
1444704779	TT	Patients with the TT genotype may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704788	CC	Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.
1444704787	CT	Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.
1444704786	TT	Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.
1449718268	CT	Patients with the CT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.
1447952963	AA	Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1184642589	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male patients who are hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfametopyrazine may have a reduced survival of red blood cells as compared to patients with the B (wildtype) haplotype (not associated with G6PD deficiency).  Sulfametopyrazine treatment does not seem to affect hemocrit level. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183679849	CC	Patients with the CC genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1183679850	CT	Patients with the CT genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1183679851	TT	Patients with the TT genotype may have decreased response to nortriptyline in people with Depression as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446897504	GG	Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897505	GT	Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotypes and an increased response as compared to patients with a GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1447952964	AT	Patients with the AT genotype may have decreased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. However, patients with the AT genotype may have increased severity of weight gain as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1184642590	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients who are heterozygous for the Mediterranean variant may have a varying degree of G6PD deficient red blood cells and an unknown effect on red blood survival when treated with sulfametopyrazine as compared to patients with the B/B (wildtype) haplotype or homozygous for the Mediterranean/Mediterranean diplotype.  Sulfametopyrazine treatment does not seem to affect hemocrit level. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449718269	TT	Patients with the TT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.
1446897506	TT	Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GG and GT genotypes genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1184642588	B (wildtype)/B (wildtype)	Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfametopyrazine may have an increased survival of red blood cells compared to patients with variants conferring G6PD deficiency (e.g. homozygous for the Mediterranean variant).  Sulfametopyrazine treatment does not seem to affect hemocrit level. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447952965	TT	Patients with the TT genotype may have decreased plasma insulin levels and decreased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1445585158	AA	Patients with the AA genotype may decreased clearance of daptomycin, resulting in increased concentrations of the drug, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of daptomycin.
1446897515	AA	Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
1449718267	CC	Patients with the CC genotype and breast cancer may have an increased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.
1448635075	*1a/*1a	Pediatric patients with epilepsy and the *1a/*1a genotype may have decreased metabolism of valproic acid and may need a decreased dose of valproic acid when compared to patients with any of the following genotype combinations: *1a/*2a,*1a/*3a,*1a/*4a,*1a/*8, *2a/*2a, *2a/*3a, *2a/*4a, *2a/*8, *3a/*3a, *3a/*4a, *3a/*8 or *4a/*8 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1446905339	GG	Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1446905340	GT	Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1446905341	TT	Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1447946044	non-null/ non-null	Patients with the non-null/ non-null genotype (has two copies of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1447987213	AA	Patients with diabetes mellitus and the AA genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987214	AG	Patients with diabetes mellitus and the AG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AA genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987215	GG	Patients with diabetes mellitus and the GG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987229	AA	Patients with depressive disorder and the AA genotype may have improved response to citalopram or escitalopram as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.
1446908927	GA	Patients with the GA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.
1447987230	AC	Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.
1446908928	GG	Patients with the GG genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.
1446908995	CT	Patients with the CT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1447946021	GG	Patients with the GG genotype and age-related macular degeneration who are treated with bevacizumab may have poorer improvement in visual acuity as compared to patients with the GT or TT genotype. However, another study finds that those with the GG genotype have better improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.
1447946022	GT	Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.
1447946023	TT	Patients with the TT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. However, another study finds that those with the TT genotype have poorer improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.
1448573640	AG	Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.
1448573641	GG	Patients with the GG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.
1448099082	CC	Patients with the CC genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099083	CG	Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1183698832	CC	Patients with the CC genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
1183698833	CG	Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
1183698834	GG	Patients with the GG genotype who have a high risk of cardiovascular disease may have a poorer anti-inflammatory response when treated with fenofibrate as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
1183703001	CC	Patients with the CC genotype and prostate cancer may have shorter progression-free survival time when treated with cyclophosphamide as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence length of progression-free survival.
1183703002	CG	Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.
1183703003	GG	Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.
1183704285	GG	Patients with the GG genotype may have increased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.
1183690415	*1/*1	Patients with two functional CYP2D6 alleles who are treated with aqueous timolol may have decreased exposure to timolol and less excerice heart rate reduction as compared to patients with two non-functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.
1183690411	*3/*3	Patients with two non-functional CYP2D6 alleles (e.g.*3/*3, *3/*4, *4/*4, *5/*4) who are treated with aqueous timolol may have increased exposure to timolol and greater excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.
1448594291	AA	Patients with the AA genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.
1444667343	TT	Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1448099025	AG	Pediatric patients with the AG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.
1448099075	GG	Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099084	GG	Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with calcium channel blockers as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1183690412	*3/*4	Patients with two non-functional CYP2D6 alleles (e.g.*3/*3, *3/*4, *4/*4, *5/*4) who are treated with aqueous timolol may have increased exposure to timolol and increased excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.
1183690413	*4/*4	Patients with two non-functional CYP2D6 alleles (e.g.*3/*3, *3/*4, *4/*4, *5/*4) who are treated with aqueous timolol may have increased exposure to timolol and increased excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.
1183690414	*5/*4	Patients with two non-functional CYP2D6 alleles (e.g.*3/*3, *3/*4, *4/*4, *5/*4) who are treated with aqueous timolol may have increased exposure to timolol and increased excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.
1444705446	AA	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
1448522768	AA	Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1183700254	GG	Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer response to treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183698827	AA	No patients with this genotype were present in the study. However, patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.
1183698828	AG	Patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.
1183698829	GG	Patients with the GG genotype and HIV may have a decreased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.
1448522769	AG	Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1183700495	CT	Patients with the CT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
1183700496	TT	Patients with the TT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
1183700509	AC	Patients with the AC genotype may have  increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
1183700510	CC	Patients with the CC genotype may have  decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
1183632191	AA	Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
1183632192	AG	Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
1448522770	GG	Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522774	CC	Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522775	CT	Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1183632193	GG	Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
1447981284	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981285	CT	Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981286	TT	Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981291	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981292	CG	Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1184472691	CC	Patients with CC genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.
1449191899	CC	Patients with the CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191900	CT	Patients with the CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191901	TT	Patients with the TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1183704344	CC	Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704345	CT	Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704346	TT	Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704354	AA	Patients with the AA genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.
1183704355	AG	Patients with the AG genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.
1183704356	GG	Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.
1184472692	CT	Patients with CT genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype, and increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.
1447981293	GG	Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981298	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981299	CT	Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1183679866	CC	Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679865	CT	Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679864	TT	Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1449564673	AA	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence the dose of warfarin.
1449564674	AG	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin.
1449564675	GG	Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence the dose of warfarin.
1449166831	CT	Individuals with the CT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.
1444700608	AG	Patients with the AG genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype or may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
1444700609	GG	Patients with the GG genotype with colorectal neoplasms who are treated with celecoxib may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
1444700785	GG	Patients with the GG genotype and hypertension who are treated with verapamil may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.
1444700810	AA	Patients with the AA genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
1444700811	AC	Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
1183700860	TT	Patients with the TT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1184472693	TT	Patients with TT genotype and pancreatic cancer who are treated with gemcitabine may have an increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.
1449166832	TT	Individuals with the TT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.
1449564678	AA	Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AA may have an increased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AC and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone.
1449166830	CC	Individuals with the CC genotype may have a decreased response to caffeine or chlorocresol as compared to individuals with the CT or TT genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.
1444700784	AG	Patients with the AG genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype or may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.
1444667353	AA	Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1183698860	AA	Patients with the AA (i.e. UGT1A1 *6/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.
1183698861	AG	Patients with the AG (i.e. UGT1A1 *1/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.
1183698862	GG	Patients with the GG (i.e. UGT1A1 *1/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.
1444667354	AG	Patients with metastasized cancer and the AG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AA genotype and improved response as compared to people with the GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1183704295	AA	Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183704294	AG	Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183704293	GG	Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183704300	CC	Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.
1183704299	CT	Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.
1183704298	TT	Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.
1183704317	AA	Patients with the AA genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.
1183704318	AC	Patients with the AC genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.
1183704319	CC	Patients with the CC genotype may have increased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sildenafil.
1183704395	AA	Patients with the AA genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
1183689996	CC	Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of sirolimus  as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.
1183689997	CT	Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of sirolimus  as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.
1183689998	TT	Transplant recipients with the TT (CYP3A4 *1/*1) genotype may require a decreased dose of sirolimus  as compared to patients with the CC (*1B/*1B) or CT (*1B/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.
1448820851	AG	Patients with the AG genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the GG genotype, or a decreased risk of neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.
1448820852	GG	Patients with the GG genotype with cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.
1450112791	CC	Patients with osteosarcoma and the CC genotype may have increased clearance of methotrexate as compared to patients with the CT or TT genotypes. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1448105712	AA	In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
1183701207	*02:07:01	Patients with one or two copies of the HLA-A*02:07:01 allele who are treated with zonisamide may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-A*02:07:01 alleles or negative for the HLA-A*02:07:01 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1447963708	CC	No patients with the CC genotype were available for analysis, but patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
1444700642	AG	Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.
1444700641	GG	Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.
1447963709	CT	Patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
1450112792	CT	Patients with osteosarcoma and the CT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1449575658	AA	The AA genotype may have decreased catalytic activity of DPYD as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1447963710	TT	Patients with the TT genotype and breast cancer may have a decreased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
1447963747	AA	Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.
1448105706	CC	Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
1448105713	AG	Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
1450112782	TT	Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112793	TT	Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1444700655	CC	Patients with the CC genotype and HIV may have an increased creatinine clearance when treated with tenofovir as compared to patients with the CT genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
1444700656	CT	Patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
1444700657	TT	Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
1448105707	CT	Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
1448105708	TT	Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
1449564371	*1/*2	Patients with the CYP2C19 *1/*2 genotype who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with omeprazole as compared to patients with the *1/*1 genotype, and a lower eradication rate as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. Patients also received amoxicillin and clarithromycin. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3  (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence eradication rate of H. pylori.
1449564372	*1/*3	Patients with the CYP2C19 *1/*3 genotype who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with omeprazole as compared to patients with the *1/*1 genotype, and a lower eradication rate as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. Patients also received amoxicillin and clarithromycin. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3  (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence eradication rate of H. pylori.
1448417902	*3	Patients with the CYP2C19*3 allele in combination with a CYP2C19*2 or *3 allele may have decreased metabolism of clomipramine as compared to patients with the CYP2C19*1/*1 genotype. The number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1444700149	*16	Patients with the CYP2C19*16 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*16 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity of CYP2C19 as compared to *1 during several in-vitro characterizations.The CYP2C19*16 allele was catalytic inactive toward mephenytoin during one in-vitro characterization with 4% of *1 activity for the substrate mephenytoin. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700150	*19	Patients with the CYP2C19*19 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*19 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity as compared to *1 during several in-vitro characterizations.  Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1449156875	CC	Patients with CC genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.
1444700151	*22	Patients with the CYP2C19*22 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*22 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for the substrate mephenytoin was reported in one study. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1447961315	GG	Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles.  Other genetic and clinical factors may also influence a patient's response.
1184516154	B (wildtype)	Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447961357	CC	Patients with the CC genotype may have 1) decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) increased endogenous cortisol compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.
1449156876	CT	Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.
1449156877	TT	Patients with the TT genotype, and HIV infection, have decreased exposure to efavirenz compared to patients with the CC, or CT genotypes. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.
1447946101	CT	Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.
1447946102	TT	Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.
1447961358	CT	Patients with the CT genotype may have decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment). Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.
1447961316	GT	Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
1447961317	TT	Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
1450372000	CC	Patients with the CC genotype may have 1) increased risk of severe toxicity when treated with fluoropyrimidines, 2) decreased metabolism of fluorouracil and 3) decreased disease-free survival times as compared to patients with the TT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1183634050	AA	Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have slightly decreased reduction of systolic blood pressure as compared to patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634051	AG	Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA genotype, and slightly decreased reduction of systolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634052	GG	Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure  as compared to patients with the AA or the AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1450373585	CC	Patients with the CC genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373612	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1183700532	CC	Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
1183697545	AA	Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697546	AG	Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697547	GG	Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1450373613	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1183700533	CT	Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
1183700534	TT	Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
1183700514	TC	Patients with the TC genotype may have  increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183700513	TT	Patients with the TT genotype may have  increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1450373614	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1183698847	CC	Patients with the CC genotype and gastrointestinal stromal tumours may have a shorter time to progression when treated with imatinib, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression.
1183698848	CG	Patients with the CG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.
1183698849	GG	Patients with the GG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.
1183700515	CC	Patients with the CC genotype may have  decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183704396	AG	Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
1183704397	GG	Patients with the GG genotype may have decreased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
1183704412	CC	Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704411	CT	Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704410	TT	Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes CC + CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1184989915	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with escitalopram may have increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and escitalopram response. Other genetic and clinical factors may also influence a patient's response to escitalopram. Please note, study population is White or Unknown.
1184989916	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with escitalopram may have a decreased response or decreased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and escitalopram response. Other genetic and clinical factors may also influence a patient's response to escitalopram. Please note, study population is White or Unknown.
1184990012	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the HTTLPR long form (L allele)/HTTLPR short form (S allele) genotype may have a decreased, but not absent, risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1183615028	E2/E2	Patients APOE E2/E2 genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the APOE E3/E3, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615029	E2/E3	Patients APOE E2/E3 genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the APOE E3/E3, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615030	E2/E4	Patients APOE E2/E4 genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the APOE E3/E3, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615031	E3/E3	Patients APOE E3/E3 genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the APOE E2/E2, E2/E3 or E2/E4 genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615032	E3/E4	Patients APOE E3/E4 genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the APOE E2/E2, E2/E3 or E2/E4 genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615033	E4/E4	Patients APOE E4/E4 genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the APOE E2/E2, E2/E3 or E2/E4 genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183690927	CC	Patients with the CC genotype who are treated with celecoxib may have an increased metabolism of celecoxib and as compared to patients with the CT and TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1183690928	CT	Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1183690929	TT	Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1448109600	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109601	GT	Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1183703762	AG	Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
1183703763	GG	Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
1183704254	CT	Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.
1183703761	AA	Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
1183704255	TT	Patients with the TT genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the toxicity to irinotecan.
1448109602	TT	Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1183704290	AA	Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
1183704289	AG	Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
1183704288	GG	Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
1183564891	GG	Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.
1183564892	GT	Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.
1183564893	TT	No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.
1183614505	AA	Patients with the AA genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
1183614506	AG	Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
1183614507	GG	Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
1183607657	CC	Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607658	CT	Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype, or a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607659	TT	Patients with the TT genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607420	CC	Patients with the CC genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183607421	CT	Patients with the CT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183607422	TT	Patients with the TT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183630739	AA	Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630740	AG	Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630741	GG	Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183631567	GG	Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1183631566	GT	Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1183631565	TT	Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1183631788	CC	Patients with the CC genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.
1183631789	CT	Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.
1183631790	TT	Patients with the TT genotype may have increased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the CC or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.
1183680512	CC	Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680513	CG	Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680514	GG	Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449564373	*2/*2	Patients with the CYP2C19 *2/*2 genotype who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with omeprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. Patients also received amoxicillin and clarithromycin. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3  (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183697389	*1/*1	Patients with the *1/*1 genotype may have increased metabolism of lovastatin as compared to patients carrying the *5 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.
1449564374	*2/*3	Patients with the CYP2C19 *2/*3 genotype who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with omeprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. Patients also received amoxicillin and clarithromycin. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3  (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183697390	*1/*10	Patients with the *1/*10 genotype may have decreased metabolism of lovastatin as compared to patients with the *1/*1 genotype, but increased metabolism of lovastatin as compared to patients with the *10/*10 genotype or who are carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.
1183697391	*10/*10	Patients with the *10/*10 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 allele, but increased metabolism of lovastatin as compared to patients carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.
1183697392	*5/*10	Patients with the *5/*10 genotype may have decreased metabolism of lovastatin as compared to patients without the *5 allele, but increased metabolism of lovastatin as compared to patients with the *5/*5 genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin.
1183697393	*5/*5	Patients with the *5/*5 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.
1447953253	AC	Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.
1447953252	CC	Patients with the CC genotype and narcolepsy may have a decreased response to modafinil as compared to patients with the AC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to modafinil.
1447953254	CT	Patients with the CT genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.
1183702161	CC	Patients with the CC genotype may required reduced dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence  warfarin dose. This variant rs56165452 defines CYP2C9*4.
1183702162	CT	Patients with the CT genotype may required reduced dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence  warfarin dose. This variant rs56165452 defines CYP2C9*4.
1183702163	TT	Patients with the TT genotype may required higher dose of warfarin as compared to patients with the CT or CC genotype. Other clinical or genetic factors may also influence  warfarin dose. This variant rs56165452 defines CYP2C9*4.
1183702965	CC	Patients with the CC genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1447954385	GG	Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1184654014	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) and an infection who are treated with co-trimoxazole may have a reduced, but not absent, risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the Canton variant). Sulfamethoxazole seems to underlie the effect on reducing red blood cell lifespan, rather than trimethoprim. Several studies find no association with increased risk in patients with G6PD deficiency. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183630677	GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC	Patients with the GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC genotype and liver cirrhosis with refractory ascites may be less likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC/del or del/del genotype. Other genetic and clinical factors may also influence response to clonidine.
1183630678	GGGGAGCTTTCCCAGAGACCC/del	Patients with the GGGGAGCTTTCCCAGAGACCC/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC genotype. Other genetic and clinical factors may also influence response to clonidine.
1183630679	del/del	Patients with the del/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC genotype. Other genetic and clinical factors may also influence response to clonidine.
1183631555	CC	Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631556	CT	Patients with the CT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1447954386	GT	Patients with the GT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1447954387	TT	Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1183631557	TT	Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631712	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have a reduced response to pantoprazole (smaller % of time with intragastric pH > 4.0, and a lower intragastric pH during a 24-hour time period) as compared to patients with the *2/*2, *2/*3, or *3/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence response to pantoprazole.
1183631713	*1/*2	Patients with the CYP2C19 *1/*2 genotype may have a reduced response to pantoprazole (smaller % of time with intragastric pH > 4.0, and a lower intragastric pH during a 24-hour time period) as compared to patients with the *2/*2, *2/*3, or *3/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence response to pantoprazole.
1183631714	*1/*3	Patients with the CYP2C19 *1/*3 genotype may have a reduced response to pantoprazole (smaller % of time with intragastric pH > 4.0, and a lower intragastric pH during a 24-hour time period) as compared to patients with the *2/*2, *2/*3, or *3/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence response to pantoprazole.
1184654015	B (wildtype)/B (wildtype)	Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) and an infection who are treated with co-trimoxazole may have a reduced, but not absent, risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the Canton variant). Sulfamethoxazole seems to underlie the effect on reducing red blood cell lifespan, rather than trimethoprim. Several studies find no association with increased risk in patients with G6PD deficiency. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184642587	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfametopyrazine may have an increased survival of red blood cells compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the Mediterranean variant). Sulfametopyrazine treatment does not seem to affect hemocrit level. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183631550	AA	Patients with the AA genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631551	AG	Patients with the AG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631552	GG	Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1447945809	*1/*1	Children with the CYP2B6*1/*1 diplotype and B-cell non-Hodgkin's lymphoma may have increased clearance of cyclophosphamide as compared to children with the *1/*6 or *6/*6 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.
1183698809	CC	Patients with the CC genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype. Other genetic and clinical factors may also influence response to these drugs.
1183698810	CT	Patients with the CT genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype, or a poorer response as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.
1183698811	TT	Patients with the TT genotype may have a poorer response to bumetanide, furosemide or torasemide, as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.
1447945810	*1/*6	Children with the CYP2B6*1/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.
1447945811	*6/*6	Children with the CYP2B6*6/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.
1183700484	CC	Patients with the CC genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
1183700485	CT	Patients with the CT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
1183700486	TT	Patients with the TT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
1447990927	AA	The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
1447990928	AG	The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the GG genotypes and increased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
1447990905	AC	Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension.
1449564679	AC	Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone.
1449564680	CC	Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype CC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone.
1183704400	AA	Patients with the AA genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
1183704401	AT	Patients with the AT genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
1183704402	TT	Patients with the TT genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
1183631288	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.
1183631289	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.
1183631290	del/del	Patients with the del/del genotype and diabetes or hypertension may have a better response when treated with benazepril or perindopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.
1448102635	CC	Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102636	CT	No significant results have been seen for patients with the CT genotype.
1448102637	TT	Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1446908328	GG	Patients with the GG genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy.
1446908329	GT	Patients with the GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy.
1446908330	TT	Patients with the TT genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy.
1447680032	ATTTGTTCATGCCT/ATTTGTTCATGCCT	Patients with colorectal cancer and the HLA-G ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1448106234	(289BP ALU)/(289BP ALU)	Patients homozygous for the 289bp ALU insertion (or "I" allele) with coronary heart disease may have a better response to treatment with salvianolate as compared to patients with heterozygous for the I allele and the del (or "D") allele or homozygous for the D allele. Other genetic and clinical factors may also influence response to salvianolate.
1448106235	(289BP ALU)/del	Patients heterozygous for the 289bp ALU insertion (or "I" allele) and the del (or "D") allele with coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients homozygous for the I allele. Other genetic and clinical factors may also influence response to salvianolate.
1448106236	del/del	Patients homozygous for the del (or "D") allele with coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients homozygous for the 289bp ALU insertion (or "I" allele). Other genetic and clinical factors may also influence response to salvianolate.
1447680031	del/ATTTGTTCATGCCT	Patients with colorectal cancer and the HLA-G del/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680030	del/del	Patients with colorectal cancer and the HLA-G del/del genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the HLA-G del/ATTTGTTCATGCCT or ATTTGTTCATGCCT/ATTTGTTCATGCCT genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1448106240	AA	Patients with the AA genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.
1448106241	AG	Patients with the AG genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.
1183630575	CC	Patients with the CC genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183630576	CT	Patients with the CT genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183630577	TT	Patients with the TT genotype and depression may be more likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183614617	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Healthy males with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have a decreased response when given bumetanide, furosemide or torasemide as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.
1183614616	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Healthy males with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype, or a decreased response as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.
1183614615	del/del	Healthy males with the del/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.
1183630693	CC	Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.
1183630694	CT	Patients with the CT genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype, or may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.
1183630695	TT	Patients with the TT genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.
1447680037	AA	Patients with colorectal cancer and the AA genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680038	AG	Patients with colorectal cancer and the AG genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680039	GG	Patients with colorectal cancer and the GG genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1448604084	CTT/CTT	Patients with cystic fibrosis and the CTT/CTT genotype may not receive benefit from cavosonstat. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.
1448604085	CTT/del	Patients with cystic fibrosis and the CTT/del genotype may not receive benefit from cavosonstat. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.
1446897480	AA	Patients with the AA genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1183631380	*1/*1	Patients with the *1/*1 genotype who are CYP2D6 normal/extensive metabolizers may have increased metabolism/clearance of zuclopenthixol as compared to patients with non-functional (*3 or*4) alleles. Other genetic and clinical factors may also influence a patient's response to zuclopenthixol.
1183631381	*1/*4	Patients with the *1/*4 genotype who are CYP2D6 intermediate metabolizers may have decreased metabolism/clearance of zuclopenthixol as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to zuclopenthixol.
1183631382	*3/*4	Patients with the *3/*4 genotype who are CYP2D6 poor metabolizers may have decreased metabolism/clearance of zuclopenthixol as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to zuclopenthixol.
1447961359	TT	Patients with the TT genotype may have 1) increased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) altered hypothalamic pituitary adrenal axis and decreased endogenous cortisol compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.
1450377189	CC	Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377190	CT	Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377191	TT	Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1447962615	CC	Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1183631715	*2/*2	Patients with the CYP2C19 *2/*2 genotype may have a better response to pantoprazole (greater % of time with intragastric pH > 4.0, and a higher intragastric pH during a 24-hour time period) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence response to pantoprazole.
1183631716	*2/*3	Patients with the CYP2C19 *2/*3 genotype may have a better response to pantoprazole (greater % of time with intragastric pH > 4.0, and a higher intragastric pH during a 24-hour time period) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence response to pantoprazole.
1183631717	*3/*3	Patients with the CYP2C19 *3/*3 genotype may have a better response to pantoprazole (greater % of time with intragastric pH > 4.0, and a higher intragastric pH during a 24-hour time period) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. One of the studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence response to pantoprazole.
1448604086	del/del	Patients with cystic fibrosis and the del/del genotype may receive benefit from cavosonstat as measured in reduction of sweat chloride content but not in change of FEV1. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.
1448603654	CC	Patients who are undergoing liver transplant and receive a liver with the CC genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.
1448603655	CG	Patients who are undergoing liver transplant and receive a liver with the CG genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.
1448603656	GG	Patients who are undergoing liver transplant and receive a liver with the GG genotype, or patients undergoing a lung transplant, may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.
1184997009	*15:18:01	Patients with one or two copies of the HLA-B*15:18:01 allele have an increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to patients with no HLA-B*15:18:01 alleles or negative for the HLA-B*15:18:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1184996887	*13:01:01	Patients with one or two copies of the HLA-B*13:01:01 allele who are treated with dapsone may have an increased risk for dapsone hypersensitivity syndrome or dapsone-induced severe cutaneous adverse reactions as compared to patients with no HLA-B*13:01:01 alleles or negative for the HLA-B*13:01:01 test. Other genetic and clinical factors may also influence a patient's response to dapsone.
1184997015	*15:19	Patients with one or two copies of the HLA-B*15:19 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*15:19 alleles or negative for the HLA-B*15:19 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1444706212	AC	Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's atorvastatin response.
1183679854	AA	Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to  patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679855	AG	Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to  patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679856	GG	Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to  patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1184512143	AC	Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response  as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1184512144	CC	Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1444706832	CC	Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448999125	*1/*1	Patients with the *1/*1 genotype and major depressive disorder 1) may have an increased metabolism of imipramine, 2) may require a higher dose of imipramine as compared to patients with two non-functional alleles (*3, *4, *5, *6) or 3) may have an increased response, 4) may require a lower dose as compared to patients with a duplicated functional allele (*1XN or *2XN). The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1183704235	CT	Patients with the CT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
1184996948	*15:11:01	Patients with one or two copies of the HLA-B*15:11:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:11:01 alleles or negative for the HLA-B*15:11:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1448999126	*1xN/*1	Patients with the *1XN/*1 genotype and major depressive disorder 1) may have a decreased response, 2) may require a higher dose of imipramine as compared to patients with the *1/*1 or *2/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1448999127	*1xN/*2	Patients with the *1XN/*2 genotype and major depressive disorder 1) may have a decreased response, 2) may require a higher dose of imipramine as compared to patients with the *1/*1 or *2/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1184996963	*57:01:01	Patients with one or two copies of the HLA-B*57:01:01 allele have an increased risk of drug-induced liver injury when treated with flucloxacillin as compared to patients with no HLA-B*57:01:01 alleles or negative for the HLA-B*57:01:01 test. Other genetic and clinical factors may also influence a patient's risk of flucloxacillin-induced adverse reactions.
1444706213	CC	Patients with the CC genotype may have increased response to atorvastatin as compared to patients with the AA genotype.  Other genetic and clinical factors may influence also a patient's atorvastatin response.
1183704234	TT	Patients with the TT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
1183704236	CC	Patients with the CC genotype may have decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
1450375342	*1	Patients with the *1 allele may have decreased metabolism of nicotine as compared to the *4 allele but increased metabolism as compared to the *6 allele. Other genetic or clinical factors may also affect a patient's metabolism of nicotine.
1447678618	TT	Patients with the TT genotype and schizophrenia may lower weight gain when treated with antipsychotics as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1450043714	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450043715	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450375055	GG	Patients with testicular cancer and the GG genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.
1183704417	CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC	Patients with the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype may have decreased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/del or del/del. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.
1183704416	CTGGTGAGGAGAGAACC/del	Patients with the CTGGTGAGGAGAGAACC/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.
1183704415	del/del	Patients with the del/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.
1184512142	AA	Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447953049	AA	Patients with the AA genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1450375056	GT	Patients with testicular cancer and the GT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375057	TT	Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.
1447679817	CC	Patients with the CC genotype and epilepsy who are treated with carbamazepine 1) may be more likely to respond to treatment 2) may be less likely to discontinue treatment as compared to patients with the TT genotype. Please note; no association was found in a large cohort and meta-analysis. Other genetic and clinical factors may also influence a patient's response to carbamazepine and treatment retention rate.
1450044592	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence a patient's risk of developing Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044593	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1447953050	AC	Patients with the AC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1447953051	CC	Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1447953055	CC	Patients with the CC genotype may have decreased plasma drug concentration when treated with efavirenz as compared to patients with the CT or TT genotypes. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.
1184642591	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Female patients who are homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfametopyrazine may have a reduced survival of red blood cells as compared to patients with the B (wildtype) haplotype (not associated with G6PD deficiency).  Sulfametopyrazine treatment does not seem to affect hemocrit level. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184748988	GG	Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.
1184642812	A- 202A_376G	Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447953056	CT	Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.
1448532367	GG	Patients with genotype GG may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1448532366	GT	Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1448532365	TT	Patients with genotype TT may have increased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes GG or GT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1184748986	CC	Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.
1184748987	CG	Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.
1447953057	TT	Patients with the TT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.
1449564342	CC	Patients with the CC genotype who are treated with warfarin may have an increased risk of over-coagulation as compared to patients with the TT genotype, although this is contradicted in one study, which found that the CC genotype may have an increased risk versus the CT genotype as well as the TT genotype. Other clinical and genetic factors may also influence risk of over-coagulation in patients administered warfarin.
1449564343	CT	Patients with the CT genotype who are treated with warfarin may have a decreased risk of over-coagulation as compared to patients with the TT genotype, although this is contradicted in one study which found that the CT genotype may have an increased risk of over-coagulation versus the TT genotype. Other clinical and genetic factors may also influence risk of over-coagulation in patients administered warfarin.
1448568523	AA	Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with cancer as compared to patients with the GG genotype, but some studies found increased survival or no association with survival. Other genetic and clinical factors may also influence a patient's response.
1448568524	AG	Patients with the AG genotype may have an average risk for progression with platinum-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
1448568525	GG	Patients with the GG genotype may have decreased risk for progression with platinum-based treatments as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
1448568210	AA	Patients with the AA genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.
1448568211	AG	Patients with the AG genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.
1448568212	GG	Patients with the GG genotype may have increased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to cetuximab.
1183684135	CC	Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684134	CT	Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684133	TT	Patients with the TT genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183565712	CC	Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
1183565713	CT	Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
1183565714	TT	Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
1183603319	CC	Women with the CC genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CT or TT genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.
1183603320	CT	Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.
1183603321	TT	Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.
1449163930	AA	Patients with the AA genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.
1449163931	AG	Patients with the AG genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.
1449163932	GG	Patients with the GG genotype may have increased metabolism of caffeine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.
1449164445	CC	Patients with the CC genotype may have increased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CT + TT. Other genetic and clinical factors may also influence the response to interferon-alpha.
1449164446	CT	Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.
1449164447	TT	Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.
1448102825	GG	Patients with the GG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)
1447960206	CC	Patients with the CC genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.
1447960207	CG	Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.
1447960208	GG	Patients with the GG genotype and hypertension may have an increased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.
1447960264	CC	Patients with the CC genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.
1447960265	CT	Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.
1448102829	GG	Patients with the GG genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.
1183564846	AA	Patients with the AA genotype and heart failure may have an increased response when treated with candesartan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence response to candesartan.
1183564847	AC	Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.
1183564848	CC	No patients with the CC genotype were present in the study analysis. However, patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.
1448102830	GT	Patients with the GT genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon.  Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.
1183631468	AA	Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631467	AG	Patients with the AG genotype may have a reduced response to simvastatin treatment (a lower  reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631466	GG	Patients with the GG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. A seperate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1446906443	AA	Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.
1446906442	AC	Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.
1446906441	CC	Patients with genotype CC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.
1446906450	CC	Patients with genotype CC may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections  as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
1446906449	CT	Patients with genotype CT may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections  as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
1448428922	CC	Patients with the CC genotype and gout may require a dose of 300 mg/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
1448428921	CT	Patients with the CT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
1444700664	AA	Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.
1444700663	AC	Patients with the AC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.
1444700662	CC	Patients with the CC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.
1444700744	CC	Patients with the CC genotype and major depression who are treated with citalopram may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1444667360	CG	Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.
1444667361	GG	Patients with the GG genotype may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.
1183704378	GT	Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.
1183704326	AA	Patients with the AA genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.
1444672978	non-null/non-null	Patients with GSTT1 non-null/non-null genotype may have decreased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype null/null. Other genetic and clinical factors may also influence the response to imatinib.
1444672979	non-null/null	Patients with GSTT1 non-null/null genotype may have decreased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype null/null. Other genetic and clinical factors may also influence the response to imatinib.
1444672980	null/null	Patients with GSTT1 null/null genotype may have increased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype non-null/non-null + non-null/null. The risk of imatinib failure was increased further if GSTT1del was accompanied by GSTM1 del. Other genetic and clinical factors may also influence the response to imatinib.
1448428920	TT	Patients with the TT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
1444700743	CT	Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype or may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1444700742	TT	Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1444700755	CC	Patients with the CC genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1448428939	CC	Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428940	CT	Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1183679872	AA	Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679873	AG	Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679874	GG	Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.
1183704327	AC	Patients with the AC genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.
1183704328	CC	Patients with the CC genotype may have lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sunitinib.
1183704377	GG	Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.
1183704379	TT	Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.
1183614740	CC	Patients with the CC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.
1183614741	CT	Patients with the CT genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.
1183614742	TT	Patients with the TT genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC or CT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.
1183615182	CC	Healthy males with the CC (CYP3A5 *3/*3) genotype may have increased metabolism of amlodipine as compared to healthy males with the CT or TT (*3/*1 or *1/*1) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.
1183615183	CT	Healthy males with the CT (CYP3A5 *3/*1) genotype may have decreased metabolism of amlodipine as compared to patients with the CC (*3/*3) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.
1183615184	TT	Healthy males with the TT (CYP3A5 *1/*1) genotype may have decreased metabolism of amlodipine as compared to patients with the CC (*3/*3) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.
1183634108	CT	Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the TT genotype and increased reduction of systolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634109	TT	Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of systolic blood pressure as compared to patients with the CC or the CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183700479	*1	Patients with the CYP2D6*1 allele may have lower S-propranolol plasma concentration when treated with propranolol as compared to patients with the CYP2D6*10 allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of propranolol.
1183700478	*10	Patients with the CYP2D6*10 allele may have higher S-propranolol plasma concentration when treated with propranolol as compared to patients with the CYP2D6*1 allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of propranolol.
1446903312	CC	Patients with the CC genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1183634107	CC	Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the CT or the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1446903313	CT	Patients with the CT genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1446903314	TT	Patients with the TT genotype and colon cancer may have a shorter time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1183614736	AA	Patients with the AA genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.
1183614737	AC	Patients with the AC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.
1183614738	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the AA or AC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.
1449167088	AA	Caucasian patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to Caucasian patients with the AG or GG genotypes. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167090	GG	Caucasian patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1448100460	AG	Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared with patients with genotype GG, or more likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
1448100461	GG	Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
1448100466	AA	Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1446899710	AA	Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449167089	AG	Caucasian patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1184989526	*08:01	Patients with one or two copies of the HLA-C*08:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1448100467	AC	Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100468	CC	Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.
1448100473	CC	Patients with the CC genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the CT and TT genotypes. Other factors may affect trough concentrations of telaprevir.
1449167095	CC	Caucasian patients with the CC genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1184997021	*15:27:01	Patients with one or two copies of the HLA-B*15:27:01 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*15:27:01 alleles or negative for the HLA-B*15:27:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1183630631	GG	Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.
1183630632	GT	Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.
1183630633	TT	Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.
1183615009	*1/*1	Patients with the CYP2B6 *1/*1 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615010	*1/*4	Patients with the CYP2B6 *1/*4 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615011	*1/*5	Patients with the CYP2B6 *1/*5 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615012	*1/*6	Patients with the CYP2B6 *1/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615013	*1/*7	Patients with the CYP2B6 *1/*7 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615014	*4/*6	Patients with the CYP2B6 *4/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615015	*5/*5	Patients with the CYP2B6 *5/*5 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615016	*5/*6	Patients with the CYP2B6 *5/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183615017	*6/*6	Patients with the CYP2B6 *6/*6 genotype and depression may have increased metabolism of mirtazapine as compared to patients with the CYP2B6 *1/*1, *1/*4, *1/*5, *1/*6, *1/*7, *4/*6, *5/*5 or *5/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.
1183631541	GG	Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631542	GT	Patients with the GT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1444700145	*1/*1	Patients with the CYP2C19*1 allele may have an increased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*5, *6, *8, *9, *10, *14, *16, *19, *22, *23, *24, *25, *26 alleles. The CYP2C19*1 allele was found to have an increased clearance of mephenytoin and an increased catalytic activity as compared to CYP2C19*5, *6, *8, *9, *10, *14, *16, *19, *22, *23, *24, *25, *26 during in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700146	*10	Patients with the CYP2C19*10 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*10 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity of CYP2C19 as compared to *1 during several in-vitro characterizations. 7% of the clearance ration of *1 for mephenytoin was reported in one study and several studies report significant lower catalytic activity. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700147	*11 + *13 + *15 + *18	Patients with the CYP2C19*11, *13, *15, *18 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. No significant differences in the clearance of mephenytoin were found during several in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700148	*14	Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*14 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterization. 65% of the clearance ratio of *1 for mephenytoin was reported, while a separate study found no differences in catalytic activity compared to CYP2C19*1. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1183631543	TT	Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631783	CC	Patients with the CC genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
1183631784	CT	Patients with the CT genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
1183631785	TT	Patients with the TT genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the CC or CT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
1183604504	AA	Patients with the AA genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.
1183604505	AG	Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.
1183604506	GG	Patients with the GG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.
1183614692	CC	Patients with the CC genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.
1183614693	CT	Patients with the CT genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype, or increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence hearing and vision-related side-effects.
1183614694	TT	Patients with the TT genotype and major depressive disorder may have increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.
1183630685	AA	Patients with the AA genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1183630686	AG	Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183630687	GG	Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1449156931	CT	Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156932	TT	Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156935	AA	Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1447679818	CT	Patients with the CT genotype and epilepsy who are treated with carbamazepine 1) may be more likely to respond to treatment 2) may be less likely to discontinue treatment as compared to patients with the TT genotype. Please note; no association was found in a large cohort and meta-analysis. Other genetic and clinical factors may also influence a patient's response to carbamazepine and treatment retention rate.
1447679819	TT	Patients with the TT genotype and epilepsy who are treated with carbamazepine 1) may be less likely to respond to treatment 2) may be more likely to discontinue treatment as compared to patients with the TT genotype. Please note; no association was found in a large cohort and meta-analysis. Other genetic and clinical factors may also influence a patient's response to carbamazepine and treatment retention rate.
1446905300	AA	Children with the AA genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to children with the GG genotype. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient's response to treatment.
1183615583	AA	Patients with the AA genotype who have hypertension and left ventricular hypertrophy may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the AG or GG genotype. However, no significant results have been seen for change in diastolic blood pressure. Additionally, a different study found no association with change in systolic or diastolic blood pressure for this genotype. Other genetic and clinical factors may also influence change in blood pressure.
1183615584	AG	Patients with the AG genotype who have hypertension and left ventricular hypertrophy may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the AA genotype. However, no significant results were seen for change in diastolic blood pressure. Additionally, a different study found no association with change in systolic or diastolic pressure for this genotype. Other genetic and clinical factors may also influence change in blood pressure.
1183615585	GG	Patients with the GG genotype who have hypertension and left ventricular hypertrophy may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the AA genotype. However, no significant results were seen for change in diastolic blood pressure. Additionally, a different study found no association with change in systolic or diastolic pressure for this genotype. Other genetic and clinical factors may also influence change in blood pressure.
1183630591	CC	Patients with the CC genotype and left ventricular hypertrophy may have a smaller percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.
1183630592	CG	Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.
1183630593	GG	Patients with the GG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.
1183634101	TT	Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1446905301	AG	Children with the AG genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to children with the GG genotype or may have a better response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to patients with the AA genotype. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient's response to treatment.
1446905302	GG	Children with the GG genotype with asthma who are treated with salmeterol or salbutamol may have a better response to treatment (as measured by a decreased risk of asthma excerbations and higher quality of life scores) as compared to children with the AA genotype. This association does not seem to apply to lung function measurements. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient's response to treatment.
1449577704	*3 + *4  + *5 + *6	Patients with two non-functional CYP2D6 alleles (e.g. *3/*3; *4/*4; *4/*6; *4/*5) (CYP2D6 poor metabolizer) who are treated with fluvoxamine may have increased AUC, Cmax and half-life time of fluvoxamine (decreased clearance) as compared to patients with two functional CYP2D6 alleles (*1/*1). However, contradictory findings are reported. Studies investigating multiple antidepressants including fluvoxamine found no association with side effects or response but one study found that *4/*4 was associated with decreased dose. Other genetic and clinical factors may also influence a patient's metabolism of fluvoxamine.
1183634099	CC	Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634100	CT	Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a  decreased reduction of diastolic blood pressure as compared to patients with the  CC genotype and increased reduction of diastolic blood pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1447680047	CC	Patients with colorectal cancer and the CC genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the CT genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447943681	CT	Patients with the CT genotype and heart failure may have decreased response to hydralazine  and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
1448102823	CC	Patients with the CC genotype and breast cancer may have a poorer response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)
1448102824	CG	Patients with the CG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)
1183630587	AA	Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.
1183630588	AG	Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence systolic blood pressure response to atenolol.
1183630589	GG	Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.
1183630673	AA	Patients with the AA genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence general side-effect burden.
1183630674	AC	Patients with the AC genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype, or a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.
1183630675	CC	Patients with the CC genotype and major depressive disorder may have a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.
1183615384	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the AG genotype. Other genetic and clinical factors may also influence time to progression.
1183615385	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.
1183615386	GG	No patients with the GG genotype were present in this study. However, patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.
1447943682	TT	Patients with the TT genotype and heart failure may have increased response to hydralazine  and isosorbide dinitrate compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
1447943695	CC	People with CC genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
1447943696	CT	People with CT genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
1183679809	CC	Patients with the CC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1447943697	TT	People with TT genotype may have increased clearance of quetiapine compared with people with genotypes CC or CT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
1447943715	AA	People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.
1447943716	AG	People with genotype AG may have decreased exposure to silibinin compared to people with genotypes GG. Other clinical and genetic factors may affect a person's exposure to silibinin.
1447943717	GG	People with genotype GG may have increased exposure to silibinin compared to people with genotypes AA or AG. Other clinical and genetic factors may affect a person's exposure to silibinin.
1183679810	CT	Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679811	TT	Patients with the TT genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1448616385	TT	Patients with the TT genotype and cancer may have an decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.
1448616392	AA	Pediatric patients with the AA genotype and medulloblastoma may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.
1448616393	AG	Pediatric patients with the AG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.
1448616394	GG	Pediatric patients with the GG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.
1448616432	AG	Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1183615536	AA	Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
1183615537	AG	Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
1183615538	GG	Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
1448616426	GG	Patients with the GG genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1448616427	GT	Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1448616428	TT	Patients with the TT genotype and NSCLC who are treated with cisplatin may have an reduced risk of severe ototoxicity as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1448105953	TT	Patients with the TT genotype are more likely to respond to repaglinide  than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
1448616431	AA	Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1183679846	AA	Patients with the AA genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AC or CC. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679845	AC	Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679844	CC	Patients with the CC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183684165	CC	Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684164	CT	Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183631272	TT	Patients with the TT genotype and non-small cell lung cancer may have increased glucuronidation of SN-38 as compared to patients with the T/del or del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38.
1183631273	del/del	Patients with the del/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT or T/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38.
1183681867	AA	Patients with the AA genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
1447954400	AG	Patients with the AG genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1447954401	GG	Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1183631271	T/del	Patients with the T/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT genotype, or increased glucuronidation of SN-38 as compared to patients with the del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38.
1183681868	AG	Patients with the AG genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
1183681869	GG	Patients with the GG genotype may have decreased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
1449311197	GG	Patients with the GG genotype and ALL or lymphoma who are treated with methotrexate may have 1) a reduced risk of myelosuppression and decreased likelihood of red blood cell transfusion 2) may have an increased risk of mucositis 3) may require a lower dose, as compared to patients with the TT genotype. The majority of studies find no association with methotrexate concentrations or toxicity and genotypes of this variant. Other genetic and clinical factors may also influence a patient's dosage and risk of methotrexate-induced toxicity.
1449311198	GT	Patients with the GT genotype and ALL or lymphoma who are treated with methotrexate may have 1) an increased risk of myelosuppression 2) may have a reduced risk of mucositis as compared to  patients with the GG genotype, and 3) may require a lower dose as compared to patients with the TT genotype. The majority of studies find no association with methotrexate concentrations or toxicity and genotypes of this variant. Other genetic and clinical factors may also influence a patient's dosage and risk of methotrexate-induced toxicity.
1449311199	TT	Patients with the TT genotype and ALL or lymphoma who are treated with methotrexate may have 1) an increased risk of myelosuppression and an increased likelihood of red blood cell transfusion 2) may have a reduced risk of mucositis 3) may require a higher dose, as compared to  patients with the GG genotype. The majority of studies find no association with methotrexate concentrations or toxicity and genotypes of this variant. Other genetic and clinical factors may also influence a patient's dosage and risk of methotrexate-induced toxicity.
1447954529	AA	Patients with the AA genotype may have lower platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the efficacy of clopidogrel.
1447954528	AG	Patients with the AG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.
1447954527	GG	Patients with the GG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.
1184348732	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1183700525	CC	Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183700524	TC	Patients with the TC genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183700523	TT	Patients with the TT genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183630603	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183630604	AG	Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183630605	GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183631481	AA	Patients with the AA genotype may have increased clearance of talinolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of talinolol.
1183631482	AG	Patients with the AG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.
1183631483	GG	Patients with the GG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.
1184642813	A- 202A_376G/A- 202A_376G	Female patients with the A- 202A_376G/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183702966	CT	Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702967	TT	Patients with the TT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1447979275	CT	Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.
1447979276	TT	Female patients with the TT genotype and rheumatoid arthritis may have a better response when treated with leflunomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.
1184642814	A- 202A_376G/B (wildtype)	Female patients with the A- 202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with sulfasalazine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G/A- 202A_376G or B/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447680048	CT	Patients with colorectal cancer and the CT genotype may have a better response to capecitabine or fluorouracil as compared to patients with the CC genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1449577702	*1/*5	Patients with the CYP2D6*1/*5 genotype who are treated with fluvoxamine may have increased steady-state plasma concentration-to-dose (C/D) ratio as compared to patients with the *1/*1 genotype. However, contradictory findings reporting no association with fluvoxamine plasma concentrations are published. Studies investigating multiple antidepressants including fluvoxamine found no association with side effects or response. Other genetic and clinical factors may also influence a patient's metabolism of fluvoxamine.
1449577703	*10/*10	Patients with the CYP2D6*10/*10 genotype who are treated with fluvoxamine may have increased 1) steady-state plasma concentration-to-dose (C/D) ratio or increased fluvoxamine plasma concentrations and 2) risk of developing gastrointestinal side effects as compared to patients with the *1/*1 genotype. However, contradictory findings with no association with plasma concentrations or side effect risk are reported. Additionally, studies investigating multiple antidepressants including fluvoxamine found no association with with side effects or response. Other genetic and clinical factors may also influence a patient's metabolism of fluvoxamine.
1183614869	CC	Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1447979274	CC	Female patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to leflunomide.
1447979281	AA	Patients with the AA genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1183614870	CG	Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614871	GG	Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183630581	CC	Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183602694	AA	Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602695	AG	Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602696	GG	Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604440	CC	Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604441	CT	Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604442	TT	Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183630715	CC	Patients with the CC genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183630716	CG	Patients with the CG genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183630717	GG	Patients with the GG genotype and diabetes may be more likely to respond to fenofibrate treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1449190399	GG	Patients with the GG genotype may have an increased likelihood of developing either heroin or cocaine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.
1449190400	GT	Patients with the GT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.
1449190401	TT	Patients with the TT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.
1449564723	CC	Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype who are treated with methotrexate may have an increased risk of leukopenia and neutropenia as compared to the AA genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.
1449564722	AA	Patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype who are treated with methotrexate may have a decreased risk of leukopenia and neutropenia as compared to the CC genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.
1447943657	GG	Patients with the GG genotype and Alzheimer's disease may have decreased response to rivastigmine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
1447943680	CC	Patients with the CC genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
1183615043	*1/*1	Patients with the CYP2B6 *1/*1 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615044	*1/*4	Patients with the CYP2B6 *1/*4 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615045	*1/*5	Patients with the CYP2B6 *1/*5 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183555572	CC	Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183555573	CT	Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183555574	TT	Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183613867	CC	Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183613868	CT	Patients with the CT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183613869	TT	Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602850	GG	Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602851	GT	Patients with the GT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602852	TT	Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183630765	CC	Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.
1183630766	CT	Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.
1183630767	TT	Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.
1183615436	*1/*1	Patients with the CYP2C19 *1/*1 genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *2/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183615437	*1/*2	Patients with the CYP2C19 *1/*2 genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *2/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183615438	*2/*2	Patients with the CYP2C19 *2/*2 genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *1/*1 or *1/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183684163	TT	Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183690893	AA	Patients with the AA genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.
1183690894	AG	Patients with the AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.
1183690895	GG	Patients with the GG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.
1183693357	CC	Patients with the CC (CYP2C9 *3/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA or AC (*1/*1 or *1/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib.
1184986255	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased metabolism of sparteine as compared to patients with the CYP2D6*4/*11 or *4/*12 or *4/*59 or *5/*7 or *5/*8 or *41/*62 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1183614500	AA	Patients with the AA genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183614501	AG	Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183614502	GG	Patients with the GG genotype and cocaine dependence may have a decreased response when treated with disulfiram as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183615230	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and conditions such as kidney disease, heart disease, hypertension and arteriosclerosis may have an increased response when treated with enalapril as compared to patients with the del/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. However, evidence is highly contradictory, with almost half the studies showing a decreased response to enalapril for this genotype. Some patients were also treated with losartan or atenolol. One study found an increased risk of kidney failure for this genotype (compared to the del/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotypes), and another a decreased response in bone mineral density (compared to the del/del genotype). Other genetic and clinical factors may also influence a patient's response to enalapril, risk of kidney failure or response in bone mineral density.
1183615231	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and conditions such as kidney disease, heart disease, hypertension and arteriosclerosis may have an increased response when treated with enalapril as compared to patients with the del/del genotype. However, evidence is highly contradictory, with one study showing a decreased response for this genotype compared to the del/del genotype, one showing an increased response compared to the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype, and another a decreased response compared to the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Some patients were also treated with losartan or atenolol. One study found a decreased risk of kidney failure for this genotype compared to ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, and another a decreased response in bone mineral density compared to del/del. Other genetic and clinical factors may also influence a patient's response to enalapril, risk of kidney failure or response in bone mineral density.
1183615232	del/del	Patients with the del/del genotype and conditions such as kidney disease, heart disease, hypertension and arteriosclerosis may have a decreased response when treated with enalapril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, evidence is highly contradictory, with almost half the studies showing an increased response to enalapril for this genotype. Some patients were also treated with losartan or atenolol. One study found a decreased risk of kidney failure for this genotype, and another an increased response in bone mineral density, both compared to the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril, risk of kidney failure or response in bone mineral density.
1183630719	CC	Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.
1183630720	CT	Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.
1183630721	TT	Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide.
1184986256	*4/*11	Patients with the CYP2D6*4/*11 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1184986257	*4/*12	Patients with the CYP2D6*4/*12 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1184986258	*4/*59	Patients with the CYP2D6*4/*59 genotype (assigned as intermediate metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1184986259	*41/*62	Patients with the CYP2D6*41/*62 genotype (assigned as intermediate metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1183612433	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence overall survival time.
1183614826	CC	Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614827	CT	Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614828	TT	Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614836	AA	Women with the AA genotype and breast cancer may have decreased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614837	AG	Women with the AG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614838	GG	Women with the GG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183607014	AA	Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607015	AC	Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607016	CC	Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183614817	CC	Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614818	CT	Human liver microsomes with the CT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614819	TT	Human liver microsomes with the TT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1184516155	B (wildtype)/B (wildtype)	Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516156	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B (wildtype) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516157	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients heterozygous for the G6PD Mediterranean variant with systemic arthritis who are treated with a high dose of aspirin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with homozygous for the G6PD Mediterranean variant or B (wildtype) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183700489	AA	Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1183700490	AC	Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1183700491	CC	Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1183679819	AA	Patients with the AA genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679820	AG	Patients with the AG genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1184516158	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Female children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B/B (wildtype) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183593446	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased resistance, decreased likelihood of early relapse, increased progression free survival and decreased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or non-small cell lung cancer-related death.
1183593447	CT	Patients with the CT genotype and non-small cell lung cancer may have decreased resistance, decreased likelihood of early relapse, increased progression free survival and decreased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or non-small cell lung cancer-related death.
1183593448	TT	Patients with the TT genotype and non-small cell lung cancer may have increased resistance, increased likelihood of early relapse, decreased progression free survival and increased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or carcinoma, non-smal cell lung cancer-related death.
1183630571	CC	Patients with the CC genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183630572	CT	Patients with the CT genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183630573	TT	Patients with the TT genotype and schizophrenia may have a better response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183614512	AA	Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.
1183614511	AG	Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.
1183614510	GG	Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.
1183630681	AA	Purified CDA proteins with the AA genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
1183630682	AG	Purified CDA proteins with the AG genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
1183630683	GG	Purified CDA proteins with the GG genotype may have increased catalytic activity when exposed to cytarabine as compared to those proteins with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
1183614482	CC	Patients with the CC genotype and left ventricular hypertrophy may have an increased response when treated with irbesartan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to irbesartan.
1183614483	CT	Patients with the CT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.
1183614484	TT	Patients with the TT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.
1183615046	*1/*6	Patients with the CYP2B6 *1/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615047	*1/*7	Patients with the CYP2B6 *1/*7 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615048	*4/*6	Patients with the CYP2B6 *4/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615049	*5/*5	Patients with the CYP2B6 *5/*5 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615050	*5/*6	Patients with the CYP2B6 *5/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615042	*6/*6	Patients with the CYP2B6 *6/*6 genotype and depression may have an increased response when treated with mirtazapine as compared to patients with the CYP2B6 *1/*1, *1/*4, *1/*5, *1/*6, *1/*7, *4/*6, *5/*5 or *5/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1183615588	CC	Patients with the CC genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
1183615589	CT	Patients with the CT genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
1183615590	TT	Patients with the TT genotype who have had a stroke may be at increased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
1183615297	CC	Patients with the CC genotype who are taking acenocoumarol may have a decreased risk of a gastrointestinal hemorrhage as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.
1183615298	CT	Patients with the CT genotype who are taking acenocoumarol may have an increased risk of a gastrointestinal hemorrhage as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.
1183615299	TT	Patients with the TT genotype who are taking acenocoumarol may have an increased risk of a gastrointestinal hemorrhage as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.
1183614471	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
1183614472	AG	Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
1183614473	GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
1183602563	AA	Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602562	AG	Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602561	GG	Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183630649	AA	Patients with the AA genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.
1183630650	AG	Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.
1183630651	GG	Patients with the GG genotype and hypertension may be more likely to respond to treatment with candesartan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to candesartan.
1183601917	AA	Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183601915	AG	Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183601918	AT	Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183601916	GG	Patients with the GG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183601919	GT	Patients with the GT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183630744	AA	Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630745	AG	Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630746	GG	Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630607	AA	Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.
1183630608	AG	Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.
1183630609	GG	Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.
1183603019	CC	Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183603018	CT	Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183603017	TT	Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183612434	CG	Patients with the CG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.
1183612435	GG	Patients with the GG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.
1183598054	CC	Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183598055	CT	Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183598056	TT	Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183615138	CC	Women with the CC genotype and mental disorders (excluding schizophrenia) may have smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1183615137	CG	Women with the CG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype, or smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1183615136	GG	Women with the GG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype. Other genetic and clinical factors may also influence weight gain.
1183630748	AA	Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630749	AG	Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630750	GG	Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614877	CC	Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614878	CG	Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614879	GG	Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183631927	CC	Patients with the CC genotype (CYP2C19*1/*1) and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the CT or TT genotype (CYP2C19*1/*17 or *17/*17). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1183631928	CT	Patients with the CT genotype (CYP2C19*1/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1183631929	TT	Patients with the TT genotype (CYP2C19*17/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1183679821	GG	Patients with the GG genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183680430	AA	Patients with the AA genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680431	AG	Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680432	GG	Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183704265	CC	Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
1444607589	*1/*1	Patients with the *1/*1 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1444607590	*1/*4	Patients with the *1/*4 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1444607591	*1/*41	Patients with the *1/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1444607592	*3/*4	Patients with the *3/*4 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1/*1, *1/*4, *4/*41, *1/*41, *5/*41, *6/*41 or *4/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1183693537	AA	Patients with the AA genotype and Schizophrenia may have a decreased, but not absent, risk for weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. However, the association was found as trend only and was not statistically significant. Other genetic and clinical factors may also influence a patient's risk for weight gain.
1183693538	AG	Patients with the AG genotype and Schizophrenia may have an increased risk for weight gain when treated with clozapine or olanzapine as compared to patients with the AA genotype and a decreased, but not absent, risk for weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. However, the association was found as trend only and was not statistically significant. Other genetic and clinical factors may also influence a patient's risk for weight gain.
1183693539	GG	Patients with the GG genotype and Schizophrenia may have an increased risk for weight gain when treated with clozapine or olanzapine as compared to patients with the AA genotype. However, the association was found as trend only and was not statistically significant. Other genetic and clinical factors may also influence a patient's risk for weight gain.
1183631560	CC	Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1444607593	*4/*1xN	Patients with the *4/*1XN genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1183631561	CG	Patients with the CG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183631562	GG	Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.
1183634264	AA	Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have  greater reduction of diastolic blood pressure as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634265	AC	Patients with the AC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA genotype, and greater reduction of diastolic blood pressure as compared to patients with the  CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634266	CC	Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183634105	GG	Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1447943687	CC	Patients with CC genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.
1447943688	CT	Patients with CT genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.
1447943689	TT	Patients with TT genotype and essential hypertension may have decreased response to telmisartan compared to patients with genotype CC and CT. Other genetic and clinical factors may influence a patient's response to telmisartan.
1183700249	AA	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to the first course of remission induction therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700250	AC	Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700251	CC	Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1447943746	AA	Patients with AA genotype and HIV may have decreased concentrations of efavirenz in plasma compared to patients with AG or GG genotypes. However, this association was not significant and was not found in another study of plasma and PBMCs. Other clinical and genetic factors may affect efavirenz concentrations.
1183700508	AA	Patients with the AA genotype may have  increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
1183631423	AA	Patients with the AA genotype may have decreased clearance of L-tryptophan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response.
1447943747	AG	Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and was not found in another study of plasma and PBMCs. Other clinical and genetic factors may affect efavirenz concentrations.
1447943748	GG	Patients with GG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and was not found in another study of plasma and PBMCs.  Other clinical and genetic factors may affect efavirenz concentrations.
1447943755	AA	Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.
1447943756	AG	Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.
1183631424	AC	Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
1183631425	CC	Patients with the CC genotype may have increased clearance of L-tryptophan as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.
1444608177	AA	Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1444608178	AG	Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1183700280	GG	Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.
1183700281	GT	Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.
1183700282	TT	Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.
1446909025	CC	Patients with the CC genotype may be less likely to respond to clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909026	TC	Patients with the TC genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909079	CC	Patients with the CC genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1446909080	CT	Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1446909081	TT	Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1446906448	TT	Patients with genotype TT may have increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections  as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
1444608179	GG	Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1448106109	TT	Patients with genotype TT may have increased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
1446909027	TT	Patients with the TT genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448106218	GG	Patients with the GG genotype may have a decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1444608443	CC	Patients with the CC genotype and autism spectrum disorders may have a better tolerance for methylphenidate treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
1444608444	CT	Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
1448106219	GT	Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1183614487	CC	Healthy males with the CC genotype may have a greater increase in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CG or GG genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.
1183614488	CG	Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.
1183614489	GG	Healthy males with the GG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.
1183614772	AA	Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614773	AG	Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614774	GG	Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183615195	CC	Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.
1183615196	CT	Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.
1183615197	TT	Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.
982031985	AA	Patients with the AA genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.
982031986	AG	Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.
982031987	GG	Patients with the GG genotype and Asthma may be more likely to respond when treated with pitrakinra as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to pitrakinra.
1444608422	AA	Patients with the AA genotype and Macular Degeneration who are treated with ranibizumab may have a lack of early response to treatment compared to patients with the AC or CC genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.
1444608423	AC	Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.
1444608424	CC	Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an early response  to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.
1183594149	AA	Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1183594150	AT	Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1444608445	TT	Patients with the TT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
1183594151	TT	Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1183630583	AA	Women with the AA genotype and hypertension may have a better blood pressure response when treated with atenolol as compared to those with the AC or CC genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
1183630584	AC	Women with the AC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to women with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
1183630585	CC	Women with the CC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to patients with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
1183630635	CC	Patients with the CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.
1183630636	CG	Patients with the CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.
1183630637	GG	Patients with the GG genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.
1183594904	CC	Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183594905	CT	Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183594906	TT	Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615318	AA	Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
1183615319	AG	Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
1183615320	GG	Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
1449164574	AA	Cancer patients with the AA genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1447946214	AA	Patients with the AA genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
1183603973	CC	Patients with the CC genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.
1447946215	AG	Patients with the AG genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
1448102860	CT	Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.
1448102861	TT	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.
1183614831	AA	Patients with the AA genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.
1183614832	AG	Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.
1183614833	GG	Patients with the GG genotype and schizophrenia may have an increased QTc interval when treated with iloperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval.
1183630752	AA	Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630753	AC	Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630754	CC	Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183607143	CC	Patients with the CC genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607144	CT	Patients with the CT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607145	TT	Patients with the TT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1444713217	*40:01:01	Patients with one or two copies of the HLA-B*40:01:01 allele have a decreased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*40:01:01 alleles or negative for the HLA-B*40:01:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1447945919	GG	Cancer patients with the GG genotype may have decreased event-free survival when treated with methotrexate as compared to patients with the TT genotype. However, some conflicting or non-significant evidence exists. Other genetic and clinical factors may also influence event-free survival.
1447945920	GT	Cancer patients with the GT genotype may have decreased event-free survival when treated with methotrexate as compared to patients with the TT genotype. However, some conflicting or non-significant evidence exists. Other genetic and clinical factors may also influence event-free survival.
1447945921	TT	Cancer patients with the TT genotype may have increased event-free survival when treated with methotrexate as compared to patients with the GG or GT genotype. However, some conflicting or non-significant evidence exists. Other genetic and clinical factors may also influence event-free survival.
1447945934	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2	Pediatric patients with the 2R/2R genotype and acute lymphoblastic leukemia may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/3R or 3R/3R genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1447961168	CC	Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with gefitinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to gefitinib.
1447961169	CT	Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.
1447961170	TT	Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.
1447945935	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Pediatric patients with the 2R/3R genotype and acute lymphoblastic leukemia may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1447945936	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Pediatric patients with the 3R/3R genotype and acute lymphoblastic leukemia may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448105801	CC	Patients with the CC genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CT or TT genotype. Patients with the CC genotype may also more likely to be eligible for shortened therapy (24 weeks instead of standard 48 weeks). The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy.
1447954399	AA	Patients with the AA genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1448105941	CC	Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
1448105942	CT	Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
1448105943	TT	Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.
1183704335	AA	Patients with the AA genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs.
1183704336	AG	Patients with the AG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs.
1183704337	GG	Patients with the GG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome  as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to NSAIDs.
1183704422	AA	Patients with the AA genotype may have increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
1183704421	GA	Patients with the GA genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
1183704420	GG	Patients with the GG genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
1447954392	CC	Patients with the CC genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1447954393	CT	Patients with the CT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1446909093	AA	The AA genotype is not associated with differences in clopi-H4 formation or antiplatelet response or increased risk of major cardiovascular events when treated with clopidogrel as compared to the TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909094	AT	The AT genotype is not associated with differences in clopi-H4 formation or antiplatelet response or increased risk of major cardiovascular events when treated with clopidogrel as compared to the TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1183631475	AA	Patients with the AA genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631476	AG	Patients with the AG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631477	GG	Patients with the GG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1446909095	TT	The TT genotype is not associated with differences in clopi-H4 formation or antiplatelet response or increased risk of major cardiovascular events when treated with clopidogrel as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448105951	CC	Patients with the CC genotype are less likely to respond to repaglinide  than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
1448105952	CT	Patients with the CT genotype are more likely to respond to repaglinide  than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
1447954394	TT	Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1444667921	GG	Patients with genotype GG and epilepsy may have an increased risk of drug toxicity when taking valproic acid as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.
1448417899	*1/*1	Patients with the CYP2C19*1/*1 genotype may have 1) increased metabolism of clomipramine as compared to patients with CYP2C19*2 and *3 alleles, 2) increased plasma levels of clomipramine as compared to patients with the CYP2C19*17/*17 genotype. Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1448417900	*17/*17	Patients with the CYP2C19*17/*17 genotype may have decreased plasma levels of clomipramine as compared to patients with the CYP2C19*1/*1 genotype. The number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence.Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1444668485	CT	Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.
1183679804	CC	Patients with the CC genotype may have decreased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1183679805	CT	Patients with the CT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1183679806	TT	Patients with the TT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1183679816	CC	Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679815	CT	Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679814	TT	Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1448417901	*2	Patients with the CYP2C19*2 allele may have decreased metabolism of clomipramine as compared to patients with the CYP2C19*1/*1 genotype. The number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's clomipramine metabolism.
1183693434	AA	Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693435	AC	Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693436	CC	Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183603972	CT	Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.
1183603971	TT	Patients with the TT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.
1444668486	TT	Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.
1444668815	del/del	Hypertensive patients with the del/del genotype may have a smaller reduction in diastolic blood pressure when treated with irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence diastolic blood pressure response.
1444668816	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Hypertensive patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have a greater reduction in diastolic blood pressure when treated with irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183700529	AG	Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.
1183700528	GG	Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.
1448102595	GT	Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
1448102596	TT	Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.
1448102607	CT	Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.
1449576933	CC	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
1183680517	AA	Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680518	AG	Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680519	GG	Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183700530	AA	Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.
1449576934	CT	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
1449576935	TT	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.
1183704260	AA	Patients with the AA genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or AT. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
1183704259	AT	Patients with the AT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
1183704258	TT	Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
1183704264	CT	Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
1183704263	TT	Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
1183704273	AA	Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.
1183545769	CG	Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183545768	GG	Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448102608	TT	Patients with the TT genotype and colorectal cancer may have increased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.
1183604886	CC	Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.
1183604887	CT	Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.
1183604888	TT	Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.
1183630757	AA	Patients with the AA genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630758	AG	Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183630759	GG	Patients with the GG genotype and asthma may have a reduced frequency of asthma exacerbationse when treated with pitrakinra as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614841	AA	Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.
1183614842	AG	Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.
1183614843	GG	Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.
1447960354	AA	No patients with the AA genotype are available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
1447960355	AG	Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
1447960356	GG	Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
1183630559	CC	Healthy males with the CC genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.
1183630560	CT	Healthy males with the CT genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.
1183630561	TT	Healthy males with the TT genotype may have a decreased response when given dobutamine as compared to healthy males with the CC or CT genotype. Other genetic and clinical factors may also influence response to dobutamine.
1183630563	AA	Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to captopril.
1183630564	AC	Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.
1183630565	CC	Patients with the CC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.
1447960413	CC	Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.
1447960414	CT	Patients with the CT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.
1447960415	TT	Patients with the TT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.
1183615425	CC	Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.
1183615426	CT	Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.
1183615427	TT	Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.
1183630643	CC	Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.
1183630644	CT	Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response.
1183630645	TT	Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, losartan, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only losartan, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.
1183630669	AA	Patients with the AA genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183630670	AG	Patients with the AG genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183630671	GG	Patients with the GG genotype and lung cancer may have a poorer response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183630697	AA	Patients with the AA genotype and schizophrenia may may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1183630698	AG	Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183630699	GG	Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183607902	CC	Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607903	CT	Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607904	TT	Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183603767	AA	Women with the AA genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to women with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain.
1450044625	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044591	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1444698364	CT	Patients with cancer and the CT genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.
1444698365	TT	Patients with cancer and the TT genotype may have decreased metabolism of gemcitabine as compared to patients with the CC genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.
1448102831	TT	Patients with the TT genotype and colorectal cancer may have a better response when treated with FOLFIRI and bevacizumab as compared to patients with the GG or GT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.
1448102853	CC	Patients with the CC genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)
1448102854	CG	Patients with the CG genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype, or an increased chance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)
1183595193	AA	Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
1183595194	AG	Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
1183595195	GG	Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
1183614781	AA	Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614782	AG	Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614783	GG	Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183680523	CT	Patients with the CT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to  patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
1183680524	TT	Patients with the TT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to  patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
1183699638	*4/*4	Patients with two non-functional CYP2D6 alleles (e.g. *4/*4, *3/*4, *4/*5) who are treated with pimozide may have increased plasma concentrations of pimozide as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). Other genetic and clinical factors may also influence the metabolism of pimozide.
1183704274	AG	Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.
1444698363	CC	Patients with cancer and the CC genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.
1448102855	GG	Patients with the GG genotype and breast cancer may have an increased chance of experiencing sensory neuropathy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy.  (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)
1448102859	CC	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.
1183680473	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have a reduced response to esomeprazole (lower % of time with intragastric pH > 4.0, and a lower median intragastric pH during a 24-hour time period) as compared to patients with the *1/*2 genotype (*2 = rs4244285). Other genetic and clinical factors may also influence response to esomeprazole.
1183680474	*1/*2	Patients with the CYP2C19 *1/*2 genotype (*2 = rs4244285) may have a better response to esomeprazole (greater % of time with intragastric pH > 4.0, and a higher median intragastric pH during a 24-hour time period) as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence response to esomeprazole.
1183680522	CC	Patients with the CC genotype may have increased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to  patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
1183704275	GG	Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.
1183697636	AG	Patients with the AG genotype and asthma may have a better response when treated with methacholine as compared to patients with the AA genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1183697635	GG	Patients with the GG genotype and asthma may have a better response when treated with methacholine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methacholine.
1183699639	*1/*1	Patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with pimozide may have decreased plasma concentrations of pimozide as compared to patients with two non-functional CYP2D6 alleles (e.g. *4/*4, *3/*4, *4/*5). Other genetic and clinical factors may also influence the metabolism of pimozide.
1183704283	AA	Patients with the AA genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.
1183704284	AG	Patients with the AG genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.
1447946216	GG	Patients with the GG genotype may have a lower elevation in systolic blood pressure and a lower incidence of side effects when given regadenoson as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
1447946221	AA	Patients with the AA genotype and osteosarcoma may be at decreased risk for mucositis when receiving methotrexate, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.
1447946222	AG	Patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.
1183679829	AG	Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183679831	GG	Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183679868	AA	Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1447946223	GG	No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.
1447946228	CC	Patients with the CC genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.
1447946229	CT	Patients with the CT genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype, or increased severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.
1183679869	AG	Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679870	GG	Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1449575659	AG	The AG genotype may have increased catalytic activity of DPYD as compared to the AA genotype and decreased catalytic activity as compared to the GG genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575660	GG	The GG genotype may have increased catalytic activity of DPYD as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1447682304	GG	Post-menopausal women with breast cancer and the GG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC or CG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.
1183679830	AA	Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1449575664	CC	The CC genotype may be associated with increased catalytic activity of DPYD as compared to the CT or TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1183603766	AC	Women with the AC genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to women with the AA genotype, or decreased weight gain when treated with olanzapine as compared to women with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain.
1183603765	CC	Women with the CC genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to women with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain.
1183630761	CC	No patients with the CC genotype were present in this study. However, patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.
1183630762	CG	Patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.
1183630763	GG	Patients with the GG genotype and rheumatoid arthritis may be less likely to respond to rituximab treatment as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to rituximab.
1183614762	AA	Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels.
1183614763	AG	Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.
1183614764	GG	Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.
1444695561	AA	Patients with the AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose.
1444695562	CA	Patients with the CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1444695563	CC	Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1444695568	AA	Patients with the AA genotype and solid tumors, may have increased response to gemcitabine compared to the CC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444695569	AC	Patients with the AC genotype and solid tumors, may have increased response to gemcitabine compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444695570	CC	Patients with the CC genotype and solid tumors, may have decreased response to gemcitabine compared to the AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1449575665	CT	The CT genotype may be associated with increased catalytic activity of DPYD as compared to the TT and decreased catalytic activity as compared to the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575666	TT	The TT genotype may be associated with decreased catalytic activity of DPYD as compared to the CT or CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575678	TT	The TT genotype is associated with increased catalytic activity of DPYD as compared to the del/del or del/T genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575677	del/T	The del/T genotype is associated with decreased catalytic activity of DPYD as compared to the TT genotype and increased catalytic activity as compared to the del/del genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449154626	GG	Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.
1448105734	CC	Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448105735	CT	Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448109560	CC	Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1448109561	CT	Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1449154624	CC	Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.
1449154625	CG	Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.
1183684156	CC	Patients with the CC genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684155	CT	Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183684154	TT	Patients with the TT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.
1183630723	AA	Purified DCK proteins with the AA genotype may have reduced clearance of gemcitabine as compared to those proteins with the AG or GG genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1183630724	AG	Purified DCK proteins with the AG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1183630725	GG	Purified DCK proteins with the GG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1448109562	TT	Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1449155312	GG	Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have shorter overall survival times when treated with sunitinib as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time.
1183679861	CC	Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.
1183679860	CT	Patients with the CT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.
1183679859	TT	Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.
1183679788	AA	Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1183679787	AG	Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1183679786	GG	Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1449747888	AA	Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747889	AG	Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747890	GG	Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449165797	AG	Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.
1449165798	GG	Patients who are undergoing liver transplantation and receive a liver from a DONOR with the GG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.
1447946045	non-null/ null	Patients with the non-null/ null genotype (has one copy of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1448115859	CC	Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1448115860	CT	Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1448115861	TT	Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1183603159	AA	Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183603160	AG	Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183603161	GG	Patients with the GG genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604229	AA	Patients with the AA genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
1183604230	AG	Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
1183604231	GG	Patients with the GG genotype and epilepsy may have decreased retention rates when treated with carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
1183614707	AA	Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1449748302	CT	Patients with the CT genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. However, conflicting evidence exists for this association. Other factors may affect concentration of tacrolimus.
1444666093	*60	Patients who carried the *60 allele with colorectal cancer may have a poorer response when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients who did not carry the allele. Other genetic and clinical factors may also influence response to TIROX treatment.
1183614708	AT	Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183614709	TT	Patients with the TT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615431	CC	Patients with the CC genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183615432	CT	Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183615433	TT	Patients with the TT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183632161	AA	Patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632162	AG	Patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632163	GG	Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183615622	GG	Patients with the GG genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.
1183615623	GT	Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.
1183615624	TT	Patients with the TT genotype and hypertension may have an increased response when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to benazepril.
1183604794	CC	Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604795	CT	Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604796	TT	Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183612734	AA	Women with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183612733	AG	Women with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183612732	GG	Women with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with captopril as compared to women with the AA or AG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183614856	CC	Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614857	CG	Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614858	GG	Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1449192315	AA	Patients with the AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence a patient's response to lumacaftor.
1449192316	AC	Patients with the AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence a patient's response to lumacaftor.
1444703071	AA	Patients with the AA genotype were not studied. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1184989914	HTTLPR short form (S allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with escitalopram may have an increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and escitalopram response. Other genetic and clinical factors may also influence a patient's response to escitalopram. Please note, study population is White or Unknown.
1444703072	AG	Patients with the AG genotype and depression who are treated with venlafaxine may have an increased risk for agitation and dysphoria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1444703073	GG	Patients with the GG genotype and depression who are treated with venlafaxine may have a decreased, but not absent, risk for agitation and dysphoria as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1444703173	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.
1449192317	CC	Patients with the CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to lumacaftor.
1449192408	CC	Patients with the CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to treatment with ivacaftor/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor/lumacaftor.
1449192409	CT	Patients with the CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence a patient's response to ivacaftor/lumacaftor.
1444703095	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1444703096	AC	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine..
1444703125	del/del	Patients with the del/del genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.
1444703175	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.
1444703174	CG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.
1444703097	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1448105802	CT	Patients with the CT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy.
1448105803	TT	Patients with the TT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient's response to HCV triple therapy.
1449192410	TT	Patients with the TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence a patient's response to ivacaftor/lumacaftor.
1449156930	CC	Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449564840	AA	Patients with the AA genotype who are treated with warfarin may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449564841	AG	Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patients required dose of warfarin.
982030723	AA	Patients with the AA genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).
1183689976	*1/*1	Patients with the CYP3A4 *1/*1 diplotype undergoing organ transplant who received a donor liver with the *1/*1 diplotype may have a decreased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the *1/*1G or *1G/*1G diplotype who received a donor liver with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.
1183689977	*1/*1G	Patients with the CYP3A4 *1/*1G diplotype undergoing organ transplant who received a donor liver with the *1/*1G or *1G/*1G diplotype may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the *1/*1 diplotype who received a donor liver with the *1/*1 diplotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.
1183689978	*1G/*1G	Patients with the CYP3A4 *1G/*1G diplotype undergoing organ transplant who received a donor liver with the *1G/*1G or *1/*1G diplotype may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the *1/*1 diplotype who received a donor liver with the *1/*1 diplotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.
1444700540	CC	Patients with the CC genotype and hypertension may have more blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
1444700539	CG	Patients with the CG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
1444700538	GG	Patients with the GG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
1444700629	AA	Patients with the AA genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1444700628	GA	Patients with the GA genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1444700627	GG	Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1449564842	GG	Patients with the GG genotype who are treated with warfarin may require higher dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449564947	AA	Patients with the AA genotype who are treated with sulfonylurea: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be more likely to have failure of therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.
1449564948	AC	Results from patients with the AC genotype were not statistically significant.
1444700643	AA	Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.
982030724	AG	Patients with the AG genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).
1449564949	CC	Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.
1444700671	AA	Patients with the AA genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700670	AC	Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700669	CC	Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700677	CC	Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1448105714	GG	Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
1448105718	CC	Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1448105719	CT	Patients with the CT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1184748882	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748885	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748886	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748887	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748890	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748891	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748892	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444700678	CT	Patients with the CT genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700679	TT	Patients with the TT genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700756	CT	Patients with the CT genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444700757	TT	Patients with the TT genotype and neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444700792	CC	Patients with the CC genotype and acute coronary syndrome who are treated with prasugrel may have an decreased, but not absent, risk for bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1448105720	TT	Patients with the TT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183680304	*1/*1	Patients with the CYP2C19 *1/*1 genotype who are infected with Helicobacter pylori (H. pylori) may have a lower eradication rate when treated with rabeprazole as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype (*2 = rs4244285; *3 = rs4986893). Patients also received various antibiotics. However, the majority of studies have found no association between CYP2C19 genotypes and H. pylori eradication rate in patients taking rabeprazole. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680305	*1/*2	Patients with the CYP2C19 *1/*2 genotype (*2 = rs4244285) who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with rabeprazole as compared to patients with the *1/*1 genotype. Patients also received various antibiotics. However, the majority of studies have found no association between CYP2C19 genotypes and H. pylori eradication rate in patients taking rabeprazole. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680306	*1/*3	Patients with the CYP2C19 *1/*3 genotype (*3 = rs4986893) who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with rabeprazole as compared to patients with the *1/*1 genotype. Patients also received various antibiotics. However, the majority of studies have found no association between CYP2C19 genotypes and H. pylori eradication rate in patients taking rabeprazole. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1183680307	*2/*2	Patients with the CYP2C19 *2/*2 genotype (*2 = rs4244285) who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with rabeprazole as compared to patients with the *1/*1 genotype. Patients also received various antibiotics. However, the majority of studies have found no association between CYP2C19 genotypes and H. pylori eradication rate in patients taking rabeprazole. Other genetic and clinical factors may also influence eradication rate of H. pylori.
1184746856	*1/*1	Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746857	*1/*1S	Patients with the *1/*1S genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1S genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746858	*11	Patients with the *11 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*11) than in those who are heterozygous for the non-functional variant (*1/*11). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746859	*12	Patients with the *12 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*12) than in those who are heterozygous for the non-functional variant (*1/*12). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746860	*14	Patients with the *14 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*14) than in those who are heterozygous for the non-functional variant (*1/*14). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746861	*16	Patients with the *16 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*16) than in those who are heterozygous for the non-functional variant (*1/*16). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746862	*17	Patients with the *17 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*17) than in those who are heterozygous for the non-functional variant (*1/*17). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746863	*18	Patients with the *18 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*18) than in those who are heterozygous for the non-functional variant (*1/*18). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746864	*1S/*1S	Patients with the *1S/*1S genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1S/*1S genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746865	*20	Patients with the *20 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*20) than in those who are heterozygous for the non-functional variant (*1/*20). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746866	*21	Patients with the *21 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*21) than in those who are heterozygous for the non-functional variant (*1/*21). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746867	*22	Patients with the *22 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*22) than in those who are heterozygous for the non-functional variant (*1/*22). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444704918	AA	Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704917	AG	Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704916	GG	Patients with the GG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have increased metabolism of etoposide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1184746868	*23	Patients with the *23 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*23) than in those who are heterozygous for the non-functional variant (*1/*23). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746869	*6	Patients with the *6 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*6) than in those who are heterozygous for the non-functional variant (*1/*6). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746870	*7	Patients with the *7 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*7) than in those who are heterozygous for the non-functional variant (*1/*7). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746871	*8	Patients with the *8 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*8) than in those who are heterozygous for the non-functional variant (*1/*8). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1184746872	*9	Patients with the *9 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1, *1/*1S or *1S/*1S genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*9) than in those who are heterozygous for the non-functional variant (*1/*9). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444704967	CC	People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
1444704966	CT	People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
1449565277	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype, and a decreased risk compared to those with the (TA)7/(TA)7 (*28/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, or tumor response. One study found a decreased overall survival time for carriers of the (TA)7 allele. One study found an increased risk of vomiting for this genotype, and another found an increased risk of treatment-related death, both compared to the (TA)6/(TA)6 genotype. Other genetic and clinical factors may also influence a patient's survival time and risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death.
1449575635	CC	The CC genotype is associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1448255889	AA	Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
1448255890	AG	Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's risk for side effects.
1448255891	GG	Patients with the GG genotype may have decreased but not non-existant risk of side effects including hyperprolactinemia and weight gain, but increased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
1184000405	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000406	B (wildtype)/B (wildtype)	Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000407	Mediterranean Haplotype	Male patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency) who are treated with phenazopyridine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000404	Mediterranean Haplotype/B (wildtype)	Female patients with the Mediterranean/B (wildtype) diplotype (heterozygous for the G6PD Mediterranean variant) who are treated with phenazopyridine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or B/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000403	Mediterranean Haplotype/Mediterranean Haplotype	Female patients with the Mediterranean/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency) who are treated with phenazopyridine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000369	A-202A_376G	Male children with typhoid fever and the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with chloramphenicol may have an increased risk of hemolysis as compared to children with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency,  with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000370	A-202A_376G/A-202A_376G	Female children with typhoid fever and the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with chloramphenicol may have an increased risk of hemolysis as compared to children with the wildtype B/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000371	A-202A_376G/B (wildtype)	Female children with typhoid fever and the A-202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with chloramphenicol may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to children with the A-202A_376G/A-202A_376G or B/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency,  with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000372	B (wildtype)	Male patients with typhoid fever and the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency,  with the B (wildtype) haplotype representing G6PD non-deficient.  Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000373	B (wildtype)/B (wildtype)	Female patients with typhoid fever and the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency,  with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1444668821	*1A/*1A	Pregnant women with the *1A/*1A (CC; slow metabolizer) genotype who consume caffeine may have a decreased likelihood of spontaneous abortion as compared to patients with the *1F/*1F (AA) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.
1444668822	*1A/*1F	Pregnant women with the *1A/*1F (AC; slow metabolizer) genotype who consume caffeine may have a decreased likelihood of spontaneous abortion as compared to patients with the *1F/*1F (AA) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.
1444668823	*1F/*1F	Pregnant women with the *1F/*1F (AA; fast metabolizer) genotype who consume caffeine may have an increased likelihood of spontaneous abortion as compared to patients with the *1A/*1A (CC) or *1A/*1F (AC) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.
1184136749	AA	Patients with the AA genotype who are treated with ondansetron may have  increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1184136750	AC	Patients with the AC genotype who are treated with ondansetron may have  decreased treatment response among patients carrying the SLC6A4  promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1184136751	CC	Patients with the CC genotype who are treated with ondansetron may have  decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1444702668	AA	Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments.
1444702667	AG	Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.
1444702666	GG	Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.
1444668817	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Hypertensive patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may have a smaller reduction in diastolic blood pressure when treated with irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence diastolic blood pressure response.
1447674062	AA	Patients with the AA genotype were not studied, however they may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.
1444702766	CC	Patients with the CC genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.
1444702767	CT	Patients with the CT genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.
1444702768	TT	Patients with the TT genotype and ankylosing spondylitis may have a better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.
1444702773	CC	Patients with the CC genotype who are opioid-dependent may have a better response when treated with methadone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to methadone.
1444702774	CT	Patients with the CT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.
1184349906	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with paroxetine may have increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine. Please note, study population is White, Mixed Population or Unknown.
1184349907	HTTLPR short form (S allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with paroxetine may have a decreased response or decreased improvement based on HAMD score reduction as compared to patients with the SLC6A4  HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine. Please note, study population is White, Mixed Population or Unknown.
1184349908	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with paroxetine may have a decreased response or decreased improvement based on HAMD score reduction as compared to patients with the SLC6A4  HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine. Please note, study population is White, Mixed Population or Unknown.
1184472742	CC	Patients with cancer and the CC genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
1184472743	CT	Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
1184472744	TT	Patients with cancer and the TT genotype may have a decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
1183960813	B (wildtype)	Male patients with the wildtype B haplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the A-202A_376G haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.
1444702775	TT	Patients with the TT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.
1444703034	*1/*1	Patients with the CYP2D6*1/*1 genotype who are treated with mianserin may have an increased plasma concentration of S-mianserin as compared to patients with the CYP2D6*1/*10 or *5/*10 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mianserin.
1444703035	*1/*10 + *5/*10	Patients with the CYP2D6*1/*10 or *5/*10 genotype who are treated with mianserin may have a decreased plasma concentration of S-mianserin as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mianserin.
1447674063	AG	Patients with the AG genotype and tumors may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.
1447674064	GG	Patients with the GG genotype and tumors may have increased metabolism of midazolam as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.
1183960814	B (wildtype)/B (wildtype)	Female patients with the wildtype B/ B diplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.
1448100482	CC	Patients with the CC genotype may 1) have increased clearance (CL/F) and 2) require higher doses of lamotrigine as compared to patients with the CT or TT genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine.
1448100483	CT	Patients with the CT genotype may 1) have decreased clearance (CL/F) and 2) require lower doses of lamotrigine as compared to patients with the CC genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine.
1448100484	TT	Patients with the TT genotype may 1) have decreased clearance (CL/F) and 2) require lower doses of lamotrigine as compared to patients with the CC genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine.
1184516029	A- 202A_376G/A- 202A_376G	Female children with lead poisoning and the A- 202A_376G/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with dimercaprol may have an increased risk of hemolysis as compared to children with the wildtype B/B diplotype (not associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447813534	CC	Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.
1447813535	CT	Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.
1447813536	TT	Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.
1184516028	A- 202A_376G	Male children with lead poisoning and the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with dimercaprol may have an increased risk of hemolysis as compared to children with the wildtype B haplotype (not associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447943630	del/del	Patients with the del/del genotype and hypertension may have increased response to metoprolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to metoprolol.
1447943655	AA	Patients with the AA genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
1447943656	AG	Patients with the AG genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
1448100474	CT	Patients with the CT genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the TT genotype. Other factors may affect trough concentrations of telaprevir.
1448100475	TT	Patients with the TT genotype and Hepatitis C may have increased trough concentrations of telaprevir compared to patients with the CC and CT genotypes. Other factors may affect trough concentrations of telaprevir.
1450044623	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes.Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044624	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1447963264	CT	Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.
1447963265	TT	Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse.
1449575637	TT	The TT genotype is associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1447963263	CC	Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.
1184987915	GG	Patients with the GG genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184987920	AA	Patients with the AA genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184987921	AG	The AG genotype has not been evaluated.
1184987922	GG	Patients with the GG genotype may have a decreased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184989982	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and sertraline response. Other genetic and clinical factors may also influence a patient's response to sertraline.
1184989983	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with sertraline may have an decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and sertraline response. Other genetic and clinical factors may also influence a patient's response to sertraline.
1184989984	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and sertraline response. Other genetic and clinical factors may also influence a patient's response to sertraline.
1184997197	*59:01:01:01	Patients with one or two copies of the HLA-B*59:01:01:01 allele may have an increased risk of Stevens-Johnson Syndrome when treated with acetazolamide. Other genetic and clinical factors may also influence a patient's risk of acetazolamide-induced adverse reactions.
1184997108	*48:04	Patients with one or two copies of the HLA-B*48:04 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*48:04 alleles or negative for the HLA-B*48:04 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1447963606	AA	Patients with the AA genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
1184987913	AA	Patients with the AA genotype may have a decreased metabolism of itopride as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184987914	AG	The AG genotype has not been evaluated.
1184997191	*58:01	Patients with one or two copies of the HLA-B*58:01 allele have a decreased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with antiepileptics as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test.
1184997215	*15:18:01/*40:01:01	Patients with the HLA-B*15:18:01/*40:01:01 genotype have an increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1447963607	AG	Patients with the AG genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
1447963608	GG	Patients with the GG genotype who smoke tobacco may have a decreased risk of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
1449575636	CT	The CT genotype is associated with decreased catalytic activity of DPYD as compared to the CC and increased catalytic activity as compared to the TT genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449718321	GG	Patients with GG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.
1450112774	GG	Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1184348775	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1450112775	GT	Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112776	TT	Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG or GT genotypes. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112780	GG	Patients with osteosarcoma and the GG genotype may have increased clearance of methotrexate as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112781	GT	Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1184348776	CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348777	TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348868	CC	Patients with the CC genotype and Schizophrenia who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the CT or TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348869	CT	Patients with the CT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype or may have greater weight gain as compared to patients with the TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348870	TT	Patients with the TT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348875	AA	Patients with the rs2268639 AA genotype and Schizophrenia and genotype TT at SNP rs13429709 who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the rs2268639 TT genotype and at least one C allele at SNP rs13429709. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348874	AT	Patients with the rs2268639 AT genotype and Schizophrenia and genotype TT at SNP rs13429709 who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the rs2268639 TT genotype and at least one C allele at SNP rs13429709. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348873	TT	Patients with the rs2268639 TT genotype and Schizophrenia who also have at least one allele C at SNP rs13429709 who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the rs2268639 AA genotype who also have genotype rs13429709 TT. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1445296901	*1/*1	Patients with CYP2C9*1/*1 may require significantly higher dose of warfarin as compared to patients with CYP2C9 *59/*59 or CYP2C9 *1/*59. Other genetic and clinical factors may also influence the dose of warfarin.
1445296900	*1/*59	Patients with CYP2C9*1/*59 may require significantly decreased dose of warfarin as compared to patients with CYP2C9 *1/*1. Other genetic and clinical factors may also influence the dose of warfarin.
1446766002	AA	Patients with the AA genotype and postoperative pain may require an increased dose when treated with fentanyl as compared to patients with the AG+GG genotype. Other genetic and clinical factors may also influence the required dose of fentanyl.
1446766003	AG	Patients with the AG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.
1446766004	GG	Patients with the GG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.
1450376937	AA	Patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AG or GG genotypes. However, contradictory evidence exists for this association with the A allele being associated with better response or the variant not associated with response. Other genetic and clinical factors may also influence response to methylphenidate.
1450376938	AG	Patients with the AG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association with the G allele being associated with poorer response or the variant not associated with response. Other genetic and clinical factors may also influence response to methylphenidate.
1450376939	GG	Patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association with the G allele being associated with poorer response or the variant not associated with response. Other genetic and clinical factors may also influence response to methylphenidate.
1447963221	CC	Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.
1447963222	CG	Patients with the CG genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.
1447963223	GG	Patients with the GG genotype and hypertension may have a smaller reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.
1447963229	AA	Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
1444698449	CC	Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698450	CT	Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698451	TT	Patients with the TT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1447963230	AC	Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
1447963231	CC	Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
1184514254	AA	Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514255	AC	Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1448108282	GG	Patients with the GG genotype who are treated with methotrexate may have a decreased likelihood of methotrexate response as compared to patients with the GT and TT genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444698442	CC	Patients with the CC genotype have an increased risk of post anesthesia apnea  when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698443	CT	Patients with the CT genotype have an increased risk of post anesthesia apnea  when treated with succinylcholine as compared to patients with the TT genotype and a decreased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698444	TT	Patients with the TT genotype have a decreased risk of post anesthesia apnea as compared to patients with the CC genotype when treated with succinylcholine. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1448108283	GT	Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GG genotype, but decreased response as compared to patients with the TT genotype. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1448108284	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GT and GG genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184514256	CC	Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1448108114	CC	Advanced non-small-cell lung cancer patients with CC genotype may less likely develop acquired resistance and more likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CT or TT genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.
1448108115	CT	Advanced non-small-cell lung cancer patients with CT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.
1444700114	*10	Patients with the CYP2C19*10 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*10 allele was found to have a decreased clearance of clopidogrel as compared to *1 during in-vitro characterization. 43% of the clearance ration of *1 for clopidogrel were reported. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700115	*11 + *13 + *15 + *18	Patients with the CYP2C19*11,*13, *15, *18 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. No significant differences in the clearance of clopidogrel were found during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1183960825	GG	Female patients with the GG genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the AA genotype (homozygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1448635076	*1a/*2a	Pediatric patients with epilepsy and the *1a/*2a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448635077	*1a/*3a	Pediatric patients with epilepsy and the *1a/*3a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448635078	*1a/*4a	Pediatric patients with epilepsy and the *1a/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1444700116	*14	Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*14 allele was found to have a decreased clearance of clopidogrel as compared to *1 during in-vitro characterization. 56% of the clearance ratio of *1 for clopidogrel were reported. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700117	*16	Patients with the CYP2C19*16 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*16 allele was catalytic inactive toward clopidogrel during in-vitro characterization. 11% of *1 activity for the substrate clopidogrel were reported. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700118	*19	Patients with the CYP2C19*19 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*19 allele was found to have a decreased clearance of clopidogrel as compared to *1 during in-vitro characterization. 40% of the clearance ratio of *1 for clopidogrel were reported. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1448635079	*1a/*8	Pediatric patients with epilepsy and the *1a/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448635080	*2a/*2a	Pediatric patients with epilepsy and the *2a/*2a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448099687	AA	Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184348741	AA	Patients with the AA genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348742	AG	Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348743	GG	Patients with the GG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1448099688	AG	Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1448099689	GG	Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184516227	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfametopyrazine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.
1184642815	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184642816	B (wildtype)/B (wildtype)	Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1444710713	*06:02:01	Patients with one or two copies of the HLA-DQB1*06:02 allele may be at risk for developing narcolepsy after receiving the vaccination against the H1N1 influenza virus as compared to patients with no HLA-DQB1*06:02 alleles or negative for the HLA-DQB1*06:02 test. However, this allele is also associated with the narcolepsy independent of the H1N1 vaccine, and it is not evident from the literature whether carrying this allele is associated with the development of narcolepsy specifically due to the H1N1 vaccine. Other genetic and clinical factors may also influence a patient's risk of developing narcolepsy.
1184512436	AA	Patients with the AA genotype who are treated with warfarin may require a higher dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184512435	GA	Patients with the GA genotype who are treated with warfarin may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184512434	GG	Patients with the GG genotype who are treated with warfarin may require a lower dose as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184753929	*1/*1	test
1184753930	*2/*2	test
1449311202	AA	Patients with the AA genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the AG or GG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.
1449311203	AG	Patients with the AG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the GG genotype, or 1) may have better response to treatment 2) may be at decreased risk of toxicity, and 3) may require a higher dose of methotrexate as compared to patients with the AA genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.
1449311204	GG	Patients with the GG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have better response to treatment 2) may be at decreased risk of toxicity 3) may require a higher dose of methotrexate, and 4) may be at lower risk of folate deficiency as compared to patients with the AA or AG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.
1449156033	TT	Patients with the TT genotype may have 1) a decreased risk of nicotine dependence and 2) a decreased response to smoking cessation therapies as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.
1183863782	CC	Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863783	CT	Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863781	TT	Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1184514460	AG	Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514461	GG	Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514465	CC	Patients with the CC genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1444698462	AC	Patients with the AC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698463	CC	Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the T genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1449156032	AT	Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.
1449156036	AA	Patients with AA genotype may have an increased likelihood of addiction to nicotine as compared to patients with the GG genotype. No significant results have been seen for an association with likelihood of smoking cessation. Additionally, some negative or contradictory findings exist. Other genetic and clinical factors may influence a patient's likelihood of nicotine addiction.
1184514454	AA	Patients with the AA genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514455	AT	Patients with the AT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514456	TT	Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514459	AA	Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514466	CT	Patients with the CT genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514467	TT	Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514470	AA	Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514471	AG	Patients with the AG genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype and a decreased risk of Heroin Dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514472	GG	Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514475	CC	Patients with the CC genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1447990605	TT	Patients with the TT genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
1449311207	CC	Pediatric patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1447990603	DEL/DEL	Patients with the DEL/DEL genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/T and TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
1184513737	AA	Patients with the AA genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1184513738	AG	Patients with the AG genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1184513739	GG	Patients with the GG genotype who are treated with escitalopram may have an increased chance of response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1184654254	*14:01:01	Patients with one or two copies of the HLA-DRB1*14:01:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-DRB1*14:01:01 alleles or negative for the HLA-DRB1*14:01:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184654257	*09:01:02	Patients with one or two copies of the HLA-DRB1*09:01:02 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-DRB1*09:01:02 alleles or negative for the HLA-DRB1*09:01:02 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449311208	CT	Pediatric patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the TT genotypes. However, they may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1447990604	DEL/T	Patients with the DEL/T genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
1447991143	*1/*1	Patients with the *1/*1 genotype may have increased metabolism of brivaracetam as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.
1447991144	*1/*2 + *1/*3	Patients with the *1/*2 or *1/*3 genotype may have decreased metabolism of brivaracetam as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.
1449311209	TT	Pediatric patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1184661224	CC	Patients with the CC genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
1444608203	CC	Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1444608204	CT	Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1444608205	TT	Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1444607779	TT	Patients with the TT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.
1444607786	CC	Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
1444607785	CT	Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
1444607784	TT	Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
1449182361	AC	Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.
1449182362	CC	Patients with the CC genotype and cancer-related pain may require a increased dose escalation of morphine as compared to patients with the AA or AC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.
1449182360	AA	Patients with the AA genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the AC or CC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.
1184661225	CT	Patients with the CT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype or a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
1449192472	AA	Patients with the AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192473	AC	Patients with the AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192474	CC	Patients with the CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449190615	TT	Patients with the TT genotype may have a lower risk of simvastatin-related myopathy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449191369	AA	Patients with the AA genotype (do not have a copy of the CFTR M1V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191370	AG	Patients with the AG genotype (one copy of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191371	GG	Patients with the GG genotype (two copies of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1444607732	CC	Patients with the CC genotype and schizophrenia may experience a greater weight gain when treated with clozapine or olanzapine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1444607733	CT	Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1444607734	TT	Patients with the TT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1444700152	*23	Patients with the CYP2C19*23 allele may have increased clearance of mephenytoin as compared to patients with the CYP2C19*1 allele. The CYP2C19*23 allele was found to have an increased clearance of mephenytoin as compared to *1 during one in-vitro characterization study. 235% of the clearance ratio of *1 for mephenytoin was reported in one study.  Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700153	*24	Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700154	*25	Patients with the CYP2C19*25 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*25 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterization. 36% of the clearance ratio of *1 for mephenytoin were reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700155	*26	Patients with the CYP2C19*26 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*26 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterizations. 42% of the clearance ratio of *1 for mephenytoin was reported in one study. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700156	*5	Patients with the CYP2C19*5 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*5 allele was catalytic inactive toward mephenytoin during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1444700157	*6	Patients with the CYP2C19*6 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*6 allele was catalytic inactive toward mephenytoin during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1448257272	GG	Patients with the GG genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.
1448257273	GT	Patients with the GT genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.
1184514212	GG	Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514211	GT	Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514210	TT	Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514220	CC	Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514219	CT	Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514218	TT	Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184472903	CC	Patients with acute myeloid leukemia and the CC genotype may have an decreased response to cytarabine and idarubicin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1444700158	*8	Patients with the CYP2C19*8 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*8 allele was found to have decreased activity of CYP2C19 as compared to *1 during several in-vitro characterizations. The CYP2C19*8 allele was catalytic inactive toward mephenytoin during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.
1448257274	TT	Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.
1448257294	GG	Patients with the GG genotype may have increased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype TT. Other genetic and clinical factors may influence the response to warfarin.
1448257293	GT	Patients with the GT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.
1184472902	CG	Patients with acute myeloid leukemia and the CG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1184472901	GG	Patients with acute myeloid leukemia and the GG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1449156818	AG	Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1184514243	CC	Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514242	CT	Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514241	TT	Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449169806	CT	Men with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.
1449169807	TT	Men with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atrovastatin.
1449170065	*33:03	Patients with one or two copies of the HLA-A*33:03 allele who are treated with lamotrigine may have a decreased risk of maculopapular exanthema as compared to patients with no HLA-A*33:03 alleles or negative for the HLA-A*33:03 test, however this is contradicted in one of the two studies. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449156819	GG	Patients with the GG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1448522776	TT	Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1183863990	CC	Patients with the CC genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.
1183863991	CT	Patients with the CT genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype and may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.
1183863992	TT	Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.
1448522780	CC	Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522781	CT	Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1449156811	AA	Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449156817	AA	Patients with the AA genotype may have a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1184661226	TT	Patients with the TT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
1449156812	AG	Patients with the AG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449156813	GG	Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449169805	CC	Men with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a greater decrease in triglycerides as compared to men with either the CT or TT genotypes. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.
1449269936	TT	Patients with the TT genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dose.
1449270029	CC	Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose requirement.
1447990278	CC	Patients with the CC genotype may have an increased risk of addiction to heroin when using heroin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.
1447990279	CT	Patients with the CT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CC genotype and an increased risk of heroin addiction as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.
1447990280	TT	Patients with the TT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.
1447991145	*2/*2 + *2/*3 + *3/*3	Patients with the *2/*2, *2/*3 or *3/*3 genotype may have decreased metabolism of brivaracetam as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.
1449270030	CT	Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype.  Other genetic and clinical factors may also influence a patient's warfarin dose requirement.
1449270031	TT	Patients with the TT genotype may require a decerased dose of warfarin as compared to patients with the CC or CT genotype.  Other genetic and clinical factors may also influence a patient's warfarin dose requirement.
1448256095	CC	Patients with the CC genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT.
1448256094	CT	Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.
1444666536	*1/*20	Patients with the *1/*20 genotype and breast or ovarian cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1444666535	*1/*8	Patients with the *1/*8 genotype and breast or ovarian cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1184747133	AG	Patients with the AG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38.
1184747134	GG	Patients with the GG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found increased enzyme activity for the G allele compared to the A allele. Other genetic and clinical factors may also influence metabolism of SN-38.
1444666537	*1/*1	Patients with the *1/*1 genotype and breast or ovarian cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the *1/*8 or *1/*20 genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1449270969	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270970	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449565196	CC	Patients with the CC genotype and heart valve replacement may require a lower stable dose of warfarin compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.
1449565197	CT	Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.
1449565198	TT	Patients with the TT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.
1449565783	*31	Patients carrying the CYP2C9*31 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1184747132	AA	Patients with the AA genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the AG or GG genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38.
1449565784	*33	Patients carrying the CYP2C9*33 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565785	*36	Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565261	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 (UGT1A1 *1/*1) genotype and HIV may have 1) a decreased likelihood for hyperbilirubinemia (up to jaundice range), 2) a decreased risk for treatment discontinuation when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence a patient's response to atazanavir.
1184989688	*02:01	Patients with the HLA-DQA1*02:01 allele with inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with no HLA-DQA1*02:01 alleles or negative for the HLA-DQA1*02:01 test. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1184516031	B (wildtype)	Male children with lead poisoning and the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184468582	AA	Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.
1184468583	AG	Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.
1184468584	GG	Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported.
1184514476	CT	Patients with the CT genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184516032	B (wildtype)/B (wildtype)	Female children with lead poisoning and the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G diplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184514477	TT	Patients with the TT genotype may have an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184516030	A- 202A_376G/B (wildtype)	Female children with lead poisoning and the A- 202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with dimercaprol may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to children with the A- 202A_376G/A- 202A_376G or B/B diplotype. Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449565262	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 (UGT1A1 *1/*28) genotype and HIV may have increased levels of bilirubin leading to an increased likelihood for hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)6/(TA)6 (*1/*1). However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atazanavir.
1449565263	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 (UGT1A1 *28/*28) genotype and HIV may have 1) increased levels of  bilirubin leading to an increased likelihood for hyperbilirubinemia (up to jaundice range), 2) an increased risk for treatment discontinuation when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype. Other genetic and clinical factors may also influence a patient's response to atazanavir.
1449565786	*37	Patients carrying the CYP2C9*37 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1184472798	CT	Patients with the CT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.
1449565787	*39	Patients carrying the CYP2C9*39 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1184472799	TT	Patients with the TT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.
1444932376	AA	Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.
1184348750	CC	Patients the CC genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348751	CG	Patients the CG genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348752	GG	Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1444666493	*1/*1	Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *3D, *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444932377	AG	Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.
1444932378	GG	Patients with cancer and the GG genotype may have decreased response to gemcitabine as compared to patients with the AG and AA genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.
1184472797	CC	Patients with the CC genotype may have increased formation of gemcitabine triphosphate as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.
1183680703	*1/*1	Patients with the TPMT *1/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1/*2 or *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.
1184516117	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516118	B (wildtype)/B (wildtype)	Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1444666494	*1/*1A	Patients with the *1/*1A genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *3D, *5, *10). Patients with the *1/*1A genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680700	*1/*2	Patients with the TPMT *1/*2 genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.
1183680701	*1/*3A	Patients with the TPMT *1/*3A genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.
1183680702	*1/*3C	Patients with the TPMT *1/*3C genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.
1444932410	CC	Patients with the CC genotype and Hypertension who are treated with hydrochlorothiazide may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.
1445619124	GT	Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619125	TT	Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1184000414	A-202A_376G	Male patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with nitrofurantoin may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000415	A-202A_376G/A-202A_376G	Female patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with nitrofurantoin may have an increased risk of hemolysis as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000416	A-202A_376G/B (wildtype)	Female patients with the A-202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with nitrofurantoin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G or B/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000417	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184000418	B (wildtype)/B (wildtype)	Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184134275	AA	Patients with the AA genotype may have increased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence response to morphine.
1184134276	AG	Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.
1184134277	GG	Patients with the GG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.
1184516119	Mediterranean Haplotype/B (wildtype)	Female patients with the Mediterranean/B (wildtype) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or B/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516120	Mediterranean Haplotype/Mediterranean Haplotype	Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516121	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516171	A- 202A_376G	Male patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516172	A- 202A_376G/A- 202A_376G	Female patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516173	A- 202A_376G/B (wildtype)	Female patients with the A-202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with a high dose of chloroquine  may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the A-/A- or B/B diplotype.  Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516174	B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516175	B (wildtype)/B (wildtype)	Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516178	Mediterranean Haplotype/Mediterranean Haplotype	Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449156048	CG	Patients with the CG genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1449156049	GG	Patients with the GG genotype may have an increased risk of developing nicotine dependence when smoking as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence risk of nicotine dependence.
1449156058	*67:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*67:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156063	*78:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*78:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156068	*13:02:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*13:02:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156073	*38:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*38:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1184654016	Canton, Taiwan-Hakka, Gifu-like, Agrigento-like	Male patients who are hemizygous for the Canton variant (associated with G6PD deficiency) and an infection may have an increased risk of hemolysis when treated with co-trimoxazole as compared to patients with the wildtype B haplotype (associated with normal G6PD enzyme levels). Sulfamethoxazole seems to underlie the effect on reducing red blood cell lifespan, rather than trimethoprim. Several studies find no association with increased risk in patients with G6PD deficiency. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184654017	Canton, Taiwan-Hakka, Gifu-like, Agrigento-like/B (wildtype)	Female patients with the Canton/B (wildtype) diplotype (heterozygous for the Canton variant) and an infection may have a varying degree of G6PD deficient red blood cells and an unknown risk of  co-trimoxazole-induced hemolysis as compared to patients with the Canton/Canton or B/B diplotype. Sulfamethoxazole seems to underlie the effect on reducing red blood cell lifespan, rather than trimethoprim. Several studies find no association with increased risk in patients with G6PD deficiency. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184654018	Canton, Taiwan-Hakka, Gifu-like, Agrigento-like/Canton, Taiwan-Hakka, Gifu-like, Agrigento-like	Female patients who are homozygous for the Canton variant (associated with G6PD deficiency) and an infection may have an increased risk of hemolysis when treated with co-trimoxazole as compared to patients with the wildtype B haplotype (associated with normal G6PD enzyme levels). Sulfamethoxazole seems to underlie the effect on reducing red blood cell lifespan, rather than trimethoprim. Several studies find no association with increased risk in patients with G6PD deficiency. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1446899667	AG	Women with breast cancer and the AG genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the GG genotypes and an increased likelihood of survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.
1446899668	GG	Women with breast cancer and the GG genotype may have an increased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.
1447814167	AA	Patients with the AA genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447814168	AG	Patients with the AG genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447814169	GG	Patients with the GG genotype may have more favorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to sorafenib.
1447814173	CC	Patients with the CC genotype may have more favorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447814174	CT	Patients with the CT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1449165051	CC	Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may have 1) a decreased response to the drug and 2) an increased risk for toxicity as compared to patients with the TT genotype. These associations have not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy and risk for toxicity.
1449165052	CT	Patients with the CT genotype and rheumatoid arthritis who are treated with methotrexate may have 1) a decreased response to the drug and 2) an increased risk for toxicity as compared to patients with the TT genotype. These associations have not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy and risk for toxicity.
1449165053	TT	Patients with the TT genotype and rheumatoid arthritis who are treated with methotrexate may have 1) an increased response to the drug and 2) a decreased risk for toxicity as compared to patients with the CC or CT genotype. These associations have not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy and risk for toxicity.
1184169284	*1/*1	Patients with the CYP2D6*1/*1 genotype who are treated with mirtazapine may have an increased clearance of mirtazapine as compared to patients with two non-functional CYP2D6 alleles (*3, *4, *5, *6) and a decreased clearance of mirtazapine as compared to patients with a duplication of a functional CYP2D6 gene. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184169285	*1/*1xN	Patients with a duplication of a functional CYP2D6 gene who are treated with mirtazapine may have an increased clearance of mirtazapine as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184169286	*1/*2xN	Patients with a duplication of a functional CYP2D6 gene who are treated with mirtazapine may have an increased clearance of mirtazapine as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184169287	*3	Patients with the CYP2D6*3 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with mirtazapine may have a decreased clearance of mirtazapine as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184169288	*4	Patients with the CYP2D6*4 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with mirtazapine may have a decreased clearance of mirtazapine as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184169289	*5	Patients with the CYP2D6*5 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with mirtazapine may have a decreased clearance of mirtazapine as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184169290	*6	Patients with the CYP2D6*6 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with mirtazapine may have a decreased clearance of mirtazapine as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of mirtazapine.
1184516176	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1184516177	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients with the heterozygous for the G6PD Mediterranean variant who are treated with a high dose of chloroquine  may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or B/B diplotype. Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1444666618	CCGG/del	Patients with the CCGG/del genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
1444666619	del/del	Patients with the del/del genotype and non-small-cell lung cancer may have longer overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the CCGG/CCGG or CCGG/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
1444666624	GG	Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666625	GT	Patients with the GT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666626	TT	Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1449154632	AA	Patients with the AA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have a decreased, but not absent, risk for drug-resistance as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.
1449154633	GA	Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.
1444666617	CCGG/CCGG	Patients with the CCGG/CCGG genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
1449154634	GG	Patients with the GG genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.
1449154756	CC	Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.
1449154757	CT	Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.
1447960266	TT	Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.
1184999870	AA	Patients with the AA genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1184999871	AG	Patients with the AG genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1184999872	GG	Patients with the GG genotype and epilepsy may be more likely to respond to antiepileptic drugs as compared to patients with the AG or AA genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1447960271	CC	No patients with the CC genotype are available for analysis, but patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.
1447960272	CT	Patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.
1446906129	CC	Patients with the CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.
1185000100	AG	Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1185000101	GG	Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1185000116	CC	Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1184233519	CG	Patients with the CG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233520	GG	Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233513	AA	Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233514	AG	Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233515	GG	Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1446907390	*1A/*1A	Patients with the CYP3A5 *1/*1 diplotype may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3/*3 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.
1185000099	AA	Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1185000117	CT	Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1446907391	*1A/*3A	Patients with the CYP3A5 *1/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.
1446907392	*3A/*3A	Patients with the CYP3A5 *3/*3  may have a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.
1184233509	CC	Patients with the CC genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233510	CT	Patients with the CT genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233511	TT	Patients with the TT genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233518	CC	Patients with the CC genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1446899666	AA	Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.
1449155304	CC	Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.
1446898178	AA	No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.
1446898179	AC	Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.
1446898180	CC	Patients with the CC genotype may have increased clearance of metformin as compared to patients with the AC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.
1444608233	AA	Individuals with the AA genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.
1444608234	AG	Individuals with the AG genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.
1444608235	GG	Individuals with the GG genotype who are addicted to methamphetamine may be more likely to experience psychosis when taking methamphetamine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.
1444608245	CC	Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have an increased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.
1444608246	CT	Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.
1444608247	TT	Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.
1444608252	*1A/*1A	Patients with the *1A/*1A genotype and schizophrenia may have a decreased risk for seizures when treated with clozapine as compared to patients with the *1F/*1F genotype. Other genetic and clinical factors may also influence the risk for seizures when taking clozapine.
1444608253	*1A/*1F	Patients with the *1A/*1F genotype and schizophrenia may have a decreased risk for seizures when treated with clozapine as compared to patients with the *1F/*1F genotype. Other genetic and clinical factors may also influence the risk for seizures when taking clozapine.
1444608254	*1F/*1F	Patients with the *1F/*1F genotype and schizophrenia may have an increased risk for seizures when treated with clozapine as compared to patients with the *1A/*1A or *1A/*1F genotype. Other genetic and clinical factors may also influence the risk for seizures when taking clozapine.
1449156091	*39:05:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:05:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156096	*39:06:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:06:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449155305	CT	Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib response.
1449155306	TT	Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer progression-free survival time when treated with sunitinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence sunitinib response.
1448099299	AA	Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448099300	AG	Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448105333	TT	Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1448099301	GG	Patients with the GG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1444666596	AA	Patients with the AA genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666597	AG	Patients with the AG genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype, and an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666598	GG	Patients with the GG genotype and non-small-cell lung cancer may have an increased response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666603	CC	Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666604	CT	Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666605	TT	Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666610	CC	Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666611	CT	Patients with the CT genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449269919	TT	Patients with genotype TT may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the response to warfarin.
1444666612	TT	Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449269917	CC	Patients with genotype CC may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to warfarin.
1444666669	AA	Patients with the AA genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666670	AG	Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666671	GG	Patients with the GG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1449269918	CT	Patients with genotype CT may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the response to warfarin.
1448101458	AA	Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1448101459	AC	Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1448101460	CC	Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666784	AA	Patients with the AA genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
1444666785	AG	Patients with the AG genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
1444666786	GG	Patients with the GG genotype and lung cancer may have an increased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
1444666698	AC	Patients with the AC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666699	CC	Patients with the CC genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1447961117	CC	Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1444666772	AA	Patients with the AA genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1444666773	AG	Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1444666774	GG	Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1444666791	CC	Patients with the CC genotype and lung cancer may have a better response to treatment with pemetrexed as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1444666792	CT	Patients with the CT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1444666793	TT	Patients with the TT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1447961110	AA	Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961111	AC	Patients with the AC genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1444666805	GG	Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666806	GT	Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666807	TT	Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.
1447961118	CT	Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961119	TT	Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1444666820	CC	Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666821	CT	Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666822	TT	Patients with the TT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival time.
1447961112	CC	Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1185000118	TT	Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1448102811	CC	Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1450044811	AA	Patients with central nervous system infections and the AA genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.
1450044812	AG	Patients with central nervous system infections and the AG genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.
1450044813	GG	Patients with central nervous system infections and the GG genotype may have decreased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.
1450044458	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT, CT, CG, or GG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044459	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044460	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044461	GG	Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044462	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448995669	AA	Patients with the AA genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the AG or GG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutations who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.
1448102812	CG	Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1448102813	GG	Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1449140269	CC	Patients with hypertension and the CC genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.
1444666349	AA	Patients with the AA genotype and prostate cancer may have increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
1444666350	AG	Patients with the AG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
1444666351	GG	Patients with the GG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
1449156141	*15:25:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:25:01 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156154	*15:32	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:32 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156132	*15:01:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:01:01:0 allele may have an decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449140270	CT	Patients with hypertension and the CT genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the TT genotypes and an increased likelihood as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.
1449140271	TT	Patients with hypertension and the TT genotype who are administered thiazides may have an increased likelihood of hyponatremia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.
1444666371	CC	Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
1444666372	CT	Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
1444666373	TT	Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
1444666378	CC	Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
1444666379	CT	Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
1444666380	TT	Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
1449156104	*39:09	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:09 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1444666552	AA	No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666553	AG	Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666554	GG	Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1449156135	*15:12	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:12 allele may have an decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156138	*15:24	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:24 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156146	*15:27:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:27:01 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156159	*15:35	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:35 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1184989726	CC	Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.
1184989727	CT	Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.
1184989692	AA	Patients with the AA genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have a reduced, but not absent, risk of pancreatitis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1184989693	AC	Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1184989694	CC	Patients with the CC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1184998965	AA	Patients with the AA genotype who are treated with morphine may have higher levels of morphine-3-glucuronide formation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998966	AG	Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998967	GG	Patients with the GG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184989728	TT	Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.
1184989732	CC	Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1184989733	CT	Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1184989734	TT	Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1184990013	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype may have a decreased, but not absent, risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR long form (L allele)/HTTLPR long form (L allele)  genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1449164575	AG	Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1449164576	GG	Cancer patients with the GG genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA or AG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1449164765	CC	Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1184998992	TT	Patients with the TT genotype who are treated with morphine may have lower levels of morphine-3-glucuronide and morphine-6-glucuronide metabolite formation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1449164766	CT	Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1184998990	CC	Patients with the CC genotype who are treated with morphine may have higher levels of morphine-3-glucuronide and morphine-6-glucuronide metabolite formation as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998991	CT	Patients with the CT genotype who are treated with morphine may have lower levels of morphine-3-glucuronide and morphine-6-glucuronide metabolite formation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1449156944	CC	Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.
1447946230	TT	Patients with the TT genotype and osteosarcoma may have increased severity of mucositis when receiving methotrexate, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.
1446899325	*1/*1	Patients with the CYP2B6 *1/*1 diplotype and chronic pain, or cancer may have increased clearance of ketamine as compared to patients with the CYP2B6 *1/*6 and *6/*6 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.
1446899326	*1/*6	Patients with the CYP2B6 *1/*6 diplotype and chronic pain, or cancer may have decreased clearance of ketamine as compared to patients with the CYP2B6 *1/*1 diplotype and increased clearance of ketamine as compared to patients with the *6/*6 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.
1444666312	CC	Patients with the CC genotype and who are heavy drinkers or have an alcohol-use disorder may have lower concentrations of topiramate, and a better response to treatment with the drug, as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.
1446899327	*6/*6	Patients with the CYP2B6 *6/*6 diplotype and chronic pain, or cancer may have decreased clearance of ketamine as compared to patients with the CYP2B6 *1/*6 and *1/*1 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.
1446899711	AC	Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1446899712	CC	Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449269934	CC	Patients with the CC genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CT or TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dose.
1444666495	*10	Patients with the *10 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*10) than in those who are heterozygous for the non-functional variant (*1/*10). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666496	*13	Patients with the *13 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*13) than in those who are heterozygous for the non-functional variant (*1/*13). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448102922	GG	Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1448102923	GT	Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1449269935	CT	Patients with the CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dose.
1447953014	GG	Patients with the GG genotype and HIV may have decreased clearance and increased plasma concentration of efavirenz as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1447953293	CC	Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
1448103885	AG	Patients with the AG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.
1444666719	CC	Patients with the CC genotype and acute lymphoblastic leukemia may have increased concentrations of methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.
1444666720	CT	Patients with the CT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.
1444666509	*37	Patients with the *37 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*37) than in those who are heterozygous for the non-functional variant (*1/*37). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666510	*3D	Patients with the *3D allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*3D) than in those who are heterozygous for the non-functional variant (*1/*3D). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666511	*5	Patients with the *5 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*5) than in those who are heterozygous for the non-functional variant (*1/*5). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666712	GG	Patients with the GG genotype and acute lymphoblastic leukemia may have an increased risk of granulocytopenia when treated with methotrexate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
1444666713	GT	Patients with the GT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
1444666714	TT	Patients with the TT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
1444666721	TT	Patients with the TT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.
1449713679	AT	Patients with the AT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713678	AA	Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1444666733	CC	Patients with the CC genotype and major depressive disorder may have a poorer response to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444666734	CT	Patients with the CT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444666735	TT	Patients with the TT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444666740	AA	Patients with the AA genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram.
1444666741	AG	Patients with the AG genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.
1444666742	GG	Patients with the GG genotype and depression may have a poorer response when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.
1449713656	AA	Patients with the AA genotype may have increased tumor response rate and  increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.
1449713657	AG	Patients with the AG genotype may have increased tumor response rate and  increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and  decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.
1449713658	GG	Patients with the GG genotype may have decreased tumor response rate and  decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.
1184999882	AA	Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs (such as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate) may have an increased risk of drug resistance as compared to patients with the GG genotype. Another study found no association. Other genetic and clinical factors may also influence a patient's response to antiepileptic drugs.
1184999883	AG	Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs (such as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate) may have an increased risk of drug resistance as compared to patients with the GG genotype.  Another study found no association. Other genetic and clinical factors may also influence a patient's response to antiepileptic drugs.
1184999884	GG	Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs (such as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate) may have a decreased,but not absent, risk of drug resistance as compared to patients with the AG or AA genotype.  Another study found no association. Other genetic and clinical factors may also influence a patient's response to antiepileptic drugs.
1448112488	AA	Patients with the AA genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to tocilizumab.
1448112489	AG	Patients with the AG genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to tocilizumab.
1448112490	GG	Patients with the GG genotype and rheumatoid arthritis may have a decreased response to tocilizumab compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect response to tocilizumab.
1444665959	AA	Patients with the AA genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665960	AG	Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment as compared to patients with the AA genotype, but a longer overall survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665961	GG	Patients with the GG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1448112495	CC	Patients with the CC genotype and rheumatoid arthritis may have increased response to tocilizumab compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect response to tocilizumab.
1448112496	CT	Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.
1448112497	TT	Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.
1444608294	CT	Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.
1444608295	TT	Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.
1444665972	AC	Patients with the AC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665973	CC	Patients with the CC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665971	AA	Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time and progression-free survival time, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444667325	GT	Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1448995138	GG	Patients with the GG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.
1444673027	AA	Patients with the AA genotype and heart conditions may have a poorer response to treatment with beta-blockers or antihypertensives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
1444673028	AT	Patients with the AT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
1444705382	CC	Patients with the CC genotype (CYP3A5 *3/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.
1444705383	CT	Patients with the CT genotype (CYP3A5 *1/*3) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the CT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.
1447679959	AA	Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.
1444667326	TT	Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444668599	AA	Patients with genotype AA may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
1444668600	AT	Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
1444668601	TT	Patients with genotype TT may have higher likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
1444673029	TT	Patients with the TT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
1447679960	AG	Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.
1447679961	GG	Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.
1448995137	GT	Patients with the TG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.
1185002309	AA	Patients with the AA genotype may require increased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose
1185002310	AG	Patients with the AG genotype may require increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose
1185002311	GG	Patients with the GG genotype may require decreased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose
1448995136	TT	Patients with the TT genotype may have increased plasma concentrations of dolutegravir as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to dolutegravir.
1448995366	*1/*1	Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.
1448995367	*1/*2	Patients with the *1/*2 genotype and bipolar disorder and other psychotic disorders may have decreased dose of valproic acid compared to patients with the *1/*1 genotype. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.
1444666497	*15	Patients with the *15 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*15) than in those who are heterozygous for the non-functional variant (*1/*15). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666498	*19	Patients with the *19 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*19) than in those who are heterozygous for the non-functional variant (*1/*19). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666499	*24	Patients with the *24 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*24) than in those who are heterozygous for the non-functional variant (*1/*24). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666500	*25	Patients with the *25 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*25) than in those who are heterozygous for the non-functional variant (*1/*25). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666501	*26	Patients with the *26 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*26) than in those who are heterozygous for the non-functional variant (*1/*26). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666502	*27	Patients with the *27 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*27) than in those who are heterozygous for the non-functional variant (*1/*27). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666503	*28	Patients with the *28 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*28) than in those who are heterozygous for the non-functional variant (*1/*28). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666504	*30	Patients with the *30 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*30) than in those who are heterozygous for the non-functional variant (*1/*30). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666505	*31	Patients with the *31 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*31) than in those who are heterozygous for the non-functional variant (*1/*31). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666506	*32	Patients with the *32 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*32) than in those who are heterozygous for the non-functional variant (*1/*32). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666507	*33	Patients with the *33 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*33) than in those who are heterozygous for the non-functional variant (*1/*33). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444666508	*34	Patients with the *34 allele 1) may have decreased inactivation of thiopurines due to decreased TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 or *1/*1A genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*34) than in those who are heterozygous for the non-functional variant (*1/*34). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444607339	AA	Genotype AA may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics.
1444607340	AG	Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics.
1444607341	GG	Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics.
1449311566	CC	Patients with the CC genotype may experience increased repaglinide exposure and improved response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.
1444607361	CC	In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.
1444607362	CT	In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.
1444607363	TT	In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.
1444607368	CC	In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.
1444607369	CT	In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.
1444607370	TT	In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.
1444607375	CC	Women with the CC genotype and breast cancer may have increased lumbar bone loss when treated with tamoxifen as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
1444607376	CT	Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
1444607377	TT	Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
1448428941	TT	Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1449311567	CT	Patients with the CT genotype may have decreased exposure of repaglinide and decreased response to repaglinide as compared to patients with the CC genotype and increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.
1448105331	GG	Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1448105332	GT	Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1444672988	CC	Patients with the CC genotype and hypertriglyceridemia may have a poorer response to treatment with fenofibrate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1444672989	CG	Patients with the CG genotype and hypertriglyceridemia may have a better response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1444672990	GG	Patients with the GG genotype and hypertriglyceridemia may have a better response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1444607304	GG	Individuals with the GG genotype may have a decreased risk of cocaine dependence as compared to individuals with the GT or TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607305	GT	Individuals with the GT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607306	TT	Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1449163273	CC	High-risk pediatric patients with acute lymphoblastic leukemia who have the CC genotype may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163274	CT	High-risk pediatric patients with acute lymphoblastic leukemia who have the CT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163275	TT	High-risk pediatric patients with acute lymphoblastic leukemia who have the TT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1450376655	AA	Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376656	AG	Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376657	GG	Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1444607311	CC	Individuals with the CC genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607312	CT	Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607313	TT	Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to those with the CC or CT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607739	CC	Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.
1444607740	CT	Patients with the CT genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.
1444607741	TT	Patients with the TT genotype may have a higher maximal rate (Vmax) of ethanol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.
1444607746	GAT/DEL	Patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607747	GAT/GAT	Patients with the GAT/GAT genotype who are treated with metformin may have an increased trough metformin steady-state concentration as compared to patients with the GAT/DEL genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607748	del/del	Patients with the del/del genotype were not studied but patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1449163308	AA	Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163309	AC	Pediatric patients with the AC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163310	CC	Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1450377205	CC	Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1444666683	GG	Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444607968	AA	Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607969	AC	Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype and decreased risk of leukopenia as compared to patients with the AA. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607970	CC	Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607974	GG	Patients with the GG genotype and systemic lupus erythematosus may be more likely to respond to treatment with rituximab, as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.
1444607975	GT	Patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.
1444607976	TT	No patients with the TT genotype were present in the study. However, patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.
1444666676	AA	Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666677	AG	Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666678	GG	Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666684	GT	Patients with the GT genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666685	TT	Patients with the TT genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666690	CC	Patients with the CC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666691	CG	Patients with the CG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444607914	AA	Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607913	GA	Patients with the GA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the AA genotype and decreased risk of leukopenia as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607912	GG	Patients with the GG genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444666692	GG	Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666697	AA	Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1446903105	*2xN	Patients with a duplication of a functional CYP2D6 gene who are treated with amitriptyline may have 1) an increased metabolism of amitriptyline and 2) decreased response as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1450372056	AA	Patients with the AA genotype may have a decreased, but not absent, severity of intoxication and a decreased response when exposed to ethanol as compared to patients with the AG and GG genotype. However, other studies have not found a significant association between this genotype and response to ethanol. Other genetic and clinical factors may also influence a patient's ethanol response.
1450372057	AG	Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, other studies have not found a significant association between this genotype and response to ethanol. Other genetic and clinical factors may also influence a patient's ethanol response.
1184756821	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased CYP2D6 enzyme activity as compared to patients with the CYP2D6*5/*9 or *4/*38 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.
1184756822	*4/*38	Patients with the CYP2D6*4/*38 genotype (assigned as a poor metabolizer phenotype) may have a decreased CYP2D6 enzyme activity as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.
1184756823	*5/*9	Patients with the CYP2D6*5/*9 genotype may have a decreased CYP2D6 enzyme activity as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.
1450372058	GG	Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, other studies have not found a significant association between this genotype and response to ethanol. Other genetic and clinical factors may also influence a patient's ethanol response.
1184987887	*1/*1	Patients with the *1/*1 diplotype and depression may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the *4/*4 genotype. Other genetic and clinical factors may also influence a patient's dose requirement.
1184987888	*1/*4	Patients with the *1/*4 diplotype and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the *1/*1 genotype or may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the *4/*4 genotype. Other genetic and clinical factors may also influence a patient's dose requirement.
1184987889	*4/*4	Patients with the *4/*4 diplotype and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's dose requirement.
1446903106	*3	Patients with the CYP2D6*3 allele who are treated with amitriptyline may have 1) increased nortriptyline plasma levels and decreased clearance of amitriptyline, and 2) in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446903107	*4	Patients with the CYP2D6*4 allele who are treated with amitriptyline may have 1) increased nortriptyline plasma levels and decreased clearance of amitriptyline, and 2) in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446903108	*41	Patients with the CYP2D6*41 allele in combination with another reduced function (*10, *41) or non-functional CYP2D6 allele who are treated with amitriptyline may have increased nortriptyline plasma levels as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1444666200	*03:01:01:01	Patients with one or two copies of the HLA-DRB1*03:01 allele have an increased risk for maculopapular eruption when treated with carbamazepine as compared to patients with no HLA-DRB1*03:01 alleles or negative for the HLA-DRB1*03:01 test. Other genetic and clinical factors may also influence a patient's risk of maculopapular eruption when treated with carbamazepine.
1444666218	*05:01:01:01	Patients with one or two copies of the HLA-DQB1*05:01:01 allele may have a decreased risk for drug hypersensitivity reactions when treated with nevirapine as compared to patients with no HLA-DQB1*05:01:01 alleles or negative for the HLA-DQB1*05:01:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.
1447991977	*1/*1	Patients with the *1/*1 diplotype may have increased DPYD activity as compared to those with the *1/*9B or *9B/*9B diplotype. Other genetic and clinical factors may also affect DPYD activity.
1447991978	*1/*9B	Patients with the *1/*9B diplotype may have decreased DPYD activity as compared to those with the *1/*1 diplotype. Other genetic and clinical factors may also affect DPYD activity.
1447991979	*9B/*9B	Patients with the *9B/*9B diplotype may have decreased DPYD activity as compared to those with the *1/*1 diplotype. Other genetic and clinical factors may also affect DPYD activity.
1444607636	AA	Patients with the AA genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607637	AG	Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607511	*1/*1	Individuals with the *1/*1 genotype may have an decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.
1444607509	*1/*3A	Individuals with the *1/*3A genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*1 genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.
1449192089	CC	Patients with the CC genotype (do not have a copy of the CFTR S945L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192090	CT	Patients with the CT genotype (one copy of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1444607510	*1/*3C	Individuals with the *1/*3C genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*1 genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.
1444607518	*1A/*1A	Individuals with the *1A/*1A genotype may have increased area under the curve (AUC) of olanzapine as compared to Individuals with the *3A/*3A genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607519	*1A/*3A	Individuals with the *1A/*3A genotype may have increased area under the curve (AUC) of olanzapine as compared to Individuals with the *3A/*3A genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607520	*3A/*3A	Individuals with the *3A/*3A genotype may have decreased area under the curve (AUC) of olanzapine as compared to Individuals with the *1A/*1A or *1A/*3A genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607528	*1/*1	Individuals with the *1/*1 genotype may have a decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*28 or *28/*28 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.
1185235061	AA	Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.
1185235062	AT	Patients with the AT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results.  Other genetic and clinical factors may also influence a patient's losartan metabolism.
1185235063	TT	Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.
1444607529	*1/*28	Individuals with the *1/*28 genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*1 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.
1444607530	*28/*28	Individuals with the *28/*28 genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*1 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.
1449192091	TT	Patients with the TT genotype (two copies of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1444607638	GG	Patients with the GG genotype who are treated with metformin may have a increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607676	CC	Patients with the CC genotype who are treated with fluoxetine may have an increased response as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444607677	CG	Patients with the CG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1184756110	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) or debrisoquine as compared to patients with the CYP2D6*4/*15 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.
1184756109	*4/*15	Patients with the CYP2D6*4/*15 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) or debrisoquine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.
1184986493	AA	Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.
1184986494	AG	Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.
1184986495	GG	Patients with the GG genotype and organ transplantation administered tacrolimus may have decreased metabolism of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.
1449191744	TT	Patients with the TT genotype (two copies of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1448997865	CC	Patients with the CC genotype and Coronary Artery Disease may be associated with increased risk of statin-related myopathy when treated with rosuvastatin as compared to the CT or  TT genotypes. Other genetic and clinical factors may also influence the risk of myopathy in patients taking rosuvastatin.
1448997866	CT	Patients with the CT genotype and Coronary Artery Disease may have an increased risk of statin-related myopathy when treated with rosuvastatin as compared to the TT genotype, and a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk of myopathy in patients taking rosuvastatin.
1448997867	TT	Patients with the TT genotype and Coronary Artery Disease may have a decreased risk of statin-related myopathy when treated with rosuvastatin as compared to the CT or  CC genotypes. Other genetic and clinical factors may also influence the risk of myopathy in patients taking rosuvastatin.
1444607725	AA	Patients with the AA genotype who are receiving hydrocodone may have a decreased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.
1444607726	AG	Patients with the AG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.
1444607727	GG	Patients with the GG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.
1444607707	GT	Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.
1444607708	TT	Patients with the TT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.
1448635622	null/non-null	Women with HIV who have the GSTM1 null/non-null genotype may have an increased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) as compared to patients with the non-null/non-null genotypes and decreased risk as compared to women with the null/null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS/TEN in women with HIV who are administered nevirapine.
1448635623	null/null	Women with HIV who have the GSTM1 null/null genotype may have an increased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) as compared to patients with the null/non-null and non-null/non-null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS/TEN in women with HIV who are administered nevirapine.
1444698456	AG	Patients with the AG genotype have an decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698457	GG	Patients with the GG genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the A genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444698461	AA	Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1444666310	AA	Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.
1444666311	AC	Patients with the AC genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.
1449564332	CC	Patients with the CC genotype who are treated with warfarin or acenocoumarol may have a decreased risk of Hemorrhage as compared to the CT or TT genotypes, however this is contradicted in nearly half the studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered warfarin or acenocoumarol.
1444706871	AA	Female patients with the AA genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706872	AC	Female patients with the AC genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706873	CC	Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706880	CC	Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1445402362	CC	Patients with the CC genotype may have increased glucuronidation of anastrozole as compared to patients with the CT or TT genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.
1445402363	CT	Patients with the CT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.
1445402364	TT	Patients with the TT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.
1444698455	AA	Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184986323	CT	Patients with the CT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype and an improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.
1184986324	TT	Patients with the TT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.
1444706863	AA	Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706864	AG	Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype.or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706865	GG	Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1449564333	CT	Patients with the CT genotype who are treated with warfarin or acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes, however this is contradicted in nearly half the studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered warfarin or acenocoumarol.
1449564334	TT	Patients with the TT genotype who are treated with warfarin or acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes, however this is contradicted in nearly half the studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered warfarin or acenocoumarol.
1184749285	AA	Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749286	AG	Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749287	GG	Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1448624878	AA	Patients with the AA genotype may have increased metabolism and decreased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to clopidogrel.
1184764190	CC	Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764191	CT	Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1448624877	AG	Patients with the AG genotype may have decreased metabolism and increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.
1444667735	AA	Patients with the AA genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
1444667736	AC	Patients with the AC genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
1444667737	CC	Patients with the CC genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
1444667728	AA	Patients with the AA genotype and open-angle glaucoma may have an increased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.
1444667729	AG	Patients with the AG genotype and open-angle glaucoma may have a decreased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost.
1448624876	GG	Patients with the GG genotype may have decreased metabolism and increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.
1449311568	TT	Patients with the TT genotype may have decreased exposure of repaglinide and decreased response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.
1449557750	*12	Patients with the *12 allele and Tuberculosis who have a rapid or intermediate acetylator phenotype may have a reduced risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with two alleles conferring a slow acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449557751	*13	Patients with the *13 allele and Tuberculosis who have a rapid or intermediate acetylator phenotype may have a reduced risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with two alleles conferring a slow acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449557752	*14	Patients with the *14 allele and Tuberculosis who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have an increased risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449557753	*4	Patients with the *4 allele and Tuberculosis who have a rapid or intermediate acetylator phenotype may have a reduced risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with two alleles conferring a slow acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1184756887	*02:02	Patients with one or two copies of the HLA-DQB1*02:02 allele who are treated with acetaminophen may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-DQB1*02:02 alleles or negative for the HLA-DQB1*02:02 test. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.
1446908889	CC	Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
1446908890	CT	Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
1446908891	TT	Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
1444701157	*1/*1	Patients with two functional CYP2D6 alleles who are treated with fluoxetine may have 1) decreased plasma concentrations of fluoxetine or (S)-fluoxetine and an increased (S)-norfluoxetine/(S)-fluoxetine ratios as compared to patients with non-functional CYP2D6 alleles (*3, *4, *5, *6) and 2) an increased plasma concentrations of fluoxetine or (S)-fluoxetine and decreased (S)-norfluoxetine/(S)-fluoxetine ratios and decreased, but not absent, risk for early treatment discontinuation as compared to patients with more than two functional CYP2D6 alleles (*1XN, *2XN).
1444701158	*1/*1xN	Patients with more than two functional CYP2D6 alleles who are treated with fluoxetine may have decreased plasma concentrations of fluoxetine or (S)-fluoxetine and increased (S)-norfluoxetine/(S)-fluoxetine ratios and increased risk for early treatment discontinuation as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444701159	*1/*2xN	Patients with more than two functional CYP2D6 alleles who are treated with fluoxetine may have decreased plasma concentrations of fluoxetine or (S)-fluoxetine and increased (S)-norfluoxetine/(S)-fluoxetine ratios and increased risk for early treatment discontinuation as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444701160	*3	Patients with the CYP2D6*3 allele who are treated with fluoxetine may have decreased (S)-norfluoxetine/(S)-fluoxetine ratios as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, contradictory findings regarding the pharmacokinetic parameters and no association with response or side effects are reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444701161	*4	Patients with the CYP2D6*4 allele who are treated with fluoxetine may have increased plasma concentrations of fluoxetine or (S)-fluoxetine and decreased (S)-norfluoxetine/(S)-fluoxetine ratios as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, contradictory findings regarding the pharmacokinetic parameters and no association with response or side effects are reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444701162	*5	Patients with the CYP2D6*5 allele who are treated with fluoxetine may have decreased (S)-norfluoxetine/(S)-fluoxetine ratios as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, contradictory findings regarding the pharmacokinetic parameters and no association with response or side effects are reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444701163	*6	Patients with the CYP2D6*6 allele who are treated with fluoxetine may have  increased plasma concentrations of fluoxetine or (S)-fluoxetine and decreased (S)-norfluoxetine/(S)-fluoxetine ratios as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, contradictory findings regarding the pharmacokinetic parameters and no association with response or side effects are reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444701227	*1/*1	Patients with the *1/*1 genotype who carry two functional alleles may have 1) increased metabolism/clearance of venlafaxine, 2) increased tolerance of higher venlafaxine dose and 3) decreased, but not absent risk for side effects as compared to patients with non-functional (*3, *4, *5, *6) and reduced functional alleles (*10, *41). Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1444701228	*10	Patients with Depressive Disorder and the *10 reduced function allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*10, *41) may have 1) decreased metabolism/clearance of venlafaxine and 2) in combination with another non-functional may have decreased tolerance of higher venlafaxine dose as compared to patients with *1/*1 genotype who carry two functional alleles. In patients with Obsessive-Compulsive Disorder no association with treatment response was found. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1446908895	CC	Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patient's response.
1446908896	CT	Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT.  Other genetic and clinical factors may also influence a patient's response.
1446908897	TT	Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT .  Other genetic and clinical factors may also influence a patient's response.
1444607777	GG	Patients with the GG genotype and non-small-cell lung cancer may be at increased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.
1184997084	*38:01:01	Patients with one or two copies of the HLA-B*38 allele have an increased likelihood of being a non-responder to therapy when treated with pegylated interferon and ribavirin, as compared to patients with no HLA-B*38 alleles or negative for the HLA-B*38 test. Other genetic and clinical factors may also influence a patient's response to pegylated interferon and ribavirin therapy. Note that the information in this clinical annotation refers to the presence of any HLA-B*38 allele. This clinical annotation appears on the HLA-B*38:01:01 allele page because this was the first *38 allele discovered.
1184757170	*4/*20	Patients with the CYP2D6*4/*20 genotype (assigned as poor metabolizer phenotype) may have a very decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of metoprolol.
1184986311	AA	Patients with the AA genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.
1184986312	AC	Patients with the AC genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype and an increased risk of diarrhea as compared to the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.
1184986313	CC	Patients with the CC genotype and cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.
1184986682	CC	Patients with the CC genotype may have a decreased metabolism of repaglinide as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1449166885	AA	Patients with the AA genotype who are administered allopurinol may have an decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1184986683	CT	The CT genotype did not differ significantly in metabolism of repaglinide as compared to patients with the CC or TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986684	TT	Patients with the TT genotype may have an metabolism of repaglinide as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986672	AA	Patients with the AA genotype may have increased metabolism of repaglinide as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986673	AG	The AG genotype did not differ significantly in metabolism of repaglinide as compared to patients with the GG or AA genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986674	GG	Patients with the GG genotype may have decreased metabolism of repaglinide as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.
1444607778	GT	Patients with the GT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.
1449166886	AG	Patients with the AG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1184997074	*38:02:01	Patients with one or two copies of the HLA-B*38:02:01 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*38:02:01 alleles or negative for the HLA-B*38:02:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1444607770	CC	Patients with the CC genotype who are treated with fluvoxamine may have an  increased risk of gastrointestinal side effects and increased response as compared to patients with the TC or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1444607771	CT	Patients with the CT genotype who are treated with fluvoxamine may have an  increased risk of gastrointestinal side effects and decreased response as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1444607772	TT	Patients with the TT genotype who are treated with fluvoxamine may have a decreased, but not absent, risk of gastrointestinal side effects and decreased response as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1185023394	CC	Patients with CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins.
1185003569	AA	Patients with the AA genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003568	AC	Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.
1449155753	AA	Women with premature births and the AA genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.
1449155754	AG	Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.
1449155755	GG	Women with premature births and the GG genotype who are treated with ritodrine may have a increased likelihood of adverse events as compared to women with premature birth and the AA or AG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.
1449155835	*51:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*51:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1184986597	GT	Patients with the GT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.
1184986598	TT	Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.
1448428119	CC	Patients with the CC genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428121	TT	Patients with the TT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428120	CT	Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428135	AA	Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1185003567	CC	Patients with the CC genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the response to trastuzumab.
1185023395	CT	Patients with CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins.
1185023396	TT	Patients with TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins.
1448428136	AG	Patients with the AG genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428137	GG	Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1449155840	*51:02:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*51:02:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1450044484	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044485	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1184764192	TT	Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184985940	*1/*1 + *1/*2	Patients with the CYP2D6*1/*1 or *1/2 genotype may have an increased metabolism of debrisoquine or dextromethorphan or sparteine as compared to patients with the CYP2D6*18/*21 or *5/*18 or *1/*21 or *10/*21 or *2/*44 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or dextromethorphan or sparteine.
1184985941	*1/*21	Patients with the CYP2D6*1/*21 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1/*2 genotype. Finding reported in case study for *1/*21 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184985942	*10/*21	Patients with the CYP2D6*10/*21 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1/*2 genotype. Finding reported in case study for *10/*21 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184985943	*18/*21	Patients with the CYP2D6*18/*21 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of debrisoquine as compared to patients with the CYP2D6*1/*1 genotype. Finding reported in case study for *18/*21 subject. Other genetic and clinical factors may also influence the metabolism of debrisoquine.
1184985944	*2/*44	Patients with the CYP2D6*2/*44 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1/*2 genotype. Finding reported in case study for *2/*44 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1184985945	*5/*18	Patients with the CYP2D6*5/*18 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Finding reported in case study for *5/*18 subject. Other genetic and clinical factors may also influence the metabolism of sparteine.
1447953299	AA	Patients with the AA genotype and asthma who are treated with corticosteroids may have an increased risk for uncontrolled asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447953300	AG	Patients with the AG genotype and asthma who are treated with corticosteroids may have an increased risk for uncontrolled asthma as compared to patients with the GG genotype or may have a reduced risk for uncontrolled asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447953301	GG	Patients with the GG genotype and asthma who are treated with corticosteroids may have a reduced risk for uncontrolled asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447953306	CC	Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.
1444667317	GG	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667318	GT	Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667319	TT	Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667324	GG	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1447953294	CT	Patients with the CT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
1447953295	TT	Although there is no data on patients with the TT genotype, one might expect patients with the TT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
1449191754	AA	Patients with the AA genotype (two copies of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1448100439	CC	Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
1448100440	CT	Patients with the CT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the TT genotypes. Other factors may affect response to adalimumab.
1446908958	CC	Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446908959	CT	Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1184986999	CC	Patients with the CC genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1449191755	AT	Patients with the AT genotype (one copy of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191756	TT	Patients with the TT genotype (do not have a copy of the CFTR F1074L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1184987043	AA	Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987000	CG	Patients with the CG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CC genotype and an increased risk of hypercholesteremia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987001	GG	Patients with the GG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987025	CC	Patients with genotype CC and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with genotype CT and TT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987026	CT	Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987027	TT	Patients with genotype TT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC and CT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987036	CC	Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987037	CT	Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987038	TT	Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987044	AG	Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987045	GG	Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1447943600	AG	Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
1447943601	GG	Patients with genotype GG and depressive disorder may have increased response to venlafaxine compared to patients with genotype AA or AG. Patients with GG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
1447943610	AA	Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
1184754234	*15/*15	Individuals with *15/*15 genotype may have decreased transport of atrasentan as compared to individuals carrying the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.
1184754237	*18/*18	Individuals with *18/*18 genotype may have decreased transport of atrasentan as compared to individuals carrying the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.
1184754238	*1A/*1A	Individuals with *1A/*1A genotype may have increased transport of atrasentan as compared to individuals carrying the *5/*5, *15/*15, *9/*9 or *18/*18 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.
1184754239	*1B/*1B	Individuals with *1B/*1B genotype may have increased transport of atrasentan as compared to individuals carrying the *5/*5, *15/*15, *9/*9 or *18/*18 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.
1184754236	*5/*5	Individuals with *5/*5 genotype may have decreased transport of atrasentan as compared to individuals carrying the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.
1184754235	*9/*9	Individuals with *9/*9 genotype may have decreased transport of atrasentan as compared to individuals carrying the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.
1184754227	*15/*15	Healthy individuals with the *15/*15 genotype may have increased plasma level of olmesartan as compared to individuals with SLCO1B1 *1B/*1B genotype. Patients with the increased plasma level may have enhanced therapeutic response to olmesartan, yet may also be at risk of dose-dependent adverse effects of olmesartan. Other genetic and clinical factors may also influence the pharmacokinetics and response to olmesartan.
1184754228	*1B/*15	Healthy individuals with the *1B/*15 genotype may have increased plasma level of olmesartan as compared to individuals with SLCO1B1 *1B/*1B genotype. Patients with the increased plasma level may have enhanced therapeutic response to olmesartan, yet may also be at risk of dose-dependent adverse effects of olmesartan. Other genetic and clinical factors may also influence the pharmacokinetics and response to olmesartan.
1184754229	*1B/*1B	Healthy individuals with the *1B/*1B genotype may have decreased plasma level of olmesartan as compared to individuals with SLCO1B1 *15/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics and response to olmesartan.
1184754555	*12/*12	Patients with the *12/*12 genotype may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1A/*1A genotype. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.
1184754556	*13/*13	Patients with the *13/*13 genotype may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1A/*1A genotype. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.
1184754558	*1A/*12	Patients with the *1A/*12 genotype may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1A/*1A genotype. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.
1184754559	*1A/*13	Patients with the *1A/*13 genotype may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1A/*1A genotype. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.
1184754557	*1A/*1A	Patients with the *1A/*1A genotype may have increased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *12/*12 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.
1184756842	*03:02	Patients with one or two copies of the HLA-C*03:02 allele and chronic renal insufficiency who are treated with allopurinol may have an increased risk of simple rash as compared to patients with no HLA-C*03:02 alleles or negative for the HLA-C*03:02 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1447943599	AA	Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
1447943611	AG	Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
1447943612	GG	Patients with the GG genotype and depressive disorder may have increased response to serotonin reuptake inhibitors compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
1445401826	CC	Patients with the CC genotype and breast cancer may have a decreased risk for anemia when treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for anemia.
1450044543	GAG/GAG	Patients with the GAG/GAG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the del/del or del/GAG genotypes. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1449166358	*1/*1	Patients with the CYP2C19 *1/*1 genotype and esophageal reflux or peptic ulcer disease may have increased metabolism of omeprazole (lower mean metabolic ratio of omeprazole to hydroxyomeprazole) as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. The study grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of omeprazole.
1449166359	*1/*2	Patients with the CYP2C19 *1/*2 genotype and esophageal reflux or peptic ulcer disease may have increased metabolism of omeprazole (lower mean metabolic ratio of omeprazole to hydroxyomeprazole) as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. The study grouped genotypes together for analysis rather than compare individual genotypes: heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of omeprazole.
1449166360	*1/*3	Patients with the CYP2C19 *1/*3 genotype and esophageal reflux or peptic ulcer disease may have increased metabolism of omeprazole (lower mean metabolic ratio of omeprazole to hydroxyomeprazole) as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. The study grouped genotypes together for analysis rather than compare individual genotypes: heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of omeprazole.
1448821502	GG	Patients with the GG genotype and HIV may have decreased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence AUC of tenofovir.
1448821503	GT	Patients with the GT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.
1448821504	TT	Patients with the TT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.
1450044544	del/GAG	Patients with the del/GAG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GAG/GAG genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1184987399	CC	Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987400	CT	Patients with the CT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987401	TT	Patients with the TT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1447990929	GG	The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
1449191397	AA	Patients with the AA genotype (two copies of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191398	AG	Patients with the AG genotype (one copy of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191399	GG	Patients with the GG genotype (do not have a copy of the CFTR E92K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449269553	CTT/del	Patients with cystic fibrosis and the CTT/del genotype may respond to tezacacftor, with or without ivacaftor as compared to placebo.Other clinical and genetic factors may also infuence response to tezacacftor with or without ivacaftor in patients with cystic fibrosis.
1448635083	*2a/*8	Pediatric patients with epilepsy and the *2a/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448635084	*3a/*4a	Pediatric patients with epilepsy and the *3a/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448635085	*4a/*8	Pediatric patients with epilepsy and the *4a/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1444876862	CT	Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
1444876863	TT	Patients with the TT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
1448635621	non-null/non-null	Women with HIV who have the GSTM1 non-null/non-null genotype may have a decreased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) as compared to patients with the null/null and null/non-null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS/TEN in women with HIV who are administered nevirapine.
1449154758	TT	Patients with the TT genotype (homozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.
1449192422	AA	Patients with the AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence a patient's response to ivacaftor/lumacaftor.
1449192423	AC	Patients with the AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence a patient's response to ivacaftor/lumacaftor.
1449564688	CC	Patients with HIV and the CC genotype may have lower plasma concentrations of efavirenz as compared to patients with the TT genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV.
1449564689	CT	Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV.
1449192424	CC	Patients with the CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to treatment with ivacaftor/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor/lumacaftor.
1449269554	del/del	Patients with cystic fibrosis and the del/del genotype may respond to tezacacftor, with or without ivacaftor as compared to placebo. Other clinical and genetic factors may also infuence response to tezacacftor with or without ivacaftor in patients with cystic fibrosis.
1449564690	TT	Patients with HIV and the TT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV.
1444930912	TT	Patients with genotype TT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all IL28B genotypes (CC, CT, or TT) regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.
1448635081	*2a/*3a	Pediatric patients with epilepsy and the *2a/*3a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1448635082	*2a/*4a	Pediatric patients with epilepsy and the *2a/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.
1449564670	CC	The CC genotype in women with breast cancer who are treated with tamoxifen (with or without anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy) may have DECREASED treatment EFFICACY in PRE-MENOPAUSAL women and INCREASED treatment EFFICACY in POST-MENOPAUSAL women as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen and other treatment regimens in pre- and post-menopausal women with breast cancer.
1449155845	*54:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*54:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1185012260	*18:01:01	Patients with one or two copies of the HLA-B*18:01:01 allele who are treated with amoxicillin-clavulanate may have increased risk of drug-induced liver injury as compared to patients with no HLA-B*18:01:01 allele.  Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1445400674	AG	Patients with the AG genotype may have a better response to the pertussis vaccine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400675	GG	Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1185002367	CC	Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002353	AA	Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002354	AG	Patients with the AG genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1449154512	CT	Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.
1444698407	CT	Patients with the CT genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the TT genotypes, and increased steady-state levels as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
1444698408	TT	Patients with the TT genotype may have increased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
1449154511	CC	Patients with epilepsy and the CC genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the CT or TT genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence the response of epileptic patients to anti-epileptic drugs.
1184986260	*5/*7	Patients with the CYP2D6*5/*7 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1184986261	*5/*8	Patients with the CYP2D6*5/*8 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.
1185002355	GG	Patients with the GG genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002359	AA	Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002360	AC	Patients with the AC genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002361	CC	Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002366	CT	Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002365	TT	Patients with the TT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002371	CC	Patients with the CC genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002372	CT	Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1446908982	AA	Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.
1446908983	AC	Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.
1446908984	CC	Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC + CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.
1448426845	CC	Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1448426846	CT	Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1184756859	*03:02	Patients with one or two copies of the HLA-C*03:02 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-C*03:02 alleles or negative for the HLA-C*03:02 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184763969	*33:03	Patients with one or two copies of the HLA-A*33:03 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with no HLA-A*33:03 alleles or negative for the HLA-A*33:03 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184756899	*13:02:01	Patients with one or two copies of the HLA-DRB1*13:02-HLA-B*58:01 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with no HLA-DRB1*13:02-HLA-B*58:01 haplotype or negative for the HLA-DRB1*13:02-HLA-B*58:01 test. The HLA-B*58:01 allele has been shown in other studies to have a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184756895	*15:02:01	Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.
1184756982	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased metabolism of metoprolol or dextromethorphan or debrisoquine compared to patients with the *29/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of metoprolol or dextromethorphan or debrisoquine.
1184756981	*1/*29	Patients with the CYP2D6*1/*29 genotype may have an increased metabolism of metoprolol or dextromethorphan or debrisoquine compared to patients with the *29/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of metoprolol or dextromethorphan or debrisoquine.
1184756980	*29/*29	Patients with the CYP2D6*29/*29 genotype may have a decreased metabolism of metoprolol or dextromethorphan or debrisoquine compared to patients with the *1/*1 or *1/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of metoprolol or dextromethorphan or debrisoquine.
1446899211	*1/*1	Patients with the CYP2D6*1/*1 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have a decreased, but not absent, risk for side effects, 2) may require an increased dose of drug compared to patients with CYP2D6*4/*4. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.
1448426847	TT	Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1448105562	AA	Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1184989672	*07:01:01:01	Patients with the HLA-DRB1*07:01 allele with inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1448105563	AG	Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1448105564	GG	Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1444705346	AA	Patients with the AA genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1450043860	AA	Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448525343	CC	Patients with the CC genotype and who are treated with atorvastatin may have 1) lower oral clearance and higher plasma concentrations of atorvastatin 2) an increased risk of composite adverse events but not an increased risk of myalgia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.
1448107203	AA	Patients with the AA genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.
1448107204	AT	Patients with the AT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.
1450043861	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. The A allele is considered to confer MH in an autosomal dominant manner. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450043862	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1448522782	TT	Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1445585665	CC	Patients with the CC genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448522786	CC	Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1445585666	CT	Patients with the CT genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1184749405	*14/*1A	Patients with the *14/*1A may have decreased lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *14/*14 genotype. Other genetic and clinical factors may also influence response to fluvastatin.
1184749406	*1A/*1A	Patients with the *1A/*1A may have decreased lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *14/*14 genotype. Other genetic and clinical factors may also influence response to fluvastatin.
1184756467	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased metabolism of debrisoquine or sparteine as compared to patients with the CYP2D6*5/*8 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or sparteine.
1184756468	*5/*8	Patients with the CYP2D6*5/*8 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of debrisoquine or sparteine as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or sparteine.
1448522787	CT	Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522788	TT	Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1184749272	AA	Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749273	AG	Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1449565203	TT	Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.
1184749274	GG	Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749276	AA	Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.
1184749277	AG	Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.
1184749278	GG	Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased likelihood of event-free survival as compared to patients with the AA genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.
1447953307	CG	Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.
1449565201	CC	Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.
1449565202	CT	Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.
1184747858	AA	Patients with the AA genotype and hypercholesterolemia who are treated with atorvastatin may have better LDL-C responses and are more likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1184747859	AG	Patients with the AG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1184747860	GG	Patients with the GG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1447953308	GG	Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.
1449155850	*55:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*55:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449155860	*56:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*56:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449155865	*56:06	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*56:06  allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449155855	*55:02:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*55:02:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156031	AA	Patients with the AA genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.
1447953201	CC	Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
1447953202	CG	Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
1447953203	GG	Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
1296598642	*13:01:01	Patients with the HLA-B*13:01 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.
1296598660	*15:05:01	Patients with the HLA-B*15:05 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*15:05 alleles or negative for the HLA-B*15:05 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.
1296666991	AA	Patients with the AA genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
1184755383	*03:01	Patients with one or two copies of the HLA-DRB1*03:01 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-C*03:01 alleles or negative for the HLA-C*03:01 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1185002373	TT	Patients with the TT genotype may require decreased dose of acenocoumarol as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185003578	AA	Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003579	AG	Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003580	GG	Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.
1296598636	*39:01:01:01	Patients with the HLA-B*39:01 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.
1296666992	AG	Patients with the AG genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
1296666993	GG	Patients with the GG genotype may have decreased response to simvastatin (higher LDL lowering effect) as compared to patients withe the AA or AG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
1444607322	AA	Patients with the AA genotype may have increased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the GG genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone.
1444607321	AG	No information available.
1444607320	GG	Patients with the GG genotype may have decreased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the AA genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone.
1444607329	CC	No patients with the CC genotype available for analysis.
1444607328	CT	Patients with the CT genotype and age-related macular degeneration may require a greater number of bevacizumab injections as compared to those with the TT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.
1444607327	TT	Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.
1444607429	CCT/CCT	Individuals with the CCT/CCT genotype may have increased clearance of olanzapine as compared to individuals with the CCT/del or del/del genotype. Other genetic and clinical factors may also influence clearance of olanzapine.
1444607430	CCT/del	Individuals with the CCT/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.
1444607431	del/del	Individuals with the del/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.
1447953356	CC	Patients with the CC genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953357	CT	Patients with the CT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1184764195	AA	Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764196	AC	Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764197	CC	Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764202	AA	Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764201	AG	Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764200	GG	Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764209	CC	Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764210	CT	Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764211	TT	Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449164867	GG	Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.
1184764362	*1/*1	Patients with the CYP2D6*1/*1 genotype who are treated with propafenone may have 1) increased metabolism of propafenone, 2) decreased, but not absent risk of  cardiac arrythmias and other side effects as compared to patients with the *10/*10 genotype. Other genetic and clinical factors may also influence a patient's response to propafenone.
1184764363	*10/*10	Patients with the CYP2D6*10/*10 genotype who are treated with propafenone may have 1) decreased metabolism of propafenone, 2) increased exposure to propafenone, 3) increased risk of  cardiac arrythmias and other side effects, 4) exaggerated beta-adrenergic blocking activity as compared to patients with *1/*1 genotype. Patients with reduced function alleles of CYP2D6 may need to adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone). Other genetic and clinical factors may also influence a patient's response to propafenone.
1449164767	TT	Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164771	CC	Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164772	CT	Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164773	TT	The TT genotype was not analyzed, but patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1446902914	AA	Patients with the AA genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.
1444703844	CC	Patients with the CC genotype were not studied. However, patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444703842	CT	Patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444703843	TT	Patients with the TT genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444703852	AA	Patients with the AA genotype were not studied. However, patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1446902931	CC	Patients with the CC genotype may have decreased risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence the response to verapamil.
1446902930	TC	Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.
1446902929	TT	Patients with the TT genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.
1448531871	GT	People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.
1446902915	AG	Patients with the AG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.
1448531872	TT	People with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.
1448531893	AA	Patients with the AA genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.
1446902916	GG	Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.
1446902922	GG	Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.
1446902923	GT	Patients with the GT genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.
1446902924	TT	Patients with the TT genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to atenolol.
1446903064	AA	Patients with the AA genotype who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the GG genotype. Other genetic factors, including other CYP2C19 alleles *17  rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient's required dose and should be taken into consideration.
1446903065	GA	Patients with the AG genotype who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the GG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient's required dose and should be taken into consideration.
1446903066	GG	Patients with the GG genotype who are treated with amitriptyline may have increased metabolism of amitriptyline (decreased amitriptyline plasma concentrations and increased nortriptyline plasma concentrations) as compared to patients with the AA or AG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient's required dose and should be taken into consideration.
1446903104	*2/*2	Patients with two functional CYP2D6 alleles who are treated with amitriptyline may have 1) decreased nortriptyline plasma levels and increased clearance of amitryptyline, and 2) a decreased, but not absent, risk for side effects as compared to patients with CYP2D6 non-functional alleles (*3, *4, *5, *6) or reduced function allelesand a decreased metabolism of amitriptyline as compared to patients with duplication of a functional CYP2D6 gene. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1448531894	AG	Patients with the AG genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.
1449749441	CT	Patients with the CT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1449749442	TT	Patients with the TT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1449749445	CC	Patients with the CC genotype may have decreased concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.
1184986746	AA	Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.
1184988841	CC	Patients with asthma and the CC genotype may have an increased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CG and GG genotypes. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
1184988842	CG	Patients with asthma and the CG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
1184986747	AG	Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype and an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.
1184986748	GG	Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.
1449749440	CC	Patients with the CC genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1449749446	CT	Patients with the CT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.
1447953012	AA	Patients with the AA genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1184986776	CC	Patients with the CC genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the CT genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986777	CT	Patients with the CT genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986778	TT	The TT genotype was not evaluated for its influence on risk of opioid dependence upon exposure to opioids.Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.
1184986781	AA	The AA genotype was only present in one individual and could not be evaluated for its influence on risk of opioid dependence upon exposure to opioids. Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.
1184986782	AG	Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986783	GG	Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1447953013	AG	Patients with the AG genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1184988843	GG	Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
1444695403	*1/*1	Patients with the CYP2C19 *1/*1 genotype and epilepsy may have increased metabolism of N-desmethylclobazam, the principal metabolite of clobazam, as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. This increase in metabolism may lead to a lower risk for adverse effects, but also a poorer response to treatment. Some studies also show an association with increased metabolism of clobazam. Other genetic and clinical factors may also influence metabolism of N-desmethylclobazam and clobazam.
1444695404	*1/*2	Patients with the CYP2C19 *1/*2 genotype and epilepsy may have increased metabolism of N-desmethylclobazam, the principal metabolite of clobazam, as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype, and decreased metabolism as compared to patients with the *1/*1 genotype. This decrease in metabolism may lead to a higher risk for adverse effects, but also a better response to treatment. Some studies also show an association with metabolism of clobazam. Other genetic and clinical factors may also influence metabolism of N-desmethylclobazam and clobazam.
1444607422	AA	Patients with the AA genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.
1449564193	AC	Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564194	CC	Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564198	AA	Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1444607423	AG	Patients with the AG genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.
1444607424	GG	Patients with the GG genotype and major depressive disorder may be more likely to enter remission when treated with antidepressants, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.
1449564192	AA	Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564199	AG	Patients with the AG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1444607461	AA	Individuals with the AA genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607462	AG	Individuals with the AG genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607463	GG	Individuals with the GG genotype may have decreased area under the curve (AUC) of olanzapine as compared to individuals with the AA or AG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607482	*1/*1	Individuals with the *1/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.
1444607483	*1/*2	Individuals with the *1/*2 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.
1444607484	*1/*3	Individuals with the *1/*3 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*1, *1/*2 or *2/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.
1444607485	*2/*2	Individuals with the *2/*2 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.
1444607486	*2/*3	Individuals with the *2/*3 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*1, *1/*2 or *2/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.
1444607487	*3/*6	Individuals with the *3/*6 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*1, *1/*2 or *2/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.
1444607594	*4/*4	Patients with the *4/*4 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1/*1, *1/*4, *4/*41, *1/*41, *5/*41, *6/*41 or *4/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1444607595	*4/*41	Patients with the *4/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1444607596	*4/*5	Patients with the *4/*5 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1/*1, *1/*4, *4/*41, *1/*41, *5/*41, *6/*41 or *4/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1444607597	*5/*41	Patients with the *5/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1449564200	GG	Patients with the GG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1447990119	*1/*1	Patients with Alzheimer Disease and the *1/*1 diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1447990120	*1/*1xN	Patients with Alzheimer Disease and the *1/*1xN diplotype (ultrarapid metabolizers) may have increased clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1/*3, *1/*4, *1/*5, *1/*6, *1/*1, *4/*1xN, *6/*1xN) or poor metabolizers (*4/*4, *4/*5). Other genetic and clinical factors may also influence donepezil clearance.
1447944815	AA	Patients with the AA genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944816	AG	Patients with the AG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1444666857	AA	Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
1444666858	AG	Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
1444666859	GG	Patients with the GG genotype and schizophrenia may have a shorter QTc interval when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
1444666865	AA	Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.
1447944817	GG	Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447990121	*1/*3	Patients with Alzheimer Disease and the *1/*3 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1447990122	*1/*4	Patients with Alzheimer Disease and the *1/*4 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1444666866	AG	Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.
1447990123	*1/*5	Patients with Alzheimer Disease and the *1/*5 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1184987057	AA	Patients with genotype AA and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987058	AC	Patients with genotype AC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the  AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987059	CC	Patients with genotype CC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the  AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987072	AA	Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987073	AG	Patients with genotype AG and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the GG genotype and an greater reduction in HDL-C as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987558	AA	Patients with the AA genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1448106509	GG	Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
1446908584	CC	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.
1446908583	CT	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 34 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.
1446908582	TT	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 34 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.
1444703850	AC	Patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1448635976	*01:01:02:01	Patients with one or two copies of the HLA-DRB3*01:01:02:01 allele who are treated with heparin may have an increased risk of heparin-induced thrombocytopenia as compared to patients with no HLA-DRB3*01:01:02:01 alleles, or who test negative for the HLA-DRB3*01:01:02:01 allele. Other clinical and genetic factors may also influence the risk of developing heparin-induced thrombocytopenia.
1444608286	AA	Patients with the AA genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.
1444608287	AG	Patients with the AG genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.
1444608288	GG	Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.
1448594292	AG	Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.
1444608293	CC	Patients with the CC genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.
1444703871	AA	Patients with the AA genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1444703872	AG	Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1448106382	AA	Patients with depressive disorder and the AA genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or GG genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.
1448106383	AG	Patients with depressive disorder and the AG genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the GG genotypes, and smaller reductions in serotonin as compared to patients with the AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.
1444703851	CC	Patients with the CC genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1448106384	GG	Patients with depressive disorder and the GG genotype may have smaller reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.
1448102485	CC	Patients with the CC genotype and chronic hepatitis C or HIV may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102486	CG	Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102487	GG	Patients with the GG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1446908589	AA	Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.
1446908590	AG	Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.
1446908591	GG	Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.
1446908598	CC	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.
1446908597	CT	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.
1446902900	AA	Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.
1446902901	AC	Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.
1444700498	CG	Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700497	GG	Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700506	AA	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700505	AG	Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444698406	CC	Patients with the CC genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
1446902902	CC	Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.
1446902907	AA	Patients with the AA genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1446902908	AC	Patients with the AC genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1446902909	CC	Patients with the CC genotype may have increased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1446908596	TT	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.
1444607598	*6/*41	Patients with the *6/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3/*4, *4/*4 or *4/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.
1447953358	TT	Patients with the TT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447959696	CC	Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959697	CT	Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1444607643	CC	Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for nausea or vomiting and be more likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy.
1444607644	CG	No significant findings available.
1444607645	GG	Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for nausea or vomiting and be less likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy.
1444607660	CC	Patients with the CC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607661	CG	Patients with the CG genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607662	GG	Patients with the GG genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607678	GG	Patients with the GG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1448107361	AA	Patients with the AA genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
1448107362	AC	Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
1444607791	AA	Patients with the AA genotype and Mental Disorders who are treated with paroxetine may have an increased risk of nausea as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444607792	AC	Patients with the AC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444607793	CC	Patients with the CC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444607798	CC	Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to atomoxetine.
1444607799	CT	Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.
1444607800	TT	Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to treatment with atomoxetine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.
1444607805	AA	Patients with the AA genotype and Psychotic Disorders who are treated with olanzapine may have increased social and clinical needs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
1447959698	TT	Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448107363	CC	Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
1184987074	GG	Patients with genotype GG and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987559	AG	Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987560	GG	Patients with the GG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1449156936	AC	Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156937	CC	Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449162914	AA	Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1184987585	CC	Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987586	CT	Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987587	TT	Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987590	CC	Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987591	CT	Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987592	TT	Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987595	AA	Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1184987596	AG	Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1449162915	AG	There is currently no evidence to show whether the AG genotype affects a patient's exposure to tramadol.
1449162916	GG	Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1296598912	AA	Patients with the AA genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
1296598913	AG	Patients with the AG genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
1296598914	GG	Patients with the AG genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
1445402165	AA	Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1448103877	CC	Patients with the CC genotype and who are addicted to methamphetamines may have an increased risk for methamphetamine-induced psychosis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
1448103864	TT	Patients with the TT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
1448103878	CT	Patients with the CT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
1448103879	TT	Patients with the TT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
1448103884	AA	Patients with the AA genotype who are given amphetamine may have decreased stop reaction time, or reduced impulsivity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence stop reaction time.
1447980852	*1a	Cells that carry the UGT1A4*1a allele may have increased clearance of lamotrigine as compared to those with the *2 allele. Other genetic and clinical factors may also influence clearance of lamotrigine.
1450379341	GG	Patients with the GG genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.
1450379342	GT	Patients with the GT genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype, or 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.
1450379343	TT	Patients with the TT genotype and who are treated with rosuvastatin 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.
1448102911	GT	Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.
1448102912	TT	Patients with the TT genotype and hepatocellular carcinoma may have a poorer response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.
1444665906	*1/*1	Patients with the CYP2D6 extensive metabolizer phenotype (e.g. *1/*1) may have an increased clearance of vortioxetine as compared to patients with the CYP2D6 poor metabolizer phenotype (e.g. *4/*4). Other genetic and clinical factors may also influence patient's clearance of vortioxetine.
1444665907	*4/*4	Patients with the CYP2D6 poor metabolizer phenotype (e.g. *4/*4) may have a decreased clearance of vortioxetine as compared to patients with the CYP2D6 extensive metabolizer phenotype (e.g. *1/*1). Other genetic and clinical factors may also influence patient's clearance of vortioxetine.
1444665986	GG	Patients with the GG genotype and colorectal cancer may have a shorter overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.
1444665987	GT	Patients with the GT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.
1444665988	TT	Patients with the TT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.
1184989414	*48:01	Patients with one or two copies of the HLA-B*48:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-B*48:01 alleles or negative for the HLA-B*48:01 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1448423698	AA	Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1444701086	CT	Patients with the CT genotype (CYP2C19*1/*17) may have an increased metabolism of citalopram or escitalopram as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's citalopram or escitalopram metabolism.
1444701087	TT	Patients with the TT genotype (CYP2C19*17/*17) may have an increased metabolism of citalopram or escitalopram as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's citalopram or escitalopram metabolism.
1448423699	AG	Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1444701085	CC	Patients with the CC genotype may have decreased metabolism of citalopram or escitalopram as compared to patients with the TT or CT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's citalopram or escitalopram metabolism.
1448423700	GG	Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448428153	AA	Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1184989962	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have increased response and decreased, but not absent, risk for side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1184989963	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype and a decreased, but not absent, risk for side effects as compared to the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1184989964	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased response and increased risk for side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1184989974	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, a study has also found no association between this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.
1448423438	AA	Patients with the AA genotype and asthma may have a poorer response when treated with zileuton as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
1448423439	AG	Patients with the AG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
1448423440	GG	Patients with the GG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
1448428154	AG	Patients with the AG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428155	GG	Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448636837	CT	Patients with the CT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and increased likelihood of pneumonitis as compared to patients with the TT genotype, and decreased likelihood as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.
1448636838	TT	Patients with the TT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.
1449154513	TT	Patients with epilepsy and the TT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have a worse response as compared to patients with the CT or CC genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.
1448636836	CC	Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of progression-free survival and increased likelihood of pneumonitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.
1448106521	CC	Patients with the CC genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106522	CT	Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1444607806	AG	Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
1444607807	GG	Patients with the GG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
1449156037	AG	Patients with AG genotype may have an increased likelihood of addiction to nicotine as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the AA genotype. No significant results have been seen for an association with likelihood of smoking cessation. Additionally, some negative or contradictory findings exist. Other genetic and clinical factors may influence a patient's likelihood of nicotine addiction.
1449156038	GG	Patients with GG genotype may have a decreased likelihood of addiction to nicotine as compared to patients with the AA genotype. No significant results have been seen for an association with likelihood of smoking cessation. Additionally, some negative or contradictory findings exist. Other genetic and clinical factors may influence a patient's likelihood of nicotine addiction.
1449156047	CC	Patients with the CC genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1444607846	AA	Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.
1444607847	AG	Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.
1444607848	GG	Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.
1444607858	AA	Patients with the AA genotype and age-related macular degeneration may have a poorer response when treated with bevacizumab as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1444607859	AT	Patients with the AT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1444607860	TT	Patients with the TT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1444607865	CC	Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of leukopenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444607866	CT	Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444607867	TT	Patients with the TT genotype were not studied but patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1184987597	GG	Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1448100575	AA	Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
1448100576	AG	Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
1448100577	GG	Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
1184987707	*02:01	Patients with one or two copies of the HLA-A*02:01 allele may have a decreased, but not absent, risk of severe cutaneous adverse reactions when treated with allopurinol as compared to patients with no HLA-A*02:01 alleles or negative for the HLA-A*02:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449564384	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have a reduced response to rabeprazole (larger % of time with intragastric pH < 4.0, and a lower intragastric pH) as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no significant associations between CYP2C19 genotypes and intragastric pH measurements. Other genetic and clinical factors may also influence response to rabeprazole.
1449564385	*1/*2	Patients with the CYP2C19 *1/*2 genotype may have a reduced response to rabeprazole (larger % of time with intragastric pH < 4.0, and a lower intragastric pH) as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype, and a better response compared to patients with the *1/*1 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no significant associations between CYP2C19 genotypes and intragastric pH measurements. Other genetic and clinical factors may also influence response to rabeprazole.
1449564386	*1/*3	Patients with the CYP2C19 *1/*3 genotype may have a reduced response to rabeprazole (larger % of time with intragastric pH < 4.0, and a lower intragastric pH) as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype, and a better response compared to patients with the *1/*1 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no significant associations between CYP2C19 genotypes and intragastric pH measurements. Other genetic and clinical factors may also influence response to rabeprazole.
1449564387	*2/*2	Patients with the CYP2C19 *2/*2 genotype may have a better response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no significant associations between CYP2C19 genotypes and intragastric pH measurements. Other genetic and clinical factors may also influence response to rabeprazole.
1449564388	*2/*3	Patients with the CYP2C19 *2/*3 genotype may have a better response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no significant associations between CYP2C19 genotypes and intragastric pH measurements. Other genetic and clinical factors may also influence response to rabeprazole.
1448100569	CC	Patients with the CC genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.
1448100570	CT	Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.
1448100571	TT	Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.
1444843495	CC	Patients with genotype CC may have higher rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1444843497	AA	Patients with genotype AA may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1444608495	GG	Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665941	AA	Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665942	AG	Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444665943	GG	Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.
1444666005	*1/*1	Individuals with the *1/*1 genotype may have increased metabolism of diclofenac as compared to individuals with the *1/*3 or *1/*8 genotype. Other genetic and clinical factors may also influence metabolism of diclofenac.
1444666006	*1/*3	Individuals with the *1/*3 genotype may have decreased metabolism of diclofenac as compared to individuals with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of diclofenac.
1444666007	*1/*8	Individuals with the *1/*8 genotype may have decreased metabolism of diclofenac as compared to individuals with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of diclofenac.
1444666125	CC	Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444666126	CT	Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444666127	TT	Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444666132	*03:01:01	Patients with one or two copies of the HLA-DPB1*03:01:01 allele have an increased risk of asthma when treated with aspirin, as compared to patients with no HLA-DPB1*03:01:01 alleles or negative for the HLA-DPB1*03:01:01 test. Other genetic and clinical factors may also influence a patient's risk of aspirin-induced asthma.
1444666139	*04:01:01:01	Patients with one or two copies of the HLA-DPB1*04:01:01:01 allele have a decreased risk of asthma when treated with aspirin as compared to patients with no HLA-DPB1*04:01:01:01 alleles or negative for the HLA-DPB1*04:01:01:01 test. Other genetic and clinical factors may also influence a patient's risk of aspirin-induced asthma.
1444666153	*11:01:01	Patients with one or two copies of the HLA-DRB1*11 allele have an increased risk of having an anaphylactoid reaction when receiving nonsteroidal anti-inflammatory drugs (NSAIDs) as compared to patients with no HLA-DRB1*11 alleles or negative for the HLA-DRB1*11 test. Other genetic and clinical factors may also influence a patient's risk of experiencing an anaphylactoid reaction when receiving NSAIDs.
1444666303	AA	Patients with the AA genotype and asthma may have a better response to treatment with tiotropium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tiotropium.
1444666304	AG	Patients with the AG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.
1444666305	GG	Patients with the GG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.
1444843496	AC	Patients with genotype AC may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1444876861	CC	Patients with the CC genotype may have increased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
1184989973	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with sertraline may have a decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, a study has also found no association between this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.
1184989972	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype or the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype. However, a study has also found no association between this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.
1184989992	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1184989993	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) genotype who are treated with fluvoxamine may have increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1184989994	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype who are treated with fluvoxamine may have decreased response or decreased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1184990002	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with mirtazapine may have increased risk of side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.
1184990003	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the HTTLPR long form (L allele)/HTTLPR short form (S allele) genotype who are treated with mirtazapine may have increased risk of side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.
1184990004	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with mirtazapine may have decreased, but not absent, risk of side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.
1184997126	*56:02	Patients with one or two copies of the HLA-B*56:02 allele have an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) when treated with phenytoin. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced adverse reactions.
1184997132	*58:01	Patients with one or two copies of the HLA-B*58:01 allele have a decreased risk of maculopapular eruption when treated with carbamazepine as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1184997138	*58:01	Patients with one or two copies of the HLA-B*58:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1184997203	*59:01:01:01	Patients with one or two copies of the HLA-B*59:01:01:01 allele may have an increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to patients with no HLA-B*59:01:01:01 alleles or negative for the HLA-B*59:01:01:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1444608012	*1/*1	Patients with the *1/*1 genotype and chronic lymphocytic leukemia may be more likely to achieve a complete response but also more likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1/*6 or *6/*6 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.
1444608013	*1/*6	Patients with the *1/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.
1444608014	*6/*6	Patients with the *6/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.
1444608029	CC	Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
1444608030	CT	Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
1444608031	TT	Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to citalopram.
1449565088	AA	Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449752245	CC	Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may have a poorer response to the drug and a decreased risk for toxicity as compared to those with the CG or GG genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity.
1449752246	CG	Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may have a poorer response to the drug and a decreased risk for toxicity as compared to those with the GG genotype, and an increased risk for toxicity as compared to the CC genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity.
1444608048	AA	Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.
1444608049	AG	Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.
1444608050	GG	Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.
1444608184	CC	Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1444608185	CT	Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1444608186	TT	Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1449565075	CT	Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have decreased severity of thrombocytopenia as compared to patients with the CC genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.
1449752247	GG	Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may have a better response to the drug and an increased risk for toxicity as compared to those with the CC or CG genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity.
1447959719	CC	Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959720	CT	Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959721	TT	Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447960273	TT	Patients with the TT genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents and gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.
1447960316	AA	Patients with the AA genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1449564400	*1/*3	Patients with the CYP2C19 *1/*3 genotype may have increased metabolism of, and decreased response to, lansoprazole as compared to patients with the *2/*2 or *2/*3 or *3/*3 genotype and decreased metabolism/increased response as compared to patients with the *1/*1 genotype or who are carriers of the *17 allele. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: ultrarapid metabolizers = *17/*17, homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2 + *2/*3 or *3/*3. One study was conducted in children. One study found no significant association between CYP2C19 genotypes and metabolism. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1449564401	*17/*17	Patients with the CYP2C19 *17/*17 genotype (*17 = rs12248560) may have increased metabolism of lansoprazole as compared to children with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1449564402	*2/*2	Patients with the CYP2C19 *2/*2 genotype may have decreased metabolism of, and increased response to, lansoprazole as compared to patients with the *1/*1, *1/*2,*1/*3 genotype or carriers of a *17 allele. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: ultrarapid metabolizers = *17/*17, homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2 + *2/*3 or *3/*3. One study was conducted in children. One study found no significant association between CYP2C19 genotypes and metabolism. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1449564403	*2/*3	Patients with the CYP2C19 *2/*3 genotype may have decreased metabolism of, and increased response to, lansoprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 * genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: ultrarapid metabolizers = *17/*17, homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2 + *2/*3 or *3/*3. One study found no significant association between CYP2C19 genotypes and metabolism. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1449564404	*3/*3	Patients with the CYP2C19 *3/*3 genotype may have decreased metabolism of, and increased response to, lansoprazole as compared to patients with the *1/*1, *1/*2,*1/*3 genotype or carriers of a *17 allele. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: ultrarapid metabolizers = *17/*17, homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2 + *2/*3 or *3/*3. One study found no significant association between CYP2C19 genotypes and metabolism. Other genetic and clinical factors may also influence metabolism of lansoprazole.
1448257153	CC	Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also impact the dose of warfarin.
1448257152	CT	Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.
1447960317	AG	Patients with the AG genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447960318	GG	Patients with the GG genotype and Crohn's disease may a poorer response to treatment with infliximab as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to infliximab.
1448257151	TT	Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.
1448257267	AA	Patients with the AA genotype may require increased dose of warfarin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of warfarin.
1448257266	AG	Patients with the AG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1448257265	GG	Patients with the GG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1444687034	CC	Patients with the CC genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687035	CT	Patients with the CT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687036	TT	Patients with the TT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1446903243	AG	Patients with the AG genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype, or a decreased risk as compare to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.
1446903244	GG	Patients with the GG genotype and cancer may have a decreased risk for hypertension when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.
1448285646	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype and increased fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1446903235	GG	Patients with the GG genotype and cancer may have decreased exposure to sunitinib and a decreased risk for experiencing drug toxicities, as compared to patients with the TT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence exposure to sunitinib and risk for drug toxicities.
1446903236	GT	Patients with the GT genotype and renal cell carcinoma may have decreased exposure to sunitinib and a decreased risk for experiencing drug toxicities, as compared to patients with the TT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence risk for drug toxicities when receiving sunitinib.
1446903101	*1/*1	Patients with two functional CYP2D6 alleles who are treated with amitriptyline may have 1) decreased nortriptyline plasma levels and increased clearance of amitryptyline, and 2) a decreased, but not absent, risk for side effects as compared to patients with CYP2D6 non-functional alleles (*3, *4, *5, *6) or reduced function alleles and a decreased metabolism of amitriptyline as compared to patients with duplication of a functional CYP2D6 gene. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446903102	*10	Patients with the CYP2D6*10 allele in combination with another reduced function (*10, *41) or non-functional CYP2D6 allele who are treated with amitriptyline may have increased nortriptyline plasma levels as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1448285647	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have decreased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) or SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1446903237	TT	Patients with the TT genotype and renal cell carcinoma may have increased exposure to sunitinib and an increased risk for experiencing drug toxicities, as compared to patients with the GG or GT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence risk for drug toxicities when receiving sunitinib.
1446903242	AA	Patients with the AA genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.
1446903103	*1xN	Patients with a duplication of a functional CYP2D6 gene who are treated with amitriptyline may have 1) an increased metabolism of amitriptyline and 2) decreased response as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1448285648	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the SLC6A4 HTTLPR short form (S allele)/SLC6A4 HTTLPR short form (S allele) genotype who are treated with fluoxetine may have increased response or increased improvement based on HAMD score reduction as compared to patients with the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting the opposite effect with an association of the SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype and increased fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444686911	GG	Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.
1444686929	CC	Patients with the CC genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686930	CT	Patients with the CT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686931	TT	Patients with the TT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686923	AA	Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686924	AG	Patients with the AG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686925	GG	Patients with the GG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686937	CC	Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686938	CT	Patients with the CT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686939	TT	Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686949	AA	Patients with the AA genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686950	AT	Patients with the AT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686951	TT	Patients with the TT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686960	CC	Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686961	CT	Patients with the CT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686962	TT	Patients with the TT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444700764	GG	Patients with the GG genotype and major depression who are treated with citalopram or escitalopram may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444700763	GT	Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444700762	TT	Patients with the TT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1449749447	TT	Patients with the TT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.
1449752552	AA	Patients with AA genotype and cancer may have increased risk of drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AG or GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence a patient's response and risk for toxicity when receiving platinum-based chemotherapy.
1449752553	AG	Patients with AG genotype and cancer may have a decreased risk of drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the AA genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence a patient's response and risk for toxicity when receiving platinum-based chemotherapy.
1449752554	GG	Patients with GG genotype and cancer may have a decreased risk of drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the AA genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence a patient's response and risk for toxicity when receiving platinum-based chemotherapy.
1444703109	AA	Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444703110	AG	Patients with the AG genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444703111	GG	Patients with the GG genotype who are treated with gemcitabine may have an increased risk for toxicity as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444704402	GG	Patients with the GG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
1444704945	CC	Patients with the CC genotype may have decreased imatinib clearance when treated with imatinib as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the clearance of imatinib.
1444704946	CT	Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.
1444704947	TT	Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.
1444704952	AA	Patients with the AA genotype may have increased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1444704953	AG	Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1444704954	GG	Patients with the GG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1444704958	AA	Patients with the AA genotype may have decreased response to candesartan in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to candesartan.
1444704959	AG	Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.
1444704960	GG	Patients with the GG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.
1444705246	AG	Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705245	GG	Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705347	AG	Patients with the AG genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1444705348	GG	Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1444705384	TT	Patients with the TT genotype (CYP3A5 *1/*1) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the TT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.
1449752568	CC	Patients with cancer and the CC genotype may have increased response when treated with platinum-based therapies as compared to patients with the CT or TT genotype. However, a few studies report no association or decreased survival and response for patients with the CC  as compared to the TT genotype only. Other genetic and clinical factors may also influence response to platinum-based regimens.
1444713241	*02:02:01:01	Patients with one or two copies of the HLA-DRB3*02:02 allele have an increased risk of agranulocytosis when treated with clozapine in people with schizophrenia as compared to patients with no HLA-DRB3*02:02 allele.  Other genetic and clinical factors may also influence a patient's risk of agranulocytosis.
1444713247	*44:03:01	Patients with one or two copies of the HLA-B*44:03 allele have an increased risk of toxic liver disease when treated with ticlopidine as compared to patients with no HLA-B*44:03 allele.  Other genetic and clinical factors may also influence a patient's risk of toxic liver disease.
1448634940	AA	Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.
1448634941	AG	Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported.  Other genetic and clinical factors may also influence the bronchodilator response.
1448634942	GG	Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported.  Other genetic and clinical factors may also influence the bronchodilator response.
1445296899	*59/*59	Patients with CYP2C9*59/*59 may require significantly decreased dose of warfarin as compared to patients with CYP2C9 *1/*1. Other genetic and clinical factors may also influence the dose of warfarin.
1447987266	CC	Patients with the CC genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
1449155830	*39:10:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:10:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156025	AA	Patients with the AA genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.
1448636850	AA	Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.
1447987267	CT	Patients with the CT genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the TT genotypes and an increased risk of neuropathy as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
1447987268	TT	Patients with the TT genotype and prostate cancer who are treated with docetaxel may have an increased risk of neuropathy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
1448636851	AG	Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis   as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.
1447813507	AA	Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype.  Other clinical or genetic factors may also influence warfarin dose.
1447813508	AG	Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype.  Other clinical or genetic factors may also influence warfarin dose.
1447813509	GG	Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AG or GG genotype.  Other clinical or genetic factors may also influence warfarin dose.
1447987231	CC	Patients with depressive disorder and the CC genotype may have worse response to citalopram or escitalopram as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.
1448636852	GG	Patients with the GG genotype and breast cancer who are treated with everolimus may have decreased likelihood of Mucositis as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.
1449155313	GT	Patients with the GT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.
1449155314	TT	Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.
1449155656	CC	Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155657	CG	Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155658	GG	Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1448999128	*2/*2	Patients with the *2/*2 genotype and major depressive disorder 1) may have an increased metabolism of imipramine, 2) may require a higher dose of imipramine as compared to patients with two non-functional alleles (*3, *4, *5, *6) or 3) may have an increased response, 4) may require a lower dose as compared to patients with a duplicated functional allele (*1XN or *2XN). The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1448999129	*2xN/*1	Patients with the *2XN/*1 genotype and major depressive disorder 1) may have a decreased response, 2) may require a higher dose of imipramine as compared to patients with the *1/*1 or *2/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1444700842	CC	Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700841	TC	Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700840	TT	Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700849	CC	Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700848	CT	Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700847	TT	Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700857	CC	Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700856	CT	Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700855	TT	Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1449713668	CC	Patients with the CC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1444701021	CC	Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
1444701020	CT	Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
1444701019	TT	Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
1444701026	CC	Patients with the CC genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.
1444701027	CT	Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.
1444701028	TT	Patients with the TT genotype may have decreased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to sildenafil.
1444702826	AA	Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital.
1444702825	AG	Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.
1449713672	AA	Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713673	AG	Patients with the AG genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713674	GG	Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449002813	CC	Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.
1449002814	CT	Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.
1444701229	*3	Patients with Depressive Disorder and the *3 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function (*9, *10, *41) allele may have 1) decreased metabolism/clearance of venlafaxine and 2) decreased tolerance of higher venlafaxine dose as compared to patients with *1/*1 genotype who carry two functional alleles. In patients with Obsessive-Compulsive Disorder no association with treatment response was found. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1444701230	*4	Patients with Depressive Disorder and the *4 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*10, *17, *41) may have 1) decreased metabolism/clearance of venlafaxine, 2) decreased tolerance of higher venlafaxine dose and 3) increased risk for side effects as compared to patients with *1/*1 genotype who carry two functional alleles. In patients with Obsessive-Compulsive Disorder an association with decreased metabolism/clearance was confirmed but no association with treatment response was found. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1444701231	*41	Patients with Depressive Disorder and the *41 reduced function allele in combination with another non-functional allele (*3, *4, *5, *6) may have decreased tolerance of higher venlafaxine dose as compared to patients with *1/*1 genotype who carry two functional alleles. In patients with Obsessive-Compulsive Disorder no association with treatment response was found. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1444701232	*5	Patients with Depressive Disorder and the *5 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*10, *41) may have 1) decreased metabolism of venlafaxine and 2) increased risk for side effects as compared to patients with *1/*1 genotype who carry two functional alleles. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1444701233	*6	Patients with Depressive Disorder and  the *6 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*10, *41) may have 1) decreased metabolism of venlafaxine and 2) increased risk for side effects as compared to patients with *1/*1 genotype who carry two functional alleles. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1447960660	CC	Patients with the CC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
1447960665	AA	Patients with the AA genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.
1444702782	CC	Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702781	CG	Patients with the CG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702780	GG	Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444703211	CT	Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444703209	TT	Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444703219	AA	Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444703218	AC	Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1447960666	AG	Patients with the AG genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.
1447960667	GG	Patients with the GG genotype and coronary artery disease may have a better response when treated with quinapril as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to quinapril.
1448635181	CG	Patients with acute lymphoblastic leukemia (ALL) and the CG genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom had the CG genotype.
1448635182	GG	Patients with acute lymphoblastic leukemia (ALL)  and the GG genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the CG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom were heterozygotes.
1449564830	CC	Patients with the CC genotype and Hepatitis C genotype 1 may have increased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have higher spontaneous clearance in acute HCV infections than patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to peg interferon and ribavirin.
1444708023	*46:01:01	Patients with one or two copies of the HLA-B*46:01:01 allele have a decreased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*46:01:01 alleles or negative for the HLA-B*46:01:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1449564831	CT	Patients with the CT genotype and Hepatitis C genotype 1 may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to peg interferon and ribavirin.
1449732689	AA	Transplant recipients with the AA genotype (also known as CYP3A4 *22/*22) may have decreased metabolism of tacrolimus, resulting in increased exposure and a lower dose requirement (among other pharmacokinetic parameters), as compared to patients with the GG genotype (CYP3A4 *1/*1). Around half of studies report an association, and half report no association. One study found an association with liver transplant donor genotype but not recipient genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence metabolism of tacrolimus.
1449732690	AG	Transplant recipients with the AG genotype (also known as CYP3A4 *1/*22) may have decreased metabolism of tacrolimus, resulting in increased exposure and a lower dose requirement (among other pharmacokinetic parameters), as compared to patients with the GG genotype (CYP3A4 *1/*1). Around half of studies report an association, and half report no association. One study found an association with liver transplant donor genotype but not recipient genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence metabolism of tacrolimus.
1449732691	GG	Transplant recipients with the GG genotype (also known as CYP3A4 *1/*1) may have increased metabolism of tacrolimus, resulting in decreased exposure and a higher dose requirement (among other pharmacokinetic parameters), as compared to patients with the AG or AA genotype (CYP3A4 *22/*1 and *22/*22). Around half of studies report an association, and half report no association. One study found an association with liver transplant donor genotype but not recipient genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence metabolism of tacrolimus.
1448636844	AA	Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.
1448636845	AC	Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.
1448636846	CC	Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of Lymphopenia as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.
1448115868	TT	Women with ovarian cancer and the TT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446905057	CC	Pediatric patients with major thalassemia and the CC genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the CT or TT genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1449156026	AG	Patients with the AG genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.
1447813528	AA	Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1447813529	AG	Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1447813530	GG	Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1449156027	GG	Patients with the GG genotype may have a decreased risk for smoking addiction, and have an increased likelihood of smoking cessation, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.
1449156081	*38:02:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*38:02:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers, but may not be associated with risk of exanthema.
1449154541	CC	Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.
1446899683	AT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899684	TT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899690	AA	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899691	AT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899692	TT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449154542	CT	Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to women with TT genotypes and increased triglycerides and decreased hdl cholsterol as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride and hdl cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.
1449156524	AA	Patients with the AA genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy or myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.
1449154543	TT	Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.
1449156525	AG	Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.
1449156526	GG	Patients with the GG genotype and cardiovascular disease who are taking a statin may have a decreased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.
1444702824	GG	Patients with genotype GG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.
1447959517	AA	Patients with the AA genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to propranolol.
1450186410	TT	Patients with the TT genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have an increased risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CC genotype. Patients may also require lower doses of thiopurines and be more likely to discontinue thiopurine treatment as compared to patients with the CC genotype, possibly due to the increased risk for adverse effects. Other genetic and clinical factors may also influence a patient's risk for leukopenia, alopecia or treatment discontinuation.
1444703531	CT	Patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.
1444703532	TT	Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.
1444703541	CC	Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703540	CT	Patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703539	TT	Patients with the TT genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703546	AA	Patients with the AA genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444703547	AG	Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444703548	GG	Patients with the GG genotype and Colorectal Neoplasms may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444703556	AA	Patients with the AA genotype and kidney transplantation may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1444703555	AG	Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1444703554	GG	Patients with the GG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1444703805	GTAAGTTG/GTAAGTTG	Patients with the GTAAGTTG/GTAAGTTG genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1450044551	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044552	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044553	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1444703217	CC	Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1449564300	AA	Patients with the AA genotype who are treated with warfarin may require a decreased dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.
1449564301	AG	Patients with the AG genotype who are treated with warfarin may require a decreased dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.
1449564302	GG	Patients with the GG genotype who are treated with warfarin may require an increased dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence dose of warfarin.
1444703277	AA	Patients with genotype AA may have decreased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype CC or AC. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
1444703276	AC	Patients with genotype AC may have increased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype AA. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
1444703275	CC	Patients with genotype CC may have increased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype AA. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
1444703343	CC	Patients with the CC genotype and asthma who are treated with aspirin may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703342	CG	Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703341	GG	Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1447672650	*1/*1	Patients with CYP2C9*1/*1 may spent longer time in therapeutic INR range (TTR) when treated with warfarin as compared to patients with CYP2C9*2 or *3. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the time in therapeutic range.
1447672651	*2	Patients with CYP2C9*2 may spent less time in therapeutic INR range (TTR) when treated with warfarin as compared to patients with CYP2C9*1/*1. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the time in therapeutic range.
1447672652	*3	Patients with CYP2C9*3 may spent less time in therapeutic INR range (TTR) when treated with warfarin as compared to patients with CYP2C9*1/*1. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the time in therapeutic range.
1448107973	AA	Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
1448107974	AG	Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
1449564305	CC	Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1444703395	AA	Female patients with the AA genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444703396	AG	Female patients with the AG genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444703397	GG	Female patients with the GG genotype and major depression may have increased response to paroxetine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1448107963	AA	Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
1448107964	AG	Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.
1448107965	GG	Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG.  Other genetic and clinical factors may also influence a patient's response.
1449564306	CG	Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449191600	CC	Patients with the CC genotype (do not have a copy of the CFTR R117C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191601	CT	Patients with the CT genotype (one copy of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191602	TT	Patients with the TT genotype (two copies of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191604	AA	Patients with the AA genotype (two copies of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191605	AG	Patients with the AG genotype (one copy of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191606	GG	Patients with the GG genotype (do not have a copy of the CFTR E193K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1444709259	*1/*1	Patients with the *1/*1 diplotype who are treated with sertraline may have lower dose-corrected drug plasma concentrations and increased clearance as compared to patients with one or two CYP2C19 no alleles (*1/*2 or *2/*2, *2/*3). Other genetic and clinical factors may also influence a patient's metabolism of sertraline.
1444709260	*1/*2	Patients with the *1/*2 diplotype who are treated with sertraline may have increased clearance as compared to patients with the *2/*2 or *2/*3 diplotype and a decreased clearance as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of sertraline.
1444709261	*2/*2	Patients with the *2/*2 diplotype who are treated with sertraline may have higher dose-corrected drug plasma concentrations and decreased clearance as compared to patients with the *1/*1 and *1/*2 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of sertraline.
1444709262	*2/*3	Patients with the *2/*3 diplotype who are treated with sertraline may have decreased clearance as compared to patients with the *1/*1 and *1/*2 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of sertraline.
1449191596	AA	Patients with the AA genotype (two copies of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191597	AC	Patients with the AC genotype (one copy of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191512	*17	Patients with the *17 reduced functional allele in combination with a non-functional (*3, *4, *5, *6, *40) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 intermediate metabolizers should be monitored closely for less than optimal response and should be offered an alternative analgesic if required. Other genetic and clinical factors may also influence a patient's response to codeine.
1449191513	*2/*2xN	Patients with more than two copies of CYP2D6 functional alleles (*1, *2) who are CYP2D6 ultrarapid metabolizers (i.e., a CYP2D6 activity score of >2.0) may have 1) increased formation of morphine following codeine administration and 2) higher risk of toxicity as compared to patients with *1/*1 genotype, who are CYP2D6 normal metabolizers. Patients who are CYP2D6 ultrarapid metabolizers should avoid codeine use due to potential for toxicity. Alternative analgesics such as morphine or a non-opioid should be considered. Other genetic and clinical factors may also influence a patient's response to codeine.
1449191598	CC	Patients with the CC genotype (do not have a copy of the CFTR D110E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1450372824	ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA	Patients with the CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA genotype and Parkinson Disease who are treated with levodopa may have increased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1449156164	*52:01:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*52:01:01:01 allele may have a decreased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1445400875	GG	Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.
1445400876	GT	Patients with acute myeloid leukemia and the GT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.
1445400877	TT	Patients with acute myeloid leukemia and the TT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.
1445400882	AA	Patients with the AA genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
1445400883	AG	Patients with the AG genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
1445400884	GG	Patients with the GG genotype and multiple myeloma may have an increased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
1449156541	AA	Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.
1447989388	AA	Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1449156542	AG	Patients with the AG genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the GG genotypes. Conversely, patients with the AG genotype may have decreased steady state levels of KDR, and an increased response to pazopanib as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism and response to pazopanib.
1449156543	GG	Patients with the GG genotype and Kidney Neoplasms may have decreased steady state levels of KDR, possibly leading to decreased metabolism of and increased response to pazopanib as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.
1450372825	ACATACACACTCAGACACACATACCATGCA/del	Patients with the CACATACCATGCAACATACACACTCAGACA/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1450372826	del/del	Patients with the del/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1445401120	AA	Patients with the AA genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401121	AC	Patients with the AC genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1446899951	CC	Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899952	CT	Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899953	TT	Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1449156086	*39:01:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:01:01:0 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1444703806	GTAAGTTG/del	Patients with the GTAAGTTG/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype or may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703807	del/del	Patients with the del/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1448278850	AA	Patients with the AA genotype may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AC or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448278851	AC	Patients with the AC genotype may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448278852	CC	Patients with the CC genotype may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1447814484	AA	Patients with genotype AA and urticaria may have increased response to desloratadine and mizolastine compared to patients with genotypes AG or GG. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.
1447814485	AG	Patients with genotype AG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.
1444704120	CC	Patients with the CC genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444704121	CG	Patients with the CG genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype or may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444704122	GG	Patients with the GG genotype who are treated with hmg coa reductase inhibitors may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1448106551	AA	Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1444705160	CC	Patients with the CC genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.
1444705161	CT	Patients with the CT genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.
1444705162	TT	Patients with the TT genotype and Hypertension may have increased risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.
1444705170	AA	Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705169	AG	Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705168	GG	Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705447	AT	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes.  Other genetic and clinical factors may also influence a patient's response to paclitaxel.  Note that rs2032582 is a tri-allelic snp.
1448106552	AG	Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448107320	AA	Patients with the AA genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have increased risk of anemia as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.
1448107321	AC	Patients with the AC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.
1448107322	CC	Patients with the CC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.
1448107481	CC	Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107482	CT	Patients with retinal disease and the CT genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the TT genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1449565151	CC	Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703497	CC	Patients with the CC genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703498	CT	Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703499	TT	Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703457	AA	Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.
1444703455	AG	Patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.
1444703456	GG	Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.
1444703461	AA	Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703462	AG	Patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703463	GG	Patients with the GG genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1449565152	CT	Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565153	TT	Patients with the TT genotype may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703489	AA	Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703490	AT	Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703491	TT	Patients with the TT genotype and asthma who are treated with aspirin may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1446897528	GG	Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897529	GT	Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1445400919	CC	Patients with the CC genotype who are alcohol-dependent may have a poorer response to treatment with naltrexone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to naltrexone.
1447681871	CC	Post-menopausal women with breast cancer and the CC genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT and TT genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.
1447814595	TT	Patients with TT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.
1445400920	CT	Patients with the CT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.
1445400921	TT	Patients with the TT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.
1447814393	TTA/TTA	Patients with the TTA/TTA genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/del genotype. Other genetic and clinical factors may also influence a patient's response.
1446897175	GG	Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1447814394	TTA/del	Patients with the TTA/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/TTA genotype. Other genetic and clinical factors may also influence a patient's response.
1445401127	AA	Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401128	AG	Patients with the AG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401129	GG	Patients with the GG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401144	AA	Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
1445401145	AG	Patients with the AG genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
1445401146	GG	Patients with the GG genotype may have decreased blood pressure when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
1446897516	AG	Patients with asthma and the AG genotype may have a decreased response to montelukast as compared to patients with the AA genotype and an increased response to GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
1446897523	GG	Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1447814395	del/del	No patients with del/del were studied. However, patients with the del/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/TTA genotype. Other genetic and clinical factors may also influence a patient's response.
1447814600	CC	Patients with the CC genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
1445401122	CC	Patients with the CC genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1448103841	AA	Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103842	AG	Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103843	GG	Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1445401255	AA	Patients with the AA genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401256	AG	Patients with the AG genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401257	GG	Patients with the GG genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401262	AA	Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401263	AG	Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401264	GG	Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401269	CC	Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.
1445401270	CT	Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.
1445401271	TT	Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.
1448532198	AA	People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
1448532199	AG	People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
1448532200	GG	People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
1445401283	AA	Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for mucositis when treated with methotrexate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of mucositis.
1445401284	AG	Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.
1445401285	GG	Patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.
1448532004	TT	Patients with the TT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.
1448532206	AA	People with the AA genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532205	AC	People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1447959518	AG	Patients with the AG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the GG genotype, but decreased response compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to propranolol.
1447959519	GG	Patients with the GG genotype and Cirrhosis may have a decreased response when treated with propranolol as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to propranolol.
1447959728	AA	Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959727	AG	Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype, or a decreased response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1444706879	CG	Female patients with the CG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706878	GG	Female patients with the GG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1449718648	GT	Patients with the GT genotype who have cancer and are treated with fluoropyrimidine-based chemotherapy may have decreased survival times as compared to patients with the GG genotype. Evidence regarding the GT genotype and drug toxicities is conflicted. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449718649	TT	Patients with the TT genotype who have cancer and are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased risk of drug toxicities and 2) increased survival times as compared to patients with the GG genotype. However, multiple studies find conflicting or negative results for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450374883	AA	Patients with the AA genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have higher adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450374884	AC	Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450373768	AA	Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1449718647	GG	Patients with the GG genotype who have cancer and are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of drug toxicities and 2) decreased survival times as compared to patients with the GT or TT genotype.  However, multiple studies find conflicting or negative results for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450374885	CC	Patients with the CC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1448639141	AA	Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1448639142	AG	Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1447959726	GG	Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1450375026	AA	Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.
1450375027	AG	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.
1450373307	CC	Patients with the CC genotype (CYP3A5*3/*3) who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant, or have other diseases, who are treated with tacrolimus may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.
1444703623	AA	Patients with the AA genotype and leukemia who are treated with methotrexate may have decreased plasma level and decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703622	AG	Patients with the AG genotype and leukemia who are treated with methotrexate may have increased plasma level and increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703621	GG	Patients with the GG genotype and leukemia who are treated with methotrexate may have increased plasma level and increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703788	CC	Patients with the CC genotype who are treated with metformin may have  decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703787	CT	Patients with the CT genotype who are treated with metformin may have  increased renal clearance and secretion clearance of metformin as compared to patients with the CC genotype or may have  decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703786	TT	Patients with the TT genotype who are treated with metformin may have  increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703795	AA	Patients with the AA genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703794	AG	Patients with the AG genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the GG genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703793	GG	Patients with the GG genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703873	GG	Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin
1444703892	AA	Patients with the AA genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703893	AG	Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703894	GG	Patients with the GG genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1450373308	CT	Patients with the CT genotype (CYP3A5*1/*3) who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.
1450373309	TT	Patients with the TT genotype (CYP3A5*1/*1) who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.
1444704015	CT	Patients with the CT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype or may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.
1445401151	AA	Patients with the AA genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
1447814175	TT	Patients with the TT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1447814616	CC	Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.
1447814617	CT	Women with the CT genotype and breast neoplasms may have less bone mineral loss when taking letrozole as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole.
1447814601	CT	Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
1447814602	TT	Patients with the TT genotype and Breast Neoplasms may be at increased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
1448097457	AA	Patients with the AA genotype and colonic neoplasms may have decreased area under the curve of irinotecan-based therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the AUC of irinotecan.
1448097458	AG	Patients with the AG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.
1448097459	GG	Patients with the GG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.
1447814618	TT	Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.
1447814426	AA	Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.
1447814427	AG	Patients with the AG genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.
1445401152	AG	Patients with the AG genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
1445401153	GG	Patients with the GG genotype may have reduced fasting glucose levels when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
1447814428	GG	Patients with the GG genotype and Alzheimer Disease may have increased response to donepezil, galantamine, or rivastigmine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.
1447943633	C/del	Patients with the C/del genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
1447943634	CC	Patients with the CC genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
1447943635	del/del	Patients with the del/del genotype and hypertension may have increased response to hydrochlorothiazide compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
1447943667	AA	Patients with the AA genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
1447943668	AG	Patients with the AG genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
1447943669	GG	Patients with the GG genotype and Alzheimer's disease may have decreased response to donepezil compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
1448097785	AA	Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1447946173	GG	Patients with the GG genotype who have invasive fungal infections may have decreased concentrations of voriconazole, as compared to patients with the AG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.
1447947086	AG	Patients with the AG genotype who are treated with atorvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype.  However, these results were not statistically significant and there are contradictory studies.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1445401424	GG	Patients with the GG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.
1446906358	CC	Patients with the CC genotype may have poorer response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.
1446906359	CT	Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.
1446906360	TT	Patients with the TT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.
1445401827	CG	Patients with the CG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
1445401828	GG	Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
1446906346	CT	Patients with the CT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
1446906345	TT	Patients with the TT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
1446906372	CC	Patients with genotype CC may have decreased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CT. Other genetic and clinical factors may also influence the metabolism of efavirenz.
1445401806	AA	Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
1445401807	AG	Patients with the AG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
1446906373	CT	Patients with genotype CT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.
1446906374	TT	Patients with genotype TT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.
1447946171	AA	No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.
1447946172	AG	Patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.
1449161339	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients who are heterozygous for the G6PD Mediterranean variant (rs5030868 genotype AG) who are treated with rasburicase may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients who are homozygous for the  G6PD Mediterranean variant (rs5030868 genotype AA, associated with G6PD deficiency) or homozygous for the B/ B wildtype diplotype (rs5030868 genotype GG, not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1449161340	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Female patients who are homozygous for the G6PD Mediterranean variant (rs5030868 genotype AA, associated with G6PD deficiency) who are treated with rasburicase may have an increased risk of methemoglobinemia and/or hemolysis as compared to patients with the wildtype B/ B diplotype (rs5030868 genotype GG). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1448999093	*1/*1	Patients with the *1/*1 diplotype (two active CYP2D6 alleles) and CYP2C9*1/*1 and CYP2C19*1/*1 combined diplotypes may have higher clearance of trimipramine as compared to patients with two inactive CYP2D6 alleles (*3, *4, *5, or *6). The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448999094	*1/*2xN	Patients with the *1/*2XN diplotype may have reduced bioavailability of trimipramine as compared to patients with two inactive CYP2D6 alleles (*3, *4, *5, or *6). The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1445400942	GT	Patients with the GT genotype and schizophrenia or schizoaffective disorder may have less weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1447960450	CC	Patients with the GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960451	CG	Patients with the CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960452	GG	Patients with the CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960584	AA	Patients with the AA genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
1449166902	GT	The GT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with an increased risk of leukopenia when treated with methotrexate as compared to the TT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449166903	TT	The TT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with a decreased risk of leukopenia when treated with methotrexate as compared to the GT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449167096	CT	Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167097	TT	Caucasian patients with the TT genotype may have a decreased risk of developing opioid dependence as compared to Caucasian patients with the CC or CT genotypes. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1448612664	CC	Patients with the CC genotype and seizures may have increased response to oxcarbazepine compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
1448612665	CT	Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
1445401307	GG	Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
1445401312	CC	Cancer patients with the CC genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for ototoxicity.
1448639143	GG	Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
1449167196	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449190666	GG	Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely to have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1447945882	TT	Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1447946829	A- 202A_376G	Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with pegloticase may have an increased risk of methemoglobinemia and/or hemolysis as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1447961124	CC	Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961232	GG	Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1447945880	CC	Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1447945881	CT	Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1447960854	AA	Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.
1447960853	AG	Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time.
1444704014	TT	Patients with the TT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.
1444704085	GG	Patients with the GG genotype and depression may have decreased response to citalopram as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444704084	GT	Patients with the GT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444704083	TT	Patients with the TT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444704093	CC	Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.
1444704092	CT	Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype or may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.
1444704091	TT	Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.
1447961125	CT	Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447960852	GG	Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence survival time.
1449645470	AA	Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645471	AG	Patients with the AG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1447943757	GG	Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.
1448106262	AA	Patients with the AA genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1448106263	AG	Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1445401188	AA	Patients with the AA genotype may have decreased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
1445401189	AG	Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
1445401190	GG	Patients with the GG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
1448613245	AA	People with the AA genotype undergoing a kidney transplantation may have increased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1448613246	AG	People with the AG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus.
1448106269	AG	Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106270	GG	Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448263288	AC	Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.
1448613247	GG	People with the GG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus.
1448263289	CC	Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.
1448613250	AA	Patients with the AA genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1449577705	*5/*10	Patients with the CYP2D6*5/*10 genotype who are treated with fluvoxamine may have increased 1) steady-state plasma concentration-to-dose (C/D) ratio or increased fluvoxamine plasma concentrations and 2) risk of developing gastrointestinal side effects as compared to patients with the *1/*1 genotype. However, contradictory finding with no association with plasma concentrations or side effect risk are reported. Additionally, studies investigating multiple antidepressants including fluvoxamine found no association with with side effects or response. Other genetic and clinical factors may also influence a patient's metabolism of fluvoxamine.
1449645472	GG	Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1448612778	GG	Patients with the GG genotype and hypertension may have an increased response to antihypertensives compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect response to antihypertensive therapy.
1448612779	GT	Patients with the GT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.
1448612780	TT	Patients with the TT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.
1448106264	GG	Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1449645476	GG	Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449566675	AA	Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.
1449566676	AC	Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.
1449566681	AA	Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have a decreased severity of thrombocytopenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.
1444672791	CC	Patients with the CC genotype may have a poorer response to treatment with clonidine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to clonidine.
1444672792	CT	Patients with the CT genotype may have a better response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.
1444672793	TT	Patients with the TT genotype may have a betterr response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.
1444696373	*1/*1	Patients with the CYP2C19*1/*1 genotype may have increased metabolism of methylphenobarbital as compared to patients with the *2/*16 genotype. Other clinical and genetic factors may also affect metabolism of methylphenobarbital.
1444696374	*2/*16	Patients with the CYP2C19*2/*16 genotype may have decreased metabolism of methylphenobarbital as compared to patients with the *1/*1 genotype. Other clinical and genetic factors may also affect metabolism of methylphenobarbital.
1448568543	CC	Patients with the CC genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1448568544	CT	Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1448257292	TT	Patients with the TT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.
1449566682	AG	Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.
1449566683	GG	Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.
1448568545	TT	Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1448103848	AA	Patients with the AA genotype and colorectal cancer may have longer progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448103849	AG	Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1449565776	*1	Patients carrying the CYP2C9*1 allele may have 1) an increased rate of phenytoin clearance as compared to patients carrying the *8, *13, *14, *16, *19, *31, *33, *36, *37, *39, *42, *43, *45, *50, *52 or *55 alleles, 2) a decreased rate of phenytoin clearance as compared to patients carrying the *27, *40, *41, *47, *49, *51, *53, *54 or *56 alleles. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1448258928	CT	Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1449565778	*13	Patients carrying the CYP2C9*13 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1448103850	GG	Patients with the GG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1449565779	*14	Patients carrying the CYP2C9*14 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1444700447	CC	Patients with the CC genotype may have  increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.
1444700448	CG	Patients with the CG genotype may have  increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.
1445401327	CC	Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.
1445401313	CT	Cancer patients with the CT genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for ototoxicity.
1445401314	TT	Cancer patients with the TT genotype may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for ototoxicity.
1448616885	CG	Patients with cancer and the CG genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.
1448616886	GG	Patients with cancer and the GG genotype who are treated with capecitabine may have a decreased (but not absent) risk of asthenia as compared to patients with the CC and CG genotypes. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.
1448616896	CC	Patients with the CC genotype  and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk  of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.
1444700121	*24	Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward clopidogrel during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700122	*25	Patients with the CYP2C19*25 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*25 allele was found to have a decreased clearance of clopidogrel as compared to *1 during in-vitro characterization. 27% of the clearance ratio of *1 for clopidogrel were reported.Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700123	*26	Patients with the CYP2C19*26 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*26 allele was found to have a decreased clearance of clopidogrel as compared to *1 during in-vitro characterization. 65% of the clearance ratio of *1 for clopidogrel were reported. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700124	*28	Patients with the CYP2C19*28 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. Although an increased clearance of clopidogrel compared to *1 was found during in-vitro characterization the reported summarized it as no effect on clearance compared to *1. Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1444700125	*9	Patients with the CYP2C19*9 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*9 allele was catalytic inactive toward clopidogrel during in-vitro characterization. 12% of *1 activity for the substrate clopidogrel were reported.Other genetic and clinical factors may also influence the metabolism of clopidogrel.
1448432263	AC	Patients with colorectal cancer with the AC genotype (G13V) may have similar response when treated with cetuximab or panitumumab as compared to patients with the CC genotype ("wild type KRAS") and improved response as compared to patients with other KRAS mutations although some studies did not observe this benefit and fewer studies have looked at this genotype as compared to CT (G13D). However current guidelines still recommend not using anti-EGFR treatments in these patients. Other genetic and clinical factors may also influence response to cetuximab or panitumumab.
1448616906	AA	Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine
1448616897	CT	Patients with the CT genotype  and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk  of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.
1444700449	GG	Patients with the GG genotype may have  decreased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.
1445401328	CT	Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.
1445401329	TT	Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.
1448616898	TT	Patients with the TT genotype  and colorectal cancer who are treated with capecitabine may have an increased risk  of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.
1447814593	CC	Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.
1447814594	CT	Patients with CT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.
1043873019	GG	Patients with the GG genotype may have increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with AA or AG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
1447814486	GG	Patients with genotype GG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.
1043873021	AA	Patients with the AA genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
1444700890	GG	Patients with the GG genotype who are treated with methotrexate may have  decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444700891	GT	Patients with the GT genotype who are treated with methotrexate may have  decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444700892	TT	Patients with the TT genotype who are treated with methotrexate may have  increased risk for toxicity and increased plasma level as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1447990124	*1/*6	Patients with Alzheimer Disease and the *1/*6 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1444704330	CC	Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704331	CT	Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704332	TT	Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704337	AA	Patients with the AA genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704338	AG	Patients with the AG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704339	GG	Patients with the GG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1447990125	*4/*1xN	Patients with Alzheimer Disease and the *4/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1043873020	AG	Patients with the AG genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
1043880393	CC	Patients with the CC genotype may require decreased dose of warfarin  in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880394	CT	Patients with the CT genotype may require decreased dose of warfarin  in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1444667904	GG	Patients with the GG genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
1444667905	GT	Patients with the GT genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
1444667906	TT	Patients with the TT genotype and diabetes mellitus may have a decreased response to pioglitazone as compared to patients with the GT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
1444701011	CC	Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.
1444701010	CT	Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.
1444701009	TT	Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.
1444701003	CC	Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.
1444701002	CT	Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.
1444701001	TT	Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.
1449752569	CT	Patients with cancer and the CT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, a few studies report no association or increased response for patients with the CT genotype as compared to the TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.
1449752570	TT	Patients with cancer and the TT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, a few studies report no association or decreased response for patients with the TT genotype as compared to the CT genotype also. Other genetic and clinical factors may also influence response to platinum-based regimens.
1446899682	AA	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1444705193	AA	Patients with the AA genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705194	AT	Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705195	TT	Patients with the TT genotype and major depression may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705202	CC	Patients with the CC genotype and major depression may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
1444705201	CG	Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
1444705200	GG	Patients with the GG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
1449752593	AA	Patients with the AA genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma or esophageal cancer or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.
1449752594	AC	Patients with the AC genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma or esophageal cancer or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.
1446906339	AA	Patients with the AA genotype may have decreased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to citalopram.
1446906338	AG	Patients with the AG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.
1446906337	GG	Patients with the GG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.
1446908960	TT	Patients with the TT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446908996	TT	Patients with the TT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1447814577	CC	Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
1448106574	AA	Patients with the AA genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1446906332	GG	Patients with the GG genotype may have decreased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1446903009	CC	Patients with the CC genotype may require an increased dose of codeine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of codeine.
1446903010	CT	No information is available for the CT genotype.
1446903011	TT	Patients with the TT genotype may require a decreased dose of codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of codeine.
1446903040	*1/*1	Patients with the CYP2C19*1/*1 genotype who are treated with amitriptyline may have increased metabolism of amitriptyline (decreased amitriptyline plasma concentrations and increased nortriptyline plasma concentrations) as compared to patients with the CYP2C19*2 or *3 alleles or decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the CYP2C19*17/*17 genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446906331	GT	Patients with the GT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype  GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1446906330	TT	Patients with the TT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype  GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1446906347	CC	Patients with the CC genotype may have increased heart rate when treated with Beta Blocking Agents as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
1446908610	CC	Patients with the CC genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
1446908611	CT	Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
1446908612	TT	No information were reported regarding patients with the TT genotype.
1447814578	CT	Patients with the CT genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
1447814579	TT	Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
1448106575	AG	Patients with the AG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448106576	GG	Patients with the GG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448106580	CC	Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448106581	CT	Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448531676	CC	Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.
1448531895	GG	Patients with the GG genotype may have higher levels of morphine as compared to patients with the AA or AG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.
1448532006	CC	Patients with the CC genotype may have decreased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to clozapine.
1448532005	CT	Patients with the CT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.
1444703477	CC	Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
1444703476	CT	Male patients with the CT genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
1444703475	TT	Male patients with the TT genotype may have increased clearance of vardenafil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
1444703505	AA	Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703504	AT	Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703506	TT	Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703513	CC	Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703511	CT	Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703512	TT	Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703989	AA	Patients with the AA genotype and major depression may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703988	AG	Patients with the AG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype or may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703987	GG	Patients with the GG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444704009	AA	Patients with the AA genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444704008	AG	Patients with the AG genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444704007	GG	Patients with the GG genotype and major depression who are treated with fluoxetine may have increased response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444704016	CC	Patients with the CC genotype and hypertension and coronary artery disease who are treated with verapamil may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.
1448531677	CT	Patients with the CT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448531678	TT	Patients with the TT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.
1444667544	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667545	AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667546	GG	Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1449190667	GT	Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely to have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1444667551	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667552	AC	Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667553	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1448106557	CC	Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448106558	CT	Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448106559	TT	Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448423050	TTAAAG/TTAAAG	Patients with the TTAAAG/TTAAAG genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the del/del genotype and the 3/3 genotype at rs151264360. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1448423051	TTAAAG/del	Patients with the TTAAAG/del genotype and the 3/3 genotype at rs151264360 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAG/TTAAAG genotype. Patients with the TTAAAG/del genotype may have a lower response to treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1448106568	CC	Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448423052	del/del	Patients with the del/del genotype and the 3/3 genotype at rs151264360 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1448106553	GG	Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1446906130	CT	Patients with the CT genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.
1446906131	TT	Patients with the TT genotype and HIV may have decreased metabolism of efavirenz resulting in higher efavirenz plasma levels as compared to patients with the CC or CT  genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.
1448106569	CT	Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448106570	TT	Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1444703232	AA	Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444703233	AC	Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444703234	CC	Patients with the CC genotype and Depressive Disorder may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444703247	CC	Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to  carbamazepine, phenytoin or valproic acid.
1444703246	CT	Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to  carbamazepine, phenytoin or valproic acid.
1444703245	TT	Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to  carbamazepine, phenytoin or valproic acid.
1444705208	CC	Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705209	CG	Patients with the CG genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705210	GG	Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705216	CC	Patients with the CC genotype may have increased likelihood of side effects when treated with citalopram as compared to patients with the TT genotype. No association was found with response or remission. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705217	CT	Patients with the CT genotype may have increased likelihood of side effects when treated with citalopram as compared to patients with the TT genotype or may have decreased likelihood of side effects when treated with citalopram as compared to patients with the CC genotype. No association was found with response or remission. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705218	TT	Patients with the TT genotype may have decreased likelihood of side effects when treated with citalopram as compared to patients with the CC genotype. No association was found with response or remission. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705225	CC	Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705224	CT	Patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705226	TT	Patients with the TT genotype were not studied. However, patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705233	AA	Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705232	AC	Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype or may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705231	CC	Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706789	AA	Patients with the AA genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444706790	AG	Patients with the AG genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype or may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444706791	GG	Patients with the GG genotype and major depression may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444706798	CC	Patients with the CC genotype and major depression may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444703415	CC	Patients with the CC genotype and HIV who are treated with tenofovir may have  increased creatinine clearance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703416	CT	Patients with the CT genotype and HIV who are treated with tenofovir may have  decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703417	TT	Patients with the TT genotype and HIV who are treated with tenofovir may have  decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1447949092	AA	Patients with AA genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
1447949091	AG	Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
1447949090	GG	Patients with GG genotype may have increased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
1444703523	GG	Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1448522750	CC	Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522751	CT	Patients with the CT genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522752	TT	Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448605501	GG	Patients with the GG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT), or conditions relating to metabolic syndrome, when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for NODAT or metabolic syndrome.
1448605499	AA	Patients with the AA genotype who are undergoing organ transplantation may have an increased risk for new-onset diabetes after transplantation (NODAT), or conditions relating to metabolic syndrome, when treated with tacrolimus or cyclosporine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for NODAT or metabolic syndrome.
1444667439	AA	Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667440	AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1448605500	AG	Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT), or conditions relating to metabolic syndrome, when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT or metabolic syndrome.
1449166887	GG	Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1444703524	GT	Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703525	TT	Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703533	CC	Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.
1448999133	*5/*5	Patients with the *5/*5, *5/*3, *5/*4 or *5/*6 genotype (two non-functional alleles) and major depressive disorder 1) may have a decreased metabolism of imipramine and 2) may require a lower dose of imipramine as compared to patients with the *1/*1, *1/*2, *2/*2, *1xN/*1, *1xN/*2, *2xN/*1 or *2xN/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1448999134	*6/*6	Patients with the *6/*6, *6/*3, *6/*4 or *6/*5 genotype (two non-functional alleles)  and major depressive disorder 1) may have a decreased metabolism of imipramine and 2) may require a lower dose of imipramine as compared to patients with the *1/*1, *1/*2, *2/*2, *1xN/*1, *1xN/*2, *2xN/*1 or *2xN/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1444700187	*9	Patients with the CYP2C19*9 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. The CYP2C19*9 allele was found to have a decreased activity towards omeprazole and decreased clearance of omeprazole as compared to *1 during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of omeprazole.
1445401391	AA	Patients with the AA genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1445401392	AG	Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1445401393	GG	Patients with the GG genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain.
1445401401	AA	Patients with the AA genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain.
1445401402	AG	Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.
1445401403	GG	Patients with the GG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.
1448999132	*4/*4	Patients with the *4/*4, *4/*3, *4/*5 or *4/*6 genotype (two non-functional alleles) and major depressive disorder 1) may have a decreased metabolism of imipramine and 2) may require a lower dose of imipramine as compared to patients with the *1/*1, *1/*2, *2/*2, *1xN/*1, *1xN/*2, *2xN/*1 or *2xN/*2 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's required dosage of imipramine.
1447960475	AA	Patients with the AA genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.
1447960476	AC	Patients with the AC genotype and cancer may have shorter progression-free survival times when treated with gemcitabine as compared to patients with the AA or CC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.
1447960477	CC	Patients with the CC genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.
1444703210	CC	Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1445401415	AA	Patients with the AA genotype and metastatic colorectal cancer may have increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.
1445401416	AG	Patients with the AG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.
1445401417	GG	Patients with the GG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.
1445401422	AA	Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.
1445401423	AG	Patients with the AG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.
1444666888	AA	Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666889	AG	Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666890	GG	Patients with the GG genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444694623	AA	Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
1444694624	AG	Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk of hypokalemia when treated with tacrolimus as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
1444694625	GG	Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
1445400705	AA	Patients with the AA genotype may have a better response to the pertussis vaccine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400706	AG	Patients with the AG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400707	GG	Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400947	GG	Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.
1444704865	CC	Patients with the CC genotype may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.
1444704864	CG	Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype or may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.
1444704863	GG	Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.
1445400948	GT	Patients with the GT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.
1445400949	TT	Patients with the TT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.
1449157959	CC	Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157960	CT	Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157961	TT	Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157954	CT	Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157955	TT	Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157965	CC	Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1444666867	GG	Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.
1444695587	AG	Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels.
1444695588	GG	Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels.
1448107294	AA	Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1448107295	AG	Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1448107296	GG	Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1444705183	AA	Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705184	AG	Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype or may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705185	GG	Patients with the GG genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706352	*15/*15	Patients with the *15/*15 genotype may have increased exposure to rosuvastatin  and decrease hepatic uptake pf rosuvastatin as compared to patients with the *1A/*1A, *1B/*1B or *1B/*15 genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706353	*18/*18	Patients with the *18/*18 genotype may have decreased hepatic uptake of rosuvastatin as compared to patients with the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706354	*1A/*1A	Patients with the *1A/*1A genotype may have decreased exposure to rosuvastatin  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706355	*1B/*15	Patients with the *1B/*15 genotype may have decreased exposure to rosuvastatin as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706356	*1B/*1B	Patients with the *1B/*1B genotype may have decreased exposure to rosuvastatin  as compared to patients with the *15/*15 genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706357	*5/*5	Patients with the *5/*5 genotype may have decreased hepatic uptake of rosuvastatin as compared to patients with the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706358	*9/*9	Patients with the *9/*9 genotype may have decreased hepatic uptake of rosuvastatin as compared to patients with the *1A/*1A or *1B/*1B genotype. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics.
1444706797	CT	Patients with the CT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype or may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706796	TT	Patients with the TT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706803	AA	Patients with the AA genotype and Mental disorders may have increased serum concentration of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1444706804	AG	Patients with the AG genotype and Mental disorders may have increased serum concentration of escitalopram as compared to patients with the GG genotype or may have decreased serum concentration of escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1444706805	GG	Patients with the GG genotype and Mental disorders may have decreased serum concentration of escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1448107313	CT	Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444667294	CC	Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667295	CT	Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667296	TT	Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.
1444667300	CC	Patients with the CC genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1444667301	CG	Patients with the CG genotype and heart failure may have a poorer response to  carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1444667302	GG	Patients with the GG genotype and heart failure may have a better response to carvedilol treatment as compared to patients with the CC or CG genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1444667441	GG	Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667455	CC	Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1444667456	CG	Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1444667457	GG	Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1444667595	AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667596	GG	Patients with asthma and the GG genotype may have a increased risk of aspirin induced asthma as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444668288	AA	In healthy volunteers as well as patients with diabetes mellitus the AA genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668289	AG	In healthy volunteers as well as patients with diabetes mellitus the AG genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the GG genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668290	GG	In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668294	CC	In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444673034	CC	Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.
1444673035	CT	Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.
1444673036	TT	Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.
1444673041	CC	Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.
1444673042	CT	Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.
1444673043	TT	Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.
1444673048	CC	Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673049	CT	Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673050	TT	Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673055	CC	Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673056	CT	Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673057	TT	Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673067	AA	Patients with the AA genotype and rheumatoid arthritis may have a poorer response when treated with rituximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to rituximab.
1444673068	AG	Patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.
1444673069	GG	No patients with the GG genotype were present in the population. However, patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.
1444700468	GG	Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444701091	*1/*1	Patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with citalopram or escitalopram may have a decreased frequency of remission and an increased dose as compared to patients with two non-functional alleles (*3, *4, *5, *6) or a reduced function allele (*10, *17, *41) and a non-functional allele. However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444700461	AA	Patients with the AA genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700462	AG	Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700463	GG	Patients with the GG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700470	CC	Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700469	CG	Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700918	CC	Patients with the CC genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
1444700919	CT	Patients with the CT genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
1444700920	TT	Patients with the TT genotype may have increased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
1444700952	GG	Patients with the GG genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700953	GT	Patients with the GT genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700954	TT	Patients with the TT genotype may have decreased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700960	AA	Patients with the AA genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
1444700911	AA	Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.
1444700912	AT	Patients with the AT genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.
1444700913	TT	Patients with the TT genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype AA or AT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.
1444700961	AG	Patients with the AG genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
1444700962	GG	Patients with the GG genotype may have decreased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
1444700978	AA	Patients with the AA genotype may have increased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype TT or AT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700979	AT	Patients with the AT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700980	TT	Patients with the TT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700987	GG	Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.
1444700986	GT	Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients.
1444700985	TT	Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.
1450361634	AG	Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450361635	GG	Patients with the GG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450361626	AA	Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450361633	AA	Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450361627	AC	Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1444673381	GG	Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673382	GT	Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673383	TT	Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673393	CC	Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673394	CT	Patients with the CT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673395	TT	Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673414	AA	Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673415	AC	Patients with the AC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673416	CC	Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.
1444706814	CC	Patients with the CC genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706813	CT	Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706812	TT	Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706820	CC	Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706821	CT	Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706822	TT	Patients with the TT genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706913	AA	Patients with the AA genotype and Schizophrenia may have increased clearance of olanzapine as compared to patients with the AG or GG genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706914	AG	Patients with the AG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706915	GG	Patients with the GG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444668295	CT	Patients with the CT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the CC genotype and a lower secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668296	TT	Patients with the TT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668308	CC	In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668309	CT	In healthy volunteers as well as patients with diabetes mellitus the CT genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the TT genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444668310	TT	In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1444673086	CC	Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
1444673087	CG	Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
1444673088	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
1444673125	AA	Patients with the AA genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
1444673126	AG	Patients with the AG genotype and schizophrenia may have an increased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
1444673127	GG	Patients with the GG genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
1444673137	CC	Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.
1444673138	CT	Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.
1444673139	TT	Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.
1444673144	AA	Patients with the AA genotype and paroxysmal nocturnal hemoglobinuria may have a better response to treatment with eculizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to eculizumab.
1444673145	AG	Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.
1444673146	GG	Patients with the GG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.
1444673074	CC	Patients with the CC genotype and rheumatoid or psoriatic arthritis may have a better response when treated with anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.
1444673075	CG	Patients with the CG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.
1444673076	GG	Patients with the GG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.
1444700530	AA	Patients with the AA genotype and depression may have a decreased response and remission rate when treated with escitalopram as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also effect patients response.
1444700516	GG	Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700517	GT	Patients with the GT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype. Patients with the GT genotype are not studied for sensitivity to imatinib, but based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700518	TT	Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700526	CC	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700525	CT	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700524	TT	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444700531	AG	Patients with the AG genotype and depression may have a increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients response.
1444700532	GG	Patients with the GG genotype and depression may have a increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients response.
1444700798	AA	Patients with the AA genotype and HIV who are treated with nevirapine  may have decreased clearance of nevirapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1444700799	AG	Patients with the AG genotype and HIV who are treated with nevirapine  may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1444700800	GG	Patients with the GG genotype and HIV who are treated with nevirapine  may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1444700871	CC	Patients with the CC genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1444700870	CT	Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1444700869	TT	Patients with the TT genotype and Hepatitis C may have an increased risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1444700878	CC	Patients with the CC genotype may have a decreased response to levodopa in people with cocaine-related disorders as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1444700877	CT	Patients with the CT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1444700876	TT	Patients with the TT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1444667251	AA	Patients with metastasized cancer and the AA genotype may have worse response to capecitabine or fluorouracil as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667252	AT	Patients with metastasized cancer and the AT genotype may have worse response to capecitabine or fluorouracil as compared to patients with the TT genotype and improved response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667253	TT	Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667258	AA	Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667259	AG	Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667260	GG	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667265	AA	Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667266	AG	Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667267	GG	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1449191508	*1/*1	Patients with the *1/*1 genotype who are treated with codeine may have 1) increased metabolism/clearance of codeine, 2) increased likelihood of response to codeine and 3) decreased, but not absent risk for side effects as compared to patients with non-functional (*3, *4, *5, *6, *40) or reduced function (*10, *17, *41) alleles. Other genetic and clinical factors may also influence a patient's response to codeine.
1449191509	*1/*1xN	Patients with more than two copies of CYP2D6 functional alleles (*1, *2) who are CYP2D6 ultrarapid metabolizers (i.e., a CYP2D6 activity score of >2.0) may have 1) increased formation of morphine following codeine administration and 2) higher risk of toxicity as compared to patients with *1/*1 genotype, who are CYP2D6 normal metabolizers. Patients who are CYP2D6 ultrarapid metabolizers should avoid codeine use due to potential for toxicity.  Alternative analgesics such as morphine or a non-opioid should be considered. Other genetic and clinical factors may also influence a patient's response to codeine.
1449191510	*1/*2xN	Patients with more than two copies of CYP2D6 functional alleles (*1, *2) who are CYP2D6 ultrarapid metabolizers (i.e., a CYP2D6 activity score of >2.0) may have 1) increased formation of morphine following codeine administration and 2) higher risk of toxicity as compared to patients with *1/*1 genotype, who are CYP2D6 normal metabolizers. Patients who are CYP2D6 ultrarapid metabolizers should avoid codeine use due to potential for toxicity.  Alternative analgesics such as morphine or a non-opioid should be considered. Other genetic and clinical factors may also influence a patient's response to codeine.
1449191511	*10	Patients with the *10 reduced functional allele in combination with a non-functional (*3, *4, *5, *6, *40) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 intermediate metabolizers should be monitored closely for less than optimal response and should be offered an alternative analgesic if required. Other genetic and clinical factors may also influence a patient's response to codeine.
1444700883	AA	Patients with the AA genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
1444700884	AG	Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
1444700885	GG	Patients with the GG genotype and open-angle glaucoma who are treated with timolol may have a decreased risk for bradycardia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
1444700356	AA	Patients with the AA genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
1444700357	AG	Patients with the AG genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
1444700358	GG	Patients with the GG genotype may have decreased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
1444700364	CC	Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700365	CT	Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700366	TT	Patients with the TT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700375	CC	Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700374	CT	Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700373	TT	Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700386	CC	Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700385	CT	Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700384	TT	Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700833	AG	Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700832	GG	Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
982030725	GG	People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).
1444703189	AA	Patients with the AA genotype who are treated with timolol may have increased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
1444703190	AG	Patients with the AG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
1444703191	GG	Patients with the GG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
1444703202	CC	Patients with the CC genotype and Coronary Artery Disease may have  decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1444703203	CG	Patients with the CG genotype and Coronary Artery Disease may have  increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype or may have  decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1444703204	GG	Patients with the GG genotype and Coronary Artery Disease may have  increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448428946	AA	Patients with the AA genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428947	AG	Patients with the AG genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428948	GG	Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1449170629	CC	Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.
1449170630	CT	Patients with the CT genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have longer of progression-free survival as compared to patients with the CC genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.
1449170809	*13	Patients with CYP2C9*13 may require more time to achieve stable dose when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.
1444673204	AA	Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673205	AG	Patients with the AG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673206	GG	Patients with the GG genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448106228	AA	Patients with the AA genotype may have an increased response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.
1448106229	AG	Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
1448106230	GG	Patients with the GG genotype may have a decreased response to bisphosphonate treatment, or may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
1449170810	*2	Patients with CYP2C9*2 may require more time to achieve stable dose when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.
1449170811	*3	Patients with CYP2C9*3 may require more time to achieve stable dose when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.
1444694569	GG	Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1184136447	AA	Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
1184136448	AG	Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
1184136449	GG	Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
1444694570	GT	Patients undergoing liver transplantation who receive a donor liver with the GT genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444694571	TT	Patients undergoing liver transplantation who receive a donor liver with the TT genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the GG or GT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1448106220	TT	Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Patients with the TT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448108128	GG	Patients with the GG genotype and tumors may have increased metabolism of erythromycin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1450044567	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448108126	AA	Patients with the AA genotype were not studied, however they may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1450044601	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044602	GT	Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1444673181	GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA	Patients with the GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673180	GGTCCCACTCTTCCCACA/del	Current literature evidence finds no significant effect of the GGTCCCACTCTTCCCACA/del genotype on progression-free survival time in patients taking docetaxel.
1444673179	del/del	Patients with the del/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1450044568	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1444680133	AA	Patients with the AA genotype and Parkinson's disease may have an increased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.
1444680134	AG	Patients with the AG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.
1444680135	GG	Patients with the GG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.
1444680140	AA	Patients with the AA genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.
1444680141	AG	Patients with the AG genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.
1444680142	GG	Patients with the GG genotype and atrial fibrillation may require a lower dose of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.
1448108127	AG	Patients with the AG genotype and tumors may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1450044569	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG and AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1444703135	TT	Patients with the TT genotype and Schizophrenia who are treated with olanzapine or risperidone may have increased time until response as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
1448107312	CC	Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1450043694	AA	Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450043695	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develop Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448097786	AG	Patients with non-small cell lung cancer and the AG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1444932411	CT	Patients with the CT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype or may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.
1450043696	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG or AA. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1444703133	CC	Patients with the CC genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
1444703134	CT	Patients with the CT genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
1444703158	CC	Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.
1444703157	CT	Patients with the CT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype or may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.
1444703156	TT	Patients with the TT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.
1444712885	*02:01	Patients with one or two copies of the HLA-DQA1*02:01 allele have an increased risk of hepatotoxicity when treated with lapatinib as compared to patients with no HLA-DQA1*02:01 alleles or negative for the HLA-DQA1*02:01 test. This allele is in strong linkage disequilibrium with HLA-DRB1*07:01. Other genetic and clinical factors may also influence a patient's risk of lapatinib-induced hepatotoxicity.
1444932412	TT	Patients with the TT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.
1448107306	CC	Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1448107307	CT	Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1448107308	TT	Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703772	CC	Patients with the CC genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms, increased likelihood of Sleep Initiation and Maintenance Disorders but decreased risk for weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1444703771	CT	Patients with the CT genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms, increased likelihood of Sleep Initiation and Maintenance Disorders but decreased risk for weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1444703770	TT	Patients with the TT genotype and major depression who are treated with nortriptyline may have more improvement in neurovegetative symptoms, decreased likelihood of Sleep Initiation and Maintenance Disorders but increased risk for weight gain as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1450375458	AA	Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1450375459	AG	Patients with the AG genotype may have an increased exposure to tramadol as compared to patients with the GG genotype, but a decreased exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1450375460	GG	Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1447963669	GG	Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.
1447963670	GT	Patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.
1447963572	*16:01:01	Patients with one or two copies of the HLA-DRB1*16:01-HLA-DQB1-*05:02 haplotype who are treated with flupirtine may have an increased risk of drug-induced liver injury (DILI) as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of flupirtine-induced adverse reactions.
1447963577	*05:02:01	Patients with one or two copies of the HLA-DQB1*05:02-HLA-DRB1-*15:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1450375463	AA	Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the CC genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1450375464	AC	There is currently no evidence to show whether the AC genotype affects a patient's exposure to tramadol.
1450375465	CC	Patients with the CC genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1450375694	CC	Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1444704036	AA	Patients with the AA genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444704035	AC	Patients with the AC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype or may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444704034	CC	Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444704044	CC	Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
1444704043	CT	Patients with the CT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
1447963434	AA	Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.
1447963435	AG	Patients with the AG genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.
1447963436	GG	Patients with the GG genotype and hypertension may have a decreased risk of stroke when treated with ACE inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of stroke.
1448267384	AG	Patients with the AG genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.
1448267385	GG	Patients with the GG genotype and heart valve replacement may require higher dose of warfarin compared to patients with the AA and AG genotypes. Other clinical and genetic factors affect warfarin dose.
1448267391	AA	Patients with the AA genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.
1445401300	GG	Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
1445401298	AA	Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.
1445401299	AG	Patients with the AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
1444668459	AA	Patients with the AA genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668460	AT	Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668461	TT	Patients with the TT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668470	AA	Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668471	AG	Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668472	GG	Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668640	G/TT	Patients with the G/TT genotype may have faster viral clearance and increased drug efficacy  in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.
1444668639	GG	Patients with the GG genotype may have slower viral clearance and decreased drug efficacy  in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin as compared to patients with genotype G/TT + TT/TT. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.
1444668641	TT/TT	Patients with the TT/TT genotype may have faster viral clearance and increased drug efficacy  in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.
1448267383	AA	Patients with the AA genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.
1445401305	AA	Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.
1445401306	AG	Patients with the AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
1448267392	AC	Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.
1448267393	CC	Patients with the CC genotype and heart valve replacement may require increased dose of warfarin compared to patients with the AA and AC genotypes. Other clinical and genetic factors affect warfarin dose.
1448267399	CC	Patients with the CC genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.
1448267400	CT	Patients with the CT genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.
1449166399	AG	Patients with the AG genotype and gastroesophageal reflux who are treated with omeprazole may have Increased absorption of omeprazole, but decreased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients gastroesophageal reflux.
1449166398	AA	Patients with the AA genotype and gastroesophageal reflux may have increased absorption rate and response  to omeprazole compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients.
1449565062	GG	Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.
1449565063	GT	Patients with the GT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.
1444701094	*3	Patients with the CYP2D6*3 allele in combination with a non-functional allele (*3, *4, *5, *6) or a reduced function allele (*10, *17, *41) who are treated with citalopram or escitalopram may have an increased frequency of remission and a decreased dose as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444701095	*4	Patients with the CYP2D6*4 allele in combination with a non-functional allele (*3, *4, *5, *6) or a reduced function allele (*10, *17, *41) who are treated with citalopram or escitalopram may have an increased frequency of remission and a decreased dose as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444701096	*41	Patients with the CYP2D6*41 allele in combination with a non-functional allele (*3, *4, *5, *6) who are treated with citalopram or escitalopram may have an increased frequency of remission and a decreased dose as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444701097	*5	Patients with the CYP2D6*5 allele in combination with a non-functional allele (*3, *4, *5, *6) or a reduced function allele (*10, *17, *41) who are treated with citalopram or escitalopram may have an increased frequency of remission and a decreased dose as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444701098	*6	Patients with the CYP2D6*6 allele in combination with a non-functional allele (*3, *4, *5, *6) or a reduced function allele (*10, *17, *41) who are treated with citalopram or escitalopram may have an increased frequency of remission and a decreased dose as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However, the majority of the studies reported contradictory finding with no association of CYP2D6 genotypes with drug clearance or differences in remission or tolerance. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1448115866	CC	Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CT or TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1449166400	GG	Patients with the GG genotype and  Gastroesphageal reflux who are treated with omeprazole may have decreased absorption rate  of omeprazole as compared to patients with the AA or AG genotypes and and decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence Response to and absorption rate of omeprazole in patients gastroesphageal reflux.
1448115867	CT	Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1444933024	GG	Patients under general anaesthesia with genotypes GG may need increased dose of propofol as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence the dose of propofol.
1444933023	GT	Patients under general anaesthesia with genotypes GT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.
1444933022	TT	Patients under general anaesthesia with genotypes TT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.
1444700504	GG	Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.
1444704871	CC	Male patients with the CC genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704872	CT	Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704873	TT	Male patients with the TT genotype may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704883	AA	Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
1444704884	AG	Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
1444704885	GG	Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
1449564307	GG	Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CC genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449564310	AA	Patients with the AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's warfarin dose.
1449564311	AC	Patients with the AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's warfarin dose.
1444704925	CC	Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
1444704924	CT	Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
1444704923	TT	Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
1444705238	AA	Patients with the AA genotype and major depression may have decreased, but not absent, risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705239	AG	Patients with the AG genotype and major depression may have decreased, but not absent, risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype or may have increased risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705240	GG	Patients with the GG genotype and major depression may have increased risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705247	AA	Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1449564337	AA	Patients with the AA genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have worse outcome (overall survival and progression-free survival) as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome.
1444704965	TT	People with the TT genotype may have increased Anxiety Disorders when exposed to caffeine as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
1449564312	CC	Patients with the CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's warfarin dose.
1449564577	CC	Patients with the CC genotype may need an increased dose of warfarin as compared to patients with the CG and GG genotypes, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.
1449559836	CC	Patients with the CC genotype and colorectal cancer who are treated with folinic acid/leucovorin, fluorouracil and irinotecan (FOLFIRI) may have decreased metabolism of irinotecan as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of irinotecan. Please note: the CC genotype was not observed in this study.
1449559837	CT	Patients with the CT genotype and colorectal cancer who are treated with folinic acid/leucovorin, fluorouracil and irinotecan (FOLFIRI) may have decreased metabolism of irinotecan as compared to the TT genotype. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449559838	TT	Patients with the TT genotype and colorectal cancer who are treated with folinic acid/leucovorin, fluorouracil and irinotecan (FOLFIRI) may have increased metabolism of irinotecan as compared to the CT genotype. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449564204	AA	Patients with the AA genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564205	AC	Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564206	CC	Patients with the CC genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1444673187	G/del	Current literature evidence finds no significant effect of the G/del genotype on progression-free survival time in patients taking docetaxel.
1444673186	GG	Patients with the GG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673188	del/del	Patients with the del/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444703706	AA	Patients with the AA genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.
1444703705	AG	Patients with the AG genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the AA genotype or may have a faster score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.
1444703704	GG	Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the AA genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.
1444703743	AA	Patients with the AA genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.
1444703742	AG	Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the AA genotype or may have a slower score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.
1449564572	AA	Patients with brain tumors, osteosarcoma, and other cancers and the AA genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients exposed to cisplatin.
1449564573	AG	Patients with brain tumors, osteosarcoma, and other cancers and the AG genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in pediatric patients exposed to cisplatin.
1449564574	GG	Patients with brain tumors, osteosarcoma, and other cancers and the GG genotype may have a decreased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of ototoxicityin patients exposed to cisplatin.
1449565296	AA	Subjects with the AA genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.
1449565297	AC	Subjects with the AC genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.
1449565266	(TA)6/6	Patients with the (TA)6/6 genotype may be associated with decreased risk of Hyperbilirubinemia when treated with sorafenib in people with hepatocellular carcinoma as compared to patients with the (TA)7/6 or (TA)7/7 genotype. Other clinical and genetic factors may also influence a patient's response to sorafenib.
1448525344	CT	Patients with the CT genotype and who are treated with atorvastatin may have 1) lower oral clearance and higher plasma concentrations of atorvastatin 2) an increased risk of composite adverse events but not an increased risk of myalgia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.
1448525345	TT	Patients with the TT genotype and who are treated with atorvastatin may have 1) higher oral clearance and lower plasma concentrations of atorvastatin 2) a decreased risk of composite adverse events but not a decreased risk of myalgia, as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.
1447962683	AA	Patients with the AA genotype who are undergoing kidney transplantation may require an increased dose of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1447962684	AG	Patients with the AG genotype who are undergoing kidney transplantation may require an increased dose of tacrolimus as compared to patients with the GG genotype, or a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1447962685	GG	Patients with the GG genotype who are undergoing kidney transplantation may require a decreased dose of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444673117	AA	Patients with the AA genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.
1444673118	AG	Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.
1444673119	GG	Patients with the GG genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.
1449565298	CC	Subjects with the CC genotype may have increased clearance of oxazepam or lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.
1449565267	(TA)6/7	Patients with the (TA)6/7 genotype may be associated with increased risk of Hyperbilirubinemia and treatment interruption when treated with sorafenib in people with hepatocellular carcinoma as compared to patients with the (TA)6/6 genotype. Other clinical and genetic factors may also influence a patient's response to sorafenib.
1449565268	(TA)7/7	Patients with the (TA)7/7 genotype may be associated with increased risk of Hyperbilirubinemia and treatment interruption when treated with sorafenib in people with hepatocellular carcinoma as compared to patients with the (TA)6/6 genotype. Other clinical and genetic factors may also influence a patient's response to sorafenib.
1444686818	GG	Patients undergoing liver transplantation who receive a donor liver with the GG genotype may have increased metabolism of tacrolimus, as compared to patients with the GT or TT genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.
1444686819	GT	Patients undergoing liver transplantation who receive a donor liver with the GT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.
1444686820	TT	Patients undergoing liver transplantation who receive a donor liver with the TT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.
1444686831	GG	Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
1444686832	GT	Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
1444686833	TT	Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
1448613365	TT	Patients with the TT genotype may have low on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448615170	AG	Postmenopausal women with HR+breast cancer and the AG genotype may have a increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615171	GG	Postmenopausal women with HR+breast cancer and the GG genotype may have a increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1444686852	CC	Patients with the CC genotype and chronic myeloid leukemia may have increased clearance of imatinib, as well as increased event-free survival time, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.
1444686853	CG	Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.
1444686854	GG	Patients with the GG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.
1444686864	AA	In human liver microsomes, the AA genotype was associated with increased glucuronidation of SN-38, as compared to the AC or CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.
1444686865	AC	In human liver microsomes, the AC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.
1444686866	CC	In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.
1449156546	CC	Patients with the CC genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449156547	CT	Patients with the CT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449156548	TT	Patients with the TT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1444686888	CC	In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the CT or TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.
1444686889	CT	In human liver microsomes, the CT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.
1444686890	TT	In human liver microsomes, the TT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.
1444687041	AA	Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687042	AC	Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687043	CC	Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448613367	CC	Patients with the CC genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613366	CT	Patients with the CT genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.
1449157953	CC	Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1444667123	*1/*1	Patients with the CYP2C19 *1/*1 genotype may have a reduced response to omeprazole (greater % of time with intragastric pH < 4.0, and a lower intragastric pH during a 24-hour time period, among other parameters) as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Two studies found no association between CYP2C19 genotypes and intragastric pH parameters. Other genetic and clinical factors may also influence response to omeprazole.
1444667124	*1/*2	Patients with the CYP2C19 *1/*2 genotype may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, among other parameters) as compared to patients with the *1/*1 genotype, and a reduced response as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Two studies found no association between CYP2C19 genotypes and intragastric pH parameters. Other genetic and clinical factors may also influence response to omeprazole.
1444667125	*1/*3	Patients with the CYP2C19 *1/*3 genotype may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, among other parameters) as compared to patients with the *1/*1 genotype, and a reduced response as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Two studies found no association between CYP2C19 genotypes and intragastric pH parameters. Other genetic and clinical factors may also influence response to omeprazole.
1444667126	*2/*2	Patients with the CYP2C19 *2/*2 genotype may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, among other parameters) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Two studies found no association between CYP2C19 genotypes and intragastric pH parameters. Other genetic and clinical factors may also influence response to omeprazole.
1444667127	*2/*3	Patients with the CYP2C19 *2/*3 genotype may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, among other parameters) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Two studies found no association between CYP2C19 genotypes and intragastric pH parameters. Other genetic and clinical factors may also influence response to omeprazole.
1444667128	*3/*3	Patients with the CYP2C19 *3/*3 genotype may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, among other parameters) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Two studies found no association between CYP2C19 genotypes and intragastric pH parameters. Other genetic and clinical factors may also influence response to omeprazole.
1445619588	AA	Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619589	AG	Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619590	GG	Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445585667	TT	Patients with the TT genotype and rheumatoid arthritis may have a decreased response to treatment with anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444703741	GG	Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the AA genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.
1444667730	GG	Patients with the GG genotype and open-angle glaucoma may have a decreased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.
1444686900	CC	Patients with the CC genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
1444686901	CT	Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
1444686902	TT	Patients with the TT genotype and Alzheimer's disease may be more likely to respond to treatment with cholinesterase inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
1444703940	AA	Patients with the AA genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.
1444703939	AG	Patients with the AG genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.
1444703938	GG	Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.
1444703955	GG	Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1444703954	GT	Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1444703953	TT	Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1444703980	CC	Patients with the CC genotype were not studied. However, patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703979	CT	Patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703978	TT	Patients with the TT genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444704042	TT	Patients with the TT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
1444704052	CC	Patients with the CC genotype and major depression may have increased response to paroxetine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444704050	CT	Patients with the CT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444704051	TT	Patients with the TT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444704062	CC	Patients with the CC genotype and rs2501873 TT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1444704063	CT	Patients with the CT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype or may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1444704064	TT	Patients with the TT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1444686798	CC	Patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1444686799	CT	Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1444686800	TT	Patients with the TT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1444686838	AA	Patients with the AA genotype who are undergoing kidney transplantation may have a greater chance of achieving target concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.
1444686839	AG	Patients with the AG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.
1444686840	GG	Patients with the GG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.
1444694576	AA	Patients undergoing liver transplantation who receive a donor liver with the AA genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444694577	AG	Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444694578	GG	Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1447672632	*1/*1	Patients with CYP2C9*1/*1 may require longer time to therapeutic INR when treated with warfarin as compared to patients with CYP2C9*2 or *3. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the time to therapeutic INR.
1447672633	*2	Patients with CYP2C9*2 may require shorter time to therapeutic INR when treated with warfarin as compared to patients with CYP2C9*1/*1. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the time to therapeutic INR.
1447672634	*3	Patients with CYP2C9*3 may require shorter time to therapeutic INR when treated with warfarin as compared to patients with CYP2C9*1/*1. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the time to therapeutic INR.
1446900187	CTA/CTA	Patients with the CTA/CTA diplotype and tuberculosis who are treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin may have an increased risk of developing drug induced hepatitis as compared to patients with the TTA/TTA diplotype. Other clinical and genetic factors may also influence risk of drug-induced hepatitis in patients on an anti-tuberculosis drug regiment.
1446900188	CTA/TCG	Patients with the CTA/TCG diplotype and tuberculosis who are treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin may have an increased risk of developing drug induced hepatitis as compared to patients with the TTA/TTA diplotype. Other clinical and genetic factors may also influence risk of drug-induced hepatitis in patients on an anti-tuberculosis drug regiment.
1446900189	CTA/TTA	Patients with the CTA/TTA diplotype and tuberculosis who are treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin may have an increased risk of developing drug induced hepatitis as compared to patients with the TTA/TTA diplotype. Other clinical and genetic factors may also influence risk of drug-induced hepatitis in patients on an anti-tuberculosis drug regiment.
1446900190	TCG/TCG	Patients with the TCG/TCG diplotype and tuberculosis who are treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin may have an increased risk of developing drug induced hepatitis as compared to patients with the TTA/TTA diplotype. Other clinical and genetic factors may also influence risk of drug-induced hepatitis in patients on an anti-tuberculosis drug regiment.
1446900191	TCG/TTA	Patients with the TCG/TTA diplotype and tuberculosis who are treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin may have an increased risk of developing drug induced hepatitis as compared to patients with the TTA/TTA diplotype. Other clinical and genetic factors may also influence risk of drug-induced hepatitis in patients on an anti-tuberculosis drug regiment.
1445402368	AA	Patients with the AA genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.
1445402369	AG	Patients with the AG genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.
1447953104	AA	Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
1447953105	AG	Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
1447953106	GG	Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
1449171450	AA	Patients with the AA genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1449171451	AG	Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1449171452	GG	Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1447959754	AA	Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959755	AG	Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1445402370	GG	Patients with the GG genotype may have increased glucuronidation of anastrozole as compared to patients with the AA or AG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.
1444667074	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have an increased response when treated with captopril as compared to patients with the del/del genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient's response to captopril.
1444667075	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have an increased response when treated with captopril as compared to patients with the del/del genotype, or a decreased response compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient's response to captopril.
1444667076	del/del	Patients with the del/del genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient's response to captopril.
1449171923	AA	Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for nausea and/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and/or vomiting.
1449748825	CC	Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for allograft loss when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for allograft loss.
1449748826	CT	Patients with the CT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.
1449748827	TT	Patients with the TT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.
1444700791	CT	Patients with the CT genotype and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1444686773	CC	Patients with the CC genotype (CYP2C19 *1/*1) undergoing transplantation may have decreased metabolism of busulfan as compared to patients with the CT (*1/*17) or TT (*17/*17) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686774	CT	Patients with the CT (CYP2C19 *1/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686775	TT	Patients with the TT (CYP2C19 *17/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686791	GG	Patients with the GG genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a greater risk for side effects as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.
1444686792	GT	Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.
1444686793	TT	Patients with the TT genotype and chronic myeloid leukemia may have a 1) a poorer response to treatment with imatinib as compared to patients with the GG or GT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.
1444687048	AA	Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687049	AT	Patients with the AT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687050	TT	Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444700790	TT	Patients with the TT genotype and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1444704269	CC	Patients with the CC genotype and Colorectal Neoplasms who are treated with capecitabine may have decreased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
1444704270	CT	Patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
1444704271	TT	Patients with the TT genotype were not studied. However, patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
1444704361	CC	Patients with the CC genotype may have increased plasma level of lopinavir as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1444704362	CT	Patients with the CT genotype may have decreased plasma level of lopinavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1444704363	TT	Patients with the TT genotype may have decreased plasma level of lopinavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1450186408	CC	Patients with the CC genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have a reduced, but not absent risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CT or TT genotype. Patients may also tolerate higher doses of thiopurines and be less likely to discontinue thiopurine treatment as compared to patients with the CT or TT genotype, possibly due to the reduced risk for adverse effects. Other genetic and clinical factors may also influence a patient's risk for leukopenia, alopecia or treatment discontinuation.
1450186409	CT	Patients with the CT genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have an increased risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CC genotype. Patients may also require lower doses of thiopurines and be more likely to discontinue thiopurine treatment as compared to patients with the CC genotype, possibly due to the increased risk for adverse effects. Other genetic and clinical factors may also influence a patient's risk for leukopenia, alopecia or treatment discontinuation.
1444695405	*1/*3	Patients with the CYP2C19 *1/*3 genotype and epilepsy may have increased metabolism of N-desmethylclobazam, the principal metabolite of clobazam, as compared to patients with the *2/*2, *2/*3 or *3/*3 genotype, and decreased metabolism as compared to patients with the *1/*1 genotype. This decrease in metabolism may lead to a higher risk for adverse effects, but also a better response to treatment. Some studies also show an association with metabolism of clobazam. Other genetic and clinical factors may also influence metabolism of N-desmethylclobazam and clobazam.
1444695406	*2/*2	Patients with the CYP2C19 *2/*2 genotype and epilepsy may have decreased metabolism of N-desmethylclobazam, the principal metabolite of clobazam, as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. This decrease in metabolism may lead to a higher risk for adverse effects, but also a better response to treatment. Some studies also show an association with decreased metabolism of clobazam. Other genetic and clinical factors may also influence metabolism of N-desmethylclobazam and clobazam.
1444695407	*2/*3	Patients with the CYP2C19 *2/*3 genotype and epilepsy may have decreased metabolism of N-desmethylclobazam, the principal metabolite of clobazam, as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. This decrease in metabolism may lead to a higher risk for adverse effects, but also a better response to treatment. Some studies also show an association with decreased metabolism of clobazam. Other genetic and clinical factors may also influence metabolism of N-desmethylclobazam and clobazam.
1444695408	*3/*3	Patients with the CYP2C19 *3/*3 genotype and epilepsy may have decreased metabolism of N-desmethylclobazam, the principal metabolite of clobazam, as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. This decrease in metabolism may lead to a higher risk for adverse effects, but also a better response to treatment. Some studies also show an association with decreased metabolism of clobazam. Other genetic and clinical factors may also influence metabolism of N-desmethylclobazam and clobazam.
1444704078	CC	Patients with the CC genotype may have increased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704077	CT	Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704076	TT	Patients with the TT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704136	AA	Patients with the AA genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704137	AG	Patients with the AG genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype or may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704138	GG	Patients with the GG genotype and Hypertension may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704145	CC	Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444704144	CT	Patients with the CT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype or may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444704143	TT	Patients with the TT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444843386	AA	Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT or AT. Other genetic and clinical factors may also influence the response to methotrexate.
1444843385	AT	Patients with the AT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.
1444843384	TT	Patients with the TT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.
1444843393	AA	Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.
1444843392	AG	Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.
1444843391	GG	Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.
1444843406	AA	Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.
1444668404	CC	Patients with the CC genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1444668405	CT	Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1444668406	TT	Patients with the TT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1449165713	*1A/*1A	Patients with the *1A/*1A genotype who have received a kidney transplant may have decreased concentrations of cyclosporine as compared to patients with the *3A/*3A genotype. Other genetic and clinical factors may also affect concentrations of cyclosporine.
1446898336	CC	Patients with the CC genotype who are smokers may have a lower chance of smoking cessation when treated with bupropion as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.
1446898337	CT	Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.
1445400941	GG	Patients with the GG genotype and schizophrenia or schizoaffective disorder may have greater weight gain when treated with clozapine or olanzapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1446899212	*1/*4	Patients with the CYP2D6*1/*4 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have an increased risk of side effects, 2) may require a decreased dose of drug compared to patients with CYP2D6*1/*1 or 1) may have a decreased, but not absent, risk for side effects, 2) may require an increased dose of drug compared to patients with CYP2D6*4/*4. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.
1448106523	TT	Patients with the TT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1449165167	GG	Patients with the GG genotype may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the AA or AG genotype. However, conflicting evidence exists for these associations. Other genetic and clinical factors may also influence methotrexate toxicity.
1446899213	*4/*4	Patients with the CYP2D6*4/*4 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have an increased risk of side effects, 2) may require a decreased dose of drug compared to patients with CYP2D6*1/*1. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.
1446897481	AC	Patients with the AC genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype, or a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1446897482	CC	Patients with the CC genotype who are treated with valproic acid may have a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1446898338	TT	Patients with the TT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.
1448106527	CC	Patients with the CC genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106528	CT	Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106529	TT	Patients with the TT genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1447960240	CC	Patients with the CC genotype may have a greater likelihood of being overanticoagulated when treated with phenprocoumon, and may require a decreased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.
1447960241	CT	Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.
1447960242	TT	Patients with the TT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.
1447960658	AA	Patients with the AA genotype and cirrhosis may have a greater decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
1444667989	CC	Patients with the CC genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.
1444667990	CT	Patients with the CT genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.
1444667991	TT	Patients with the TT genotype and cancer may have a poorer response to treatment with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to progression.
1447959756	GG	Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448100441	TT	Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1447960659	AC	Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
1448107279	CC	Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107280	CG	Patients with retinal disease and the CG genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the GG genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1450044480	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1444686909	AA	Patients with the AA genotype who are undergoing kidney transplantation may have lower dose-adjusted trough concentrations of cyclosporine, and have a greater likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.
1444686910	AG	Patients with the AG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.
1447960585	AC	Patients with the AC genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
1447960586	CC	Patients with the CC genotype and rheumatoid arthritis may have an increased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
1447960625	AA	Patients with the AA genotype may have poorer humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
1447960626	AC	Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
1447960627	CC	Patients with the CC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
1450044481	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448107205	TT	Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased, but not absent, risk for acute allograft rejection within 3 month after transplantation as compared to patients with the AA genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.
1449170466	AA	Patients with the AA genotype and cancer who are treated with granisetron or palonosetron may have a lower response and increased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.
1449170467	AC	Patients with the AC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.
1444704380	AA	Patients with the AA genotype may have increased resistance to etoposide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704381	AG	Patients with the AG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704382	GG	Patients with the GG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444694557	CC	No patients with the CC genotype were present in the population. However, patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444694558	CT	Patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444694559	TT	Patients undergoing liver transplantation who receive a donor liver with the TT genotype may require a decreased dose of tacrolimus as compared to patients who receive a donor liver with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.
1444700898	CC	Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
1444700899	CT	Patients with the CT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
1444700900	TT	Patients with the TT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
1449170468	CC	Patients with the CC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.
1449170808	*1/*1	Patients with CYP2C9*1/*1 may require less time to achieve stable dose when treated with warfarin as compared to patients with CYP2C9*2, *3 or *13. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.
1444704389	AA	Patients with the AA genotype and Hypertension may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704388	AT	Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype or may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704387	TT	Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704394	AA	Patients with the AA genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1444704395	AG	Patients with the AG genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1444704396	GG	Patients with the GG genotype and Alcoholism may have decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1444704404	AA	Patients with the AA genotype and Parkinson Disease may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
1444704403	AG	Patients with the AG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype or may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
1444703641	AA	Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703642	AT	Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703643	TT	Patients with the TT genotype may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703672	CC	Patients with the CC genotype may have increased risk for neutropenia when treated with gemcitabine as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444703671	CT	Patients with the CT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444703670	TT	Patients with the TT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444843405	AG	Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.
1444843404	GG	Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.
1444934609	AA	Patients with the AA genotype and Kidney Transplantation may have decreased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
1444934610	AC	Patients with the AC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
1444934611	CC	Patients with the CC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
1448634750	TT	Patients with the TT genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the CT and CC genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.
1448634890	CC	Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for each of the CC, CT, and TT genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.
1444930644	CC	Patients with genotype CC may have increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1444930645	CT	Patients with genotype CT may have decreased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1444930646	TT	Patients with genotype TT may have decreased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1448634891	CT	Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for each of the CC, CT, and TT genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.
1448634892	TT	Patients with TT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for each of the CC, CT, and TT genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.
1449155645	CC	Patients with the CC genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155646	CT	Patients with the CT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155647	TT	Patients with the TT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1444686978	CC	Patients with the CC genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686979	CT	Patients with the CT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686980	TT	Patients with the TT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686985	AA	Patients with the AA genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686986	AG	Patients with the AG genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686987	GG	Patients with the GG genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686992	AA	Patients with the AA genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686993	AG	Patients with the AG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686994	GG	Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686999	CC	Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687000	CG	Patients with the CG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687001	GG	Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687008	CC	Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687006	CT	Patients with the CT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687007	TT	Patients with the TT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1449155651	AA	Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155652	AT	Patients with the AT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155653	TT	Patients with the TT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1444687027	AA	Patients with the AA genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687028	AG	Patients with the AG genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687029	GG	Patients with the GG genotype and inflammatory bowel diseases may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1449155641	GG	Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1447945032	CC	Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.
1447945033	CG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.
1447945034	GG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.
1449002818	CC	Patients with the CC genotype may have increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
1449005463	AA	Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.
1449005464	AG	Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study.  Other genetic and clinical factors may also influence response to imatinib.
1448106033	GG	Genotype GG may be associated with increased disease control rate and increased overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.
1448106070	AA	Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.
1448106071	AC	Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.
1448106072	CC	Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz
1450180286	AA	Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.
1448612666	TT	Patients with the TT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
1450180287	AG	Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.
1450180288	GG	Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.
1449005465	GG	Patients with the GG genotype and chronic myeloid leukemia may have a better response to imatinib treatment as compared to patients with the AA or AG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.
1448602112	CC	People who smoke and have the CC genotype may have decreased clearance and increased exposure to cotinine compared to people with the AA and AC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
1449140067	TT	Patients with the TT genotype and bladder cancer may have decreased metabolism of temsirolimus as compared to patients with the CC or CT genotypes, and an decreased likelihood of adverse events  including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.
1449003265	AA	Patients with the AA genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.
1449003266	AG	Patients with the AG genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.
1449003267	GG	Patients with the GG genotype may have decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.
1447953173	AA	Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953174	AG	Patients with the AG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953175	GG	Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953180	AA	Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953181	AG	Patients with the AG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953182	GG	Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953219	GG	Patients with the GG genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1447953220	GT	Patients with the GT genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1447953221	TT	Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1447953225	GG	Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953226	GT	Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953227	TT	Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953231	AA	Patients with autism spectrum disorder (ASD), or mood disorders and the AA genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.
1447953232	AG	Patients with autism spectrum disorder (ASD), or mood disorders and the AG genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype; patients with the AG genotype may have an increased likelihood of weight gain as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.
1447953233	GG	Patients with autism spectrum disorder (ASD), or mood disorders and the GG genotype may have an increased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the AG or AA genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.
1447953237	AA	Patients with the AA genotype who are treated with atorvastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447953238	AC	Patients with the AC genotype who are treated with atorvastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447953239	AT	Patients with the AT genotype who are treated with atorvastatin may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447947087	GG	Patients with the GG genotype who are treated with atorvastatin may have an increased response to treatment and a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1448100780	CT	Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the TT genotype, and decreased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448100781	TT	Patients with the TT genotype may have decreased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448100788	CC	Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448100789	CT	Patients with the CT genotype may have decreased clearance of midazolam as compared to patients with the TT genotype, and increased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448100790	TT	Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448107531	(CCCACCCGA)12/(CCCACCCGA)10	Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107532	(CCCACCCGA)12/(CCCACCCGA)12	Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with fluoxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107533	(CCCACCCGA)12/(CCCACCCGA)9	Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448101241	CT	Patients with the CT genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.
1448101242	TT	Patients with the TT genotype and HIV may have a decreased risk for neuropathy when treated with stavudine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.
1448101273	AA	Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101274	AT	Patients with the AT genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101275	TT	Patients with the TT genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101280	CC	Patients with the CC genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101281	CG	Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101282	GG	Patients with the GG genotype may have a decreased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1449190668	TT	Patients without an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely to have decreased response rate (RR) and decreased progression-free survival (PFS) time compared to patients who have activating somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568. Patients who have no mutation are presented here as TT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1447944884	AA	Patients with genotype AA and schizophrenia may have decreased response to antipsychotics compared to patients with AC or CC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
1447944885	AC	Patients with genotype AC and schizophrenia may have increased response to antipsychotics compared to patients with AA genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
1447944886	CC	Patients with genotype CC and schizophrenia may have increased response to antipsychotics compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
1447944821	CC	Patients with the CC genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
1447944822	CT	Patients with the CT genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
1447944823	TT	Patients with the TT genotype and depressive disorder may have an increased response to fluvoxamine compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
1449166744	*92	Patients with the CYP2D6*92 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele construct was found catalytically inactive during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166745	*93	Patients with the CYP2D6*93 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1448999177	*1/*1	Patients with the CYP2D6*1/*1 genotype who are treated with clomipramine may have 1) a decreased, but not absent, risk for side effects as compared to patients with the CYP2D6*4 allele, 2) increased plasma concentration of clomipramine and desmethyl clomipramine as compared to patients with a duplication of a functional CYP2D6 gene, 3) decreased plasma concentration of clomipramine and desmethyl clomipramine as compared to patients with two non-functional CYP2D6 alleles. The number of studies for clomipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1448999178	*1/*1xN	Patients with a duplication of a functional CYP2D6 gene may have decreased plasma concentration of clomipramine and desmethyl clomipramine when treated with clomipramine as compared to patients with the CYP2D6*1/*1 genotype. The number of studies for clomipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1448999179	*2/*2	Patients with the CYP2D6*1/*1 genotype who are treated with clomipramine may have 1) a decreased, but not absent, risk for side effects as compared to patients with the CYP2D6*4 allele, 2) increased plasma concentration of clomipramine and desmethyl clomipramine as compared to patients with a duplication of a functional CYP2D6 gene, 3) decreased plasma concentration of clomipramine and desmethyl clomipramine as compared to patients with two non-functional CYP2D6 alleles. The number of studies for clomipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1447944857	CC	Patients with the CC genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
1447944858	CG	Patients with the CG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
1447944859	GG	Patients with the GG genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the CC or CG genotypes. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
1448102276	*1/*10	CYP2D6 *1/*10 is associated with decreased inhibition of CYP2D6 when exposed to berberine and coptisine and increased exposure to dextromethorphan as compared to the *1/*1 genotype. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.
1448102277	*10/*10	CYP2D6 *10/*10 is associated with decreased inhibition of CYP2D6 when exposed to berberine and coptisine and increased exposure to dextromethorphan as compared to the *1/*1 genotype. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.
1448102275	*1/*1	CYP2D6 *1/*1 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine and decreased exposure to dextromethorphan as compared to the *1/*10 or *10/*10 genotypes. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.
1449166746	*94	Patients with the CYP2D6*94 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166747	*95	Patients with the CYP2D6*95 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1448106274	AA	Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106275	AG	Patients with the AG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype, or an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106276	GG	Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106280	CC	Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106281	CT	Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106282	TT	Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1448106394	GG	Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106395	GT	Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106396	TT	Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106400	GG	Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106401	GT	Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106402	TT	Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28.Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106406	AA	Patients with HIV and the AA genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106407	AC	Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1447953240	CC	Patients with the CC genotype who are treated with atorvastatin may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447953241	TT	Patients with the TT genotype who are treated with atorvastatin may have a better  response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447953272	AA	Patients with the AA genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.
1447953273	AG	Patients with the AG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.
1447953274	GG	Patients with the GG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.
1447953279	AA	Patients with the AA genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
1447953280	AG	Patients with the AG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
1447953281	GG	Patients with the GG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
1447953313	AA	Patients with the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953314	AG	Patients with the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953315	GG	Patients with the GG genotype may have an increased response to risperidone as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447986904	AA	Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447986905	AG	Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447986906	GG	Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447953335	AA	Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of  neutropenia when treated with lenalidomide.
1447953336	AG	Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of  neutropenia when treated with lenalidomide.
1447953337	GG	Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of  neutropenia when treated with lenalidomide.
1447953342	AA	Patients with the AA genotype and multiple myeloma may have an increased response to thalidomide as compared to patients with the AC and CC genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with genotypes AC and CC. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.
1447953343	AC	Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.
1447681872	CT	Post-menopausal women with breast cancer and the CT genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the TT genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.
1447681873	TT	Post-menopausal women with breast cancer and the TT genotype who are taking letrozole, with or without a statin, may have increased plasma concentrations of triglycerides as compared to women with the CT and CC genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.
1447681878	CC	Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1447681879	CT	Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1447681880	TT	Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1449166767	*1	Patients with the CYP2D6*1 allele may have increased clearance of tamoxifen as compared to patients with the CYP2D6*10 or *87 or *90 or *91 or *93 or *95 or *98 allele. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1449166768	*10	Patients with the CYP2D6*10 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1449166770	*90	Patients with the CYP2D6*90 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1447814187	AA	Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1447814188	AG	Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1447814189	GG	Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1447946006	CC	Patients with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a smaller drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447946007	CT	Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447946008	TT	Patients with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1448106423	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1449166769	*87	Patients with the CYP2D6*87 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1448101450	AA	Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1448106418	AA	Patients with nasopharyngeal cancer and the AA genotype may have less severe anemia and neutropenia as compared to patients with the AG genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448106419	AG	Patients with nasopharyngeal cancer and the AG genotype may have more severe anemia and neutropenia as compared to patients with the AA genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448106429	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1447980970	AA	Patients with the AA genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.
1447980971	AG	Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.
1447980972	GG	Patients with the GG genotype and Type 2 Diabetes may have decreased response to metformin compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affects response to metformin.
1448106430	CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1447964350	GG	Patients with the GG genotype and stomach cancer may have better poorer survival outcomes when treated with fluorouracil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival outcome.
1448106431	TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448106582	TT	Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448106632	CC	Patients with the CC genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype. Other genetic and clinical factors may also influence body mass index.
1447981277	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981278	CT	Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981279	TT	Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981374	CC	Patients with the CC genotype and cancer may have increased clearance of 2',2'-; difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.
1447981375	CT	Patients with the CT genotype and cancer may have decreased clearance of 2',2'-; difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.
1447981376	TT	No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'-; difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.
1447981380	CC	Patients with the CC genotype and cancer may have longer overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have decreased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the TT genotype. Other genetic and clinical factors may also influence survival times.
1447981381	CT	Patients with the CT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
1447981382	TT	Patients with the TT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Patients with the TT genotype may also have increased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the CC genotype.Other genetic and clinical factors may also influence survival times.
1448106408	CC	Patients with HIV and the CC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106647	AA	Patients with the AA genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of busulfan.
1448106648	AC	Patients with the AC genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.
1448106649	CC	Patients with the CC genotype and acute myeloid leukemia may have increased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.
1448106670	AA	Patients with the AA genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
1448106671	AG	Patients with the AG genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
1448106672	GG	Patients with the GG genotype and schizophrenia may have an increased likelihood of obesity when treated with olanzapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
1448106711	CC	Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1448106712	CT	Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1448106713	TT	Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1448106751	AA	Patients with the AA genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.
1448106752	AC	Patients with the AC genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.
1448106753	CC	Patients with the CC genotype and schizophrenia may have an increased risk for weight gain when treated with antipsychotics as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.
1448106761	CC	Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448106762	CT	Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448106763	TT	Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1448107492	(CCCACCCGA)12/(CCCACCCGA)9	Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107493	(CCCACCCGA)9/(CCCACCCGA)9	Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1447953344	CC	Patients with the CC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.
1447953349	CC	Patients with the CC genotype may have increased response to risperidone as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953350	CG	Patients with the CG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953351	GG	Patients with the GG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447959734	CT	Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype, or a decreased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959733	TT	Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1449564644	CC	Patients with the CC genotype (CYP3A5 *3/*3) may require a lower dose of cyclosporine to reach target blood concentration as compared to patients with the CT (CYP3A5 *1/*3) or TT (CYP3A5 *1/*1) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.
1449564645	CT	Patients with the CT (CYP3A5 *1/*3) genotype may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.
1447960213	AA	Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1447960214	AG	Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1447960215	GG	Patients with the GG genotype and non-small-cell lung cancer may have a better response to platinum-based chemotherapy as compared to patients with the AA or AG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1448106288	CC	Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1448106289	CG	Patients with the CG genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1448104341	CC	Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.
1448104342	CT	Patients with the TC genotype and HIV who are treated with ritonavir may have higher triglyceride (increased risk of Hypertriglyceridemia) levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448104343	TT	Patients with the TT genotype and HIV who are treated with ritonavir may have higher triglyceride levels (increased risk of Hypertriglyceridemia) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448106290	GG	Patients with the GG genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1448101451	AC	Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1448101452	CC	Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1183618205	AA	Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183618206	AG	Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183618207	GG	Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1448100041	CC	Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.
1448100042	CT	Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.
1448100043	TT	Patients with the TT genotype may have decreased plasma drug concentrations of particular statins as compared to patients with the CC or CT genotype. For some statins this is associated with decreased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.
1448102409	CC	Patients with the CC genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
1448102410	CT	Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
1448102411	TT	Patients with the TT genotype and HIV may have decreased cognitive impairment when taking methamphetamines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
1448102426	ATTTGTTCATGCCT/ATTTGTTCATGCCT	Patients with depressive disorder and the ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.
1448102425	del/ATTTGTTCATGCCT	Patients with depressive disorder and the del/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.
1448102424	del/del	Patients with depressive disorder and the del/del genotype may have an improved response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.
1448102441	AA	Patients with the AA genotype and hepatitis C or HIV may have a better response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102442	AG	Patients with the AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102443	GG	Patients with the GG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1445402423	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1445402424	AG	Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1445402425	GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1447943660	AA	Patients with the AA genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine .
1447943661	AG	Patients with the AG genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.
1447943662	GG	Patients with the GG genotype and Alzheimer's disease may have decreased response to galantamine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.
1447983820	AA	Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447983821	AG	Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447983822	GG	Patients with the GG genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447981393	AA	Patients with the AA genotype and cancer may have increased clearance of gemcitabine, and decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.
1447981394	AG	Patients with the AG genotype and cancer may have increased clearance of gemcitabine as compared to patients with the GG genotype, or decreased clearance as compared to patients with the AA genotype. Patients may also have decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to those with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.
1447981395	GG	Patients with the GG genotype and cancer may have decreased clearance of gemcitabine as compared to patients with the AA genotype, and increased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.
1448124244	AA	Patients with the AA genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124245	AG	Patients with the AG genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448107483	TT	Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448124218	TT	Patients with the TT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124246	GG	Patients with the GG genotype may have decreased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448106633	CT	Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.
1448106634	TT	Patients with the TT genotype who smoke tobacco may have a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.
1447987025	AA	Patients with the AA genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.
1447987026	AG	Patients with the AG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.
1447987027	GG	Patients with the GG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have decreased metabolism of efavirenz as compared to patients with the AA or AG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.
1448108073	AG	Subjects with AG genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.
1448108074	GG	Subjects with GG genotypes may have decreased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with AA genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.
1448109573	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448107874	A/del	Patients with the A/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448107875	AA	Patients with the A/A genotype who are treated with clopidogrel may have an average catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448107876	del/del	Patients with the del/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448107924	CC	Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448107925	CT	Patients with the CT genotype and schizophrenia who are treated with risperidone may be more likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448107926	TT	Patients with the TT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448108239	CC	Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1448108240	CT	Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1448108241	TT	Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
1448108072	AA	Subjects with AA genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.
1448109574	GT	Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109575	TT	Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109581	GT	Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109582	TT	Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1447961138	AA	Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961139	AG	Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961140	GG	Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961146	CC	Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961147	CT	Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961148	TT	Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961153	CC	Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961154	CT	Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961155	TT	Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961160	CC	Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961161	CT	Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961162	TT	Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961196	CC	Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.
1447961197	CT	Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.
1447961198	TT	Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.
1447962631	AA	Patients with the AA genotype and stomach cancer may have increased metabolism of tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447962630	AG	Patients with the AG genotype and stomach cancer may have decreased metabolism of tegafur as compared to patients with the AA genotype, or increased metabolism as compared to patients with the GG gentoype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447962629	GG	Patients with the GG genotype and stomach cancer may have decreased metabolism of tegafur as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447962705	AA	Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962706	AG	Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962707	GG	No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962746	CC	Patients with the CC genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962747	CT	Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962748	TT	Patients with the TT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC genotype, or a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447682295	AA	Post-menopausal women with breast cancer and the AA genotype may have increased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.
1447682296	AC	Post-menopausal women with breast cancer and the AC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AA genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.
1447682297	CC	Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or AA genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.
1449167197	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167198	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167207	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167208	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167209	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167193	GT	Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167194	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1448604319	CT	Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.
1449732172	AA	Patients with the AA genotype (DPYD *1/*1) and cancer who are treated with fluorouracil may have 1) a decreased but not absent risk for drug toxicities, 2) increased response, 3) increased clearance of fluorouracil and 4) decreased DPYD activity as compared to patients with the AG or GG genotypes (DPYD *1/*9A or *9A/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448102624	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2	Patients with the 2R/2R genotype and colorectal cancer may have a decreased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/3R or 3R/3R genotype. Other genetic and clinical factors may also influence risk of asthenia.
1448102625	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Patients with the 2R/3R genotype and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.
1448102626	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Patients with the 3R/3R genotype and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.
1448106307	CT	Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT  genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1448106308	TT	Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1447984149	AC	Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447984150	CC	Patients with the CC genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447984327	*51:01:01	Patients with one or two copies of the HLA-B*51:01:01 allele have an increased risk of Stevens-Johnson Syndrome when treated with phenobarbital as compared to patients with no HLA-B*51:01:01 alleles or negative for the HLA-B*51:01:01 test.
1447987206	CC	Patients with diabetes mellitus and the CC genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987207	CG	Patients with diabetes mellitus and the CG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987208	GG	Patients with diabetes mellitus and the GG genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1448112609	AA	Patients with the AA genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112610	AC	Patients with the AC genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112611	CC	Patients with the CC genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AC genotypes. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112616	CC	Patients with the CC genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1447984148	AA	Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1448112087	AA	Patients with the AA genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AC or CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone.  A single study reported its association with response to latanoprost by comparing the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.
1448112088	AC	Patients with the AC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype AA and a decreased response compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.
1448112056	GG	Patients with the GG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
1448112602	AA	Patients with the AA genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112603	AG	Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112604	GG	Patients with the GG genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AG genotypes. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112617	CT	Patients with the CT genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448108116	TT	Advanced non-small-cell lung cancer patients with TT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.
1448108949	CC	Patients with the CC genotype may have Increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1448108950	CT	Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1450361628	AT	Patients with the AT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450361629	CC	Patients with the CC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1449157280	CC	African-American patients with the CC genotype may have a decreased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CT or TT genotypes. This association was not seen in European-American patients. Response to buprenorphine treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to buprenorphine.
1448108897	CG	Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
1448108898	GG	Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
1448108951	TT	Patients with the TT genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1043880395	TT	Patients with the TT genotype may require increased dose of warfarin  in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.
1449002819	TC	Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
1449002820	TT	Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
1448099845	CC	Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.
1448099846	CT	Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.
1448099847	TT	Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.
1449157291	CT	African-American patients with the CT genotype may have an increased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.
1449157292	TT	African-American patients with the TT genotype may have an increased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.
1447943762	AA	Patients with AA genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AG and GG genotype. Other clinical and genetic factors may affect response to antipsychotics.
1447943763	AG	Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.
1447943764	GG	Patients with GG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.
1447943774	CC	Patients with genotype CC and hypertension have increased response to atenolol compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect patient response to atenolol.
1447943775	CT	Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol.
1447943776	TT	Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol.
1447982734	GG	Patients with the GG genotype and asthma who are treated with corticosteroids may have an increased response to corticosteroids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447982735	GT	Patients with the GT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447982736	TT	Patients with the TT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447982743	CC	Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982742	CT	No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982741	TT	Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982747	AA	Patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982748	AG	No information are available for the AG genotype. However, patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982749	GG	Patients with the GG genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982758	CC	Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982757	CT	No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982756	TT	Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982765	CC	Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982764	CT	No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982763	TT	Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982770	AA	Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1447982771	AG	Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1448102661	AA	Patients with the AA genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102662	AC	Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102663	CC	Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102668	AA	Patients with the AA genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.
1448102669	AC	Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.
1448102670	CC	Patients with the CC genotype and non-small-cell lung cancer may have an increased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for disease progression.
1449564683	G/TT	Patients with the G/TT genotype and Hepatitis C, genotype 1 may have decreased response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with TT/TT genotype. Please note: this SNP has been found to be in high LD with rs12979860, and in one case rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy.
1449564684	GG	Patients with the G/G genotype and Hepatitis C, genotype 1 may have decreased response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with TT/TT genotype. Please note: this SNP has been found to be in high LD with rs12979860, and in one case rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy.
1449564685	TT/TT	Patients with the TT/TT genotype and Hepatitis C, genotype 1 may have improved response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with G/TT or G/G genotypes. Please note: this SNP has been found to be in high LD with rs12979860, and in one case rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy.
1448106340	CC	Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448106341	CT	Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448106342	TT	Women with ovarian cancer and the TT genotype may have an increased  likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448106366	GG	Patients with ovarian cancer and the GG genotype may have a decreased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the CC or CG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.
1448106370	CC	Patients with lupus and the CC genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.
1448106371	CT	Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.
1449144300	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144301	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449565288	(TA)6/(TA)6	In human liver microsomes, the (TA)6/(TA)6 genotype was found to result in the increased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the (TA)7/(TA)7 genotype.
1449144122	*1	Postoperative patients who carry at least one copy of the SLC22A1*1 allele may have increased tramadol consumption over the first 24 hours following surgery as compared to patients with no SLC22A1*1 alleles. Other genetic and clinical factors may also influence a patient's tramadol dosing following surgery.
1448097720	CC	Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.
1448097721	CT	Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.
1448097722	TT	Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.
1449565780	*16	Patients carrying the CYP2C9*16 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565781	*19	Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565782	*27	Patients carrying the CYP2C9*27 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1448097683	AA	The AA genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
1448097684	AC	The AC genotype may be associated with increased CYP4F2 activity and decreased vitamin e metabolism as compared to the AA genotype and decreased metabolism as compared to the CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
1448097685	CC	The CC genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or AA genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
1446897774	*1/ *2 (PMID: 11503014)	Patients with renal cell carcinoma and the *1/*2 (PMID: 11503014) diplotype may have an increased risk of neutropenia when treated with sunitinib as compared to individuals with any the *1/*2 (PMID: 11503014) or *1/*1 diplotype. Other clinical or genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are taking sunitinib.
1448112618	TT	Patients with the TT genotype and bladder cancer may have an increased response to cisplatin-based therapies compared to patients with the CC and CT genotypes. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1449144294	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144295	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144296	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449565289	(TA)7/(TA)7	In human liver microsomes, the (TA)7/(TA)7 genotype was found to result in the decreased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the (TA)6/(TA)6 genotype.
1448109607	CC	Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CT or TT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109608	CT	Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1447749019	AA	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1447749020	AG	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1447749021	GG	Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose.
1183491451	AA	Patients with the AA genotype may have a lower risk of coronary disease and may be less likely to benefit from atorvastatin treatment as compared to patients with the AG or GG genotype. However, one study has contradicted this observation. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491452	AG	Patients with the AG genotype may have a higher risk of coronary disease and may be more likely to benefit from atorvastatin treatment as compared to patients with the AA genotype. However, one study has contradicted this observation. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491453	GG	Patients with the GG genotype may have a higher risk of coronary disease and may be more likely to benefit from atorvastatin treatment as compared to patients with the AA genotype. However, one study has contradicted this observation. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1448109609	TT	Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or CT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1183615106	*1/*1	Healthy individuals with the CYP2C9 *1/*1 genotype may have increased metabolism of losartan as compared to patients with the *1/*3, *1/*5, *1/*6, *5/*6, *5/*8, or *1/*13 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1183491459	AA	Patients with the AA genotype may have a lower risk of coronary disease and may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491460	AG	Patients with the AG genotype may have a higher risk of coronary disease and may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491461	GG	Patients with the GG genotype may have a higher risk of coronary disease and may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1448112054	CC	Patients with the CC genotype and anxiety disorder or major depression may have increased risk of becoming agitated when taking citalopram compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
1183615107	*1/*13	Healthy individuals with the CYP2C9 *1/*13 genotype may have decreased metabolism of losartan as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1448112055	CG	Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
1183615108	*1/*3	Healthy individuals with the CYP2C9 *1/*3 genotype may have decreased metabolism of losartan as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1183615109	*1/*5	Healthy individuals with the CYP2C9 *1/*5 genotype may have decreased metabolism of losartan as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1183615110	*1/*6	Healthy individuals with the CYP2C9 *1/*6 genotype may have decreased metabolism of losartan as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1183615111	*5/*6	Healthy individuals with the CYP2C9 *5/*6 genotype may have decreased metabolism of losartan as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1183615112	*5/*8	Healthy individuals with the CYP2C9 *5/*8 genotype may have decreased metabolism of losartan as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of losartan.
1447983174	AA	Patients with the AA genotype may have a decreased response to topiramate as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448995368	*1/*3	Patients with the *1/*3 genotype and bipolar disorder and other psychotic disorders may have decreased dose of valproic acid compared to patients with the *1/*1 genotype. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.
1447961126	TT	Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1448525752	*38:01:01	Patients with one or two copies of the HLA-B*38:01 allele who are treated with lamotrigine may have an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to patients with no HLA-B*38:01 alleles or negative for the HLA-B*38:01 test. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.
1447982772	GG	Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1447983173	AC	Patients with the AC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983172	CC	Patients with the CC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983971	*1/*1	Patients with the *1/*1 diplotype and acute myeloid leukemia may have a decreased response to cytarabine, daunorubicin, and dexarazoxane as compared to the *1/*2 (PMID: 11503014) or the *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotypes. Other clinical and genetic factors may also influence to cytarabine, dexarazoxane, or daunorubicin in patients with acute myeloid leukemia.
1447983972	*1/*2 (PMID: 11503014)	Patients with the *1/*2 diplotype and acute myeloid leukemia may have a decreased response to cytarabine, daunorubicin, and dexarazoxane as compared to the *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotype and increased response as compared to the *1/*1 diplotype. Other clinical and genetic factors may also influence to cytarabine, dexarazoxane, or daunorubicin in patients with acute myeloid leukemia.
1447983973	*2 (PMID: 11503014)/*2 (PMID: 11503014)	Patients with the *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotype and acute myeloid leukemia may have a increased response to cytarabine, daunorubicin, and dexarazoxane as compared to the *1/*2 (PMID: 11503014) or the *1/*1 diplotypes. Other clinical and genetic factors may also influence to cytarabine, dexarazoxane, or daunorubicin in patients with acute myeloid leukemia.
1447986912	AA	Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447986913	AG	Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447986914	GG	Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447990920	AG	The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the GG genotypes and decreased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
1448097824	AA	Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
1447990921	GG	The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
1448106372	TT	Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.
1448106424	AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448106425	GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448107534	(CCCACCCGA)9/(CCCACCCGA)9	Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448613040	AA	People with the AA genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613041	AG	People with the AG genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613042	GG	People with the GG genotype may have increased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448633941	AA	Patients with the AA genotype and  who are treated with warfarin may require increased dose as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.
1448633942	AG	Patients with the AG genotype and  who are treated with warfarin may require increased dose as compared to patients with the GG genotypes and decreased dose as compared to those with the AA genotype. Other clinical and genetic factors may also influence dose of warfarin.
1448633943	GG	Patients with the GG genotype and  who are treated with warfarin may require decreased dose as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence dose of warfarin.
1449161123	CC	Patients with the CC genotype may have a decreased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.
1449161124	CT	Patients with the CT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.
1449161125	TT	Patients with the TT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.
1448107630	CC	Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.
1448613034	AA	People with the AA genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613035	AG	People with the AG genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613036	GG	People with the GG genotype may have decreased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.
1449161711	AA	Patients with the AA genotype who are treated with naltrexone may have a decreased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AG or GG genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1449161712	AG	Patients with the AG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1446896598	AA	Patients with the AA genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
1446896599	AG	Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
1446896600	GG	Patients with the GG genotype may have decreased concentrations of erlotinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
1447814182	CC	Patients with the CC genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1447814181	CG	Patients with the CG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1447814180	GG	Patients with the GG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1447960747	CC	Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960748	CT	Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960749	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960777	CC	Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960778	CT	Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960779	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1448107547	(CCCACCCGA)12/(CCCACCCGA)9	Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107548	(CCCACCCGA)9/(CCCACCCGA)9	Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107546	(CCCACCCGA)12/(CCCACCCGA)12	Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with antidepressants 1) may have an increased risk of adverse drug reactions after switching treatment for the second time 2) may be more likely to have a lack of a response to treatment as compared to other genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.
1447990504	CC	Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1447990505	CT	Patients with the CT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1447990506	TT	Patients with the TT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1447962623	CT	Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.
1447962624	TT	Patients with the TT genotype may have a greater increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.
1447962775	AA	Patients with the AA genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962776	AG	Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962777	GG	Patients with the GG genotype and hypercholesterolemia who have high baseline HDL levels may have a smaller increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962857	AA	Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.
1447962858	AG	Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.
1447962859	GG	Patients with the GG genotype and hypercholesterolemia may have an increased risk for myalgia when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.
1447962886	AA	Patients with the AA genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
1447962887	AG	Patients with the AG genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
1447962888	GG	Patients with the GG genotype and pancreatic cancer or HIV may have increased metabolism and decreased concentrations of nelfinavir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
1447962929	*27	The CYP2B6*27 allele may result in decreased expression and enzymatic activity of CYP2B6, as compared to the CYP2B6*1 allele. A patient with the *6/*27 genotype who was treated with efavirenz was noted to have had a dose reduction/stoppage of therapy.
1447962930	*28	The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6/*28 genotype who was treated with efavirenz was noted to have had a dose reduction/stoppage of therapy and experienced efavirenz toxicity.
1447987082	AA	Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987083	AG	Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1448108896	CC	Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
1448108852	GG	Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
1447987084	GG	No patients with the GG genotype were available for analysis, but patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1448108861	CC	Patients with the CC genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.
1448108862	CT	Patients with the CT genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.
1448108863	TT	Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.
1447949634	CC	Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949635	CT	Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949636	TT	Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1446908536	GG	Patients with an activating somatic EGFR mutation are presented in this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with erlotinib vs standard chemotherapy. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1446908537	GT	Patients with an activating somatic EGFR mutation are presented in this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with erlotinib vs standard chemotherapy. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1446908538	TT	Patients who have no activating somatic EGFR mutation were NOT included in these studies where this annotation is derived from. In this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients who have somatic mutation. Genotypes are not compared in this annotation.
1447962663	GG	Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962664	GT	Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962665	TT	Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962668	GG	Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962669	GT	Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962670	TT	Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447963671	TT	No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.
1449171466	*1A/*1A	Pediatric patients with the *1/*1 genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus as compared to patients with the *1/*1C or *1C/*1C genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.
1449171467	*1A/*1C	Pediatric patients with the *1/*1C genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.
1449171468	*1C/*1C	Pediatric patients with the *1C/*1C genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.
1447963862	CC	Patients with the CC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963863	CT	Patients with the CT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963864	TT	Patients with the TT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447964144	CTT/CTT	Patients with the CTT/CTT genotype and cystic fibrosis may not respond when treated with cysteamine as compared to patients with the CTT/del or del/del genotypes. Other genetic and clinical factors may also influence the efficacy of cysteamine.
1447964145	CTT/del	Patients with the CTT/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.
1447964146	del/del	Patients with the del/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.
1448108022	AA	Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
1447964280	AA	Patients with the AA genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964281	AG	Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964282	GG	Patients with the GG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964326	CC	Patients with the CC genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
1447964327	CG	Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
1447964328	GG	Patients with the GG genotype and asthma may have a decreased risk of aspirin intolerance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
1448105602	CC	Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1448105603	CT	Patients with the CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1448105604	TT	Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.
1448105736	TT	Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448107631	CT	Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.
1448107632	TT	Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.
1448108023	AC	Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
1448108024	CC	Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.
1447961189	AA	No patients with the AA genotype are available for analysis, but patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.
1447961190	AC	Patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.
1447961191	CC	Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.
1447964513	*1/*1	Women with breast cancer and the CYP2C19 *1/*1 genotype who are treated with tamoxifen may have increased metabolism of tamoxifen, but a poorer response to the drug as compared to those with the *1/*2 or *2/*2 genotype. Women with breast cancer and the *1/*1 genotype may have an improved response to the drug as compared to those with the *1/*17 or *17/*17 genotype. One study finds an improved response to tamoxifen in patients with the *1/*1 genotype as compared to those with the *2/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.
1447964514	*1/*2	Women with breast cancer and the CYP2C19 *1/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1/*2 genotype as compared to those with the *2/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.
1447964515	*1/*17 + *17/*17	Women with breast cancer and the CYP2C19 *1/*17 or *17/*17 genotype who are treated with tamoxifen may have poorer response to tamoxifen as compared to those with the *1/*1 genotype. However, some studies find no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.
1447964516	*2/*2	Women with breast cancer and the CYP2C19 *2/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2/*2 genotype as compared to those with the *1/*1 or *1/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.
1448102392	CC	Patients with the CC genotype (*1/*1): 1) may have decreased activation of clopidogrel 2) may have a decreased, but not absent, risk for bleeding with clopidogrel as compared to patients with the CT or TT genotype 3) may have an increased risk for adverse cardiovascular events as compared to patients with a CT or TT genotype. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events.
1448102393	CT	Patients with the CT (*1/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with the CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *1/*17 genotype as of yet. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events.
1449564778	*1/*1	Patients with the *1/*1 diplotype may have a decreased incidence of stroke and decreased platelet reactivity, as compared to patients with the *1/*2, or *2/*2 diplotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence patient response to clopidogrel and aspirin.
1446897775	*1/*1	Patients with renal cell carcinoma and the *1/*1 diplotype may have an increased risk of neutropenia when treated with sunitinib as compared to individuals with any the *2 (PMID: 11503014)/*2 (PMID: 11503014)  diplotype. Other clinical or genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are taking sunitinib.
1446897773	*2 (PMID: 11503014)/*2 (PMID: 11503014)	Patients with renal cell carcinoma and the *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotype may have a decreased risk of neutropenia when treated with sunitinib as compared to individuals with the *1/*2 (PMID: 11503014) or *1/*1 diplotype. Other clinical or genetic factors may also influence risk of neutropenia in patients with renal cell carcinoma who are taking sunitinib.
1448097787	GG	Patients with non-small cell lung cancer and the GG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1449564779	*1/*17	Patients with the *1/*17 diplotype may have a decreased incidence of stroke, and decreased platelet reactivity, as compared to patients with the *1/*1, *1/*2, or *2/*2 diplotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence patient response to clopidogrel and aspirin.
1449564780	*1/*2	Patients with the *1/*2 diplotype may have a decreased incidence of stroke decreased platelet reactivity, as compared to patients with the *2/*2 diplotypes, but an increased incidence of stroke and increased platelet reactivity as compared to patients with the *1/*1, *1/*17, or *17/*17 diplotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence patient response to clopidogrel and aspirin.
1448104052	AA	Female patients with the AA genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104053	AG	Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104054	GG	Female patients with the GG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448103930	CC	Patients with the CC genotype may have an increased risk for flucloxacillin-induced liver injury as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
1448103931	CT	Patients with the CT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
1448103932	TT	Patients with the TT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
1448603299	CC	Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603300	CT	Children with the CT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603301	TT	Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
1445594567	AA	Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594568	AG	Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594569	GG	Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445601680	CC	Patients with the CC genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445601681	CG	Patients with the CG genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the GG genotype and an increased response as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445601682	GG	Patients with the GG genotype and and essential hypertension may have an increased response when treated with hypertension as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1446905009	AA	Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1448104045	CC	Female patients with the CC genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104046	CG	Female patients with the CG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or increased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104047	GG	Female patients with the GG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448603305	AA	Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603306	AG	Children with the AG genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1447963748	AC	Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.
1447963749	CC	Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.
1447963750	CT	Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.
1447979497	CC	Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979496	CG	Patients with the CG genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979495	GG	Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979502	CC	Patients with the CC genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979503	CT	Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1447979504	TT	Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1447979511	CC	Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979510	CT	Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979509	TT	Patients with the TT genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979516	GG	Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979517	GT	Patients with the GT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979518	TT	Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447990791	AA	Peripheral blood mononuclear cells (PBMC) from individuals with the AA genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and GG genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
1447990792	AG	Peripheral blood mononuclear cells (PBMC) from individuals with the AG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the GG and less sensitive as compared to PBMCs from individuals with the AA genotype. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
1447990793	GG	Peripheral blood mononuclear cells (PBMC) from individuals with the GG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and AA genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
1447990919	AA	The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.
1449161713	GG	Patients with the GG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1449732101	TT	No patients with the TT genotype (DPYD *4/*4) were available for analysis, but patients with the CT genotype (DPYD *1/*4) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of toxicity and 2) decreased DPYD activity as compared to patients with the CC genotype (DPYD *1/*1). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449732100	CT	Patients with the CT genotype (DPYD *1/*4) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of toxicity and 2) decreased DPYD activity as compared to patients with the CC genotype (DPYD *1/*1). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1446896673	AA	Patients with genotype AA may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896674	AG	Patients with genotype AG may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896675	GG	Patients with genotype GG may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896679	AA	Patients with genotype AA may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896680	AC	Patients with genotype AC may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896681	AT	Patients with genotype AT may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896682	CC	Patients with genotype CC may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1446896683	TT	Patients with genotype TT may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1447983921	*1/*1	Patients with the *1/*1 genotype may have decreased exposure to tolperisone as compared to patients with the *1/*4, *1/*5, *4/*4 genotypes. Other clinical and genetic factors may also influence patient exposure to tolperisone.
1447983922	*1/*4	Patients with the *1/*4 genotype may have increased exposure to tolperisone as compared to patients with the *1/*1 genotype and decreased exposure as compared to the *4/*4 genotype. Other clinical and genetic factors may also influence patient exposure to tolperisone.
1447983923	*1/*5	Patients with the *1/*5 genotype may have increased exposure to tolperisone as compared to patients with the *1/*1 genotype and decreased exposure as compared to the *4/*4 genotype. Other clinical and genetic factors may also influence patient exposure to tolperisone.
1447981504	CC	Patients with the CC genotype and pancreatic cancer may have a shorter overall survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival times.
1447981505	CT	Patients with the CT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
1447981506	TT	Patients with the TT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
1447983924	*4/*4	Patients with the *4/*4 genotype may have increased exposure to tolperisone as compared to patients with the *1/*1, *1/*4, and *1/*5 genotypes. Other clinical and genetic factors may also influence patient exposure to tolperisone.
1447983942	AA	Pediatric patients with epilepsy and the AA genotype may have increased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AC or CC genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
1447983943	AC	Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
1447983944	CC	Pediatric patients with epilepsy and the CC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
1447963690	AA	Patients with the AA genotype may be less likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence THC dependency.
1447963691	AC	Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.
1447963692	CC	Patients with the CC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.
1448568017	*1/*1	Healthy individuals with the *1/*1 genotype may have increased metabolism of and decreased exposure to flurbiprofen as compared to those with *1/*2 or *1/*3 genotypes. Other genetic and clinical factors may also influence pharmacokinetics of flurbiprofen in an individual.
1448568018	*1/*2	Healthy individuals with the *1/*2 genotype may have decreased metabolism of and increased exposure to flurbiprofen as compared to those with the *1/*1 genotype. Other genetic and clinical factors may also influence pharmacokinetics of flurbiprofen in an individual.
1447980701	AA	Patients with the AA genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980702	AG	Patients with the AG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or less severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980703	GG	Patients with the GG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1448568019	*1/*3	Healthy individuals with the *1/*3 genotype may have decreased metabolism of and increased exposure to flurbiprofen as compared to those with the *1/*1 genotype. Other genetic and clinical factors may also influence pharmacokinetics of flurbiprofen in an individual.
1447980715	AA	Patients with the AA genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980716	AG	Patients with the AG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or more severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980717	GG	Patients with the GG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980708	AA	Patients with the AA genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
1447980709	AG	Patients with the AG genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype, or less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
1447980710	GG	Patients with the GG genotype who are heroin dependent may have less severe side effects when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
1447980726	CC	Patients with the CC genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980727	CT	Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the TT genotype, and a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980728	TT	Patients with the TT genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980742	CC	Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1446905010	AG	Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1446905011	GG	Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1446905021	AA	Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1446905020	AG	Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1446905022	GG	Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1449565171	GT	Cancer patients with the GT genotype who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. However, several subsequent studies have found no association between the GT genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1449565172	TT	Cancer patients with the TT genotype who are treated with irinotecan may have a decreased risk of Neutropenia as compared to patients with the GG genotype. However, several subsequent studies have found no association between the TT genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1449565175	AA	Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the AA or GG genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1449565187	AG	The AG genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the GG genotypes, and increased concentrations of UGT1A1 and increased glucoronidation of oxazepam. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.
1449565188	GG	The GG genotype is associated with increased concentrations of UGT1A1 and increased glucoronidation of oxazepam as compared to the AA and AG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.
1449565191	CC	Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1449565170	GG	Cancer patients with the GG genotype who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. However, several subsequent studies have found no association between the GG genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
1449565186	AA	The AA genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the AG and GG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.
1449565192	CT	Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1449565193	TT	Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1448124220	CC	Patients with the CC genotype may have decreased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124219	CT	Patients with the CT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448260764	*15:27:01	Patients with one or two copies of the HLA-B*15:27:01 allele may have an increased risk of cutaneous adverse drug reactions when treated with clindamycin as compared to patients with no HLA-B*15:27:01 alleles or negative for the HLA-B*15:27:01 test.
1446905058	CT	Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1446905059	TT	Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1448603307	GG	Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of PONV.
1449140066	CT	Patients with the CT genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype. Patients with the CT genotype who are administered temsirolimus may also have a decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CC genotypes and a increased likelihood as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.
1449140065	CC	Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype, and an increased likelihood of adverse events  including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.
1448604318	CC	Patients with the CC genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.
1448613013	CC	Patients with the CC genotype and schizophrenia may have increased response to amisulpride as measured by the PANSS general as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to amisulpride.
1448613014	CT	Patients with the CT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.
1448603311	AA	Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
1448594867	CT	Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.
1448594868	TT	Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.
1448594866	CC	Patients with the CC genotype may have increased clearance of metformin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of metformin.
1448601688	AA	Patients with the AA genotype may have increased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the GG or AG genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.
1448601689	AG	Patients with the AG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.
1448603312	AC	Children with the AC genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603313	CC	Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of PONV.
1447960405	AA	Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1445402228	CC	Patients with the CC genotype and cancer may have longer survival times when treated with cisplatin as compared to patients with the CT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.
1445402229	CT	Patients with the CT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.
1445402230	TT	Patients with the TT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.
1449147575	AA	Patients with genotype AA and colonic neoplasms may have decreased response to  fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with genotypes AG and GG. However, other studies showed as increased response to oxaliplatin. Studies also conflict as to whether patients with AA genotype are at increased risk of toxicity, such as developing neutropenia, when taking oxaliplatin, compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin.
1449147576	AG	Patients with genotype AG and colonic neoplasms may have decreased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with genotypes GG. However, other studies showed an increased response to oxaliplatin. Studies also conflict as to whether patients with AG genotype are at increased risk of toxicity, such as developing neutropenia, when taking oxaliplatin, compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin.
1449147577	GG	Patients with genotype GG and colonic neoplasms may have increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with genotypes AA and AG. However, other studies showed decreased response to oxaliplatin. Studies also conflict as to whether patients with AA genotype are at increased risk of toxicity, such as developing neutropenia, when taking oxaliplatin, compared to patients with AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin.
1446897344	CC	Patients with the CC genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
1446897345	CT	Patients with the CT genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
1446897346	TT	Patients with the TT genotype and post-operative pain may require an increased dose of fentanyl as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
1446899697	AA	Patients with the AA genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AC and CC genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.
1446899698	AG	Patients with the AG genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the CC genotype and a lower likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.
1446899699	CC	Patients with the CC genotype may have a lower likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AA genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.
1447960398	AA	Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960399	AG	Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960400	GG	Patients with the GG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1448102394	TT	Patients with the TT (*17/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with a CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *17/*17 genotype as of yet. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events.
1447980743	CG	Patients with the CG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980744	GG	Patients with the GG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980755	CC	Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980756	CT	Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980757	TT	Patients with the TT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1449171924	AC	Patients with the AC genotype who are undergoing kidney transplantation may have an increased risk for nausea and/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and/or vomiting.
1449171925	CC	Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for nausea and/or vomiting when treated with tacrolimus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for nausea and/or vomiting.
1448099120	AA	No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448097781	CC	Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097782	CT	Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097783	TT	Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC and CT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1447990906	CC	Patients with hypertension and the CC genotype may have a worse response to enalapril as compared to patients with the AA or AC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.
1448098954	AA	Patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.
1448098955	AG	Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.
1448098956	GG	Patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.
1448099121	AC	Patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448099122	CC	Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448573508	GG	Patients with the GG genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.
1446897530	TT	Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GT and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1448999180	*2/*2xN	Patients with a duplication of a functional CYP2D6 gene may have decreased plasma concentration of clomipramine and desmethyl clomipramine when treated with clomipramine as compared to patients with the CYP2D6*1/*1 genotype. The number of studies for clomipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1448999181	*3	Patients with the CYP2D6*3 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with clomipramine may have 1) an increased plasma concentration of clomipramine and desmethyl clomipramine, 2) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Contradictory findings (no association with side effects or differences in plasma concentration) have been reported for clomipramine, and the number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1448999182	*4	Patients with the CYP2D6*4 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with clomipramine may have 1) an increased plasma concentration of clomipramine and desmethyl clomipramine, 2) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Contradictory findings (no association with side effects or differences in plasma concentration) have been reported for clomipramine, and the number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1448999183	*5	Patients with the CYP2D6*5 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with clomipramine may have 1) an increased plasma concentration of clomipramine and desmethyl clomipramine, 2) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Contradictory findings (no association with side effects or differences in plasma concentration) have been reported for clomipramine, and the number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1448999184	*6	Patients with the CYP2D6*6 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with clomipramine may have 1) an increased plasma concentration of clomipramine and desmethyl clomipramine, 2) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Contradictory findings (no association with side effects or differences in plasma concentration) have been reported for clomipramine, and the number of studies for clomipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's response to clomipramine.
1449166737	*1	Patients with the CYP2D6*1 allele may have 1) an increased clearance of tolterodine as compared to patients with the CYP2D6*10 or *93 or *94 or *95 allele, 2) may have increased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*92 or *96 allele, and 3) similar enzyme activity of CYP2D6 compared to CYP2D6*87 or *88 or *89 or *90 or *91 or *97 or *98 allele. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166738	*10	Patients with the CYP2D6*10 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166739	*87	Patients with the CYP2D6*87 allele may havesimilar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166740	*88	Patients with the CYP2D6*88 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166741	*89	Patients with the CYP2D6*89 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166742	*90	Patients with the CYP2D6*90 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166743	*91	Patients with the CYP2D6*91 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1447960252	AA	Patients with the AA genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
1447960253	AC	Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
1447960254	CC	Patients with the CC genotype and cancer may have decreased survival time and a decreased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
1447989389	AG	Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1447989390	GG	Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.
1448097407	CC	Patients with the CC genotype and breast neoplasms may have reduced disease-free survival when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.
1447961233	GT	Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1447961234	TT	Patients without an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have decreased response rate (RR) and decreased progression-free survival (PFS) time compared to patients who have activating somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568. Patients who have no mutation are presented here as TT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.
1448097408	CT	Patients with the CT genotype and breast neoplasms may have increased disease-free survival when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.
1448097409	TT	No patients with the TT genotype were included in analysis of the association between genotype and disease-free survival in response to tamoxifen treatment in patients with breast neoplasms.
1450180237	AA	Patients with the AA genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.
1450044614	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044615	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044616	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1447960329	AA	Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1446898859	CC	Patients with schizophrenia, or autism spectrum disorder (ASD) and the CC genotype, may have a decreased likelihood of weight gain as compared to patients with the CT and TT genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients with ASD or schizophrenia who are taking risperidone, clozapine, or olanzapine.
1446898860	CT	Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.
1446898861	TT	Patients with schizophrenia, or autism spectrum disorder (ASD) and the TT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.
1449165623	AG	Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.
1449165624	GG	Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.
1449165622	AA	Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.
1447960330	AG	Patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960331	GG	No patients with the GG genotype were available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1448106829	AA	Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
1448106830	AG	Patients with the AG genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
1448106831	GG	Patients with the GG genotype and schizophrenia may have slower improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
1446905763	GG	Patients with the GG genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
1446905762	GT	Patients with the GT genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
1446905761	TT	Patients with the TT genotype may have increased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
1447960347	CC	Patients with the CC genotype and non-small-cell lung cancer may have a shorter median survival time and a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival time and hematologic toxicity.
1447960348	CT	Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time and an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time and hematologic toxicity.
1447960349	TT	Patients with the TT genotype and non-small-cell lung cancer may have a longer median survival time and an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time and hematologic toxicity.
1448617076	AA	Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.
1448432264	CC	Patients with the colorectal cancer with the CC genotype ("wild type KRAS") and no other KRAS mutations may have increased response when treated with cetuximab or panitumumab as compared to patients with KRAS mutations although some studies suggest that the CT genotype at this locus has similar response to CC. Other genetic and clinical factors may also influence response to cetuximab or panitumumab.
1448432265	CT	Patients with colorectal cancer with the CT genotype (G13D) may have similar response when treated with cetuximab or panitumumab as compared to patients with the CC genotype ("wild type KRAS") and improved response as compared to patients with other KRAS mutations although some studies did not observe this benefit. However current guidelines still recommend not using anti-EGFR treatments in these patients. Other genetic and clinical factors may also influence response to cetuximab or panitumumab.
1449732099	CC	Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased but not absent risk of toxicity and 2) increased DPYD activity as compared to patients with the CT genotype (DPYD *1/*4). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449732094	CC	Patients with the CC genotype (DPYD *5/*5) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased likelihood of nausea, vomiting, and leukopenia, 2) decreased response and 3) decreased clearance of fluorouracil as compared to patients with the TT genotype (DPYD *1/*1). However, other studies find no associations or contradictory associations with fluoropyrimidine-induced drug toxicity or response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449732095	CT	Patients with the CT genotype (DPYD *1/*5) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased response and 2) an increased likelihood of hyperammonemia as compared to patients with the TT genotype (DPYD *1/*1). However, the vast majority of studies find no association between this diplotype and fluoropyrimidine-induced drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448616433	GG	Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1449732096	TT	Patients with the TT genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased likelihood of nausea, vomiting, and leukopenia, 2) increased response and 3) increased clearance of fluorouracil as compared to patients with the CT or CC genotype (DPYD *1/*5 or *5/*5). However, other studies find no associations or contradictory associations with fluoropyrimidine-induced drug toxicity or response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448617077	CA	Patients with the CA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype and increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.
1448102805	AA	Patients with the AA genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102806	AC	Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102807	CC	Patients with the CC genotype and hepatitis C or HIV may have an increased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102817	AA	Patients with the AA genotype and breast cancer may have a better response when treated with docetaxel and epirubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
1448102818	AG	Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
1448102819	GG	Patients with the GG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
1448522437	GG	Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
1448522438	GT	Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
1448617078	CC	Patients with the CC genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's survival probability.
1445402428	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response when treated with lisinopril as compared to patients with the del/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.
1445402429	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del	Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may have an increased response when treated with lisinopril as compared to patients with the del/del genotype, or a decreased response when treated with lisinopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.
1445402430	del/del	Patients with the del/del genotype may have a decreased response when treated with lisinopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.
1449269581	AA	Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1449269582	AG	Patients with the AG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1448616383	CC	Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.
1448616384	CT	Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.
1445402445	AA	Patients with the AA genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.
1445402446	AG	Patients with the AG genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.
1445402447	GG	Patients with the GG genotype and breast cancer may have a poorer response to docetaxel treatment as compared to patients with the AA or AG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.
1447963184	AA	Patients with the AA genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
1447963185	AT	Patients with the AT genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
1447963186	TT	Patients with the TT genotype may have increased clearance of cefotaxime as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
1449269583	GG	Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.
1449270488	AA	Patients with the AA genotype may have reduced alcohol consumption as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.
1449270489	AG	Patients with the AG genotype may have reduced alcohol consumption as compared to patients with the GG genotype, but an increased level of alcohol consumption compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.
1447963806	CT	Women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype.  No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.
1447963807	TT	No women with the TT genotype were available for analysis, but women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype.  No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.
1448106654	AA	Patients with the AA genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1448106655	AC	Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1448106656	CC	Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1445402166	AG	Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1445402167	GG	Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1448097809	TT	Patients with kidney transplantation and the TT genotype may have increased metabolism of mycophenolic acid as compared to patients with the del/del or del/T or del/del genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
1448097808	del/T	Patients with kidney transplantation and the del/T genotype may have decreased metabolism of mycophenolic acid as compared to patients with the TT genotypes but increased metabolism of mycophenolic acid as compared to patients with the del/del genotype. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
1448097807	del/del	Patients with kidney transplantation and the del/del genotype may have decreased metabolism of mycophenolic acid as compared to patients with the de/T or TT genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
1448624480	AA	Patients with the AA genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).
1448624481	AG	Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).
1447962616	CT	Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1447962617	TT	Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1449564791	non-null/null	Patients with cancer and the GSTM1 null/non-null genotype who are treated with cisplatin or oxaliplatin may have decreased likelihood of disease free survival and increased incidence of recurrence as compared to patients with the null/null genotypes. Other clinical and genetic factors may also influence disease free survival and incidence of disease recurrence in patients who are treated with platinum compounds.
1449564792	null/null	Patients with cancer and the GSTM1 null/null genotype who are treated with cisplatin or oxaliplatin compounds may have increased likelihood of disease free survival and decreased incidence of recurrence as compared to patients with the null/non-null and non-null/non-null genotypes. Other clinical and genetic factors may also influence disease free survival and incidence of disease recurrence in patients who are treated with platinum compounds.
1449564790	non-null/non-null	Patients with cancer and the GSTM1 non-null/non-null genotype who are treated with cisplatin or oxaliplatin may have decreased likelihood of disease free survival and increased incidence of recurrence as compared to patients with the null/null genotypes. Other clinical and genetic factors may also influence disease free survival and incidence of disease recurrence in patients who are treated with platinum compounds.
1447979282	AT	Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1447979283	TT	Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1448624482	GG	Patients with the GG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have Increased likelihood of neutropenia or leukopenia as compared to patients with the AA or AG genotypes.  Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).
1450371847	*6/*6	Patients with HIV and the CYP3A5 *6/*6 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1450371848	*6/*7	Patients with HIV and the CYP3A5 *6/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1450371846	*3A/*7	Patients with HIV and the CYP3A5 *3/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1450371849	*7/*7	Patients with HIV and the CYP3A5 *7/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.
1446905846	AA	Patients with the AA genotype may have decreased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.
1446905847	AG	Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.
1446905848	GG	Patients with the GG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.
1446905852	AA	Patients with the AA genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.
1446905853	AG	Patients with the AG genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.
1446905854	GG	Patients with the GG genotype may have increased dose of acenocoumarol or phenprocoumon as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.
1447960406	AG	Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960407	GG	Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960373	CC	Patients with the CC genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960374	CT	Patients with the CT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960375	TT	Patients with the TT genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960381	AA	Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960382	AT	Patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960383	TT	No patients with the TT genotype were available for analysis, but patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.
1447960462	TT	Patients with the TT genotype and schizophrenia may have lower weight gain when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
1448604320	TT	Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.
1449183234	del/del	Transplant recipients with the del/del (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus and require a higher dose of the drug as compared to patients with the A/del or AA (*1/*7 or *7/*7) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.
1448993590	AA	Patients with the AA genotype may have a increased metabolism of mephenytoin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1448993591	AG	Patients with the AG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1448993592	GG	Patients with the GG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1449191608	GG	Patients with the GG genotype (two copies of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191609	GT	Patients with the GT genotype (one copy of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191610	TT	Patients with the TT genotype (do not have a copy of the CFTR L206W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1447682180	*1	Patients with the *1 allele may have increased metabolism/clearance of haloperidol as compared to patients with two reduced function alleles (*10), one reduced function and one non-functional (*3, *4, or *5) allele, or two non-functional alleles. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447682181	*10	Patients with the *10 allele may have decreased metabolism/clearance of haloperidol as compared to patients with two fully functional alleles (*1/*1). However, an approximately equal number of studies have found the *10 allele to not be associated with decreased metabolism/clearance of haloperidol as compared to patients with two fully functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447682182	*17	Patients with the *17 allele may have increased metabolism/clearance of haloperidol as compared to patients with two non-functional (*3, *4, or *5) alleles. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447682183	*2	Patients with the *2 allele may have increased metabolism/clearance of haloperidol as compared to patients with two reduced function alleles (*10), one reduced function and one non-functional (*3, *4, or *5) allele, or two non-functional alleles. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447682184	*3	Patients with the *3 allele may have decreased metabolism/clearance of haloperidol as compared to patients with two fully functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447682185	*4	Patients with the *4 allele may have decreased metabolism/clearance of haloperidol as compared to patients with two fully functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447682186	*5	Patients with the *5 allele may have decreased metabolism/clearance of haloperidol as compared to patients with two fully functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's response to haloperidol.
1447960460	CC	Patients with the CC genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
1447960461	CT	Patients with the CT genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
1445402474	AG	Patients with the AG genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the GG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone.
1445402475	GG	Patients with the GG genotype who are being treated with methadone for heroin addiction may require a decreased dose of the drug as compared to patients with the AA or AG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone.
1449164683	CC	Patients with the CC genotype and Type 2 diabetes may have a better response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to OADs.
1446897972	AA	Patients with the AA genotype may have 1) increased exposure to doxorubicin metabolites and 2) increased response to anthracycline regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
1446897973	AG	Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.
1446897974	GG	Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
1449164871	AA	Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449164872	AG	Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449164873	GG	Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449165015	AA	Patients with the AA genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449165016	AG	Patients with the AG genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449165017	GG	Patients with the GG genotype may have: 1) increased likelihood of Drug Toxicity, 2) decreased response when treated with methotrexate as compared to patients with genotypes AA or AG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449165461	AC	Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.
1447983956	AA	Individuals with Tobacco Use Disorder and the AA genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447983957	AG	Individuals with Tobacco Use Disorder and the AG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1447983958	GG	Individuals with Tobacco Use Disorder and the GG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1449164684	CT	Patients with the CT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.
1449164685	TT	Patients with the TT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.
1449165462	CC	Patients with the CC genotype with cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.
1447990056	CC	Patients with the CC genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, and as compared to patients with the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.
1447990057	CT	Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.
1447990058	TT	Patients with the TT genotype and Lewy Body disease or Alzheimer's disease may have worse response to rivastigmine as compared to patients with the CC genotype, as well as the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.
1448105778	GT/GT	Patients with the GT/GT genotype may have increased dose of phenytoin in people with Epilepsy as compared to patients with genotype del/del or GT/del. Other genetic and clinical factors may also influence the dose of phenytoin.
1448105779	GT/del	Patients with the GT/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT/GT. Other genetic and clinical factors may also influence the dose of phenytoin.
1448105780	del/del	Patients with the del/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT/GT. Other genetic and clinical factors may also influence the dose of phenytoin.
1448109630	GG	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
1448109738	AA	Patients with genotype AA may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or AC, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1448109739	AC	Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1448106242	GG	Patients with the GG genotype and osteoporosis or osteopenia may have a better response when treated with alendronate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to alendronate.
1448106256	AA	Patients with the AA genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.
1448106257	AC	Patients with the AC genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.
1449167221	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1448106258	CC	Patients with the CC genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for mucositis.
1448109740	CC	Patients with genotype CC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1449167222	AC	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167223	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167224	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167225	CG	Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167226	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1447960601	AA	Patients with the AA genotype and hypertension may have a greater reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence pulse wave velocity.
1447960602	AC	Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.
1447960603	CC	Patients with the CC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.
1447961324	CC	Patients with the CC genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447961325	CT	Patients with the CT genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447961326	TT	Patients with the TT genotype who use methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447963065	CC	Cells with the CC genotype may have decreased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CT genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
1447963066	CT	Cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
1447963067	TT	No cells with the TT genotype were available for analysis, but cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
1447990285	CC	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.
1447990286	CT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.
1447990287	TT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.
1448107544	(CCCACCCGA)10/(CCCACCCGA)9	Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107545	(CCCACCCGA)12/(CCCACCCGA)10	Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448097713	AA	Patients with non-small cell lung cancer and the AA genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097714	AC	Patients with non-small cell lung cancer and the AC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097715	CC	Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448107543	(CCCACCCGA)10/(CCCACCCGA)10	Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with antidepressants 1) may have a reduced risk of adverse drug reactions after switching treatment for the second time 2) may be less likely to have a lack of a response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447990946	CC	The CC genotype in patients with depressive disorder who are taking citalopram or escitalopram may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CT or TT genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.
1447990947	CT	The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.  Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.
1447990948	TT	The TT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with lower baseline serotonin levels and smaller decreases in serotonin levels as compared to the CT or CC genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.
1448102783	*3	Patients who carry the *3 allele and have colorectal cancer may have an increased risk for vomiting when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients without the *3 allele. Other genetic and clinical factors may also influence risk for vomiting on TIROX.
1448102889	CC	Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.
1448102769	*44:02:01:01	Patients with one or two copies of the HLA-B*44 allele have an increased likelihood of having a sustained response to interferon-alpha and ribavirin therapy, as compared to patients with no HLA-B*44 alleles or negative for the HLA-B*44 test. Other genetic and clinical factors may also influence a patient's response to interferon-alpha and ribavirin therapy. Note that the information in this clinical annotation refers to the presence of any HLA-B*44 allele. This clinical annotation appears on the HLA-B*44:02:01:01 allele page because this was the first *44 allele discovered.
1448102774	non-null/non-null	Patients with the non-null/non-null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a greater chance of achieving complete remission, and a decreased risk of experiencing drug toxicities, as compared to patients with the non-null/null or null/null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.
1448102775	non-null/null	Patients with the non-null/null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a poorer chance of achieving complete remission, and an increased risk of experiencing drug toxicities, as compared to patients with the non-null/non-null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.
1448102776	null/null	Patients with the null/null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a poorer chance of achieving complete remission, and an increased risk of experiencing drug toxicities, as compared to patients with the non-null/non-null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.
1448102890	CT	Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.
1448102891	TT	Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.
1448102895	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the HTTLPR long form (L allele)/HTTLPR long form (L allele) genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR short form (S allele)/L allele and HTTLPR S allele/S allele genotypes. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.
1448102896	HTTLPR short form (S allele)/HTTLPR long form (L allele)	Patients with the HTTLPR short form (S allele)/HTTLPR long form (L allele) genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR L allele/L allele genotype. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.
1448102897	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the HTTLPR short form (S allele)/HTTLPR short form (S allele) genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR L allele/L allele genotype. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.
1446905145	*1/*1	Patients with the *1/*1 diplotype 1) may have increased metabolism of desipramine as compared to patients with the *5/*10 or *10/*10 diplotype or carriers of the *3, *4 or *5 allele 2) may have reduced exposure to desipramine as compared to patients with *1/*41, *1/*17, *2/*41, *1/*4, or *41/*41 diplotypes 3) may have reduced clearance of desipramine and better response to treatment as compared to patients with the *2XN allele. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905146	*1/*17	Patients with the *1/*17 diplotype may have increased exposure to desipramine as compared to patients with *1/*1, *1/*2 or *2/*2 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446900192	TTA/TTA	Patients with the TTA/TTA diplotype and tuberculosis who are treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin may have a decreased risk of developing drug induced hepatitis as compared to patients with the the following diplotypes: TCG/TTA, TCG/TCG, CTA/TTA, CTA/TCG, or CTA/CTA . Other clinical and genetic factors may also influence risk of drug-induced hepatitis in patients on an anti-tuberculosis drug regiment.
1448107975	GG	Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG.  Other genetic and clinical factors may also influence a patient's response.
1449165476	CA	Patients with the AC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.
1446905147	*1/*2	Patients with the *1/*2 diplotype 1) may have increased metabolism of desipramine as compared to patients with the *5/*10 or *10/*10 diplotype 2) may have reduced exposure to desipramine as compared to patients with *1/*41, *1/*17, *2/*41, *1/*4 or *41/*41 diplotypes. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905148	*1/*4	Patients with the *1/*4 diplotype may have reduced metabolism and increased exposure to desipramine as compared to patients with *1/*1, *1/*2 or *2/*2 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905149	*1/*41	Patients with the *1/*41 diplotype may have increased exposure to desipramine as compared to patients with *1/*1, *1/*2 or *2/*2  diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905150	*10/*10	Patients with the *10/*10 diplotype may have reduced metabolism of desipramine as compared to patients with the *1/*1 or *1/*2 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905151	*1xN	Patients with the *1XN allele may who are treated with desipramine may have a reduced response to treatment as compared to patients with the *1/*1 diplotype.  The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1448107611	AA	Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
1448107612	AC	Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
1448107613	CC	Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
1449165477	CC	Patients with the CC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.
1448106306	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1449157281	CT	African-American patients with the CT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to buprenorphine treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to buprenorphine.
1449157282	TT	African-American patients with the TT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to buprenorphine treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to buprenorphine.
1449166920	CC	Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1447990126	*4/*4	Patients with Alzheimer Disease and the *4/*4 diplotype (poor metabolizers) may have reduced clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1/*3, *1/*4, *1/*5, *1/*6, *1/*1, *4/*1xN, *6/*1xN) or ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Poor metabolizers may also be more  likely to experience adverse events (though this was not statistically significant). Other genetic and clinical factors may also influence donepezil clearance.
1447990127	*4/*5	Patients with Alzheimer Disease and the *4/*5 diplotype (poor metabolizers) may have reduced clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1/*3, *1/*4, *1/*5, *1/*6, *1/*1, *4/*1xN, *6/*1xN) or ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Poor metabolizers may also be more  likely to experience adverse events (though this was not statistically significant). Other genetic and clinical factors may also influence donepezil clearance.
1447990128	*6/*1xN	Patients with Alzheimer Disease and the *6/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4/*4, *4/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1/*1xN, *1XN/*1XN). Other genetic and clinical factors may also influence donepezil clearance.
1448106294	CC	Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1448106295	CG	Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in people with HIV who are taking atazanavir and ritonavir.
1448106296	GG	Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1449166921	CT	Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1449166922	TT	Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke with the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1449157966	CT	Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157967	TT	Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1448099061	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448099062	AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1449166915	CC	Patients with the CC genotype may metabolize nicotine more rapidly as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.
1449166916	CT	Patients with the CT genotype may metabolize nicotine more rapidly as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.
1449166917	TT	Patients with the TT genotype may metabolize nicotine more slowly as compared to patients with the CT CC genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.
1447961346	AA	Patients with the AA genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence alcoholism risk.
1447961347	AC	Patients with the AC genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype, or more likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.
1447961348	CC	Patients with the CC genotype who are African-American may be more likely to become addicted to alcohol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.
1447947091	AA	Patients with the AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947092	AG	Patients with the AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype, or may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947093	GG	Patients with the GG genotype and Coronary Artery Disease who are treated with statins may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947097	AA	Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947098	AG	Patients with the AG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947099	GG	Patients with the GG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447963754	AA	Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.
1447963755	AG	Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.
1447963756	GG	Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.
1447964094	CT	Patients with the CT genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.
1447964095	TT	Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.
1447964348	AA	Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1447964093	CC	Patients with the CC genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.
1447964349	AG	Patients with the AG genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1448102924	TT	Patients with the TT genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1448102928	AA	Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1448102929	AG	Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1448102930	GG	Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1448102939	AA	Patients with the AA genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.
1448102940	AG	Patients with the AG genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.
1448102941	GG	Patients with the GG genotype and node-positive breast cancer may have longer disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence disease-free survival time.
1448103886	GG	Patients with the GG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.
1448103924	TT	Patients with the TT genotype and post-operative pain may be more likely to require rescue analgesic administration as compared to patients with the CT or CC genotype.  Additionally, patients with the TT genotype who are addicted to heroin may require an increased dose of methadone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.
1448107491	(CCCACCCGA)12/(CCCACCCGA)12	Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with paroxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107488	(CCCACCCGA)10/(CCCACCCGA)10	Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1448107489	(CCCACCCGA)10/(CCCACCCGA)9	Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1450373856	CC	Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.
1450373857	CT	Patients with the CT genotype may have an increased analgesic response to morphine as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to morphine.
1450373858	TT	Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.
1449266584	CC	Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266585	CT	Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266586	TT	Patients with the TT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1448107490	(CCCACCCGA)12/(CCCACCCGA)10	Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1445594493	AA	Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594494	AT	Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594495	TT	Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT or AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594500	AA	Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594501	AT	Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594502	TT	Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594507	AA	Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594508	AT	Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594509	TT	Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1446897179	AA	Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897180	AG	Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897181	GG	Patients with the GG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446905152	*2/*41	Patients with the *2/*41 diplotype may have increased exposure to desipramine as compared to patients with *1/*1, *1/*2 or *2/*2 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905153	*2xN	Patients with the *2XN allele may have higher clearance of desipramine and reduced response as compared to patients with the *1/*1 diplotype.  The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905154	*3	Patients with the *3 allele may have reduced metabolism of desipramine as compared to patients with the *1/*1 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905155	*4	Patients with the *4 allele may have reduced metabolism of desipramine as compared to patients with the *1/*1 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446903041	*17/*17	Patients with the CYP2C19*17/*17 (rs12248560) genotype who are treated with amitriptyline may have increased metabolism of amitriptyline (decreased amitriptyline plasma concentrations and increased nortriptyline plasma concentrations) as compared to patients with the CYP2C19*1/*1. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446903042	*2	Patients with the CYP2C19*2 (rs4244285) allele who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the CYP2C19*1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446903043	*3	Patients with the CYP2C19*3 (rs4986893) allele who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the CYP2C19*1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1448106694	AA	No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.
1447991856	*1/*1xN	Patients with the CYP2D6*1/*1XN genotype (carriers of more than two functional CYP2D6 alleles) may have a reduced response to dolasetron as compared to patients with the same genotype who were administered granisetron. Other clinical and genetic factors may also influence response to dolasetron in patients with postoperative nausea and vomiting.
1448613251	AG	Patients with the AG genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1448613252	GG	Patients with the GG genotype and kidney transplantation may have decreased exposure (Concentration/Dose) to tacrolimus compared to patients with the AG and AA genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1448615163	AA	Postmenopausal women with HR+ breast cancer and the AA genotype may have decreased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448106695	AG	Women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.
1448106696	GG	Women with the GG genotype and breast cancer may have lesser aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy.
1448615164	AC	Postmenopausal women with HR+ breast cancer and the AC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448099063	GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448099102	AA	Patients with the AA genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448099103	AG	Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448099104	GG	Patients with the GG genotype and schizophrenia may have a smaller increase or decrease in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448099231	AA	Patients with nasopharyngeal cancer and the AA genotype may have a decreased severity of neutropenia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448106770	CC	Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype. Other genetic and clinical factors may also influence  hypersensitivity to asparaginase.
1448106771	CT	Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence  hypersensitivity to asparaginase.
1448613015	TT	Patients with the TT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.
1449157290	CC	African-American patients with the CC genotype may have an increased response to methadone when being treated for opioid dependence, as compared to patients with the CT or TT genotypes. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.
1449166945	CG	Patients with the CG genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the GG genotypes and decreased clearance leading to improved response to metformin as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.
1449166946	GG	Patients with the GG genotype and Type II diabetes mellitus may have decreased clearance of metformin leading to improved response to metformin as compared to patients with the CG and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.
1446903544	CC	In pediatric patients with asthma and the CC genotype may have an increased response to beta-adrenergic inhalants as compared to patients with the CT and TT genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.
1446903543	CT	In pediatric patients with asthma and the CT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CC genotypes and an increased response to beta-adrenergic inhalants as compared to patients with the TT genotype. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.
1446903542	TT	In pediatric patients with asthma and the TT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CT and CC genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.
1449166944	CC	Patients with the CC genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the CG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and response to metformin in people with Type II diabetes mellitus.
1446903565	AA	Individuals who smoke and have the AA genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the AG or GG genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1446903566	AG	Individuals who smoke and have the AG genotype may have decreased rates of nicotine clearance, and as a consequence may smoke less when compared to individuals who smoke and have the GG genotypes, and increased rates of metabolism as compared to patients with the AA genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1446903567	GG	Individuals who smoke and have the GG genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the AG or AA genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1446903572	CC	Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1446903573	CT	Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1446903574	TT	Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.
1446903579	AA	Patients with diabetes mellitus and the AA genotype may have a decreased response to metformin as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.
1446903580	AC	Patients with diabetes mellitus and the AC genotype may have a decreased response to metformin as compared to patients with the CC genotypes and an increased response as compared to patients with the AA genotype. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.
1446903581	CC	Patients with diabetes mellitus and the CC genotype may have an increased response to metformin as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.
1449156945	CT	Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype who is also a CYP3A4 low or intermediate expresser. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.
1449156946	TT	Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.
1447992421	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group.
1447992422	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group.
1447992423	GG	Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CG and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group.
1448099219	CC	Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448099220	CT	Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448099221	TT	Patients with nasopharyngeal cancer and the TT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448099225	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099226	AT	Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099227	TT	Patients with nasopharyngeal cancer and the TT genotype who are treated with docetaxel may have a increased severity of neutropenia as compared to patients with the AT or AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099236	AA	Patients with nasopharyngeal cancer and the AA genotype may have more severe anemia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099237	AG	Patients with nasopharyngeal cancer and the AG genotype may have less severe anemia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098317	CT	Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098318	TT	Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia who are treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099247	CC	Patients with the CC genotype and HIV infection may have decreased metabolism of indinavir compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence indinavir metabolism.
1448099248	CT	Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.
1448099249	TT	Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.
1448099253	AA	Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
1448099254	AG	Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
1447982678	CC	Patients with the CC genotype may have increased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982677	CT	No information are available for the CT genotype. However, patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982676	TT	Patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982690	AA	Patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1448107281	GG	Patients with retinal disease and the GG genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CG or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1447982691	AG	No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1446905156	*41/*41	Patients with the *41/*41 diplotype may have increased exposure to desipramine as compared to patients with *1/*1, *1/*2 or *2/*2 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905157	*5	Patients with the *5 allele may have reduced metabolism of desipramine as compared to patients with the *1/*1 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446905158	*5/*10	Patients with the *5/*10 diplotype may have reduced metabolism of desipramine as compared to patients with the *1/*1 or *1/*2 diplotype. The number of studies for desipramine pharmacogenomics is limited. Since secondary amine tricyclic antidepressants have comparable pharmacokinetic properties see also annotations for nortriptyline for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of desipramine.
1446906307	AA	Patients with the AA genotype and depression who are treated with citalopram or antidepressants may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1446906308	AG	Patients with the AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1446906309	GG	Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1447982692	GG	Patients with the GG genotype may have increased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447947347	*1/*1	Healthy individuals with the CYP2C19 *1/*1 genotype may have increased metabolism of pantoprazole, as shown by a decreased area under the concentration-time curve (AUC), as compared to individuals with the *1/*2 (*2 = rs4244285) genotype. Other genetic and clinical factors may also influence metabolism of pantoprazole.
1447947348	*1/*2	Healthy individuals with the CYP2C19 *1/*2 genotype may have decreased metabolism of pantoprazole, as shown by an increased area under the concentration-time curve (AUC), as compared to individuals with the *1/*2 (*2 = rs4244285) genotype. Other genetic and clinical factors may also influence metabolism of pantoprazole.
1448107288	CC	Patients with the CC genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448107289	CT	Patients with the CT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype or may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448107290	TT	Patients with the TT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1448100134	AA	Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100135	AG	Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448099232	AG	Patients with nasopharyngeal cancer and the AG genotype may have a increased severity of neutropenia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448100113	AG	Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.
1448100114	GG	Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.
1448100136	GG	Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448106772	TT	Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence  hypersensitivity to asparaginase.
1448106776	GG	Patients with the GG genotype may have a reduced risk for developing prostate cancer when treated with aspirin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
1448106777	GT	Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
1448100153	AA	Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100154	AG	Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100155	GG	Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448106778	TT	Patients with the TT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
1448107336	CC	Patients with the CC genotype may have decreased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1448107337	CT	Patients with the CT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1448100167	CC	Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100168	CT	Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100169	TT	Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448107338	TT	Patients with the TT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1448107342	CC	Patients with the CC genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1448107343	CT	Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1448107344	TT	Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1448100524	CT	Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.
1448100525	TT	Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.
1448100632	AA	Patients with the AA genotype may have a better response to treatment with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methadone.
1448100523	CC	Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.
1447679540	AA	Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.
1446897193	CC	Patients with the CC genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897194	CT	Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897195	TT	Patients with the TT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897215	*1/*1	Patients with the CYP2D6*1/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40/*42 or *3/*4XN or *4XN/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1446897216	*3/*4xN	Patients with the CYP2D6*3/*4XN genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1446897217	*40/*42	Patients with the CYP2D6*40/*42 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1446897219	*4xN/*36 + *4/*36	Patients with the CYP2D6*4x2/*36 or *4/*36 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1446897218	*4xN/*56	Patients with the CYP2D6*4XN/*56 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.
1448106412	CC	Patients with HIV and the CC genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CT or TT genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106413	CT	Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1448106414	TT	Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.
1447679541	AG	Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.
1447679542	GG	Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.
1447944777	CT	Patients with the CT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.
1447944776	CC	Patients with the CC genotype and schizophrenia may have an increased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.
1447944778	TT	Patients with the TT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to amisulpride.
1447944808	CC	Patients with the CC genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944809	CG	Patients with the CG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944810	GG	Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1448099255	GG	Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
1448105886	AA	Patients with the AA genotype may have increased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1448105887	AG	Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1448105888	GG	Patients with the GG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1449165460	AA	Patients with the AA genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.
1449165465	AA	Patients with the AA genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.
1449165466	AG	Patients with the AG genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.
1448106031	AA	Genotype AA may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.
1448106032	AG	Genotype AG may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.
1448601912	CC	Patients with the CC genotype and major depressive disorder may have an increased response to venlafaxine compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect response to venlafaxine.
1448601913	CT	Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.
1448104251	AA	Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.
1448104252	AG	Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.
1448104253	GG	Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.
1448602110	AA	People who smoke and have the AA genotype may have increased clearance and decreased exposure to cotinine compared to people with the AC and CC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
1448602111	AC	People who smoke and have the AC genotype may have increased clearance and decreased exposure to cotinine compared to people with the CC genotype. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
1449165467	GG	Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.
1448104322	TT	Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
1448105766	AA	Patients with the AA genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.
1448105767	AC	Patients with the AC genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.
1448105768	CC	Patients with the CC genotype may have decreased dose of warfarin as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the dose of warfarin.
1448601914	TT	Patients with the TT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.
1449165475	AA	Patients with the AA genotype and cancer may have a decreased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AC or CC genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.
1447947349	*17/*17	Healthy individuals with the CYP2C19 *17/*17 genotype may have increased metabolism of pantoprazole, as shown by clearance, as compared to individuals with the *1/*1 or *1/*17 genotype.  Other genetic and clinical factors may also influence metabolism of pantoprazole.
1448107529	(CCCACCCGA)10/(CCCACCCGA)10	Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1447953074	CC	Patients with the CC genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.
1447953075	CG	Patients with the CG genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.
1447953076	GG	Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.
1447953080	CC	Patients with the CC genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1447953081	CT	Patients with the CT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1447953082	TT	Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
1448107530	(CCCACCCGA)10/(CCCACCCGA)9	Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with fluoxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.
1447953118	AA	Patients with the AA genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447953119	AG	Patients with the AG genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447953120	GG	Patients with the GG genotype and schizophrenia may have an increased response to olanzapine as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447953125	CC	Patients with the CC genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953126	CG	Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953127	GG	Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the CG and CG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953164	AA	Patients with the AA genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1447953165	AT	Patients with the AT genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1447953166	TT	Patients with the TT genotype and schizophrenia may have a decreased response to antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1448107314	TT	Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1448100652	CC	Female patients with the CC genotype may have less of a decrease in bone mineral density when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.
1448100653	CT	Female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.
1448100654	TT	No patients with the TT genotype were available for analysis, but female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.
1448100663	CC	Patients with the CC genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
1448100664	CT	Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
1448100665	TT	Patients with the TT genotype and breast cancer may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
1448100689	CC	Patients with the CC genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.
1448100690	CT	Patients with the CT genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.
1448100691	TT	Patients with the TT genotype who are addicted to smoking may have a better response to treatment with bupropion as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.
1448100697	CC	Patients with the CC genotype who are addicted to smoking and are trying to quit may have a reduced cravings for nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence nicotine cravings.
1448100633	AG	Patients with the AG genotype may have a better response to treatment with methadone as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.
1448100634	GG	Patients with the GG genotype may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.
1448100698	CT	Patients with the CT genotype who are addicted to smoking and are trying to quit may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.
1448100699	TT	Patients with the TT genotype who are addicted to smoking and are trying to quite may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.
1448100736	CC	Patients with the CC genotype and macular degeneration may have a poorer improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CT or TT genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.
1448100737	CT	Patients with the CT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.
1448100738	TT	Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.
1448100764	CC	Patients with the CC genotype and hypertension may have poorer blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CT or TT genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.
1448100765	CT	Patients with the CT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.
1448100766	TT	Patients with the TT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.
1448100779	CC	Patients with the CC genotype may have increased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.
1449156309	AA	Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of  neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.
1447963051	CC	Patients with the CC genotype were not studied. Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447963052	CG	Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447963053	GG	Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447963059	A	Patients with the A allele and HIV may have a lesser decline in adiponectin when treated with antiretroviral therapy as compared to patients with the G allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy.
1447963060	G	Patients with the G allele and HIV may have a greater decline in adiponectin when treated with antiretroviral therapy as compared to patients with the A allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy.
1448106486	AA	Patients with the AA genotype may be less likely to experience myopathy when treated with statins as compared to patients with the AG or GG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1448106487	AG	Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1448106488	GG	Patients with the GG genotype may be more likely to experience myopathy when treated with statins as compared to patients with the AA or AG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1448106494	AA	Women with the AA genotype were not studied. However, women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
1448099151	AA	Patients with the AA genotype and bone fractures may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to tramadol.
1448099152	AC	Patients with the AC genotype and bone fractures may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. Other genetic and clinical factors may also influence response to tramadol.
1448106495	AC	Women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
1448106496	CC	Women with the CC genotype and breast neoplasms may have an increased risk of bone density loss when exposed to letrozole as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
1447963236	AA	Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cocaine-related death.
1447963237	AC	Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.
1449156310	AG	Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of  neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.
1448099153	CC	Patients with the CC genotype and bone fractures may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tramadol.
1448106507	CC	Patients with the CC genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
1449156447	AA	Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.
1449156448	AC	Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.
1449156449	AT	Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.
1449156450	CC	Patients with renal cell carcinoma and the CC genotypes may have an INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the AA, AC, AT, CT, or TT genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.
1449156451	CT	Patients with renal cell carcinoma and the CT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.
1448106592	CC	Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.
1448106593	CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1448106594	TT	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.
1447982846	G	Patients with the G allele may have increased expression of LDLR as compared to patients with the A allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.
1448106545	AA	Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106586	AA	Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.
1448106587	AG	Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.
1448106619	AA	Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of neutropenia when treated with mercaptopurine as compared to patients with the CC genotype. This may be related to the increased 6-methylmercaptopurine nucleotide metabolite concentrations in patients with the AA genotype as compared to those with the CC genotype. Other genetic and clinical factors may also influence risk of neutropenia.
1448261904	*12	Patients with the *12 allele who have a rapid or intermediate acetylator phenotype may have increased metabolism of isoniazid as compared to patients with two slow NAT2 alleles. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1448261905	*13	Patients with the *13 allele who have a rapid or intermediate acetylator phenotype may have increased metabolism of isoniazid as compared to patients with two slow NAT2 alleles. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1448261906	*14	Patients with the *14 allele who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have decreased metabolism of isoniazid as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1448106538	AA	Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106539	AG	Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106540	GG	Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.
1448106588	GG	Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.
1448261907	*4	Patients with the *4 allele who have a rapid or intermediate acetylator phenotype may have increased metabolism of isoniazid as compared to patients with two slow NAT2 alleles. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1448109616	CC	Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109709	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1448109710	AC	Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC, or increased likelihood as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1183685519	AA	Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1183685520	AG	Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1183685521	GG	Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1448109711	CC	Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1448109720	AA	Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109721	AG	Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1447990195	CT	Patient with the CT genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
1447990196	TT	Patient with the TT genotype and Alzheimer's Disease may have an increased response to rivastigmine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
1448109722	GG	Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109785	GG	Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109786	GT	Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1447990219	AA	Patients with the AA genotype who are treated with ritonavir may have a decreased intracellular/plasma trough concentration as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
1447990220	AC	Patients with the AC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
982043295	GC	Breast cancer patients with GC + CC genotypes have decreased progression-free survival (PFS), overall survival (OS) and, increased absolute leucocyte and neutrophil counts when treated with docetaxel and doxorubicin when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982043296	GG	Breast cancer patients with GG genotypes have increased progression-free survival (PFS), overall survival (OS) and, decreased absolute leucocyte and neutrophil counts when treated with docetaxel and doxorubicin when compared to patients with CC + GC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1447943702	AA	Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.
1447943703	AG	Patients with genotype AG and narcolepsy may have increased response to modafinil compared to patients with genotypes AA or GG. Other clinical and genetic factors may affect a patient's response to modafinil.
1447943704	GG	Patients with genotype GG and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.
1450044579	CC	Patients with the CC genotype  may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044580	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044581	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448099164	CT	Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099165	TT	Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099180	CT	Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099181	TT	Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099190	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
1448099191	AG	Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
1449166771	*91	Patients with the CYP2D6*91 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1449166772	*93	Patients with the CYP2D6*93 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1449166773	*95	Patients with the CYP2D6*95 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1449166774	*98	Patients with the CYP2D6*98 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. Other genetic and clinical factors may also influence the metabolism of tamoxifen.
1448102371	AG	Patients with the AG genotype may have an increased risk for heroin addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.
1447947120	E4/E4	Patients with the E4/E4 genotype who are treated with simvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. However, patients with the E4/E4 diplotype who have had a myocardial infarction may have an increased risk of mortality as compared to other genotypes, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment.  Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1448256860	CT	Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1448256861	TT	Patients with the TT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis and 2) a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1448256866	AA	Patients with the AA genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448102788	*2a	Patients who carry the *2a allele and have colorectal cancer may have an increased risk for vomiting when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients without the *2a allele. Other genetic and clinical factors may also influence risk for vomiting on TIROX.
1448102793	GG	Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448256859	CC	Patients with the CC genotype and non-small-cell lung cancer may have 1) a decreased risk for pneumonitis and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1447949307	AA	Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.
1447949308	AG	Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.
1447949309	GG	Patients who receive a kidney with the GG genotype may have increased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AA or AG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.
1447960951	AC	Patients with the AC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
1447960952	CC	Patients with the CC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
1448102372	GG	Patients with the GG genotype may have a decreased risk for heroin addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.
1448256867	AG	Patients with the AG genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256868	GG	Patients with the GG genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1449157115	*1/*1	Patients with Crohn's disease and the TPMT *1/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*3A, *1/*3C, *1/*3D or *1/*3E diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.
1449157116	*1/*3A	Patients with Crohn's disease and the TPMT *1/*3A diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3A specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.
1449157117	*1/*3C	Patients with Crohn's disease and the TPMT *1/*3C diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3C specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.
1447681904	AA	Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1447681905	AG	Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the GG genotypes and increased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1447681906	GG	Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have increased plasma concentrations of triglycerides as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1449154574	TT	Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.
1447990145	AA	Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.
1447990146	AC	Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.
1448262547	CC	Patients with the CC genotype may have higher on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448262548	CT	Patients with the CT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448262549	TT	Patients with the TT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448260921	CC	Patients with the CC genotype may have decreased metabolism of amitriptyline as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
1447983188	CC	Patients with the CC genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the TT genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983187	CT	No information are available for patients with the CT genotype. However, patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983186	TT	Patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.
1448261908	*5	Patients with the *5 allele who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have decreased metabolism of isoniazid as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1448261909	*6	Patients with the *6 allele who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have decreased metabolism of isoniazid as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1448261910	*7	Patients with the *7 allele who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have decreased metabolism of isoniazid as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence isoniazid metabolism and clearance.
1449154572	CC	Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.
1449154573	CT	Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.
1447990221	CC	Patients with the CC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
1448109787	TT	Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109790	CC	Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109791	CT	Patients with the CT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109792	TT	Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109804	GG	Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109805	GT	Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109806	TT	Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109814	AA	Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109815	AG	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1450374091	CC	Patients with the CC genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374092	CT	Patients with the CT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374093	TT	Patients with the TT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1448099127	AA	Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448109816	GG	Patients with the GG genotype may have a dcreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or AA genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.
1448109825	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.
1448109826	AC	Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.
1448109827	CC	Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.
1450375682	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450374188	GG	Patients with the GG genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of methadone.
1450374189	GT	Patients with the GT genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of methadone.
1450374190	TT	Patients with the TT genotype who are being treated with methadone for heroin addiction may require a decreased dose of the drug as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence dose of methadone.
1447947066	CC	Patients with the CC genotype may have decreased plasma concentration of  atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
1447947067	CT	Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
1447947068	TT	Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
1448525461	G/del	Patients with the G/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1448525460	GG	Patients with the GG genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1448099208	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have an increased severity of neutropenia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099209	AG	Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099213	AA	Patients with the AA genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.
1448099192	GG	Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
1448099202	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel  may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099203	AG	Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel  may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099204	GG	Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel  may have a increased severity of anemia as compared to patients with the AA or AG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099214	AG	Patients with the AG genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.
1448099215	GG	Patients with the GG genotype and inflammatory diseases who are treated with anti-TNF therapies may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.
1448099259	CC	Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.
1448099260	CT	Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.
1448099261	TT	Patients with the TT genotype may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.
1448099265	AA	Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.
1448525454	CC	Patients with the CC genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1448525455	CT	Patients with the CT genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1448525456	TT	Patients with the TT genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1449002803	AA	Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1449002804	AG	Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1447963238	CC	Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.
1447983167	CC	Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983166	CT	Patients with the CT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983165	TT	Patients with the TT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447963404	*1/*1	Patients with two functional CYP2C19 alleles (*1/*1) may have increased metabolism of mephenytoin compared to patients with *2/*2, *2/*3, *3/*3, *2/5, *2/*6 and *2/*7 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963405	*2/*2	Patients with two no function CYP2C19 alleles (*2/*2) (rs4244285) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963406	*2/*3	Patients with two no function CYP2C19 alleles (*2/*3) (rs4244285/rs4986893) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963407	*2/*5	Patients with two no function CYP2C19 alleles (*2/*5) (rs4244285/rs56337013) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963408	*2/*6	Patients with two no function CYP2C19 alleles (*2/*6) (rs4244285/rs72552267) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963409	*2/*7	Patients with two no function CYP2C19 alleles (*2/*7) (rs4244285/rs72558186) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963410	*2/*8	Patients with two no function CYP2C19 alleles (*2/*8) (rs4244285/rs41291556) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447963411	*3/*3	Patients with two no function CYP2C19 alleles (*3/*3) (rs4986893) may have decreased metabolism of mephenytoin compared to patients with *1/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.
1447983159	AG	Patients with the AG genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1447983160	GG	No information were reported regarding patients with the GG genotype.
1447983194	AA	Patients with the AA genotype were not studied.
1447983193	AG	Patients with the AG genotype and depression who are treated with venlafaxine may experience agitation and dysphoria. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983195	GG	Patients with the GG genotype were not studied.
1448616912	CC	Patients with the CC genotype and Cancer who are treated with Capecitabine may have an increased risk of of Diarrhea as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine
1448616913	CT	Patients with the CT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine
1449002799	AG	Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA genotype, and decreased clearance as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.
1448616914	TT	Patients with the TT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine
1449002800	GG	Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.
1450372313	CT	Patients with the CT genotype (DPYD *1/*6) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased metabolism of fluorouracil and 2) increased risk for drug toxicities as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450372314	TT	Patients with the TT genotype (DPYD *6/*6) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased metabolism of fluorouracil and 2) increased risk for drug toxicities when treated with as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450375676	AA	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1448098963	CC	Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.
1448098964	CT	Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.
1450371703	AA	Patients with rheumatoid arthritis and the AA genotype may have an increased response to tocilizumab as compared to patients with the AC or CC genotypes. Note that an increased response was only seen with one metric at one timepoint from the three analyzed in the study. Other genetic or clinical factors may also affect a patient's response to tocilizumab.
1450371704	AC	Patients with rheumatoid arthritis and the AC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.
1450371705	CC	Patients with rheumatoid arthritis and the CC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.
1450375677	AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375678	GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450373752	AA	Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373753	AG	Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373754	GG	Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1448098965	TT	Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.
1448099026	GG	Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.
1449748204	AA	Patients with the AA genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.
1449748205	AG	Patients with the AG genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.
1449748206	GG	Patients with the GG genotype may have a decreased lipid-lowering response to rosuvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.
1450375028	GG	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.
1450375343	*4	Patients with the *4 allele may have increased metabolism of nicotine as compared to the *1 allele. Other genetic or clinical factors may also affect a patient's metabolism of nicotine.
1450375344	*6	Patients with the *6 allele may have decreased metabolism of nicotine as compared to the *1 allele. Other genetic or clinical factors may also affect a patient's metabolism of nicotine.
1448525462	del/del	Patients with the del/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1449565166	GG	Pediatric patients with major thalassemia and the GG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype GT, therefore there is no information for patients with the GG or TT genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1448573509	GT	Patients with the GT genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.
1447727196	non-null/non-null	Children with the non-null/non-null genotype (has two copies of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have an increased risk of hearing impairment as compared to children with the null/null genotype (no copies of the GSTM1 gene). No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1447727197	non-null/null	Children with the non-null/null genotype (has one copy of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have an increased risk of hearing impairment as compared to children with the null/null genotype (no copies of the GSTM1 gene). No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1447727198	null/null	Children with the null/null genotype (has no copies of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have a reduced, but not absent, risk of hearing impairment as compared to children with the non-null/non-null or non-null/null genotype. No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1448099128	AG	Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448099129	GG	Patients with the GG genotype may have decreased clearance of rifampin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448099572	CC	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.
1448099571	CT	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.
1449565167	GT	Pediatric patients with major thalassemia and the GT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype GT, therefore there is no information for patients with the GG or TT genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1448573510	TT	Patients with the TT genotype may have increased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the GG genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.
1448099466	AG	Patients with the AG genotype may have decreased clearance of sulfasalazine as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).
1448099467	GG	Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).
1448099570	TT	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.
1448099604	CC	Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
1448099605	CT	Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
1448099606	TT	Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
1448099266	AC	Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.
1448099267	CC	Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment.
1449157302	AA	Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1449157303	AG	Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1449157304	GG	Patients with the GG genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA or AG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1450044603	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops Malignant Hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450375689	AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1448099292	CC	Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448099293	CT	Patients with the CT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype or may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1448099294	TT	Patients with the TT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1449157297	AA	Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1450044486	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448099325	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448099326	AG	Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel  may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448098356	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098357	AG	Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099170	GT	Patients with nasopharyngeal cancer and the GT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099171	TT	Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the GT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448612498	GG	Individuals with the GG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449564847	TT	Patients with the TT genotype who are treated with acenocoumarol or phenprocoumon may require a lower dose as compared to patients with the CC genotype, although some suggest that it may also require a lower dose as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol or phenprocoumon dose.
1449156311	GG	Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of  neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.
1447945754	AA	Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
1447945755	GA	Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
1447945756	GG	Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
1449564845	CC	Patients with the CC genotype who are treated with acenocoumarol or phenprocoumon may require a higher dose as compared to patients with the TT and CT genotypes, although some suggest that it may only require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol or phenprocoumon dose.
1449564846	CT	Patients with the CT genotype who are treated with acenocoumarol or phenprocoumon may require a lower dose as compared to patients with the CC genotype, although some suggest that the CT genotype may also require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol or phenprocoumon dose.
1449576624	AA	Patients with cardiovascular disease and the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.
1448099158	CT	Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099159	TT	Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448615165	CC	Postmenopausal women with HR+ breast cancer and the CC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1449156489	AG	Patients with the AG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the GG genotype, and increased exposure as compared to patients with the AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.
1448616907	AG	Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine
1448100251	AA	Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.
1448100252	AG	Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.
1448100253	GG	Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.
1448616908	GG	Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine
1450377324	CC	Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.
1449164103	*1/*1	Patients with the *1/*1 diplotype may require a higher dose of warfarin as compared to patients with the *2 or *3 CYP2C9 alleles. CYP2C9*1/*1 is considered a fully functional genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449164104	*1/*2	Patients with the *1/*2 diplotype may require a lower dose of warfarin as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449575670	CC	The CC genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.
1448099274	CC	Patients with nasopharyngeal cancer and the CC genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099275	CT	Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia as compared to patients with the CC or TT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099276	TT	Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1450377325	CT	Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.
1448100300	TT	Patients with the TT genotype may require a decreased dose of warfarin, and may be at increased risk of over-anticoagulation, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin and risk of over-anticoagulation.
1449575671	CT	The CT genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the TT genotype and increased expression, but decreased catalytic activity as compared to the CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.
1448276323	AA	Patients with the AA genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.
1448276324	AG	Patients with the AG genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.
1448100315	AA	Patients with the AA genotype and epilepsy may have decreased clearance of lamotrigine compared to patients with the GG genotype, though studies conflict. Other factors may affect clearance of lamotrigine.
1448100316	AG	Patients with the AG genotype and epilepsy may have decreased clearance of lamotrigine compared to patients with the GG genotype, though studies conflict. Other factors may affect clearance of lamotrigine.
1448100317	GG	Patients with the GG genotype and epilepsy may have increased clearance of lamotrigine compared to patients with the AA and AG genotypes, though studies conflict. Other factors may affect clearance of lamotrigine.
1449575676	del/del	The del/del genotype is associated with decreased catalytic activity of DPYD as compared to the del/T or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1448276325	GG	Patients with the GG genotype may have decreased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to thiopurines.
1450377183	CC	Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1449575672	TT	The TT genotype is associated with increased expression of DPYD, but decreased catalytic activity as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.
1450377184	CT	Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377185	TT	Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1449165046	GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
1449165047	GT	Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
1448099936	GG	Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
1448099937	GT	Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
1448099938	TT	Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
1448112089	CC	Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AA or AC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.
1448112158	CC	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.
1448112159	CT	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.
1448099910	AA	Patients with choroidal neovascularization and the AA genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.
1448099911	AC	Patients with choroidal neovascularization and the AC genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.
1448099912	CC	Patients with choroidal neovascularization and the CC genotype may have increased response to photodynamic therapy compared to patients with the AA and AC genotypes. Other factors may affect response to photodynamic therapy.
1448099930	C/del	Patients with the C/del genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
1448099931	CC	Patients with the C/C genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
1448099932	del/del	Patients with the del/del genotype and cancer who are treated with capecitabine may have an increased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the CC or C/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
1448112160	TT	Patients with the TT genotype and hormone insensitive breast cancer may experience increased risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the CT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.
1447943734	AA	Patients with genotype AA and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
1447943735	AC	Patients with genotype AC and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
1447943736	CC	Patients with genotype CC and schizophrenia may have decreased response to olanzapine compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
1449564431	*2/*2	Patients with the *2/*2 genotype may have an increased likelihood of overcoagulation when treated with acenocoumarol as compared to patients with the *1/*1 genotype. Other clinical and genetic factors may also influence likelihood of overcoagulation in patients administered acenocoumarol.
1449564432	*2/*3	Patients with the *2/*3 genotype may have an increased likelihood of overcoagulation when treated with acenocoumarol as compared to patients with the *1/*1 genotype. Other clinical and genetic factors may also influence likelihood of overcoagulation in patients administered acenocoumarol.
1449564433	*3/*3	Patients with the *3/*3 genotype may have an increased likelihood of overcoagulation when treated with acenocoumarol as compared to patients with the *1/*1 genotype. Other clinical and genetic factors may also influence likelihood of overcoagulation in patients administered acenocoumarol.
1449564493	*1/*1	Individuals with the *1/*1 genotype who are treated with metoprolol may have increased metabolism/clearance of metoprolol as compared to individuals with 1 or more reduced (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele. Other genetic and clinical factors may also influence metabolism of metoprolol.
1449564494	*10	Individuals with the *10 reduced functional allele in combination with a reduced function (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metoprolol, as compared to patients with *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564495	*17	Individuals with the *17 reduced functional allele in combination with a reduced function (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564496	*29	Individuals with the *29 reduced functional allele in combination with a reduced function (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564428	*1/*1	Patients with the *1/*1 genotype may have a decreased likelihood of overcoagulation when treated with acenocoumarol as compared to patients carrying one or two copies of the *2 or *3 alleles. Other clinical and genetic factors may also influence likelihood of overcoagulation in patients administered acenocoumarol.
1448100336	CC	Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.
1448100337	CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1449564429	*1/*2	Patients with the *1/*2 genotype may have an increased likelihood of overcoagulation when treated with acenocoumarol as compared to patients with the *1/*1 genotype. Other clinical and genetic factors may also influence likelihood of overcoagulation in patients administered acenocoumarol.
1449564430	*1/*3	Patients with the *1/*3 genotype may have an increased likelihood of overcoagulation when treated with acenocoumarol as compared to patients with the *1/*1 genotype. Other clinical and genetic factors may also influence likelihood of overcoagulation in patients administered acenocoumarol.
1449564497	*3	Individuals with the *3 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*9, *10, *17, *29, *31, *41, *45, *46) may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564498	*31	Individuals with the *31 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*9, *10, *17, *29, *31, *41, *45, *46) may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564499	*35/*35	Individuals with the *35/*35 genotype who are treated with metoprolol may have increased metabolism/clearance of metoprolol and a smaller decrease in heart rate as compared to individuals with 1 or more reduced function (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564500	*4	Individuals with the *4 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*9, *10, *17, *29, *31, *41, *45, *46) may have decreased metabolism/clearance of metoprolol and a greater decrease in heart rate as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449564501	*41	Individuals with the *41 reduced functional allele in combination with a reduced function (*9, *10, *17, *29, *41) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metoprolol, and a greater decrease in heart rate as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1448106620	AC	Patients with the AC genotype and acute lymphoblastic leukemia may have an increased risk of neutropenia when treated with mercaptopurine as compared to patients with the CC genotype. This may be related to the increased 6-methylmercaptopurine nucleotide metabolite concentrations in patients with the AC genotype as compared to those with the CC genotype. However, one study found a decreased risk for leukopenia for patients with the AC genotype as compared to those with the CC genotype. Other genetic and clinical factors may also influence risk of neutropenia.
1448106621	CC	Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk of neutropenia when treated with mercaptopurine as compared to patients with the AA or AC genotype. This may be related to the decreased 6-methylmercaptopurine nucleotide metabolite concentrations in patients with the CC genotype as compared to those with the AA or AC genotype. However, one study found an increased risk of leukopenia for patients with the CC genotype as compared to those with the AC genotype. Other genetic and clinical factors may also influence risk of neutropenia.
1448100363	AA	Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100364	AT	Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100365	TT	No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100372	AA	No patients with the AA genotype were available for analysis, but patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100373	AG	Patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100374	GG	Patients with the GG genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100384	AA	Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100385	AT	Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100386	TT	No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100391	CC	Patients with the CC genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CT and TT genotypes. Other factors may affect response to these drugs.
1448100392	CT	Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.
1448100393	TT	Patients with the TT genotype and schizophrenia may have decreased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CC and CT genotypes. Other factors may affect response to these drugs.
1448100429	CT	Patients with the CT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1448100430	TT	Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448100496	CC	Patients with the CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. Other factors may affect concentrations of lamotrigine.
1448100421	AA	Patients with the AA genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the AG and GG genotypes. Other factors may affect response to adalimumab.
1448100422	AG	Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.
1448100423	GG	Patients with the GG genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the AA and AG genotypes. Other factors may affect response to adalimumab.
1448100428	CC	Patients with the CC genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
1448100497	CT	Patients with the CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. Other factors may affect concentrations of lamotrigine.
1448100498	TT	Patients with the TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. Other factors may affect concentrations of lamotrigine.
1448602874	GT	Patients with the GT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602875	TT	Patients with the TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448100510	AA	Patients with the AA genotype and Type 2 Diabetes may have decreased response to sitagliptin or vildagliptin compared to patients with the GG genotype. Other factors may affect response to sitagliptin and vildagliptin.
1448100511	GG	Patients with the GG genotype and Type 2 Diabetes may have increased response to sitagliptin or vildagliptin compared to patients with the AA genotype. Other factors may affect response to sitagliptin and vildagliptin.
1448100516	CC	Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.
1448100517	CT	Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.
1448100518	TT	Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.
1448602873	GG	Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602881	AA	Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448423705	AA	Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1449157885	AA	Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotype. They also may have a shorter time between waking in the morning and the first cigarette as compared to the AG or GG genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.
1449157886	AG	Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.
1449157887	GG	Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.
1448602880	AG	Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448101061	AA	Patients with the AA genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1448101062	AG	Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1448101063	GG	Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1448101081	CC	Pediatric patients undergoing heart transplantation who have the CC genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.
1448276372	CC	Patients with the CC genotype and ANCA-associated vasculitis may have shorter time to failure when treated with rituximab compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to rituximab.
1448276373	CT	Patients with the CT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.
1448423706	AG	Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423707	GG	Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1449156452	TT	Patients with renal cell carcinoma and the TT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.
1449164145	CC	Patients with the CC genotype may require decreased doses of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164146	CG	Patients with the CG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the CC genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164147	GG	Patients with the GG genotype may require increased doses of warfarin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1448101098	CC	Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.
1448106805	AA	Patients with the AA genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448106806	AG	Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448106807	GG	Patients with the GG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448101116	AA	Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448101117	AG	Patients with the AG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448101118	GG	Patients with the GG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448101158	AA	Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101159	AG	Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype, or decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101160	GG	Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101170	AA	Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101171	AG	Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101172	GG	Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for nicotine addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101177	CC	Patients with the CC genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101178	CT	Patients with the CT genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101179	TT	Patients with the TT genotype may have an increased risk for smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1449164151	GG	Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164129	GG	Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164130	GT	Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164131	TT	Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1448100349	CC	Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.
1448100350	CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1448100351	TT	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.
1447947008	CC	Patients with the CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.
1447947009	CT	Patients with the CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.
1447947010	TT	Patients with the TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.
1448102835	AA	Patients with the AA genotype and prostate cancer may have shorter progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448102836	AG	Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448102837	GG	Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448102841	CC	Patients with the CC genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.
1448102842	CT	Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.
1448102843	TT	Patients with the TT genotype and hepatitis C may have an increased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for anemia.
1448102847	CC	Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.
1448102848	CT	Patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.
1448102849	TT	No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.
1448104139	AG	Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1448104140	GG	Patients with the GG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have an increased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1448104320	CC	Patients with the CC genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
1448104321	CT	Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
1447679979	CT	Patients with the CT genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the TT genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.
1447679980	TT	Patients with the TT genotype and Epilepsy may have lower metabolism of carbamazepine and may require a decreased dose of carbamazepine as compared to patients with the the CC or CT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.
1448102794	GT	Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448102795	TT	Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448103944	AA	Patients with the AA genotype may have an increased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103912	CC	Patients with the CC genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
1448103913	CT	Patients with the CT genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
1448103914	TT	Patients with the TT genotype who are addicted to heroin may have decreased withdrawal symptoms when treated with methadone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
1448103937	GG	Patients with the GG genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103938	GT	Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103939	TT	Patients with the TT genotype and type 2 diabetes may have a better response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103945	AG	Patients with the AG genotype may have an increased risk for alcoholism as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103946	GG	Patients with the GG genotype may have a decreased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103951	CC	Patients with the CC genotype may have an increased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103952	CT	Patients with the CT genotype may have an increased risk for alcoholism as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103953	TT	Patients with the TT genotype may have a decreased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103958	CC	Patients with the CC genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448103959	CG	Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448103960	GG	Patients with the GG genotype may have an increased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448103965	GG	Patients with the GG genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103966	GT	Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103967	TT	Patients with the TT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103975	AA	Patients with the AA genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103976	AC	Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103977	CC	Patients with the CC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448104007	AA	Patients with the AA genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.
1448104008	AT	Patients with the AT genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype, or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1449752598	AA	Patients with the AA genotype may have 1) an increased risk for nephrotoxicity 2) decreased survival and 3) a poorer response when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. However, some studies find no association with drug toxicity, and one study found a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1449752599	AG	Patients with the AG genotype who are treated with platinum-based chemotherapy may have an increased risk for nephrotoxicity as compared to patients with the GG genotype. The findings for response and overall survival are inconclusive. Patients with the AG genotype may have an increased response compared to patients with the AA genotype. However, another study showed an increased response compared to patients with the GG genotype. Additionally, some studies find no association with drug toxicity or survival. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1449752600	GG	Patients with the GG genotype may have 1) decreased but not absent risk for toxicity, 2) increased survival and 3) a better response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. However, some studies find no association with drug toxicity, and one study found a poorer response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1446897542	CC	Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes.
1446897543	CG	Patients with breast cancer and the genotype CG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.
1446897544	GG	Patients with breast cancer and the genotype GG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.
1446897548	CC	Patients with breast cancer and the CC genotype may have an increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CG and GG. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases who are taking anastrozole or letrozole.
1446897549	CG	Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.
1446897550	GG	Patients with breast cancer and the GG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CC. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.
1449752789	CC	Patients with the CC genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.
1447963091	AA	Patients with the AA genotype may have a decreased risk for tobacco addiction as compared to patients with the GG genotype. Patients with the AA genotype may also show decreased levels of cotinine as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels.
1448101082	CT	Pediatric patients undergoing heart transplantation who have the CT genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.
1448101083	TT	Pediatric patients undergoing heart transplantation who have the TT genotype may have an increased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.
1448101096	AA	Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.
1448101097	AC	Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.
1447963092	AG	Patients with the AG genotype may have a decreased risk for tobacco addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Patients with the AG genotype may also show decreased levels of cotinine as compared to those with the GG genotype, or increased levels as compared to those with the AA genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels.
1447963093	GG	Patients with the GG genotype may have an increased risk for tobacco addiction as compared to patients with the AA genotype. Patients with the GG genotype may also show increased levels of cotinine as compared to those with the AA genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels.
1447962845	AA	Patients with the AA genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.
1447962846	AG	Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.
1447962847	GG	Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.
1448112199	GT	Patients with the GT genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.
1448112200	TT	Patients with the TT genotype and breast cancer may have decreased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the GG and GT genotypes. Other clinical and genetic factors may affect the metabolism of tamoxifen.
1448633837	*1/*1	Patients with the CYP2B6 *1/*1 may have increased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *6/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.
1448633836	*1/*6	Patients with the CYP2B6 *1/*6 may have increased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *6/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.
1448256093	TT	Patients with the TT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.
1448256691	CC	Patients with the CC genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1448633835	*6/*6	Patients with the CYP2B6 *6/*6 may have decreased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *1/*1 or *1/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.
1447982827	AA	Patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.
1447982828	AG	No information are available for the AG genotype. However, patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.
1447982829	GG	Patients with the GG genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.
1448101204	AA	Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
1448101205	AG	Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
1448101206	GG	Patients with the GG genotype and chronic hepatitis C may be more likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
1448101254	AA	Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101255	AG	Patients with the AG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101256	GG	Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
1448112198	GG	Patients with the GG genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.
1448256692	CT	Patients with the CT genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1448256693	TT	Patients with the TT genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.
1446908617	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
1446908618	CT	Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
1446908619	TT	No information were reported regarding patients with the TT genotype.
1446908624	AA	Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.
1446908625	AG	Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.
1446908626	GG	Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 34 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.
1446908651	*1/*1	Patients with two functional CYP2D6 alleles who are treated with nortriptyline may have decreased metabolism of nortriptyline as compared to patients with a duplication of a functional CYP2D6 gene and 1) increased metabolism of nortriptyline (decreased nortriptyline plasma levels), 2) a decreased, but not absent, risk for side effects as compared to patients with CYP2D6 non-functional alleles (*3, *4, *5, *6) or reduced function alleles (*10). Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908652	*1/*1xN	Patients with a duplication of a functional CYP2D6 gene who are treated with nortriptyline may have an increased metabolism of nortriptyline (decreased nortriptyline plasma concentration and increased maximum plasma concentration of 10-hydroxy nortriptyline) as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908653	*1/*2xN	Patients with a duplication of a functional CYP2D6 gene who are treated with nortriptyline may have an increased metabolism of nortriptyline (decreased nortriptyline plasma concentration and increased maximum plasma concentration of 10-hydroxy nortriptyline) as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908654	*2/*2	Patients with two functional CYP2D6 alleles who are treated with nortriptyline may have decreased metabolism of nortriptyline as compared to patients with a duplication of a functional CYP2D6 gene and 1) increased metabolism of nortriptyline (decreased nortriptyline plasma levels), 2) a decreased, but not absent, risk for side effects as compared to patients with CYP2D6 non-functional alleles (*3, *4, *5, *6) or reduced function alleles (*10). Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908655	*3	Patients with the CYP2D6*3 allele who are treated with nortriptyline may have 1) decreased metabolism of nortriptyline (increased nortriptyline plasma levels), 2) in combination with another non-functional allele (*3, *4, *5, *6) or reduced function allele (*10) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908656	*4	Patients with the CYP2D6*4 allele who are treated with nortriptyline may have 1) decreased metabolism of nortriptyline (increased nortriptyline plasma levels), 2) in combination with another non-functional allele (*3, *4, *5, *6) or reduced function allele (*10) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908657	*5	Patients with the CYP2D6*5 allele who are treated with nortriptyline may have 1) decreased metabolism of nortriptyline (increased nortriptyline plasma levels), 2) in combination with another non-functional allele (*3, *4, *5, *6) or reduced function allele (*10) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908658	*5/*10 + *10/*10	Patients with the CYP2D6*10/*10 or *5/*10 genotype who are treated with nortriptyline may have 1) decreased metabolism of nortriptyline (increased nortriptyline plasma levels), 2) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908659	*6	Patients with the CYP2D6*6 allele who are treated with nortriptyline may have 1) decreased metabolism of nortriptyline (increased nortriptyline plasma levels), 2) in combination with another non-functional allele (*3, *4, *5, *6) or reduced function allele (*10) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1446908676	AA	Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1446908675	AG	Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1447953111	AA	Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.
1447953112	AG	Women with the AG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.
1447953113	GG	Women with the GG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.
1447953132	CC	Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
1447953133	CT	Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
1447953134	TT	Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
1447953140	AA	Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels and another found increased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447953141	AG	Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447953142	GG	Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may a larger reduction in LDL as compared to patients with the AA or AG genotype. However, one study found no association with LDL levels and another found decreased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1448102799	AA	Patients with the AA genotype and hepatitis C or HIV may have an increased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102800	AT	Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102801	TT	Patients with the TT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1447960438	CC	Patients with the CC genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
1447960439	CG	Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
1447960440	GG	Patients with the GG genotype and coronary artery disease may require an increased dose of catecholamines as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
1447960516	AA	Patients with the AA genotype and breast cancer may have an increased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1447960517	AG	No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype.
1447960518	GG	Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1448104009	TT	Patients with the TT genotype and schizophrenia may have a decreased response to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1449164105	*1/*3	Patients with the *1/*3 diplotype may require a lower dose of warfarin as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449164106	*2/*2	Patients with the *2/*2 diplotype may require a lower dose of warfarin as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors may also influence the dose of warfarin.
1449164107	*2/*3	Patients with the *2/*3 diplotype may require a lower dose of warfarin as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1448616416	AA	Children with the AA genotype and cancer may have a lower, but not absent, risk for hearing loss with cisplatin treatment compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448616417	AT	Children with the AT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448616418	TT	Children with the TT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1447986981	GG	Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
1447986982	GT	Patients with the GT genotype and essential hypertension who are administered atenolol may have a increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
1447986983	TT	Patients with the TT genotype and essential hypertension who are administered atenolol may have an increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
1447986988	CC	Patients with the CC genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
1447986989	CT	Patients with the CT genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype, or increased clearance as compared to those with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
1447986990	TT	Patients with the TT genotype may have increased clearance of sulfinpyrazone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
1448616421	AA	Patients with the AA genotype may have decreased risk of cisplatin-induced ototoxicity as compared to patients with AC or CC genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.
1448616422	AC	Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.
1448616423	CC	Patients with the CC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.
1447987012	AA	Patients with the AA genotype and HIV who do not have the rs3745274 TT genotype may have decreased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.
1447987013	AG	Patients with the AG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.
1447987014	GG	Patients with the GG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.
1447987032	AA	Patients with the AA genotype and HIV may have increased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.
1449164108	*3/*3	Patients with the *3/*3 diplotype may require a lower dose of warfarin as compared to patients with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449164117	CC	Patients with the CC genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1448098795	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448098796	CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1448098797	TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.
1449270867	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449004216	CC	Patients with acute coronary syndrome and the CC genotype may have decreased response to clopidogrel as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.
1449270868	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270869	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449004217	CT	Patients with acute coronary syndrome and the CT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.
1449004218	TT	Patients with acute coronary syndrome and the TT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.
1446908868	AA	Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1446908869	AC	Patients with the AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1446908870	CC	Patients with the CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1446908881	CC	Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1446908882	CT	Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1446908883	TT	Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1449270490	GG	Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.
1449270873	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270874	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1446908970	AA	Patients with the AA genotype 1) may have increased metabolism of clopidogrel and 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG and AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449270875	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449002794	CT	Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.
1449002795	TT	Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.
1446908674	GG	Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1446908681	CC	Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.
1446908682	CT	Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.
1446908683	TT	Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.
1446908690	AA	Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.
1446908689	AG	Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.
1446908688	GG	Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.
1448106823	AA	Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448106824	AG	Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448106825	GG	Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1447946241	AC	Patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.
1447946242	CC	Patients with the CC genotype and osteosarcoma who are receiving methotrexate may have an increased risk for metastasis, as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.
1447946240	AA	No patients with the AA genotype were available for analysis, but patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.
1448106811	CC	Patients with the CC genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1449002798	AA	Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. They also may have decreased clearance of isoniazid as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.
1448106812	CT	Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448106813	TT	Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1447960561	AA	Patients with the AA genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960562	AG	Patients with the AG genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960563	GG	Patients with the GG genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960568	CC	Patients with the CC genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960569	CT	Patients with the CT genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960570	TT	Patients with the TT genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960651	AA	Patients with the AA genotype and hypertension may have a smaller reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
1447960652	AC	Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
1447960653	CC	Patients with the CC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
1447960702	*1/*1	Patients with two functional CYP2C19 alleles (*1/*1) may have increased metabolism of icotinib as compared to patients with one or two CYP2C19 loss-of-function alleles (*2 or *3). Other genetic and clinical factors may influence a patient's response to icotinib.
1447960703	*1/*2	Patients with CYP2C19*2 may have may have decreased metabolism of icotinib as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's response to icotinib.
1447960704	*1/*3	Patients with CYP2C19*3 may have may have decreased metabolism of icotinib as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's response to icotinib.
1447961339	AA	Patients with the AA genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447961340	AG	Patients with the AC genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447961341	GG	Patients with the GG genotype who take methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1449001866	C	Male patients with the C genotype and schizophrenia who are treated with antipsychotics such as olanzapine or clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the G genotype. However, contradictory findings are reported. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk of weight gain with antipsychotics.
1447962605	CC	Patients with the CC genotype who are also CYP2A6 normal metabolizers may have decreased metabolism of nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
1447962606	CT	Patients with the CT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
1447962607	TT	Patients with the TT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
1449001957	C	Male patients with the C genotype and schizophrenia, treated with antipsychotics, in particular olanzapine and risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype G. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.
1449001958	CC	Female patients with the CC genotype and schizophrenia, treated with antipsychotics, in particular olanzapine and risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.
1449001959	CG	Female patients with the CG genotype and schizophrenia, treated with antipsychotics, in particular olanzapine and risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.
1447946046	null/null	Patients with the null/null (has no copies of the GSTM1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null/ null or the non-null/ non-null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1447946109	CC	Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.
1447946110	CT	Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.
1447946111	TT	Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.
1447946116	A	Males with basal cell carcinoma who are hemizygous for the A allele may have a better response to treatment with imiquimod as compared to males hemizygous for the T allele. Other genetic and clinical factors may also influence response to imiquimod treatment.
1447946117	T	Males with basal cell carcinoma who are hemizygous for the T allele may have a poorer response to treatment with imiquimod as compared to males hemizygous for the A allele. Other genetic and clinical factors may also influence response to imiquimod treatment.
1449191514	*3	Patients with the *3 non-functional allele in combination with another non-functional (*3, *4, *5, *6, *40) or reduced function (*10, *17, *41) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid codeine use due to lack of efficacy.  Alternative analgesics such as morphine or a non-opioid should be considered. Other genetic and clinical factors may also influence a patient's response to codeine.
1447987033	AG	Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.
1447987034	GG	Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.
1449191515	*4	Patients with the *4 non-functional allele in combination with another non-functional (*3, *4, *5, *6, *40) or reduced function (*10, *17, *41) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid codeine use due to lack of efficacy.  Alternative analgesics such as morphine or a non-opioid should be considered.  Other genetic and clinical factors may also influence a patient's response to codeine.
1447987047	CC	Patients with the CC genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987048	CT	Patients with the CT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype, or decreased clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987049	TT	Patients with the TT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987054	AA	Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987055	AC	Patients with the AC genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987056	CC	Patients with the CC genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1449005384	AA	Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.
1449005385	AG	Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.
1449005386	GG	Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the GG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.
1446908971	AG	Patients with the AG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1446908972	GG	Patients with the GG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449164157	AA	Patients with the AA genotype may require decreased doses of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164158	AG	Patients with the AG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the AA genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1446909000	AA	Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909001	AC	Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1446909002	CC	Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1449164152	GT	Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype, and increased doses as compared to the GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164153	TT	Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1449164159	GG	Patients with the GG genotype may require increased doses of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1446909012	GG	Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.
1446909013	TG	Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.
1446909014	TT	Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.
1446909018	CC	Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1446909019	CT	Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1446909020	TT	Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1447960486	CC	Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
1447960487	CT	Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
1447960488	TT	Patients with the TT genotype and hypertension may have a lesser reduction in blood pressure when treated with enalapril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
1449156467	GT	Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.
1449645494	GG	Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449156468	TT	Patients with the TT genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.
1449191516	*40	Patients with the *40 non-functional allele in combination with another non-functional (*3, *4, *5, *6, *40) or reduced function (*10, *17 *41) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 intermediate metabolizers should be monitored closely for less than optimal response and should be offered an alternative analgesic if required. Other genetic and clinical factors may also influence a patient's response to codeine.
1449645489	GT	Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645490	TT	Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449156488	AA	Patients with the AA genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the AG and GG genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.
1448602887	CC	Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602886	CT	Patients with the CT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602885	TT	Patients with the TT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1449645495	GT	Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645496	TT	Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645500	AA	Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1446899932	CC	Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899933	CT	Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899934	TT	Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448602879	GG	Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602956	AA	Patients with the AA genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448602957	AG	Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448602958	GG	Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1449156490	GG	Patients with the GG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the AG and AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.
1449157118	*1/*3D	Patients with Crohn's disease and the TPMT *1/*3D diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3D specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.
1449157119	*1/*3E	Patients with Crohn's disease and the TPMT *1/*3E diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3E specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.
1449191588	CC	Patients with the CC genotype (do not carry a copy of the CFTR R74W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191589	CT	Patients with the CT genotype (one copy of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191592	CC	Patients with the CC genotype (two copies of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191593	CG	Patients with the CG genotype (one copy of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1447962763	CC	Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962764	CT	Patients with the CT genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the TT genotype, and a smaller increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962765	TT	Patients with the TT genotype and hypercholesterolemia may have a smaller increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447963651	GG	Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.
1447963652	GT	Patients with the GT genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also influence response to clozapine.
1447963653	TT	Patients with the TT genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.
1449191594	GG	Patients with the GG genotype (do not have a copy of the CFTR D110H variant) and cystic fibrosis have an unknown response to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191590	TT	Patients with the TT genotype (two copies of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1446897985	AA	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.
1446897986	AC	Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.
1446897987	AT	Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.
1446897988	CC	Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.
1446897989	TT	Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane  may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.
1446897992	AA	Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.
1446897993	AG	Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.
1446897994	GG	Patients with the GG genotype and acute myeloid leukemia may have a poorer response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the AA or AG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.
1448108785	AA	Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1449165486	AA	Patients with the AA genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AA genotype had increased survival times compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.
1449165487	AG	Patients with the AG genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.
1449165714	*1A/*3A	Patients with the *1A/*3A genotype who have received a kidney transplant may have decreased concentrations of cyclosporine as compared to patients with the *3A/*3A genotype. Other genetic and clinical factors may also affect concentrations of cyclosporine.
1449165715	*3A/*3A	Patients with the *3A/*3A genotype who have received a kidney transplant may have increased concentrations of cyclosporine as compared to patients with the *1A/*1A and *1A/*3A genotypes. Other genetic and clinical factors may also affect concentrations of cyclosporine.
1447963676	AA	Patients with the AA genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447963677	AG	Patients with the AG genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447963678	GG	Patients with the GG genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447979688	*10	Patients who carry the *10 allele may have decreased metabolism of tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1449165488	GG	Patients with the GG genotype and cancer may have increased survival times when treated with cetuximab as compared to patients with the AA or AG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the GG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.
1446897487	AC	Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.
1446897488	CC	Patients with colorectal cancer and the CC genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the AC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.
1449191517	*41	Patients with the *41 reduced functional allele in combination with another non-functional allele (*3, *4, *5, *6, *40)  may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 intermediate metabolizers should be monitored closely for less than optimal response and should be offered an alternative analgesic if required. Other genetic and clinical factors may also influence a patient's response to codeine.
1447960504	AA	Patients with the AA genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.
1447960505	AG	Patients with the AG genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.
1447960506	GG	Patients with the GG genotype and non-small-cell lung cancer may have a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.
1447960718	CC	Patients with the CC genotype and HIV may have decreased concentrations of nevirapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
1447960719	CT	Patients with the CT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
1447960720	TT	Patients with the TT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
1447960733	CC	Patients with the CC genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960734	CT	Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960735	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1449191518	*5	Patients with the *5 non-functional allele in combination with another non-functional (*3, *4, *5, *6, *40) or reduced function (*10, *17, *41) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid codeine use due to lack of efficacy. Consider alternative analgesics such as morphine or a non-opioid. Other genetic and clinical factors may also influence a patient's response to codeine.
1449191519	*6	Patients with the *6 non-functional allele in combination with another non-functional (*3, *4, *5, *6, *40) or reduced function (*10, *17, *41) allele may have 1) decreased metabolism/clearance of codeine, 2) decreased likelihood of response to codeine as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid codeine use due to lack of efficacy. Consider alternative analgesics such as morphine or a non-opioid. Other genetic and clinical factors may also influence a patient's response to codeine.
1447962643	CC	Patients with the CC genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.
1447962644	CT	Patients with the CT genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.
1449191570	AA	Patients with the AA genotype (two copies of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191571	AT	Patients with the AT genotype (one copy of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1445401808	GG	Patients with the GG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
1449157298	AC	Patients with the AC genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype, or a better response as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1449157299	CC	Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1449183086	AA	Patients with the AA genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1449183087	AG	Patients with the AG genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1448265019	AA	Patients with genotype AA may have increased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
1448265020	AG	Patients with genotype AG may have increased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
1445401849	AA	Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1445401850	AC	Patients with the AC genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1445401851	CC	Patients with the CC genotype and breast cancer may have an decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1445401860	AA	Patients with the AA genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
1445401861	AG	Patients with the AG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
1445401862	GG	Patients with the GG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
1449183088	GG	Patients with the GG genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1448265021	GG	Patients with genotype GG may have decreased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
1445401967	CC	Patients with the CC genotype (POR *1/*1) and familial hypercholesterolemia may have a greater decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CT (*1/*28) or TT (*28/*28) genotype. Other genetic and clinical factors may also influence response to atorvastatin.
1445401968	CT	Patients with the CT genotype (POR *1/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (*1/*1). Other genetic and clinical factors may also influence response to atorvastatin.
1445401969	TT	Patients with the TT genotype (POR *28/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (POR *1/*1). Other genetic and clinical factors may also influence response to atorvastatin.
1447963444	AA	Patients with the AA genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
1447963445	AG	Patients with the AG genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
1447963446	GG	Patients with the GG genotype and chronic myeloid leukemia may have a lower rate of major cytogenetic response when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
1447963460	CC	Pediatric patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to corticosteroids.
1447963461	CG	Pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.
1447963462	GG	No patients with the GG genotype were available for analysis, but pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.
1449002805	GG	Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA or AG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1449002808	AA	Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease, abnormal liver-function tests and decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.
1449002809	AG	Patients with the AG genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease, abnormal liver-function tests and decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with GG genotype or may have decreased risk for toxic liver disease, abnormal liver-function tests and increased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.
1447964017	AA	Patients with the AA genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.
1447964018	AG	Patients with the AG genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the GG genotype, and increased plasma levels as compared to those with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.
1447964019	GG	Patients with the GG genotype and HIV may have increased plasma levels of efavirenz as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.
1449002810	GG	Patients with the GG genotype who are treated with drugs for treatment of tuberculosis may have decreased risk for toxic liver disease, abnormal liver-function tests and increased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.
1449002815	TT	Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.
1449003720	CT	Patients with the CT genotype may have increased concentrations of oseltamivir compared to patients with the TT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.
1449003721	TT	Patients with the TT genotype may have decreased concentrations of oseltamivir compared to patients with the CT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.
1449003808	G/del	Patients with the G/del genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the del/del genotype or a decreased risk of venous thrombosis compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003962	AA	Patients with the AA genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.
1449003963	AG	Patients with the AG genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.
1449003964	GG	Patients with the GG genotype who are taking clopidogrel may have decreased resistance to clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.
1449164118	CT	Patients with the CT genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1449164119	TT	Patients with the TT genotype and rs3212198 T allele who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype in combination with any allele of rs3212198. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1449164125	TT	Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.
1450372226	AA	Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.
1450372228	GG	Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the AA genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.
1447979689	*11	Patients who carry the *11 allele may have decreased metabolism of tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447979690	*18A	Cells with the *18A allele may have decreased CYP2A6 catalytic activity when assayed with tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447979691	*19	Cells with the *19 allele may have decreased CYP2A6 catalytic activity when assayed with tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1450372227	AG	Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.
1446901293	AA	Patients with renal cell carcinoma and the AA genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
1446901294	AT	Patients with renal cell carcinoma and the AT genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
1446901295	TT	Patients with renal cell carcinoma and the TT genotype may have an increased likelihood of hypertension when taking sunitinib as compared to patients with the AA and AT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
1446901313	CC	Patients with renal cell carcinoma and the CC genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.
1446901314	CT	Patients with renal cell carcinoma and the CT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.
1446901315	TT	Patients with renal cell carcinoma and the TT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.
1447979692	*1A/*1A	Patients with the *1A/*1A genotype may have increased metabolism of tegafur as compared to those who carry the *4A, *4C, *7, 9A, *10, *11, *18A and *19 genotypes. Other genetic and clinical factors may also influence metabolism of tegafur.
1449162597	AA	Patients with the AA genotype may be at an increased risk of experiencing cognitive dysfunction while being treated with fentanyl than patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.
1449162598	AG	Patients with the AG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.
1449162599	GG	Patients with the GG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.
1447962645	TT	Patients with the TT genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the CC genotype. This may be due to increased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the T allele as compared to those with the C allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.
1447962718	CC	Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962719	CT	Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962720	TT	Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962725	CC	Patients with the CC genotype may have a smaller increase in HDL cholesterol when treated with pravastatin as compared to patients with the CT or TT genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962726	CT	Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962727	TT	Patients with the TT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962732	CC	Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with pravastatin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962733	CG	Patients with the CG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962734	GG	Patients with the GG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962739	CC	Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the TT genotype, and a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962740	CT	Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962741	TT	Patients with the TT genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448125501	CC	Patients with genotype CC have shorter progression-free survival time when treated with sorafenib as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence the response to sorafenib.
1448255332	CT	Patients with the CT genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype, or a decreased risk and increased activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.
1448125502	CT	Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.
1448125503	TT	Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.
1448255331	CC	Patients with the CC genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.
1448255333	TT	Patients with the TT genotype and cancer may have a decreased risk for toxicity when treated with fluoropyrimidines, as well as increased DPYD activity, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.
1448107094	AA	Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1448107095	AG	Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1448107096	GG	Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1446898011	CC	Women with the CC genotype and obesity and polycystic ovarian syndrome (PCOS) may have an increased response to liraglutide as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898012	CT	Women with the CT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898013	TT	Women with the TT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898018	AA	Women with obesity and polycystic ovarian syndrome (PCOS) and the AA genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898019	AG	Women with obesity and polycystic ovarian syndrome (PCOS) and the AG genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898020	GG	Women with obesity and polycystic ovarian syndrome (PCOS) and the GG genotype may have a decreased response to liraglutide as compared to women with the AA and AG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1445737076	GG	Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.
1445737077	GT	Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.
1445737078	TT	Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.
1446898004	CC	Patients with the CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.
1446898005	CT	Patients with the CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.
1446898006	TT	Patients with the TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.
1449191572	TT	Patients with the TT genotype (do not have a copy of the CFTR I336K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191576	CC	Patients with the CC genotype (do not have a copy of the CFTR T338I variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191577	CT	Patients with the CT genotype (one copy of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1447960198	CC	Patients with the CC genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
1447960199	CG	Patients with the CG genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
1447960200	GG	Patients with the GG genotype may experience slower desensitization to effects of terbutaline as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
1447961331	AA	Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961332	AG	Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961333	GG	Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1449191578	TT	Patients with the TT genotype (two copies of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191580	AA	Patients with the AA genotype (two copies of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191581	AG	Patients with the AG genotype (one copy of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191582	GG	Patients with the GG genotype (do not have a copy of the CFTR E56K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191584	CC	Patients with the CC genotype (do not have a copy of the CFTR P67L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191585	CT	Patients with the CT genotype (one copy of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191586	TT	Patients with the TT genotype (two copies of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment.FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449004018	AA	People with AA  genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.
1449004019	AG	People with AG  genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.
1449004020	GG	People with GG  genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.
1445402177	AA	Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AT or TT genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1445402178	AT	Patients with the AT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1445402179	TT	Patients with the TT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1445402184	AA	Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1445402185	AG	Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1445402186	GG	Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.
1447987061	AA	Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987062	AG	Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987063	GG	Patients with the GG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
982031999	CC	Patients with the CC genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's response to risperidone.
1445402396	*1/*1	Patients with the *1/*1 diplotype who are administered bupropion may have decreased exposure to bupropion as compared to patients with the *1/*2 and *2/*2 diplotypes. Other clinical and genetic factors may also influence metabolism of bupropion.
1445402397	*1/*2	Patients with the *1/*2 diplotype who are administered bupropion may have increased exposure to bupropion as compared to patients with the *2/*2 diplotypes and increased exposure as compared to patients with the *1/*1 diplotype. Other clinical and genetic factors may also influence metabolism of bupropion.
1445402398	*2/*2	Patients with the *2/*2 diplotype who are administered bupropion may have increased exposure to bupropion as compared to patients with the *1/*2 and *1/*1 diplotypes. Other clinical and genetic factors may also influence metabolism of bupropion.
1447987068	AA	Patients with the AA genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987069	AG	Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987070	GG	Patients with the GG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447979693	*4A + *4C	Patients who carry the *4A or *4C alleles (CYP2A6 gene deletion) may have decreased metabolism of tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447979694	*7	Patients who carry the *7 allele may have decreased metabolism of tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
1447979695	*9A	Patients who carry the *9A allele may have decreased metabolism of tegafur as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence metabolism of tegafur.
982032000	CG	Patients with the CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's response to risperidone.
982032001	GG	Patients with the GG genotype and Schizophrenia may be more likely to respond when treated with risperidone as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may influence a patient's response to risperidone.
1448101444	CC	Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1448101445	CT	Patients with the CT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1447963249	AA	Patients with the AA genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.
1447963250	AG	Patients with the AG genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.
1447963251	GG	Patients with the GG genotype with high cholesterol may have a better response when treated with pravastatin or simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.
1447962869	CC	Patients with the CC genotype may have decreased clearance of pravastatin as compared to patients with the CG genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
1447962870	CG	Patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
1447962871	GG	No patients with the GG genotype were available for analysis, but patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
1447963731	AA	Patients with the AA genotype with cancer who are treated with gemcitabine 1) may be more likely to experience neutropenia and 2) may have decreased progression-free survival (PFS) as compared to patients with the AG or GG genotype. However, evidence is very contradictory for this association: one study found a decreased risk for hematological toxicity in those with the AA genotype, one study found increased PFS in those with the AA genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.
1447963732	AG	Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.
1447963733	GG	Patients with the GG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, evidence is very contradictory for this association: one study found an increased risk for hematological toxicity in those with the GG genotype, one study found decreased PFS in those with the GG genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.
1448109593	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109594	AC	Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1447979534	AA	Hepatic cells with the AA genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979535	AG	Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979536	GG	Hepatic cells with the GG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1448101446	TT	Patients with the TT genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1445402113	AA	Patients with the AA genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402114	AG	Patients with the AG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402115	GG	Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to clozapine.
1447960220	AA	Patients with the AA genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.
1447960221	AG	Patients with the AG genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype, or increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.
1447960222	GG	Patients with the GG genotype may have increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.
1448106358	CC	Patients with chronic hepatitis C genotype 1 and the CC genotype who also carry the CT or TT genotype at rs12979860 may have a decreased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.
1448106352	AA	Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448106353	AG	Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448106354	GG	Women with ovarian cancer and the GG genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1447960186	AA	Patients with the AA genotype and heart failure may have decreased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960187	AG	Patients with the AG genotype and heart failure may have decreased emergency department (ED) visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the GG genotype, and increased ED visits and hospital utilization as compared to those with the AA genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960188	GG	Patients with the GG genotype and heart failure may have increased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1448106359	CT	Patients with chronic hepatitis C genotype 1 and the CT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.
1448106360	TT	Patients with chronic hepatitis C genotype 1 and the TT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.
1446896664	*1/*1	Patients with CYP2D6 extensive (e.g. *1/*1), intermediate (e.g. *4/*10) or poor (e.g. *4/*4) metabolizer genotypes are more likely to have an increased response to ondansetron as compared to those with CYP2D6 ultrarapid metabolizer genotypes (e.g. *1/*1XN). This increased response leads to a reduced risk of vomiting after chemotherapy or anesthesia. No significant associations have been seen for nausea. For complete lists of metabolizer genotypes designated as ultrarapid, extensive, intermediate and poor, and explanations as to the meaning of these designations, please refer to the papers listed under evidence. Other genetic and clinical factors may also influence a patient's risk of vomiting after chemotherapy or anesthesia.
1446896665	*1/*1xN	Patients with CYP2D6 ultrarapid metabolizer genotypes (e.g. *1/*1XN) are more likely to have a decreased response to ondansetron as compared to any other metabolizer genotype group (extensive - e.g. *1/*1, intermediate - e.g. *4/*10 or poor - e.g. *4/*4). This decreased response leads to a higher risk of vomiting after chemotherapy or anesthesia. No significant associations have been seen for nausea. For complete lists of metabolizer genotypes designated as ultrarapid, extensive, intermediate and poor, and explanations as to the meaning of these designations, please refer to the papers listed under evidence. Other genetic and clinical factors may also influence a patient's risk of vomiting after chemotherapy or anesthesia.
1447682247	*1	Patients with the *1 allele may have increased metabolism/clearance of aripiprazole as compared to patients with two reduced function alleles (*10 or *41), one reduced function and one non-functional (*3, *4, *5, or *6) allele, or two non-functional alleles. Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1447682248	*10	Patients with the *10 allele may have decreased metabolism/clearance of aripiprazole as compared to patients with two fully functional alleles (*1 or *2). Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1447682249	*2	Patients with the *2 allele may have increased metabolism/clearance of aripiprazole as compared to patients with two reduced function alleles (*10 or *41), one reduced function and one non-functional (*3, *4, *5, or *6) allele, or two non-functional alleles. Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1449311534	*15/*1A	Patients with the *15/*1A diplotype may have increased exposure of repaglinide as compared to patients with the *1B/*1B, *1A/*1B or *1A/1A diplotype.  Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics.
1446899482	CC	Patients with the CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of enalapril.
1446899483	CT	Patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of enalapril.
1447964294	CC	Patients with the CC genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964295	CT	Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964296	TT	Patients with the TT genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964503	AA	Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
1447964504	AT	Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
1447682250	*4	Patients with the *4 allele may have decreased metabolism/clearance of aripiprazole as compared to patients with two fully functional alleles (*1 or *2). Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1447682251	*41	Patients with the *41 allele may have decreased metabolism/clearance of aripiprazole as compared to patients with two fully functional alleles (*1, *2). Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1447682252	*5	Patients with the *5 allele may have decreased metabolism/clearance of aripiprazole as compared to patients with two fully functional alleles (*1 or *2). Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1447682253	*6	Patients with the *6 allele may have decreased metabolism/clearance of aripiprazole as compared to patients with two fully functional alleles (*1 or *2). Other genetic and clinical factors may also influence a patient's response to aripiprazole.
1447964505	TT	Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
1449311539	*15/*1B	Patients with the *15/*1B diplotype may have increased exposure of repaglinide as compared to patients with the *1A/*1B and *1A/*1A diplotypes. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics.
1449311535	*1A/*1A	Patients with the *1A/*1A diplotype may have increased exposure of repaglinide, including increased AUC and decreased clearance of repaglinide as compared to patients with the *1B/*1B or *1B/*15 diplotype.  Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics.
1449311536	*1A/*1B	Patients with the *1A/*1B diplotype may have increased exposure of repaglinide, including increased AUC and decreased clearance of repaglinide as compared to patients with the *1B/*1B diplotype.  Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics.
1447964537	AA	Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.
1447964538	AG	Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.
1447981315	AA	Infants and children with the AA genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
1447981316	AG	Infants and children with the AG genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
1447981317	GG	Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
1449565146	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449565147	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype or may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449565148	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1447962676	AA	Cells with the AA genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962677	AC	Cells with the AC genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype, or increased activity as compared to those with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962678	CC	Cells with the CC genotype may have increased enzymatic activity toward SN-38 as compared to cells with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447960845	AA	Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.
1447960846	AG	Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time.
1447960847	GG	Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.
1447981300	TT	Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447987089	CC	No patients with the CC genotype were available for analysis, but patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987090	CT	Patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987091	TT	Patients with the TT genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1448099422	AG/AG	Patients with nasopharyngeal cancer and the AG/AG diplotype may have increased metabolism of docetaxel as compared to patients with the AG/GA and GA/GA diplotypes. Other clinical and genetic factors may also influence metabolism of docetaxel.
1448099423	AG/GA	Patients with nasopharyngeal cancer and the AG/GA diplotype may have decreased metabolism of docetaxel as compared to patients with the AG/AG diplotype. Other clinical and genetic factors may also influence metabolism of docetaxel.
1448099424	GA/GA	Patients with nasopharyngeal cancer and the GA/GA diplotype may have decreased metabolism of docetaxel as compared to patients with the AG/AG diplotype. Other clinical and genetic factors may also influence metabolism of docetaxel.
1449165036	GG	Patients with the GG genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate toxicity.
1449165037	GT	Patients with the GT genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype, or a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.
1449165038	TT	Patients with the TT genotype and rheumatoid arthritis who are taking methotrexate may have a decreased risk for adverse events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.
1447981412	GG	Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
1447981413	GT	Patients with the GT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
1447981414	TT	Patients with the TT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
1447979555	AA	Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979556	AG	Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979557	GG	Hepatic cells with the GG genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979550	AA	Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AC or CC genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979551	AC	Hepatic cells with the AC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447979552	CC	Hepatic cells with the CC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.
1447980679	CC	Patients with the CC genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose.
1447980680	CT	Patients with the CT genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype, or an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.
1447980681	TT	Patients with the TT genotype who are heroin dependent may require an increased dose of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.
1447981432	CC	Patients with the CC genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.
1447981433	CG	Patients with the CG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.
1447981434	GG	Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.
1447981498	AA	Patients with the AA genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981499	AG	Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981500	GG	Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1449165048	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype.  This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
1449166361	*2/*2	Patients with the CYP2C19 *2/*2 genotype and esophageal reflux or peptic ulcer disease may have decreased metabolism of omeprazole (higher mean metabolic ratio of omeprazole to hydroxyomeprazole) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The study grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of omeprazole.
1449166362	*2/*3	Patients with the CYP2C19 *2/*3 genotype and esophageal reflux or peptic ulcer disease may have decreased metabolism of omeprazole (higher mean metabolic ratio of omeprazole to hydroxyomeprazole) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The study grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of omeprazole.
1446899892	AA	Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899893	AC	Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899894	CC	Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899907	AA	Women with ovarian cancer and the AA genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899908	AG	Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1446899909	GG	Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.
1448101222	AA	Patients with the AA genotype who are smokers may have decreased physical responses to smoking as compared to patients with the CC genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
1448101223	AC	Patients with the AC genotype who are smokers may have increased physical responses to smoking as compared to patients with the CC genotype, or decreased physical responses as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
1448101224	CC	Patients with the CC genotype who are smokers may have increased physical responses to smoking as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
1446906407	AA	Patients with genotype AA may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.
1446906408	AG	Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.
1446906409	GG	Patients with genotype GG may have decreased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to Farglitazar.
1446906416	AA	Patients with genotype AA may have decreased response to calcium channel blockers in people with Hypertension as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to calcium channel blockers.
1446906415	AG	Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.
1446906414	GG	Patients with genotype GG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.
1448101262	CC	Patients with the CC genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101263	CG	Patients with the CG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1448106346	CC	Women with ovarian cancer and the CC genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.
1448106347	CT	Women with ovarian cancer and the CT genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.
1448106348	TT	Women with ovarian cancer and the TT genotype may have a worse response, such as shorter survival times, when treated with carboplatin and taxanes as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.
1447945969	AA	Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AG or GG genotype. However, a different study found that the AA genotype was associated with poorer response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945970	AG	Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the AG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945971	GG	Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the GG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945980	AA	Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.
1447945981	AT	Patients with the AT genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.
1447945982	TT	Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have an increased risk for worsening of working memory as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.
1447945987	AA	Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945988	AG	Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945989	GG	Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945994	CC	Patients with the CC genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945995	CT	Patients with the CT genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945996	TT	Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447960933	G/del	Patients with the G/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
1447960932	GG	Patients with the GG genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with bupropion as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.
1447960934	del/del	Patients with the del/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
1447960940	G/del	Patients with the G/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
1447960939	GG	Patients with the GG genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.
1447960941	del/del	Patients with the del/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.
1447964539	GG	Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.
1447980769	AA	Patients with the AA genotype and growth hormone deficiency who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant may require a decreased dose of recombinant human growth hormone (somatropin) as compared to patients with the CC genotype who are also homozygotes of the full length GHR gene. Other genetic and clinical factors may also influence dose of somatropin.
1448103897	CC	Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
1449188547	CC	Patients with the CC genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.
1449188548	CT	Patients with the CT genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the TT genotypes and increased likelihood as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.
1448103898	CT	Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype  but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
1448103899	TT	Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
1448102348	CC	Patients with the CC genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.
1448102349	CT	Patients with the CT genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.
1448102458	CC	Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448099432	AA	Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.
1448099433	AG	Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.
1448099434	GG	Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.
1448102459	CT	Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102460	TT	Patients with the TT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102350	TT	Patients with the TT genotype may have an increased risk of drug-induced torsades de pointes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.
1448103891	AA	Patients with the AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
1448103892	AG	Patients with the AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
1448103893	GG	Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
1445402221	AA	Patients with the AA genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
1445402222	AC	Patients with the AC genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
1445402223	CC	Patients with the CC genotype and multiple sclerosis may have a poorer response to treatment with interferon beta 1a/1b as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
1447981476	GG	Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981477	GT	Patients with the GT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981478	TT	Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981486	GG	Patients with the GG genotype and pancreatic cancer may have a longer time to progression and overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.
1447981487	GT	Patients with the GT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.
1447981488	TT	Patients with the TT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.
1447981492	CC	Patients with the CC genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981493	CT	Patients with the CT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981494	TT	Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1449156466	GG	Patients with the GG genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.
1447990241	CT	Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.
1447990242	TT	Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.
1449156460	AA	Patients with renal cell carcinoma and the AA genotype may have a decreased overall survival, or "clinical benefit" defined as defined as either partial response or stable disease, as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1449156461	AC	Patients with renal cell carcinoma and the AC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1449156462	AT	Patients with renal cell carcinoma and the AT genotype may have a decreased overall survival as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1449156463	CC	Patients with renal cell carcinoma and the CC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1448624622	AA	Patients with the AA (UGT1A1 *6/*6) genotype with cancer who are treated with irinotecan-based regimens may have 1) an increased risk of thrombocytopenia or diarrhea as compared to patients with the GG (*1/*1) genotype, and 2) may have decreased tumor response, progression-free survival or overall survival, as compared to patients with the AG (*1/*6) or GG (*1/*1) genotype. However, one study found increased progression-free survival or overall survival for patients who carried the A (*6) allele. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea.
1448624623	AG	Patients with the AG (*1/*6) genotype with cancer who are treated with irinotecan-based regimens may have 1) an increased risk of thrombocytopenia or diarrhea as compared to patients with the GG (*1/*1) genotype, and 2) may have increased tumor response, progression-free survival or overall survival as compared to patients with the AA (*6/*6) genotype. However, some studies have found no association with diarrhea, tumor response, progression-free survival or overall survival for this genotype as compared to those with the GG genotype. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea.
1447964544	AA	Patients with the AA genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
1448624624	GG	Patients with the GG (*1/*1) genotype with cancer who are treated with irinotecan-based regimens may have 1) a decreased risk of thrombocytopenia or diarrhea as compared to patients with the AA (*6/*6) or AG (*1/*6) genotype, and 2) may have increased tumor response, progression-free survival or overall survival, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea.
1446906428	CC	Patients with genotype CC may have decreased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to methadone.
1446906429	CT	Patients with genotype CT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.
1446906430	TT	Patients with genotype TT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.
1447960235	GG	Patients with the GG genotype and hypertension may have a lesser reduction in systolic blood pressure when treated with nifedipine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
1447960797	CC	Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960798	CT	Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960233	AA	Patients with the AA genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
1447960234	AG	Patients with the AG genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
1447960799	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960805	GG	Patients with the GG genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960806	GT	Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960807	TT	Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447964545	AG	Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
1447964546	GG	Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
1447980771	AC	This genotype was not analyzed in this study.
1447980770	CC	Patients with the CC genotype and growth hormone deficiency who are also homozygotes of the full length GHR gene may require an increased dose of recombinant human growth hormone (somatropin) as compared to patients with the AA genotype who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant. Other genetic and clinical factors may also influence dose of somatropin.
1447980877	AA	Pediatric patients with the AA genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
1447947130	E2/E2	Patients with the E2/E2 genotype who are treated with statins may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947131	E2/E3	Patients with the E2/E3 genotype who are treated with statins may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947132	E2/E4	Patients with the E2/E4 genotype who are treated with statins may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447980878	AG	Pediatric patients with the AG genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
1447980879	GG	Pediatric patients with the GG genotype and HIV may have increased clearance of nevirapine as compared to pediatric patients with the AA or AG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
1447980851	*2	Cells that carry the UGT1A4*2 allele may have decreased clearance of lamotrigine as compared to those with the *1a allele. Other genetic and clinical factors may also influence clearance of lamotrigine.
1447947133	E3/E3	Patients with the E3/E3 genotype who are treated with statins may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2, E2/E3 or E2/E4 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947134	E3/E4	Patients with the E3/E4 genotype who are treated with statins may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2, E2/E3 or E2/E4 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447947135	E4/E4	Patients with the E4/E4 genotype who are treated with statins may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the E2/E2, E2/E3 or E2/E4 genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1447980865	*1a	Cells that carry the UGT1A4*1a allele may have decreased clearance of testosterone as compared to those with the *3a allele. Other genetic and clinical factors may also influence clearance of testosterone.
1447980866	*3a	Cells that carry the UGT1A4*3a allele may have increased clearance of testosterone as compared to those with the *1a allele. Other genetic and clinical factors may also influence clearance of testosterone.
1447980899	AA	Patients with the AA genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
1447980900	AG	Patients with the AG genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
1447980901	GG	Patients with the GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
1447981077	AA	Patients with the AA genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1447981078	AG	Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1447981079	GG	Patients with the GG genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1447981097	AA	Patients with the AA genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.
1447981098	AG	Patients with the AG genotype and age-related macular degeneration may have greater improvement in visual acuity when treated with bevacizumab as compared to patients with the AA or GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.
1447946146	AA	No patients with the AA genotype were available for analysis, but patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447946147	AG	Patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447946148	GG	Patients with the GG genotype may have a better response to treatment with infliximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to infliximab.
1446905293	CC	Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1446905294	CG	Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1446905295	GG	Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1446905357	AA	Patients with the AA genotype may have a better response to antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1448615591	AA	Patients with the AA genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and GG genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.
1446903109	*5	Patients with the CYP2D6*5 allele who are treated with amitriptyline may have 1) increased nortriptyline plasma levels and decreased clearance of amitriptyline, and 2) in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446903110	*6	Patients with the CYP2D6*6 allele who are treated with amitriptyline may have 1) increased nortriptyline plasma levels and decreased clearance of amitriptyline, and 2) in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) an increased risk for side effects as compared to patients with two functional CYP2D6 alleles. Other genetic and clinical factors may also influence a patient's response to amitriptyline.
1446905358	AG	Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1446905359	GG	Patients with the GG genotype may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1446905363	CC	Patients with the CC genotype (CYP2D6*1/*1) and depression who are treated with tricyclic antidepressants 1) may have a decreased likelihood of switching treatment indicating a reduced risk of side effects 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects.
1446905364	CT	Patients with the CT genotype (CYP2D6*1/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects as compared to patients with the CC genotype (CYP2D6*1/*1) 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4) or may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects.
1446905365	TT	Patients with the TT genotype (CYP2D6*4/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects 2) may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects.
1447987108	CC	Patients with the CC genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987109	CT	Patients with the CT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987110	TT	Patients with the TT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1450375683	AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375684	GG	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1448104024	CC	Patients with the CC genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1447990298	CC	In vitro, the CC genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the CG and GG genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.
1447990299	CG	In vitro, the CG genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the GG genotype and increased expression of TRAF1, decreased expression of MIRLET7I and decreased sensitivity to endoxifen as compared to the CC genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.
1447990300	GG	In vitro, the GG genotype is associated with increased expression of TRAF1, decreased expression of MIRLET7I, and decreased sensitivity to endoxifen as compared to the CG and CC genotypes. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.
1448104025	CT	Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104026	TT	Patients with the TT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104031	CC	Patients with the CC genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104032	CT	Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104033	TT	Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448107080	CC	Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1448107081	CT	Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1448107082	TT	Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1448104038	CC	Patients with the CC genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448104039	CT	Patients with the CT genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448104040	TT	Patients with the TT genotype have a decreased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1450368663	CC	No patients with the CC genotype were available for analysis, but patients with the CT genotype and cancer who are treated with fluorouracil may have an increased risk for drug toxicity as compared to patients with the TT genotype. The CC genotype may also be associated with decreased DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450368664	CT	Patients with the CT genotype and cancer who are treated with fluorouracil may have an increased risk for drug toxicity as compared to patients with the TT genotype. The CT genotype is also associated with decreased DPYD activity as compared to the TT genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450368665	TT	Patients with the TT genotype and cancer who are treated with fluorouracil may have a decreased risk for drug toxicity, and increased DPYD activity, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1446898818	AA	Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.
1446898819	AC	Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.
1446898820	CC	Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.
1448102370	AA	Patients with the AA genotype may have an increased risk for heroin addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.
1447813541	AA	Individuals with the AA genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or GG genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.
1446902344	*1/*1	Patients with the *1/*1 diplotype and major depressive disorder 1) may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the *1/*2 or *2/*2 diplotype 2) may have increased metabolism of impramine as compared to patients with the *2/*3 diplotype 3) and may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the *1/*17 or *17/*17 diplotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1446902345	*1/*17	Patients with the *1/*17 diplotype and major depressive disorder may have decreased dose-corrected plasma concentrations of imipramine as compared to patients with the *1/*1 diplotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1446902346	*1/*2	Patients with the *1/*2 diplotype and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the *1/*1 diplotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1446902347	*17/*17	Patients with the *17/*17 diplotype and major depressive disorder may have decreased dose-corrected plasma concentrations of imipramine as compared to patients with the *1/*1 diplotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1446902348	*2/*2	Patients with the *2/*2 diplotype and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the *1/*1 diplotype. For patients with the CYP2C19 poor metabolizer phenotype (e.g. *2/*2) decreased imipramine clearance and increased plasma concentrations are reported as compared to patients with the *1/*1 genotype. The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1448101264	GG	Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1447813542	AG	Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.
1447813543	GG	Individuals with the GG genotype and HIV may have a increased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or AA genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.
1447981099	GG	Patients with the GG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.
1447981160	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981161	CG	Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981162	GG	Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981209	AA	Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981210	AT	Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981211	TT	Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981224	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981225	CT	Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981226	TT	Patients with the TT genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981252	CC	Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981253	CT	Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981254	TT	Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981261	AA	Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981262	AG	Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981263	GG	Patients with the GG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981270	AA	Patients with the AA genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981271	AG	Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981272	GG	Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447987119	CC	Patients with the CC genotype and tobacco use disorder may have a worse response (lack of abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
1448634056	CC	Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448634057	CT	Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448634058	TT	Children with the TT genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448617531	C	Patients with the 1095C allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss
1450371715	AA	Patients with rheumatoid arthritis and the AA genotype may have an increased response to rituximab as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to rituximab.
1450371716	AG	Patients with rheumatoid arthritis and the AG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.
1450371717	GG	Patients with rheumatoid arthritis and the GG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.
1448617156	AA	Patients with the AA genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617157	AC	Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1447987120	CT	Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
1447987121	TT	Patients with the TT genotype and tobacco use disorder may have an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
1448104138	AA	Patients with the AA genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1448108786	AG	Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448108787	GG	Patients with the GG genotype may have a decreased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448617158	AT	Patients with the AT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617159	CC	Patients with the CC genotype who are administered atazanavir may have decreased risk of hyperbilirubinemia as compared to patients with the AA, AT, TT, AC, or CT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617160	CT	Patients with the CT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617161	TT	Patients with the TT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1449164507	CC	Patient with CC genotype may have decreased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CT + TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy.
1449164508	CT	Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy.
1449164509	TT	Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy.
1449164517	CC	Patient with CC + CT genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy.
1449164518	CT	Patient with CT + CC genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy.
1450112765	CC	Patients with the CC genotype may have decreased clearance and decreased distribution of volume of methotrexate as compared to patients with the CT or TT genotypes, although this is contradicted in three studies. In one study, the T allele was associated with decreased clearance, and in the other two there was no association with variant and concentrations of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate.
1450043716	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450180238	AG	Patients with the AG genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.
1450180239	GG	Patients with the GG genotype may be at a decreased risk of developing both alcohol and drug dependence as compared to patients with the AA or AG genotypes. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.
1450375688	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1449164519	TT	Patient with TT genotypes may have an increased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy.
1449166748	*96	Patients with the CYP2D6*96 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele construct was found catalytically inactive during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166749	*97	Patients with the CYP2D6*97 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1449166750	*98	Patients with the CYP2D6*98 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.
1450044563	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044564	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044565	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the  AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1447983139	CC	Patients with the CC genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1447983146	AA	Patients with the AA genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
1447983147	AC	Patients with the AC genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
1447983148	CC	Patients with the CC genotype and epilepsy who are treated with valproic acid may have increased bone density as compared to patients with the AA + AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
1447983158	AA	Patients with the AA genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1448109567	GG	Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1450372307	AA	Patients with the AA genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AC or CC genotype (DPYD *1/*13 or *13/*13). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448109568	GT	Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1446902349	*2/*3	Patients with the *2/*3 diplotype and major depressive disorder may have reduced metabolism of imipramine as compared to patients with the *1/*1 diplotype. For patients with the CYP2C19 poor metabolizer phenotype (e.g. *2/*3) decreased imipramine clearance and increased plasma concentrations are reported as compared to patients with the *1/*1 genotype.The number of studies for imipramine pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, doxepin, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of imipramine.
1447983140	CT	Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1447983141	TT	No information were reported regarding patients with the TT genotype.
1448109569	TT	Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1447947115	E2/E2	Patients with the E2/E2 genotype who are treated with simvastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E2/E4, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1447947116	E2/E3	Patients with the E2/E3 genotype who are treated with simvastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the E3/E3, E2/E4, E3/E4 or E4/E4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1447947117	E2/E4	Patients with the E2/E4 genotype who are treated with simvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. However, patients with the E2/E4 diplotype who have had a myocardial infarction may have an increased risk of mortality as compared to other genotypes, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment.  Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1447982783	CC	Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.
1447982782	CT	Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.
1447982781	TT	Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.
1447982799	GG	Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.
1447982800	GT	Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.
1447982801	TT	Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.
1447982792	CC	Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982791	CT	No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982790	TT	Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982808	AA	Patients with the AA genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982807	AG	No information are available for the AG genotype. However, patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982806	GG	Patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982815	CC	Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982814	CT	No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982813	TT	Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982822	AA	Patients with the AA genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.
1447982821	AG	No information are available for the AG genotype. However, patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.
1447982820	GG	Patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.
1447982836	AA	Patients with the AA genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.
1447982835	AG	Patients with the AG genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.
1447982834	GG	Patients with the GG genotype and psoriasis who are treated with fumaric acid esters may have a decreased response as patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's drug response.
1447982845	A	Patients with the A allele may have increased expression of LDLR as compared to patients with the G allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.
1448109614	AA	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448109615	AC	Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA and decreased likelihood as compared to patients with the CC genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1449645482	GG	Patients with the GG genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1448109553	AA	Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1449645483	GT	Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1448107640	AA	Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449645484	TT	Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645488	GG	Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1447990194	CC	Patient with the CC genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
1448107641	AG	Patients with the AG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype or may have decreased red blood cell folate as compared to patients with the AA genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1448107642	GG	Patients with the GG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have decreased red blood cell folate as compared to patients with the AA genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1448109554	AC	Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
1448263580	AA	Patients with the AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine.
1448109555	CC	Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.
982042113	AA	Colon cancer patients with  AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the  tumor recurrence time.
982042112	CA	Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the  tumor recurrence time.
982042111	CC	Colon cancer patients with CC genotype may have shorter time to tumor recurrence when treated 5-fluorouracil compared to patients with CA + AA genotypes. Other genetic and clinical factors may also influence the  tumor recurrence time.
982043294	CC	Breast cancer patients with GC + CC genotypes have decreased progression-free survival (PFS), overall survival (OS) and, increased absolute leucocyte and neutrophil counts when treated with docetaxel and doxorubicin when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1448263581	AG	Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine.
1448263582	GG	Patients with the GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine.
1449645477	GT	Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645478	TT	Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449564592	CC	Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CG and GG genotype. One study found no association between the CC genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence incidence of toxicity to leucovorin, tegafur, capecitabine and fluorouracil.
1449564593	CG	Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype. Another study found no association between the CG genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence incidence of toxicity to leucovorin, tegafur, capecitabine and fluorouracil.
1450044545	del/del	Patients with the del/del genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GAG/GAG genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the del allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449191889	AA	Patients with the AA genotype (two copies of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191890	AG	Patients with the AG genotype (one copy of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1448423770	GG	Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence quetiapine response.
1450112766	CT	Patients with the CT genotype may have increased clearance and increased distribution of volume of methotrexate as compared to patients with the CC genotype although this is contradicted in three studies. In one study, the T allele was associated with decreased clearance, and in the other two there was no association with variant and concentrations of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate.
1450112767	TT	Patients with the TT genotype may have increased clearance and distribution of volume of methotrexate as compared to patients with the CC genotype, although this is contradicted in three studies. In one study, the T allele was associated with decreased clearance, and in the other two there was no association with variant and concentrations of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate.
1449191891	GG	Patients with the GG genotype (do not have a copy of the CFTR G1244E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1448109595	CC	Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or AA, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.
1448423771	GT	Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1448616181	*1/*1	Patients with the TPMT *1/*1 genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *1/*3A or *3A/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.
1448616182	*1/*3A	Patients with the TPMT *1/*3A genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *3A/*3A genotype, and increased risk of ototoxicity as compared to patients with the *1/*1 genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.
1448616183	*3A/*3A	Patients with the TPMT *3A/*3A genotype, may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the *1/*1 or *1A/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.
1450372308	AC	Patients with the AC genotype (DPYD *1/*13) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) partial DYPD deficiency and 2) an increased risk and increased severity of drug toxicity as compared to patients with the AA genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448423772	TT	Patients with the TT genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423790	AA	Patients with the AA genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1447947118	E3/E3	Patients with the E3/E3 genotype who are treated with simvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1447947119	E3/E4	Patients with the E3/E4 genotype who are treated with simvastatin may have a reduced response (decreased reduction in LDL-cholesterol) as compared to patients with the E2/E2 or E2/E3 genotype. However, patients with the E3/E4 diplotype who have had a myocardial infarction may have an increased risk of mortality as compared to other genotypes, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment.  Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1450372309	CC	Patients with the CC genotype (DPYD *13/*13) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DYPD deficiency and 2) an increased risk and increased severity of drug toxicity as compared to patients with the AA genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449575698	AA	The AA genotype is associated with decreased expression of DPYD as compared to the AT or TT genotypes. Other clinical and genetic factors may also influence DPYD protein expression.
1449575700	TT	The TT genotype is associated with increased expression of DPYD as compared to the AT or AA genotypes. Other clinical and genetic factors may also influence DPYD protein expression.
1449575692	AA	The AA genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.
1450372312	CC	Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased metabolism of fluorouracil and 2) decreased risk for drug toxicities as compared to patients with the CT or TT genotype (DPYD *1/*6 or *6/*6). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448423791	AG	Patients with the AG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423792	GG	Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.
1448424041	GG	Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.
1449575693	AG	The AG genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the GG genotypes and increased catalytic activity and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.
1448424042	GT	Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.
1448424043	TT	Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.
1448427400	GG	Patients with the GG genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1449575699	AT	The AT genotype is associated with increased expression of DPYD as compared to the TT genotypes and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence DPYD protein expression.
1449575694	GG	The GG genotype is associated with increased catalytic activity and decreased expression of DPYD protein as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.
1449169486	CC	Patients with the CC genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the TT genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.
1449169487	CT	Patients with the CT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.
1449169488	TT	Patients with the TT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.
1448594293	GG	Patients with the GG genotype who undergo anesthesia with propofol may have increased clearance of the drug as compared to patients with the AA or AG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.
1449169552	GG	The GG genotype is associated with an increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.
1449169553	GT	The GT genotype is associated with increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the TT genotype and decreased risk as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.
1449169554	TT	The TT genotype is associated with a decreased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.
1449169718	AA	Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449169719	AG	Patients with the AG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449169720	GG	Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449163936	AA	Patients with the AA genotype may have increased metabolism of caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.
1449163937	AC	Patients with the AC genotype may have increased metabolism of caffeine as compared to patients with the CC genotype, or decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.
1449163938	CC	Patients with the CC genotype may have decreased metabolism of caffeine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.
1449170186	AA	Patients with the AA genotype who are treated with allopurinol may have a decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AG or GG genotypes. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01.  Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.
1449170187	AG	Patients with the AG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.
1449170188	GG	Patients with the GG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.
1447952829	GG	Patients with the GG genotype and schizophrenia may have a worse response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1447952833	AA	Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.
1447952834	AG	Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.
1447952835	GG	Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.
1448115910	(CCCACCCGA)10	Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.
1448115911	(CCCACCCGA)9	Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.
1448115912	CCCACCCGA)12/(CCCACCCGA)12	Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.
1448601690	GG	Patients with the GG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.
1447945834	AA	Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence progression-free survival time.
1447945835	AC	Current literature evidence finds no significant effect of the AC genotype on progression-free survival time in patients taking docetaxel.
1447945836	CC	Patients with the CC genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444686785	CC	Patients with the CC (CYP2C9 *1/*1) genotype undergoing hemopoietic stem cell transplant may have increased metabolism of busulfan as compared to patients with the CT (*1/*2) or TT (*2/*2) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686786	CT	Patients with the CT (CYP2C9 *1/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686787	TT	Patients with the TT (CYP2C9 *2/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
1444706168	GG	Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.
1444706167	TG	Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.
1444706166	TT	Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.
1444706205	CC	Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes.  Other genetic and clinical factors may influence also a patient's exposure to rifampicin.
1448601694	AA	Patients with the AA genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.
1448601695	AG	Patients with the AG genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.
1448601696	GG	Patients with the GG genotype and coronary disease may have decreased response to clopidogrel treatment compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect clopidogrel response.
1449001786	A	Male patients with the A genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the G genotype in autistic children. This gene is on the X chromosome and male patients only have one allele. Other genetic and clinical factors may also influence a patient's response.
1449001783	AA	Female patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
1448266988	AA	Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.
1448266989	AC	Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.
1448266990	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the AA and AC genotypes. Other clinical and genetic factors may affect risk of toxicity.
1449001784	AG	Female patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
1449001867	CC	Female patients with the CC genotype and schizophrenia who are treated with antipsychotics such as olanzapine or clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.
1449001868	CG	Female patients with the CG genotype and schizophrenia who are treated with antipsychotics such as olanzapine or clozapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.
1449001869	G	Male patients with the G genotype and schizophrenia who are treated with antipsychotics such as olanzapine or clozapine may have an increased risk of weight gain as compared to patients with the C genotype. However, contradictory findings are reported. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk of weight gain with antipsychotics.
1449001787	G	Male patients with the G genotype may have a better response to risperidone as compared to patients with the A genotype in autistic children. This gene is on the X chromosome and male patients only have one allele. Other genetic and clinical factors may also influence a patient's response.
1449001785	GG	Female patients with the GG genotype may have better response to risperidone as compared to patients with the AA or AG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
1449001859	C	Male patients with the C genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the T genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain.
1449001860	CC	Female patients with the CC genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.
1449001861	CT	Female patients with the CT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain, or an association in the opposite direction. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.
1449001862	T	Male patients with the T genotype and psychiatric disorders who are treated with antipsychotics may have a decreased risk of weight gain as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain.
1449001863	TT	Female patients with the TT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.
1449001870	GG	Female patients with the GG genotype and schizophrenia who are treated with antipsychotics such as olanzapine or clozapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.
1449167509	GT	Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167510	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167539	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449164599	AA	Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.
1449164600	AT	Cancer patients with the AT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.
1449164601	TT	Cancer patients with the TT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.
1449167522	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167523	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167524	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167525	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167526	GT	Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167527	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167540	AC	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167541	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167542	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167543	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167544	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167553	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167554	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167555	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167564	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167565	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449166363	*3/*3	Patients with the CYP2C19 *3/*3 genotype and esophageal reflux or peptic ulcer disease may have decreased metabolism of omeprazole (higher mean metabolic ratio of omeprazole to hydroxyomeprazole) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The study grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence metabolism of omeprazole.
1449191645	AA	Patients with the AA genotype (two copies of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449170471	AA	Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.
1449191646	AG	Patients with the AG genotype (one copy of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1448568518	AA	Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AG or GG genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AA might have a decreased, but not absent, risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.
1448568519	AG	Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.
1448568520	GG	Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.
1449191647	GG	Patients with the GG genotype (do not have a copy of the CFTR R352Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449576569	CT	Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576568	TT	Patients with the TT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576576	*1A/*1A	Patients with the *1A/*1A may have increased plasma concentrations of montelukast as compared to patients with the *3 allele, or decreased concentration of the *4 allele. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449191655	AA	Patients with the AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191656	AC	Patients with the AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449576574	*3	Patients with the *3 allele may have decreased plasma concentrations of montelukast as compared to patients carrying *1A/*1A. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576575	*4	Patients with the *4 allele may have increased plasma concentrations of montelukast as compared to patients carrying *1A/*1A. Other genetic and clinical factors may also influence the metabolism of montelukast.
1444706204	TC	Tuberculosis patients with the TC genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's exposure to rifampicin.
1444706203	TT	Tuberculosis patients with the TT genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's exposure to rifampicin.
1444706247	CC	Patients with the CC genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.
1444706248	CT	Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.
1444706249	TT	Patients with the TT genotype may be at decreased risk of myopathy when treated with simvastatin as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.
1444842115	*14:03	Patients with one or two copies of the HLA-C*14:03 allele who are treated with ticlopidine may have an increased risk of toxic liver disease as compared to patients with no HLA-C*14:03 alleles or negative for the HLA-C*14:03 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1444842162	*1/*1	Patients with renal cell carcinoma carrying and the *1/*1 extensive metabolizer genotype when treated with pazopanib may have decreased risk but not absence of hyperbilirubinemia as compared to those with the *28, *37, *6 alleles. Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.
1444842163	*28 + *37 + *6	Patients with renal cell carcinoma carrying *28, *37 and/or *6 alleles when treated with pazopanib may have increased risk of hyperbilirubinemia as compared to those with the extensive metabolizer genotype (*1/*1). Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.
1444842164	*28/*28	Patients with renal cell carcinoma carrying and the *28/*28 genotype when treated with pazopanib may have increased risk of hyperbilirubinemia as compared to those with the extensive metabolizer genotype (*1/*1, *1/*28). Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.
1448102934	AA	Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.
1448102935	AC	Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.
1448102936	CC	Patients with the CC genotype and cystic fibrosis may have increased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.
1447979297	AA	Female patients with the AA genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.
1447979298	AG	Female patients with the AG genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. In males, this association may be in the opposite direction. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.
1447979299	GG	Female patients with the GG genotype may have an increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AA genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.
1448101128	AA	Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1448101129	AG	Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1448101130	GG	Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.
1448522756	AA	Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522757	AG	Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522758	GG	Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448602212	CC	Children with the CC genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.
1448602213	CT	Children with the CT genotype and major depressive disorder may respond worse to fluoxetine therapy compared to patients with the CC and TT genotypes. Other clinical and genetic factors may affect response to fluoxetine.
1448602214	TT	Children with the TT genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.
1448602251	AA	Patients with the AA genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.
1448602252	AG	Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.
1448602253	GG	Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.
1450374104	AC	Patients with the AC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1449156375	AA	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype, although the association is reversed in one study and contradicted in one other. The AA genotype may be associated with a decreased response to warfarin as well as an increased risk of hemorrhage as compared to the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1449156376	AG	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype, although the association is reversed in one study (increased vs. AA) and contradicted in one other. The AG  genotype may be associated with a decreased response to warfarin as well as an increased risk of hemorrhage as compared to the GG genotype.Other clinical or genetic factors may also influence warfarin dose.
1449156377	GG	Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA or AG genotypes, although the association is reversed in one study and contradicted in one other. The GG  genotype may be associated with an increased response to warfarin as well as a decreased risk of hemorrhage as compared to the GG genotype.Other clinical or genetic factors may also influence warfarin dose.
1449156416	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449156417	AC	Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449156418	CC	Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1450374103	AA	Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374105	CC	Patients with the CC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374919	AA	Patients with the AA genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1449564594	GG	Patients with GG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and  leucovorin as compared to patients with the CC genotype. One study found no association between the GG genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence incidence of toxicity to leucovorin, tegafur, capecitabine and fluorouracil.
1448532204	CC	People with the CC genotype may have decreased exposure to dabigatran compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532207	CT	People with the CT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532208	TT	People with the TT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532215	AA	People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.
1448532214	AC	People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.
1448532213	CC	People with the CC genotype may have decreased exposure to rivaroxaban compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.
1448532216	CT	People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.
1448532217	TT	People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.
1450042817	*1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*114 + *2/*5 + *2/*10 + *1/*4 + *2/*2 + *2/*4 + *1/*3 + *2/*41	Patients who are designated as CYP2D6 extensive metabolizers and have lung cancer may have a decreased risk for rash or hepatotoxicity when treated with gefitinib as compared to patients designated as CYP2D6 poor metabolizers. Additionally, healthy individuals who are designated as CYP2D6 extensive metabolizers may have decreased concentrations of gefitinib as compared to those who are designated as CYP2D6 poor metabolizers. Other genetic and clinical factors may also influence risk for rash or hepatotoxicity, or concentrations of gefitinib.
1450042818	*1/*10 + *2/*10 + *1/*5 + *5/*10 + *10/*10	Patients who are designated as CYP2D6 poor metabolizers and have lung cancer may have an increased risk for rash or hepatotoxicity when treated with gefitinib as compared to patients designated as CYP2D6 extensive metabolizers. Other genetic and clinical factors may also influence risk for rash or hepatotoxicity.
1450042819	*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN	Healthy individuals who are designated as CYP2D6 poor metabolizers may have increased concentrations of gefitinib as compared to individuals designated as CYP2D6 extensive metabolizers. Other genetic and clinical factors may also influence concentrations of gefitinib.
1450044523	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044524	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044525	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044515	CC	Individuals with the CC genotype and central core myopathy may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044516	CG	Individuals with the CG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449564625	AA	Patients with the AA genotype may have an improved response to hmg coa reductase inhibitors and a decreased risk of coronary artery disease as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1449564626	AG	Patients with the AG genotype may have an improved response to hmg coa reductase inhibitors and a decreased risk of coronary artery disease as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors and increased risk of coronary artery disease as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1449166633	*1	Patients with the CYP2D6*1 allele may have 1) an increased clearance of dapoxetine as compared to patients with the CYP2D6*10 or *87 or *88  or *91 or *93 or *95 or *97  or *98 allele, and 2) similar clearance compared to CYP2D6*89 or *90 or *94 allele. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449564567	CC	Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes CT or TT. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP's association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.
1449564568	CT	Patients with the CT genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure)  compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP's association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.
1449564569	TT	Patients with the TT genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP's association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.
1449564627	GG	Patients with the GG genotype may have a worse response to hmg coa reductase inhibitors and an increased risk of coronary artery disease as compared to patients with the AG and AA genotypes. However, in one study the GG genotype was associated with worse response to rosuvastatin as compared to the AA genotype (not AG). Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1449564646	TT	Patients with the TT genotype (CYP3A5 *1/*1) may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype,  although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.
1449564653	AA	Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.
1449564654	AG	Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.
1449564655	GG	Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.
1449564663	AA	Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have an increased risk of experiencing leukopenia, and possibly thrombocytopenia and neutropenia, as compared to patients with the AG and GG genotypes, however, this is contradicted in one study. Other clinical and genetic factors may also influence risk of leukopenia in patients with renal cell carcinoma who are administered sunitinib.
1449717847	*1/*1	Patients with the CYP2C19*1/*1 genotype who are treated with citalopram or escitalopram may have an increased drug clearance/metabolism as compared to patients with CYP2C19*2, *3 or *4 allele and a decreased drug clearance/metabolism as compared to patients with CYP2C19*1/*17 or *17/*17 genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1449717848	*1/*17	Patients with the CYP2C19*1/*17 genotype who are treated with citalopram or escitalopram may have an increased drug clearance/metabolism as compared to patients with CYP2C19*1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1449166634	*10	Patients with the CYP2D6*10 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166635	*87	Patients with the CYP2D6*87 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449717849	*17/*17	Patients with the CYP2C19*17/*17 (rs12248560) genotype who are treated with citalopram or escitalopram may have an increased drug clearance/metabolism as compared to patients with CYP2C19*1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1448097825	AC	Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
1448097826	CC	Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
1448098341	CC	Patients with nasopharyngeal cancer and the CC genotype may have less severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098342	CT	Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia as compared to patients with the CC genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098346	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to the GG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.
1448098347	GG	Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.
1448099578	CC	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.
1448099577	CT	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.
1448099576	TT	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.
1448100127	AA	Patients with major depressive disorder and the AA genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100128	AG	Patients with major depressive disorder and the AG genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100129	GG	Patients with major depressive disorder and the GG genotype may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448100237	CC	Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
1448100238	CT	Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1448100239	TT	Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448100834	CC	Women with the CC genotype and breast or ovarian cancer may have a decreased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CT or TT genotype. However, a large study found opposing results for this association. Other genetic and clinical factors may also influence risk for peripheral neuropathy.
1448100835	CT	Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, a large study found opposing results for this association. Other genetic and clinical factors may also influence risk for peripheral neuropathy.
1448100836	TT	Women with the TT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC or CT genotype. However, a large study found opposing results for this association. Other genetic and clinical factors may also influence risk for peripheral neuropathy.
1449156556	CC	Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449156528	CC	Patients with colorectal or breast cancer and the CC genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.
1449156529	CT	Patients with colorectal or breast cancer and the CT genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.
1449156530	TT	Patients with colorectal or breast cancer and the TT genotype may have a worse response to bevacizumab-based treatment regimens as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.
1449156551	CC	Patients with colorectal cancer and the CC genotype may have a decreased response to tipiracil hydrochloride and trifluridine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449156552	CT	Patients with colorectal cancer and the CT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449156553	TT	Patients with colorectal cancer and the TT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449156557	CT	Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449156558	TT	Individuals with the TT genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449156574	AA	Individuals with the AA genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449156575	AG	Individuals with the AG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GG genotype but may have and an improved response as compared to individuals with the AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449156576	GG	Individuals with the GG genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1449156579	CC	Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.
1449156580	CT	Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.
1449156581	TT	Patients with the TT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.
1449161081	AA	Patients with the genotype AA may have increased response to aripiprazole in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aripiprazole.
1449161082	AG	Patients with the genotype AG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Though this association was found not statistically significant. Other genetic and clinical factors may also influence the response to aripiprazole.
1449161083	GG	Patients with the genotype GG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to aripiprazole.
1449192942	*1	Patients with the CYP2D6*1 allele may have an increased clearance of methadone as compared to patients with the CYP2D6*10 or *87 or *89 or *90 or *93 or *95 or *97 or *98 allele. Other genetic and clinical factors may also influence the metabolism of methadone.
1449192943	*10	Patients with the CYP2D6*10 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with methadone. However, a study in patients found no association between the *10 allele and methadone clearance Other genetic and clinical factors may also influence the metabolism of methadone.
1449192944	*87	Patients with the CYP2D6*87 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1449192945	*89	Patients with the CYP2D6*89 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1449192946	*90	Patients with the CYP2D6*90 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1450044517	GG	Individuals with the GG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient of develops Malignant Hyperthermia. Please note: the G allele is thought to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450372036	CC	Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of fluoropyrimidine drugs and 2) decreased, but not non-existent, risk for drug toxicity as compared to patients with the CT or TT genotype (DPYD *1/*2A or *2A/*2A). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.
1450372037	CT	Patients with the CT genotype (DPYD *1/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.
1450372038	TT	Patients with the TT genotype (DPYD *2A/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have complete DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.
1450377217	AG	Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377218	GG	Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450379239	AA	Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.
1450379240	AC	Patients with the AC genotype and diabetes mellitus may have a worse response to sulfonylureas as compared to the AA and CC genotypes. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.
1450379241	CC	Patients with the CC genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.
1449564587	GG	Patients with the GG genotype and epilepsy who are administered lamotrigine may have decreased serum concentrations of lamotrigine, as well as a worse response to lamotrigine as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence metabolism of and response to lamotrigine.
1449564588	GT	Patients with the GT genotype and epilepsy who are administered lamotrigine may have decreased serum concentrations of lamotrigine, as well as worse response to lamotrigine as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence metabolism of and response to lamotrigine.
1449564589	TT	Patients with the TT genotype and epilepsy who are administered lamotrigine may have increased serum concentrations of lamotrigine, as well as improved response to lamotrigine as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence metabolism of response to lamotrigine.
1448999095	*3/*3	Patients with two non-functional CYP2D6 alleles (e.g. *3/*3, *3/*4, *4/*4, *3/*5 or *3/*6, *5/*5) 1) may have reduced clearance of trimipramine as compared to patients with the wildtype  CYP2D6 *1/*1, CYP2C9*1/*1 and CYP2C19*1/*1 combined diplotypes, 2) may have increased bioavailability of trimipramine as compared to patients with the CYP2D6 *1/*2XN diplotype. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448999096	*4/*4	Patients with two non-functional CYP2D6 alleles (e.g. *3/*3, *3/*4, *4/*4, *3/*5 or *3/*6, *5/*5) 1) may have reduced clearance of trimipramine as compared to patients with the wildtype  CYP2D6 *1/*1, CYP2C9*1/*1 and CYP2C19*1/*1 combined diplotypes, 2) may have increased bioavailability of trimipramine as compared to patients with the CYP2D6 *1/*2XN diplotype. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448999097	*5/*5	Patients with two non-functional CYP2D6 alleles (e.g. *3/*3, *3/*4, *4/*4, *3/*5 or *3/*6, *5/*5) 1) may have reduced clearance of trimipramine as compared to patients with the wildtype  CYP2D6 *1/*1, CYP2C9*1/*1 and CYP2C19*1/*1 combined diplotypes, 2) may have increased bioavailability of trimipramine as compared to patients with the CYP2D6 *1/*2XN diplotype. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448999098	*6/*6	Patients with two non-functional CYP2D6 alleles (e.g. *3/*3, *3/*4, *4/*4, *3/*5 or *3/*6, *5/*5) 1) may have reduced clearance of trimipramine as compared to patients with the wildtype  CYP2D6 *1/*1, CYP2C9*1/*1 and CYP2C19*1/*1 combined diplotypes, 2) may have increased bioavailability of trimipramine as compared to patients with the CYP2D6 *1/*2XN diplotype. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1449166636	*88	Patients with the CYP2D6*88 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166637	*89	Patients with the CYP2D6*89 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166638	*90	Patients with the CYP2D6*90 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166639	*91	Patients with the CYP2D6*91 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166640	*93	Patients with the CYP2D6*93 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449191657	CC	Patients with the CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449564578	CG	Patients with the CG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.
1449564579	GG	Patients with the GG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.
1448526088	AA	Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.
1448428953	CC	Patients with the CC genotype and gout may be more likely to require a dose other than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428954	CT	Patients with the CT genotype and gout may be more likely to require a dose other than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428955	TT	Patients with the TT genotype and gout may be more likely to require a dose of 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448525760	*11:01:01	Patients with one or two copies of the HLA-A*11:01 allele who are treated with carbamazepine may have an increased risk of adverse reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), as compared to patients with no HLA-A*11:01 alleles or negative for the HLA-A*11:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1448526089	AG	Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.
1448526090	GG	Patients with the GG genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.
1449003884	CT	Patients with the CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype, or increased metabolism compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine in patients.
1449003885	TT	Patients with the TT genotype may have increased metabolism of nicotine as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.
1449003928	CC	Patients with the CC genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003929	CT	Patients with the CT genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003930	TT	Patients with the TT genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003877	AA	Patients with the AA genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003878	AC	Patients with the AC genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the CC genotype or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003879	CC	Patients with the CC genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003920	TTTT/TTTT	Patients with the TTTT/TTTT genotype may have a decreased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the TTTT/del or del/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003921	TTTT/del	Patients with the TTTT/del genotype may have a decreased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the del/del genotype, but an increased risk as compared to patients with the TTTT/TTTT genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003922	del/del	Patients with the del/del genotype may have an increased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the TTTT/del or TTTT/TTTT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1448266010	AA	Patients with the AA genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor.
1448266011	AG	Patients with the AC genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor.
1448266012	GG	Patients with the GG genotype and cystic fibrosis may not respond to ivacaftor treatment, depending what other variant is the cause of the cystic fibrosis. Other clinical and genetic factors may affect response to ivacaftor.
1449169687	AA	Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.
1449169688	AT	Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.
1449169689	TT	Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.
1448423056	TTAAAG/TTAAAG	Patients with the  TTAAAG/TTAAAG genotype who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity and may develop less severe oral mucositis as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.
1448423057	TTAAAG/del	Patients with the  TTAAAG/del genotype who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity and may develop less severe oral mucositis as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.
1448423058	del/del	Patients with the del/del genotype who are treated with methotrexate may have an increased risk of hepatotoxicity and may develop more severe oral mucositis as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.
1448634790	AA	Patients with genotypes AA may have decreased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to beta blocking agents.
1448634789	AG	Patients with genotypes AG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.
1448634788	GG	Patients with genotypes GG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.
1449161160	GG	Patients with the GG genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449161159	GT	Patients with the GT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449155486	CC	Patients with the CC genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.
1449155487	CT	Patients with the CT genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.
1449155488	TT	Patients with the TT genotype may be more likely to develop an addiction to crack cocaine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.
1449161129	AA	Patients with the AA genotype may have an increased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.
1449161130	AG	Patients with the AG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.
1449161131	GG	Patients with the GG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.
1449161158	TT	Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1450397916	*59:01:01:01	Patients with one or two copies of the HLA-B*59:01:01:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with methazolamide as compared to patients with no HLA-B*59:01:01:01 alleles or negative for the HLA-B*59:01:01:01 test. Other genetic and clinical factors may also influence a patient's risk of methazolamide-induced adverse reactions.
1450415180	*1/*1	Individuals with the CYP2D6*1/*1 diplotype may have an increased dose of metoprolol as compared to patients with CYP2D6*4/*4 genotype. Other genetic and clinical factors may also influence metoprolol dose.
1450415181	*4/*4	Individuals with the CYP2D6*4/*4 diplotype may have a decreased dose of metoprolol as compared to patients with CYP2D6*1/*1 genotype. Other genetic and clinical factors may also influence metoprolol dose.
1449167566	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167580	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167591	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167592	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167593	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167581	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167582	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449168309	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168310	AC	Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168311	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168316	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168317	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1450379347	GG	Patients with the GG genotype and gout may have improved response when treated with allopurinol and may require a decreased dose as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to or dose of allopurinol.
1450379348	GT	Patients with the GT genotype and gout may have worse response when treated with allopurinol, and may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to and dose of allopurinol.
1450379349	TT	Patients with the TT genotype and gout may have worse response when treated with allopurinol and may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to and dose of allopurinol.
1448267813	CC	Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
1448267814	CT	Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
1448267815	TT	Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
1449004222	AA	Pediatric patients with epilepsy and the AA genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.
1449004223	AG	Pediatric patients with epilepsy and the AG genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotypes and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.
1449004224	GG	Pediatric patients with epilepsy and the GG genotype who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.
1449166641	*94	Patients with the CYP2D6*94 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166642	*95	Patients with the CYP2D6*95 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166643	*97	Patients with the CYP2D6*97 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166644	*98	Patients with the CYP2D6*98 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.
1449166659	*1	Patients with the CYP2D6*1 allele may have an increased clearance of risperidone as compared to patients with the CYP2D6*10 or *87 or *88 or *89 or *90 or *91 or *93 or *94 or *95 or *97 or *98. Other genetic and clinical factors may also influence the metabolism of risperidone.
1449166660	*10	Patients with the CYP2D6*10 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449166661	*87	Patients with the CYP2D6*87 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone.
1449166662	*88	Patients with the CYP2D6*88 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone.
1449166663	*89	Patients with the CYP2D6*89 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449166664	*90	Patients with the CYP2D6*90 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449004493	AA	Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the AC and CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449004494	AC	Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449004775	CC	Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449004776	CG	Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449004777	GG	Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449004760	GG	Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.
1449156266	*08:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*08:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156257	*04:03	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:03 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156260	*01:02:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*01:02:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as well as toxic liver disease as compared to non-carriers.
1449156263	*10:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*10:01:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156269	*04:04:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*04:04:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156272	*01:03	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*01:03 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449166688	*88	Patients with the CYP2D6*88 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166689	*89	Patients with the CYP2D6*89 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166690	*90	Patients with the CYP2D6*90 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166691	*91	Patients with the CYP2D6*91 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449004761	GT	Patients with mesothelioma and the GT genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.
1449004762	TT	Patients with mesothelioma and the TT genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the GG and GT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.
1449156275	*04:06	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:06  allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449156278	*04:07	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:07 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449167315	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1450044555	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the C allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044556	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448573617	AA	Patients with the AA genotype and ulcerative colitis may have a decreased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus response.
1448573618	AG	Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.
1448573619	GG	Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.
1449161164	CC	Patients with the CC genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449161165	CT	Patients with the CT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449161166	TT	Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449164606	AG	Patients with the AG genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype, or less likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1449164607	GG	Patients with the GG genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1450375061	CC	Patients with testicular cancer and the CC genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375062	CT	Patients with testicular cancer and the CT genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375063	TT	Patients with testicular cancer and the TT genotype may have an increased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.
1449004729	AA	Patients with the AA genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1449004730	AG	Patients with the AG genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1449004731	GG	Patients with the GG genotype and Epilepsy who are treated with carbamazepine may have  increased concentration-to-dose ratios as compared to patients with the AA or AG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1449166720	*95	Patients with the CYP2D6*95 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166721	*97	Patients with the CYP2D6*97 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166722	*98	Patients with the CYP2D6*98 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1450374920	AC	Patients with the AC genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450374921	CC	Patients with the CC genotype and attention deficit disorder with hyperactivity may have a decreased, but not absent, risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1449168318	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168730	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168731	GT	Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448635187	GGAGTC/del	Patients with acute lymphoblastic leukemia (ALL) and the GGAGTC/del genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GGAGTC/GGAGTC genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of three adolescents, one of whom was compound heterozygous for additional variants in NUDT15.
1448635188	del/del	Patients with acute lymphoblastic leukemia (ALL) and the GGAGTC/GGAGTC genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the GGAGTC/del genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of three adolescents, one of whom was compound heterozygous for additional variants in NUDT15.
1449168332	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168333	CT	Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168334	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168339	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168340	CG	Patients with the CG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168341	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168345	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168346	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168347	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168352	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168353	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168732	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168354	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168359	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168360	AT	Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168361	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168366	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168367	CG	Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449003988	*1A/*1A	Patients with the *1A/*1A genotype may require a decreased dose of oxycodone as compared to patients with the *3A/*3A genotype. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.
1449003989	*1A/*3A	Patients with the *1A/*3A genotype may require a decreased dose of oxycodone as compared to patients with the *3A/*3A genotype. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.
1449003990	*3A/*3A	Patients with the *3A/*3A genotype may require an increased dose of oxycodone as compared to patients with the *1A/*1A or *1A/*3A genotypes. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.
1449003953	*27:05:02	Patients who carry at least one HLA-B*27:05:02 allele may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with no HLA-B*27:05:02 alleles. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449004495	CC	Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of myelosuppression and neutropenia as compared to the AA and AC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449004524	AA	Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of Anemia and Neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.
1448267401	TT	Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.
1449004525	AG	Patients with nasopharyngeal cancer and the AG genotype may have an increased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.
1449004526	GG	Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype AA and AG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.
1449004530	AA	Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AG and GG genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449004531	AG	Patients with nasopharyngeal cancer and the AG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449004532	GG	Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype.  There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449713234	AG	Patients with the AG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.
1449713235	GG	Patients with the GG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.
1449713233	AA	Patients with the AA genotype and multiple sclerosis may have a decreased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.
1449003948	*08:01:01	Patients who carry at least one copy of the HLA-B*08:01:01 allele may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with no HLA-B*08:01:01 alleles. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449166692	*93	Patients with the CYP2D6*93 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166693	*94	Patients with the CYP2D6*94 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166694	*95	Patients with the CYP2D6*95 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449747956	*1A/*1A	Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *1A/*1A genotype may have a lower likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *3A/*3A genotype. Other clinical and genetic factors may also influence risk of nephrotoxicity.
1449747957	*1A/*3A	Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *1A/*3A genotype may have a lower likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *3A/*3A genotype. Other clinical and genetic factors may also influence risk of nephrotoxicity.
1449564716	AA	Patients with chronic hepatitis C and the AA genotype may have an increased risk of anemia but a decreased risk of thrombocytopenia when compared to patients with the AC and CC genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify "normal ITPas activity" vs. "deficient". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
1449747894	AA	Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747895	AG	Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449166695	*97	Patients with the CYP2D6*97 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449747896	GG	Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449166696	*98	Patients with the CYP2D6*98 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166711	*1	Patients with the CYP2D6*1 allele may have an increased clearance of amitriptyline as compared to patients with the CYP2D6*10 or *87 or *88 or *89 or *90 or *91 or *93 or *94 or *95 or *97 or *98. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449156318	AA	Patients with the AA genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.
1449166712	*10	Patients with the CYP2D6*10 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166713	*87	Patients with the CYP2D6*87 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166714	*88	Patients with the CYP2D6*88 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166715	*89	Patients with the CYP2D6*89 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166716	*90	Patients with the CYP2D6*90 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449190653	*15:02:01	Patients with one or two copies of the HLA-B*15:02:01 allele may have an increased risk of Stevens-Johnson Syndrome (SJS) when treated with oxcarbazepine as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test. FDA-approved drug labeling information and CPIC guidelines recommend the use of alternative therapies instead of oxcarbazepine in patients carrying the HLA-B*15:02:01 allele. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1450375695	CG	Patients with the CG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375696	CT	Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375697	GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375690	GG	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375698	GT	Patients with the GT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375699	TT	Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375736	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375737	AG	Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375738	GG	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450376321	GG	Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)
1449166890	CC	Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.
1449166891	CT	Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.
1449166892	TT	Patients with acute lymphoblastic leukemia and the TT genotype may have an increased risk of leukopenia, as compared to patients with the CC and CT genotypes, but may also experience increased rates of event-free survival, as well as overall survival as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.
1449166949	AA	In healthy volunteers the AA genotype may be associated with increased secretory clearance of metformin and in patients with diabetes mellitus may result in decreased efficacy (increased HbA1c levels), as compared to patients with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1450376322	GT	Patients with the GT genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the TT genotype but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)
1450376323	TT	Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)
1450377206	CT	Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377207	TT	Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377216	AA	Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1448125855	CC	Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.
1448125856	CT	Patients with the CT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.
1448125857	TT	Patients with the TT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.
1448427401	GT	Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427402	TT	Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1449004005	AA	Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449004006	AC	Patients with the AC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449004007	CC	Patients with the CC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1448602387	AA	Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
1448602388	AG	Patients with hypertension and the AG genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
1448602389	GG	Patients with hypertension and the GG genotype may have decreased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
1448603293	GG	Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603294	GT	Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603295	TT	Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1449004001	CC	Patients with the CC genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or TT genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.
1449004002	CT	Patients with the CT genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the TT genotype, but decreased binding affinity compared to the CC genotype. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.
1449004003	TT	Patients with the TT genotype may have decreased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or CC genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.
1449003936	AA	Patients with the AA genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1448267375	AA	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.
1448267376	AG	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.
1448267377	GG	Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA and GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.
1449005095	*1A/*1A	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A4 *1A/*1A genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A4 *1A/*1B genotypes. Post-transplantation, kidney recipients with the CYP3A4*1A/*1A genotypes may have higher concentrations of cyclosporine and tacrolimus as compared to patients with the CYP3A4 *1A/*1B genotypes.  Other clinical and genetic factors may also influence risk of transplant rejection and pharmacokinetics of tacrolimus and cyclosporine in recipients of kidneys.
1449005096	*1A/*1B	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A4 *1A/*1B genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A4 *1A/*1A genotypes. Post-transplantation, kidney recipients with the CYP3A4*1A/*1B genotype may have lower concentrations of cyclosporine and tacrolimus as compared to patients with the CYP3A4 *1A/*1A genotypes .  Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.
1449154371	AA	Patients with the genotype AA may have better response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AG or GG, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.
1449154372	AG	Patients with genotype AG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.
1449154373	GG	Patients with genotype GG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.
1449154376	AA	Patients with the AA genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1449154377	AG	Patients with the AG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1449154378	GG	Patients with the GG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1449166665	*91	Patients with the CYP2D6*91 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449166666	*93	Patients with the CYP2D6*93 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449154466	*1A	Individuals carrying one or two copies of the *1A allele may metabolize atazanavir more rapidly as compared to individuals with the one or more copies of the *3A, *6, or *7 alleles, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1449154467	*3A	Individuals with one *3A allele in combination with one functional (*1A) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3A, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1A/*1A genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1449154468	*6	Individuals with one *6 allele in combination with one functional (*1A) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3A, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1A/*1A genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1449164354	*1/*1	Patients with the *1/*1 genotype and heart failure may have decreased concentrations of sildenafil as compared to patients with the *1/*22 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.
1449164355	*1/*22	Patients with the *1/*22 genotype and heart failure may have increased concentrations of sildenafil as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.
1448122880	*1/*1	Patients with CYP2C19*1/*1 genotype who have non-valvular atrial fibrillation may require higher warfarin maintenance dose than patients with *1/*2 or *1/*3 or *2/*2 or *2/*3 or *3/*3 genotype. Other genetic and clinical factors may also influence the dose of warfarin.
1448122875	*1/*2	Patients with CYP2C19*1/*2 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.
1448122876	*1/*3	Patients with CYP2C19*1/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.
1448122877	*2/*2	Patients with CYP2C19*2/*2 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.
1448122878	*2/*3	Patients with CYP2C19*2/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.
1448122879	*3/*3	Patients with CYP2C19*3/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.
1449001960	G	Male patients with the G genotype and schizophrenia, treated with antipsychotics, in particular olanzapine and risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype C. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.
1449001961	GG	Female patients with the GG genotype and schizophrenia, treated with antipsychotics, in particular olanzapine and risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.
1449005043	CC	Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.
1449004752	AA	Patients with Mesothelioma and the AA genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.
1449004753	AG	Patients with Mesothelioma and the AC genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.
1449004754	CC	Patients with Mesothelioma and the CC genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the AA and AC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.
1449004756	AA	Patients with mesothelioma and the AA genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.
1449004757	AG	Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.
1449004758	GG	Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.
1449005037	CC	Pregnant patients infected with malaria and the CC genotype may have lower concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response.  Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.
1449005038	CT	Pregnant patients infected with malaria and the CT genotype may have lower concentrations of lumefantrine as compared to patients with the TT genotype and elevated concentrations as compared to patients with the CC genotype. There is no association with response.  Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.
1449005039	TT	Pregnant patients infected with malaria and the TT genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response.  Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.
1449005044	CT	Pregnant patients infected with malaria and the CT genotype may have elevated concentrations of lumefantrine as compared to patients with the TT genotype, and lower concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.
1449005045	TT	Pregnant patients infected with malaria and the TT genotype may have lower concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.
1449005049	CC	Pregnant patients with malaria and the CC genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.
1449166951	GG	In healthy volunteers the GG genotype may be associated with decreased secretory clearance of metformin, and in patients with diabetes mellitus may result in an increase efficacy (decreased HbA1c levels) as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1449718307	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2	Patients with the 2R/2R genotype may have an increased risk for toxicity, an increased survival time, and an increased response to fluoropyrimidine chemotherapy regimens as compared to patients with the 2R/3R or 3R/3R genotype. However, contradictory or non-significant evidence exists for all three of these associations. Other genetic and clinical factors may also influence a patient's risk for toxicity, survival time and response.
1449166950	AG	In healthy volunteers the AG genotype may be associated with decreased secretory clearance of metformin and in patients with diabetes mellitus may result in an increase in efficacy (decreased HbA1c levels) as compared to patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.
1448532230	*1/*1	Patients with the CYP2C19 *1/*1 genotype who are infected with Helicobacter pylori (H. pylori) may have a decreased likelihood of eradication when treated with pantoprazole as compared to patients with the *1/*2, *1/*3, *2/*2, *2/*3, or *3/*3 genotype. Patients also received amoxicillin and clarithromycin or metronidazole. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). However, only two studies assessed eradication in pantoprazole alone; one of these found no significant results. The remainder analyzed this outcome for pantoprazole along with omeprazole, esomeprazole, or other proton pump inhibitors. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448532231	*1/*2	Patients with the CYP2C19 *1/*2 genotype infected with Helicobacter pylori (H. pylori) may have a decreased likelihood of eradication when treated with pantoprazole as compared to patients with the *2/*2, *2/*3, or *3/*3 genotype, and an increased likelihood of eradication as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin or metronidazole. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). However, only two studies assessed eradication in pantoprazole alone; one of these found no significant results. The remainder analyzed this outcome for pantoprazole along with omeprazole, esomeprazole, or other proton pump inhibitors. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448532232	*1/*3	Patients with the CYP2C19 *1/*3 genotype infected with Helicobacter pylori (H. pylori) may have a decreased likelihood of eradication when treated with pantoprazole as compared to patients with the *2/*2, *2/*3, or *3/*3 genotype, and an increased likelihood of eradication as compared to patients with the *1/*1 genotype. Patients also received amoxicillin and clarithromycin or metronidazole. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). However, only two studies assessed eradication in pantoprazole alone; one of these found no significant results. The remainder analyzed this outcome for pantoprazole along with omeprazole, esomeprazole, or other proton pump inhibitors. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1449005388	AA	Individuals with tobacco use disorder and the AA genotype may have an improved response to bupropion as compared to individuals with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.
1449005389	AG	Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.
1449718308	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Patients with the 2R/3R genotype may have an increased survival time and response as compared to patients with the 3R/3R genotype, and a decreased response as compared to patients with the 2R/2R genotype, when receiving fluoropyrimidine chemotherapy regimens. A SNP within the third repeat may modify the actions of the 3R allele. Other genetic and clinical factors may also influence a patient's risk for survival time and response.
1448423797	CC	Patients with the CC genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423798	CG	Patients with the CG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423799	GG	Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.
1449005390	GG	Individuals with tobacco use disorder and the GG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.
1449003937	AG	Patients with the AG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AA genotype, but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003938	GG	Patients with the GG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449004009	AA	Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients in patients taking isoniazid.
1448256874	GG	Patients with the GG genotype and non-small cell lung cancer may have decreased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
1448256875	GT	Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
1448256876	TT	Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
1448276374	TT	Patients with the TT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.
1449004010	AG	Patients with the AG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449004011	GG	Patients with the GG genotype who are taking isoniazid may have a decreased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449168368	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168373	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168374	GT	Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168375	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168380	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168381	CT	Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168382	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168387	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168388	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168389	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168394	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168395	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168396	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449154457	*1A	Individuals carrying one or two copies of the *1A allele may metabolize atazanavir more rapidly as compared to individuals with the one or more copies of the *3A, *6, or *7 alleles. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1449154458	*3A	Individuals with one *3A allele in combination with one functional (*1A) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3A, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1A/*1A genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1449154459	*6	Individuals with one *6 allele in combination with one functional (*1A) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3A, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1A/*1A genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1448605617	CC	Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone, a smaller change in HbA1c, and a decreased risk of edema as compared to patients with the TT genotype (CYP2C8*1/*1). One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.
1448605618	CT	Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone and a decreased risk of edema compared to patients with the TT genotype (CYP2C8*1/*1). No association was found when considering blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.
1448605619	TT	Patients with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of rosiglitazone, a larger change in HbA1c, and an increased risk of edema as compared to patients with the CC (CYP2C8*3/*3) or CT (CYP2C8*3/*1) genotype. One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.
1449154460	*7	Individuals with one *7 allele in combination with one functional (*1A) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3A, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1A/*1A genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1449154477	CC	Patients with the CC genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and an increased likelihood of asthenia as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.
1449154469	*7	Individuals with one *7 allele in combination with one functional (*1A) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3A, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1A/*1A genotype. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.
1448266181	CC	Patients with genotype CC may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.
1448266180	CG	Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.
1448266179	GG	Patients with genotype GG may have better rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.
1449154478	CT	Patients with the CT genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.
1449166565	*1	Patients with the CYP2D6*1 allele may have 1) an increased clearance of atomoxetine as compared to patients with the CYP2D6*10 or *87 or *88 or *90 or *91 or *92 or *93 or *95 or *96 or *97 allele, 2) decreased clearance compared to patients with the CYP2D6*94 allele, and 3) similar clearance compared to CYP2D6*89 or *98 allele. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166566	*10	Patients with the CYP2D6*10 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166567	*87	Patients with the CYP2D6*87 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (as defined in this study only as A5V without 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1450042592	*10	Patients with schizophrenia who carry the *10 allele may have an increased risk for tardive dyskinesia when treated with antipsychotics as compared to patients with the *1/*1 genotype. However some studies have found no association with tardive dyskinesia. Additionally, some evidence suggests that this association may only be significant in males. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450042593	*14	Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450042594	*3	Patients with schizophrenia who carry the *3 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1/*1 genotype. Note that the *3 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450042595	*4	Patients with schizophrenia who carry the *4 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1/*1 genotype. Several studies assess this association with *4 in combination with other loss-of-function alleles (e.g. *3, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450042596	*5	Patients with schizophrenia who carry the *5 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1/*1 genotype. Several studies assess this association with *5 in combination with other loss-of-function alleles (e.g. *3, *4). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450042597	*6	Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450042598	*7	Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.
1450044492	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GT and TT. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044493	GT	Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044494	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the T allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044557	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CG or CC genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450043611	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448821716	AA	Patients with cancer and the AA genotype who are treated with gemcitabine may have a decreased incidence of hematologic or GI toxicity when compared to patients with the CC genotype, however evidence is contradictory. The effect of the genotype on CDA expression and function is also contradictory. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.
1448426940	*04:01:01	Patients with multiple sclerosis and one or two copies of the HLA-DRB1*04 allele may have a better response to interferon beta-1a treatment as compared to patients with no HLA-DRB1*04 alleles or negative for the HLA-DRB1*04 test. Other genetic and clinical factors may also influence a patient's response to interferon beta-1a treatment.
1448426946	*15:01:01:01	Patients with multiple sclerosis and one or two copies of the HLA-B*15 allele may have a poorer response to interferon beta-1a treatment as compared to patients with no HLA-B*15 alleles or negative for the HLA-B*15 test. Other genetic and clinical factors may also influence a patient's response to interferon beta-1a treatment.
1448821717	AC	Patients with cancer and the AC genotype who are treated with gemcitabine may have an increased incidence of hematologic or GI toxicity when compared to patients with the AA genotype, although the evidence is contradictory. The effect of the genotype on CDA expression or function is also contradictory. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.
1448573304	AA	Patients with the AA genotype may have decreased dose of warfarin in African American patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the dose of warfarin.
1448532233	*2/*2	Patients with the CYP2C19 *2/*2 genotype infected with Helicobacter pylori (H. pylori)  may have an increased likelihood of eradication when treated with pantoprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. Patients also received amoxicillin and clarithromycin or metronidazole. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893).  However, only two studies assessed eradication in pantoprazole alone; one of these found no significant results. The remainder analyzed this outcome for pantoprazole along with omeprazole, esomeprazole, or other proton pump inhibitors. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448532234	*2/*3	Patients with the CYP2C19 *2/*3 genotype infected with Helicobacter pylori (H. pylori)  may have an increased likelihood of eradication when treated with pantoprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. Patients also received amoxicillin and clarithromycin or metronidazole. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893).  However, only two studies assessed eradication in pantoprazole alone; one of these found no significant results. The remainder analyzed this outcome for pantoprazole along with omeprazole, esomeprazole, or other proton pump inhibitors. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448532235	*3/*3	Patients with the CYP2C19 *3/*3 genotype infected with Helicobacter pylori (H. pylori)  may have an increased likelihood of eradication when treated with pantoprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. Patients also received amoxicillin and clarithromycin or metronidazole. Studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizer = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893).  However, only two studies assessed eradication in pantoprazole alone; one of these found no significant results. The remainder analyzed this outcome for pantoprazole along with omeprazole, esomeprazole, or other proton pump inhibitors. Other genetic and clinical factors may also influence likelihood of H. pylori eradication.
1448573303	AG	Patients with the AG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1448573302	GG	Patients with the GG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1448615174	AA	Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.
1448615175	AG	Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotype and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.
1448615176	GG	Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.
1449168401	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168402	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168403	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448573517	*1/*1	People with extensive metabolizer genotypes may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.
1448573515	*1/*2	People with intermediate metabolizer genotypes may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.
1448573516	*2/*17	People with intermediate metabolizer genotypes may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.
1448259029	AA	Patients with the AA genotype may have decreased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype TT.
1448259028	AT	Patients with the AT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.
1448259027	TT	Patients with the TT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.
1448573514	*2/*2	People with poor metabolizer genotypes may have increased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with intermediate and extensive metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.
1449168407	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168408	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168409	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168414	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168415	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168416	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168421	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168422	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168423	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168428	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168429	AC	Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168430	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448613361	CC	Patients with the CC genotype may have lower on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613360	CT	Patients with the CT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613359	TT	Patients with the TT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448615607	*13:01:01	Patients with one or two copies of the HLA-B*13:01:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS) when treated with phenytoin as compared to patients with no HLA-B*13:01:01 alleles or negative for the HLA-B*13:01:01 test. However, one study found no association between the allele and adverse reactions. Other genetic and clinical factors may also affect risk for severe cutaneous adverse reactions in patients receiving phenytoin.
1449154479	TT	Patients with the TT genotype and cancer who are treated with Capecitabine may have an increased risk of of nausea and vomiting as compared to patients with the CC or CT genotypes and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.
1449154482	CC	Patients with the CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
1449154483	CT	Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
1449154484	TT	Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
1449154506	CC	Patients with the CC genotype and epilepsy who are treated with carbamazepine or oxcarbazepine may have a decreased likelihood of a good response within as compared to patients with the CT or TT genotypes, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.
1449154507	CT	Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.
1449154508	TT	Patients with the TT genotype and epilepsy who are treated with carbamazepine may have an increased likelihood of a good response as compared to patients with the CC or CT genotypes, although most studies have found no association with response. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.
1449166568	*88	Patients with the CYP2D6*88 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele (in this study only defined as V104A) was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166569	*89	Patients with the CYP2D6*89 allele may have similar clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166570	*90	Patients with the CYP2D6*90 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166571	*91	Patients with the CYP2D6*91 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S with 2988G>A not considered) was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166572	*92	Patients with the CYP2D6*92 allele may have no or severely decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele was found to have not measurable intrinsic clearance due to severely decreased activity in in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166573	*93	Patients with the CYP2D6*93 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166574	*94	Patients with the CYP2D6*94 allele may have increased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G with 100C>T, P34S not considered) was found to have increased intrinsic clearance during in-vitro characterization with atomoxetine.  Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1450043612	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448266831	CC	Patients with the CC genotype (CYP3A5 *3/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.
1448266832	CT	Patients with the CT genotype (CYP3A5 *1/*3) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.
1448266833	TT	Patients with the TT genotype (CYP3A5 *1/*1) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.
1448522442	AA	Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.
1448522443	AG	Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.
1448522444	GG	Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.
1448522447	AA	Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
1448522448	AG	Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
1448522449	GG	Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
1450043613	TT	Patients with the TT genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT and CC. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044583	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448522457	CC	Patients with the CC genotype and cancer may have increased response to fluorouracil-containing chemotherapy regimens, as well as a decreased risk for and a later onset of sensory neuropathy, as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.
1448522458	CT	Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.
1448522459	TT	Patients with the TT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.
1448522462	AA	Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
1448573527	*1/*17	People with the ultra-rapid metabolizer genotype may have increased metabolism of 3,4-methylenedioxymethamphetamine compared to people with the intermediate metabolizer genotype. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.
1448262905	CC	Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT or CT in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262904	CT	Patients with the CT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262912	CC	Patients with the CC genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262911	CG	Patients with the CG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262910	GG	Patients with the GG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262903	TT	Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1449191548	*3	Patients with the *3 allele in combination with another non-functional allele (*3, *4, *5, *6) who are treated with paroxetine may have a decreased clearance of paroxetine (higher paroxetine plasma concentrations) as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. However, an association with treatment response or severity of side effects is not conclusive. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449191549	*4	Patients with the *4 allele in combination with another non-functional allele (*3, *4, *5, *6) who are treated with paroxetine may have a decreased clearance of paroxetine (higher paroxetine plasma concentrations) as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. However, an association with treatment response or severity of side effects is not conclusive. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1448573526	*1/*2	People with the intermediate metabolizer genotype may have decreased metabolism of 3,4-methylenedioxymethamphetamine compared to people with the ultra-rapid metabolizer genotype. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.
1448573528	*17/*17	People with the ultra-rapid metabolizer genotype may have increased metabolism of 3,4-methylenedioxymethamphetamine compared to people with the intermediate metabolizer genotype. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.
1448573525	*2/*17	People with the intermediate metabolizer genotype may have decreased metabolism of 3,4-methylenedioxymethamphetamine compared to people with the ultra-rapid metabolizer genotype. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.
1448432219	AA	Patients with the AA genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448432220	AG	Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448432221	GG	Patients with the GG genotype and colorectal cancer may have longer progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1449191547	*2/*2xN	Patients with the CYP2D6*2/*2xN genotype (carriers of more than two functional CYP2D6 alleles) who are treated with paroxetine may have an increased clearance of paroxetine (lower or undetectable drug plasma levels) which may effect response as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449157002	AA	Patients carrying the AA genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.
1449157003	AG	Patients carrying the AG genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.
1448526042	AA	Patients with the AA genotype who are opioid-dependent may have a better response to treatment with methadone as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone response.
1448526043	AG	Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone response.
1448526044	GG	Patients with the GG genotype who are opioid-dependent may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone response.
1449168442	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168443	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168444	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168435	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168436	GT	Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168437	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168449	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168450	CG	Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168451	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168456	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168457	CG	Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168458	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168734	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168735	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168736	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168470	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168471	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168472	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168477	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168478	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449162244	*1/*1	Patients with the CYP2C9*1/*1 genotype may have an increased clearance of meloxicam compared to patients with the CYP2C9*3/*3 genotype. Other genetic and clinical factors may also influence response to meloxicam.
1448573606	CC	Patients with the CC genotype (CYP3A5 *3/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.
1448573607	CT	Patients with the CT genotype (CYP3A5 *1/*3) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.
1448573608	TT	Patients with the TT genotype (CYP3A5 *1/*1) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.
1449166575	*95	Patients with the CYP2D6*95 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H with 100C>T, P34S not considered) was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166576	*96	Patients with the CYP2D6*96 allele may have no or severely decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele was found to have not measurable intrinsic clearance due to severely decreased activity in in-vitro characterization with atomoxetine.Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166577	*97	Patients with the CYP2D6*97 allele may have decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with atomoxetine.Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1448617532	T	Patients with the 1095T allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095C allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.
1449162243	*1/*3	Patients with the CYP2C9*1/*3 genotype may have an increased clearance of meloxicam compared to patients with the CYP2C9*3/*3 genotype. Other genetic and clinical factors may also influence response to meloxicam.
1449162242	*3/*3	Patients with the CYP2C9*3/*3 genotype may have a decreased clearance of meloxicam compared to patients with the CYP2C9*1/*1 or *1/*3 genotype. Other genetic and clinical factors may also influence response to meloxicam.
1449162251	CC	Patients with the CC genotype who are treated with ketorolac and undergo oral surgery may have a slower analgesic onset as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.
1449162252	CT	Patients with the CT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.
1449162253	TT	Patients with the TT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.
1449166578	*98	Patients with the CYP2D6*98 allele may have similar clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only H463D was considered) was found to have similar intrinsic clearance during in-vitro characterization with atomoxetine. Other genetic and clinical factors may also influence the metabolism of atomoxetine.
1449166667	*94	Patients with the CYP2D6*94 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449166668	*95	Patients with the CYP2D6*95 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1449166669	*97	Patients with the CYP2D6*97 allele may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1448522463	AG	Patients with the AG genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
1448522464	GG	Patients with the GG genotype and colorectal cancer may have increased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.
1448265268	CC	Patients with the CC genotype and Psoriasis may have decreased response to ustekinumab compared to patients with the CT genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265250	AA	Patients with the AA genotype may have increased response to etanercept in people with Arthritis, Rheumatoid as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.
1448265251	AG	Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.
1448265252	GG	Patients with the GG genotype may have decreased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to etanercept.
1448265269	CT	Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265270	TT	Patients with the TT genotype and Psoriasis were not found to have different response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265282	GG	Evidence conflicts as to whether patients with the GG genotype and psoriasis have decreased response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265283	GT	Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265284	TT	Evidence conflicts as to whether patients with the TT genotype and psoriasis have increased response to ustekinumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to ustekinumab.
1450044584	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1448522472	AA	Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia.
1448522473	AG	Patients with the AG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia.
1448522474	GG	Patients with the GG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia.
1450044585	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044631	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT genotype. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044632	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044633	TT	Patients with the TT genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1448821718	CC	Patients with the CC genotype who are treated with gemcitabine may have increased incidence of hematologic or GI toxicity when compared to patients with the AA genotype, however evidence is contradictory. The effect of the genotype on CDA expression or function is also contradictory.Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.
1448997850	AA	Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of adverse events in response to treatment as compared to patients with the GG or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1448997851	AG	Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have  increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1448255845	CC	Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
1448255846	CT	Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
1448255847	TT	Patients with the TT genotype (CYP3A5 *1/*1) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
1448997852	GG	Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1449003942	A/A	Patients with the AA genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A/del or del/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003943	A/del	Patients with the A/del genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AA genotype, but a decreased risk as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449157004	GG	Patients carrying the GG genotype who are receiving methadone maintenance therapy (MMT) may experience decreased insomnia as a side-effect of treatment as compared patients carrying the AA or AG genotypes. Other genetic and clinical factors may also affect development of insomnia during MMT.
1448281099	H1/H1	Patients who are carrier of the P2RY12 H1/H1 haplotype may have a decreased, but not absent, risk for high on-clopidogrel platelet reactivity when treated with clopidogrel as compared to patients who are carrier of the P2RY12 H2/H2 haplotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1448281101	H1/H2	Patients with the H1/H2 haplotype may have increased risk of high on-clopidogrel platelet reactivity when treated with clopidogrel as compared to patients with the H1/H1 haplotype. Other genetic and clinical factors may affect a patient's response to clopidogrel.
1448281100	H2/H2	Patients who are carrier of the P2RY12 H2/H2 haplotype may have an increased risk for high on-clopidogrel platelet reactivity when treated with clopidogrel as compared to patients who are carrier of the P2RY12 H1/H1 haplotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1449166963	CC	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a worse response to methotrexate as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449166964	CT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have an improved response to methotrexate as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449166965	TT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an improved response to methotrexate as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449166972	AA	Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1449168479	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168484	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168485	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168486	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449167238	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167239	AC	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167240	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167241	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167242	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167243	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168491	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168492	AG	Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168493	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168738	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168739	AT	Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168740	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168505	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168506	AC	Patients with the AC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168507	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168512	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168513	CT	Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168514	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168519	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168520	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448256102	CC	Patients with the CC genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT.
1448256101	CT	Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT.
1448256100	TT	Patients with the TT genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC or CT.
1448265559	AA	Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265560	AG	Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265561	GG	Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265567	CC	Patients with the CC genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265568	CT	Patients with the CT genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265569	TT	Patients with the TT genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the CC genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265583	AA	Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265584	AG	Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265585	GG	Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265600	AA	Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265601	AG	Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265602	GG	Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448427561	AA	Patients with the AA genotype may have increased clozapine plasma concentrations, as well as an increased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.
1448427562	AG	Patients with the AG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.
1450044605	AA	Patients with the AA genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044606	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044607	GG	Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044535	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044536	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044537	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450180229	(TA)6/(TA)6	Women with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence bone mineral density.
1450180230	(TA)6/(TA)7	Women with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence bone mineral density.
1450180231	(TA)7/(TA)7	Women with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) genotype and osteoporosis may have increased hip bone mineral density when treated with raloxifene as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. Other genetic and clinical factors may also influence bone mineral density.
1450369168	AA	Patients with the AA genotype and alcoholism may have an increased response to acamprosate as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.
1450369169	AT	Patients with the AT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the TT genotype and a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.
1450369170	TT	Patients with the TT genotype and alcoholism may have a decreased response to acamprosate as compared to patients with the AA or AT genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.
1450373630	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1449269515	AA	Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.
1449269516	AG	Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.
1449269517	GG	Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.
1448259310	CC	Female, post-menopausal patients with the CC genotype and schizophrenia may have a decreased response to raloxifene compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to raloxifene.
1448259311	CT	Female, post-menopausal patients with the CT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.
1448259312	TT	Female, post-menopausal patients with the TT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.
1448260922	TC	Patients with the TC genotype may have decreased metabolism of amitriptyline as compared to patients with the TT genotype or may have increased metabolism of amitriptyline as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
1448260923	TT	Patients with the TT genotype may have increased metabolism of amitriptyline levels as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.
1448263590	AA	Patients with the AA genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AG and GG genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other factors may affect concentration of lamotrigine.
1448263591	AG	Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotype. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine.
1448263592	GG	Patients with the GG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine.
1449003944	del/del	Patients with the del/del genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A/del or AA genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449166973	AG	Patients with the AG genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) as compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1449166974	GG	Patients with the GG genotype who are treated with atorvastatin may have a reduced response to treatment (as measured by a lower reduction in LDL-cholesterol or total cholesterol) as compared to patients with the AG or AA genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1449167324	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449003978	AA	Patients with the AA genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449003979	AG	Patients with the AG genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449003980	GG	Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.
1449167325	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167326	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167346	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167347	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167348	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168533	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168534	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168535	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168521	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168526	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168527	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168540	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448634960	AA	Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compared to patients with the GG or AG genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.
1448634961	AG	Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.
1448634962	GG	Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.
1449168541	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168542	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168547	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168548	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168549	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168554	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168555	AC	Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168556	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168528	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168561	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168562	AC	Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168563	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168567	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168568	CG	Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448266858	AA	Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine.
1448266859	AG	Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.
1448266860	GG	Patients with the GG genotype and epilepsy may have decreased metabolism of carbamazepine and may need a decreased dose as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.
1448427563	GG	Patients with the GG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.
1448427570	non-null/non-null	Patients with the non-null/non-null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null/null genotype. Other genetic and clinical factors may also influence neutropenia risk.
1448427569	null/non-null	Patients with the null/non-null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null/null genotype. Other genetic and clinical factors may also influence neutropenia risk.
1448427568	null/null	Patients with the null/null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null/non-null or non-null/non-null genotype. Other genetic and clinical factors may also influence neutropenia risk.
1448427592	non-null/non-null	Patients with the non-null/non-null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null/null genotype. Other genetic and clinical factors may also influence neutropenia risk.
1448427591	null/non-null	Patients with the null/non-null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null/null genotype. Other genetic and clinical factors may also influence neutropenia risk.
1448427590	null/null	Patients with the null/null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null/non-null or non-null/non-null genotype. Other genetic and clinical factors may also influence neutropenia risk.
1448633926	AA	Patients with the AA genotype who are treated with warfarin may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.
1448568156	AA	Patients with AA genotype may have decreased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1448568155	AG	Patients with AG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1448568154	GG	Patients with GG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1448633927	AG	Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.
1449144302	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1448522439	TT	Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
1449144306	CC	Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144307	CT	Patients with the CT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449161580	*1/*1	Patients receiving livers from donors with the CYP3A4*1/*1 genotype may have increased metabolism of tacrolimus as compared to patients with the CYP3A4*1/*20 genotype. Other genetic and clinical factors, such as CYP3A5*3 (rs776746), may also influence metabolism of tacrolimus.
1449161581	*1/*20	Patients receiving livers from donors with the CYP3A4*1/*20 genotype (rs67666821) may have decreased metabolism of tacrolimus as compared to patients with the CYP3A4*1/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3 (rs776746), may also influence metabolism of tacrolimus.
1449166431	CC	People with the CC genotype and kidney transplantation may have increased exposure to tacrolimus, as measured by the concentration/dose ratio, compared to people with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1449166432	CT	People with the CT genotype and kidney transplantation may have decreased exposure to tacrolimus, as measured by the concentration/dose ratio, compared to people with the CC genotype. Other clinical and genetic factors may affect exposure to tacrolimus.
1450374005	AA	Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.
1449188848	AA	Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.
1449188849	AG	Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.
1449188850	GG	Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.
1449005050	CT	Pregnant patients with malaria and the CT genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the TT genotypes and lower concentrations and worse response to lumefantrine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.
1449005051	TT	Pregnant patients with malaria and the TT genotype may have lower concentrations and worse response to lumefantrine as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.
1449005197	AA	Patients with the AA genotype may require a decreased dose of warfarin as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence dose of warfarin.
1449005198	AG	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.
1449005199	GG	Patients with the GG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.
1449144308	TT	Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144312	CC	Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144313	CT	Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144314	TT	Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144318	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144319	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1450374006	AG	Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.
1450373631	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450374007	GG	Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.
1450373632	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1449167368	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167369	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167370	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1448632495	AA	Patients with the AA genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.
1449167398	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167399	AC	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167400	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167357	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167358	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167359	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1448632494	AG	Patients with the AG genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.
1448632493	GG	Patients with the GG genotype may have improved overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.
1449167401	AT	Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167402	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167403	CG	Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167404	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167405	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167406	GT	Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167407	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167416	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167417	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167418	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449564835	CC	Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449564836	CT	Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449564837	TT	Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449147611	CC	Patients with the CC genotype who are taking buprenorphine for pain may have an increased analgesic response as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence analgesic response to buprenorphine.
1449147612	CT	Patients with the CT or TT genotypes who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.
1449147613	TT	Patients with the CT or TT genotypes who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.
1449565176	AG	Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the AA or GG genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1449732709	AG	Patients with the AG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance of tacrolimus as compared to patients with the AA genotype, and decreased dose requirements of tacrolimus as compared to patients with the GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.
1449732708	AA	Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.
1449156967	CC	Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1449156968	CG	Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1449564825	AA	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1449564826	AC	Patients with the AC genotype may require a decreased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1449564827	CC	Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
1449191545	*10/*10 + *1/*10	Patients with the *10/*10 or *1/*10 genotype who are treated with paroxetine may have increased plasma concentrations/ decreased clearance of paroxetine as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449191546	*2	Patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with paroxetine may have 1) a decreased clearance of paroxetine as compared to patients with more than 2 functional CYP2D6 alleles (*1xN, *2xN) and 2) an increased clearance of paroxetine as compared to patients with two non-functional CYP2D6 alleles (*3, *4, *5, *6) or *10/*10 genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449564832	TT	Patients with the TT genotype and Hepatitis C genotype 1 may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to peg interferon and ribavirin.
1449565168	TT	Pediatric patients with major thalassemia and the TT genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the GT or GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype GT, therefore there is no information for patients with the GG or TT genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1448616401	GG	Patients with the GG genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448616402	GT	Patients with the GT genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448259319	CC	Post menopausal women with the CC genotype and schizophrenia may have increased response to raloxifene compared to patients with the CG genotype. Other genetic and clinical factors may affect response to raloxifene.
1448259320	CG	Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene.
1448259321	GG	No patients with the GG genotype were studied.
1448264190	CC	Patients with the CC genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.
1448264189	CG	Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.
1448264188	GG	Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes CC or CG. Other genetic and clinical factors may also influence peginterferon response.
1448265891	GG	Patients with the GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, patients with the GG genotype may also have an increased risk for immunological failure, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448265892	GT	Patients with the GT genotype may have a decreased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the TT genotype. One study shows an increased risk for sleep disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448265893	TT	Patients with the TT genotype may have an increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG or GT genotype. However, patients with the TT genotype may also have a decreased risk for immunological failure, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448616403	TT	Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448616406	CC	Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448616407	CT	Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448616408	TT	Children with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448616411	CC	Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448616412	CT	Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1449144320	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144324	CC	Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144325	CG	Patients with the CG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144326	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144330	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144331	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144332	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144336	CC	Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144337	CT	Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response when compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144338	TT	Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144342	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144343	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144344	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144348	CC	Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144349	CT	Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144350	TT	Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144354	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144355	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144356	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144360	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144361	AC	Patients with the AC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CC genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1448624767	AA	Patients with the AA genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1448624768	AG	Patients with the AG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1448624769	GG	Patients with the GG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1449167438	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167439	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167427	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167440	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167449	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167450	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167428	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167451	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167476	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167429	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167477	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167478	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167491	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1448995670	AG	Patients with the AG genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the GG genotype or those who are not taking oral contraceptives and a decreased risk of DVT as compared to patients with the AA genotype. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.
1448995671	GG	Patients with the GG genotype who are taking oral contraceptives (OCs) may have a decreased risk for deep vein thrombosis (DVT), as compared to patients with the AA or AG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA or AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.
1449167492	GT	Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168569	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168574	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448603287	GG	Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for respiratory depression when treated with opioids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
1448603288	GT	Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
1448603289	TT	Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
1448624486	CC	Patients with the CC genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased of likelihood of leukopenia or neutropenia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).
1448624487	CT	Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).
1448624488	TT	Patients with the TT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).
1449168575	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168576	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168581	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168582	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168583	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168588	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168589	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168590	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168595	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168596	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168597	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168602	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168603	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1448616413	TT	Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
1448126028	AA	Patients with AA genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1448126029	AG	Patients with AG genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1448126030	GG	Patients with GG genotype may have increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
1448258929	TT	Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1448633928	GG	Patients with the GG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.
1448997124	CC	Patients with acute myeloid leukemia and the CC genotype may have a decreased response to cytarabine and idarubicin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1448997125	CT	Patients with acute myeloid leukemia and the CT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1448997126	TT	Patients with acute myeloid leukemia and the TT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1449003795	AA	Patients with the AA genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003796	AG	Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003797	GG	Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003787	GG	Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003788	GT	Patients with the GT genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the TT genotype or an increased risk of coronary artery disease compared to patients with the GG. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003789	TT	Patients with the TT genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003819	CC	Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003820	CT	Patients with the CT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the TT genotype or an increased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003821	TT	Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449144362	CC	Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144372	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144373	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144378	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144379	AG	Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144380	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144374	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144384	GG	Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144385	GT	Patients with the GT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144386	TT	Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449156328	AA	Patients with the AA genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.
1449156329	AC	Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.
1449144402	AA	Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.
1449144403	AC	Patients with the AC genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the CC genotype and and worse response as compared to the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.
1449144404	CC	Patients with the CC genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.
1449156319	AG	Patients with the AG genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.
1449156320	GG	Patients with the GG genotype and cancer may have a decreased risk of drug toxicity and may not require dose modification when administered capecitabine and/or fluorouracil as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.
1448276467	*1A/*1A	Patients with CYP2C8 *1A/*1A may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with CYP2C8 *3/*3 or *1A/*3. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276466	*1A/*3	Patients with CYP2C8 *1A/*3 may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with CYP2C8 *1A/*1A. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276475	CC	Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276476	CT	Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276477	TT	Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276533	AA	Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.
1448276534	AC	Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.
1448276535	CC	Patients with the CC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.
1448276465	*3/*3	Patients with CYP2C8 *3/*3 may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with CYP2C8 *1A/*1A. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276546	AA	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.
1448276547	AG	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.
1448276548	GG	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.
1448426881	*1A/*1A	Patients with CYP3A5*1A/*1A had a significantly higher granisetron clearance and reduced exposure as compared to patients with *3A/*3A in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.
1448426880	*1A/*3A	Patients with CYP3A5*1A/*3A had a significantly higher granisetron clearance and reduced exposure as compared to patients with *3A/*3A in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.
1448426879	*3A/*3A	Patients with CYP3A5*3A/*3A had a significantly lower granisetron clearance and increased exposure as compared to patients with *1A/*1A or *1A/*3A in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.
1448426890	*1/*1	Patients with CYP1A1*1/*1 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1/*2A in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.
1448426889	*1/*2A	Patients with CYP1A1*1/*2A had a significantly higher granisetron clearance and reduced exposure as compared to patients with *1/*1 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.
1448426978	AA	Patients with the AA genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448426979	AG	Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448426980	GG	Patients with the GG genotype and psoriasis may have a higher psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448426984	AA	Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1448426985	AC	Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1449156969	GG	Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1449156976	AA	Patients with the AA genotype and non-small cell lung cancer may have an improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.
1449156977	AG	Patients with the AG genotype and non-small cell lung cancer may have improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.
1449156978	GG	Patients with the GG genotype and non-small cell lung cancer may have a worse response when treated with platinum compounds as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.
1449168604	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168609	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168610	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168611	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168616	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168617	CG	Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168618	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168623	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168624	AT	Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168625	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168693	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168694	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168695	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168700	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168701	GT	Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168702	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168707	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168708	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168709	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449003825	AA	There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.
1449003826	AG	Patients with the AG genotype may have an increased risk of alcoholism compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.
1449003827	GG	Patients with the GG genotype may have a decreased risk of alcoholism compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.
1448126004	AA	Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.
1448126005	AG	Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.
1448126006	GG	Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.
1449003814	C/del	Patients with the C/del genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the del/del genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003813	CC	Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the C/del or del/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003815	del/del	Patients with the del/del genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the C/del or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003841	AA	Patients with the AA genotype who are taking methadone may have an increased response as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to methadone treatment.
1449003842	AG	Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003843	GG	Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003847	AA	Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003848	AC	Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003849	CC	Patients with the CC genotype who are taking methadone may have an increased response as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to methadone treatment.
1449003854	*01:02:01 + *03:02 + *07:01:01 + *08:01 + *12:02:01 + *14:02:01 + *16:01:01	Patients with one or more HLA-C alleles from the C1 group (i.e. *01, *03, *07, *08, *12, *14 or *16) may have an increased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients as compared to patients with two HLA-C alleles from the C2 group (i.e. *02, *04, *05, *06, *15 or *17).
1449003853	*02:02:01 + *04:01:01:01 + *05:01:01:01 + *06:02:01:01 + *15:02:01 + *17:01:01:01	Patients with two alleles from the C2 group of HLA-C alleles (i.e. *02, *04, *05, *06, *15 or *17) may have a decreased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients as compared to patients with one or more HLA-C alleles from the C1 group (i.e. *01, *03, *07, *08, *12, *14 or *16).
1449003871	GG	Patients with the GG genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003872	GT	Patients with the GT genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the TT genotype or a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003873	TT	Patients with the TT genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003883	CC	Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.
1449565056	CC	Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
1449166875	CC	Organ transplant patients with the CC genotype who are administered tacrolimus may have increased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and TT genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.
1449166876	CT	Organ transplant patients with the CT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CC genotype. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.
1449156337	CC	Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.
1449004809	CC	Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have increased concentrations of methotrexate as compared to patients with the CT and TT genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449004810	CT	Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449565057	CT	Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.
1449565058	TT	Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.
1449004811	TT	Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449156338	CT	Patients with the CT genotype and beta-thalassemia who are treated with deferasirox may have decreased concentrations of deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.
1449156330	CC	Patients with the CC genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.
1449156339	TT	Patients with the TT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.
1449156342	AA	Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and GG genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156343	AG	Patients with the AG genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the GG genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449166877	TT	Organ transplant patients with the TT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and CC genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.
1449565064	TT	Patients with the TT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.
1449183232	A/del	Transplant recipients with the A/del (CYP3A5 *1/*7) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the del/del (*1/*1) genotype, and have increased metabolism and require a higher dose of the drug as compared to patients with the AA (*7/*7) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.
1448426986	CC	Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1449183227	CC	Transplant recipients with the CC (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus and require a higher dose of the drug as compared to patients with the CT or TT (*1/*6 or *6/*6) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.
1449000138	AA	Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449000139	AG	Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449191542	*1/*1	Patients with the CYP2D6*1/*1 genotype who are treated with paroxetine may have 1) a decreased clearance of paroxetine as compared to patients with more than two functional CYP2D6 alleles (*1xN, *2xN) and 2) an increased clearance of paroxetine as compared to patients with two non-functional CYP2D6 alleles (*3, *4, *5, *6) or *10/*10 genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449191543	*1/*1xN	Patients with the CYP2D6*1/*1xN genotype (carriers of more than two functional CYP2D6 alleles) who are treated with paroxetine may have an increased clearance of paroxetine (lower or undetectable drug plasma levels) which may effect response as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1448530597	GG	Patients with the GG genotype and kidney transplantation may have decreased risk of acute renal toxicity when taking tacrolimus compared to patients with the GT or TT genotypes. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
1448530598	GT	Patients with the GT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
1448530599	TT	Patients with the TT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
1449191544	*1/*2xN	Patients with the CYP2D6*1/*2xN genotype (carriers of more than two functional CYP2D6 alleles) who are treated with paroxetine may have an increased clearance of paroxetine (lower or undetectable drug plasma levels) which may effect response as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449000140	GG	Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449183228	CT	Transplant recipients with the CT (CYP3A5 *1/*6) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the CC (*1/*1) genotype, and have increased metabolism and require a higher dose of the drug as compared to patients with the TT (*6/*6) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.
1449167493	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167505	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167506	CG	Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167507	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167508	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449183229	TT	Transplant recipients with the TT (CYP3A5 *6/*6) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the CT or CC (*1/*6 or *1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.
1449169603	CC	Subjects with the CC genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169604	CT	Subjects with the CT genotype may have increased exposure to atorvastatin as compared to subjects with the CC or TT genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449168714	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168715	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168716	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168721	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168722	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168723	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449169605	TT	Subjects with the TT genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169682	AA	Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AG or GG genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169683	AG	Patients with the AG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169684	GG	Patients with the GG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169677	AA	Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AC or CC genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169678	AC	Patients with the AC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169679	CC	Patients with the CC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449170182	AA	Patients with the AA genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.
1449170183	AC	Patients with the AC genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.
1449170184	CC	Patients with the CC genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA or AC genotypes. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.
1449170175	GG	Patients with the GG genotype and who are treated with allopurinol may have a decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA or AG genotypes. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.
1449166670	*98	Patients with the CYP2D6*98 allele (in this study only defined by 4110C>G) may have decreased clearance of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele was found to have decreased intrinsic clearance during in-vitro characterization with risperidone. Other genetic and clinical factors may also influence the metabolism of risperidone
1450044561	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044539	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044540	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044541	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1449166685	*1	Patients with the CYP2D6*1 allele may have an increased clearance of venlafaxine as compared to patients with the CYP2D6*10 or *87 or *88 or *89 or *90 or *91 or *93 or *94 or *95 or *97 or *98. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1447943593	AA	Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.
1447943594	AG	Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.
1447943595	GG	Patients with the GG genotype and depressive disorder may have an increased response to agomelatine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to agomelatine.
1447952821	GG	Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.
1447952822	GT	Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.
1447952823	TT	Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.
1447952827	AA	Patients with the AA genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1447952828	AG	Patients with the AG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1449166686	*10	Patients with the CYP2D6*10 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1449166687	*87	Patients with the CYP2D6*87 allele may have decreased clearance of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with venlafaxine. Other genetic and clinical factors may also influence the metabolism of venlafaxine.
1448259108	AA	Patients with the AA genotype and Alzheimer's Disease may not experience increasing creatinine levels when taking captopril compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
1448259109	AT	Patients with the AT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
1448259110	TT	Patients with the TT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
1449156344	GG	Patients with the GG genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156347	CC	Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156348	CT	Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156349	TT	Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1448265370	*1/*1	Women with extensive metabolizer genotypes and epilepsy who are taking valproic acid may have decreased risk of becoming overweight compared to patients with intermediate and poor metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.
1448265371	*1/*2	Women with intermediate metabolizer genotypes and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with extensive metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.
1448265372	*1/*3	Women with intermediate metabolizer genotypes and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with extensive metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.
1448265373	*2/*3	Women with poor metabolizer genotypes and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with extensive metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.
1449156352	AA	Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156353	AT	Patients with the AT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449156354	TT	Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1449166717	*91	Patients with the CYP2D6*91 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166718	*93	Patients with the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449166719	*94	Patients with the CYP2D6*94 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. Other genetic and clinical factors may also influence the metabolism of amitriptyline.
1449164605	AA	Patients with the AA genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1449166433	TT	People with the TT genotype and kidney transplantation may have decreased exposure to tacrolimus, as measured by the concentration/dose ratio, compared to people with the CC genotype. Other clinical and genetic factors may affect exposure to tacrolimus.
1448263867	GG	Patients with the GG genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.
1448263868	GT	Patients with the GT genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.
1448263869	TT	Patients with the TT genotype and breast cancer may have an increased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for neutropenia.
1448636932	AA	Patients with the AA genotype and breast cancer who are treated with everolimus may have a decreased likelihood of leukopenia and an increased likelihood of hyperglycemia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or hyperglycemia in patients with breast cancer who are treated with everolimus.
1448636933	AG	Patients with the AG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia as compared to patients with the AA genotype, and a decreased likelihood of leukopenia as compared to patients with the GG genotype. In addition, the AG genotype may have an increased likelihood of hyperglycemia as compared to patients with the AA genotype, and a decreased likelihood as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.
1448636934	GG	Patients with the GG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia and a decreased likelihood of hyperglycemia as compared to patients with the AG or AA genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.
1449147417	AG	Individuals with the AG genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.
1449147418	GG	Individuals with the GG genotype may have decreased renal and secretory clearance of metformin as compared to individuals with the AA genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.
1449174820	AA	Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1449174821	TA	Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1449174822	TT	Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1450376137	TT	Patients with the TT genotype may require an increased dose of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376308	*1/*1	Patients with *1/*1 genotypes may have increased metabolism, decreased plasma concentration, decreased toxicity and decreased adverse drug reactions when treated with phenytoin in epilepsy when compared to patients with *1/*2, *1/*3, *2/*3 *2/*2 or *3/*3 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1449266596	CC	Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449170094	*58:01	Patients with one or two copies of the HLA-B*58:01 allele have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with allopurinol as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449266597	CT	Patients with the CT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266598	TT	Patients with the TT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1450376135	CC	Patients with the CC genotype may require a decreased dose of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376309	*1/*2	Patients with *1/*2 genotypes may have decreased metabolism, increased plasma concentration and increased adverse drug reactions when treated with phenytoin in epilepsy when compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1449269475	CC	Patients with the CC genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.
1450376136	CT	Patients with the CT genotype may require a decreased dose of morphine as compared to patients with the TT genotype but an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450044502	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to be inherited in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044503	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449270022	CC	Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1450044504	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.  Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449269507	*1A/*1A	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *1A/*1A genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *3A/*3A genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.
1449269508	*1A/*3A	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *1A/*3A genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *3A/*3A genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.
1449269509	*3A/*3A	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3A/*3A genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1A/3A and *3A/*3A genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.
1449269528	AA	Patients with the AA genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.
1449269529	AG	Patients with the AG genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.
1449269530	GG	Patients with the GG genotype may have an increased response to clopidogrel (increased platelet reactivity) as compared to patients with the AA genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.
1449269543	AA	The AA genotype is not clearly associated with risk of opioid-related disorder.
1449269544	AG	Patients with the AG genotype may have a greater risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1449269545	GG	Patients with the GG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1449270023	CT	Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with the CC genotype, but an increased dose compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1449270024	TT	Patients with the TT genotype who are treated with warfarin may require a decreased dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1449188532	AA	Patients with the AA genotype may require a lower dose of acenocoumarol as compared to patients with the AG or GG genotypes. Other clinical and genetic factors  may also affect dose of acenocoumarol.
1449188533	AG	Patients with the AG genotype may require a lower dose of acenocoumarol as compared to patients with the GG genotype and a higher dose as compared to the AA genotypes. Other clinical and genetic factors  may also affect dose of acenocoumarol.
1449188534	GG	Patients with the GG genotype may require a higher dose of acenocoumarol as compared to patients with the AG or AA genotypes. Other clinical and genetic factors  may also affect dose of acenocoumarol.
1449188715	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188716	CT	Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449713006	*11:01:01	Epileptic patients with the HLA-A*11:01 allele may be at an increased risk of experiencing psychiatric adverse events when taking levetiracetam as compared to patients who do not carry the HLA-A*11:01 allele. Other genetic and clinical factors may also affect a patient's risk of experiencing psychiatric adverse events when taking levetiracetam.
1449188549	TT	Patients with the TT genotype may have an increased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.
1449713686	GG	Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713509	*1A/*1A	Patients with *1A/*1A  genotypes may have increased pioglitazone metabolism as compared to patients with the *2 or *3 alleles. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.
1449713510	*2	Patients with the *2 allele may have decreased pioglitazone metabolism as compared to patients with *1A/*1A genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.
1449713511	*3	Patients with the *3 allele may have decreased plasma concentration and increased clearance when exposed to pioglitazone as compared to patients with *1A/*1A genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.
1449188685	AA	Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188686	AG	Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188687	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188703	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188704	CT	Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188705	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188709	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188710	CT	Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188711	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449713685	AG	Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1448525765	*08:01	Patients with one or two copies of the HLA-C*08:01 allele who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1448525770	*08:01	Patients with one or two copies of the HLA-C*08:01 allele who are treated with phenytoin may have an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) or maculopapular exanthema (MPE) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced adverse reactions.
1448525734	*24:02:01:01	Patients with the HLA-A*24:02:01:01 allele may have an increased risk of severe cutaneous adverse reactions (SCARs) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) when treated with carbamazepine as compared to patients with no HLA-A*24:02:01:01 alleles. Other genetic and clinical factors may also influence risk of SCARs or DRESS.
1449564717	AC	Patients with chronic hepatitis C and the AC genotype may have an decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the AA genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify "normal ITPas activity" vs. "deficient". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
1448526094	CC	Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.
1448526095	CT	Patients with the CT genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.
1448526096	TT	Patients with the TT genotype and Rheumatoid Arthritis may have increased response to tocilizumab as compared to patients with the CC or CT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.
1448526100	CC	Patients with the CC genotype and rheumatoid arthritis may have a better response when treated with tocilizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tocilizumab response.
1448526101	CT	Patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.
1448526102	TT	Patients with the TT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.
1448600722	CC	Children with the CC genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the CT or TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
1448600723	CT	Children with the CT genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
1448600724	TT	Children with the TT genotype and gating mutations in cystic fibrosis may have decreased response to ivacaftor compared to children with the CC or CT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
1448603642	GG	Patients with the GG genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.
1448603643	GT	Patients with the GT genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.
1448603644	TT	Patients with the TT genotype and kidney or lung transplantation may experience increased metabolism of tacrolimus resulting in decreased exposure as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence metabolism of tacrolimus.
1448640309	CC	Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased response to treatment as compared to those with the CT genotype (DPYD *1/*2A). However, a number of studies find no association with response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448640310	CT	Patients with the CT genotype (DPYD *1/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased response to treatment as compared to those with the CC genotype (DPYD *1/*1). However, a number of studies find no association with response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448640311	TT	No patients with the TT (DPYD *2A/*2A) have been studied, but patients with the CT genotype (DPYD *1/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased response to treatment as compared to those with the CC genotype (DPYD *1/*1). However, a number of studies find no association with response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1448522762	AA	Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522763	AG	Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522764	GG	Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1449271030	CG	Patients with breast cancer and the CG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271031	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271035	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271036	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271037	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449269476	CT	Patients with the CT genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.
1449269477	TT	Patients with the TT genotype may have a decreased response to oxycodone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to oxycodone.
1449271059	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271060	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271061	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271065	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271066	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271067	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271071	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271072	GT	Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271073	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271077	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271078	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449140231	AA	Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.
1449140232	AG	Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.
1449140233	GG	Patients with the GG genotype and bladder cancer may have decreased exposure to sirolimus and temsirolimus as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.
1449140252	G/G	Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1449140253	G/del	Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1449140254	del/del	Patients with the del/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1449270927	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270928	GT	Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270921	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270922	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270923	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270917	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270918	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449269562	CC	Patients with the CC genotype may need increased dose of warfarin as compared to patients with the GG or CG genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.
1449269563	CG	Patients with the CG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.
1449564923	CC	Patients with the CC genotype may require a decreased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or TT genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.
1449270919	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449564908	AA	Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
1449564909	AC	Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
1449564910	CC	Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
1449188721	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188722	GT	Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449564050	*1/*1 + *1/*2 + *1/*5 + *1/*6 + *2/*5 + *2/*6 + *5/*6 + *6/*6	Patients with the *1/*1, *1/*2, *1/*5, *1/*6, *2/*5, *2/*6, *5/*6 or *6/*6 genotype (analyzed as a group) may have decreased clearance of bupropion, resulting in decreased concentrations of hydroxybupropion (a metabolite of bupropion), as compared to patients with the *1/*4, *2/*4, *4/*5 or *4/*6 genotype (analyzed as a group). Additionally, those with the *1/*1 genotype may have decreased clearance as compared to those with the *1/*22 genotype. Other genetic and clinical factors may also influence a patient's exposure to bupropion or hydroxybupropion.
1449564051	*1/*1 + *1/*5 + *1/*22 + *22/*22	Patients with the *1/*1, *1/*5, *1/*22 or *22/*22 genotype (analyzed as a group) may have increased concentrations of hydroxybupropion (a metabolite of bupropion), as compared to patients with the *1/*6, *1/*18, *6/*6, or *6/*18 genotype (analyzed as a group). However, one study finds that those with the *1/*1 genotype have decreased clearance as compared to those with the *1/*22 genotype. Other genetic and clinical factors may also influence a patient's exposure to hydroxybupropion.
1449564052	*1/*4 + *2/*4 + *4/*5 + *4/*6	Patients with the *1/*4, *2/*4, *4/*5 or *4/*6 genotype (analyzed as a group) may have increased clearance of bupropion, resulting in increased concentrations of hydroxybupropion (a metabolite of bupropion), as compared to patients with the *1/*1, *1/*2, *1/*5, *1/*6, *1/*18, *2/*5, *2/*6, *5/*6, *6/*6 or *6/*18 genotype (analyzed as a group). Additionally, those with the *1/*1 genotype may have decreased clearance as compared to those with the *1/*22 genotype. Other genetic and clinical factors may also influence a patient's exposure to bupropion or hydroxybupropion.
1449564053	*1/*6 + *1/*18 + *6/*6 + *6/*18	Patients with the *1/*6, *6/*6, *1/*18 or *6/*18 genotype (analyzed as a group) may have decreased concentrations of hydroxybupropion (a metabolite of bupropion), as compared to patients with the *1/*1, *1/*4, *1/*5, *1/*22, *2/*4, *4/*5, *4/*6, or *22/*22 genotype (analyzed as a group). However, one study finds that those with the *1/*1 genotype have decreased clearance as compared to those with the *1/*22 genotype. Other genetic and clinical factors may also influence a patient's exposure to hydroxybupropion.
1449565238	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 (UGT1A1 *1/*28) genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.
1449565239	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 (UGT1A1 *28/*28) genotype and HIV may be at increased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.
1449565246	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 (UGT1A1*1/*1) genotype may have lower glucuronidation of carvedilol as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.
1449565247	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 (UGT1A1*1/*28) genotype may have higher glucuronidation of carvedilol as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype, or lower glucuronidation as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.
1449751924	*3	Patients with CYP2C19*3 (rs4986893) allele in combination with another loss-of-function (*2, *3, *4, *5, *6, *8) or one functional allele (*1) may have 1) poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449751925	*4	Patients with CYP2C19*4 (rs28399504) allele in combination with another loss-of-function (*2, *3, *4, *5, *6, *8) or one functional allele (*1) may have 1) poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449183233	AA	Transplant recipients with the AA (CYP3A5 *7/*7) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the A/del or del/del (*1/*7 or *1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.
1449188717	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1448616982	CC	Patients with cancer and the CC genotype who are treated with capecitabine may have decreased (but not absent) risk of hyperbilirubinemia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616983	CT	Patients with cancer and the CT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616984	TT	Patients with cancer and the TT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448602510	CC	Patients with the CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.
1448602511	CT	Patients with the CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.
1448602512	TT	Patients with the TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.
1448615592	AG	Patients with the AG genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the GG genotypes, and a decreased likelihood as compared to patients with the AA genotype. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.
1448615593	GG	Patients with the GG genotype who are treated with phenytoin may have an decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and AA genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.
1448636700	AG	Patients with the AG genotype and metastatic breast cancer who are treated with everolimus may have Increased concentrations of everolimus as compared to patients with the GG genotype. Other clinical and genetic factors may also influence everolimus concentrations in patients with metastatic breast cancer who are treated with everolimus.
1448636701	GG	Patients with the GG genotype and metastatic breast cancer who are treated with everolimus may have decreased concentrations of everolimus as compared to patients with the AG genotype. Other clinical and genetic factors may also influence concentrations of everolimus in patients with metastatic breast cancer who are treated with everolimus.
1448616989	AA	Patients with cancer and the AA genotype may have a decreased risk of hyperbilirubinemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616990	AG	Patients with cancer and the AG genotype may have an increased risk of hyperbilirubinemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616992	CC	Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.
1448616993	CT	Patients with cancer and the CT genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.
1448616994	TT	Patients with cancer and the TT genotype who are treated with capecitabine may have an increased risk of nausea and vomiting as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.
1449564210	CC	Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564211	CT	Patients with the CT genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564212	TT	Patients with the TT genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449271079	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449751992	AA	Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine.
1449751993	AG	Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.
1449751994	GG	Patients with the GG genotype may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.
1449271290	HTTLPR long form (L allele)/HTTLPR long form (L allele)	Patients with the L/L genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be less likely to drop out of treatment than patients with the S/S genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.
1449271291	HTTLPR long form (L allele)/HTTLPR short form (S allele)	Patients with the L/S genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be less likely to drop out of treatment than patients with the S/S genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.
1449271292	HTTLPR short form (S allele)/HTTLPR short form (S allele)	Patients with the S/S genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be more likely to drop out of treatment than patients with the L/L genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.
1449271362	CC	Patients with the CC genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.
1449271363	CT	Patients with the CT genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.
1449271364	TT	Patients with the TT genotype and sickle-cell anemia may have increased levels of glucuronidation of morphine as compared to patients with the CC or CT genotypes and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.
1449275240	AA	Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1449275241	AG	Patients with the AG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1449275242	GG	Patients with the GG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1449752240	AA	Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449752241	AG	Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.
1449752242	GG	Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449752252	AA	Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AA genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449270929	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270933	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270934	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270935	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270939	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270940	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270909	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270910	GT	Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270911	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449155697	*1/*1	Patients with the CYP3A4 *1/*1 diplotype may have decreased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1/*22 or *22/*22 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.
1449155698	*1/*22	Patients with the CYP3A4 *1/*22 diplotype may have increased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1/*1 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.
1449155699	*22/*22	Patients with the CYP3A4 *22/*22 diplotype may have increased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1/*1 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.
1449155705	AA	Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.
1449155706	AG	Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.
1449155707	GG	Patients with the GG genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.
1449270913	AA	Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270914	AG	Patients with breast cancer and the AG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but an increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270915	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270941	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449188733	AA	Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188734	AG	Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188735	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188745	AA	Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188746	AG	Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188747	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188751	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188752	CT	Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188723	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188727	AA	Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188728	AG	Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188729	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188753	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188757	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188758	CG	Patients with the CG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188759	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1448602936	AA	Patients with the AA genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.
1448602937	AG	Patients with the AG genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.
1448602938	GG	Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.
1449190106	AA	Patients with the AA genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.
1449190107	AG	Patients with the AG genotype and receiving chemotherapy treatment may have increased severity of nausea as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.
1449190108	GG	Patients with the GG genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.
1448605579	*35:05:01	Patients with one or two copies of the HLA-B*35:05 allele have an increased risk of drug-induced liver injury (DILI) when taking minocycline as compared to patients with no HLA-B*35:05 alleles or negative for the HLA-B*35:05 test. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury when taking minocycline.
1449310416	*2xN	Patients who carry multiple *2 alleles in addition to a *1 allele, and therefore have a CYP2D6 ultrarapid metabolizer phenotype, may be at an increased risk of experiencing drug toxicity as a result of taking hydrocodone as compared to patients who do not have a CYP2D6 ultrarapid metabolizer phenotype. CYP2D6 ultrarapid metabolizers may also have increased metabolism of hydrocodone as compared to CYP2D6 poor metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism in a patient as well as their risk of experiencing drug toxicity as a result of taking hydrocodone.
1449566336	*24:02:01:01	Patients with one or two copies of the HLA-A*24:02:01:01 allele may have an increased risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS/TEN), when treated with phenytoin as compared to patients with no HLA-A*24:02:01:01 alleles or negative for the HLA-A*24:02:01:01 test. However, this allele was seen in linkage with HLA-A*02:01. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced SJS/TEN.
1449566381	AA	Patients with the AA genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.
1449566382	AG	Patients with the AG genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.
1449566383	GG	Patients with the GG genotype and hypertension may have a decreased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.
1449566331	*15:02:01	Patients with one or two copies of the HLA-B*15:02:01 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with phenytoin as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced adverse reactions.
1449564247	*1/*1	Patients with CYP2C9*1/*1 may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients with CYP2C9*2, *3, *5, *6 or *11. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449564248	*11	Patients with CYP2C9*11 may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449564249	*2	Patients with CYP2C9*2 may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449564250	*3	Patients with CYP2C9*3 may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449564251	*5	Patients with CYP2C9*5 may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449564252	*6	Patients with CYP2C9*6 may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449564261	CC	Patients with the CC genotype (*3/*3) and who are recipients of transplants may have decreased metabolism of sirolimus and require a lower dose as compared to patients with the CT and TT genotype (*1/*3 and *3*/3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.
1448423070	TTAAAG/TTAAAG	Patients with the TTAAAG/TTAAAG genotype and Colorectal Cancer who are treated with fluorouracil-based adjuvant therapy may have a better response as compared to patients with the TTAAAG/del or del/del genotype who also have rs45445694 genotype 2R/2R. Other genetic and clinical factors may also influence a patient's response to treatment.
1448423071	TTAAAG/del	Patients with the TTAAAG/del genotype who also have rs45445694 genotype 2R/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1448423072	del/del	Patients with the del/del genotype who also have rs45445694 genotype 2R/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1449296316	AA	Patients with the AA genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients.
1449296317	AG	Patients with the AG genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients.
1449296292	AA	Patients with the AA genotype may be more likely to experience insomnia as a result of consuming caffeine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.
1449296293	AC	Patients with the AC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.
1449296294	CC	Patients with the CC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.
1449296318	GG	Patients with the GG genotype may have increased metabolism of folic acid as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect folic acid metabolism in patients.
1449296324	CC	Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to metformin.
1449296323	CT	Patients with the CT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.
1449296322	TT	Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.
1449296330	CC	Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1449296329	CT	Patients with the CT genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1449296328	TT	Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.
1449296336	CC	Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.
1449296335	CG	Patients with the CG genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.
1449296334	GG	Patients with the GG genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to metformin.
1449310802	*1/*1	Patients with the SLC22A1*1/*1 genotype may have decreased exposure to fenoterol and also decreased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1 *3, *4, *5 or *6 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449310808	*1/*2	Patients with the SLC22A1*1/*2 genotype may have decreased exposure to fenoterol and also decreased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1 *3, *4, *5 or *6 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449310803	*2/*2	Patients with the SLC22A1*2/*2 genotype may have decreased exposure to fenoterol and also decreased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1 *3, *4, *5 or *6 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449310804	*3	Patients with the SLC22A1*3 allele may have increased exposure to fenoterol and also increased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1*1 or *2 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449168060	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168061	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449270945	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270951	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449155715	CC	Patients with nasopharyngeal cancer and the CC genotype may have an increased risk of anemia as compared to the CT and TT genotypes. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449155716	CT	Patients with nasopharyngeal cancer and the CT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449155717	TT	Patients with nasopharyngeal cancer and the TT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.
1449270952	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270953	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270957	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270946	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270947	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270958	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270959	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270981	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449155734	AA	Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis.  Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.
1449168323	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168324	AT	Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168325	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449154545	AA	Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.
1449154546	AG	Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased hdl cholsterol as compared to women with GG genotypes and increased levels of triglycerides and decreased levels of hdl cholsterol as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.
1449154547	GG	Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol concentrations as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.
1449191954	CTT/CTT	Patients with the CTT/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis have an unknown likelihood of experiencing adverse events while being treated with ivacaftor and lumacaftor, as the frequency of adverse events may be influenced by the presence of other CFTR variants. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor and lumacaftor.
1449191955	CTT/del	Patients with the CTT/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis have an unknown likelihood of experiencing adverse events while being treated with ivacaftor and lumacaftor, as the frequency of adverse events may be influenced by the presence of other CFTR variants. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor and lumacaftor.
1449191956	del/del	Patients with the del/del genotype (two copies of the CFTR F508del variant) and cystic fibrosis may experience a high frequency of adverse events when being treated with ivacaftor and lumacaftor. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor and lumacaftor.
1449565251	(TA)6/(TA)6	Liver microsomes with the (TA)6/(TA)6 genotype may have increased glucuronidation activity for belinostat as compared to those with the (TA)7/(TA)7 genotype. No association with pharmacokinetic parameters in human subjects has been seen. Other genetic and clinical factors may also influence glucuronidation of belinostat.
1449565248	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 (UGT1A1*28/*28) genotype may have higher glucuronidation of carvedilol as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.
1449565252	(TA)6/(TA)7	Liver microsomes with the (TA)6/(TA)7 genotype may have increased glucuronidation activity for belinostat as compared to those with the (TA)7/(TA)7 genotype, or decreased glucuronidation activity as compared to those with the (TA)6/(TA)6 genotype. No association with pharmacokinetic parameters in human subjects has been seen. Other genetic and clinical factors may also influence glucuronidation of belinostat.
1449565253	(TA)7/(TA)7	Liver microsomes with the (TA)7/(TA)7 genotype may have decreased glucuronidation activity for belinostat as compared to those with the (TA)6/(TA)6 genotype. No association with pharmacokinetic parameters in human subjects has been seen. Other genetic and clinical factors may also influence glucuronidation of belinostat.
1449565256	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 (UGT1A1*1/*1) genotype and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence risk for hyperbilirubinemia.
1449565257	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 (UGT1A1*1/*28) genotype and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence risk for hyperbilirubinemia.
1449565258	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 (UGT1A1*28/*28) genotype and ischemic heart disease may have an increased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the (TA)6/(TA)7 (*1/*28) or (TA)6/(TA)6 (*1/*1) genotype. Other genetic and clinical factors may also influence risk for hyperbilirubinemia.
1449565271	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) with Neoplasms who are treated with irinotecan-based regimens may require an increased dose of irinotecan, as compared to patients with the (TA)6/(TA)7 (*1/*28) or (TA)7/(TA)7 (*28/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's irinotecan dose requirement.
1449565272	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) with Neoplasms who are treated with irinotecan-based regimens may require a decreased dose of irinotecan as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's irinotecan dose requirement.
1449565273	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) with Neoplasms who are treated with irinotecan-based regimens may require a decreased dose of irinotecan, as compared to patients with the (TA)6/(TA)6 (*28/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's irinotecan dose requirement.
1450375754	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375755	CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375756	TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1449564279	*1/*1	Patients with the CYP2C9*1/*1 genotype may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying either CYP2C9*2 or *3, however this is contradicted in several studies. Other genetic and clinical factors may also influence the risk of bleeding in patients administered warfarin.
1449564262	CT	Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.
1449564263	TT	Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.
1449564280	*1/*2	Patients with the CYP2C9*1/*2 genotype may have increased risk of bleeding when treated with warfarin as compared to patients with CYP2C9*1/*1 genotype, however this is contradicted in several studies. Other genetic and clinical factors may also influence the risk of bleeding in patients administered warfarin.
1449717851	*3	Patients with the CYP2C19*3 allele (rs4986893) who are treated with citalopram or escitalopram may have a decreased drug clearance/metabolism and decreased tolerance, especially in combination with another loss-of-function allele (*2, *3, *4, *6, *8) (poor metabolizer phenotype) as compared to patients with the CYP2C19*1/*1 genotype. Contradictory findings reported no association of CYP2C19 genotype with tolerance, also no association with response or remission are reported. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1448617233	AA	Patients with the AA genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.
1448617234	AG	Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.
1448617235	GG	Patients with the GG genotype may have decreased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to aspirin.
1450375742	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375743	CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1449717226	CC	Patients with the CC genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.
1449717227	CT	Patients with the CT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.
1449717228	TT	Patients with the TT genotype and pulmonary fibrosis may have increased response to N-acetylcysteine compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect response to N-acetylcysteine.
1449717850	*2	Patients with the CYP2C19*2 allele (rs4244285) who are treated with citalopram or escitalopram may have a decreased drug clearance/metabolism and decreased tolerance, especially in combination with another no function allele (*2, *3, *4, *6, *8) (poor metabolizer phenotype) as compared to patients with the CYP2C19*1/*1 genotype. Contradictory findings reported no association of CYP2C19 genotype with tolerance, also no association with response or remission are reported. One study reported an association of poor metabolizers with increased remission if tolerant to citaolpram. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1450375744	TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375760	AA	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375761	AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375762	GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1448573629	AA	Patients with AA genotype may have higher success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with AC or CC genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.
1448573630	AC	Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.
1448573631	CC	Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.
1449310805	*4	Patients with the SLC22A1*4 allele may have increased exposure to fenoterol and also increased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1*1 or *2 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449310806	*5	Patients with the SLC22A1*5 allele may have increased exposure to fenoterol and also increased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1*1 or *2 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449310807	*6	Patients with the SLC22A1*6 allele may have increased exposure to fenoterol and also increased cardiovascular and metabolic adverse reactions to fenoterol as compared to patients with SLC22A1*1 or *2 allele. Other genetic and clinical factors may also influence the response to fenoterol.
1449564338	AG	Patients with the AG genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype and a worse outcome as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome.
1449564339	GG	Patients with the GG genotype and Breast Neoplasms and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome.
1449564344	TT	Patients with the TT genotype who are treated with warfarin may have a decreased risk of over-coagulation as compared to patients with the CT or CC genotype, although this is contradicted in one study which found that it had a decreased risk of over-coagulation as compared only to patients with the CC genotype. Other clinical and genetic factors may also influence risk of over-coagulation in patients administered warfarin.
1449564347	*1/*1	The *1/*1 diplotype may be associated with increased clearance of atazanavir when taken alone, or when taken with ritonavir, as well as increased clearance of ritonavir as compared to the *1/*2 and *2/*2 diplotypes. It may also be associated with decreased likelihood of hyperbilirubinemia when atazanavir is administered without ritonavir, as compared to the *1/*2 or *2 /*2 diplotypes. Other clinical and genetic factors may also influence clearance of atazanavir and ritonavir, as well as likelihood of hyperbilirubinemia in subjects administered atazanavir without ritonavir.
1449564348	*1/*2 (PMID: 11503014)	The *1/*2 diplotype may be associated with decreased clearance of atazanavir when taken alone, or when taken with ritonavir, as well as decreased clearance of ritonavir as compared to the *1/*1 diplotype. The *1/*2 diplotype may also be associated with increased clearance of atazanavir  when taken alone, or when taken with ritonavir, as well as increased clearance of ritonavir as compared to the *2 /*2 diplotype. The *1/ *2 diplotype may also be associated with increased likelihood of hyperbilirubinemia when atazanavir is administered without ritonavir as compared to the *1 /*1 diplotype and decreased likelihood of hyperbilirubinemia as compared to the *2 /*2 diplotype. Other clinical and genetic factors may also influence clearance of atazanavir and ritonavir, as well as likelihood of hyperbilirubinemia in subjects administered atazanavir without ritonavir.
1449564349	*2 (PMID: 11503014)/*2 (PMID: 11503014)	The *2 /*2 diplotype may be associated with decreased clearance of atazanavir when taken alone, or with ritonavir, as well as decreased clearance of ritonavir as compared to the *1/*1 or *1 / *2 diplotypes. It may also be associated with an increased likelihood of hyperbilirubinemia when atazanavir is administered without ritonavir as compared to the *1/*1 or *1/*2 diplotypes. Other clinical and genetic factors may also influence clearance of atazanavir, as well as likelihood of hyperbilirubinemia in subjects administered atazanavir without ritonavir.
1449564375	*3/*3	Patients with the CYP2C19 *3/*3 genotype who are infected with Helicobacter pylori (H. pylori) may have a higher eradication rate when treated with omeprazole as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. Patients also received amoxicillin and clarithromycin. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3  (*2 = rs4244285; *3 = rs4986893). Other genetic and clinical factors may also influence eradication rate of H. pylori.
1449004550	CC	Patients with epilepsy and the CC genotype may have a worse response to oxcarbazepine as compared to patients with the CT or TT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.
1449004551	CT	Patients with epilepsy and the CT genotype may have a worse response to oxcarbazepine as compared to patients with the TT genotype and an improved response as compared to patients with the CC genotype. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.
1449004552	TT	Patients with epilepsy and the TT genotype may have improved response to oxcarbazepine as compared to patients with the CC and CT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.
1449155735	AG	Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis.  Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.
1449155736	GG	Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis.  Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.
1449168062	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168067	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168630	AA	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449156220	*01:01:01	Patients with one or two copies of the HLA-DRB1*01:01:01 allele have an increased risk of nevirapine-induced adverse reactions, such as fever, rash or hepatotoxicity, as compared to patients with no HLA-DRB1*01:01:01 alleles or negative for the HLA-DRB1*01:01:01 test. Please note that some studies only examined whether patients had the HLA-DRB1*01 type. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.
1449168068	AT	Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168069	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168631	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168632	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168637	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168638	AC	Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168639	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168644	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168645	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168646	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449169492	GG	Patients with the GG genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.
1449169493	GT	Patients with the GT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.
1449565284	(TA)6/(TA)6	Women with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, an in vitro study found an increased clearance of raloxifene as compared to the *1/*28 and *28/*28 gentoype. Other genetic and clinical factors may also influence metabolism of raloxifene.
1449565285	(TA)6/(TA)7	Women with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, an in vitro study found a decreased clearance as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of raloxifene.
1449565286	(TA)7/(TA)7	Women with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) genotype and osteoporosis may have increased metabolism of raloxifene as compared to patients with the (TA)6/(TA)7 (*1/*28) or (TA)6/(TA)6 (*1/*1) genotype. However, an in vitro study found a decreased clearance of raloxifene as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence metabolism of raloxifene.
1449565278	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia and diarrhea at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, overall gastrointestinal toxicities (diarrhea, nausea, vomiting, and mucositis combined), or tumor response. One study found a decreased overall survival time for carriers of the (TA)7 allele. One study found an increased risk of vomiting for this genotype, and another found an increased risk of treatment-related death, both compared to the (TA)6/(TA)6 genotype. Other genetic and clinical factors may also influence a patient's survival time and risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death.
1449565280	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that patients with the (TA)6/(TA)6 genotype had increased UGT1A1 enzyme activity compared to those with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38.
1449565281	(TA)6/(TA)7	Patients with the (TA)6/(TA)7 genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)6 genotype, or increased metabolism compared to patients with the (TA)7/(TA)7 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that livers with the (TA)6/(TA)7 genotype had decreased UGT1A1 enzyme activity compared to livers with the (TA)6/(TA)6 genotype, and increased activity compared to livers with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38.
1449565282	(TA)7/(TA)7	Patients with the (TA)7/(TA)7 genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)7 or (TA)6/(TA)6 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that patients with the (TA)7/(TA)7 genotype had decreased UGT1A1 enzyme activity compared to those with the (TA)6/(TA)6 or (TA)6/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38.
1449565291	(TA)6/(TA)6	Patients with transfusion-dependent anemias (such as thalassemia) and the (TA)6/(TA)6 genotype may have increased concentrations of deferasirox as compared to patients with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. Other clinical and genetic factors may also influence concentrations of deferasirox.
1449565292	(TA)6/(TA)7	Patients with transfusion-dependent anemias (such as thalassemia) and the (TA)6/(TA)7 genotype may have decreased concentrations of deferasirox as compared to patients with the (TA)6/(TA)6 genotype and increased concentrations as compared to patients with the (TA)7/(TA)7 genotype. Additionally, a 3 year old female patient with major thalassemia and this genotype developed a series of adverse reactions when receiving deferasirox. Other clinical and genetic factors may also influence concentrations of deferasirox.
1449565293	(TA)7/(TA)7	Patients with transfusion-dependent anemias (such as thalassemia) and the (TA)7/(TA)7 genotype may have decreased concentrations of deferasirox as compared to patients with the (TA)6/(TA)6 and (TA)6/(TA)7 genotype. Other clinical and genetic factors may also influence concentrations of deferasirox.
1449565789	*41	Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565790	*42	Patients carrying the CYP2C9*42 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565791	*43	Patients carrying the CYP2C9*43 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565792	*45	Patients carrying the CYP2C9*45 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565788	*40	Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565793	*47	Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449171164	CC	Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449171165	CT	It is currently unclear how the CT genotype affects a patient's risk of developing heroin dependence.
1449171166	TT	Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449564281	*1/*3	Patients with CYP2C9*1/*3 genotype may have increased risk of bleeding when treated with warfarin as compared to patients with CYP2C9*1/*1, however this is contradicted in several studies. Other genetic and clinical factors may also influence the risk of bleeding in patients administered warfarin.
1449564282	*2/*2	Patients with the CYP2C9 *2/*2  genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CYP2C9*2/*2 genotype, however this is contradicted in several studies. Other genetic and clinical factors may also influence the risk of bleeding in patients administered warfarin.
1449564283	*2/*3	Patients with the CYP2C9 *2/*3  genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CYP2C9*2/*2 genotype, however this is contradicted in several studies. Other genetic and clinical factors may also influence the risk of bleeding in patients administered warfarin.
1449171170	AA	Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449564284	*3/*3	Patients with the CYP2C9 *3/*3  genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CYP2C9*2/*2 genotype, however this is contradicted in several studies. Other genetic and clinical factors may also influence the risk of bleeding in patients administered warfarin.
1449190491	AA	Patients with the AA genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
1449190492	AC	Patients with the AC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
1449190493	CC	Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
1449190496	*1/ *1xN	Patients with more than two copies of CYP2D6 fully functional alleles who are CYP2D6 ultrarapid metabolizers (i.e., a CYP2D6 activity score of >2.0) may have higher risk of toxicity/side effects (respiratory depression, cardiotoxicity or nausea) as compared to patients with *1/*1 genotype who are CYP2D6 normal metabolizers. Patients who are CYP2D6 ultrarapid metabolizers should reduce tramadol dose or choose another drug (e.g., acetaminophen, NSAID, morphine-not oxycodone or codeine) due to potential for toxicity  and should be alert to adverse drug events. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190497	*1/*1	Patients with the *1/*1 genotype who are treated with tramadol may have 1) increased metabolism of tramadol, 2) increased likelihood of response to tramadol and 3) decreased, but not absent risk for side effects as compared to patients with non-functional or reduced function alleles. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190498	*10	Patients with the *10 reduced function allele in combination with a non-functional or another reduced function allele may have decreased metabolism of tramadol as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid tramadol use due to lack of efficacy and should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190499	*2	Patients with the *2 allele and another fully functional allele who are treated with tramadol may have 1) increased metabolism of tramadol, 2) increased likelihood of response to tramadol and 3) decreased, but not absent risk for side effects as compared to patients with non-functional or reduced function alleles. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190500	*2/ *2xN	Patients with more than two copies of CYP2D6 fully functional alleles who are CYP2D6 ultrarapid metabolizers (i.e., a CYP2D6 activity score of >2.0) may have higher risk of toxicity/side effects (respiratory depression, cardiotoxicity or nausea) as compared to patients with *1/*1 genotype who are CYP2D6 normal metabolizers. Patients who are CYP2D6 ultrarapid metabolizers should reduce tramadol dose or choose another drug (e.g., acetaminophen, NSAID, morphine-not oxycodone or codeine) due to potential for toxicity  and should be alert to adverse drug events. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190501	*3	Patients with the *3 non-functional allele in combination with another non-functional or reduced function allele may have 1) decreased metabolism of tramadol, 2) decreased likelihood of response to tramadol as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid tramadol use due to lack of efficacy and should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449171171	AC	Patients with the AC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449171172	CC	Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449170827	CC	Patients with the CC genotype may spent more time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype TT or CT. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the response to warfarin.
1449170828	CT	Patients with the CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the response to warfarin.
1449170829	TT	Patients with the TT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. Contradictory findings have also been reported. Other genetic and clinical factors may also influence the response to warfarin.
1449170954	*1/*1	Patients with Breast Cancer and the *1/*1 genotype who are CYP2D6 normal metabolizers may have 1) an increased metabolism of tamoxifen resulting in increased endoxifen concentrations, 2) decreased likelihood of recurrence, 3) increased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with two no function alleles (such as CYP2D6*3, *4, *5, *6) or a *10 or *41 allele in combination with a no function allele or another *10 or *41 allele. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449170955	*10	Patients with Breast Cancer and the *10 allele in combination with a no function allele (such as CYP2D6*3, *4, *5, *6) or another *10 or *41 allele may have 1) an decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations, 2) increased likelihood of recurrence, 3) decreased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with the *1/*1 genotype or CYP2D6 normal metabolizers. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449170956	*3	Patients with Breast Cancer and the *3 allele in combination with another no function allele (such as CYP2D6*3, *4, *5, *6) or a*10 or *41 allele may have 1) an decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations, 2) increased likelihood of recurrence, 3) decreased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with the *1/*1 genotype or CYP2D6 normal metabolizers. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449170957	*4	Patients with Breast Cancer and the *4 allele in combination with another no function allele (such as CYP2D6*3, *4, *5, *6) or a *10 or *41 allele may have 1) an decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations, 2) increased likelihood of recurrence, 3) decreased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with the *1/*1 genotype or CYP2D6 normal metabolizers. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449170958	*41	Patients with Breast Cancer and the *41 allele in combination with a no function allele (such as CYP2D6*3, *4, *5, *6) or another *10 or *41 allele may have 1) an decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations, 2) increased likelihood of recurrence, 3) decreased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with the *1/*1 genotype or CYP2D6 normal metabolizers. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449170959	*5	Patients with Breast Cancer and the *5 allele in combination with another no function allele (such as CYP2D6*3, *4, *5, *6) or a *10 or *41 allele may have 1) an decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations, 2) increased likelihood of recurrence, 3) decreased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with the *1/*1 genotype or CYP2D6 normal metabolizers. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449170960	*6	Patients with Breast Cancer and the *6 allele in combination with another no function allele (such as CYP2D6*3, *4, *5, *6) or a *10 or *41 allele may have 1) an decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations, 2) increased likelihood of recurrence, 3) decreased event-free and recurrence-free survival, when treated with tamoxifen in an adjuvant setting, as compared to patients with the *1/*1 genotype or CYP2D6 normal metabolizers. For the outcome measures (point 2 and 3) studies supporting the association and studies showing contradictory findings not supporting the association exist. Other genetic and clinical factors may also influence a patient's response to tamoxifen treatment.
1449188691	AA	Patients with the AA genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188692	AG	Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449169494	TT	Patients with the TT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.
1449564664	AG	Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have a decreased risk of experiencing leukopenia, and possibly thrombocytopenia and neutropenia, as compared to patients with the AA genotypes, however, this is contradicted in one study. Other clinical and genetic factors may also influence risk of leukopenia in patients with renal cell carcinoma who are administered sunitinib.
1449564665	GG	Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have a decreased risk of experiencing leukopenia, and possibly thrombocytopenia and neutropenia, as compared to patients with the AA genotypes, however, this is contradicted in one study. Other clinical and genetic factors may also influence risk of leukopenia in patients with renal cell carcinoma who are administered sunitinib.
1449188739	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188740	CT	Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188741	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449270993	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449564503	*6	Individuals with the *6 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*9, *10, *17, *29, *31, *41, *45, *46) may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also metabolism of and response to metoprolol.
1449564504	*9	Individuals with the *9 reduced functional allele in combination with a reduced function (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449190675	GG	Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients.
1449190676	GT	Patients with the  GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients.
1449190677	TT	Patients with the  TT genotype may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients.
1449270982	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270983	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270987	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270988	AC	Patients with breast cancer and the AC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270989	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449189238	GG	Patients with the GG genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189239	GT	Patients with the GT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189240	TT	Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the GG or GT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449645453	CT	Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645454	TT	Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645452	CC	Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645458	AA	Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645459	AG	Patients with the AG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645460	GG	Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1450342737	AA	Patients with AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency.
1450342738	AG	Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency.
1449565424	AA	Patients with the AA genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565425	AG	Patients with the AG genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565794	*49	Patients carrying the CYP2C9*49 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565795	*50	Patients carrying the CYP2C9*50 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565418	GG	Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565419	GT	Patients with the GT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565420	TT	Patients with the TT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565426	GG	Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the AA or AG genotypes. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565796	*51	Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1450342739	GG	Patients with GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG and AA genotype. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency.
1448124592	AC	Patients with the AC genotype and kidney transplant may have increased risk of neutropenia when treated with valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.
1448124593	CC	Patients with the CC genotype and kidney transplant may have decreased risk of neutropenia when treated with valganciclovir compared to patients with the AC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.
1448124606	CC	Patients with the CC genotype and kidney transplantation may have reduced risk of neutropenia when taking valganciclovir compared to patients with the CT genotype. Other genetic and clinical factors may affect response to valganciclovir.
1448124607	CT	Patients with the CT genotype and kidney transplantation may have increased risk of neutropenia when taking valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect response to valganciclovir.
1448265176	AA	Patients with the AA genotype may have a decreased, but not absent, risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.
1448265177	AT	Patients with the AT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.
1448265178	TT	Patients with the TT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.
1448573562	CC	Patients with the CC genotype and Attention Deficit Disorder may require an increased dose of methylphenidate as compared to patients with the CT genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.
1448573563	CT	Patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.
1448573564	TT	Patients with the TT genotype were not studied, however patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.
1449190502	*4	Patients with the *4 non-functional allele in combination with another non-functional or reduced function allele may have 1) decreased metabolism of tramadol, 2) decreased likelihood of response to tramadol as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid tramadol use due to lack of efficacy and should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190503	*5	Patients with the *5 non-functional allele in combination with another non-functional or reduced function allele may have 1) decreased metabolism of tramadol, 2) decreased likelihood of response to tramadol as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid tramadol use due to lack of efficacy and should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449190504	*6	Patients with the *6 non-functional allele in combination with another non-functional or reduced function allele may have 1) decreased metabolism of tramadol, 2) decreased likelihood of response to tramadol as compared to patients with *1/*1 genotype, who carry two functional alleles. Patients who are CYP2D6 poor metabolizers should avoid tramadol use due to lack of efficacy and should be alert to symptoms of insufficient pain relief. Other genetic and clinical factors may also influence a patient's response to tramadol.
1449271029	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449191748	AA	Patients with the AA genotype (two copies of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191749	AG	Patients with the AG genotype (one copy of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449004854	CC	Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2)  may have a decreased, but not absent, risk for GI toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity when treated with methotrexate.
1449191750	GG	Patients with the GG genotype (do not have a copy of the CFTR R1070Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192416	CC	Patients with the CC genotype (two copies of the CFTR R347P variant) and cystic fibrosis may not respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192417	CG	Patients with the CG genotype (one copy of the CFTR R347P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192413	AA	Patients with the AA genotype (two copies of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H.  Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449188697	CC	Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188698	CT	Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188699	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1448531612	AA	The AA genotype may be associated with a greater risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AG and GG genotypes.
1448531613	AG	The AG genotype may be associated with a reduced risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AA genotype.
1448531614	GG	The GG genotype may be associated with a reduced risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AA genotype.
1448531654	AA	Patients with the AA genotype and colorectal neoplasm may have decreased exposure to SN-38 compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.
1448531655	AT	Patients with the AT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448531656	TT	Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448531804	CC	Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia when taking irinotecan compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531805	CT	Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531806	TT	Patients with the TT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1449270880	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270881	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449192414	AC	Patients with the AC genotype (one copy of the CFTR R347H variant and one copy of the CFTR R347P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. R347P is not on this list of approved variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449188693	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449192418	GG	Patients with the GG genotype (do not have a copy of the CFTR R347H or R347P variants) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449270879	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449718244	CC	Patients with the CC genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718245	CG	Patients with the CG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718246	GG	Patients with the GG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449270994	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270995	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270999	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449169599	CC	Subjects with the CC genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449271000	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271001	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449162195	AA	Patients with the AA genotype and cancer may have a decreased risk of drug toxicities when treated with fluoropyrimidine-based chemotherapy as compared to patients with the AG and GG genotypes. Other studies have found no association with drug toxicity and fluoropyrimidine-based chemotherapy. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449162196	AG	Patients with the AG genotype and cancer may have an increased risk of drug toxicities when treated with fluoropyrimidine-based chemotherapy as compared to patients with the AA or GG genotypes. Other studies have found no association with drug toxicity and fluoropyrimidine-based chemotherapy. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449162197	GG	Patients with the GG genotype and cancer may have a decreased risk of drug toxicities when treated with fluoropyrimidine-based chemotherapy as compared to patients with the AA and AG genotypes. Other studies have found no association with drug toxicity and fluoropyrimidine-based chemotherapy. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449169597	AA	Subjects with the AA genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169598	AC	Subjects with the AC genotype may have an increased exposure to atorvastatin as compared to individuals with the AA or CC genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449271005	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271006	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271007	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449718250	GG	Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.
1449718251	GT	Patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.
1449271041	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271042	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271043	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271047	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271048	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271049	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449565797	*52	Patients carrying the CYP2C9*52 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565798	*53	Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565799	*54	Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565800	*55	Patients carrying the CYP2C9*55 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565801	*56	Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449565777	*8	Patients carrying the CYP2C9*8 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient.
1449566677	CC	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.
1449566687	AA	Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased likelihood of drug toxicity and increased likelihood of overall survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566688	AG	Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566689	GG	Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566699	AA	Patients with the AA genotype and non-small cell lung cancer may have decreased severity of thrombocytopenia and increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566700	AC	Patients with the AC genotype and non-small cell lung cancer may have increased severity of thrombocytopenia and decreased likelihood of overall survival in as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566701	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased severity of thrombocytopenia and increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449575641	CC	The CC genotype may be associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449147200	CC	Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.
1449147201	CT	Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.
1449147202	TT	Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.
1449004855	CT	Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype and decreased clearance as compared to the TT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC genotype and decreased risk as compared to the TT genotype.
1449004856	TT	Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC or CT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC or CT genotype.
1449156888	AC	Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1448256883	AA	Patients with the AA genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256884	AG	Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256885	GG	Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256892	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256893	CT	Patients with the CT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256894	TT	Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256900	CC	Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
1448256901	CG	Patients with the CG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
1448256902	GG	Patients with the GG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
1448258738	AA	Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.
1448258737	AG	Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
1449156889	CC	Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1449156887	AA	Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.
1449750845	CC	Patients with the CC genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750846	CT	Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750847	TT	Patients with the TT genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449187688	AC	Patients with the AC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype or may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.
1449187689	CC	Patients with the CC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.
1449192611	AA	Patients with the AA genotype (two copies of the CFTR R117H variant) and cystic fibrosis may have an improved response when treated with ivacaftor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor.
1449192612	AG	Patients with the AG genotype (one copy of the CFTR R117H variant) and cystic fibrosis may have an improved response when treated with ivacaftor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor.
1449192433	AA	Patients with the AA genotype (two copies of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192434	AG	Patients with the AG genotype (one copy of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192435	GG	Patients with the GG genotype (do not have a copy of the CFTR G1249R variant) and cystic fibrosis have an unknown response to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192613	GG	Patients with the GG genotype (do not carry a copy of the CFTR R117H variant) and cystic fibrosis may not respond when treated with ivacaftor as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor.
1449192770	CTT/CTT	The CTT/CTT genotype (no copies of the CFTR F508del variant) is not an indication for the combination drug of ivacaftor plus lumacaftor in patients with cystic fibrosis.
1449192572	AA	Patients with the AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, another study did not see an effect of ivacaftor on CFTR-A561E activity. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192573	AC	Patients with the AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, another study did not see an effect of ivacaftor on CFTR-A561E activity. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192574	CC	Patients with the CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449750841	GT	Patients with the GT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence duloxetine response.
1449751566	CC	Patients with the CC genotype (*1/*1) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.
1449751567	CT	Patients with the CT genotype (*1/*17) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.
1449192741	AA	Ivacaftor is indicated in cystic fibrosis patients with the AA genotype (two copies of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192742	AG	Ivacaftor is indicated in cystic fibrosis patients with the AG genotype (one copy of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192743	GG	Indication of ivacaftor in cystic fibrosis patients with the GG genotype (no copies of the CFTR G551D variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449751568	TT	Patients with the TT genotype (*17/*17) and alcoholism may have a decreased response to phenazepam as compared to patients with the CC (*1/*1) or CT (*1/*17) genotypes. Other genetic and clinical factors may also affect a patient's response to phenazepam.
1448266415	CC	Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448266416	CT	Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.
1448266417	TT	Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.
1449713669	CT	Patients with the CT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713670	TT	Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449713680	TT	Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1448123064	*1/*1	Patients with CYP2C9 *1/*1 genotype may have increased clearance and decreased exposure to zafirlukast as compared to CYP2C9 *1/*3 or CYP2C9 *1/*13. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.
1448123063	*1/*13	Patients with CYP2C9 *1/*13 genotype may have decreased clearance and increased exposure to zafirlukast as compared to CYP2C9 *1/*1. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.
1448123062	*1/*3	Patients with CYP2C9 *1/*3 genotype may have decreased clearance and increased exposure to zafirlukast as compared to CYP2C9 *1/*1. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.
1448266398	AA	This study did not contain individuals with the AA genotype, though individuals with the AA genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
1448266399	AG	Patients with the AG genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
1448266400	GG	Patients with the GG genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the AG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
1448266431	CC	Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448266432	CT	Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448266433	TT	Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448531663	AA	Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531664	AG	Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531665	GG	Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448567799	CC	Patients with the CC genotype who underwent kidney transplantation may have increased trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.
1448567800	CT	Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.
1448567801	TT	Patients with the TT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.
1448567805	*1/*1	In human liver microsomes, the *1/*1 genotype is associated with increased metabolism of sirolimus as compared to the *1/*22 or *22/*22 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.
1448567806	*1/*22	In human liver microsomes, the *1/*22 genotype is associated with decreased metabolism of sirolimus as compared to the *1/*1 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.
1448567807	*22/*22	In human liver microsomes, the *22/*22 genotype is associated with decreased metabolism of sirolimus as compared to the *1/*1 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.
1449713684	AA	Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.
1449575642	CT	The CT genotype may be associated with decreased catalytic activity of DPYD as compared to the TT genotypes and increased catalytic activity as compared to the CC genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575643	TT	The TT genotype may be associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575647	GG	The GG genotype is associated with increased catalytic activity of DPYD as compared to the GT and TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575648	GT	The GT genotype is associated with decreased catalytic activity of DPYD as compared to the GG genotype and increased catalytic activity as compared to the TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575649	TT	The TT genotype is associated with decreased catalytic activity of DPYD as compared to the GT and GG genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575686	AA	Patients with the AA genotype (DPYD *11/*11) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Additionally, those with the *11 allele may be at risk for drug toxicity when receiving fluorouracil. Other genetic and clinical factors may also affect DPYD activity and risk for fluorouracil-induced toxicity.
1449575687	AC	Patients with the AC genotype (DPYD *1/*11) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Additionally, those with the *11 allele may be at risk for drug toxicity when receiving fluorouracil. Other genetic and clinical factors may also affect DPYD activity and risk for fluorouracil-induced toxicity.
1449575688	CC	Patients with the CC genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AA or AC genotype (DPYD *11/*11 or *1/*11). Other genetic and clinical factors may also affect DPYD activity.
1449575741	CC	Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TT genotype. However, this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's required warfarin dose.
1449575742	CT	Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the TT genotype. However, this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's required warfarin dose.
1449575743	TT	Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC and CT genotypes. However, this is contradicted in some studies.  Other genetic and clinical factors may also influence a patient's required warfarin dose.
1449575766	AA	Patients with the AA genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.
1449575767	AG	Patients with the AG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.
1449575768	GG	Patients with the GG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the AA or AG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.
1449576311	TT	Patients with the TT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.
1449576555	CC	Patients with the CC genotype may have increased plasma concentrations of montelukast as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576554	CT	Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576309	CC	Patients with the CC genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.
1449576310	CT	Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.
1449576553	TT	Patients with the TT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576561	*1/*1	Patients with the *1/*1 genotype may have increased plasma concentrations of montelukast as compared to patients with the *2/*2 or *1/*2 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576560	*1/*2	Patients with the *1/*2 genotype may have decreased plasma concentrations of montelukast as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576559	*2/*2	Patients with the *2/*2 genotype may have decreased plasma concentrations of montelukast as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576570	CC	Patients with the CC genotype may have increased plasma concentrations of montelukast as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449167335	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167336	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167337	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1448258736	GG	Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
1448260758	*51:01:01	Patients with one or two copies of the HLA-B*51:01:01 allele may have an increased risk of cutaneous adverse drug reactions when treated with clindamycin as compared to patients with no HLA-B*51:01:01 alleles or negative for the HLA-B*51:01:01 test.
1448636926	AA	Patients with the AA genotype and breast cancer who are treated with everolimus may have decreased likelihood of drug discontinuation as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of discontinuation in patients with breast cancer who are treated with everolimus.
1448636927	AG	Patients with the AG genotype and breast cancer who are treated with everolimus may have decreased likelihood of  of drug discontinuation as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of drug discontinuation in patients with breast cancer who are treated with everolimus.
1448636928	GG	Patients with the GG genotype  and breast cancer who are treated with everolimus may have increased likelihood of drug discontinuation as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence drug discontinuation in patients with breast cancer who are treated with everolimus.
1449564718	CC	Patients with chronic hepatitis C and the CC genotype may have an decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the AA genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify "normal ITPas activity" vs. "deficient". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.
1449564781	*17/*17	Patients with the *17/*17 diplotype may have a decreased incidence of stroke and decreased platelet reactivity, as compared to patients with the *1/*2, or *2/*2 diplotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence patient response to clopidogrel and aspirin.
1449564782	*2/*2	Patients with the *2/*2 diplotype may have an increased incidence of stroke and decreased platelet reactivity, as compared to patients with the *1/*1, *1/*17, *17/*17, *1/*2 diplotypes. However, this has been contradicted in some studies. Other clinical and genetic factors may also influence patient response to clopidogrel and aspirin.
1449167465	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167466	CG	Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167467	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168726	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168727	GT	Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168728	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449565237	(TA)6/(TA)6	Patients with the (TA)6/(TA)6 (UGT1A1 *1/*1) genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.
1449192870	AA	People with opioid addiction and the AA genotype may have decreased concentrations of methadone compared to people with the AC genotypes, but may not require different doses, and reports conflict as to the direction of the association between genotype and methadone concentration and clearance. Other clinical and genetic factors may affect methadone dose and clearance.
1449192871	AC	People with opioid addiction and the AC genotype may have increased concentrations of methadone compared to people with the AA and CC genotypes, but may not require different doses, and reports conflict as to the direction of the association between genotype and methadone concentration and clearance. Other clinical and genetic factors may affect methadone dose and clearance.
1449192685	AA	Patients with the Aa genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor/tezacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor/tezacaftor.
1449192686	AG	Patients with the AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor/tezacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor/tezacaftor.
1449192687	GG	Patients with the GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor/tezacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor/tezacaftor.
1449192872	CC	People with opioid addiction and the CC genotype may have decreased concentrations of methadone compared to people with the AC genotypes, but may not require different doses, and reports conflict as to the direction of the association between genotype and methadone concentration and clearance. Other clinical and genetic factors may affect methadone dose and clearance.
1449192947	*93	Patients with the CYP2D6*93 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1449192948	*95	Patients with the CYP2D6*95 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1449192771	CTT/del	Patients with cystic fibrosis and the CTT/del genotype (one copy of the CFTR F508del variant)may experience a limited benefit from treatment with the combination drug of ivacaftor plus lumacaftor, as shown by improvement in sweat chloride concentrations CFQ-R questionnaire scores when compared to treatment with placebo. However, ppFEV1, BMI or body weight did not show a significant improvement following ivacaftor/lumacaftor treatment. This genotype is not an indication for use of the combination drug of ivacaftor plus lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence a patient's response to the combination drug of ivacaftor plus lumacaftor.
1449192772	del/del	Patients with the del/del genotype (two copies of the F508del variant) may benefit from treatment with the combination drug of ivacaftor plus lumacaftor, as shown by improvement in sweat chloride concentrations and/or forced expiratory volume in 1 second (FEV1) when compared to treatment with placebo. This genotype is an indication for use of the combination drug of ivacaftor plus lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence a patient's response to the combination drug of ivacaftor plus lumacaftor.
1449192782	AA	Patients with the AA genotype (two copies of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192783	AG	Patients with the AG genotype (one copy of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192784	GG	Patients with the GG genotype (do not have a copy of the CFTR S549N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192949	*97	Patients with the CYP2D6*97 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1449192950	*98	Patients with the CYP2D6*98 allele may have decreased clearance of methadone as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with methadone. Other genetic and clinical factors may also influence the metabolism of methadone.
1448266840	AA	Patients with the AA genotype and epilepsy may have increased concentrations of carbamazepine compared to patients with the AG and GG genotypes when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.
1448266841	AG	Patients with the AG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.
1448266842	GG	Patients with the GG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.
1450373763	AA	Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373764	AG	Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1448613111	*01:01:01/*01:01:01	Patients with the *01:01:01 haplotype may have reduced risk of statin-related myopathy when taking statins compared to patients with the *04:06:01 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.
1448613110	*04:06:01/*01:01:01	Patients with the *04:06:01 haplotype may have increased risk of statin-related myopathy when taking statins compared to patients without the *04:06:01 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.
1448613112	*04:06:01/*04:06:01	Patients with the *04:06:01 haplotype may have increased risk of statin-related myopathy when taking statins compared to patients without the *04:06:01 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.
1450373765	GG	Patients with pancreatic cancer and the GG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450377341	CC	Patients who are undergoing liver transplantation and receive a donor liver with the CC genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.
1450373769	AG	Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450377342	CT	Patients who are undergoing liver transplantation and receive a donor liver with the CT genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.
1450373770	GG	Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450377343	TT	Patients who are undergoing liver transplantation and receive a donor liver with the TT genotype may have a decreased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the CC or CT genotype. Other genetic and clinical factors may also influence risk for NODM.
1450375712	CC	Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1449168088	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168089	CT	Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1450375713	CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375714	TT	Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1449170472	AG	Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.
1449170473	GG	Patients with the GG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.
1449191870	AA	Patients with the AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191871	AG	Patients with the AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191872	GG	Patients with the GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191876	CC	Patients with the CC genotype (two copies of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191877	CG	Patients with the CG genotype (one copy of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191878	GG	Patients with the GG genotype (do not have a copy of the CFTR G970R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449715586	GG	Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715587	GT	Patients with the GT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715588	TT	Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449191894	AA	Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191895	AG	Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191896	GG	Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449270963	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270964	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449270965	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1448256720	CC	Patients with the CC genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1448256721	CT	Patients with the CT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1448256722	TT	Patients with the TT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1448256736	AA	Patients with the AA genotype and heroin-dependence who are treated with methadone maintenance therapy may have decreased plasma concentrations of R-methadone compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect concentrations of R-methadone.
1448256737	AG	Patients with the AG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.
1448256738	GG	Patients with the GG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.
1448264358	*04:03:01	Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.
1448422841	AA	Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422842	AG	Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422843	GG	Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422848	AA	Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422849	AG	Patients with the AG genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422850	GG	Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1449168081	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168082	CT	Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168083	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449157427	AA	Patients with alcoholism and the AA genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.
1449157428	AG	Patients with alcoholism and the AG genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.
1449157429	GG	Patients with alcoholism and the GG genotype may have a longer survival time as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence survival time in patients with alcoholism.
1449157537	AA	Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449157538	AG	Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449157539	GG	Patients with genotype GG may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1449191550	*5	Patients with the *5 allele in combination with another non-functional allele (*3, *4, *5, *6) who are treated with paroxetine may have a decreased clearance of paroxetine (higher paroxetine plasma concentrations) as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. However, an association with treatment response or severity of side effects is not conclusive. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449191551	*6	Patients with the *6 allele in combination with another non-functional allele (*3, *4, *5, *6) who are treated with paroxetine may have a decreased clearance of paroxetine (higher paroxetine plasma concentrations) as compared to patients with the CYPD6*1/*1 or *2/*2 genotype. However, an association with treatment response or severity of side effects is not conclusive. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1449191613	*1/*1	Patients with the *1/*1 genotype who carry two functional alleles may have an increased metabolism/clearance of doxepin and a decreased, but not absent, risk for side effects as compared to patients with two non-functional (*3, *4, *5) CYP2D6 alleles and a decreased metabolism/clearance of doxepin as compared to patients carrying more than two copies of CYP2D6 functional alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191614	*1/*1xN	Patients carrying more than two copies of CYP2D6 functional alleles may have an increased metabolism/clearance of doxepin as compared to patients with *1/*1 or *1/*2 genotype who carry two functional CYP2D6 alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191615	*1/*2	Patients with the *1/*2 genotype who carry two functional alleles may have an increased metabolism/clearance of doxepin and a decreased, but not absent, risk for side effects as compared to patients with two non-functional (*3, *4, *5) CYP2D6 alleles and a decreased metabolism/clearance of doxepin as compared to patients carrying more than two copies of CYP2D6 functional alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191616	*1/*2xN	Patients carrying more than two copies of CYP2D6 functional alleles may have an increased metabolism/clearance of doxepin as compared to patients with *1/*1 or *1/*2 genotype who carry two functional CYP2D6 alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191617	*3	Patients with the CYP2D6*3 non-functional allele in combination with another non-functional (*3, *4, *5) may have a decreased metabolism/clearance of doxepin an increased risk for side effects as compared to patients with *1/*1 genotype who carry two functional alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191618	*4	Patients with the CYP2D6*4 non-functional allele in combination with another non-functional (*3, *4, *5) may have a decreased metabolism/clearance of doxepin and an increased risk for side effects as compared to patients with *1/*1 genotype who carry two functional alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191619	*5	Patients with the CYP2D6*5 non-functional allele in combination with another non-functional (*3, *4, *5) may have a decreased metabolism/clearance of doxepin an increased risk for side effects as compared to patients with *1/*1 genotype who carry two functional alleles. The number of studies for doxepin pharmacogenomics is limited. However, since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, trimipramine and clomipramine for further evidence. Other genetic and clinical factors may also influence a patient's response to doxepin treatment.
1449191666	AA	Patients with the AA genotype (do not have a copy of the CFTR D579G variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191667	AG	Patients with the AG genotype (one copy of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449167113	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167114	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167115	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167132	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167133	CT	Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167134	TT	Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167263	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167264	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167265	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167274	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167275	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167276	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167285	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167286	AG	Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167287	GG	Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167252	AA	Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate than patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167253	AC	Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate than patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167254	CC	Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate than patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168090	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168672	CC	Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168673	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168674	TT	Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168679	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449747958	*3A/*3A	Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *3A/*3A genotype may have a higher likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *1A/*1A or *1A/*3A genotypes. Other clinical and genetic factors may also influence risk of nephrotoxicity.
1449748814	AA	Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.
1449748815	AG	Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.
1449296073	AA	Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing opioid dependence.
1449296074	AC	Patients with the AC genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing opioid dependence.
1449296075	CC	Patients with the CC genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect risk of developing opioid dependence.
1449717110	AA	Patients with cancer and the AA genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.
1449717111	AG	Patients with cancer and the AG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype, or decreased as compared to the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.
1450361631	TT	Patients with the TT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450372001	CT	Patients with the CT genotype may have 1) increased risk of severe toxicity when treated with fluoropyrimidines and 2) decreased metabolism of fluorouracil as compared to patients with the TT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449717112	GG	Patients with cancer and the GG genotype may experience decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.
1449748816	GG	Patients with the GG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.
1449564904	AA	The AA (CYP2C9 *1/*1) genotype may be associated with a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to the CC or AC genotypes, although this is contradicted in most studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients treated with acenocoumarol or warfarin.
1449564905	AC	The AC (CYP2C9 *1/*3) genotype may be associated with a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to the CC and an increased risk as compared to the AA genotype, although this is contradicted in most studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients treated with acenocoumarol or warfarin.
1449564906	CC	The CC (CYP2C9 *3/*3) genotype may be associated with an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to the AA or AC genotypes, although this may be contradicted in most studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients treated with acenocoumarol or warfarin.
1449564942	CC	Patients with the CC genotype and type II diabetes who are treated with sulfonylureas: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the TT genotype 2) May be more likely to experience treatment failure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.
1449564943	CT	Results from patients with the CT genotype were not statistically significant.
1449564944	TT	Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.
1450361630	CT	Patients with the CT genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1448260853	CC	Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1448260854	CT	Patients with the CT genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the TT genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1448260855	TT	Patients with the TT genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1448525397	AA	Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448525398	AG	Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448525399	GG	Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448262926	CC	Patients with the CC genotype may have increased time in therapeutic range when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262925	CG	Patients with the CG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262924	GG	Patients with the GG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1449165171	AA	Patients with the AA genotype may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence methotrexate toxicity.
1449161920	TTAAAG/TTAAAG	Patients with the TTAAAG/TTAAAG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have decreased survival time, and decreased risk of toxicity, as compared to patients with the TTAAAG/del or del/del genotypes. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient's response to treatment.
1449165172	AG	Patients with the AG genotype may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence methotrexate toxicity.
1449168651	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168652	CT	Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168653	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168658	GG	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449165173	GG	Patients with the GG genotype may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence methotrexate toxicity.
1449168659	GT	Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168660	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168665	AA	Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168666	AT	Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168667	TT	Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449003783	CC	Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003784	CT	Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the TT genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449733533	AA	Patients with the AA genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.
1449733534	AG	Patients with the AG genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.
1449733535	GG	Patients with the GG genotype and HIV may have an increased risk of developing sensory neuropathy when taking stavudine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.
1449171443	AA	Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.
1449171444	AC	Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.
1449003785	TT	Patients with the TT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003791	AA	Patients with the AA genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003792	AG	Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003793	GG	Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003807	GG	Patients with the GG genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the G/del or del/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003809	del/del	Patients with the del/del genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the G/del or GG genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449751922	*1/*1	Patients with two functional CYP2C19 alleles (*1/*1): may have 1) increased metabolism of clopidogrel and 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with one or two CYP2C19 loss-of-function alleles (*2, *3, *4, *5, *6, *8). Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449003779	CC	Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003780	CT	Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk for venous thrombosis compared to the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003781	TT	Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449751923	*2	Patients with CYP2C19*2 (rs4244285) allele in combination with another loss-of-function allele (*2, *3, *4, *5, *6, *8) or one functional allele (*1) may have 1) poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449271351	CC	Female patients with the CC genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.
1449271352	CT	Female patients with the CT genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.
1449271353	TT	Female patients with the TT genotype may have increased levels of cocaine, ethanol or nicotine use, which may lead to an increased risk of developing substance dependence, as compared to female patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.
1449191437	CC	Patients with the CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191438	CT	Patients with the CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191439	TT	Patients with the TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449564728	*2 (PMID: 11503014)/*2 (PMID: 11503014)	Patients with renal cell carcinoma and the ABCB1 *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotype may show a decreased response to sunitinib as compared to patients with any other combination diplotype, including, but not limited to, ABCB1*1/*1 or ABCB1 *1/*2 (PMID: 11503014), although this is contradicted in one study. Other clinical and genetic factors may also influence response to sunitinib.
1449564798	*04:01:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:01 allele may have an increased risk of cutaneous manifestations of drug sensitivity, including DRESS Syndrome or SJS/TEN as compared to non-carriers, but may not be associated with risk of exanthema.
1449164584	AA	Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1449164585	AG	Cancer patients with the AG genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1449164586	GG	Cancer patients with the GG genotype who are treated with doxorubcin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
1449564924	CT	Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence  a patient's phenprocoumon or acenocoumarol dose requirement.
1449244630	CC	Patients with the CC genotype may require decreased dosage of morphine as compared to patients with the TT genotype. However, another study has found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements.
1449564726	*1/*1	Patients with renal cell carcinoma and the ABCB1 *1/*1 may show an increased response to sunitinib as compared to patients with the ABCB1 *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to sunitinib.
1449564727	*1/*2 (PMID: 11503014)	Patients with renal cell carcinoma and the ABCB1 *1/*2 (PMID: 11503014) diplotype may show an increased response to sunitinib as compared to patients with the ABCB1 *2 (PMID: 11503014)/*2 (PMID: 11503014) diplotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to sunitinib.
1449244631	CT	There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.
1449244632	TT	Patients with the TT genotype may require increased dosage of morphine as compared to patients with the CC genotype. However, another study has found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements.
1449270971	TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271395	AA	Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449311186	AA	Patients with the AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1449564925	TT	Patients with the TT genotype may require an increased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.
1449269564	GG	Patients with the GG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.
1449269571	CC	Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.
1449269572	CT	Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT, and increased dose as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.
1449269573	TT	Genotype TT may be associated with increased dose of warfarin as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.
1449564953	CC	Patients with diabetes melitus and the CC genotype who are taking sulfonylureas (gliclazides, glibenclamide, glimepiride, glipizide, or gliquidone) may have worse response as compared to patients with the CT or TT genotypes, although this is contradicted in some studies, and one found that the CT genotype had an improved response as compared to the CC or TT genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes melitus.
1449564954	CT	Patients with diabetes melitus and the CT genotype who are taking sulfonylureas (gliclazides, glibenclamide, glimepiride, glipizide, or gliquidone) may have improved response as compared to patients with the CC genotypes, although this is contradicted in some studies, and one found that the CT genotype had an improved response as compared to the CC or TT genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes melitus.
1449564955	TT	Patients with diabetes melitus and the TT genotype who are taking sulfonylureas (gliclazide, glibenclamide, glimepiride, glipizide, or gliquidone) may have improved response as compared to patients with the CC genotypes, although this is contradicted in some studies, and one found that the CT genotype had an improved response as compared to the CC or TT genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes melitus.
1449269586	CC	Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the CT and TT genotypes, however, no association was found in the majority of studies, and in one study, the CC genotype was associated with an increased dose of warfarin. Other clinical and genetic factors may also influence dose of warfarin.
1449269587	CT	Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the CT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin.
1449269588	TT	Patients with the TT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the TT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin.
1450372002	TT	Patients with the TT genotype may have 1) decreased but not absent risk of severe toxicity when treated with fluoropyrimidines, 2) increased metabolism of fluorouracil and 3) increased disease-free survival times as compared to patients with the CC or CT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450373586	CT	Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373587	TT	Patients with the TT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1449269614	GG	Patients atrial fibrillation and the GG genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.
1449269615	GT	Patients atrial fibrillation and the GT genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.
1449269616	TT	Patients with atrial fibrillation and the TT genotype may have decreased clearance and increased concentrations of apixaban as compared to patients with the GG and GT genotypes. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.
1448612684	CC	Patients with the CC genotype and multiple myeloma may have increased response to lenalidomide and thalidomide treatment compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect progression of multiple myeloma.
1448612685	CG	Patients with the CG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.
1448612686	GG	Patients with the GG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.
1448612858	GG	Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
1448612859	GT	Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
1448612860	TT	Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
1448614967	TT	Patients with the TT genotype may have decreased clearance of rocuronium as compared to patients with the del/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.
1448614966	del/T	Patients with the T/del genotype may have decreased clearance of rocuronium as compared to patients with the del/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.
1448614965	del/del	Patients with the del/del genotype may have increased clearance of rocuronium as compared to patients with the del/T and TT genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.
1449161921	TTAAAG/del	Patients with the TTAAAG/del genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have increased survival time as compared to those with the TTAAAG/TTAAAG genotyoe, and decreased risk of toxicity as compared to those with the del/del genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient's response to treatment.
1449161922	del/del	Patients with the del/del genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have increased survival time, and increased risk of drug toxicity, as compared to patients with the TTAAAG/TTAAAG or TTAAAG/del genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient's response to treatment.
1449188681	GG	Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188682	GT	Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449188683	TT	Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.
1449170057	*02:07:01	Patients with one or two copies of the HLA-A*02:07:01 allele who are treated with lamotrigine may have an increased risk of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) or Maculopapular Exanthema (MPE) as compared to patients with no HLA-A*02:07:01 alleles or negative for the HLA-A*02:07:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1450385800	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450385801	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450385802	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1449171455	CC	Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of tacrolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.
1449171456	CT	Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of tacrolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.
1449171457	TT	Transplant recipients with the TT (CYP3A4 (*1/*1) genotype may require a decreased dose of tacrolimus as compared to patients with the CT (*1B/*1) or CC (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.
1448266601	AA	Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.
1448266602	AT	Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.
1448266603	TT	Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.
1448266611	CC	Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
1448266612	CT	Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
1448266613	TT	Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
1448531103	GG	Patients with the GG genotype and stenosis may be less likely to suffer from a transient ischemic attack than patients with the GT or TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.
1448531104	GT	Patients with the GT genotype and stenosis may be less likely to suffer from a transient ischemic attack than patients with the TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.
1448531105	TT	Patients with the TT genotype and stenosis may be more likely to suffer from a transient ischemic attack than patients with the GG or GT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.
1449171445	CC	Patients with the CC genotype who are undergoing organ transplantation may have increased metabolism and dose requirements of tacrolimus, as compared to patients with the AA, AC, CT or TT genotypes. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.
1449171446	CT	Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.
1449171447	TT	Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.
1449191668	GG	Patients with the GG genotype (two copies of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191672	CC	Patients with the CC genotype (do not have a copy of the CFTR R668C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191673	CT	Patients with the CT genotype (one copy of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449171940	CC	Patients with the CC genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus, and require an increased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.
1449171941	CT	Patients with the CT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.
1449171942	TT	Patients with the TT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.
1449191674	TT	Patients with the TT genotype (two copies of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1448525561	GG	Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.
1448525562	GT	Pediatric patients with the GT genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.
1448525563	TT	Pediatric patients with the TT genotype who are undergoing hematopoietic stem cell transplantation may have an increased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for SOS.
1448617490	CC	The CC genotype carriers had lower tenofovir renal clearance, and higher  AUC than TT genotype.
1448617491	CT	The TC  genotype carriers had lower tenofovir renal clearance, and higher  AUC than TT genotype.
1448617492	TT	The TT genotype is associated with higher tenofovir renal clearance, and lower AUC compared to TC and CC cariers.
1449189244	AA	Patients with the AA genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189245	AT	Patients with the AT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189246	TT	Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the AA or AT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449271011	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271012	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271013	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449192552	CTT/CTT	Indication of ivacaftor in cystic fibrosis patients with the CTT/CTT genotype (no copies of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192553	CTT/del	Indication of ivacaftor in cystic fibrosis patients with the CTT/del genotype (one copy of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192554	del/del	Ivacaftor is not recommended in cystic fibrosis patients with the del/del genotype (two copies of the F508del variant). A clinical trial of ivacaftor in patients with the del/del genotype showed ivacaftor was ineffective in these patients, though this study was not powered to examine efficacy. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449271017	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271018	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449140225	AA	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.
1449140226	AC	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.
1449140227	CC	Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus or sirolimus as compared to patients with the AA or AC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.
1449269836	CC	Patients with atrial fibrillation and the CC genotype may have increased concentrations of apixaban as compared to patients with the TT genotype, although this is contraindicated by another study which found that the CC genotype was associated with increased clearance of apixaban as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.
1449269837	CT	Patients with atrial fibrillation and the CT genotype may have increased concentrations of apixaban as compared to genotype TT, although this is contraindicated by another study which found that the CT and TT genotypes were associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.
1449269838	TT	Patients with atrial fibrillation and the TT genotype may have decreased concentrations of apixaban as compared to patients with the CC and CT genotype and may be associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.
1449269863	*1/*1xN	Patients with schizophrenia and one or two copies of the *1xN allele may experience extrapyramidal symptoms, hepatic cytolysis and weight gain when treated with haloperidol, levomepromazine, and risperidone. Other clinical and genetic factors may also influence extrapyramidal symptoms, hepatic cytolysis, and weight gain when treated with haloperidol, levomepromazine, and risperidone.
1449269864	*4/*41	Patients with schizophrenia and the *4/*41 genotype may experience binge eating disorder, constipation, dystonia, extrapyramidal symptoms, galactorrhea, psychomotor agitation and weight gain when treated with aripiprazole, quetiapine and risperidone. Other clinical and genetic factors may also influence constipation, dystonia, extrapyramidal symptoms, galactorrhea, psychomotor agitation and weight gain when treated with aripiprazole, quetiapine and risperidone.
1449269940	CC	Patients with thromboembolism and the CC genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.
1449269941	CT	Patients with thromboembolism and the CT genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the TT genotypes and decreased risk as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.
1449269942	TT	Patients with thromboembolism and the TT genotype may have a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.
1449564969	CC	Patients with the CC genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the CT and TT genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.
1449564970	CT	Patients with the CT genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the TT genotypes, and worse response as compared to CC genotype. This is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.
1449564971	TT	Patients with the TT genotype and and Alzheimer Disease may have a worse response to donepezil (faster cognitive decline) as compared to patients with the CT and CC genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.
1449269950	AA	Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449269951	AG	Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449269952	GG	Patients with the GG genotype: 1) may have sufficient metabolism of clopidogrel and increased formation of active drug metabolite 2) may have a decreased risk for secondary cardiovascular events with clopidogrel as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for secondary cardiovascular events when taking clopidogrel based on their genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449269966	CC	Patients with the CC genotype may have decreased concentrations of Vitamin K as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.
1449269967	CT	Patients with the CT genotype may have increased concentrations of Vitamin K as compared to patients with the CC. Other clinical and genetic factors may also influence concentrations of Vitamin K.
1449269968	TT	Patients with the TT genotype may have increased concentrations of Vitamin K as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.
1448615143	AA	Postmenopausal women with HR+ breast cancer and the AA genotype may be less likely to experience arthralgia when treated with anastrozole as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615144	AG	Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615145	GG	Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448123837	AG	Patients with the AG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.
1448123838	GG	Patients with the GG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.
1448264349	*15:01:01:01	Patients with one or two copies of the HLA-B*15:01 allele may have a decreased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-B*15:01 alleles or negative for the HLA-B*15:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.
1448615149	AA	Postmenopausal women with HR+ breast cancer and the AA genotype may have increased plasma concentrations of anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
1448615150	AC	Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
1448615151	CC	Postmenopausal women with HR+ breast cancer and the CC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
1448636113	AA	Patients with the AA genotype may have increased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV.
1448123836	AA	Patients with the AA genotype and schizophrenia may have increased response to clozapine compared to patients with the AG and GG genotypes. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.
1448636114	AG	Patients with the AG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV.
1448636115	GG	Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV.
1449002526	*1/*1	Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *2, *3A, *3B, *3C, *4). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449002527	*2	Patients with the *2 allele 1) may have decreased inactivation of thiopurines due to deficient TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *2/*3A) than in those who are heterozygous for the non-functional variant (*1/*2). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449002528	*3A	Patients with the *3A allele 1) may have decreased inactivation of thiopurines due to deficient TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3A/*3B) than in those who are heterozygous for the non-functional variant (*1/*3A). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449191678	CC	Patients with the CC genotype (two copies of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191679	CT	Patients with the CT genotype (one copy of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191680	TT	Patients with the TT genotype (do not have a copy of the CFTR L927P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449171946	*1A/*1A	Patients with the *1A/*1A genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus as compared to patients with the *1A/*3; and *3/*3 genotypes. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449171947	*1A/*3	Patients with the *1A/*3 genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1A/*1A genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449171948	*3/*3	Patients with the *3/*3 genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1A/*1A genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449172006	*1A/*1A	Patients with the *1A/*1A genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1A/*3 and *3/*3 genotypes. However, one study found that those with the *1A/*1A variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1A/*3 or *3/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.
1449172007	*1A/*3	Patients with the *1A/*3 genotype who are undergoing kidney transplantation may have an increased risk for kidney dysfunction as compared to patients with the *1A/*1A genotypes. However, one study found that those with the *1A/*3 variant had increased estimated glomerular filtration rate, or better kidney function, as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence kidney dysfunction.
1449172008	*3/*3	Patients with the *3/*3 genotype who are undergoing kidney transplantation may have an increased risk for kidney dysfunction as compared to patients with the *1A/*1A genotypes. However, one study found that those with the *3/*3 variant had increased estimated glomerular filtration rate, or better kidney function, as compared to those with the *1A/*1A genotype. Other genetic and clinical factors may also influence kidney dysfunction.
1449191704	CC	Patients with the CC genotype (two copies of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191705	CG	Patients with the CG genotype (one copy of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191706	GG	Patients with the GG genotype (do not have a copy of the CFTR L997F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191710	GG	Patients with the GG genotype (two copies of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191711	GT	Patients with the GT genotype (one copy of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191712	TT	Patients with the TT genotype (do not have a copy of the CFTR F1052V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191718	CC	Patients with the CC genotype (two copies of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192477	GG	Patients with the GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192478	GT	Patients with the GT genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449192479	TT	Patients with the TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449271023	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449168680	AG	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168681	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168686	CC	Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168687	CG	Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168688	GG	Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449271024	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271025	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271019	GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449169536	CC	Subjects with the CC genotype may have decreased concentrations of valproic acid as compared to those with TT genotype (one study, not significant, and one meta-analysis). Other clinical and genetic factors may also influence concentrations of valproic acid in healthy subjects and subjects with epilepsy.
1449169537	CT	Subjects with the CT genotype may have increased AUCs of valproic acid as compared to the CC genotype, although this association is not significant. Other clinical and genetic factors may also influence response to and concentrations of valproic acid in healthy subjects and subjects with epilepsy.
1449169538	TT	Subjects with the TT genotype may have increased concentrations of valproic acid as compared to those with CC genotype (one study, not significant, and one meta-analysis). Other clinical and genetic factors may also influence concentrations of valproic acid in healthy subjects and subjects with epilepsy.
1449169542	CC	Pediatric subjects with the CC genotype may have increased concentrations of valproic acid as compared to those with TT genotype, however, this is contradicted in one study, which found no association. Other clinical and genetic factors may also influence concentrations of valproic acid in pediatric subjects with epilepsy.
1449169543	CT	There is no association between the CT genotype and concentrations of valproic acid in pediatric subjects. Other clinical and genetic factors may also influence concentrations of valproic acid in pediatric subjects with epilepsy.
1449169544	TT	Pediatric subjects with the TT genotype may have decreased concentrations of valproic acid as compared to those with CC genotype, however, this is contradicted in one study, which found no association. Other clinical and genetic factors may also influence concentrations of valproic acid in pediatric subjects with epilepsy.
1449170048	*15:02:01	Patients with one or two copies of the HLA-B*15:02:01 allele may have an increased risk for Stevens-Johnson Syndrome or toxic epidermal necrolysis (SJS/TEN) when receiving lamotrigine as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test. However, this association has only been found in meta-analyses; no individual study has shown a significant association between the *15:02:01 allele and lamotrigine-induced SJS/TEN. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.
1449271053	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271054	CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271055	TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271396	AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449565100	GG	Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased response and an increased risk of adverse drug events as compared to patients with the AA or AG genotype. However, contradictory evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence a patient's response and risk of adverse drug events when treated with methotrexate.
1449565068	CC	Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have shorter overall survival as compared to patients with the CT and TT genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.
1449565069	CT	Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.
1449565070	TT	Patients with the TT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.
1449269987	CC	Patients with the CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449269988	CT	Patients with the CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449269989	TT	Patients with the TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to warfarin.
1449005374	AA	Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the AC or CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.
1448997143	GG	Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better overall survival as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1448997144	GT	Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1448997145	TT	Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1449565089	AG	Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565090	GG	Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449005375	AC	Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.
1449005376	CC	Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the CC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of LDL cholesterol concentrations as compared to patients with the AC or AA genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.
1449565117	AA	Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.
1449565118	AG	Patients with the AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.
1448264340	*40:02:01	Patients with one or two copies of the HLA-B*40:02:01 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-B*40:02:01 alleles or negative for the HLA-B*40:02:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.
1448265607	AA	Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265608	AG	Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265609	GG	Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448601775	*10	Individuals with two CYP2A6*10 alleles or one CYP2A6*10 allele  in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28A/B) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601776	*19	Individuals with two CYP2A6*19 alleles or one CYP2A6*19 allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601777	*1A/*1A	Individuals with the CYP2A6*1A/*1A genotype may have decreased metabolism of nicotine as compared to individuals with the CYP2A6 *1B1/*1B1 or *1X2B/*1X2B genotype and an increased metabolism of nicotine as compared to patients carrying any combination of following alleles *2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601778	*1B1/*1B1	Individuals with the CYP2A6*1B1/*1B1 genotype may have increased metabolism of nicotine as compared to patients with the *1A/*1A genotype and an increased metabolism of nicotine as compared to individuals carrying any combination of following alleles *2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601779	*1X2B	Individuals with one or two CYP2A6*1X2B alleles may have increased metabolism of nicotine as compared to patients with the CYP2A6 *1A/*1A genotype as well as compared to individuals with one ora combination of two of the following alleles: *2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601780	*2	Individuals with two CYP2A6*2 alleles, or one CYP2A6*2 allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601781	*20	Individuals with two CYP2A6*20 alleles, or one CYP2A6*20 allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601782	*24A	Individuals with two CYP2A6*24A alleles, or one CYP2A6*24A allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601783	*26	Individuals with two CYP2A6*26 alleles or one CYP2A6*26 allele  in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601784	*27	Individuals with two CYP2A6*27 alleles or one CYP2A6*27 allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601785	*4A	Individuals with two CYP2A6*4A alleles, or one CYP2A6*4A allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601786	*7	Individuals with two CYP2A6*7 alleles, or one CYP2A6*4A allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1448601787	*9A	Individuals who are homozygous for CYP2A6*9A, CYP2A6*1A/*9A heterozygous, or carry one CYP2A6*9A allele in combination with another poor metabolizer allele (*2, *4A, *7, *9A, *10, *19, *20, *24A, *26, *27 or *28) may have decreased metabolism of nicotine as compared to individuals with the *1A/*1A, *1B1/*1B1 or *1X2B/*1X2B genotypes. Other genetic and clinical factors may also influence metabolism of nicotine.
1449171011	*1/*1B	Patients with opioid-related disorders and the CYP3A4*1/*1B diplotype may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with other CYP3A4 diplotypes. Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.
1449171116	CC	Patients with the CC genotype may have decreased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP.
1449171117	CT	Patients with the CT genotype may have increased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP.
1449171118	TT	There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.
1449171122	CC	Patients with the CC genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.
1449171123	CT	Patients with the CT genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.
1449171124	TT	Patients with the TT genotype may have increased serum concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.
1449191719	CG	Patients with the CG genotype (one copy of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191720	GG	Patients with the GG genotype (do not have a copy of the CFTR H1054D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191724	AA	Patients with the AA genotype (do not have a copy of the CFTR K1060T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191725	AC	Patients with the AC genotype (one copy of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191726	CC	Patients with the CC genotype (two copies of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191730	AA	Patients with the AA genotype (two copies of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191731	AG	Patients with the AG genotype (one copy of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191732	GG	Patients with the GG genotype (do not have a copy of the CFTR R1066H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191736	AA	Patients with the AA genotype (two copies of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191737	AG	Patients with the AG genotype (one copy of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191738	GG	Patients with the GG genotype (do not have a copy of the CFTR A1067T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191760	CC	Patients with the CC genotype (two copies of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191761	CG	Patients with the CG genotype (one copy of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449645440	CC	Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645441	CT	Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645442	TT	Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1448532317	CC	Patients with genotype CC may have decreased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype TT. Other genetic and clinical factors may also influences response to  ledipasvir/sofosbuvir therapy.
1448532316	CT	Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to  ledipasvir/sofosbuvir therapy.
1448532315	TT	Patients with genotype TT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to  ledipasvir/sofosbuvir therapy.
1449645446	CC	Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645447	CT	Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449191904	AA	Patients with the AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191905	AG	Patients with the AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191906	GG	Patients with the GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449271397	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.
1449271587	AA	Patients with the AA genotype who are receiving methadone maintenance therapy may have increased clearance of methadone, leading to decreased plasma concentration of methadone as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations.
1449271588	AG	Patients with the AG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. One study has also found that patients with the AG genotype may have increased plasma concentrations of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations.
1449271589	GG	Patients with the GG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. One study has also found that patients with the GG genotype may have decreased plasma concentrations of methadone as compared to patients with the AG genotype. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations.
1449311188	GG	Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1449311187	AG	Patients with the AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1449645434	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645435	CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645436	TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645448	TT	Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1448263857	CC	Patients with the CC genotype and breast cancer may have a decreased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for anemia.
1448263858	CT	Patients with the CT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
1448263859	TT	Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
1449732710	GG	Patients with the GG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance and dose requirements of tacrolimus, as compared to patients with the AA or AG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.
1449750542	TT	Patients with the TT (POR *28/*28) genotype and Kidney Transplantation who are treated with tacrolimus 1) may have an increased risk for developing new-onset diabetes after transplantation, 2) in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3  (rs776746) may require an increased dose of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1449750775	AA	Patients with the AA genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.
1450373591	AA	Patients with the AA genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.
1450373592	AG	Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.
1450373593	GG	Patients with the GG genotype and cancer may have decreased clearance of imatinib, as well as an increased response and an increased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.
1449750776	AC	Patients with the AC genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.
1449750834	CC	Patients with the CC genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750835	CT	Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750777	CC	Patients with the CC genotype and colorectal cancer may have increased overall survival time when treated with cetuximab as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence overall survival time.
1449750836	TT	Patients with the TT genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750840	GG	Patients with the GG genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence duloxetine response.
1450373606	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.
1450373607	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.
1450373608	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.
1450373597	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.
1450373598	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.
1450373599	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.
1448615596	CC	Patients with the CC genotype and Epilepsy who are treated with phenytoin may have an increased metabolism of phenytoin, decreased plasma free phenytoin concentration, and a decreased, but not absent, risk of drug toxicity as compared to patients with the CT and TT genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.
1448615597	CT	Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.
1448615598	TT	Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.
1448617482	*1/*1	Patients with the CYP2C19*1/*1, CYP2C9*1/*1 and CYP2D6*1/*1 combined diplotypes may have higher clearance of trimipramine as compared to patients with the CYP2C19*2/*2 or *1/*2 genotype. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448617483	*1/*2	Patients with the CYP2C19*1/*2 diplotype (intermediate metabolizers) may have reduced clearance of trimipramine as compared to patients with CYP2C19*1/*1, CYP2C9*1/*1 and CYP2D6*1/*1 combined diplotypes. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448617484	*2/*2	Patients with the CYP2C19*2/*2 diplotype (poor metabolizers) may have reduced clearance of trimipramine as compared to patients with CYP2C19*1/*1, CYP2C9*1/*1 and CYP2D6*1/*1 combined diplotypes. Patients with the CYP2C19 poor metabolizer phenotype (such as *2/*2) may have an increased trimipramine and lower desmethyltrimipramine plasma concentrations as compared to patients with the *1/*1 genotype. The number of studies for trimipramine pharmacogenomics is limited. Since tricyclics have comparable pharmacokinetic properties see also annotations for amitriptyline, imipramine, clomipramine and doxepin for further evidence. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.
1448634528	AA	Patients with the AA and stable coronary artery disease who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence risk hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.
1448634529	AT	Patients with the AT genotype and stable coronary artery disease who are treated with clopidogrel may have increased risk of hemorrhage as compared to patients with the AA genotype and decreased risk as compared to the TT genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.
1448634530	TT	Patients with the TT genotype and stable coronary artery disease who are treated with clopidogrel may have Increased risk of  of hemorrhage as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.
1449146787	AA	Patients with non-small cell lung cancer and the AA genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.
1449146788	AG	Patients with non-small cell lung cancer and the AG genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.
1449144366	AA	Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144367	AC	Patients with the AC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CC genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144368	CC	Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1448126024	AA	Patients with genotype AA may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
1448126023	AT	Patients with genotype AT may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
1448126022	TT	Patients with genotype TT may have increased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to sorafenib.
1449191772	GG	Patients with the GG genotype (do not have a copy of the CFTR D1270N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191773	GT	Patients with the GT genotype (one copy of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191762	GG	Patients with the GG genotype (do not have a copy of the CFTR D1152H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191766	GG	Patients with the GG genotype (two copies of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191767	GT	Patients with the GT genotype (one copy of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191768	TT	Patients with the TT genotype (do not have a copy of the CFTR S1235R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191774	TT	Patients with the TT genotype (two copies of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191850	AA	Patients with the AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191851	AG	Patients with the AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191852	GG	Patients with the GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449564389	*3/*3	Patients with the CYP2C19 *3/*3 genotype may have a better response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH) as compared to patients with the *1/*1, *1/*2 or *1/*3 genotype. The majority of studies grouped genotypes together for analysis rather than compare individual genotypes: homozygous extensive metabolizers = *1/*1, heterozygous extensive metabolizers = *1/*2 + *1/*3 and poor metabolizers = *2/*2, *2/*3 + *3/*3 (*2 = rs4244285; *3 = rs4986893). Several studies found no significant associations between CYP2C19 genotypes and intragastric pH measurements. Other genetic and clinical factors may also influence response to rabeprazole.
1449564505	*45	Individuals with the *45 reduced function allele who in combination with a reduced (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metropolol. Other genetic and clinical factors may also influence a patient's response to metoprolol.
1449564506	*46	Individuals with the *46 reduced function allele who in combination with a reduced (*9, *10, *17, *29, *31, *41, *45, *46) or non-functional (*3, *4, *5, *6) allele may have decreased metabolism/clearance of metropolol. Other genetic and clinical factors may also influence a patient's response to metoprolol.
1449564502	*5	Individuals with the *5 non-functional allele in combination with another non-functional (*3, *4, *5, *6) or reduced function allele (*9, *10, *17, *29, *31, *41, *45, *46) may have decreased metabolism/clearance of metoprolol as compared to patients with *1/*1 genotype, who carry two functional alleles. Other genetic and clinical factors may also influence metabolism of and response to metoprolol.
1449004822	AA	Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1449004823	AG	Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1449004824	GG	Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1449004827	CC	Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1449004828	CT	Pediatric patients with the CT genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1449004829	TT	Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1449004898	CT	Cancer patients with the CT genotype who are treated with methotrexate may have 1) a decreased likelihood of drug toxicity as compared to those with the TT genotype, and an increased likelihood as compared to those with the CC genotype 2) a poorer response as compared to those with the CC genotype and 3) decreased concentrations of methotrexate as compared to those with the TT genotype. However, multiple incidences of negative or contradictory evidence exists for all three of these associations. Other genetic or clinical factors may influence a patient's response to methotrexate.
1449004899	TT	Cancer patients with the TT genotype who are treated with methotrexate may have 1) an increased likelihood of drug toxicity as compared to those with the CC or CT genotype, 2) a poorer response as compared to those with the CC genotype and 3) increased concentrations of methotrexate as compared to those with the CC or CT genotype. However, multiple incidences of negative or contradictory evidence exists for all three of these associations. Other genetic or clinical factors may influence a patient's response to methotrexate.
1449005028	A/del	Pregnant patients infected with malaria and the A/del genotype, may have elevated concentrations of lumefantrine as compared to patients with the del/del genotypes, and lower concentrations of lumefantrine as compared to patients with the AA genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria.
1449005027	AA	Pregnant patients infected with malaria and the AA genotype, may have elevated concentrations of lumefantrine as compared to patients with the A/del or del/del genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria.
1449005029	del/del	Pregnant patients infected with malaria and the del/del genotype, may have lower concentrations of lumefantrine as compared to patients with the A/del or AA genotypes. There is no association with response. Other clinical andgenetic factors may also influence concentrations of lumefantrine in pregnant infected with malaria.
1449565136	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449565137	CT	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype or may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449564658	CC	Patients with the CC genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1449576923	CC	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
1449576924	CT	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
1449576925	TT	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.
1449565138	TT	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1449576928	AA	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.
1449564659	CT	Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1449564660	TT	Patients with the TT genotype may have decreased clearance of gemcitabine as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect clearance of gemcitabine.
1449156502	CC	Patients with the CC genotype and HIV may have increased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.
1449156503	CT	Patients with the CT genotype and HIV may have increased exposure to atazanavir as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.
1449156504	TT	Patients with the TT genotype and HIV may have decreased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.
1450044505	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449309919	*1A/*1A	Pediatric patients with nephrotic syndrome and the *1A/*1A diplotype may have increased clearance of tacrolimus as compared to patients with the *3A/*3A diplotype. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.
1449309920	*1A/*3A	Pediatric patients with nephrotic syndrome and the *1A/*3A diplotype may have increased clearance of tacrolimus as compared to patients with the *3A/*3A diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.
1449309921	*3A/*3A	Pediatric patients with nephrotic syndrome and the *3A/*3A diplotype may have decreased clearance of tacrolimus as compared to patients with the *1A/*1A or *1A/*3A diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.
1450044506	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC, CG, AA or AG. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450375076	AA	Patients with testicular cancer and the AA genotype may have an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.
1450375077	AC	Patients with testicular cancer and the AC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.
1450375078	CC	Patients with testicular cancer and the CC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.
1449002529	*3B	Patients with the *3B allele 1) may have decreased inactivation of thiopurines due to deficient TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *3B/*3C) than in those who are heterozygous for the non-functional variant (*1/*3B). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449002530	*3C	Patients with the *3C allele 1) may have decreased inactivation of thiopurines due to deficient TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *2/*3C) than in those who are heterozygous for the non-functional variant (*1/*3C). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449002531	*4	Patients with the *4 allele 1) may have decreased inactivation of thiopurines due to deficient TPMT activity and 2) may have an increased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with the *1/*1 genotype. These effects may be more pronounced in those who are homozygous for two non-functional variants (e.g. *2/*4) than in those who are heterozygous for the non-functional variant (*1/*4). Other genetic and clinical factors may also influence a patient's risk for toxicity.
1448603627	CC	No patients with the CC genotype were available for analysis, but patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.
1448603628	CT	Patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.
1448603629	TT	Patients with the TT genotype who are undergoing lung transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.
1449140071	AA	Patients with the AA genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and increased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.
1449140072	AG	Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.
1449140073	GG	Patients with the GG genotype and bladder cancer who are treated with temsirolimus may have increased exposure as compared to patients with the AA or AG genotypes and decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.
1448567995	CC	Patients with the CC genotype who underwent kidney transplantation may have increased dose-adjusted trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.
1448567996	CT	Patients with the CT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.
1448567997	TT	Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.
1449146789	GG	Patients with non-small cell lung cancer and the GG genotype who are treated with platinum-based chemotherapy may have an increased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the AA or AG genotypes. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.
1450376310	*1/*3	Patients with *1/*3 genotypes may have decreased metabolism, increased plasma concentration, increased toxicity and increased adverse drug reactions when treated with phenytoin in epilepsy when compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1450376311	*2/*2	Patients with *2/*2 genotypes may have decreased metabolism, increased plasma concentration, increased toxicity and increased adverse drug reactions when treated with phenytoin in epilepsy when compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1450376312	*2/*3	Patients with *2/*3 genotypes may have decreased metabolism, increased plasma concentration, increased toxicity and increased adverse drug reactions when treated with phenytoin in epilepsy when compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1448820987	*07:01:01:01	Patients with one or two copies of the HLA-DRB1*07:01 allele have an increased risk of hepatotoxicity when treated with lapatinib as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. This allele is in strong linkage disequilibrium with HLA-DQA1*02:01. Other genetic and clinical factors may also influence a patient's risk of lapatinib-induced hepatotoxicity.
1450377326	TT	Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.
1450415404	AA	Patients with the AA genotype and major depressive disorder may have a poorer response to treatment with antidepressants as compared to patients with the GG genotype. However, some studies show no association with response or remission. Other genetic and clinical factors may also influence response to antidepressants.
1450415405	AG	Patients with the AG genotype and major depressive disorder may have a poorer response to treatment with antidepressants as compared to patients with the GG genotype. However, some studies show no association with response or remission. Other genetic and clinical factors may also influence response to antidepressants.
1450415406	GG	Patients with the GG genotype and major depressive disorder may have a better response to treatment with antidepressants as compared to patients with the AA or AG genotype. However, some studies show no association with response or remission. Other genetic and clinical factors may also influence response to antidepressants.
1450376313	*3/*3	Patients with *3/*3 genotypes may have decreased metabolism, increased plasma concentration, increased toxicity and increased adverse drug reactions when treated with phenytoin in epilepsy when compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1449557361	CC	The CC genotype may be associated with decreased metabolism of irinotecan as compared to the CT or TT genotype in patients with metastatic colorectal cancer. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449557362	CT	The CT genotype may be associated with decreased metabolism of irinotecan as compared to the TT genotype and increased metabolism as compared to the CC genotype in patients with metastatic colorectal cancer. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449557363	TT	The TT genotype may be associated with increased metabolism of irinotecan as compared to the CT or CC genotype in patients with metastatic colorectal cancer. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449005338	*1A/*1A	Patients with the CYP3A5 *1A/*1A genotype who are administered midazolam may have faster clearance rates, and increased metabolism of midazolam as compared to patients with the CYP3A5 *3A/*3A genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.
1449005339	*1A/*3A	Patients with the CYP3A5 *1A/*3A genotype who are administered midazolam may have faster clearance rates, and increased metabolism of midazolam as compared to patients with the CYP3A5 *3A/*3A genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.
1449005340	*3A/*3A	Patients with the CYP3A5 *3A/*3A genotype who are administered midazolam may have slower clearance rates, and decreased metabolism of midazolam as compared to patients with the CYP3A5 *1A/*3A or *1A/*1A genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.
1449311537	*1B/*1B	Patients with the *1B/*1B diplotype may have decreased exposure of repaglinide, including decreased AUC and increased clearance of repaglinide as compared to patients with the *1A/*1A, *1A/*1B, *1B/*15, *15/*1A or *5/*1A diplotype. However, this genotype is not associated with blood glucose-lowering effect of repaglinide. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics.
1449311538	*5/*1A	Patients with the *5/*1A diplotype may have increased exposure of repaglinide as compared to patients with the *1B/*1B diplotype.  Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics.
1449556774	CC	Patients with the CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid in patients.
1449556775	CT	Patients with the CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid in patients.
1449005399	AA	Pediatric patients undergoing surgery with the AA genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.
1449005400	AG	Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.
1449005401	GG	Pediatric patients undergoing surgery with the GG genotype may have a decreased likelihood of adverse events, as well as an improved response to sevoflurane and remifentanil as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.
1449005454	AA	Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.
1449005455	AG	Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.
1449005456	GG	Patients with the GG genotype and chronic myeloid leukemia may have an increased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the AA or AG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.
1449556776	TT	Patients with the TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid in patients.
1449557754	*5	Patients with the *5 allele and Tuberculosis who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have an increased risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449557755	*6	Patients with the *6 allele and Tuberculosis who have another slow acetylator NAT2 allele (e.g. *5, *6, *7, *14) may have an increased risk of developing hepatotoxicity induced by isoniazid-containing anti-TB drug regimens, as compared to those with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.
1449309997	AA	Patients with inflammatory bowel diseases, or precursor cell lymphoblastic leukemia-lymphoma and the AA genotype who are treated with azathioprine may metabolize it more slowly and have decreased likelihood of adverse events as compared to patients with the CC genotype, however this is contradicted in most studies. Other clinical and genetic factors may also influence likelihood of adverse events in patients with inflammatory bowel disease.
1449309998	AC	Patients with inflammatory bowel diseases, or precursor cell lymphoblastic leukemia-lymphoma and the AC genotype who are treated with azathioprine may metabolize it more rapidly and may have an increased likelihood of adverse events as compared to patients with the CC genotype, however this is contradicted in most studies. Other clinical and genetic factors may also influence likelihood of adverse events in patients with inflammatory bowel disease.
1449309999	CC	Patients with inflammatory bowel diseases, or precursor cell lymphoblastic leukemia-lymphoma and the CC genotype who are treated with azathioprine may metabolize it more rapidly and may have an increased likelihood of adverse events as compared to patients with the AA genotype, however this is contradicted in most studies. Other clinical and genetic factors may also influence likelihood of adverse events in patients with inflammatory bowel disease.
1449169727	CC	Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449169728	CG	Patients with the CG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449169729	GG	Patients with the  GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1449565119	GG	Patients with the GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.
1449565122	CC	Patients with the CC genotype and Rheumatoid Arthritis may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565123	CT	Patients with the CT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype or may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449310003	CC	Patients with the CC genotype and hypertension may have a worse response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.
1449310004	CG	Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.
1449310015	AA	Patients with cancer and the AA genotype who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.
1449310016	AG	Patients with cancer and the AG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.
1449310017	GG	Patients with cancer and the GG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.
1449565124	TT	Patients with the TT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449565177	GG	Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AG or GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the AA or GG genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.
1449147009	*1/*1	Elderly patients with the *1/*1 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are heterozygous or homozygous for the *2 or *3 allele. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.
1449147010	*1/*2	Elderly patients with the *1/*2 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are homozygous for the *2 or *3 allele and an increased risk of hypoglycemia as compared to patients who are *1/*1. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.
1449147011	*1/*3	Elderly patients with the *1/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are homozygous for the *2 or *3 allele and an increased risk of hypoglycemia as compared to patients who are *1/*1. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.
1449146842	AA	Patients with colorectal cancer and the AA genotype may have a worse response to tipiracil hydrochloride and trifluridine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146843	AG	Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146844	GG	Patients with colorectal cancer and the GG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1448266848	AA	African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
1448266849	AG	African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
1448266850	GG	African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
1449147012	*2/*2	Elderly patients with the *2/*2 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1/*1, *1/*2 or *1/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.
1449147013	*2/*3	Elderly patients with the *2/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1/*1, *1/*2 or *1/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.
1449147014	*3/*3	Elderly patients with the *3/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1/*1, *1/*2 or *1/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.
1449147026	CC	Patients with genotypes CC may have decreased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype TT or CT.
1449147025	CT	Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.
1449147024	TT	Patients with genotypes TT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.
1449147047	*15:02:01	Patients with one or two copies of the HLA-B*15:02:01 allele have an increased risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1449147416	AA	Individuals with the AA genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.
1449717852	*4	Patients with the CYP2C19*4 allele (rs28399504) who are treated with citalopram or escitalopram may have a decreased drug clearance/metabolism and decreased tolerance, especially in combination with another no function allele (*2, *3, *4, *6, *8) (poor metabolizer phenotype) as compared to patients with the CYP2C19*1/*1 genotype. Contradictory findings reported no association of CYP2C19 genotype with tolerance, also no association with response or remission are reported. One study reported an association of poor metabolizers with increased remission if tolerant to citaolpram. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1450369313	*1/*1	Patients with the *1/*1 genotype or two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with atomoxetine may 1) decreased response; 2) decreased risk for side effects such as decreased appetite, tremor, increase in pulse and diastolic; 3) higher dose as compared to patients with two non-functional CYP2D6 alleles (*3, *4, *5, *6). Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1450369314	*1/*2	Patients with the *1/*2 genotype or two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with atomoxetine may 1) decreased response; 2) decreased risk for side effects such as decreased appetite, tremor, increase in pulse and diastolic; 3) higher dose as compared to patients with two non-functional CYP2D6 alleles (*3, *4, *5, *6). Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1450369315	*10	Patients with the CYP2D6*10 allele may have decreased clearance of atomoxetine as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). However no association with differences in adverse event rates when treated with atomoxetine was reported. Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1450369316	*2/*2	Patients with the *2/*2 genotype or two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2) who are treated with atomoxetine may 1) decreased response; 2) decreased risk for side effects such as decreased appetite, tremor, increase in pulse and diastolic; 3) higher dose as compared to patients with two non-functional CYP2D6 alleles (*3, *4, *5, *6). Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1450369317	*3	Patients with the CYP2D6*3 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with atomoxetine may have 1) increased response; 2) increased risk for side effects such as decreased appetite, tremor, increase in pulse and diastolic; 3) lower dose to increase tolerability as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1450369318	*4	Patients with the CYP2D6*4 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with atomoxetine may have 1) increased response; 2) increased risk for side effects such as decreased appetite, tremor, increase in pulse and diastolic; 3) lower dose to increase tolerability as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1450044464	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044465	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044466	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450369319	*5	Patients with the CYP2D6*5 allele in combination with another non-functional CYP2D6 allele (*3, *4, *5, *6) who are treated with atomoxetine may have 1) increased response; 2) increased risk for side effects such as decreased appetite, tremor, increase in pulse and diastolic; 3) lower dose to increase tolerability as compared to patients with two functional CYP2D6 alleles (*1/*1, *1/*2, *2/*2). Other genetic and clinical factors may also influence a patient's response to atomoxetine.
1449577577	*1/*1	Patients with the *1/*1 genotype who are treated with flecainide may have higher clearance of flecainide as compared to patients with non-functional or reduced functional alleles. Other genetic and clinical factors may also influence the clearance of flecainide.
1449577578	*10	Patients with the *10 reduced functional allele in combination with another non-functional or reduced function allele may have lower clearance of flecainide as compared to patients with *1/*1 genotype who carry two functional alleles. Patients who are CYP2D6  intermediate metabolizers may need lower dose of flecainide, record ECG, and monitor plasma concentration. Other genetic and clinical factors may also influence the clearance, dose and response to flecainide.
1449577579	*21	Patients with the *21 non-functional allele in combination with another non-functional or reduced function allele may have lower clearance of flecainide as compared to patients with *1/*1 genotype who carry two functional alleles. Patients who are CYP2D6 poor or intermediate metabolizers may need lower dose of flecainide, record ECG, and monitor plasma concentration. Other genetic and clinical factors may also influence the clearance, dose and response to flecainide.
1449577580	*36	Patients with the *36 reduced functional allele in combination with another non-functional or reduced function allele may have lower clearance of flecainide as compared to patients with *1/*1 genotype who carry two functional alleles. Patients who are CYP2D6  intermediate metabolizers may need lower dose of flecainide, record ECG, and monitor plasma concentration. Other genetic and clinical factors may also influence the clearance, dose and response to flecainide.
1449577581	*4	Patients with the *4 non-functional allele in combination with another non-functional or reduced function allele may have lower clearance of flecainide as compared to patients with *1/*1 genotype who carry two functional alleles. Patients who are CYP2D6 poor or intermediate metabolizers may need lower dose of flecainide, record ECG, and monitor plasma concentration. Other genetic and clinical factors may also influence the clearance, dose and response to flecainide.
1449577582	*5	Patients with the *5 non-functional allele in combination with another non-functional or reduced function allele may have lower clearance of flecainide as compared to patients with *1/*1 genotype who carry two functional alleles. Patients who are CYP2D6 poor or intermediate metabolizers may need lower dose of flecainide, record ECG, and monitor plasma concentration. Other genetic and clinical factors may also influence the clearance, dose and response to flecainide.
1450041954	CC	Patients with the CC genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
1450041955	CG	Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
1450041956	GG	Patients with the GG genotype may have a higher thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
1449753226	AG	Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449753227	GG	Patients with the GG genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449645464	AA	Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645465	AG	Patients with the AG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645466	GG	Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645501	AC	Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645502	AT	There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.
1449645503	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645504	CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645505	TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645509	AA	Patients with the AA genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645510	AC	Patients with the AC genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645511	CC	Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645515	AA	Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645516	AC	Patients with the AC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645517	AT	There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.
1449645518	CC	Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645519	CT	Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645520	TT	Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645524	AA	Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645525	AC	Patients with the AC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645526	AT	There is currently no published evidence to suggest how the AT genotype may affect O-desmethyl-tramadol sulfation in patients.
1449645527	CC	Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645528	CT	Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645529	TT	Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645533	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645534	CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645535	TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645539	CC	Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1450376317	*31:01:02	Patients with one or two copies of the HLA-A*31:01:02 allele who are treated with carbamazepine may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-A*31:01:02 alleles or negative for the HLA-A*31:01:02 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.
1450376820	CC	Patients (mainly pediatric patients) with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to methylphenidate treatment as compared to patients with the CG or GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376821	CG	Patients (mainly pediatric patients) with the CG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376822	GG	Patients (mainly pediatric patients) with the GG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1449645540	CT	Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645541	TT	Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645545	CC	Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645546	CT	Patients with the CT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645547	TT	Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645557	GG	Patients with the GG genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645558	GT	Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645559	TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645563	GG	Patients with the GG genotype may have an increased rate of sulfation of morphine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645564	GT	Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645565	TT	Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645569	GG	Patients with the GG genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645570	GT	Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645571	TT	Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645575	GG	Patients with the GG genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645576	GT	Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645577	TT	Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449715842	AA	Patients with the AA genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's likelihood of vomiting as a result of taking fentanyl.
1449715843	AT	Patients with the AT genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's likelihood of vomiting as a result of taking fentanyl.
1449715844	TT	Patients with the TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's likelihood of vomiting as a result of taking fentanyl.
1449752790	CG	Patients with the CG genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.
1449752791	GG	Patients with the GG genotype and colorectal cancer may have decreased survival times when treated with irinotecan-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.
1449753236	CC	Patients with the CC genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449753237	CT	Patients with the CT genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1450372567	*1/*1	Patients with the CYP2C19*1/*1 diplotype (normal metabolizers) may have increased metabolism of voriconazole as compared to patients with the CYP2C19*1/*2 or *1/*3 diplotypes (intermediate metabolizers) or the CYP2C19*2/*2, *3/*3 or *2/*3 diplotypes (poor metabolizers), or may have decreased metabolism of voriconazole as compared to patients with the CYP2C19*1/*17 or *17/*17 diplotypes (rapid and ultrarapid metabolizers). Consequently, patients with the *1/*1 genotype may have a decreased likelihood of discontinuation of voriconazole due to undetectable levels or a lack of response, as compared to rapid or ultrarapid metabolizers, and a decreased likelihood of discontinuation due to elevated, potentially toxic levels of voriconazole or adverse effects as compared to intermediate or poor metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372568	*1/*17	Patients with the CYP2C19*1/*17 diplotype (rapid metabolizers) may have increased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers), the CYP2C19*1/*2 or *1/*3 diplotypes (intermediate metabolizers), or the CYP2C19*2/*2, *2/*3 or *3/*3 diplotypes (poor metabolizers), or may have decreased metabolism as compared to patients with the CYP2C19*17/*17 diplotype (ultrarapid metabolizers). Consequently, patients with the *1/*17 genotype may have an increased risk for discontinuation of voriconazole due to undetectable levels of the drug or lack of response, and may require an increase in dose to achieve target levels, as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372569	*1/*2	Patients with the CYP2C19*1/*2 diplotype (intermediate metabolizers) may have decreased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers) or the CYP2C19 *1/*17 or *17/*17 diplotypes (rapid and ultrarapid metabolizers, respectively), or may have increased metabolism as compared to patients with the CYP2C19*2/*2, *3/*3 or *2/*3 diplotypes (poor metabolizers). Consequently, patients with the *1/*2 genotype may have an increased risk for adverse effects when receiving voriconazole, and may require a decrease in dose of voriconazole in order to achieve target levels, as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372570	*1/*3	Patients with the CYP2C19*1/*3 diplotype (intermediate metabolizers) may have decreased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers) or the CYP2C19 *1/*17 or *17/*17 diplotypes (rapid and ultrarapid metabolizers, respectively), or may have increased metabolism as compared to patients with the CYP2C19*2/*2, *3/*3 or *2/*3 diplotypes (poor metabolizers). Consequently, patients with the *1/*3 genotype may have an increased risk for adverse effects when receiving voriconazole, and may require a decrease in dose of voriconazole in order to achieve target levels, as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372571	*17/*17	Patients with the CYP2C19*17/*17 diplotype (ultrarapid metabolizers) may have increased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers), CYP2C19*1/*17 diplotype (rapid metabolizers), CYP2C19*1/*2 or *1/*3 diplotypes (intermediate metabolizers) or the CYP2C19*2/*2, *2/*3 or *3/*3 diplotypes (poor metabolizers). Consequently, patients with the *17/*17 genotype may have an increased risk for discontinuation of voriconazole due to undetectable levels of the drug or lack of response, and may require an increase in dose to achieve target levels, as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372572	*2/*2	Patients with the CYP2C19*2/*2 diplotype (poor metabolizers) may have decreased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers), the CYP2C19*1/*2 or *1/*3 diplotypes (intermediate metabolizers) or the CYP2C19*1/*17 or *17/*17 diplotypes (rapid and ultrarapid metabolizers). Consequently, patients with the *2/*2 genotype may have an increased risk for adverse effects when receiving voriconazole as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372573	*2/*3	Patients with the CYP2C19*2/*3 diplotype (poor metabolizers) may have decreased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers), the CYP2C19*1/*2 or *1/*3 diplotypes (intermediate metabolizers) or the CYP2C19*1/*17 or *17/*17 diplotypes (rapid and ultrarapid metabolizers). Consequently, patients with the *2/*3 genotype may have an increased risk for adverse effects when receiving voriconazole as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1450372574	*3/*3	Patients with the CYP2C19*3/*3 diplotype (poor metabolizers) may have decreased metabolism of voriconazole as compared to patients with the CYP2C19*1/*1 diplotype (normal metabolizers), the CYP2C19*1/*2 or *1/*3 diplotypes (intermediate metabolizers) or the CYP2C19*1/*17 or *17/*17 diplotypes (rapid and ultrarapid metabolizers). Consequently, patients with the *3/*3 genotype may have an increased risk for adverse effects when receiving voriconazole as compared to normal metabolizers. Other genetic and clinical factors may also influence voriconazole metabolism, response and adverse effects.
1449713371	AA	Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.
1449713372	AG	Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.
1449713373	GG	Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.
1450373850	AA	Patients with the AA genotype who are treated with opioids for pain may have an increased response and therefore require a lower dose as compared to patients with the AG or GG genotypes. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's opioids dosage and response.
1450373851	AG	Patients with the AG genotype who are treated with opioids for pain may have an increased response and therefore require a lower dose as compared to patients with the GG genotype but a decreased response and higher dose requirement as compared to patients with the AA genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's opioids dosage and response.
1450373852	GG	Patients with the GG genotype who are treated with opioids for pain may have an decreased response and therefore require a higher dose as compared to patients with the AA or AG genotypes. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's opioids dosage and response.
1449716058	AA	Patients with the AA genotype may require an increased dose of opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.
1449716059	AG	Patients with the AG genotype may require an increased dose of opioids as compared to patients with the GG genotype, but a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioids dose requirements.
1449716060	GG	Patients with the GG genotype may require a decreased dose of opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.
1449716180	AA	Patients with the AA genotype may experience an increased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of a patient's nausea and vomiting as a result of taking fentanyl.
1449716181	AG	Patients with the AG genotype may experience a decreased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nausea and vomiting as a result of taking fentanyl.
1449716182	GG	There is currently no information concerning the effect of the GG genotype on the severity of nausea and vomiting as a result of taking fentanyl. Other genetic and clinical factors may also affect the severity of a patient's nausea and vomiting as a result of taking fentanyl.
1449716209	AA	Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716210	AG	Patients with the AG genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716211	GG	Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716957	*12	Patients carrying the *12 allele and receiving letrozole to treat breast cancer may have increased concentrations and decreased clearance of letrozole as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect letrozole concentrations and clearance in a patient.
1449716958	*17	Patients carrying the *17 allele and receiving letrozole to treat breast cancer may have increased concentrations and decreased clearance of letrozole as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect letrozole concentrations and clearance in a patient.
1449716953	*1A/*1A	Patients with the *1/*1 genotype and receiving letrozole to treat breast cancer may have decreased concentrations and increased clearance of letrozole as compared to patients carrying the *2, *4, *9, *12 or *17 alleles. Other genetic and clinical factors may also affect letrozole concentrations and clearance in a patient.
1449716954	*2	Patients carrying the *2 allele and receiving letrozole to treat breast cancer may have increased concentrations and decreased clearance of letrozole as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect letrozole concentrations and clearance in a patient.
1449716955	*4A	Patients carrying the *4 allele and receiving letrozole to treat breast cancer may have increased concentrations and decreased clearance of letrozole as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect letrozole concentrations and clearance in a patient.
1449716956	*9	Patients carrying the *9 allele and receiving letrozole to treat breast cancer may have increased concentrations and decreased clearance of letrozole as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect letrozole concentrations and clearance in a patient.
1449752999	CC	CC genotype may be associated with a decreased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the TT or CT genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.
1449753000	CT	CT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.
1449753001	TT	TT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.
1450373522	AA	Postoperative patients with the AA genotype may have higher morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.
1450373523	AG	Postoperative patients with the AG genotype may have higher morphine requirements as compared to patients with the GG genotype, but lower morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.
1450373524	GG	Postoperative patients with the GG genotype may have lower morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.
1450372317	AA	Patients with the AA genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450372318	AT	Patients with the AT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450372319	TT	Patients with the TT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of the drug and 2) decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotypes. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449164859	CC	Individuals with the CC genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449164860	CT	Individuals with the CT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449164861	TT	Individuals with the TT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.
1449713214	AA	Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.
1449713215	AG	Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.
1449713216	GG	Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.
1449717300	AA	Patients with the AA genotype may have higher ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
1449717299	AG	Patients with the AG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
1449717298	GG	Patients with the GG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
1449752158	CC	Patients with the CC genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1449752159	CG	Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1449752160	GG	Patients with the GG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1450044519	AA	Patients with the AA genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AC or CC. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044520	AC	Patients with the AC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044521	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450180244	(TA)6/(TA)6	Patients with the UGT1A1 (TA)6/(TA)6 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.
1450180245	(TA)6/(TA)7	Patients with the UGT1A1 (TA)6/(TA)7 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.
1450180246	(TA)7/(TA)7	Patients with the UGT1A1 (TA)7/(TA)7 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)6/(TA)6 or (TA)6/(TA)7 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.
1449718252	TT	No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.
1450368634	CC	Patients with the CC genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk of drug toxicity and increased likelihood of dose intervention as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449732173	AG	Patients with the AG genotype (DPYD *1/*9A) and cancer who are treated with fluorouracil may have 1) an increased risk for drug toxicities, 2) decreased response and 3) increased DPYD activity as compared to patients with the AA genotype (DPYD *1/*1). Patients with the AG genotype were also found to have increased clearance of fluorouracil as compared to those with the GG genotype (DPYD *9A/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance, and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449732174	GG	Patients with the GG genotype (DPYD *9A/*9A) and cancer who are treated with fluorouracil may have 1) an increased risk for drug toxicities, 2) decreased response, 3) decreased clearance of fluorouracil and 4) increased DPYD activity as compared to patients with the AA or AG genotype (DPYD *1/*1 or *1/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance, and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1449713740	GG	Patients with ankylosing spondylitis and the GG genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.
1449713741	GT	Patients with ankylosing spondylitis and the GT genotype may have a decreased response to etanercept as compared to patients with the GG or TT genotypes. Other genetic and clinical factors may also affect a patient's response to etanercept.
1449713742	TT	Patients with ankylosing spondylitis and the TT genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.
1450415853	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner. This clinical annotation is based on one study and there were no individuals with the AA genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450415852	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450415851	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1449749606	CC	Patients undergoing a liver transplant who carry the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement.
1449749607	CT	Patients undergoing a liver transplant who carry the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement.
1449749608	TT	Patients undergoing a liver transplant who carry the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement.
1449749612	CC	Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement.
1449749613	CT	Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement.
1450373618	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.
1450373619	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.
1450373620	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.
1449749510	CC	Patients with the CC (*3/*3) genotype and are recipients of a kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). However, some studies show a decreased risk of nephrotoxicity for patients with the CC genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.
1449749511	CT	Patients with the CT genotype (*1/*3) and are recipients of a kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). However, some studies show an increased risk of nephrotoxicity for patients with the CT genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.
1449749512	TT	Patients with the TT (*1/*1) genotype and are recipients of kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). However, some studies show an increased risk of nephrotoxicity for patients with the TT genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.
1449749614	TT	Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement.
1450368635	CG	Patients with the CG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have an increased risk of drug toxicity and increased likelihood of a dose intervention as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450368636	GG	Patients with the GG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased risk of drug toxicity and decreased likelihood of dose intervention as compared to patients with the CC or CG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.
1450368639	G/del	Patients with the G/del genotype (DPYD *1/*3) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
1450368640	GG	Patients with the GG genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the G/del or del/del genotype (DPYD *1/*3 or *3/*3). Other genetic and clinical factors may also affect DPYD activity.
1450368641	del/del	Patients with the del/del genotype (DPYD *3/*3) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity.
1449752253	AC	Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AC genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449752254	CC	Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1449752838	*15:01:01:01	Patients carrying one or two copies of the HLA-DRB1*15:01 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-DRB1*15:01 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752839	*16:02:01	Patients carrying one or two copies of the HLA-DRB1*16:02 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-DRB1*16:02 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449748303	TT	Patients with the TT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the CC or CT genotype. Other factors may affect concentration of tacrolimus.
1449753051	CC	Genotype CC may be associated with increased uptake of adefovir dipivoxil as compared to genotype TT or CT. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.
1449753052	CT	Genotype CT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.
1449753053	TT	Genotype TT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.
1449576929	AG	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
1449576930	GG	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.
1449576938	GG	Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.
1449576939	GT	Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.
1449576940	TT	Patients with the TT genotype; 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.
1449575831	*1/*1	Patients with acute lymphoblastic leukemia (ALL) and the NUDT15*1/*1 genotype who are treated with mercaptopurine may tolerate higher doses of mercaptopurine, and suffer fewer toxic effects as compared to patients with NUDT15*2, *3, *4, *5, or *6 alleles. Other genetic and clinical factors may also influence dose of mercaptopurine and incidence of toxicity in patients with ALL.
1449575832	*2	Patients with the NUDT15*2 allele who are treated with mercaptopurine may tolerate lower doses of mercaptopurine, especially in combination with another decreased function allele (*2, *3, *4, *5, *6) as compared to patients with the NUDT15*1/*1 genotype. Other genetic and clinical factors may also influence dose of mercaptopurine and incidence of toxicity in patients with ALL.
1449575833	*3	Patients with the NUDT15*3 allele who are treated with mercaptopurine may tolerate lower doses of mercaptopurine, especially in combination with another decreased function allele (*2, *3, *4, *5, *6) as compared to patients with the NUDT15*1/*1 genotype. Other genetic and clinical factors may also influence dose of mercaptopurine and incidence of toxicity in patients with ALL.
1449575834	*4	Patients with the NUDT15*4 allele who are treated with mercaptopurine may tolerate lower doses of mercaptopurine, especially in combination with another decreased function allele (*2, *3, *4, *5, *6) as compared to patients with the NUDT15*1/*1 genotype. Other genetic and clinical factors may also influence dose of mercaptopurine and incidence of toxicity in patients with ALL.
1449575835	*5	Patients with the NUDT15*5 allele who are treated with mercaptopurine may tolerate lower doses of mercaptopurine, especially in combination with another decreased function allele (*2, *3, *4, *5, *6) as compared to patients with the NUDT15*1/*1 genotype. Other genetic and clinical factors may also influence dose of mercaptopurine and incidence of toxicity in patients with ALL.
1449575836	*6	Patients with the NUDT15*6 allele who are treated with mercaptopurine may tolerate lower doses of mercaptopurine, especially in combination with another decreased function allele (*2, *3, *4, *5, *6) as compared to patients with the NUDT15*1/*1 genotype. Other genetic and clinical factors may also influence dose of mercaptopurine and incidence of toxicity in patients with ALL.
1449165721	AA	Patients with the AA genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) all as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.
1449165722	AG	Patients with the AG genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the GG genotype. Patients with the AG genotype and organ transplantation administered cyclosporine may have 1) increased metabolism 2) increased clearance and 3) decreased risk of adverse events as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.
1449165723	GG	Patients with the GG genotype and organ transplantation administered cyclosporine may have a 1) increased metabolism of cyclosporine 2) increased clearance of cyclosporine and 3) a decreased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the AA genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.
1449564417	*2/*2	Patients with the *2/*2 genotype may require a decreased dose of acenocoumarol as compared to patients with the *1/*1, *1/*2, *1/*3 genotypes, although this is contradicted by some studies. Other genetic and clinical factors may also influence a patient's required acenocoumarol dosage.
1449564418	*2/*3	Patients with the *2/*3 genotype may require a decreased dose of acenocoumarol as compared to patients with the *1/*1, *1/*2, *1/*3 genotypes, although this is contradicted by some studies. In addition, the *2/*3 genotype may be associated with longer time to achieve stable dose as compared to the *1/*1 genotypes, and shorter time as compared to the *3/*3 genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's required acenocoumarol dosage.
1449564419	*3/*3	Patients with the *3/*3 genotype may require a decreased dose of acenocoumarol as compared to patients with the *1/*1, *1/*2, *1/*3 genotypes, although this is contradicted by some studies. In addition, the *3/*3 genotype may be associated with longer time to achieve stable dose as compared to the *1/*3 and *1/*1 genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's required acenocoumarol dosage.
1449712806	AA	Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.
1449712807	AG	Patients with epilepsy and the AG genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the GG genotypes but improved response as compared to the AA genotype. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.
1449712808	GG	Patients with epilepsy and the GG genotype may have increased concentrations of oxcarbazepine and improved response as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.
1449576625	AG	Patients with cardiovascular disease and the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GG genotype and decreased likelihood as compared to the AA genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.
1450044547	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.  Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044548	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044549	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044609	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1449718309	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3	Patients with the 3R/3R genotype may have a decreased but not absent risk for toxicity, a decreased survival time and a decreased response to with fluoropyrimidine chemotherapy regimens as compared to patients with the 2R/2R or 2R/3R genotype. However, contradictory or non-significant evidence exists for all three of these associations. In addition a SNP within the third repeat may modify the actions of the 3R allele. Other genetic and clinical factors may also influence a patient's risk for toxicity, survival and response.
1449576626	GG	Patients with cardiovascular disease and the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.
1449566693	CC	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566694	CT	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566695	TT	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.
1449718302	CC	Patients with CC genotype and breast cancer may have a decreased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.
1449718303	CG	Patients with CG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.
1449718304	GG	Patients with GG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.
1450042357	*1	Patients with the CYP2D6*1 allele may have 1) an increased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*9 or *25 or *26 or *28 or *32 or *39 or *43 or *45 or *48 or *70 allele, 2) similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*22 or *23 or *24 or *27 or *33 or *49 allele, and 3) increased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*7 or *10 or *12 or *14A or *14B or *17 or *18 or *29 or *30 or *31 or *36 or *37 or *40 or *46 or *47 or *50 or *51 or *52 or *54 or *55 or *57 or *61 or *62 or *63 or *64 or *65 or *71 or *72 or *75 allele. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042358	*10	Patients with the CYP2D6*10 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042360	*114	Patients with the CYP2D6*114 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*114 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042359	*12	Patients with the CYP2D6*12 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*12 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042361	*14	Patients with the CYP2D6*14 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*14 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042362	*17	Patients with the CYP2D6*17 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*17 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450397920	*01:02:01	Patients with one or two copies of the HLA-C*01:02:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with methazolamide as compared to patients with no HLA-C*01:02:01 alleles or negative for the HLA-C*01:02:01 test. Other genetic and clinical factors may also influence a patient's risk of methazolamide-induced adverse reactions.
1449732312	A	Patients with the 1555A allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555G allele.  Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.
1449732313	G	Patients with the 1555G allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555A allele. In the majority of studies, every individual who carried the 1555G allele developed hearing loss after receiving aminoglycoside antibiotics. Most individuals studied were homoplasmic for the G allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.
1450044610	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044611	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044587	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044588	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044589	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450042631	*1	Patients with the *1 allele may have increased metabolism/clearance of risperidone as compared to patients with two reduced function alleles (*10), one reduced function and one non-functional (*4, *5, or *14) allele, or two non-functional alleles. Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042632	*10	Patients with the *10 allele may have decreased metabolism/clearance of risperidone as compared to patients with two fully functional alleles (*1/*1). One study found that patients with the *10 allele showed increased severity of weight gain due to treatment with risperidone as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042633	*14	Patients with the *14 allele may have decreased metabolism/clearance of risperidone as compared to patients with two fully functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042634	*1xN	Patients with the *1xN allele may have increased metabolism/clearance of risperidone as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042635	*3	Patients with the *3 allele may have decreased metabolism/clearance of risperidone as compared to patients with the *1/*1xN genotype (ultrarapid metabolizers). Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042636	*4	Patients with the *4 allele may have decreased metabolism/clearance of risperidone as compared to patients with two fully functional alleles (*1/*1) or ultrarapid metabolizers (*1/*1xN). Patients with the *4 allele may also respond better to treatment with risperidone as compared to patients with the *1/*1 genotype, though conflicting evidence exists. Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042637	*5	Patients with the *5 allele may have decreased metabolism/clearance of risperidone as compared to patients with two fully functional alleles (*1/*1) or ultrarapid metabolizers (*1/*1xN). Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042638	*6	Patients with the *6 allele may have decreased metabolism/clearance of risperidone as compared to patients with the *1/*1xN genotype (ultrarapid metabolizers). Other genetic and clinical factors may also influence a patient's metabolism of risperidone.
1450042363	*18	Patients with the CYP2D6*18 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*18 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042364	*22	Patients with the CYP2D6*22 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*22 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042365	*23	Patients with the CYP2D6*23 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*23 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042366	*24	Patients with the CYP2D6*24 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*24 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042367	*25	Patients with the CYP2D6*25 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*25 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042368	*26	Patients with the CYP2D6*26 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*26 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042369	*27	Patients with the CYP2D6*27 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*27 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042370	*28	Patients with the CYP2D6*28 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*28 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042371	*29	Patients with the CYP2D6*29 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*29 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042372	*30	Patients with the CYP2D6*30 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*30 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042373	*31	Patients with the CYP2D6*31 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*31 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042374	*32	Patients with the CYP2D6*32 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*32 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042375	*33	Patients with the CYP2D6*33 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*33 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042376	*36	Patients with the CYP2D6*36 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*36 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042377	*37	Patients with the CYP2D6*37 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*37 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042378	*40	Patients with the CYP2D6*40 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*40 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042379	*43	Patients with the CYP2D6*43 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*43 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042380	*45	Patients with the CYP2D6*45 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*45 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450180263	AA	Female patients with the AA genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.
1450180264	AC	Female patients with the AC genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype and a decreased risk of Stevens-Johnson syndrome as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.
1450180265	CC	Female patients with the CC genotype and acquired immunodeficiency syndrome (AIDS) may have a decreased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.
1449751926	*5	Patients with CYP2C19*5 (rs56337013) allele in combination with another loss-of-function (*2, *3, *4, *5) or one functional allele (*1) may have 1) poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449751927	*6	Patients with CYP2C19*6 (rs72552267) allele in combination with another loss-of-function (*2, *3, *4, *5, *6, *8) or one functional allele (*1) may have 1) poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1449751928	*8	Patients with CYP2C19*8 (rs41291556) allele in combination with another loss-of-function (*2, *3, *4, *5, *6, *8) or one functional allele (*1) may have 1) poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with two functional alleles (*1/*1). Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.
1448308333	CC	Patients with the CC genotype may have increased opioid analgesic requirements after surgery as compared to patients with the CT or TT genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.
1448308334	CT	Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.
1448308335	TT	Patients with the TT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.
1450044288	AA	Patients with the AA genotype may require a lower dose of warfarin (may require a dose reduction of 934 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1450044289	AG	Patients with the AG genotype may require a lower dose of warfarin (may require a dose reduction of 692 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1450044290	GG	Patients with the GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.
1449156041	AA	Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
1449156042	AG	Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
1449156043	GG	Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
1449716485	*1A/*1A	Patients with the *1/*1 genotype may have decreased plasma concentrations of fentanyl and increased clearance as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also affect a patient's plasma concentrations of fentanyl.
1449716486	*1A/*3A	Patients with the *1/*3 genotype may have decreased plasma concentrations of fentanyl and increased clearance as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also affect a patient's plasma concentrations of fentanyl.
1449716487	*3A/*3A	Patients with the *3/*3 genotype may have increased plasma concentrations of fentanyl and decreased clearance as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also affect a patient's plasma concentrations of fentanyl.
1450112759	CC	Patients with lymphoblastic leukemia-lymphoma and the CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.
1450112760	CT	Patients with lymphoblastic leukemia-lymphoma and the CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.
1450112761	TT	Patients with lymphoblastic leukemia-lymphoma and the TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.
1449000792	C	Male patients with the C genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the G genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
1449000789	CC	Female patients with the CC genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
1450042381	*46	Patients with the CYP2D6*46 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*46 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042382	*47	Patients with the CYP2D6*47 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*47 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042383	*49	Patients with the CYP2D6*49 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*49 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042384	*50	Patients with the CYP2D6*50 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*50 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042385	*51	Patients with the CYP2D6*51 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*51 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042386	*52	Patients with the CYP2D6*52 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*52 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042387	*54	Patients with the CYP2D6*54 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*54 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042388	*55	Patients with the CYP2D6*55 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*55 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042389	*57	Patients with the CYP2D6*57 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*57 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042390	*61	Patients with the CYP2D6*61 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*61 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042391	*62	Patients with the CYP2D6*62 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*62 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042392	*63	Patients with the CYP2D6*63 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*63 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042393	*64	Patients with the CYP2D6*64 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*64 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042394	*65	Patients with the CYP2D6*65 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*65 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042395	*7	Patients with the CYP2D6*7 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*7 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042396	*70	Patients with the CYP2D6*70 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*70 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042397	*71	Patients with the CYP2D6*71 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*71 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1450042398	*9	Patients with the CYP2D6*9 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*9 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.
1449000790	CG	Female patients with the CG genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
1449000793	G	Male patients with the G genotype who are treated with antipsychotics may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
1449000791	GG	Female patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.
1449193002	*15:02:01	Patients with one or two copies of the HLA-B*15:02:01 allele may have an increased risk of maculopapular eruption (MPE) when treated with oxcarbazepine as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test. However, a number of studies on MPE have found negative results. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.
1448256293	AA	Patients with the AA genotype and chronic hepatitis C may not require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.
1448256294	AC	Patients with the AC genotype and chronic hepatitis C may not require a dose reduction or ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.
1448256295	CC	Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.
1449645362	CC	Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645363	CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645364	TT	Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645368	CC	Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645369	CT	Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645370	TT	Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645374	CC	Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645375	CT	Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645376	TT	Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645380	CC	Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645381	CT	Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645382	TT	Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645388	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645389	CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645390	TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645394	CC	Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645395	CT	Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645396	TT	Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645400	CC	Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645401	CT	Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645402	TT	Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645416	AA	Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645417	AC	Patients with the AC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645418	CC	Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645410	CC	Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645411	CT	Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645412	TT	Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449748158	CC	Patients with the CC genotype and organ transplantation may have reduced clearance of everolimus compared to patients with the TT genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus.
1449748159	CT	Patients with the CT genotype and organ transplantation may have reduced clearance of everolimus compared to patients with the TT genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus.
1449748160	TT	Patients with the TT genotype and organ transplantation may have increased clearance of everolimus compared to patients with the CC genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus.
1449748189	AA	Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.
1449748190	AG	Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.
1449748191	GG	Patients with the GG genotype may have a decreased lipid-lowering response to simvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.
1449645422	AA	Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645423	AC	Patients with the AC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645424	CC	Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645428	AA	Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645429	AC	Patients with the AC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645430	CC	Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645551	CC	Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645552	CT	Patients with the CT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449645553	TT	Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.
1449717943	GG	Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717944	GT	Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717945	TT	Patients with the TT genotype may have a shorter recovery time from general anesthesia as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1450374899	AA	Patients with the AA genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.
1450374898	AG	Patients with the AG genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.
1450374897	GG	Patients with the GG genotype and attention deficit hyperactivity disorder (ADHD) who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score may have a decreased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence response to methylphenidate.
1450376190	CC	Patients with the CC genotype who are undergoing kidney or heart transplants may have a decreased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.
1450376191	CT	Patients with the CT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.
1450376192	TT	Patients with the TT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.
1449715915	AA	Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715916	AG	Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715917	GG	Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715921	AA	Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715922	AC	Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715923	AT	Patients with the AT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715924	CC	Patients with the CC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715925	CT	Patients with the CT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715926	TT	Patients with the TT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715930	AA	Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715931	AG	Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715932	GG	Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449716037	AA	Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716038	AC	Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716039	CC	Patients with the CC genotype may have a decreased response to fentanyl as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716380	*1A/*1A	Patients with the *1/*1 genotype may be at a decreased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.
1449716381	*1A/*3A	Patients with the *1/*3 genotype may be at a decreased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.
1449716382	*3A/*3A	Patients with the *3/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1/*1 and *1/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.
1449716388	AA	Patients with the AA genotype may experience improved efficacy of opioids and may require a decreased dose as compared to patients with the GG and possiblly AG genotypes, although this is contradicted in most studies, which report no association between the allele with dose or efficacy of opioids for pain. Other genetic and clinical factors may also influence a dose and efficacy of opioids for pain.
1449747867	AA	Patients with the AA genotype who are undergoing kidney transplantation or liver transplantation (donor genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.
1449747868	AG	Patients with the AG genotype who are undergoing kidney transplantation or liver transplantation (donor genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype, or decreased concentrations as compared to the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.
1449747869	GG	Patients with the GG genotype who are undergoing kidney transplantation or liver transplantation (donor genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.
1450373491	CC	Patients with the CC genotype may have a decreased response to methadone in the treatment of heroin dependence as compared to patients with the CT or TT genotypes. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.
1450373492	CT	Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.
1450373493	TT	Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.
1450373485	AA	Individuals with the AA genotype may have improved response to opioids and may require a decreased dose as compared to individuals with the AG or GG genotypes. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to opioid drugs.
1450373486	AG	Individuals with the AG genotype may experience decreased response to opioids and may require an increased dose as compared to individuals with the AA genotype. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response on opioid drugs.
1450373487	GG	Individuals with the GG genotype may experience decreased response to opioids and may require an increased dose as compared to individuals with the AA genotype. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response on opioid drugs.
1449716389	AG	Patients with the AG genotype may experience improved efficacy of opioids and may require a decreased dose as compared to patients with the GG genotypes, although this is contradicted in most studies, which report no association between the allele with dose or efficacy of opioids for pain. Other genetic and clinical factors may also influence a dose and efficacy of opioids for pain.
1449716390	GG	Patients with the GG genotype may experience decreased efficacy of opioids and may require an increased dose as compared to patients with the AA and possibly AG genotypes, although this is contradicted in most studies, which report no association between the allele with dose or efficacy of opioids for pain. Other genetic and clinical factors may also influence a dose and efficacy of opioids for pain.
1449716394	AA	Patients with the AA genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.
1449716395	AC	Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.
1449716396	AT	Patients with the AT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.
1449716397	CC	Patients with the CC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.
1449716398	CT	Patients with the CT genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.
1449716399	TT	Patients with the TT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.
1450373636	CC	Patients with the CC genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373637	CT	Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373638	TT	Patients with the TT genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1449716766	AA	Patients with the AA genotype may have a decreased response to fentanyl and may therefore require an increased dose as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.
1449716767	AG	Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.
1449716768	GG	Patients with the GG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.
1449716597	*1/*1	Patients with the *1/*1 genotype may have increased metabolism of fentanyl, leading to decreased plasma concentrations of fentanyl as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect plasma concentrations of fentanyl in a patient.
1449753231	AA	Patients with the AA genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449753232	AG	Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1450042274	*1	Patients with the CYP2D6*1 allele may have 1) an increased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*7 or *10 or *12 or *14A or *17 or *18 or *29 or *36 or *37 or *40 or *47 or *49 or *50 or *51 or *54 or *55 or *57 or *62 or *71 or *72 or *75 or *89 or *92 or *93 or *96 allele, 2) similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*27 or *39 or *48 allele when assayed with bufuralol or dextromethorphan, 3) increased clearance of bufuralol as compared to patients with the CYP2D6*10 or *17 or *14B or *87 or *88 or *89 or *90 or *91 or *93 or *94 or *95 or *97 or *98 allele, and 4) decreased clearance of bufuralol as compared to patients with the CYP2D6*53 allele. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042275	*10	Patients with the CYP2D6*10 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol or dextromethorphan as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have significantly decreased enzymatic activity and decreased clearance during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042276	*114	Patients with the CYP2D6*114 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*114 allele was found to have a no enzymatic activity during in vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042277	*12	Patients with the CYP2D6*12 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*12 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042278	*14	Patients with the CYP2D6*14 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*14 allele construct was found to have decreased intrinsic clearance during in vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042279	*17	Patients with the CYP2D6*17 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol or dextromethorphan as compared to patients with the CYP2D6*1 allele. The CYP2D6*17 allele was found to have decreased enzymatic activity and decreased clearance during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042280	*18	Patients with the CYP2D6*18 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*18 allele was found to have significantly decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042281	*27	Patients with the CYP2D6*27 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*48 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042282	*29	Patients with the CYP2D6*29 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*29 allele was found to have decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042283	*36	Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042284	*37	Patients with the CYP2D6*37 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*37 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042285	*39	Patients with the CYP2D6*39 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*39 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042286	*40	Patients with the CYP2D6*40 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*40 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042287	*47	Patients with the CYP2D6*47 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*47 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1449716598	*1/*1G	Patients with the *1/*1G genotype may have increased metabolism of fentanyl, leading to decreased plasma concentrations of fentanyl as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect plasma concentrations of fentanyl in a patient.
1449716599	*1G/*1G	Patients with the *1G/*1G genotype may have decreased metabolism of fentanyl, leading to increased plasma concentrations of fentanyl as compared to patients with the *1/*1 or *1/*1G genotypes. Other genetic and clinical factors may also affect plasma concentrations of fentanyl in a patient.
1449716771	*1/*1	Patients with the *1/*1 genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.
1449716772	*1/*1G	Patients with the *1/*1G genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.
1449716773	*1G/*1G	Patients with the *1G/*1G genotype may require a decreased dose of fentanyl to manage postoperative pain as compared to patients with the *1/*1 or *1/*1G genotype. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.
1450042288	*48	Patients with the CYP2D6*48 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*48 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042289	*49	Patients with the CYP2D6*49 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*49 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042290	*50	Patients with the CYP2D6*50 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*50 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042291	*51	Patients with the CYP2D6*51 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*51 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042292	*53	Patients with the CYP2D6*53 allele may have increased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*53 allele construct was found to have increased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042293	*54	Patients with the CYP2D6*54 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*54 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042294	*55	Patients with the CYP2D6*55 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*55 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042295	*57	Patients with the CYP2D6*57 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*57 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042296	*62	Patients with the CYP2D6*62 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*62 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042297	*7	Patients with the CYP2D6*7 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*7 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042298	*71	Patients with the CYP2D6*71 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*71 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042299	*72	Patients with the CYP2D6*72 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*72 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042300	*75	Patients with the CYP2D6*75 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*75 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042301	*87	Patients with the CYP2D6*87 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042302	*88	Patients with the CYP2D6*88 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042303	*89	Patients with the CYP2D6*89 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan and decreased clearance with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042304	*90	Patients with the CYP2D6*90 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450373624	AA	Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373625	AG	Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373626	GG	Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1449718255	AA	Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.
1449718256	AG	Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.
1449718257	GG	Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.
1449718261	CC	Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.
1449718262	CT	Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.
1449718263	TT	Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.
1449576612	AA	Patients with the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.
1449576613	AG	Patients with the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the GG genotypes and a decreased likelihood as compared to the AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.
1449576614	GG	Patients with the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of experiencing rhabdomyolysis as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.
1449576618	GG	Patients with cardiovascular disease and the GG genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GT or TT genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.
1449576619	GT	Patients with cardiovascular disease and the GT genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the TT genotype and a decreased likelihood as compared to the GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.
1449576620	TT	Patients with cardiovascular disease and the TT genotype who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.
1450042305	*91	Patients with the CYP2D6*91 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042306	*92	Patients with the CYP2D6*92 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042307	*93	Patients with the CYP2D6*93 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan and decreased clearance with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042308	*94	Patients with the CYP2D6*94 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042309	*95	Patients with the CYP2D6*95 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042310	*96	Patients with the CYP2D6*96 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.
1450042311	*97	Patients with the CYP2D6*97 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450042312	*98	Patients with the CYP2D6*98 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.
1450375037	CC	There is currently no available evidence on the effect of the CC genotype on a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375038	CT	Patients with testicular cancer and the CT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375039	TT	Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.
1449752843	*24:02:01:01	Patients carrying one or two copies of the HLA-A*24:02 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-A*24:02 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1450043992	AA	Cancer patients with the AA genotype may have an increased risk of neuropathy when treated with paclitaxel as compared to patients with the AG and GG genotypes. Additionally, patients with the AA genotype in combination with the rs2032582 AA genotype may have an increased risk for neutropenia as compared to patients with the rs1045642 AG or GG genotypes in combination with the rs2032582 AC or CC genotypes. Other genetic and clinical factors may influence the risk of adverse events in patients receiving paclitaxel.
1450043993	AG	Cancer patients with the AG genotype may have an increased risk of neuropathy when treated with paclitaxel as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Additionally, patients with the AG genotype in combination with the rs2032582 AC genotype may have a decreased risk for neutropenia as compared to patients with the AA genotype in combination with the rs2032582 AA genotype. Other genetic and clinical factors may influence the risk of adverse events in patients receiving paclitaxel.
1450043994	GG	Cancer patients with the GG genotype may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA or AG genotype. Additionally, patients with the GG genotype in combination with the rs2032582 CC genotype may have a decreased risk for neutropenia as compared to patients with the AA genotype in combination with the rs2032582 AA genotype. Other genetic and clinical factors may influence the risk of adverse events in patients receiving paclitaxel.
1450376749	AA	Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376748	AG	Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376747	GG	Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450375067	GG	Patients with testicular cancer and the GG genotype may have a decreased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375068	GT	Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375069	TT	Patients with testicular cancer and the TT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.
1450376651	AA	Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AT or TT genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other.  Other genetic and clinical factors may also influence response to methylphenidate.
1450376652	AT	Pediatric patients with the AT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.
1450376653	TT	Pediatric patients with the TT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other.  Other genetic and clinical factors may also influence response to methylphenidate.
1450377550	*57:01:01	HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*57:01 allele may have an increased risk of DRESS Syndrome or SJS/TEN as compared to non-carriers.
1449576904	CC	Patients with the CC genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
1449576905	CT	Patients with the CT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
1449576906	TT	Patients with the TT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
1449576913	AA	Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.
1449576914	AG	Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.
1449576915	GG	Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.
1449576918	CC	Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
1449576919	CT	Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
1449576920	TT	Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
1450375718	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375719	CT	Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1449748590	CC	Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1449748591	CT	Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1449748592	TT	Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1450375730	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375720	TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375724	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375725	CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375726	TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375731	CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375732	TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1449577787	GG	Patients with the GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations.
1449577788	GT	Patients with the GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype.  However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations.
1449577789	TT	Patients with the TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype.  However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations.
1450044618	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant  when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044619	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044620	GG	Patients with the GG genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449752812	CC	Patients with the CC genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752813	CT	Patients with the CT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752814	TT	Patients with the TT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1450044488	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044489	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044490	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele confers susceptibility to MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044595	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.
1450044596	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044597	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044598	GG	Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044599	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044511	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1449718273	AA	Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.
1449718274	AG	Patients with AG genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.
1449718275	GG	Patients with GG genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.
1449718279	AA	Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.
1449718280	AG	Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.
1449718281	GG	Patients with GG genotype and breast cancer may have an increased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.
1449718285	CC	Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.
1449718286	CT	Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.
1449718287	TT	Patients with TT genotype and breast cancer may have an increased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.
1449718291	AA	Patients with AA genotype and breast cancer may have an increased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.
1449718292	AG	Patients with AG genotype and breast cancer may have an increased risk of nausea as compared to the GG genotype, and a decreased risk of vomiting as compared to the AA genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.
1449718293	GG	Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.
1449718325	CC	Patients with CC genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.
1449718326	CT	Patients with CT genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.
1449718327	TT	Patients with TT genotype and breast cancer may have an increased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.
1449718333	CC	Patients with the CC genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718334	CT	Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1450042858	AA	Patients with the AA genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.
1450042859	AC	Patients with the AC genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.
1450042860	CC	Patients with the CC genotype may have increased exposure to atazanavir as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.
1450044512	CT	Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044513	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044531	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1450044532	GT	Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044533	TT	Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1449718335	TT	Patients with the TT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718339	AA	Patients with the AA genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718340	AG	Patients with the AG genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718341	GG	Patients with the GG genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.
1449718345	AA	Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.
1449718346	AG	Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.
1449718347	GG	Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.
1449732333	C	Patients with the 1494C allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.
1449732334	T	Patients with the 1494T allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494C allele. In the majority of studies, every individual who carried the 1494T allele developed hearing loss after receiving aminoglycoside antibiotics. Almost all individuals studied were homoplasmic for the T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.
1450044496	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044497	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044498	CC	Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044499	CG	Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044500	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA, AG, CC, CG. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1449717793	*1/*1	Patients with the *1/*1 genotype and heart failure may require an increased dose of metoprolol as compared to patients with the *1/*4 or *4/*4 genotypes. Other genetic and clinical factors may also affect a patient's metoprolol dose requirements.
1449717794	*1/*4	Patients with the *1/*4 genotype and heart failure may require a decreased dose of metoprolol as compared to patients with the **1/*1 genotype but an increased dose as compared to patients with the *4/*4 genotype. Other genetic and clinical factors may also affect a patient's metoprolol dose requirements.
1449717795	*4/*4	Patients with the *4/*4 genotype and heart failure may require a decreased dose of metoprolol as compared to patients with the *1/*1 or *1/*4 genotypes. Other genetic and clinical factors may also affect a patient's metoprolol dose requirements.
1449717801	*1/*1	Patients with heart disease or healthy individuals with the CYP2D6 *1/*1 genotype may have increased clearance of carvedilol as compared to those with the *1/*4, *1/*5 or *10/*10 genotype. Other genetic and clinical factors may also influence clearance of carvedilol.
1449717802	*1/*2	Healthy individuals with the CYP2D6 *1/*2 genotype may have increased clearance of carvedilol as compared to those with the *10/*10 genotype. Other genetic and clinical factors may also influence clearance of carvedilol.
1449717803	*1/*4	Patients with the CYP2D6 *1/*4 genotype and heart disease may have decreased clearance of carvedilol as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence clearance of carvedilol.
1449717804	*1/*5	Patients with the CYP2D6 *1/*5 genotype and heart disease may have decreased clearance of carvedilol as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence clearance of carvedilol.
1449717805	*10/*10	Patients with heart disease or healthy individuals with the CYP2D6 *10/*10 genotype may have decreased clearance of carvedilol as compared to those with the *1/*1 or *1/*2 genotype. Other genetic and clinical factors may also influence clearance of carvedilol.
1449717814	*1/*1	Patients with the *1/*1 genotype and heart failure may require a decreased dose of carvedilol as compared to patients with the *1/*4 or *4/*4 genotypes. Other genetic and clinical factors may also affect a patient's metoprolol dose requirements.
1449717815	*1/*4	Patients with the *1/*4 genotype and heart failure may require an increased dose of carvedilol as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect a patient's metoprolol dose requirements.
1449717816	*4/*4	Patients with the *4/*4 genotype and heart failure may require an increased dose of carvedilol as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect a patient's metoprolol dose requirements.
1450044527	AA	Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044528	AG	Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).
1450044529	GG	Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.
1449715368	*1/*1	Patients with the *1/*1 genotype and postoperative pain may have increased fentanyl dose requirements as compared to patients with the *18B/*18B genotype. However, this association was only seen at one timepoint and there was no significance difference between *1/*1 and *1/*18B patients at either timepoint. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.
1449715369	*1/*18B	Patients with the *1/*18B genotype and postoperative pain do not have significantly different fentanyl dose requirements as compared to patients with the *1/*1 or *18B/*18B genotypes. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.
1449715370	*18B/*18B	Patients with the *18B/*18B genotype and postoperative pain may have decreased fentanyl dose requirements as compared to patients with the *1/*1 genotype. However, this association was only seen at one timepoint and there was no significance difference between *1/*18B and *18B/*18B patients at either timepoint. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.
1449715592	CC	Patients with the CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715593	CT	Patients with the CT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715594	TT	Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450374097	AA	Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374098	AG	Patients with the AG genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374099	GG	Patients with the GG genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1449715425	*1/*1	Patients with the *1/*1 genotype may have increased sufentanil dose requirements and increased sufentanil plasma concentrations as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements or their plasma concentrations of sufentanil.
1449715426	*1/*1G	Patients with the *1/*1G genotype may have increased sufentanil dose requirements and increased sufentanil plasma concentrations as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements or their plasma concentrations of sufentanil.
1449715427	*1G/*1G	Patients with the *1G/*1G genotype may have decreased sufentanil dose requirements and decreased sufentanil plasma concentrations as compared to patients with the *1/*1 or *1/*1G genotypes. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements or their plasma concentrations of sufentanil.
1449715598	AA	Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715599	AC	Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715600	CC	Patients with the CC genotype may have a decreased response to fentanyl as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715628	AA	Patients with the AA genotype may experience an increased severity of respiratory depression as a result of taking alfentanil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of respiratory depression in patients taking alfentanil.
1449715629	AG	Patients with the AG genotype may experience an increased severity of respiratory depression as a result of taking alfentanil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of respiratory depression in patients taking alfentanil.
1449715630	GG	Patients with the GG genotype may experience a decreased severity of respiratory depression as a result of taking alfentanil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of respiratory depression in patients taking alfentanil.
1450375082	AA	Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375043	AA	Patients with testicular cancer and the AA genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.
1450375044	AG	Patients with testicular cancer and the AG genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.
1450375045	GG	Patients with testicular cancer and the GG genotype may have an increased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.
1450044123	A/del	Patients with the A/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1450044124	AA	Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1450044125	del/del	Patients with the del/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1450044136	A/del	Patients with the A/del genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1450044137	AA	Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1450044138	del/del	Patients with the del/del genotype and Coronary Artery Disease may be less likely to benefit from pravastatin treatment as compared to patients with the AA or A/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1450375083	AG	Patients with testicular cancer and the AG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375084	GG	Patients with testicular cancer and the GG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.
1450375748	AA	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375749	AG	Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375750	GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450376141	AA	Patients with the AA genotype may require a decreased dose of morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376142	AG	Patients with the AG genotype may require a decreased dose of morphine as compared to patients with the GG genotype but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376143	GG	Patients with the GG genotype may require an increased dose of morphine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
